<SEC-DOCUMENT>0001698530-20-000059.txt : 20200812
<SEC-HEADER>0001698530-20-000059.hdr.sgml : 20200812
<ACCEPTANCE-DATETIME>20200812084446
ACCESSION NUMBER:		0001698530-20-000059
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200812
DATE AS OF CHANGE:		20200812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXICURE, INC.
		CENTRAL INDEX KEY:			0001698530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				815333008
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39011
		FILM NUMBER:		201094245

	BUSINESS ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077
		BUSINESS PHONE:		847-673-1700

	MAIL ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Max-1 Acquisition Corp
		DATE OF NAME CHANGE:	20170221
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>xcur-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:36122004-6e71-4c8e-9305-4e03dfe42d12,g:561987fc-3e06-47a9-afb8-202603d40cef,d:87c412b98f4a4c10b3a3081e33f1cbca--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xcur="http://www.exicuretx.com/20200630" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xcur-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV8zLTEtMS0xLTA_dd91e02c-6fdb-4346-a989-006b32745baf">0001698530</ix:nonNumeric><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV80LTEtMS0xLTA_9af6838d-458a-4032-bfa3-f72a30c1d5a6">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV8xMy0xLTEtMS0w_327c9742-2b08-4114-8ea9-7f21855c147f">2020</ix:nonNumeric><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV8xNC0xLTEtMS0w_045a763e-d33c-4c4e-a5ea-39ffc7c7fe00">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV8xNS0xLTEtMS0w_0f3e691d-c373-4569-a007-674509c645de">false</ix:nonNumeric><ix:nonNumeric contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217" name="xcur:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTQ4ODA_7c7ddbd2-6787-47de-91af-9e663bcf7a25">P6Y</ix:nonNumeric><ix:nonNumeric contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217" name="xcur:CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTY3MzY_cca5baed-3744-4471-869d-43a351036895">P30D</ix:nonNumeric><ix:nonNumeric contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" name="xcur:OperatingLeaseAssetRemainingUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDIzMg_bc0ddf39-3aa8-49b3-b360-0d3d3fd3ba3d">P0Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xcur-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1942a18648da4a2baa5c6f6dcbc62801_I20200810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i738818d3ada14fb59ae41e5c0547ff93_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4340bc2a3caf476e9ea1655692119072_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76587ca4c99d49da89121e59315b11c9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e81cc37885946329de84c2812052368_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081c44d7528546cba2417fec5251bb86_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669ca094820a403bb6fe6191fea9d033_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d5a6f3c0f64d0b92f3d4c01084e89b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a2b6489ddf141a7bf39c57e8c6c374d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac2f608277bb4d11b8c650acaa7156a4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia600341070154f04b665acb7c655fde4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae69caa952548968e3db1374a9441bf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffcf7f98338c48b2a74d5c64bcbb09cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f18a5fae5146fdac7af880c302d1f0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ebe7513efbb4572897a2eff0bbe5839_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1abd752d57f494da5a5dcd7e17f6c8b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4929d22fbb34f5bb8e001e11fca287f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i346241752b2b49a69f5d211b6a9d45fd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87bf2cd1655f4fab8c904201cabea717_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id117ecfcad3043b9afe9dd6651b61ef9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25b2e786a1684d32b3eb638cf322b195_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629055e5f5f9450696b0cdd1b8c62aaf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057811d1d09040a098af94d1675312a5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b2128138ac484d800e0f7ffac985fc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3377b36eefd4b7dbcd8a37028612f32_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ac35850023477bb1b027d27cf6499d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf91bb3242b54554bf09467575ed8032_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i251a593531414918acbfa4bea82baa82_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b80e31064445acb2afbf5c674a8d22_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda7464d50394c8da8f759b3fe9c27f6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48514485d5c5481a815ea5cb4ec4f071_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fce0dd8830b423089b11cd5506c2b50_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85a381bc7624171a8e7ce667919dcf2_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16628e25dfeb457db79ff5741f4b4746_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd3596a8daa44dafa2c2640d7eaf3704_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibae0a4d897b84e4d9577c9afadfbfeaa_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b397f6da68451f925c80fb3973ef2d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7a7c38c82d4bb58ce35946a0c4b0db_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb258cc2165d4dcbaeb2ae16188d95fb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b302e66ac63416b82f00e6f82fdf6d7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b16abc11334de6979be196b3664e81_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic80e034dbbc84fb499846b28fc08af31_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d996f1250448ddb4ffa272adecd35a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235890d5628b4e7baba46b8ea6aa194f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59a965bf3b8a48eb80d080bf600a28cd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb3dae634064c17b1ab1c0817e8c5ea_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5e1c54705464203b36edb7644fc518c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="agreements"><xbrli:measure>xcur:agreements</xbrli:measure></xbrli:unit><xbrli:context id="if425dcd784314579ba01872343ba1d3d_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i213132da6481483c807931ec91868df7_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xcur:DevelopmentandCommercializationLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1efc8f38914d529f3fa0003f78cbce_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0168a43217c4457bc65313c2af4fb05_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56e80b2cc5be4ab4acf0eef51f34220c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>xcur:target</xbrli:measure></xbrli:unit><xbrli:context id="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-17</xbrli:startDate><xbrli:endDate>2019-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3af79e6a06594c0cb23b1951b9373a0c_D20190217-20190217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-17</xbrli:startDate><xbrli:endDate>2019-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee37ebd534aa4705869ea2175ce06b24_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4755b498baa24be79491012d4f532c62_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68fbc221ed948318252eb995a6db2b6_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a49e1430c4d4a889f71e3a5a377bb5a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a0a13c38254ea983e0bb5a38ca17de_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bfb10b6658e4029a82a1c4c79504c5a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i352899e868b047baae4f3cc5f48173b4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5bb134266b43198e6a9ac71d907554_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18277ad2812a4ef9966ee81eceda653f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad32dfdbf9ce43d4a96d7847ec6e4876_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf30ba5997b64586b6fd2b6487a3b25e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3e2b30098dd4ce39f205fbcaecabc6e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ab7faaf6324bbe806b1945f6ef544f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd78f631ebaa4338ba6f8984c802d444_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i209cc24d339e4dca80c79600e75bf93a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3438766d2dcd44c49ffa9224566847b8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbffc60721ce4820bf8a858d521a4af2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f8930d5532948af84a2e264d978cb22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8a62227b6e4249b0ad9da0af747eac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331baf183969422d81b4084c1e01f301_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d33f191228d4786a0f292468de4d908_D20200302-20200302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-02</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id642410749d845f68e04f5594e957ca4_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofperiods"><xbrli:measure>xcur:numberOfPeriods</xbrli:measure></xbrli:unit><xbrli:context id="id8e4fcd0750e4f00b604afc9f08aeaf4_D20200228-20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerSquarefeet"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xcur:squarefeet</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="vote_per_share"><xbrli:measure>xcur:vote_per_share</xbrli:measure></xbrli:unit><xbrli:context id="i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xcur:CommonStockIssuedDecember2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-23</xbrli:startDate><xbrli:endDate>2019-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be9f363b86d4627be1d61061c00986b_I20191223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xcur:CommonStockIssuedDecember2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2cea85073354474aa680437e75f26a7_D20191223-20191223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-23</xbrli:startDate><xbrli:endDate>2019-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa443308cf5477596e1014cee13ebba_D20200106-20200106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-06</xbrli:startDate><xbrli:endDate>2020-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic86b7ec9cc274bf8af157b6700465ac9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164e4b30480d4e978a2812a8cd07749a_I20210327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fde2bf7394d44a09eddfef7c0f06b5a_I20210428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fb9e0113525465fa92492e072f0e43e_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c03ff4e8b5c4b699019abb27907654d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61094c0deb84e1bbf2fd681155a9f0c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f9fe0651d84de1b85aafe4a8643eec_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6eadd66fe2e43af9a25c3f417c84b26_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d6effdfbf94d41a083294b170f3969_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibebc8ba07dd245ff97b780fc24472240_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87bbbbbd85fc49b8852959fd449af5cf_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9527a967dad3415598f73d2c86f453fc_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b932d51abde4221b44077fb53a41b3b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53eada77c822436c8d20ad774d619503_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfbd26204cc426c8a8cf03400f66926_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7040eb168bef4211b4772b89a21e6728_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1913cdd58d478da612d3f93c8f7a38_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb6b302afc2b47db9a9b8aa6e84aac60_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bdba642bc224cb9b89f1de3feabde3e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aec036201f748fd8269f237b2461bcc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e189a56ebb44a6ba95910fba45564d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e9583ff1ce6495cb0331d2a1569e1b0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib66e2fa725c1452382443738ad2ef816_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6091d038421c443d91771f31d4e2744c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff390c5c87441f5a73f86f5f1529e92_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7e6c0acc9b4b93871186f77defb445_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa95d698f7954c17a13d43f11eded42c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b30acdba4af4f89add54dddf14c23da_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie283a4656c2e4cdaa3544e7bf804c7f9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75055b5483aa4b45aa64e739ee644b07_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c0c8245bda4b29885459d2a7e6d51f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ade10577cb447f84773dd52aecc06c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33522e08954144b987a6d23ea7b62c6b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce249e9e67f47b1986e46049614d74e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9736fd4b7b724ef987739ec27346148b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7685322cfa540bbb195c55945e40155_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d810f21c820439283d2493920890171_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32d42b33c7f4559bb28b9b2c085cd77_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if786421abd8449ad82c258035991f29f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94b2debb8cee40d0bb95dee385f1e248_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if03a9ef0110a48da8f43355f7dde35e9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i139534750c32411998ec9f0fdd20ed30_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b43d4dad70748079a0e514fc136284e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4b2a726e7e9422a8c57cb8fe49f6a15_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ffab51ce3540d2b6096242b70529a6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2525709ae7045c3a4de1f8fb444dbbe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42288e5a324249c8ad74cc662005b838_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1cbfa891ae54142b5e3a160e784d461_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b10df2779c4412ab3932dd163fe9b82_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03266b4db72b4437b1cf9918fecc673e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e24f66b20e44fa2a7b4a0991ca309f1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bfcdc5fa8c740d39d1e6fc1c52b74fe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6929f02de29e445e90d7b545c93b3af6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0b49eff48349d3963e85732d3bb079_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcad2a390bdd4ccab4037a9659048f33_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0091985621104c5e88db831ff8c58475_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9661f3db7077445e851858b6e5f7c6e5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i011f06514d6143e1839cabbd9accc3ca_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02b9a6c3e74421db29f69c537e41533_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d51345bb8494da4a30ff3ab1bc494f9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8d4534186e24013a51b6dcd1d6b3342_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3027180e50c94a839a0b60625e670750_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i090111c614884f2a89c5715d09e61e69_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6d01430580442ebd48b712adfce654_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61aaf687d2943e6bc6fe6367d618ffb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic85d5d22e929404c83658bc0fc8c47ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596ed322af7d456da621e01fa6bae736_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62b770fba5bd404fbbf086617f231ac1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i715f59046cbd4cfbb6149afc299e8098_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1651c5e27f48129604544f4d17c53d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ff5dbe93184b128cf458121e2b9869_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36aea1c3046543f0b3cc27b52ff37040_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7954e090c66944f88a4e2606c991d18b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib02e96a8734943609865d9b4c35421f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i246dadd6c8d449999b2f9717794c470c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad9873452934a32ae8e3aeda1e17fe8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62277363f7143ce854422660983079f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadbc031755e743459e0e460fe0824f64_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie70b0b8cf2fe4c808ff9025d45a5b3ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia533935aed984b759f799fea1a30903b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceff6e292b6d4b45910614df9290865b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6b9adc9d0d410e84335056934458af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f49042851ab48aa8b238a225a70ee62_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b2c3b884bc46fcaabeebaa66bf2635_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i649b1d02f04843e6bfb8ceea9915423c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76cfaf0a85c64451bf8e5033f3d6e411_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae71687b96be4ca7a964da2662807ebb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0591281256d2426a9cbbf549dd04a8a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eafdf3617e8409faef961085fcec21c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c04023fda4245f69834e13098d0ccc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic748766b36734327aef19e1e2042ee49_I20160217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06fbc20f828d41caa9a80bcd7a6e2759_I20160217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9977feb034be4c9caaf5b5df369b7ff1_I20160217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e54b1c09a54de19e18102cdfcb8cbd_I20160217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d24130c57c40ba8b47fd15cceac12a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6024f8bbc354cab9a3781b1178e5869_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2082cdeebbe94488abda3ef417d3e1be_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c9f635fc1cf441fb44103b2e37aabec_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5c0eb47d394449b742692f031dee63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc5af07dc354cc8a9057ae7da0af850_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica899e5f992445b1b2e0565819005804_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7894134fb44db79f503167f8288191_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_1"></div><div style="min-height:31.5pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%;"><tr><td style="width:1.0%;"></td><td style="width:16.497%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.497%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.497%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.497%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.012%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">______________________________________</span></div><div style="text-align:center;margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTIy_81f1c6b1-8e88-47f1-98aa-33e0fcca745f">10-Q</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">______________________________________</span></div><div style="text-indent:-22.5pt;padding-left:22.5pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTIz_5ba556ec-c4e8-43b1-8db5-fb53b09b9ff3">&#9746;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI1_44078d12-43b4-45fd-bebb-69d99edd85df">June 30, 2020</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">or</span></div><div style="text-indent:-22.5pt;padding-left:22.5pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI0_0cdf1000-4df3-42f3-b7ce-3fa347434023">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI2_20419736-d78e-40be-8f2e-8823b47a383d">001-39011</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">______________________________________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI3_7fac0794-7d41-4e9d-8db5-c0834394dcf4">EXICURE, INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">_____________________________________</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:46.888%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.883%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:47.029%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NGQxMDUzMDQ4NzI0NGIwMDkyODc4ZjVmNTZiYTJjMTgvdGFibGVyYW5nZTo0ZDEwNTMwNDg3MjQ0YjAwOTI4NzhmNWY1NmJhMmMxOF8wLTAtMS0xLTM0_04f80054-49a3-4817-b57d-ed3db7df20a7">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NGQxMDUzMDQ4NzI0NGIwMDkyODc4ZjVmNTZiYTJjMTgvdGFibGVyYW5nZTo0ZDEwNTMwNDg3MjQ0YjAwOTI4NzhmNWY1NmJhMmMxOF8wLTItMS0xLTM2_6e9862be-3ea3-4d09-83fe-02cc07289f7a">81-5333008</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(State or other jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">incorporation or organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(IRS Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI4_6e7b8b2f-27fb-4d42-9c36-8d4dfe75f75e">2430 N. Halsted St.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTMw_3f1effd0-6a78-4a97-b15d-76222701bdc8">Chicago</ix:nonNumeric>, <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTMx_2dfa486b-8427-400f-a19b-6619de457823">IL</ix:nonNumeric> <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTMy_ef302467-c625-4673-b911-bcce0f8ae186">60614</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Address of principal executive offices)</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%;"><ix:nonNumeric contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjQ4_0e28c671-d73f-44f5-b41b-db4cdc2f7c5f">8045 Lamon Avenue</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%;"><ix:nonNumeric contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjQ5_1a627494-5cf2-48d2-8b84-c3bd2629dedb">Suite 410</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%;"><ix:nonNumeric contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjUw_f078c61b-556f-4cc2-8a63-7c39a9db10d3">Skokie</ix:nonNumeric>, <ix:nonNumeric contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjUx_4c91a85f-18ad-4389-a3cf-47b0a3e6a30d">IL</ix:nonNumeric> <ix:nonNumeric contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjUz_95352bd7-2b27-4bd2-a48b-7c4d6ca0866a">60077</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Former address of principal executive offices, if changed since last report)</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Registrant&#8217;s telephone number, including area code <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM0_6047f5d1-e6f5-4b76-9ce8-21ff770a3694">(847)</ix:nonNumeric> <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM1_c788b7ee-2b92-434b-be29-1e4bd89c710f">673-1700</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.944%;"><tr><td style="width:1.0%;"></td><td style="width:35.106%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.516%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.481%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.516%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:40.981%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6ZTUzZTkxZGNhMDc0NDg4NWIzYjdiM2I3YjkxYTRhODAvdGFibGVyYW5nZTplNTNlOTFkY2EwNzQ0ODg1YjNiN2IzYjdiOTFhNGE4MF8xLTAtMS0xLTU1_de187fbb-74b1-4fd9-bf28-891ae8c871e6">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6ZTUzZTkxZGNhMDc0NDg4NWIzYjdiM2I3YjkxYTRhODAvdGFibGVyYW5nZTplNTNlOTFkY2EwNzQ0ODg1YjNiN2IzYjdiOTFhNGE4MF8xLTItMS0xLTU3_b5dd8cc3-36e8-48d2-a422-ac2981fd8c6b">XCUR</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6ZTUzZTkxZGNhMDc0NDg4NWIzYjdiM2I3YjkxYTRhODAvdGFibGVyYW5nZTplNTNlOTFkY2EwNzQ0ODg1YjNiN2IzYjdiOTFhNGE4MF8xLTQtMS0xLTU5_f794321f-635b-4438-a35c-f61b5571a5fb">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM2_75534961-52d6-462b-8f1e-c9705815c335">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-top:3pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM3_c12b8d29-cbda-461c-813c-05629dc6c855">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:15.777%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.716%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:52.861%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.527%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.719%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NjZiZGIyNWUwZDY1NDQ2NThkNWRhN2M4NDY0NTY0ZjAvdGFibGVyYW5nZTo2NmJkYjI1ZTBkNjU0NDY1OGQ1ZGE3Yzg0NjQ1NjRmMF8xLTAtMS0xLTY1_e9b56ad2-ef1c-43e0-8c0e-0a9ab568aa3d">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9746;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NjZiZGIyNWUwZDY1NDQ2NThkNWRhN2M4NDY0NTY0ZjAvdGFibGVyYW5nZTo2NmJkYjI1ZTBkNjU0NDY1OGQ1ZGE3Yzg0NjQ1NjRmMF8xLTQtMS0xLTcx_f5033e5f-874d-4819-8826-d13eb272c576">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Emerging growth company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NjZiZGIyNWUwZDY1NDQ2NThkNWRhN2M4NDY0NTY0ZjAvdGFibGVyYW5nZTo2NmJkYjI1ZTBkNjU0NDY1OGQ1ZGE3Yzg0NjQ1NjRmMF8yLTQtMS0xLTcy_3700774e-7abb-4ba4-9ec5-4b585da56fdb">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM4_3cbfee17-1a26-43a0-85a0-ada4ecfdc2a7">&#9746;</ix:nonNumeric></span></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTQy_734daa8c-8aa5-418d-910b-226042d29108">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of August 10, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i1942a18648da4a2baa5c6f6dcbc62801_I20200810" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjg2_16f2cb80-6e0e-410e-a8c2-383e77b1e1bf">87,228,586</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%;"><tr><td style="width:1.0%;"></td><td style="width:16.497%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.497%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.497%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.497%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.012%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_7"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:86.461%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.738%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_13">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_16">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_19">Unaudited Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_25">Unaudited Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_28">Unaudited Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_31">Unaudited Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_34">Unaudited Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_34">11</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_37">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_40">13</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_103">Item 2. Management's Discussion and Analysis and Results of Operations</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_103">32</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_130">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_130">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_133">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_133">48</a></span></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_136">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_139">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_139">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_139">50</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_142">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_142">51</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_145">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_145">88</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_148">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_148">88</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_151">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_151">88</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_154">Item 5. Other Information</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_154">88</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_157">Item 6. Exhibits</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_157">89</a></span></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_160">Signatures</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_160">91</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q, or this Quarterly Report, contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">about:   </span></div><div style="text-indent:-15.75pt;padding-left:36pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;padding-left:12.25pt;">our expectations regarding the impact of the ongoing coronavirus 2019, or COVID-19, pandemic including the expected</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;"> duration of disruption and immediate and long-term delays, interruptions or other adverse effects to clinical trials, and patient enrollment and clinical activation, delays in regulatory review, preclinical research and development (&#8220;R&amp;D&#8221;), collaboration and partnership programs, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy overall, and the overall impact of the coronavirus pandemic on our business, financial condition and results of operations;</span></div><div style="text-indent:2.25pt;"><span><br/></span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our estimates of expenses, ongoing losses, future revenue and capital requirements, including our expectations relating to our needs for additional financing; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the initiation, timing, progress and results of our current and future preclinical studies, clinical trials, collaboration and partnership programs,  including our ongoing clinical trials and any planned clinical trials for cavrotolimod (AST-008) or any of our product candidates, and the research and development programs we pursue;</span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our ability to advance our product candidates into, and successfully complete, clinical trials;</span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the timing and likelihood of regulatory filings for our current and future product candidates including any Investigational New Drug, or IND, application, Investigational Medicinal Product Dossier, or IMPD, Clinical Trial Application, or CTA, New Drug Application, or NDA, or other regulatory submissions;</span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;</span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of market acceptance of our product candidates, including reimbursement that may be received from payors;</span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the diversion of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others or voluntarily adopted in connection with the ongoing COVID-19 pandemic;</span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our dependence on current and future collaborators for advancement of therapeutic candidates pursuant to the terms of such collaborations, including ability to obtain and maintain regulatory approval and commercialization, if approved; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the status of clinical trials, development timelines and discussions with regulatory authorities related to product candidates under development by us and our collaborators;</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our receipt and timing of any milestone payments or royalties under any current or future research collaboration and license agreements or arrangements; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our ability to identify and develop therapeutic candidates for treatment of additional disease indications; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the rate and degree of market acceptance of any approved therapeutic candidates; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the commercialization of any approved therapeutic candidates; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the implementation of our business model and strategic plans for our business, technologies and therapeutic candidates; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our ability to obtain additional funds for our operations; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our ability to obtain and maintain intellectual property protection for our technologies and therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our reliance on third parties to conduct our preclinical studies and clinical trials; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial supplies; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our expectations regarding our ability to attract and retain qualified key management and technical personnel; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or JOBS Act;</span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">statements regarding our internal controls; </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">the impact of government laws and regulations as well as developments relating to our competitors or our industry; and </span></div><div style="text-indent:-15.75pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt;">other factors that may impact our financial results.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should refer to the section titled &#8220;Risk Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report also contains or may contain estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.  </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except where the context otherwise requires, in this Quarterly Report, the &#8220;Company,&#8221; &#8220;Exicure,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refers to Exicure, Inc., a Delaware corporation, and, where appropriate, our wholly owned subsidiary, Exicure Operating Company. </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I - FINANCIAL INFORMATION</span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_16"></div><div style="margin-top:6pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Financial Statements.</span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_19"></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNC0xLTEtMS0w_46e8c094-92ef-4560-bb40-a9783e2e92e8"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNC0xLTEtMS0w_96552db5-aebc-49e7-8807-b8d68ba6c998">17,198</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNC0zLTEtMS0w_3664ed73-41de-419b-890a-adcacccd2a50"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNC0zLTEtMS0w_a6e352d8-8f75-437f-a252-b3480d6cb501">48,460</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNS0xLTEtMS0w_2979f1c4-5deb-4218-961a-7de98eb4e739">68,579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNS0zLTEtMS0w_80fd6e15-fa80-4335-b62f-b516178d1f5e">62,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNi0xLTEtMS0w_9cb13b90-c14c-47c7-a42d-c3eeb79eee42">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNi0zLTEtMS0w_e574a76a-0619-47b0-bcb4-4d3659d7ad98">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled revenue receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:UnbilledReceivablesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNy0xLTEtMS0w_9971daa5-2360-45cd-a752-1ff269fb72da">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:UnbilledReceivablesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNy0zLTEtMS0w_b26f6663-d63e-4dda-97f2-0c1a827efe98">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfOC0xLTEtMS0w_49265e8a-fe6a-4584-a245-f8164e219243">3,588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfOC0zLTEtMS0w_be8a29dc-af5c-4285-8f25-5fea869f220b">1,955</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfOS0xLTEtMS0w_46224a2d-a2bf-4066-941f-ca958a1dc84b">89,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfOS0zLTEtMS0w_cce2bd7a-01f2-4c35-9049-935f1eefba7b">112,776</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTAtMS0xLTEtMA_d5c478d8-7cae-4fc6-8964-cf3f8405ce32">4,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTAtMy0xLTEtMA_742cebd0-bb05-47e8-b617-2b06bc9483a0">2,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTEtMS0xLTEtMA_f915e929-94cd-4fdf-bcd8-d7060f01d239">2,266</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTEtMy0xLTEtMA_0b877b09-f0b4-4e21-98b3-a2697c5cab0f">388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTItMS0xLTEtMA_f43d53b2-f667-4cbe-93cf-a3d6bc171e8b">96,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTItMy0xLTEtMA_1bc1572a-97bc-4136-9825-298b3e1743c2">115,263</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of long-term debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTUtMS0xLTEtMA_a5d8fa25-037e-42fb-82df-b00d6dee9910">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTUtMy0xLTEtMA_19e1ce8a-fbee-4f34-bba7-53262d357d9e">4,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTYtMS0xLTEtMA_0c4bdce5-3532-4449-97d0-be924ae140fa">1,540</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTYtMy0xLTEtMA_88f8a02e-78c8-40d6-8811-ab842c85d39f">1,814</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTctMS0xLTEtMA_fb3df85a-1724-4a1e-af3d-829f0a0a99c1">1,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTctMy0xLTEtMA_8731db52-7a8e-4076-a9f7-2cddace627eb">2,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76587ca4c99d49da89121e59315b11c9_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTgtMS0xLTEtMA_7d8b1f06-8781-473b-8439-1008dacd2bf1">10,880</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTgtMy0xLTEtMA_bea8c408-cbbf-45eb-a242-13216b6eb16b">21,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTktMS0xLTEtMA_1b7dc8ad-fdf6-49e8-ba39-c81fb386c6c5">14,367</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTktMy0xLTEtMA_d21d0947-e016-4b55-a080-7f390545e847">31,087</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability, noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:zerodash" name="xcur:CommonStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjEtMS0xLTEtMA_663c0734-b9bb-437f-96d3-0764d76a3016">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="xcur:CommonStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjEtMy0xLTEtMA_7db31e18-7df2-421c-ad72-95626b5cf06c">414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue, noncurrent</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjItMS0xLTEtMA_e98462da-085e-4be8-9855-595b5698a642">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjItMy0xLTEtMA_7456f240-d13a-4377-9a7e-a638c584bea1">2,956</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjMtMS0xLTEtMA_62c1ad92-d5d6-4399-825b-8416eeba272f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjMtMy0xLTEtMA_e1460f36-3993-4fb8-9a3b-da90a396435c">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total liabilities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjQtMS0xLTEtMA_cf4f421d-ca5c-4a95-a296-3c6fb6e86b2c">14,367</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjQtMy0xLTEtMA_665f4f50-fa6d-4873-8e5d-8a7532263de7">34,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5NjY_070eac3d-b3fb-43bd-b2f4-c6848b30d09b"><ix:nonFraction unitRef="usdPerShare" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5NjY_d1ed639c-dc92-4728-8c5c-d670c5abb881">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5Nzk_7414bc40-7690-4868-93af-7d179868c213"><ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5Nzk_f1039ac1-9936-4952-88a2-b92009d459ba">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5OTE_6bb7b3ab-f580-4594-a4a0-7a4528e2b5d6"><ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5OTE_ec18f4f4-f23f-4907-9388-e4d9909f559f">87,206,346</ix:nonFraction></ix:nonFraction> issued and outstanding, June&#160;30, 2020; <ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2MjgwMDM_071ffed6-c284-4844-be36-300f1563df3f"><ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2MjgwMDM_8eb06ff0-af88-4de4-90a5-f2058fb08e98">86,069,263</ix:nonFraction></ix:nonFraction> issued and outstanding, December&#160;31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMS0xLTEtMA_cf596ff8-d371-49b1-abe3-ce7039b04e40">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMy0xLTEtMA_40c4007a-d2e1-43b4-aad5-2946cd6bd58d">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjgtMS0xLTEtMA_eab2c4ca-8be2-462d-ab2a-41e9901d2f9a">165,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjgtMy0xLTEtMA_bbcfa1ce-aba2-4be9-9e0d-b8884fcd0407">162,062</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjktMS0xLTEtMA_237f260a-6645-404e-9252-2bbe9887589d">338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjktMy0xLTEtMA_b005d07f-7002-4ebc-aa44-cc79f7c80e95">27</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzAtMS0xLTEtMA_d489427b-2022-4ff6-80a2-609e2ab770aa">84,458</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzAtMy0xLTEtMA_ec84e25f-7ec9-4bce-a1de-f13a71bd2bac">81,297</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total stockholders' equity</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzEtMS0xLTEtMA_6855912c-2d5b-4ef6-af47-7a1913c793fe">81,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzEtMy0xLTEtMA_5195bfe7-a133-4da7-8b1c-1c63c1d2b0e6">80,747</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:22.5pt;padding-left:13.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzItMS0xLTEtMA_0b0d5e8a-9e04-42e0-812b-db2c0c132be8">96,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzItMy0xLTEtMA_62b1c048-e16a-4d6c-8b05-45b1ae1ddcb3">115,263</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="text-indent:18pt;text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:63pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_25"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.512%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.301%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.461%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.663%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Collaboration revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMy0xLTEtMS0w_2af5822a-feab-41d7-9adf-9a4d3219e8ac">4,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMy0zLTEtMS0w_62972ec3-4ba1-4cf5-9c35-d7bfb1cecbb5">434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMy01LTEtMS0w_2c19b3fa-0c14-40c1-90d4-aef739c318d6">14,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMy03LTEtMS0w_bd54facd-7b2b-4aeb-a5fc-b9f5e1e8e91d">459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNC0xLTEtMS0w_7ca79d43-67e2-4e84-97dc-990926b879fb">4,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNC0zLTEtMS0w_708a16ec-4f66-48e5-9126-2688da32c108">434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNC01LTEtMS0w_895b3c3c-4203-4828-aeea-21c5b1698fec">14,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNC03LTEtMS0w_789fe8ed-8683-4dcb-9f93-6deb5d1e5718">459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Research and development expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNi0xLTEtMS0w_bc5e138e-e4f9-46f3-909e-9d078c3913a0">7,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNi0zLTEtMS0w_bfb6b2b0-75ae-499f-9851-1f8515e706b1">3,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNi01LTEtMS0w_d0a708c3-5934-454a-9856-7772afe47594">13,083</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNi03LTEtMS0w_135c7669-98cd-4343-ad1c-879a1117d688">6,828</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;General and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNy0xLTEtMS0w_1f6d9c72-5522-4911-bb07-289e5a5e1d9c">2,229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNy0zLTEtMS0w_5ee00b0c-421b-42ac-bc52-ffa0f8c96513">1,985</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNy01LTEtMS0w_7a2ecf3e-a17f-4d39-803a-b8fb2d7393b5">4,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNy03LTEtMS0w_21f39e7f-33b0-408f-8162-04a73ebff26b">4,193</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOC0xLTEtMS0w_569f6063-24c2-45a3-9cf0-8e6a9a5af9ca">9,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOC0zLTEtMS0w_723c3ee4-32c2-446d-ac1c-d6850acc5ad9">5,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOC01LTEtMS0w_9ef83915-2fa3-4243-aba4-8af40cbf0352">17,886</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOC03LTEtMS0w_cd685bb9-9991-4460-b26b-a8e6e071bdb3">11,021</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOS0xLTEtMS0w_df1d40e1-f89a-4536-9fc9-d1d6a680d616">4,390</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOS0zLTEtMS0w_e6da9b06-8614-49ed-8221-8d0f700c8879">4,984</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOS01LTEtMS0w_b760b7d0-b737-40ef-a040-669a591e2111">3,856</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOS03LTEtMS0w_256f8df0-148c-4823-a600-b06247c47baa">10,562</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTEtMS0xLTEtMA_1d4a6f0b-3c13-42e6-87e2-6c263d575a76">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTEtMy0xLTEtMA_b6de7ae2-a2f5-4884-978d-04a636b679f9">82</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTEtNS0xLTEtMzYy_1f1100e2-d5e6-4378-9ec0-df37247a3ab2">43</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTEtNy0xLTEtMzcw_7dc7cbf0-9529-4ce9-bedc-aa2b910b8cac">187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTItMS0xLTEtMA_8a5acfe0-1d32-455b-958f-df5fb348b918">267</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTItMy0xLTEtMA_2ce85c2e-0718-4ce5-889b-83584b930980">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTItNS0xLTEtMzYy_86094d02-0f39-439a-a5de-d4407897111a">627</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTItNy0xLTEtMzcw_efeab7bf-03e4-4496-b866-38843946c340">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTMtMS0xLTEtMA_839e4d37-3008-47b2-ad08-665d4265c882">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTMtMy0xLTEtMA_005c6eb9-8174-425b-ad39-d976103bf347">203</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTMtNS0xLTEtMA_5a2e785e-7728-4e63-abba-ab9685880b9b">128</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTMtNy0xLTEtMA_d9656941-27ef-486f-8413-6a8343456054">386</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTQtMS0xLTEtMA_6d7c1bd1-1224-4e89-8c73-62cc730f480c">192</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTQtMy0xLTEtMA_accd8c35-bb62-4688-9205-033547ddf4b5">116</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTQtNS0xLTEtMA_9c566e9f-ac86-46c3-80e1-efaf43b4bcaa">153</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTQtNy0xLTEtMA_9eaa5f55-c34f-44c7-a7d4-6ef5998294ba">253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTUtMS0xLTEtMA_f9d52dec-3666-486d-b55a-1d1bd256ac1f">79</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTUtMy0xLTEtMA_784e4905-3a16-430e-ae09-4c48457ed45b">236</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTUtNS0xLTEtMA_970b6433-ab7c-4353-a887-1c1dc408fe3c">695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTUtNy0xLTEtMA_61963c8c-8986-4159-b2e5-048fed819646">56</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtMS0xLTEtMA_45ab79a6-d84b-4fdd-a623-72f0987e6a52"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtMS0xLTEtMA_d032db37-b24b-4e75-bb5e-e10ae0dad0c3">4,311</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtMy0xLTEtMA_be754e46-6692-49b9-a504-ee954cede3ad">5,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtNS0xLTEtMA_aa77327a-8d61-4b80-8eb1-755f7855fdd0">3,161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtNy0xLTEtMA_a6b3785d-1d43-4588-bcbd-aeb9de41e11e">10,506</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted loss per common share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTgtMS0xLTEtMA_2280e16f-c71e-4951-9be0-43252cabeee6">0.05</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTgtMy0xLTEtMA_c587e538-b4c0-430c-9b3d-e59fc5acd6e9">0.12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTgtNS0xLTEtODY3_7c389b82-cf7f-4aa0-859f-52b7240005eb">0.04</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTgtNy0xLTEtODY3_c8be8e55-066a-4c25-8382-450ea2623a7a">0.24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMjEtMS0xLTEtMA_6d1b2e7e-a2c4-443e-9f1f-dc615a8f85f3">87,174,533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMjEtMy0xLTEtMA_a3697f8a-3640-4b3c-b852-9ba91ac8fbe7">44,368,174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMjEtNS0xLTEtODY3_6c85577f-d14b-4112-b6b9-19e0e078c006">87,126,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMjEtNy0xLTEtODY3_04e67d21-fb23-4d51-bda6-44fc4a09bf5b">44,363,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_28"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.038%;"><tr><td style="width:1.0%;"></td><td style="width:41.203%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.430%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.932%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.944%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.932%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.944%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.932%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.083%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi0xLTEtMS0w_45ab79a6-d84b-4fdd-a623-72f0987e6a52"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi0xLTEtMS0w_d032db37-b24b-4e75-bb5e-e10ae0dad0c3">4,311</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi0zLTEtMS0w_73314c47-cca8-4a87-bb4f-2688a099ca0c">5,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi01LTEtMS00NDM_ec5ef035-449f-424a-8859-af879ed4ddfc">3,161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi03LTEtMS00NDM_e1a7d887-dfab-473d-aa85-2c228c853b38">10,506</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of taxes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Unrealized gains on available for sale securities, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNC0xLTEtMS0w_7f3cbca0-508c-4c10-a9a3-ab5645ae19f5">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNC0zLTEtMS0w_03ae76ed-08fc-4c6d-a1ab-aa6304462561">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNC01LTEtMS00NDM_8557d5e5-16dc-4037-96ab-0abdf7e8fb45">365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNC03LTEtMS00NDM_669f60ee-7659-490a-a49b-74d0717aff9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNS0xLTEtMS0w_93bf2f5b-ac2a-4ec3-9f89-e969d5297b13">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNS0zLTEtMS0w_e0a0437f-2428-423c-9fca-da4c9b694295">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNS01LTEtMS00NDM_689a63d0-17e3-4555-b409-75efc082ff6f">365</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNS03LTEtMS00NDM_4e7b897c-4c71-492d-8e14-844f09081fd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNi0xLTEtMS0w_260b10f8-3e9b-41ac-9b38-ab10bf0ce083">3,956</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNi0zLTEtMS0w_d2d1a56a-e1d0-4063-a2c1-4890d09765f6">5,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNi01LTEtMS00NDM_5b09357d-019d-4267-ad05-96cc202b828b">2,796</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNi03LTEtMS00NDM_dd07070e-b394-4e65-97e2-d9caf53daa16">10,506</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:49.5pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_31"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-indent:18pt;text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except shares)</span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:37.467%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.680%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.976%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.648%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.069%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.384%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.610%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.654%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-in- Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i081c44d7528546cba2417fec5251bb86_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi0xLTEtMS0w_7ab98dd9-7800-41e7-a444-515949da45e5">86,069,263</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i081c44d7528546cba2417fec5251bb86_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi0zLTEtMS0w_bff85f59-c29e-45e1-96d3-2e071c41e6c9">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i669ca094820a403bb6fe6191fea9d033_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi01LTEtMS0w_6b2abbfd-eaa8-40b6-ada6-bfbac2b1d0d6">162,062</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i69d5a6f3c0f64d0b92f3d4c01084e89b_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi03LTEtMS0w_7c6fcd16-65a4-43eb-b2d5-8f1768169b9c">81,297</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4a2b6489ddf141a7bf39c57e8c6c374d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi05LTEtMS0w_01bfc673-f7e5-4014-8ef7-7d978cf31e49">27</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi0xMS0xLTEtMA_c98f29e0-1154-4731-a050-27e880df055d">80,747</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac2f608277bb4d11b8c650acaa7156a4_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNC01LTEtMS0w_7197a969-f726-49fa-af6b-0735a34377df">441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia600341070154f04b665acb7c655fde4_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNC0xMS0xLTEtMA_c748925b-dc44-4aae-b16a-8ad4c1ab5306">441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ae69caa952548968e3db1374a9441bf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNS0xLTEtMS0w_b44a11d2-df0a-40a5-a568-e99941d034d5">1,081,184</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iac2f608277bb4d11b8c650acaa7156a4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNS01LTEtMS0w_d618a5b1-3a26-4f34-9a99-fd2b09eeb06b">2,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia600341070154f04b665acb7c655fde4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNS0xMS0xLTEtMA_00a77981-a5f0-43a6-b931-bd1334886717">2,766</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffcf7f98338c48b2a74d5c64bcbb09cf_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNi05LTEtMS0w_3e988483-b844-41c8-8948-350379485d28">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia600341070154f04b665acb7c655fde4_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNi0xMS0xLTEtMA_7e0d1749-a8c5-4604-89f4-b5a7faffb5f2">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99f18a5fae5146fdac7af880c302d1f0_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNy03LTEtMS0w_dbb5c406-9c7f-4286-a8cd-023ab51259b6">1,150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia600341070154f04b665acb7c655fde4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNy0xMS0xLTEtMA_b0b447da-ab57-4165-ba90-8d6219869b4e">1,150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8ebe7513efbb4572897a2eff0bbe5839_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC0xLTEtMS0w_a1e59d0b-d2d9-430e-b5ae-049fb3a99400">87,150,447</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ebe7513efbb4572897a2eff0bbe5839_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC0zLTEtMS0w_5854a279-6c4d-4ee6-8000-b6a31514c1a8">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1abd752d57f494da5a5dcd7e17f6c8b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC01LTEtMS0w_8cbe6e7f-b41b-45b4-aa90-2cdc5967daaa">165,269</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if4929d22fbb34f5bb8e001e11fca287f_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC03LTEtMS0w_f4104d41-7687-4c4b-ae76-d49b9977862b">80,147</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i346241752b2b49a69f5d211b6a9d45fd_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC05LTEtMS0w_87eb8775-d74a-4cb4-b95a-d1a29369f6cc">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87bf2cd1655f4fab8c904201cabea717_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC0xMS0xLTEtMA_8ccd7e03-9539-40a4-8785-3d09fd1117c0">85,114</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id117ecfcad3043b9afe9dd6651b61ef9_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOS0xLTEtMS01MTk_fdabc364-967b-44a3-9d6e-c0fcc7ec36b5">55,899</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25b2e786a1684d32b3eb638cf322b195_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOS01LTEtMS01MTk_785271ac-b607-465e-8624-bd7ad5b7fa12">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOS0xMS0xLTEtNTE5_1ca19be5-9527-4b1e-b852-aad0c660ec46">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25b2e786a1684d32b3eb638cf322b195_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTAtNS0xLTEtNTE5_e24c52ea-335e-4e5a-861e-11461a0b7d6c">544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTAtMTEtMS0xLTUxOQ_d5420d28-8309-47a2-bbd9-d491a0740450">544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTEtOS0xLTEtNTE5_1c6d8ceb-dcd8-44c3-bf87-d1146722ad39">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTEtMTEtMS0xLTUxOQ_f35aa9bd-415a-4d2a-8ade-0fda0331b9e7">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i629055e5f5f9450696b0cdd1b8c62aaf_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTItNy0xLTEtNTE5_450eb2f2-7e92-4b6f-9bed-cda645818bf5">4,311</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTItMTEtMS0xLTUxOQ_3a7c00d5-4b60-4b0b-b797-b98a3525f720">4,311</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i057811d1d09040a098af94d1675312a5_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtMS0xLTEtNTE5_03b33ded-39c1-4036-a394-4ead1eef59a6">87,206,346</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i057811d1d09040a098af94d1675312a5_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtMy0xLTEtNTE5_181def90-9c1d-49da-9729-8075f2475cee">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3b2128138ac484d800e0f7ffac985fc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtNS0xLTEtNTE5_4be99a8a-5ffb-4732-b374-1c34f223f2dc">165,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia3377b36eefd4b7dbcd8a37028612f32_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtNy0xLTEtNTE5_cf526033-77e0-41ac-96e9-7794b4439c57">84,458</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0ac35850023477bb1b027d27cf6499d_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtOS0xLTEtNTE5_59490168-09ad-4ffa-86b5-3b02d2daa6f4">338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtMTEtMS0xLTUxOQ_d1be7ad3-446b-423e-b411-163d7ab030f1">81,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:18pt;text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:37.583%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.912%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.976%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.648%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.837%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.921%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.610%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.001%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-in- Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaf91bb3242b54554bf09467575ed8032_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi0xLTEtMS0w_f9859761-f31f-4a87-9c41-67d996ab5c80">44,358,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf91bb3242b54554bf09467575ed8032_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi0zLTEtMS0w_4a3ce8d5-e30f-4dbf-b23c-1ad102b0aebc">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i251a593531414918acbfa4bea82baa82_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi01LTEtMS0w_e5cf7f0d-0fe5-4adf-81ac-de626b2e7d54">75,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42b80e31064445acb2afbf5c674a8d22_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi03LTEtMS0w_dbfe1e72-2851-437e-bb7b-1915990932d6">54,994</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idda7464d50394c8da8f759b3fe9c27f6_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi05LTEtMS0w_ac187b20-3304-4574-a64d-31d2ed146230">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48514485d5c5481a815ea5cb4ec4f071_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi0xMS0xLTEtMA_13cd4755-699d-4c41-9ea5-72c34362bbad">20,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fce0dd8830b423089b11cd5506c2b50_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNC01LTEtMS0w_4188df16-8b37-44db-8320-a20c5703c1b4">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id85a381bc7624171a8e7ce667919dcf2_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNC0xMS0xLTEtMA_e55f8aca-e356-4ede-92c8-28d16640ec21">489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i16628e25dfeb457db79ff5741f4b4746_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNS03LTEtMS0w_ca4197cc-e421-4bf5-a5f9-5facb2d0b5de">5,286</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id85a381bc7624171a8e7ce667919dcf2_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNS0xMS0xLTEtMA_8601e407-f2f6-4603-83b0-6107b477cfaa">5,286</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifd3596a8daa44dafa2c2640d7eaf3704_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi0xLTEtMS0w_65c5ebf3-cb95-4853-99d6-05b0c19a7b2a">44,358,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd3596a8daa44dafa2c2640d7eaf3704_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi0zLTEtMS0w_92c1f7c7-0e87-44c9-9f64-22d141916916">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibae0a4d897b84e4d9577c9afadfbfeaa_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi01LTEtMS0w_dd54f969-31d9-46f2-bab6-f86b5300bb50">76,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51b397f6da68451f925c80fb3973ef2d_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi03LTEtMS0w_9989df7e-a307-4363-8be6-4ad413e38a07">60,280</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d7a7c38c82d4bb58ce35946a0c4b0db_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi05LTEtMS0w_d09dcc83-9977-46ff-ba8d-a5346ca67a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb258cc2165d4dcbaeb2ae16188d95fb_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi0xMS0xLTEtMA_1c4f54be-e85a-4440-b42f-cc46c09656df">16,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise of options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b302e66ac63416b82f00e6f82fdf6d7_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNy0xLTEtMS0w_b4e53978-92eb-4613-afd9-1730a387918b">11,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9b16abc11334de6979be196b3664e81_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNy01LTEtMS0w_a2889ca7-d761-44fb-a3c8-25af065aee8d">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNy0xMS0xLTEtMA_b5b9788d-efc4-4c3a-9e25-edbf3ae62eee">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9b16abc11334de6979be196b3664e81_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfOC01LTEtMS0w_af33d1e2-9f9b-48e7-97ac-80ba5d910850">439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfOC0xMS0xLTEtMA_02d09035-35bd-4c6e-b44a-ba9725256b9d">439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic80e034dbbc84fb499846b28fc08af31_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfOS03LTEtMS0w_a1b9b387-2020-4df6-a88e-58ad198bdca9">5,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfOS0xMS0xLTEtMA_1e9f4c59-3eea-4b61-9212-b657ffd66f6f">5,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i74d996f1250448ddb4ffa272adecd35a_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtMS0xLTEtMA_58f0af15-2b0c-4243-821c-1acc8a3bc6a5">44,369,790</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74d996f1250448ddb4ffa272adecd35a_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtMy0xLTEtMA_f7db07f1-6762-46df-ab9a-72940fb09865">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i235890d5628b4e7baba46b8ea6aa194f_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtNS0xLTEtMA_5306826e-ff8a-4284-b19f-27782096ba13">76,887</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i59a965bf3b8a48eb80d080bf600a28cd_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtNy0xLTEtMA_235f6767-343e-46d9-82e5-416ddbf85d63">65,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bb3dae634064c17b1ab1c0817e8c5ea_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtOS0xLTEtNTA0_55f027c5-da82-40a9-8480-822d0aa25352">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5e1c54705464203b36edb7644fc518c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtMTEtMS0xLTA_26bc8835-96bd-41cd-93d9-a3a7691fd335">11,391</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_34"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMy0xLTEtMS0w_609fcf28-de4a-4349-8e57-2e8cea21b606">3,161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMy0zLTEtMS0w_b63a74e5-f504-4217-839e-105094c7e069">10,506</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfNS0xLTEtMS0w_40ac0227-041c-4a71-9e94-7c489a096a57">335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfNS0zLTEtMS0w_af7153aa-4e5f-46c4-b511-ed6901f2ebac">174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfNy0xLTEtMS0w_863ddd4b-3b3b-44b4-8ae0-42ca5a6ca8e8">985</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfNy0zLTEtMS0w_52f213cc-568c-4aba-8127-542191b0be36">928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of long-term debt issuance costs and fees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfOC0xLTEtMS0w_b01e0911-a74d-4431-b450-ececb8411c7e">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfOC0zLTEtMS0w_56afab92-98d5-4ea8-a5c3-352b147f9312">86</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfOS0xLTEtMS0w_e79bf0f1-383e-4403-8a96-3f71a55628b1">356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfOS0zLTEtMS0w_5e183e08-262a-46f3-8fb4-e0c186459dba">36</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of warrant liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTAtMS0xLTEtMA_03a7f39b-1891-449c-8b78-f6b8077b0485">157</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTAtMy0xLTEtMA_e0838cb3-61bc-429d-b72a-b60b68f72b50">256</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unbilled revenue receivable and accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTItMS0xLTEtMA_1bceb500-ff17-4e65-9a6d-f04f52a9dab5">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTItMy0xLTEtMA_3abe804b-5237-41ea-a2b4-47cca5bbea1b">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTMtMS0xLTEtMA_23903540-dc53-4068-8578-5ba4b2596acb">1,551</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTMtMy0xLTEtMA_f657cbd2-a468-4eec-bc78-7c1f9ae2d52d">257</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTQtMS0xLTEtMA_d11fd230-99b1-43e3-b8c1-a269fd13f8a9">1,034</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTQtMy0xLTEtMA_4adfccc7-3b0d-4388-9a27-ce721c0801b9">112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTUtMS0xLTEtMA_b8ec4edb-3ad8-4fad-bc30-36aedc394e6a">22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTUtMy0xLTEtMA_025f3d71-fc14-485c-807d-485dade93f1f">403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTYtMS0xLTEtMA_cb755a03-2618-44a1-98df-2c9884b8649e">647</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTYtMy0xLTEtMA_bf2bee19-0db3-4733-ae46-2cc44e412f2a">66</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTctMS0xLTEtMA_edd9cd47-784a-4ccf-856d-d790f044fdd4">13,949</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTctMy0xLTEtMA_f34162a2-3ac3-4eac-bdee-ff8780e0a7f2">541</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other noncurrent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTgtMS0xLTEtMA_1aa3f693-b7b1-42dc-ac65-179113a98be5">59</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTgtMy0xLTEtMA_fb0e96c5-6752-4927-b2c8-9c4f20cb3702">194</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTktMS0xLTEtMA_60809586-bc30-4051-a254-de84d18874f3">18,814</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTktMy0xLTEtMA_6f792113-4d38-4dc7-8e88-31e57c8d2ba7">8,996</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of available for sale securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjEtMS0xLTEtMA_9fcc4a74-ee9a-43ac-8e1b-3abe9d846b4f">38,072</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjEtMy0xLTEtMA_b078ef7a-410f-4bd5-aed5-4ec30e280693">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale or maturity of available for sale securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjItMS0xLTEtMA_6573c58b-40e8-49a6-8bcd-862fce1707e0">32,103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjItMy0xLTEtMA_9de2251e-eb80-41df-9f76-5d91895030af">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjMtMS0xLTEtMA_4232bcf1-a869-40a3-ba25-adaecb8a21ed">2,996</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjMtMy0xLTEtMA_2b81a5b4-09f6-4885-9415-15ec1966235e">62</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjQtMS0xLTEtMA_9e645ca8-018f-40a4-a676-4e08f5c406e5">8,965</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjQtMy0xLTEtMA_2623c23e-84a3-48a7-9378-54eb337d5818">62</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from common stock offering</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjYtMS0xLTEtMA_6ad6c6fc-567f-460a-bd19-24c2ca9c5a84">2,973</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjYtMy0xLTEtMA_0c269de5-e2ea-4241-8b0b-4433d22e47f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of common stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjktMS0xLTEtMA_716405d6-8c31-4132-a6e2-c06bc7ef50b3">50</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjktMy0xLTEtMA_b1e76aa9-6861-476c-b791-7427d4b73204">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayment of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzAtMS0xLTEtMA_9de18113-9f3b-4a6e-a011-653fc352e690">4,999</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzAtMy0xLTEtMA_21f96a02-a069-465b-a323-7d5db576a60d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of long-term debt fees and issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzEtMS0xLTEtMA_d0ea34ba-75e3-4fc2-9ed9-f6aadfec28b5">100</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzEtMy0xLTEtMA_c4b10aed-8bb0-4358-8790-692cdd80d492">52</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of common stock financing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="xcur:PaymentsOfCommonStockFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzItMS0xLTEtMA_7038a3b1-b56b-4535-8d43-e596f345d0dc">207</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="xcur:PaymentsOfCommonStockFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzItMy0xLTEtMA_4201ed32-3703-4aef-b189-dc94c92fbe79">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzQtMS0xLTEtMA_1b659285-60f7-4f20-9a79-db053e77cb36">2,283</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzQtMy0xLTEtMA_0e36b3ee-e9f3-46cf-b011-41e12fb88e0f">35</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzYtMS0xLTEtMA_f708262e-fb96-49a0-88d4-f8b5301be9b2">30,062</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzYtMy0xLTEtMA_b2b92055-7685-4ff2-a2be-94ccaaeb2469">9,093</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash - beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzctMS0xLTEtMA_3664ed73-41de-419b-890a-adcacccd2a50"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzctMS0xLTEtMA_a6e352d8-8f75-437f-a252-b3480d6cb501">48,460</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48514485d5c5481a815ea5cb4ec4f071_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzctMy0xLTEtMA_bf036a49-f238-43fb-ac9a-49fe1519533e">26,268</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash - end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzgtMS0xLTEtMA_093afe04-fd49-4423-ba83-fb97b1f6f5c2">18,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia5e1c54705464203b36edb7644fc518c_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzgtMy0xLTEtMA_3358460d-0196-42b1-a05a-c4a909857474">17,175</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Debt fees (accrued expenses)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjAzZmQwNDMxZjAxMDQ5YjFhMGJhMzdkZmQwMWQ4YmU2L3RhYmxlcmFuZ2U6MDNmZDA0MzFmMDEwNDliMWEwYmEzN2RmZDAxZDhiZTZfNS0xLTEtMS0w_04851276-d45c-4607-ab96-c0f7ffadd338">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjAzZmQwNDMxZjAxMDQ5YjFhMGJhMzdkZmQwMWQ4YmU2L3RhYmxlcmFuZ2U6MDNmZDA0MzFmMDEwNDliMWEwYmEzN2RmZDAxZDhiZTZfNS0zLTEtMS0w_b8d2b05d-8bc7-41ce-af2b-473f804b35c5">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures (accounts payable and accrued expenses)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjAzZmQwNDMxZjAxMDQ5YjFhMGJhMzdkZmQwMWQ4YmU2L3RhYmxlcmFuZ2U6MDNmZDA0MzFmMDEwNDliMWEwYmEzN2RmZDAxZDhiZTZfOS0xLTEtMS0w_616370e9-eac5-442b-8da0-7711862ae16e">60</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjAzZmQwNDMxZjAxMDQ5YjFhMGJhMzdkZmQwMWQ4YmU2L3RhYmxlcmFuZ2U6MDNmZDA0MzFmMDEwNDliMWEwYmEzN2RmZDAxZDhiZTZfOS0zLTEtMS0w_e2e8cfcc-efa5-465f-89f8-472e907280dc">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the amounts shown in the unaudited condensed consolidated statements of cash flows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:69.314%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.943%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMS0xLTEtMS0w_46e8c094-92ef-4560-bb40-a9783e2e92e8"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMS0xLTEtMS0w_96552db5-aebc-49e7-8807-b8d68ba6c998">17,198</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMS0zLTEtMS0w_3664ed73-41de-419b-890a-adcacccd2a50"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMS0zLTEtMS0w_a6e352d8-8f75-437f-a252-b3480d6cb501">48,460</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash included in other noncurrent assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMi0xLTEtMS0w_d0f5a79e-34e2-461c-b1cc-669d3c0bec00">1,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMi0zLTEtMS0w_111dd177-de71-4044-ba4b-a919ef7c3d2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMy0xLTEtMS0w_05f7be8d-7b5e-48d6-8c98-6a027a4ed480">18,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMy0zLTEtMS0w_94e75d95-8240-4d35-b093-da972413ed5a">48,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_37"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_40"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfOTI1MA_65581e6d-e458-46c5-af60-32b1893965e0" continuedAt="ie32f41a1e6b34615ae1f5bbd171337ef" escape="true">Description of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ie32f41a1e6b34615ae1f5bbd171337ef" continuedAt="iaae1f811138e40b6915e86304f0d12bb"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Exicure, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, genetic disorders and other indications based on our proprietary Spherical Nucleic Acid (&#8220;SNA&#8221;) technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. The Company believes that the design of its SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company is working to advance its SNA therapeutic candidates through multiple clinical trials, including the ongoing Phase 1b/2 clinical trial of cavrotolimod (AST-008) in cancer patients. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that one of the key strengths of its proprietary SNAs is that they have the potential to enter a number of different cells and organs. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immunoncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. As a consequence, the Company has expanded its pipeline into neurology, and has conducted early stage research activities in ophthalmology, pulmonology, and gastroenterology. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Throughout these unaudited condensed consolidated financial statements, the terms the &#8220;Company&#8221; and &#8220;Exicure&#8221; refer to Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfOTI0NQ_35fcd2dd-1d08-4d3c-b1e5-384b650da9ba" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements as of June 30, 2020 and December 31, 2019, and for the three and six months ended June 30, 2020 and 2019, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfOTI0OA_dc0697c9-1e96-4975-9c57-9bcb8e4a52a0" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div></ix:nonNumeric><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Risks and Uncertainties</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#8217;s routine communication to address employee and business concerns and providing frequent updates to the Company&#8217;s board of directors (the &#8220;Board&#8221;).  As of July 1, 2020, the Company took occupancy of approximately <ix:nonFraction unitRef="sqft" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfMjc0ODc3OTA4MDI0MQ_fc19802c-dc5a-4782-8036-f9b1eda4dfba">30,000</ix:nonFraction> square feet of laboratory and office space in its new headquarters in Chicago, Illinois.  Since then, the Company has operated under COVID-19 social distancing guidelines and has generally operated with 100% of its R&amp;D staff on-site.  The Company&#8217;s office and general and administrative team continues to work predominantly from home. The Company&#8217;s preclinical development program in Friedreich&#8217;s ataxia (&#8220;FA&#8221;) is ongoing and it continues to expect that IND-enabling studies for the Company&#8217;s FA therapeutic candidate, XCUR-FXN, will begin in late 2020.  The Company also continues to progress its collaborations with Allergan Pharmaceuticals International Limited (&#8220;Allergan&#8221;) and DERMELIX, LLC, d/b/a Dermelix Biotherapeutics (&#8220;Dermelix&#8221;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience significant disruptions to its preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.</span></div></ix:continuation><div style="text-indent:18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="iaae1f811138e40b6915e86304f0d12bb" continuedAt="ic8d05b35c12c4731ab6638ddc5d1e024"><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company anticipates that the COVID-19 pandemic may have an impact on the clinical development timelines for its cavrotolimod (AST-008) clinical program. The extent to which the COVID-19 pandemic will impact the Company&#8217;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the pandemic, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity Risk</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, the Company has generated an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfNTc5OA_95d336a7-81e0-4536-b8d8-80ed09802b9e">103,295</ix:nonFraction> since inception and expects to incur significant expenses and negative cash flows for the foreseeable future.  Based on the Company&#8217;s current operating plans, it believes that existing working capital at June 30, 2020 is sufficient to fund the Company for at least the next 12 months. Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  The Company has historically principally raised capital through the sale of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  The Company believes raising capital in the current market could be very difficult for early stage biotech companies like Exicure.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could in the future negatively affect its operations.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Financial Information</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim condensed consolidated balance sheet as of June 30, 2020, the interim condensed consolidated statements of operations for the three and six months ended June 30, 2020 and 2019, the interim condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2020 and 2019, the interim condensed consolidated statements of changes in stockholders&#8217; equity for the three and six months ended June 30, 2020 and 2019, and the interim condensed consolidated statements of cash flows for the six months ended June, 2020 and 2019, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of June 30, 2020, the results of its operations for the three and six months ended June 30, 2020 and 2019, and the results of its cash flows for the six months ended June 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2019 are unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative </span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="ic8d05b35c12c4731ab6638ddc5d1e024"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of results to be expected for the year ending December 31, 2020, or any other interim periods, or any future year or period.</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfOTI1Mw_c8ec7dfb-50c5-4690-a535-97338f4f4172" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div id="i87c412b98f4a4c10b3a3081e33f1cbca_43"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80My9mcmFnOjkwMDNkMzdhODNjMzRlMjRiYjJkZmY2NzNiNDk3YWY0L3RleHRyZWdpb246OTAwM2QzN2E4M2MzNGUyNGJiMmRmZjY3M2I0OTdhZjRfMTk4Ng_30cc9d43-974a-48c0-b923-97edd041c8ec" continuedAt="i7828455dcda6431ebdb3214b9dcf5365" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i7828455dcda6431ebdb3214b9dcf5365"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80My9mcmFnOjkwMDNkMzdhODNjMzRlMjRiYjJkZmY2NzNiNDk3YWY0L3RleHRyZWdpb246OTAwM2QzN2E4M2MzNGUyNGJiMmRmZjY3M2I0OTdhZjRfMjc0ODc3OTA3MTQzMQ_3e785ee6-a025-46ee-ae0c-b0ca02b33b63" escape="true"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 10, 2020. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_46"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMzI5ODUzNDkwNDkxMA_b8cd01b4-294d-43cd-9475-59bee4110b3f" continuedAt="i4b99e179ce654e398d22fa790c305644" escape="true">Collaborative Research and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i4b99e179ce654e398d22fa790c305644" continuedAt="iffaa50e6b3ec42d3a8512e501e0e6a17"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Allergan Collaboration Agreement</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Agreement&#160;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 13, 2019 (the &#8220;Effective Date&#8221;), the Company entered into a Collaboration, Option and License Agreement (the &#8220;Allergan Collaboration Agreement&#8221;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan, was acquired by AbbVie Inc. (&#8220;AbbVie&#8221;). Accordingly, all references to &#8220;Allergan&#8221; in the defined terms including, but not limited to, &#8220;Allergan,&#8221; &#8220;Allergan Collaboration Agreement,&#8221; &#8220;Allergan R&amp;D Services&#8221; and &#8220;Allergan JDC Services,&#8221; should be read and construed as references to AbbVie. Pursuant to the Allergan Collaboration Agreement, the Company granted to Allergan exclusive access and options to license SNA based therapeutics arising from <ix:nonFraction unitRef="agreements" contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfODcz_5c16b8a5-4e86-4ebf-8260-7ca104023c15">two</ix:nonFraction> collaboration programs related to the treatment of hair loss disorders (each, a &#8220;Collaboration Program&#8221;). Under each such license (obtained in connection with the exercise of an Option, as defined and discussed further below), the Company would grant to Allergan exclusive, royalty-bearing, sublicenseable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the Allergan Collaboration Agreement, the Company will use commercially reasonable efforts to conduct <ix:nonFraction unitRef="agreements" contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTM5NQ_76464c49-2d30-4ca7-9101-e54842a15d5b">two</ix:nonFraction> Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific Collaboration Program targets (each, a &#8220;Program Target&#8221;).</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of the Effective Date, the Company and Allergan have agreed upon a development plan for each Collaboration Program that describes the development activities and timelines required to advance such Collaboration Program through first IND filing (each, a &#8220;Development Plan&#8221;).  The activities described in the Development Plan are conducted under the supervision of the Joint Development Committee (the &#8220;JDC&#8221;) consisting of three members from each of the Company and Allergan. The Company is primarily responsible for performing early stage discovery and preclinical activities (the &#8220;Initial Development Activities&#8221;) set forth in the Development Plan for each Collaboration Program and will be solely responsible for all costs and expenses related to the Initial Development Activities. Allergan may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> testing as set forth in a Development Plan.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the completion of all Initial Development Activities, the Company is required to deliver to Allergan a report that describes the results of the Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Collaboration Program as determined by the JDC (the &#8220;Initial Development Report&#8221;).  Following the delivery of the Initial Development Report for a Collaboration Program, Allergan will have the ability for a defined period of time (the &#8220;Initial Option Exercise Period&#8221;) to exercise an option (each an &#8220;Option&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each a &#8220;Licensed Product&#8221;) that results from such Collaboration Program during the term of the Allergan Collaboration Agreement.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At Allergan&#8217;s sole option, Allergan may extend the Initial Option Exercise Period (the &#8220;Option Extension&#8221;) and require the Company to perform IND-enabling activities described in the Development Plan (the &#8220;IND-Enabling Activities&#8221;), subject to the payment of additional consideration (&#8220;Extension Exercise&#8221;). If Allergan exercises the Option Extension, the Company would be responsible for conducting the IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the IND-Enabling Activities, the Company is required to deliver a report that describes the results of the IND-Enabling Activities (the &#8220;IND-Enabling Activities Data Package&#8221;) to Allergan. Following the delivery of IND-Enabling Activities Data Package, Allergan will have the ability for a defined period of time (the &#8220;Extended Option Exercise Period&#8221;) to exercise an Option with respect to such Collaboration Program. After the exercise of an Option with respect to a Collaboration Program, Allergan will be responsible for all development, manufacturing, and commercialization activities, and costs and expense associated with such activities in connection with Licensed Products arising from such Collaboration Program.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="iffaa50e6b3ec42d3a8512e501e0e6a17" continuedAt="i5e2ef85977bc4858b42a5390ab6abfeb"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s obligation to conduct the activities defined in the Development Plan under the Allergan Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date Allergan exercises an Option, (ii) the date Allergan abandons a Collaboration Program and foregoes its Option to that Collaboration Program, or (iii) the fifth anniversary of the Effective Date (the &#8220;Research Term&#8221;). If the Initial Option Exercise Period or Extended Option Exercise Period is still in effect for a Collaboration Program or if the Company has not delivered a complete Initial Development Report or, if Allergan made an Extension Exercise for a Collaboration Program, a complete IND-Enabling Activities Data Package for such Collaboration Program, as determined by the JDC, then the Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the Effective Date.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Allergan Collaboration Agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNTgwNg_c3f39d8e-9945-442f-aa28-65607957e414">25,000</ix:nonFraction> upfront, non-refundable, non-creditable cash payment (the &#8220;Allergan Upfront Payment&#8221;) related to the Company&#8217;s research and development costs for conducting the Development Plan for two Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such Collaboration Programs.  The option exercise fee during the Initial Option Exercise Period is $<ix:nonFraction unitRef="usd" contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNjM3Mg_12022e20-34d2-415a-a3d6-855abe029ecb">10,000</ix:nonFraction> per Collaboration Program.  If Allergan elects to extend the Initial Option Exercise Period, Allergan is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNjUxNw_5d4fccee-96ea-4da5-81ad-2231ed5bdb35">10,000</ix:nonFraction>.  If Allergan elects to exercise its option during the Extended Option Exercise Period, Allergan must pay the Company the option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i213132da6481483c807931ec91868df7_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNjY2NQ_c4a9045c-d750-4b60-8bd5-1b8bee734d60">15,000</ix:nonFraction>.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the exercise by Allergan of an Option with respect to a Collaboration Program, Allergan would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on a Licensed Product by Licensed Product basis. On a Licensed Product by Licensed Product basis, for the first Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iec1efc8f38914d529f3fa0003f78cbce_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE2Mw_a9053275-f56c-4a3b-8bc2-b8e16bd8e791">55,000</ix:nonFraction> for development milestone payments and $<ix:nonFraction unitRef="usd" contextRef="iec1efc8f38914d529f3fa0003f78cbce_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzIwNQ_898fac8f-b810-401e-a6f3-ba1b26ee5e73">132,500</ix:nonFraction> for product approval and launch milestone payments. The Company is also eligible for up to $<ix:nonFraction unitRef="usd" contextRef="iec1efc8f38914d529f3fa0003f78cbce_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzI5OQ_87200d14-8fbf-4a22-a8dd-f1c538cacd9b">175,000</ix:nonFraction> in sales milestone payments on a Collaboration Program by Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by Allergan to obtain certain third party intellectual property rights.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, to the extent there is any Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a Licensed Product by Licensed Product and country by country basis from the date of the first commercial sale of each Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such Licensed Product in such country, (ii) the tenth anniversary of the first commercial sale of such Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such Licensed Product in such country.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allergan may terminate the Allergan Collaboration Agreement for any reason or no reason, either in its entirety or on a Collaboration Program by Collaboration Program basis, at any time on <ix:nonNumeric contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113" format="ixt-sec:durday" name="xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfODcyMw_fef84101-906d-49a9-b810-8d4bc0870391">90</ix:nonNumeric> days&#8217; prior written notice to the Company. Unless earlier terminated, the term of the Allergan Collaboration Agreement shall continue until (i) if both Option Exercise Periods expire without Allergan exercising either Option, the expiration of the later to expire Option Exercise Period, and (ii) if either or both Options are exercised on a Licensed Product-by-Licensed Product and country-by-country basis, the expiration of the royalty term for such Licensed Product in such country. Either party may terminate the Allergan Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Termination of the Allergan Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the Allergan Collaboration Agreement will not preclude </span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="i5e2ef85977bc4858b42a5390ab6abfeb" continuedAt="i3de40a294abe41c18b000cd78225810d"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the Allergan Collaboration Agreement. If either party terminates the Allergan Collaboration Agreement, the license and rights granted to Allergan with respect to the terminated Collaboration Program or License Product shall terminate. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting Analysis</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that Allergan is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the Allergan Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the Research Term (the &#8220;Allergan R&amp;D Services&#8221;), and (ii) Joint Development Committee services during the Research Term (the &#8220;Allergan JDC Services&#8221;). The Company has concluded that the Allergan R&amp;D Services is not distinct from the Allergan JDC Services during the Research Term. The JDC provides oversight and management of the overall Allergan Collaboration Agreement, and the members of the JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The JDC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and Allergan. Further, the JDC services are critical to the ongoing evaluation of a Collaboration Program and the drafting and evaluation of the Initial Development Report and the IND-Enabling Data Package. Accordingly, the Company&#8217;s participation on the JDC is essential to Allergan receiving value from the Allergan R&amp;D Services and as such, the Allergan JDC Services along with the Allergan R&amp;D Services are considered one performance obligation (the &#8220;Collaboration Program Services&#8221;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of the Effective Date of the Allergan Collaboration Agreement, the total transaction price was determined to be $<ix:nonFraction unitRef="usd" contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTIxNjg_68064773-bda3-4d0f-b851-4e7dbde5eb7e">25,000</ix:nonFraction>, consisting solely of the Allergan Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Effective Date of the Allergan Collaboration Agreement, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Allergan.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of June 30, 2020, the Company determined that any development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at June 30, 2020.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will recognize revenue related to the Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June 30, 2020, the Company recognized revenue under the Allergan Collaboration Agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="ie0168a43217c4457bc65313c2af4fb05_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjIzOQ_2565fca0-8953-4344-b8da-96e6112db735">4,833</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i56e80b2cc5be4ab4acf0eef51f34220c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjI0Mw_9055396a-6848-46b7-be62-155158682f15">13,949</ix:nonFraction>, respectively.  As of June 30, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i76587ca4c99d49da89121e59315b11c9_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTM5Njk_7d8b1f06-8781-473b-8439-1008dacd2bf1">10,880</ix:nonFraction> of deferred revenue related to the Allergan Collaboration Agreement, which is classified as current on the unaudited condensed consolidated balance sheet.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="i3de40a294abe41c18b000cd78225810d" continuedAt="i418f5c3790324d1ea0ced75e9b3f90b9"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Dermelix Collaboration Agreement</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Agreement&#160;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 17, 2019, Exicure entered into a License and Development Agreement with Dermelix (the &#8220;Dermelix Collaboration Agreement.&#8221;)  Pursuant to the Dermelix Collaboration Agreement, the Company granted to Dermelix exclusive, worldwide royalty-bearing license rights to, develop, manufacture, have manufactured, use and commercialize the Company&#8217;s SNA technology for the treatment of Netherton Syndrome (&#8220;NS&#8221;) and, at Dermelix&#8217;s option, up to <ix:nonFraction unitRef="target" contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217" decimals="INF" format="ixt-sec:numwordsen" name="xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTQ2Mjg_a07f43c9-ac87-491e-9329-76a2aed6fcff">five</ix:nonFraction> additional specified orphan diseases that are within the dermatology field. Upon written notice to the Company, Dermelix may exercise its option at any time following the effective date of the Dermelix Collaboration Agreement until the date that is <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTQ4ODA_7c7ddbd2-6787-47de-91af-9e663bcf7a25">six</span> (6) years from the date that the first collaboration SNA therapeutic achieves first dosing in humans in a Phase 1 clinical trial for NS.  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dermelix will initially seek to develop a targeted therapy for the treatment of NS.  Under the terms of the Dermelix Collaboration Agreement, the Company will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will assume subsequent development, commercial activities and financial responsibility for such indications.  Dermelix will pay the costs and expenses of development and commercialization of any licensed products under the Dermelix Collaboration Agreement, including the Company&#8217;s expenses incurred in connection with development activities and in accordance with the development budget.  Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTU3OTM_df1350c6-4e06-4b11-9045-96da7f66d215">1,000</ix:nonFraction>, to be applied against the initial $<ix:nonFraction unitRef="usd" contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTU4MzE_ad3c8a83-59b1-4931-bd71-a2119778d7a9">1,000</ix:nonFraction> of the Company&#8217;s development expenses.  If Dermelix exercises any of its option rights for additional indications, Dermelix will pay an option exercise fee equal to $<ix:nonFraction unitRef="usd" contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTU5OTk_7fbe78d7-94e0-4e66-9a1f-711b124519b9">1,000</ix:nonFraction> for each exercised option (each, an &#8220;Option Exercise Fee&#8221;).  Any Option Exercise Fee will be applied against the Company&#8217;s development expenses with respect to the particular indication for which the option was exercised.  </span></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Dermelix Collaboration Agreement, the Company shall have the right to pursue the development and commercialization of SNA technology for the treatment of orphan diseases which are neither NS nor one of the additional specified orphan diseases selected by Dermelix pursuant to its option rights.  If the Company commences development activities of SNA technology for the treatment of such an orphan disease, the Company will notify Dermelix in writing of such development and Dermelix will have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTY3MzY_cca5baed-3744-4471-869d-43a351036895">thirty</span> (30) days following receipt of such notice to use one of its remaining option rights on such orphan disease.  If Dermelix does not use one of its remaining option rights on such orphan disease, or has no option rights remaining, then the Company will have no further obligations to Dermelix with respect to the development of SNA therapeutics for such orphan disease and shall be free to continue commercialization and development activities with respect thereto.  </span></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, the Company shall be eligible to receive additional cash payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i3af79e6a06594c0cb23b1951b9373a0c_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTczOTM_c6506980-17b7-4f08-b000-7f733e5175ca">13,500</ix:nonFraction> upon achievement of certain development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i3af79e6a06594c0cb23b1951b9373a0c_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTc0NzI_634cfd1a-c28a-4d2e-a0ba-c41447307fed">152,500</ix:nonFraction> upon achievement of certain sales milestones.  The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program.  The commercial sales milestones are payable upon achievement of specified aggregate annual product sales thresholds.  In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company will receive low double-digit royalties on annual net sales for such licensed products.  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting Analysis</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that Dermelix is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance.  The Company identified performance obligations under the Dermelix Collaboration Agreement for the license of intellectual property for the NS therapeutic candidate and associated research and development services for the NS therapeutic candidate.  The Company determined that the performance obligations were not separately identifiable and were not distinct or distinct within the context of the contract due to the specialized nature of the services to be provided by Exicure, specifically with respect to the </span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="i418f5c3790324d1ea0ced75e9b3f90b9"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company&#8217;s expertise related to SNA technology, and the interdependent relationship between the performance obligations.  As such, the Company concluded that there is a single identified performance obligation.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential development and regulatory milestone, which is considered variable consideration, was zero, as the achievement of those milestones is uncertain and highly susceptible to factors outside of the Company&#8217;s control.  Accordingly, all such milestones were excluded from the transaction price.  Management will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur and adjust the transaction price as necessary.  Sales-based royalties, including commercial sales milestone payments based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate.  The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue associated with the performance obligation will be recognized as services are provided using a cost-to-cost measure of progress method.  The transfer of control occurs over time and, in management&#8217;s judgment, this input method is the best measure of progress towards satisfying the performance obligation under the Dermelix Collaboration Agreement and reflects a faithful depiction of the transfer of goods and services.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company initially recorded the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMjA1MDY_0b22f599-de2c-4fdf-b341-b18fd379fb83">1,000</ix:nonFraction> as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to zero during 2019 by recognizing revenue as services were provided.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="iee37ebd534aa4705869ea2175ce06b24_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjMyMQ_b22dcd99-da7d-4fba-b1f4-21b73531075c">14</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4755b498baa24be79491012d4f532c62_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjM2MA_a3f23fce-60da-45a1-85b3-b10104f8fcf4">81</ix:nonFraction> of revenue under the Dermelix Collaboration Agreement during the three and six months ended June 30, 2020, respectively, which reflects reimbursement by Dermelix for additional costs incurred by Exicure for early stage development costs beyond the initial $<ix:nonFraction unitRef="usd" contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217" decimals="-3" format="ixt:numdotdecimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMjA5NDM_27ce9db1-9fea-4f01-b2d2-d3915e832ed9">1,000</ix:nonFraction> upfront payment.  The Company expects to incur additional early stage development costs and expects to be reimbursed by Dermelix for such costs under the terms of the Dermelix Collaboration Agreement.  The Company will recognize both revenue and research and development expense for such costs on a gross basis during the period in which those costs are incurred.   The Company recognized&#160;$<ix:nonFraction unitRef="usd" contextRef="ib68fbc221ed948318252eb995a6db2b6_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjM5Nw_14bc6588-026c-468b-a824-cf1c6bcdcdaa">434</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="usd" contextRef="i7a49e1430c4d4a889f71e3a5a377bb5a_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjQyMw_63093a6a-a8b1-4e62-8fa6-780e39557012">459</ix:nonFraction> of revenue under the Dermelix Collaboration Agreement during the three and six months ended June 30, 2019, respectively,&#160;which related to amortization of the above-mentioned deferred revenue related to the upfront payment for services provided during that period.</span></div></ix:continuation><div id="i87c412b98f4a4c10b3a3081e33f1cbca_49"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzQ3_ff2dd737-c12b-4529-a4c3-c77022f57970" continuedAt="idc476c43c1794b4195f3f955f9fe0f9f" escape="true">Supplemental Balance Sheet Information</ix:nonNumeric></span></div><ix:continuation id="idc476c43c1794b4195f3f955f9fe0f9f" continuedAt="i4dd431a86fa2432dac93de6cf17f2c49"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzQ4_c5c5147c-2e06-4582-b9c2-7c66398588e6" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid expenses and other current assets</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.903%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.905%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical, contract research and manufacturing costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMS0xLTEtMS0w_d96e510d-182f-4552-a8b2-4885dd82e077">2,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMS0zLTEtMS0w_4ab1c6bd-c393-469c-8f7a-c3d0d4f59d4e">481</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMi0xLTEtMS0w_a57089cd-27f2-47d7-abdf-8d7f6c489905">221</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMi0zLTEtMS0w_0f076d7e-3860-45d5-a662-6f0904233a5d">236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMy0xLTEtMS0w_1c991e57-a8b1-4a81-bd6f-f16503e0e93e">212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMy0zLTEtMS0w_1096b638-020d-478d-816f-e0af93783990">533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfNC0xLTEtMS0w_315d786b-f837-4c62-9596-b00bcd4ff440">952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfNC0zLTEtMS0w_605a8d3f-98ee-49b3-a71e-88f5afdf9b42">705</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfNS0xLTEtMS0w_0e74822f-9176-4d89-a5d6-df78d24f8066">3,588</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfNS0zLTEtMS0w_f0c849d2-5625-4d96-8840-b564ffa5521b">1,955</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="i4dd431a86fa2432dac93de6cf17f2c49"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzU3_b2336af2-aa5a-4508-bfd5-63cbdda2fd68" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and equipment, net</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.903%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.905%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scientific equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8a0a13c38254ea983e0bb5a38ca17de_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMS0xLTEtMS0w_fce67e07-8046-4be1-b6c9-206f8f3282a0">3,315</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bfb10b6658e4029a82a1c4c79504c5a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMS0zLTEtMS0w_93520e9f-fb1a-4340-ab53-344d07330de5">2,795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i352899e868b047baae4f3cc5f48173b4_I20200630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMi0xLTEtMS0w_ea396df4-2fc2-4750-8049-7a6116d96c0c">192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e5bb134266b43198e6a9ac71d907554_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMi0zLTEtMS0w_dda22972-76d4-42bf-aa26-6869b2a2f8fe">192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers and software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i18277ad2812a4ef9966ee81eceda653f_I20200630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMy0xLTEtMS0w_d3c28815-8eb0-46f3-85f5-27924607fe26">48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad32dfdbf9ce43d4a96d7847ec6e4876_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMy0zLTEtMS0w_f8f24d2a-bcc0-4990-bab4-f4a9b3de4d62">32</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf30ba5997b64586b6fd2b6487a3b25e_I20200630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNC0xLTEtMS0w_d278b349-17d6-41f3-8c51-235ddce3a4b5">41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id3e2b30098dd4ce39f205fbcaecabc6e_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNC0zLTEtMS0w_e06753d3-c3c5-4f0a-a60b-a5eba3c221c2">41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83ab7faaf6324bbe806b1945f6ef544f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNS0xLTEtMS0w_20ab3535-dbe8-4559-87ce-f10da52c249b">2,512</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd78f631ebaa4338ba6f8984c802d444_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNS0zLTEtMS0w_d9a1b90a-dced-4fed-9c7f-9fd5376af8c7">356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, gross</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNi0xLTEtMS0w_c569bd56-bd63-4166-bc67-ec3c3d3168e8">6,108</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNi0zLTEtMS0w_8539a432-e871-4de8-ad93-b0828798ae84">3,416</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNy0xLTEtMS0w_a54dc94c-d356-4476-a8d5-76ae6f51642b">1,644</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNy0zLTEtMS0w_830b0326-25e1-43d0-9255-28b7345962d3">1,317</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfOC0xLTEtMS0w_275519c2-acc8-4545-97e8-85408d345142">4,464</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfOC0zLTEtMS0w_145f5af0-ad7e-462f-ae9b-f575691bbfd5">2,099</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMTYz_acfd90a9-a901-429c-934f-f5b67c5939e7">187</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMTcw_e78d4293-a380-4e16-9e1d-7f82f1e529c7">87</ix:nonFraction> for the three months ended June 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfNzE0NjgyNTU4MTAzOQ_f3775c4f-b546-465f-98c8-f5338166e6f6">335</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfNzE0NjgyNTU4MTAxMw_f0823d05-33da-4c88-864c-4ffe3797d0a6">174</ix:nonFraction> for the six months ended June 30, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzUx_1fcf6424-5488-44f2-83ab-7220c2d7aeda" escape="true"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other noncurrent assets</span></div><div style="margin-top:5pt;margin-bottom:9pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.903%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.905%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMS0xLTEtMS0w_ee52a920-dba7-4a64-8f61-a8fb9f29f0dd">1,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMS0zLTEtMS0w_05cd5348-15af-4bc3-8afc-4dabb0a5eff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid lease costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="xcur:PrepaidLeaseCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMi0xLTEtMS0yODI1_ddd08885-3e2a-48ba-8d64-42148d98384b">823</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:zerodash" name="xcur:PrepaidLeaseCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMi0zLTEtMS0yODMw_5636da3c-6789-438f-8523-7e25328a9e2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMy0xLTEtMS0zNjQ4_8b015b76-9430-4cc5-8945-c6222ffb66b8">233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMy0zLTEtMS0zNjUz_c082f651-4321-43f3-a435-a8a9c6fb12f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMi0xLTEtMS0w_ec3ecbcf-5261-4162-9b8c-e4d724f9b5bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMi0zLTEtMS0w_746d1388-b21d-4f3c-97bb-69cf0369c63b">356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMy0xLTEtMS0w_25c48102-33df-4882-a6f2-ecfd4fc0d505">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMy0zLTEtMS0w_9cc8b0c8-80ef-495b-b3cb-7d847a079e80">32</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total other noncurrent assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfNC0xLTEtMS0w_0fbbeeca-5726-4d20-aadd-4417ff873fa5">2,266</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfNC0zLTEtMS0w_e5cfe8c4-0723-418c-ada2-19f1d4c354c2">388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzUy_df733520-c163-4580-a70e-48b895c2f437" escape="true"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued expenses and other current liabilities</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.903%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.905%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll-related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMS0xLTEtMS0w_527d9da8-919d-4c77-aaa3-881343f05f20">706</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMS0zLTEtMS0w_20e57a44-aade-421f-843d-14bfd646529e">920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMi0xLTEtMS0w_0f999d5f-d204-454d-9679-f422883ac9b0">362</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMi0zLTEtMS0w_319b27e3-6743-4358-8b44-4dd0789f43e8">254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical, contract research and manufacturing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNC0xLTEtMS0w_bb3699e8-1fb2-4eb7-b4b3-c022011a89ac">303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNC0zLTEtMS0w_71134d21-c53e-46b9-b20c-9dde91b2b394">515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="xcur:CommonStockWarrantLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNC0xLTEtMS03MzU_57bcafe5-94e0-417b-8e32-8acd33b6739a">257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:zerodash" name="xcur:CommonStockWarrantLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNC0zLTEtMS03MzU_2e5b3b70-af1d-49db-a825-5247d55e6da9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMy0xLTEtMS0w_0aba786e-0bed-4bc3-a735-f62696a2e869">196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMy0zLTEtMS0w_0a034201-16aa-48a2-aca9-40c8b9c3f751">292</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNS0xLTEtMS0w_f4148989-f5aa-4321-8a12-3cc8b9241f35">123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNS0zLTEtMS0w_53087c99-f091-42bb-bf37-6f04b7718658">454</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNi0xLTEtMS0w_2f4de307-fac2-4060-a234-56ff966d8e05">1,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNi0zLTEtMS0w_5a267007-a438-48c5-a351-f1757d68599e">2,435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzUz_5bba01f4-f2bc-4d6c-8ece-a2cf299666ff" escape="true"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other noncurrent liabilities</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.903%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.905%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmY4ZjgwY2EzZTcyOTRhZjZhN2QxYzkyYzgyOWUyN2JjL3RhYmxlcmFuZ2U6ZjhmODBjYTNlNzI5NGFmNmE3ZDFjOTJjODI5ZTI3YmNfMS0xLTEtMS0w_8e70f1e4-8d3c-471a-9303-097bd73ea820">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmY4ZjgwY2EzZTcyOTRhZjZhN2QxYzkyYzgyOWUyN2JjL3RhYmxlcmFuZ2U6ZjhmODBjYTNlNzI5NGFmNmE3ZDFjOTJjODI5ZTI3YmNfMS0zLTEtMS0w_75fce0b8-d9e0-4251-9bad-b175d6e7a663">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total other noncurrent liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmY4ZjgwY2EzZTcyOTRhZjZhN2QxYzkyYzgyOWUyN2JjL3RhYmxlcmFuZ2U6ZjhmODBjYTNlNzI5NGFmNmE3ZDFjOTJjODI5ZTI3YmNfMy0xLTEtMS0w_c55b57fd-3f15-4d6e-94bf-04ee60bdfca5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmY4ZjgwY2EzZTcyOTRhZjZhN2QxYzkyYzgyOWUyN2JjL3RhYmxlcmFuZ2U6ZjhmODBjYTNlNzI5NGFmNmE3ZDFjOTJjODI5ZTI3YmNfMy0zLTEtMS0w_d628fe5a-da56-424d-be7b-08bdd5b556a7">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt;text-align:center;margin-top:6pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_52"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RleHRyZWdpb246ZTNmZTRhZjM2Nzc4NDFjYWI1Y2YzOTcwNTY3MzllOWVfMTMwMg_c35c8988-381f-4ca2-9e7a-5c0116eb8937" continuedAt="i7319674f637e4bdcbcfcabca46a8cef3" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i7319674f637e4bdcbcfcabca46a8cef3"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and December 31, 2019, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:InvestmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RleHRyZWdpb246ZTNmZTRhZjM2Nzc4NDFjYWI1Y2YzOTcwNTY3MzllOWVfMTMwMw_dc1749dc-3a28-4832-b6a3-0693bb979666" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:282.75pt;"><tr><td style="width:1.0pt;"></td><td style="width:211.00pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:67.75pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">One year or less</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" name="xcur:DebtSecuritiesAvailableForSaleCurrentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmQ2ZWEyMzhiODMwMzRhZDNhNTcxMzhlMGU5NDVkOGVkL3RhYmxlcmFuZ2U6ZDZlYTIzOGI4MzAzNGFkM2E1NzEzOGUwZTk0NWQ4ZWRfMC0xLTEtMS0w_e0a71923-c4c4-4072-a3c2-b134fa3a2091">92</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After one year but within two years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" name="xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmQ2ZWEyMzhiODMwMzRhZDNhNTcxMzhlMGU5NDVkOGVkL3RhYmxlcmFuZ2U6ZDZlYTIzOGI4MzAzNGFkM2E1NzEzOGUwZTk0NWQ4ZWRfMS0xLTEtMS0w_03899ba7-d94c-47dd-b70d-15c67f1f0021">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" name="xcur:DebtSecuritiesAvailableforSalePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmQ2ZWEyMzhiODMwMzRhZDNhNTcxMzhlMGU5NDVkOGVkL3RhYmxlcmFuZ2U6ZDZlYTIzOGI4MzAzNGFkM2E1NzEzOGUwZTk0NWQ4ZWRfMi0xLTEtMS0w_5ac245bb-7e30-4528-86a1-6fc77be90609">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All of the Company&#8217;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RleHRyZWdpb246ZTNmZTRhZjM2Nzc4NDFjYWI1Y2YzOTcwNTY3MzllOWVfMTMwNA_bc900cfe-af0e-49a0-9fd7-76ab8837d620" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June 30, 2020&#160;and December 31, 2019 were as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.826%;"><tr><td style="width:1.0%;"></td><td style="width:44.247%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.565%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.672%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.787%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.672%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.390%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.672%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.395%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i209cc24d339e4dca80c79600e75bf93a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMi0xLTEtMS0w_869fce11-e852-4411-8442-7021ce1267ad">15,166</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i209cc24d339e4dca80c79600e75bf93a_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMi0zLTEtMS0w_a5603ba7-513d-4aa9-afd6-d92569b67c54">22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i209cc24d339e4dca80c79600e75bf93a_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMi01LTEtMS0w_8d7499c6-1818-4031-9530-a02d5b412204">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i209cc24d339e4dca80c79600e75bf93a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMi03LTEtMS0w_93553c03-b5e1-49e2-acf7-08621980d8ce">15,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3438766d2dcd44c49ffa9224566847b8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMy0xLTEtMS0w_f8e8a632-4ac9-4594-8785-2bcea13e9cdc">44,798</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3438766d2dcd44c49ffa9224566847b8_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMy0zLTEtMS0w_e5b27b8b-077b-41a5-845d-4a131883497b">271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3438766d2dcd44c49ffa9224566847b8_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMy01LTEtMS0w_ba22ad25-db90-4ae7-90ff-8aaa61193ef5">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3438766d2dcd44c49ffa9224566847b8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMy03LTEtMS0w_a7217a9b-ff64-4313-94aa-2ce356da5936">45,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNC0xLTEtMS0w_57b5a00a-f8f3-47ef-b1a2-17c0ee56759b">2,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNC0zLTEtMS0w_20912e34-6c84-4784-8968-f867d4e3b3c0">18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNC01LTEtMS0w_5bd3f0cf-71f2-4fbd-9d3e-92d3177a0171">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNC03LTEtMS0w_baf3972a-b7e3-4d6e-a1ae-21d2ec038fc6">2,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNS0xLTEtMS0w_07588bdb-d057-4efc-90c6-fc78816f134f">6,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNS0zLTEtMS0w_c7881b50-9ab8-4d98-9fa4-57d07804b69a">31</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNS01LTEtMS0w_0f1dd66f-8615-4c82-b3a4-9bccad0878bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNS03LTEtMS0w_b4af5a4a-9d8e-4adf-a07b-3787694d4c9b">6,051</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNi0xLTEtMS0w_299ee6f2-d65f-45a4-b1e1-d2157bce2f26">68,241</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNi0zLTEtMS0w_a1d5b8a2-a9a7-4c7f-a17c-1303d1084a83">342</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNi01LTEtMS0w_dbdace94-c4e0-4dd1-b3c2-1afa346e0970">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNi03LTEtMS0w_91b08a7e-a637-403c-b136-f8c14977f9a1">68,579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.025%;"><tr><td style="width:1.0%;"></td><td style="width:43.950%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.852%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.680%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.852%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.680%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.680%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.206%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icbffc60721ce4820bf8a858d521a4af2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMi0xLTEtMS0w_2bc53a0f-ad3a-451d-9101-454c6c5a30bd">13,932</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icbffc60721ce4820bf8a858d521a4af2_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMi0zLTEtMS0w_7e62a7bd-abfb-4ac4-b9ee-083b2c188cd4">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icbffc60721ce4820bf8a858d521a4af2_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMi01LTEtMS0w_c6633247-97d2-4992-a44a-fbff88c622ad">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icbffc60721ce4820bf8a858d521a4af2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMi03LTEtMS0w_72a50f7f-63ec-4a7c-b9ba-672fdb3750ee">13,931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f8930d5532948af84a2e264d978cb22_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMy0xLTEtMS0w_85e848af-6e14-481c-a20d-85b06bb2ea4b">36,620</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f8930d5532948af84a2e264d978cb22_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMy0zLTEtMS0w_4e778a1a-f916-499f-b7de-2325503125ef">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9f8930d5532948af84a2e264d978cb22_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMy01LTEtMS0w_423401e8-83cd-448e-a0ca-5c51f4b617b2">24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f8930d5532948af84a2e264d978cb22_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMy03LTEtMS0w_04f5b9b8-4c9d-47a4-8bd5-2780d4a69402">36,597</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf8a62227b6e4249b0ad9da0af747eac_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNC0xLTEtMS0w_89cebbe7-bd22-48f6-966d-fd67dead7b89">4,513</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf8a62227b6e4249b0ad9da0af747eac_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNC0zLTEtMS0w_93cc1a68-0e70-4039-8d8b-3f7d8ccf19b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icf8a62227b6e4249b0ad9da0af747eac_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNC01LTEtMS0w_6abc98dd-6e02-43be-82f9-49f275ff5acc">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icf8a62227b6e4249b0ad9da0af747eac_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNC03LTEtMS0w_4a1a8322-d295-4632-b088-87a34d7608c2">4,512</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i331baf183969422d81b4084c1e01f301_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNS0xLTEtMS0w_0704c722-0d3e-4698-a646-854b24a69ac4">9,786</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i331baf183969422d81b4084c1e01f301_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNS0zLTEtMS0w_7e1f1948-a9e7-47be-9ccd-e3022c34a164">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i331baf183969422d81b4084c1e01f301_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNS01LTEtMS0w_1341153a-6c1b-47d7-985b-f97ed6f2d63c">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i331baf183969422d81b4084c1e01f301_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNS03LTEtMS0w_634356f8-81ff-491b-be38-0ead4aefb743">9,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNi0xLTEtMS0w_81a6d54d-9f1a-401e-8c48-beb43a717479">64,851</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNi0zLTEtMS0w_2c6b9cf0-18b3-48f0-87d3-d98c9c16e50c">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNi01LTEtMS0w_16d09b7e-6fac-4d39-aef8-bc61e37052d5">29</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNi03LTEtMS0w_db35d4eb-8bed-47a9-97bf-5bdc0984db8f">64,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i87c412b98f4a4c10b3a3081e33f1cbca_55"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfMjc0ODc3OTA3MDE2OA_04204069-bc3b-4f97-afd3-6a49c0fa5546" continuedAt="i07a9d1073335483eaff7b47a4baa0d25" escape="true">Debt</ix:nonNumeric></span></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i07a9d1073335483eaff7b47a4baa0d25" continuedAt="i2aed14562a3e4a23b9ef67d03076e87d">On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#8220;Hercules&#8221;) and subsequent amendments thereto  (the &#8220;Hercules Loan Agreement&#8221;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="i5d33f191228d4786a0f292468de4d908_D20200302-20200302" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfMzU5_af9d3134-673b-47d0-8b01-413b8fbc8b72">4,999</ix:nonFraction> and the end of term fee of $<ix:nonFraction unitRef="usd" contextRef="i5d33f191228d4786a0f292468de4d908_D20200302-20200302" decimals="-3" name="xcur:PaymentsForDebtEndTermFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfMzg5_e6f3e68e-dcaa-4029-b0c6-2c490da35712">100</ix:nonFraction>.</ix:continuation></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2aed14562a3e4a23b9ef67d03076e87d">The Company paid interest on the Hercules Loan Agreement of $<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfNDUz_a731d753-7f21-4212-850e-852bd9452ea3">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfNDYw_46d822f7-38dd-4927-b807-9b654ca82507">152</ix:nonFraction> during the three months ended June 30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfNzE0NjgyNTU4MTIyNQ_7945430a-3aeb-4802-b119-670d966e2bba">142</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfNzE0NjgyNTU4MTI1MA_0af4f955-d939-4f68-ae4f-c9695edfaa4d">301</ix:nonFraction> during the six months ended June 30, 2020 and 2019, respectively.</ix:continuation></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_58"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfNTUwNA_9dcdf5a3-20b8-439c-b96a-ccf94827f2a9" continuedAt="i71016eaf53714f1c8c83139089516fe5" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i71016eaf53714f1c8c83139089516fe5" continuedAt="i66a82f4caf504b47bbeccd2231afef50"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Chicago Lease</span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has approximately <ix:nonFraction unitRef="sqft" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="0" format="ixt-sec:numwordsen" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDI4OQ_3bd5722e-0919-479a-b036-068a668c81a5">thirty thousand</ix:nonFraction> square feet of office and laboratory space in Chicago, Illinois (the &#8220;Chicago Lease&#8221;). The original term (the &#8220;Original Term&#8221;) of the Chicago Lease is <ix:nonNumeric contextRef="id642410749d845f68e04f5594e957ca4_I20200228" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMTY5OQ_6f8d6910-07de-4335-9b44-fa40fa64e8a6">10</ix:nonNumeric> years, commencing on July 1, 2020 (the &#8220;Commencement Date&#8221;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;<ix:nonFraction unitRef="numberofperiods" contextRef="id8e4fcd0750e4f00b604afc9f08aeaf4_D20200228-20200228" decimals="INF" format="ixt-sec:numwordsen" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMTkyMw_e8e730f8-2b0d-4560-80d3-d89349ad25f6">two</ix:nonFraction>&#160;additional successive periods of <ix:nonNumeric contextRef="id642410749d845f68e04f5594e957ca4_I20200228" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMTk1OQ_af624e5e-9545-4d06-aca7-549d48945aef">five years</ix:nonNumeric> each (the &#8220;Extension Periods&#8221;) at the then prevailing effective market rental rate.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial annual base rent during the Original Term is $<ix:nonFraction unitRef="usdPerSquarefeet" contextRef="id642410749d845f68e04f5594e957ca4_I20200228" decimals="INF" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjEwMw_f56eba44-e613-4ecd-af0f-840ddcb8049f">37.00</ix:nonFraction> per square foot per year, or approximately $<ix:nonFraction unitRef="usd" contextRef="id642410749d845f68e04f5594e957ca4_I20200228" decimals="-3" format="ixt:numdotdecimal" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjE0OQ_8220b75e-4edf-4316-83fc-846c115e0a40">1,113</ix:nonFraction> for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of <ix:nonFraction unitRef="number" contextRef="id642410749d845f68e04f5594e957ca4_I20200228" decimals="INF" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjMzOQ_57ae1c02-8676-4eb3-9cfd-bb5db53c5673">3</ix:nonFraction>%, for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="id642410749d845f68e04f5594e957ca4_I20200228" decimals="-3" format="ixt:numdotdecimal" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjM3MA_bb292d35-b429-49b5-8c9c-f20e803ed686">12,761</ix:nonFraction> over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes are subject to certain abatements. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Landlord will contribute a maximum of $<ix:nonFraction unitRef="usd" contextRef="id8e4fcd0750e4f00b604afc9f08aeaf4_D20200228-20200228" decimals="-3" format="ixt:numdotdecimal" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0NQ_b8d015b8-9574-4f34-9b1f-df762259f0d1">3,159</ix:nonFraction> toward tenant improvements. In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the Landlord in an initial amount of $<ix:nonFraction unitRef="usd" contextRef="id642410749d845f68e04f5594e957ca4_I20200228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjkxNQ_ea4cc07e-2834-4dda-86d5-5faa08d55227">1,200</ix:nonFraction>, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the Landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="id8e4fcd0750e4f00b604afc9f08aeaf4_D20200228-20200228" decimals="-3" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMzIwOQ_f2d13cfe-9287-4b94-b470-7c7ba6d4680d">87</ix:nonFraction> which amount had been adjusted for the abatement as set forth in the lease agreement. Prior to the Commencement Date, the Company also paid the landlord approximately $<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="xcur:LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfNzE0NjgyNTU5MDk3MA_4c48e25a-88ac-44d6-93d6-5f69b74c8be0">736</ix:nonFraction> toward tenant improvements.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $<ix:nonFraction unitRef="usd" contextRef="id642410749d845f68e04f5594e957ca4_I20200228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMzQ2Ng_7504be6d-6b65-4dfe-b761-f91b2e96d617">1,200</ix:nonFraction>, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#8217;s unaudited condensed consolidated balance sheet at June 30, 2020.&#160;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Chicago Lease has not yet commenced for accounting purposes as of&#160;June 30, 2020. As a result, the Company has not yet recognized an operating lease asset or operating lease liability on the unaudited condensed consolidated balance sheet for the Chicago Lease. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Skokie Lease</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s lease agreement for office and laboratory space in Skokie, Illinois commenced in March 2012 and expires in February 2021 (the &#8220;Skokie Lease&#8221;). In connection with the Company&#8217;s relocation of its headquarters from Skokie, Illinois to its new facility in Chicago, Illinois on July 1, 2020, the Company determined that the remaining useful life of the operating lease asset underlying the Skokie Lease at June 30, 2020 was <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDIzMg_bc0ddf39-3aa8-49b3-b360-0d3d3fd3ba3d">zero</span> and therefore recognized remaining amortization expense related to the Skokie Lease of $<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfNjU5NzA2OTc3NjU2MA_306cdb4d-4fb4-4799-91be-5e73f8ce4290">211</ix:nonFraction> during the three months ended June 30, 2020.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="i66a82f4caf504b47bbeccd2231afef50"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDI1MQ_0524692b-c790-4dbe-8419-8034ae3111a9" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of the Company&#8217;s lease liability as of June 30, 2020 were as follows:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:75.849%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.349%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Operating Leases </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfMS0yLTEtMS0xMTE1_21d82471-cadc-4f41-971f-bf9fa69a3f6b">147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfMi0yLTEtMS0xMTE1_0e8e2375-42d8-4116-965c-93d0ebfea6c8">59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfNC0yLTEtMS0xMTE1_2d950ead-9476-42ae-a386-524c7e048354">206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfNS0yLTEtMS0xMTE1_4fd1d4d5-ee68-49c4-9488-ec0c92b80ed4">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfNi0yLTEtMS0xMTE1_cf1d14fb-e7ae-4746-8851-00f2250c8b3f">196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfOC0yLTEtMS0xMTE1_0aba786e-0bed-4bc3-a735-f62696a2e869">196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:-13.5pt;padding-left:13.5pt;margin-bottom:9pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)  &#160;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Excluded from the table above are the lease payments associated with the Chicago Lease that has not commenced as of the end of the period, which is July 1, 2020 (the date the asset was made available to the Company by the lessor).</span></div></ix:nonNumeric></ix:continuation><div id="i87c412b98f4a4c10b3a3081e33f1cbca_64"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">8. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjc0ODc3OTA3NDIyNw_81904baf-8dfd-4e2c-ae39-5a5984ebcf4a" continuedAt="i40f96eaae6c14ddf87dd6df8b350e67a" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i40f96eaae6c14ddf87dd6df8b350e67a" continuedAt="i0d27e7bc1c354b3aa21c4bca4ee36968"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and December 31, 2019, the Company had <ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTA1_471993cc-ba0a-4797-bd45-2de7bc30d43f"><ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTA1_785301a1-9902-4a74-b9a6-279862db99d7">10,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTQ1_9c29255f-4d9e-4214-ac46-0457d32176cb"><ix:nonFraction unitRef="usdPerShare" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTQ1_e077f277-8562-4119-8f48-90554dde46a3">0.0001</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYz_487bfebd-0f01-41be-aac7-c36eacd28ed1"><ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYz_558a2f9a-cf09-4664-9c30-1c8a3ed80a08"><ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYz_758cefc3-8f8c-464b-bc69-40a08724df8b"><ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYz_97a640f0-05a7-4c78-8ab9-47870ae70f98">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and December 31, 2019, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjgx_bc1361a9-1e71-4b6f-9bb2-0fa0c3e5d806"><ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjgx_f63ba504-9689-4c0b-992b-1dbef6acac5d">200,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzE4_748b1340-adb0-47fc-949f-c4c6a39dc8c2"><ix:nonFraction unitRef="usdPerShare" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzE4_81491800-a803-4227-9118-a149c69ae3eb">0.0001</ix:nonFraction></ix:nonFraction>.  As of June 30, 2020 and December 31, 2019, the Company had <ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfNzE0NjgyNTU4MzczOA_3276140d-d702-40ab-8d76-f43e94787a93"><ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfNzE0NjgyNTU4MzczOA_e532b872-23a1-47af-bb70-bfc64e1d1d43">87,206,346</ix:nonFraction></ix:nonFraction>  shares and <ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzk4_67f9c638-bbb6-45b1-bdbf-594d69d6ba15"><ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzk4_bf428cb2-8c21-42e0-970b-340f08c134f2">86,069,263</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively.  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of shares of the Company&#8217;s common stock are entitled to <ix:nonFraction unitRef="vote_per_share" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="xcur:CommonStockVotingRightsforEachShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzI5ODUzNDg4NjQ0OA_6277d836-1e2c-4a4c-aa30-88830f773de2">one</ix:nonFraction> vote per share on all matters to be voted upon by the Company&#8217;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Company&#8217;s Board out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of the Company&#8217;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#8217;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#8217;s common stock. The outstanding shares of the Company&#8217;s common stock are fully paid and&#160;non-assessable.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">December 2019 Offering</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 23, 2019, the Company sold <ix:nonFraction unitRef="shares" contextRef="i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTU0Mg_f0fa44d0-8679-4b4a-9dae-fd59f7e1655a">10,000,000</ix:nonFraction> shares of its common stock at the public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4be9f363b86d4627be1d61061c00986b_I20191223" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYwNA_28f9a406-913e-44bd-ad4b-492ee1db33fb">2.75</ix:nonFraction> per share in an underwritten public offering, for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTY3NQ_395b25d6-c0fe-473d-bfdf-2d83468f1aa1">27,500</ix:nonFraction> and estimated net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223" decimals="-3" format="ixt:numdotdecimal" name="xcur:ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTcwOA_57682cd8-70e6-4d3a-ac9a-e5ce84446718">25,344</ix:nonFraction> after deducting underwriting discounts and commission and other offering expenses payable by the Company (the &#8220;December 2019 Offering&#8221;).  In addition, the Company granted the underwriters a 30-day option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ia2cea85073354474aa680437e75f26a7_D20191223-20191223" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTk0MQ_22a86193-4a5b-446f-9be7-e78ef7596aa6">1,500,000</ix:nonFraction> shares of common stock offered in the common stock offering. On January 6, 2020, the underwriters partially exercised the option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="icfa443308cf5477596e1014cee13ebba_D20200106-20200106" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjA5OQ_7e2ec339-7ad5-4d53-a944-01734d36630e">1,081,184</ix:nonFraction> shares of common stock at the public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4be9f363b86d4627be1d61061c00986b_I20191223" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjE1Nw_28f9a406-913e-44bd-ad4b-492ee1db33fb">2.75</ix:nonFraction> per share for additional gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="icfa443308cf5477596e1014cee13ebba_D20200106-20200106" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjIwMw_9e1ef977-2016-4d48-a878-2b80afccef66">2,973</ix:nonFraction> and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="icfa443308cf5477596e1014cee13ebba_D20200106-20200106" decimals="-3" format="ixt:numdotdecimal" name="xcur:ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjIyNg_d4979f70-faf6-410a-a55c-a4d74dc78490">2,766</ix:nonFraction> after deducting underwriting discounts and commission and other offering expenses.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The shares sold in the December 2019 Offering were sold pursuant to a registration statement on Form S-3 that was declared effective by the SEC on July 24, 2019.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="i0d27e7bc1c354b3aa21c4bca4ee36968"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock Warrants</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As of June 30 2020, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ic86b7ec9cc274bf8af157b6700465ac9_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjU0MA_f7e740c8-7512-4bab-97d6-a1eb976b3ce7">413,320</ix:nonFraction> shares of common stock at a price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzI5ODUzNDg4NjQ1OQ_0afa2aa4-c6a3-4127-b0ca-7f664c178d78">3.00</ix:nonFraction>&#160;per share remain outstanding.  The Warrants expire as follows: <ix:nonFraction unitRef="shares" contextRef="i164e4b30480d4e978a2812a8cd07749a_I20210327" decimals="INF" format="ixt:numdotdecimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjY0Ng_b1bbf427-8227-4e71-b8f8-62bfe6d4a802">163,174</ix:nonFraction> warrants expire on March 27, 2021; <ix:nonFraction unitRef="shares" contextRef="i4fde2bf7394d44a09eddfef7c0f06b5a_I20210428" decimals="INF" format="ixt:numdotdecimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjY4NA_0e39e186-298e-45e4-a0ec-96f702e659bb">132,884</ix:nonFraction> expire on April 28, 2021; and <ix:nonFraction unitRef="shares" contextRef="i7fb9e0113525465fa92492e072f0e43e_I20210503" decimals="INF" format="ixt:numdotdecimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjcxNw_1323fcf5-5d5f-4593-a953-faa6e3c623d0">117,262</ix:nonFraction> expire on May 3, 2021.  The Warrants are classified as a liability which is remeasured each period at fair value. See Note 12,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;for more information on the fair value of the common stock warrant liability.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzExNQ_f8078312-5a3c-4c08-9be8-29fcb64efd9b" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%;"><tr><td style="width:1.0%;"></td><td style="width:56.469%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.710%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.854%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.710%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9c03ff4e8b5c4b699019abb27907654d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMS0yLTEtMS0w_0930064b-f431-4ea1-96fb-69d479fe3926">27</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4a2b6489ddf141a7bf39c57e8c6c374d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMS00LTEtMS0w_9b1595e2-b836-4fce-8ad4-02d0f951bde1">27</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib61094c0deb84e1bbf2fd681155a9f0c_D20200101-20200331" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMi0yLTEtMS0w_9fc11fc6-353d-45ab-bde6-45cbe358b272">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffcf7f98338c48b2a74d5c64bcbb09cf_D20200101-20200331" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMi00LTEtMS0w_5133597d-b9f2-4bbc-9b99-201d6e5b3788">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib61094c0deb84e1bbf2fd681155a9f0c_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMy0yLTEtMS0w_35c086c6-5e52-4452-8651-d528a96f7bba">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffcf7f98338c48b2a74d5c64bcbb09cf_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMy00LTEtMS0w_86d7fb85-7df8-49b0-919e-787a533db88b">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i63f9fe0651d84de1b85aafe4a8643eec_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNC0yLTEtMS0w_d1e52c4a-24b0-41e2-a239-2344496e1a8a">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i346241752b2b49a69f5d211b6a9d45fd_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNC00LTEtMS0w_68784d2e-e399-44f4-ab40-051086148716">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6eadd66fe2e43af9a25c3f417c84b26_D20200401-20200630" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNS0yLTEtMS0xMzM1_4c622706-d500-4e54-a59e-2604860e683e">352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNS00LTEtMS0xMzM1_521fd628-b712-4a5b-9995-1d81ae5eb7a4">352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6eadd66fe2e43af9a25c3f417c84b26_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNi0yLTEtMS0yNjI5_5771663a-5ce6-4f0a-9178-2c4435ab5c50">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNi00LTEtMS0yNjM2_7a90c008-6740-4003-b496-32b801c25ee9">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6eadd66fe2e43af9a25c3f417c84b26_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNi0yLTEtMS0xMzM1_8e5223e8-c261-4e83-a8b7-6e49d012274b">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNi00LTEtMS0xMzM1_139033e8-f4d5-4697-b13d-a53a48b005c8">355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5d6effdfbf94d41a083294b170f3969_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNy0yLTEtMS0xMzM1_ea7c1e41-7582-486f-ab48-6bbb0333aa6d">338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0ac35850023477bb1b027d27cf6499d_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNy00LTEtMS0xMzM1_bc4273f8-17cd-4edd-9b9a-0596a9bad315">338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net loss reclassified from accumulated other comprehensive loss resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfODc5NjA5MzAyNjk2Nw_90d617c2-a6e5-4d76-81d5-f79ee7e19349">23</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfODc5NjA5MzAyNjk3NA_8f635784-5256-4d03-83ba-ffafa7281896">6</ix:nonFraction>, respectively, for the three months ended June 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfODc5NjA5MzAyNjk4NQ_d408a061-1737-4e14-9327-dac84ad9f795">9,404</ix:nonFraction>.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_70"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">9. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjk3NA_ecd8d721-4f93-421a-b7e8-d8d74f600c83" continuedAt="if9a3f1888fe14058afb8f30ebf989c35" escape="true">Equity-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="if9a3f1888fe14058afb8f30ebf989c35" continuedAt="ib7b505715ba94dc7be2ed17a6d3867b4"><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) <ix:nonFraction unitRef="shares" contextRef="ibebc8ba07dd245ff97b780fc24472240_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjMy_8e881f03-4d99-4a1b-b5b5-2fda240ccfcf">4,600,000</ix:nonFraction> shares, (ii) <ix:nonFraction unitRef="number" contextRef="i87bbbbbd85fc49b8852959fd449af5cf_I20200101" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjQ4_0fb505ac-4f76-42c0-b8e0-fb16ab31c3eb">5</ix:nonFraction>% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Company&#8217;s Board. The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by <ix:nonFraction unitRef="shares" contextRef="i9527a967dad3415598f73d2c86f453fc_I20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfNTc5_281c2914-6bfe-4496-9451-6b8ccc840bc4">4,303,463</ix:nonFraction> shares, effective January 1, 2020.</span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, the aggregate number of common stock options available for grant under the 2017 Equity Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i6b932d51abde4221b44077fb53a41b3b_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfNzQ1_8c002076-b427-4621-a5e5-547efbdeeba0">2,283,019</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjk3NQ_e1b82a84-a2d6-44e7-b6bb-76a57d4c7b3d" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="text-align:center;margin-top:17pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53eada77c822436c8d20ad774d619503_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMi0xLTEtMS0w_63679f24-7681-48bd-94b9-95d823e9b223">203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbfbd26204cc426c8a8cf03400f66926_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMi0zLTEtMS0w_0513d2a8-89ed-4298-8fee-a313fc9ed08d">103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7040eb168bef4211b4772b89a21e6728_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMi01LTEtMS0w_8f7f29ff-41f0-40ad-b3d9-2686183ba1b1">360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e1913cdd58d478da612d3f93c8f7a38_D20190101-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMi03LTEtMS0w_1af40ab6-a3d7-4459-b39d-aa160b78b567">224</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb6b302afc2b47db9a9b8aa6e84aac60_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMy0xLTEtMS0w_190b52cb-302e-4466-9351-97860691ca3d">341</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5bdba642bc224cb9b89f1de3feabde3e_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMy0zLTEtMS0w_e821d481-7801-4ab4-86f5-9732d16bb3de">336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4aec036201f748fd8269f237b2461bcc_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMy01LTEtMS0w_2f99f1e0-1ad6-48cd-8e74-498dfdf8fca4">625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7e189a56ebb44a6ba95910fba45564d_D20190101-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMy03LTEtMS0w_c02c1745-d34e-46ea-b810-3e81e43c9468">704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfNC0xLTEtMS0w_d45a1c16-807d-4e77-b9a3-af8209075816">544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfNC0zLTEtMS0w_78f135c2-a7cf-494d-b6b8-8a2dd542baac">439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfNC01LTEtMS0w_e7ac93fc-3cf0-41ff-9fe6-6ff3bf4a8da0">985</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfNC03LTEtMS0w_83c604f4-f716-46b7-85ac-77fa78ceacb5">928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unamortized equity-based compensation expense at June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfOTEx_32094946-e04c-49f2-8f85-0a5aa92e9990">4,893</ix:nonFraction>, which is expected to be amortized over a weighted-average period of <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjc0ODc3OTA3MjUwNQ_c3d55d3d-b86c-48ab-952e-b46490565b1b">2.9</ix:nonNumeric> years. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjk3MA_6681f1bf-6cb4-4c81-8e8d-f1e6475606aa" continuedAt="i39b7683bae7b45fe8384511d8cef99cf" escape="true">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</ix:nonNumeric></span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i39b7683bae7b45fe8384511d8cef99cf" continuedAt="i8107d4ca4f63492080813fb7d8d5a6fd"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:56.493%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.352%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.354%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i1e9583ff1ce6495cb0331d2a1569e1b0_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMi0xLTEtMS0wL3RleHRyZWdpb246ZGE5ZDcxZWYwMTFlNDhhZDgwMWJkNGJiOWMyNjI3NDZfMjc0ODc3OTA2OTQ2Mw_ebaf1c08-006c-47e0-9c9d-70a1d986267f">5.2</ix:nonNumeric> to <ix:nonNumeric contextRef="ib66e2fa725c1452382443738ad2ef816_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMi0xLTEtMS0wL3RleHRyZWdpb246ZGE5ZDcxZWYwMTFlNDhhZDgwMWJkNGJiOWMyNjI3NDZfMjc0ODc3OTA2OTQ2OQ_853641c7-9af6-4f2b-ac09-f2ed1721f4ff">6.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i6091d038421c443d91771f31d4e2744c_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMi0zLTEtMS0wL3RleHRyZWdpb246MWQ0MjkzZTA4MDg0NDNmZjg4MDFhYmFiMDcwNTFkOTlfMjc0ODc3OTA2OTQ2Mw_6a6cbf0c-0ddd-4d6b-9ac0-c2866f9c3bad">5.3</ix:nonNumeric> to <ix:nonNumeric contextRef="i8ff390c5c87441f5a73f86f5f1529e92_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMi0zLTEtMS0wL3RleHRyZWdpb246MWQ0MjkzZTA4MDg0NDNmZjg4MDFhYmFiMDcwNTFkOTlfMjc0ODc3OTA2OTQ2OA_e2d41f01-5288-45e9-90d7-e647e5e0baec">6.1</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i1e9583ff1ce6495cb0331d2a1569e1b0_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0xLTEtMS0wL3RleHRyZWdpb246ZDg3MmMwMjJjMDVjNDljYzgwMWVhYTVmNGFjMzE2YTJfMjc0ODc3OTA2OTQ4NA_a000ef67-96b9-45c7-bc73-19fbf8d578b6">0.41</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib66e2fa725c1452382443738ad2ef816_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0xLTEtMS0wL3RleHRyZWdpb246ZDg3MmMwMjJjMDVjNDljYzgwMWVhYTVmNGFjMzE2YTJfMjc0ODc3OTA2OTUwMQ_7d241415-543c-438a-9700-99d7cb80e7ac">1.68</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="i6b7e6c0acc9b4b93871186f77defb445_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0xLTEtMS0wL3RleHRyZWdpb246ZDg3MmMwMjJjMDVjNDljYzgwMWVhYTVmNGFjMzE2YTJfMjc0ODc3OTA2OTUwOA_03acc9b1-181e-401f-a320-1a817238e410">0.67</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i6091d038421c443d91771f31d4e2744c_D20190101-20190630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0zLTEtMS0wL3RleHRyZWdpb246ZjgyOTI2NjdiYzk5NDY4NmFjN2NiYWMxNDQyOThlZTVfMjc0ODc3OTA2OTQ4NA_343871be-e85d-4be8-bcc8-233c9b0b236a">1.86</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8ff390c5c87441f5a73f86f5f1529e92_D20190101-20190630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0zLTEtMS0wL3RleHRyZWdpb246ZjgyOTI2NjdiYzk5NDY4NmFjN2NiYWMxNDQyOThlZTVfMjc0ODc3OTA2OTQ5MQ_1fd717ac-8278-4be0-b381-1e55e30c77a0">2.56</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="iaa95d698f7954c17a13d43f11eded42c_D20190101-20190630" decimals="6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0zLTEtMS0wL3RleHRyZWdpb246ZjgyOTI2NjdiYzk5NDY4NmFjN2NiYWMxNDQyOThlZTVfMjc0ODc3OTA2OTQ5OA_04046f59-36e5-430d-ac8d-ba303595efb7">2.34</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i1e9583ff1ce6495cb0331d2a1569e1b0_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0xLTEtMS0wL3RleHRyZWdpb246OTZiZDYyMGNhY2JmNDhmMTkwMDE0MmZlOWE1YmJhNzdfMjc0ODc3OTA2OTQ4NA_095db685-a3e7-47a7-ad1d-74455008239f">81.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib66e2fa725c1452382443738ad2ef816_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0xLTEtMS0wL3RleHRyZWdpb246OTZiZDYyMGNhY2JmNDhmMTkwMDE0MmZlOWE1YmJhNzdfMjc0ODc3OTA2OTQ5MQ_55fda61f-9ddc-40c6-bd6e-08d7ca681c70">85.8</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="i6b7e6c0acc9b4b93871186f77defb445_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0xLTEtMS0wL3RleHRyZWdpb246OTZiZDYyMGNhY2JmNDhmMTkwMDE0MmZlOWE1YmJhNzdfMjc0ODc3OTA2OTQ5OQ_a708bcef-a1f1-45a7-80e8-ba9e400e4336">83.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i6091d038421c443d91771f31d4e2744c_D20190101-20190630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0zLTEtMS0wL3RleHRyZWdpb246ZmE4NGM1MDhlMzhmNDQyZDhlZDUzMWIyZTgwMDRiZWZfMjc0ODc3OTA2OTQ4NA_a91e34a0-0d7a-451d-9efc-2d570b7a92aa">83.2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8ff390c5c87441f5a73f86f5f1529e92_D20190101-20190630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0zLTEtMS0wL3RleHRyZWdpb246ZmE4NGM1MDhlMzhmNDQyZDhlZDUzMWIyZTgwMDRiZWZfMjc0ODc3OTA2OTQ5MQ_6ee7e4be-225f-417e-af61-bc1605956a62">86.7</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="iaa95d698f7954c17a13d43f11eded42c_D20190101-20190630" decimals="5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0zLTEtMS0wL3RleHRyZWdpb246ZmE4NGM1MDhlMzhmNDQyZDhlZDUzMWIyZTgwMDRiZWZfMjc0ODc3OTA2OTQ5OA_e94968ee-762d-4b74-8740-d05318707914">84.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeiture rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNS0xLTEtMS0w_e9d0ae0c-30e7-4ed3-8584-47366d5d2417">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNS0zLTEtMS0w_6b943bbf-eaa9-4e15-9ce9-bf52a2336865">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNi0xLTEtMS0w_1c0f1f12-438b-4b8f-9e9a-6b9e2bba312f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNi0zLTEtMS0w_1650fa43-abed-4617-aec9-6564ec3779e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></ix:continuation></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="ib7b505715ba94dc7be2ed17a6d3867b4"><ix:continuation id="i8107d4ca4f63492080813fb7d8d5a6fd"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2020 and 2019 are summarized in the table below:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"></td><td style="width:54.500%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.348%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:19.350%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0b30acdba4af4f89add54dddf14c23da_I20200630" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0xLTEtMS0wL3RleHRyZWdpb246ZjdlNzhlZDlkNjJlNDk4ZGI3MWU3MmZhOWQ2Yzk0YWJfMjc0ODc3OTA2OTQ4NA_d5d8e33b-b112-47cc-ad32-36e7b50d7466">1.19</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ie283a4656c2e4cdaa3544e7bf804c7f9_I20200630" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0xLTEtMS0wL3RleHRyZWdpb246ZjdlNzhlZDlkNjJlNDk4ZGI3MWU3MmZhOWQ2Yzk0YWJfMjc0ODc3OTA2OTQ5MA_0d0299af-0673-4752-bd27-bb689556ac5c">2.80</ix:nonFraction>; weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="i75055b5483aa4b45aa64e739ee644b07_I20200630" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0xLTEtMS0wL3RleHRyZWdpb246ZjdlNzhlZDlkNjJlNDk4ZGI3MWU3MmZhOWQ2Yzk0YWJfMjc0ODc3OTA2OTUwMA_22476b94-37e0-48a6-a37f-8eac1870df20">1.85</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0b30acdba4af4f89add54dddf14c23da_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0zLTEtMS0wL3RleHRyZWdpb246YWM5MTFkYjI3ZTg5NDNjNGJkMjM2ZjllZDIzMTFmZWRfMjc0ODc3OTA2OTQ4NA_615ededa-5dfc-4001-9cb6-185654357f78">1.19</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ie283a4656c2e4cdaa3544e7bf804c7f9_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0zLTEtMS0wL3RleHRyZWdpb246YWM5MTFkYjI3ZTg5NDNjNGJkMjM2ZjllZDIzMTFmZWRfMjc0ODc3OTA2OTQ4OQ_8f73c740-da95-46c3-a990-79f2285c22fd">2.80</ix:nonFraction>; weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="i75055b5483aa4b45aa64e739ee644b07_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0zLTEtMS0wL3RleHRyZWdpb246YWM5MTFkYjI3ZTg5NDNjNGJkMjM2ZjllZDIzMTFmZWRfMjc0ODc3OTA2OTQ5OQ_a56c8b80-a5ee-442e-a7d1-b83520d3bbbb">1.85</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic9c0c8245bda4b29885459d2a7e6d51f_I20190630" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0xLTEtMS0wL3RleHRyZWdpb246YTBiYmUyYzUxNjNkNDFjZTk3ZDI1Y2M2NzNjY2QxNmJfMjc0ODc3OTA2OTQ4Mw_6307e23b-c725-41b1-8bf2-46a90b314fcb">2.78</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3ade10577cb447f84773dd52aecc06c_I20190630" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0xLTEtMS0wL3RleHRyZWdpb246YTBiYmUyYzUxNjNkNDFjZTk3ZDI1Y2M2NzNjY2QxNmJfMjc0ODc3OTA2OTQ5MA_0a388ed3-641a-4363-9ff2-95b8b93c53dd">2.80</ix:nonFraction>:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="i33522e08954144b987a6d23ea7b62c6b_I20190630" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0xLTEtMS0wL3RleHRyZWdpb246YTBiYmUyYzUxNjNkNDFjZTk3ZDI1Y2M2NzNjY2QxNmJfMjc0ODc3OTA2OTQ5Ng_79781aa8-2fba-4964-b67c-00af05cf005f">2.79</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic9c0c8245bda4b29885459d2a7e6d51f_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0zLTEtMS0wL3RleHRyZWdpb246MzlmOWZhZjhiZWQyNGU0YTkyNjU2MDU3OWQ3NGZhM2ZfMjc0ODc3OTA2OTQ4Mw_4570b37b-ce62-48a4-bfe6-1cedbf24a186">2.78</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3ade10577cb447f84773dd52aecc06c_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0zLTEtMS0wL3RleHRyZWdpb246MzlmOWZhZjhiZWQyNGU0YTkyNjU2MDU3OWQ3NGZhM2ZfMjc0ODc3OTA2OTQ5MA_d31ac6c5-daca-40a9-8cb1-6cbd8fd80840">2.80</ix:nonFraction>:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="i33522e08954144b987a6d23ea7b62c6b_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0zLTEtMS0wL3RleHRyZWdpb246MzlmOWZhZjhiZWQyNGU0YTkyNjU2MDU3OWQ3NGZhM2ZfMjc0ODc3OTA2OTQ5Ng_3c6c3868-4859-41b1-a52a-7fa9fd82f7bf">2.79</ix:nonFraction></span></div></td></tr></table></div></ix:continuation><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average grant date fair value of common stock options granted in the six months ended June 30, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjgyOQ_2f942cc4-6e9d-4073-8973-4bced63ac3cc">1.29</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjgzNg_8ee5ac58-b1e0-4906-86b9-8d1500da5404">1.99</ix:nonFraction> per common stock option, respectively.</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjk3Mw_ce363963-7455-4626-b7c8-cc1657301a27" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding - December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMS0xLTEtMS0w_6161519a-cf09-4328-a50e-2ba25c9d1398">5,697,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMS0zLTEtMS0w_f9d8fed9-0f24-4580-8286-6e4853821abe">2.34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i3ce249e9e67f47b1986e46049614d74e_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMS01LTEtMS0w_b13ed066-b85a-469c-8d95-0aa5ddb6dfcf">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMS03LTEtMS0w_57a7b233-cc41-4c4b-8d7f-95ea5d7d898a">4,625</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMi0xLTEtMS0w_c3a79cc5-6932-492a-9157-4fda1a8f6832">2,075,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMi0zLTEtMS0w_bb426894-b8e0-41b6-873b-d7f0b6808aaa">1.85</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMy0xLTEtMS0w_e23f2160-f331-4c8c-a397-44fae53301d5">55,899</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMy0zLTEtMS0w_48767d30-7256-465e-ac03-4a18528ba276">0.89</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNC0xLTEtMS0w_8b929286-b7e3-4103-b17e-80fd46d55080">18,750</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNC0zLTEtMS0w_6b047a3b-1bec-4342-b930-abc2aae191f0">2.78</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding - June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNS0xLTEtMS0w_a4af8871-2621-4363-812c-bbc58362ba48">7,698,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNS0zLTEtMS0w_70afbed9-b998-40bf-b8d2-cd8b05b1a84a">2.22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNS01LTEtMS0w_32133008-f376-4599-977e-390eef548573">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNS03LTEtMS0w_1af860a7-b395-4bc5-b446-efcd9ede5147">4,738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable - June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNi0xLTEtMS0w_4b2a441c-7c95-4142-9df3-aeb6c92c3f2c">4,372,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNi0zLTEtMS0w_5548f52c-b6d6-4cd6-8963-a267df771e32">2.12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNi01LTEtMS0w_2643c8c5-6c0e-4e8d-981f-580bb5d12b0c">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNi03LTEtMS0w_be5caff2-79a2-465c-867b-d3286b51e0aa">3,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and Expected to Vest -<br/>June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNy0xLTEtMS0w_277bad4d-f4e5-4b3f-b469-7d318b9e0c18">7,442,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNy0zLTEtMS0w_d2129076-113b-4643-9e0d-5f3d7cb00adf">2.22</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNy01LTEtMS0w_1de92007-73ea-4f80-836a-a4c6c7c04c0a">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNy03LTEtMS0w_dca22c76-5812-46a7-b8ca-736feecec673">4,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt;text-align:center;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate intrinsic value of common stock options exercised during the six months ended June 30, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfNjU5NzA2OTc3MDEzNg_0cea14ae-142a-4f66-91e7-c564bfc5892f">89</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfNjU5NzA2OTc3MDE0Mg_3499e7a2-3fe6-49d7-8268-12314933c7a7">17</ix:nonFraction>, respectively.</span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_76"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">10. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83Ni9mcmFnOmE5NWQ2Y2U1NjQ3NzRmMDY4NGRlZDJlMWUzMzgxNzAzL3RleHRyZWdpb246YTk1ZDZjZTU2NDc3NGYwNjg0ZGVkMmUxZTMzODE3MDNfMjc0ODc3OTA3MjMwOA_996ed796-34a6-4610-b9fe-5836c082c135" continuedAt="i2d6556697e3447689497b6d1fac621db" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2d6556697e3447689497b6d1fac621db" continuedAt="iadad2a22c3754803bca2b21043db9490">The Company incurred a pretax loss in each of the three and six months ended June 30, 2020 and 2019, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended.  The effective tax rate is <ix:nonFraction unitRef="number" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83Ni9mcmFnOmE5NWQ2Y2U1NjQ3NzRmMDY4NGRlZDJlMWUzMzgxNzAzL3RleHRyZWdpb246YTk1ZDZjZTU2NDc3NGYwNjg0ZGVkMmUxZTMzODE3MDNfNTIx_6306d225-3f37-4d0f-8269-de91129e0e57"><ix:nonFraction unitRef="number" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83Ni9mcmFnOmE5NWQ2Y2U1NjQ3NzRmMDY4NGRlZDJlMWUzMzgxNzAzL3RleHRyZWdpb246YTk1ZDZjZTU2NDc3NGYwNjg0ZGVkMmUxZTMzODE3MDNfNTIx_f6f9f734-e138-4929-a25c-7358d8ca0bd5">0</ix:nonFraction></ix:nonFraction>% in each of the three and six months ended June 30, 2020 and 2019 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</ix:continuation></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iadad2a22c3754803bca2b21043db9490">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). The CARES Act, among other things, allows for a five-year carry back of federal net operating losses generated in 2018 through 2020 and removes the 80% taxable income limitation for net operating loss deductions for tax years ending before 2021.</ix:continuation> While the Company continues to analyze the relevant provisions of the CARES Act, the provisions of the legislation did not have an impact on the Company&#8217;s income taxes.</span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_82"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">11. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RleHRyZWdpb246MmUwZjRhZGUyMTUwNDE5Yzg2YWUxODQ5NzgxZTdlMTBfMzI5ODUzNDg4NDU0MA_c31b1964-6812-4d22-91a7-364f49e26e01" continuedAt="ifc8fdbd7901340e3910b1fe0365ec158" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ifc8fdbd7901340e3910b1fe0365ec158" continuedAt="i0801a1872d5f47d0ae0015eb7598e95c"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RleHRyZWdpb246MmUwZjRhZGUyMTUwNDE5Yzg2YWUxODQ5NzgxZTdlMTBfMTIwNQ_c48b1e7e-4346-416e-a083-0fbc628a0142" continuedAt="i8208c1fc10ff4d138c720321a28e6825" escape="true">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the </ix:nonNumeric></ix:continuation></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="i0801a1872d5f47d0ae0015eb7598e95c"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i8208c1fc10ff4d138c720321a28e6825">net loss reported in those periods.</ix:continuation>  Therefore, basic and diluted loss per common share is the same for each of the three and six months ended June 30, 2020 and 2019.</span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RleHRyZWdpb246MmUwZjRhZGUyMTUwNDE5Yzg2YWUxODQ5NzgxZTdlMTBfMTIxMA_f6f68ed6-5ded-4de0-a0fa-a368511f94bc" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is the computation of loss per common share for the three and six months ended June 30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.142%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.908%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.908%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.908%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.911%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfMi0xLTEtMS0w_8dcc1af1-4fca-4e49-9107-c52ceea49165">4,311</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfMi0zLTEtMS0w_ec32a994-75b4-4a46-af47-b966ba32c43f">5,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfMi01LTEtMS0w_cbb955c4-d182-4a13-8a74-b0876726940e">3,161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfMi03LTEtMS0w_41b0fe9b-7153-483a-a4ed-2214ba20a4e6">10,506</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfNC0xLTEtMS0w_6d1b2e7e-a2c4-443e-9f1f-dc615a8f85f3">87,174,533</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfNC0zLTEtMS0w_a3697f8a-3640-4b3c-b852-9ba91ac8fbe7">44,368,174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfNC01LTEtMS04MjA_6c85577f-d14b-4112-b6b9-19e0e078c006">87,126,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfNC03LTEtMS04MjA_04e67d21-fb23-4d51-bda6-44fc4a09bf5b">44,363,115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted loss per common share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfOC0xLTEtMS0w_2280e16f-c71e-4951-9be0-43252cabeee6">0.05</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfOC0zLTEtMS0w_c587e538-b4c0-430c-9b3d-e59fc5acd6e9">0.12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfOC01LTEtMS04MDg_7c389b82-cf7f-4aa0-859f-52b7240005eb">0.04</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfOC03LTEtMS04MDg_c8be8e55-066a-4c25-8382-450ea2623a7a">0.24</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RleHRyZWdpb246MmUwZjRhZGUyMTUwNDE5Yzg2YWUxODQ5NzgxZTdlMTBfMzI5ODUzNDg4NDU0MQ_f39aee6c-22aa-4327-9a62-b45125938507" escape="true"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outstanding securities presented below were excluded from the calculation of loss per common share for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%;"><tr><td style="width:1.0%;"></td><td style="width:69.082%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.054%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.607%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.057%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">As of June 30,</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9736fd4b7b724ef987739ec27346148b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwYjU0NjE4ZjU4OTQwNWI5ZjQzZGU0ODllMTdjMmM2L3RhYmxlcmFuZ2U6YjBiNTQ2MThmNTg5NDA1YjlmNDNkZTQ4OWUxN2MyYzZfMi0xLTEtMS0w_b95bd4f3-4cea-4a2e-828c-34675734f032">7,698,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib7685322cfa540bbb195c55945e40155_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwYjU0NjE4ZjU4OTQwNWI5ZjQzZGU0ODllMTdjMmM2L3RhYmxlcmFuZ2U6YjBiNTQ2MThmNTg5NDA1YjlmNDNkZTQ4OWUxN2MyYzZfMi0zLTEtMS0w_de9f9565-a8ba-46fe-984d-6f90f8c51792">5,078,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4d810f21c820439283d2493920890171_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwYjU0NjE4ZjU4OTQwNWI5ZjQzZGU0ODllMTdjMmM2L3RhYmxlcmFuZ2U6YjBiNTQ2MThmNTg5NDA1YjlmNDNkZTQ4OWUxN2MyYzZfMy0xLTEtMS0w_9bdbf203-ae9a-4bcd-a9cc-a6bd5afa9d6b">413,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie32d42b33c7f4559bb28b9b2c085cd77_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwYjU0NjE4ZjU4OTQwNWI5ZjQzZGU0ODllMTdjMmM2L3RhYmxlcmFuZ2U6YjBiNTQ2MThmNTg5NDA1YjlmNDNkZTQ4OWUxN2MyYzZfMy0zLTEtMS0w_85cf90f7-ed4c-40bf-a638-868516909d0e">413,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i87c412b98f4a4c10b3a3081e33f1cbca_85"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">12. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjUyNA_d805a2f9-c7f0-4014-86b3-29a1e3838ee3" continuedAt="iea12e24519f04aa29779b63446bbfc99" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="iea12e24519f04aa29779b63446bbfc99" continuedAt="ide9d1cb60eac40d1b235abfd914fb8de"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASC Topic 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjUzMA_bfa3c533-7f70-48a3-8065-2aebf85e29e4" continuedAt="ie65d6bc8fe444e018fef51cb1c23c03b" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.955%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.660%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.441%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.982%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if786421abd8449ad82c258035991f29f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMy0xLTEtMS0w_f6a008d1-5664-45b6-a1be-c0aef2c548dc">7,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94b2debb8cee40d0bb95dee385f1e248_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMy0zLTEtMS0w_59e3c665-3957-439a-a49d-4fea29d253f5">7,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if03a9ef0110a48da8f43355f7dde35e9_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMy01LTEtMS0w_9552406a-e32e-44dc-afe2-d0a873bf286b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i139534750c32411998ec9f0fdd20ed30_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMy03LTEtMS0w_5052f5f1-ebeb-439c-b026-5c0b8298b032">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b43d4dad70748079a0e514fc136284e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNi0xLTEtMS0w_b71a290f-32f0-4ebf-967e-2f575cdf65d8">15,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4b2a726e7e9422a8c57cb8fe49f6a15_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNi0zLTEtMS0w_72f7be6f-106c-40f3-9d00-f361e3602849">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5ffab51ce3540d2b6096242b70529a6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNi01LTEtMS0w_11410b28-9828-4601-aa5c-9037c3c0e436">15,188</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2525709ae7045c3a4de1f8fb444dbbe_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNi03LTEtMS0w_96aade44-271a-4bca-a858-d96a77f4c351">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i42288e5a324249c8ad74cc662005b838_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNy0xLTEtMS0w_746e2094-9e65-4f4c-8959-477590a41161">45,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1cbfa891ae54142b5e3a160e784d461_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNy0zLTEtMS0w_22ba49ab-7867-41be-bab5-8a227ccc7713">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b10df2779c4412ab3932dd163fe9b82_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNy01LTEtMS0w_cae6f42c-7c7a-4e84-ab40-01ab6f48c53e">45,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03266b4db72b4437b1cf9918fecc673e_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNy03LTEtMS0w_123b8aeb-64bb-4ae2-9665-ecfe19354562">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e24f66b20e44fa2a7b4a0991ca309f1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOC0xLTEtMS0w_6b0f3966-d06f-4714-aef1-229a52157bf5">2,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bfcdc5fa8c740d39d1e6fc1c52b74fe_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOC0zLTEtMS0w_05f33601-e109-4185-916e-7f02eb8589e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6929f02de29e445e90d7b545c93b3af6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOC01LTEtMS0w_28308000-8e1a-4d2c-8457-f3217a0fb5eb">2,275</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c0b49eff48349d3963e85732d3bb079_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOC03LTEtMS0w_ff1b9069-9779-4ea6-b3fc-a81a0fbe1c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcad2a390bdd4ccab4037a9659048f33_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOS0xLTEtMS0w_0e9874e8-4864-472a-9f70-5bec79aa0f46">6,051</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0091985621104c5e88db831ff8c58475_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOS0zLTEtMS0w_f55ba1b0-ab7b-407a-94c5-3f6f3230edd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9661f3db7077445e851858b6e5f7c6e5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOS01LTEtMS0w_7251ca90-e7ba-4a03-ad23-bfbfd506776a">6,051</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i011f06514d6143e1839cabbd9accc3ca_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOS03LTEtMS0w_5630d29c-ba79-4ece-b27e-c457441b2fb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia02b9a6c3e74421db29f69c537e41533_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTAtMS0xLTEtMA_c5cba3ba-65e0-4ba6-aea0-d5595cb03261">76,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d51345bb8494da4a30ff3ab1bc494f9_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTAtMy0xLTEtMA_4687b10d-64fa-47bd-be71-52194538c51d">7,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8d4534186e24013a51b6dcd1d6b3342_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTAtNS0xLTEtMA_7008064d-3f69-49bb-83bb-8f4a12d9d282">68,579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3027180e50c94a839a0b60625e670750_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTAtNy0xLTEtMA_60c7e5b2-dae4-457c-8ac2-6c05cdaa7d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia02b9a6c3e74421db29f69c537e41533_I20200630" decimals="-3" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTMtMS0xLTEtMA_8ed7427b-9ffc-4146-b4e1-9a786439ca8a">257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d51345bb8494da4a30ff3ab1bc494f9_I20200630" decimals="-3" format="ixt:zerodash" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTMtMy0xLTEtMA_4e5d4cfa-2db1-4d7d-8dd5-d5371d094817">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8d4534186e24013a51b6dcd1d6b3342_I20200630" decimals="-3" format="ixt:zerodash" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTMtNS0xLTEtMA_c978af8a-a2ea-4114-b73a-f860a7dae8ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3027180e50c94a839a0b60625e670750_I20200630" decimals="-3" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTMtNy0xLTEtMA_04cbeaf0-fca7-4dd5-9145-3a0352c8f408">257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia02b9a6c3e74421db29f69c537e41533_I20200630" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTQtMS0xLTEtMA_8c4afb5b-2858-414e-8c76-9497b6b5cd46">257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d51345bb8494da4a30ff3ab1bc494f9_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTQtMy0xLTEtMA_1149dbcd-920f-41d6-a4ac-edff43f44787">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8d4534186e24013a51b6dcd1d6b3342_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTQtNS0xLTEtMA_4d87dbbe-1164-474c-b293-f0c26e7ce013">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3027180e50c94a839a0b60625e670750_I20200630" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTQtNy0xLTEtMA_8f36495b-6706-4e13-a950-907078a6194a">257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="ide9d1cb60eac40d1b235abfd914fb8de" continuedAt="i8c02c5ae18394884a59009c94c90176e"><ix:continuation id="ie65d6bc8fe444e018fef51cb1c23c03b"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 are as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.628%;"><tr><td style="width:1.0%;"></td><td style="width:45.923%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.937%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.011%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.937%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.184%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.283%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.665%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.460%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i090111c614884f2a89c5715d09e61e69_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMy0xLTEtMS0w_acc1edbf-5d6e-44d1-85c3-5eff63c949b0">31,078</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a6d01430580442ebd48b712adfce654_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMy0zLTEtMS0w_b79e25be-93b6-422b-91b2-6c966c00f5c4">31,078</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if61aaf687d2943e6bc6fe6367d618ffb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMy01LTEtMS0w_b3482d0a-683f-4ede-b224-b305af0472f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic85d5d22e929404c83658bc0fc8c47ed_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMy03LTEtMS0w_83f4d23d-8c2f-48a8-8f76-ff10521fda8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i596ed322af7d456da621e01fa6bae736_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNC0xLTEtMS0w_0f55eb67-8ecf-4654-b648-efd532739fe5">2,498</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i62b770fba5bd404fbbf086617f231ac1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNC0zLTEtMS0w_c89886f6-a387-4b65-ba74-50b6a6666679">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i715f59046cbd4cfbb6149afc299e8098_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNC01LTEtMS0w_b68d009a-ad3a-42ba-9c3d-b738df388295">2,498</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b1651c5e27f48129604544f4d17c53d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNC03LTEtMS0w_37973ae5-0d8f-44d1-bd96-8f11b271b01b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i81ff5dbe93184b128cf458121e2b9869_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNi0xLTEtMS0w_51730853-2ed1-4feb-876d-1ea824e501ec">11,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i36aea1c3046543f0b3cc27b52ff37040_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNi0zLTEtMS0w_b4d7a6ea-09ef-47d4-bb86-2c6e22445721">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7954e090c66944f88a4e2606c991d18b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNi01LTEtMS0w_eddf49b1-3f5b-4208-8171-642bbd92a6d7">11,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib02e96a8734943609865d9b4c35421f7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNi03LTEtMS0w_4da3446a-0757-451e-b824-83329c82c180">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i246dadd6c8d449999b2f9717794c470c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNy0xLTEtMS0w_886d141c-bf42-4bb7-9902-861311c4a3f8">36,597</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ad9873452934a32ae8e3aeda1e17fe8_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNy0zLTEtMS0w_0af71f8b-4c5d-4678-92e3-79ec592a80f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id62277363f7143ce854422660983079f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNy01LTEtMS0w_c2f37950-54db-469c-ab68-6efca72e5bc5">36,597</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadbc031755e743459e0e460fe0824f64_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNy03LTEtMS0w_d781c801-7632-4d92-a44b-3329ba2403f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie70b0b8cf2fe4c808ff9025d45a5b3ff_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOC0xLTEtMS0w_0735d388-f916-4e91-afc5-5515b26e948b">4,512</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia533935aed984b759f799fea1a30903b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOC0zLTEtMS0w_a897662d-af6b-4ac6-80ba-6b63af889c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iceff6e292b6d4b45910614df9290865b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOC01LTEtMS0w_5b31e5d3-ed41-4a19-9a62-968c4d06bc6b">4,512</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d6b9adc9d0d410e84335056934458af_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOC03LTEtMS0w_dddb019e-6c6a-4392-a9c0-37d7695924ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2f49042851ab48aa8b238a225a70ee62_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOS0xLTEtMS0w_8c0666b8-68de-4ab8-a47b-e4db257f88f7">9,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6b2c3b884bc46fcaabeebaa66bf2635_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOS0zLTEtMS0w_912e1157-ff69-4be5-9322-e83148b2c864">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i649b1d02f04843e6bfb8ceea9915423c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOS01LTEtMS0w_dbdd36fa-099a-41da-b4ff-bd721dfa6e03">9,784</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76cfaf0a85c64451bf8e5033f3d6e411_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOS03LTEtMS0w_bc1e4581-db46-43cf-9bc5-1ab90073f315">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae71687b96be4ca7a964da2662807ebb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTAtMS0xLTEtMA_fd77f9d3-b86d-4be5-bbfb-12fd4644ac26">95,902</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0591281256d2426a9cbbf549dd04a8a1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTAtMy0xLTEtMA_828fb80d-853c-45cb-ad25-bc1b3063b4fa">31,078</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1eafdf3617e8409faef961085fcec21c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTAtNS0xLTEtMA_16beeb32-0617-4fc9-877b-e09745ec1364">64,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7c04023fda4245f69834e13098d0ccc6_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTAtNy0xLTEtMA_07b7b836-74cc-4af1-89d2-d7ae0b2d1976">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae71687b96be4ca7a964da2662807ebb_I20191231" decimals="-3" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTMtMS0xLTEtMA_ed8f1cf1-d4a3-48a6-b7d4-f64f93bde73e">414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0591281256d2426a9cbbf549dd04a8a1_I20191231" decimals="-3" format="ixt:zerodash" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTMtMy0xLTEtMA_ae550ee3-1aed-4c81-a585-a770b3af7e1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1eafdf3617e8409faef961085fcec21c_I20191231" decimals="-3" format="ixt:zerodash" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTMtNS0xLTEtMA_ef455c49-a19d-4121-a339-bae439f46e47">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7c04023fda4245f69834e13098d0ccc6_I20191231" decimals="-3" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTMtNy0xLTEtMA_43f742aa-c774-4143-8fad-41b9f3e9f711">414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae71687b96be4ca7a964da2662807ebb_I20191231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTQtMS0xLTEtMA_1fc7bed2-1f86-4dd4-8661-d1b49cd16322">414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0591281256d2426a9cbbf549dd04a8a1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTQtMy0xLTEtMA_00183fc3-2741-448e-83e0-1fa753d42bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1eafdf3617e8409faef961085fcec21c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTQtNS0xLTEtMA_0d60dd45-bee3-4e45-a0c8-423d3597a6de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7c04023fda4245f69834e13098d0ccc6_I20191231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTQtNy0xLTEtMA_b42bb224-649e-4bbf-8f1b-90b16e9a8bff">414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s common stock warrant liability (refer to Note 8, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stockholders&#8217; Equity</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for more information) is classified within Level 3 of the fair value hierarchy.  The fair value of the common stock warrant liability was determined using the Black-Scholes option-pricing model.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the common stock warrant liability is based significantly on the fair value of the Company&#8217;s common stock.  At the date of issuance, the common stock warrant liability was determined using the following weighted-average assumptions: expected term of <ix:nonNumeric contextRef="ic748766b36734327aef19e1e2042ee49_I20160217" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMTc1Mg_215bc4a3-1fee-407a-bd42-ae6f1dcc5dd4">2.0</ix:nonNumeric> years, risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i06fbc20f828d41caa9a80bcd7a6e2759_I20160217" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMTc4Mw_c9c9358c-49c1-4691-af44-8105d8318e0d">1.53</ix:nonFraction>%, expected volatility of <ix:nonFraction unitRef="number" contextRef="i9977feb034be4c9caaf5b5df369b7ff1_I20160217" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMTgxMA_14a1e0aa-c626-411c-a536-8e30a4867801">78.97</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i48e54b1c09a54de19e18102cdfcb8cbd_I20160217" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMTgxOA_89d2dc40-3b84-48ad-82cb-c174a06ae7a7">no</ix:nonFraction> expected dividends.  </span></div><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjUyMQ_0375c84f-41d1-48cd-88d9-2301bc4a34d3" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following weighted-average assumptions were used to estimate the fair value of the common stock warrant liability at June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:76.685%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.315%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i57d24130c57c40ba8b47fd15cceac12a_I20200630" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjAxYjhiOGM4NGZmNTQ2NTFhODc1YWJjZGYyMWMyNjg0L3RhYmxlcmFuZ2U6MDFiOGI4Yzg0ZmY1NDY1MWE4NzVhYmNkZjIxYzI2ODRfMS0xLTEtMS0w_f155f63a-67ce-4040-be70-a1317617e92f">0.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic6024f8bbc354cab9a3781b1178e5869_I20200630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjAxYjhiOGM4NGZmNTQ2NTFhODc1YWJjZGYyMWMyNjg0L3RhYmxlcmFuZ2U6MDFiOGI4Yzg0ZmY1NDY1MWE4NzVhYmNkZjIxYzI2ODRfMi0xLTEtMS0w_f310bf2b-7049-4e5c-8013-875c5604e3d1">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2082cdeebbe94488abda3ef417d3e1be_I20200630" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjAxYjhiOGM4NGZmNTQ2NTFhODc1YWJjZGYyMWMyNjg0L3RhYmxlcmFuZ2U6MDFiOGI4Yzg0ZmY1NDY1MWE4NzVhYmNkZjIxYzI2ODRfMy0xLTEtMS0w_2d05b15a-71dd-4638-91ae-4dfaa37a63a0">93.09</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0c9f635fc1cf441fb44103b2e37aabec_I20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjAxYjhiOGM4NGZmNTQ2NTFhODc1YWJjZGYyMWMyNjg0L3RhYmxlcmFuZ2U6MDFiOGI4Yzg0ZmY1NDY1MWE4NzVhYmNkZjIxYzI2ODRfNC0xLTEtMS0w_6715a11c-8f9a-46f5-9592-2e7fbf95efc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A 10% change in the estimate of expected volatility at June 30, 2020 would increase or decrease the fair value of the common stock warrant liability in the amount of $<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjE0OA_674b2e63-c9f7-40a5-bca4-752e9d7a4154">33</ix:nonFraction>.  A 10% change in the estimate of fair value of the common stock at June 30, 2020 would increase or decrease the fair value of the common stock warrant liability in the amount of $<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" name="xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjMzMA_fbcfb370-abc8-4efd-afab-d16001a4b5ca">59</ix:nonFraction>.</span></div></ix:continuation><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><ix:continuation id="i8c02c5ae18394884a59009c94c90176e"><ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjUyNw_08de2858-864b-4da6-8335-b6d88ea1b0f4" escape="true"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.237%;"><tr><td style="width:1.0%;"></td><td style="width:71.741%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.259%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c5c0eb47d394449b742692f031dee63_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFkYmZhNjcwMDdlZDRlYTE4ZTg3YzAxYWU2MWUzM2VmL3RhYmxlcmFuZ2U6MWRiZmE2NzAwN2VkNGVhMThlODdjMDFhZTYxZTMzZWZfMi0xLTEtMS0w_93684e95-baf0-48ac-aea0-7a95a1c757ba">414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain included in other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFkYmZhNjcwMDdlZDRlYTE4ZTg3YzAxYWU2MWUzM2VmL3RhYmxlcmFuZ2U6MWRiZmE2NzAwN2VkNGVhMThlODdjMDFhZTYxZTMzZWZfNC0xLTEtMS0w_03a7f39b-1891-449c-8b78-f6b8077b0485">157</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfc5af07dc354cc8a9057ae7da0af850_I20200630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFkYmZhNjcwMDdlZDRlYTE4ZTg3YzAxYWU2MWUzM2VmL3RhYmxlcmFuZ2U6MWRiZmE2NzAwN2VkNGVhMThlODdjMDFhZTYxZTMzZWZfNS0xLTEtMS0w_0ca82810-5ac0-417c-83e0-1855d801f0ef">257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i87c412b98f4a4c10b3a3081e33f1cbca_91"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">13. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85MS9mcmFnOmIxNGI2Yzc3YmM4NjQ3ZWJiMmY2NDFkMTlmODVlYWRhL3RleHRyZWdpb246YjE0YjZjNzdiYzg2NDdlYmIyZjY0MWQxOWY4NWVhZGFfMjgxNA_e99b23a1-85ea-4c4a-8a7e-b0c2205ee6b2" continuedAt="ibb3b5eb63bbb40628fd5aac21efbaa3d" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ibb3b5eb63bbb40628fd5aac21efbaa3d" continuedAt="i271c6bcd7cc641b39e4b4ab95596cecf"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to Note 7,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for a discussion of the commitments associated with the Company&#8217;s lease agreements.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Northwestern University License Agreements</span></div></ix:continuation><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i271c6bcd7cc641b39e4b4ab95596cecf">On December 12, 2011, (1) AuraSense, LLC, the Company&#8217;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;Assigned Field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#8220;Restated License Agreement&#8221;). In February 2016, the Company obtained exclusive license as to NU&#8217;s rights in certain SNA technology it jointly owns with NU (the &#8220;Co-owned Technology License&#8221;). The Company&#8217;s license to NU&#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;Wound Healing License&#8221;). The Company&#8217;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  As of December 31, 2019, all pending patent applications under the Wound Healing License have been abandoned.  As of June 30, 2020, the Company has paid to NU an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="xcur:PaymentsforLicenseAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85MS9mcmFnOmIxNGI2Yzc3YmM4NjQ3ZWJiMmY2NDFkMTlmODVlYWRhL3RleHRyZWdpb246YjE0YjZjNzdiYzg2NDdlYmIyZjY0MWQxOWY4NWVhZGFfMjc1MA_9e66a424-1b9d-40ba-bc0e-16e4658002dd">8,229</ix:nonFraction> in consideration of each of the obligations described above.</ix:continuation> </span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_94"></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">14. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85NC9mcmFnOjIwMzU5MDM0ZWViOTQ4NGZhOWY5MzhhMDY5NWI4NjdjL3RleHRyZWdpb246MjAzNTkwMzRlZWI5NDg0ZmE5ZjkzOGEwNjk1Yjg2N2NfNDMy_25147056-76d9-4689-a328-ee1f689602b4" continuedAt="i964e58c7c36d4a94a4b8e05b39eccc8e" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i964e58c7c36d4a94a4b8e05b39eccc8e">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board. The Company paid $<ix:nonFraction unitRef="usd" contextRef="ica899e5f992445b1b2e0565819005804_D20190101-20190630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85NC9mcmFnOjIwMzU5MDM0ZWViOTQ4NGZhOWY5MzhhMDY5NWI4NjdjL3RleHRyZWdpb246MjAzNTkwMzRlZWI5NDg0ZmE5ZjkzOGEwNjk1Yjg2N2NfMjAx_a9994309-37b5-4298-b5cb-e7b3fbd4de34"><ix:nonFraction unitRef="usd" contextRef="i3f7894134fb44db79f503167f8288191_D20200101-20200630" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85NC9mcmFnOjIwMzU5MDM0ZWViOTQ4NGZhOWY5MzhhMDY5NWI4NjdjL3RleHRyZWdpb246MjAzNTkwMzRlZWI5NDg0ZmE5ZjkzOGEwNjk1Yjg2N2NfMjAx_c768b270-d39a-431a-a2a3-76e6a1e6dd5f">50</ix:nonFraction></ix:nonFraction> in each of the six months ended June 30, 2020 and 2019 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited condensed consolidated statement of operations.</ix:continuation></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_100"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXICURE, INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share data)</span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">15. <ix:nonNumeric contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xMDAvZnJhZzo0YmViNTAwNTM1Yzk0ZDgzODA4MmMyZjYzOTJmMzE0OS90ZXh0cmVnaW9uOjRiZWI1MDA1MzVjOTRkODM4MDgyYzJmNjM5MmYzMTQ5XzQzMQ_5f457193-3802-417d-9b18-187f1a9f7576" continuedAt="i4c74b87e8e7544eeb5ba2d837d831fd5" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4c74b87e8e7544eeb5ba2d837d831fd5">The Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements.</ix:continuation></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The following information should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q, or Quarterly Report, and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission, or SEC, on March 10, 2020, or the Annual Report. This discussion and analysis contains forward-looking statements that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks and uncertainties, including, but not limited to, those set forth under the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A.  Such factors may be amplified by the COVID-19 pandemic and its current or future impact on our business and the global economy.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_106"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical-stage biotechnology company developing therapeutics for immuno-oncology, genetic disorders and other indications based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. We are working to advance our SNA therapeutic candidates through multiple clinical trials, including the ongoing Phase 1b/2 clinical trial of cavrotolimod (AST-008) in cancer patients. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that one of the key strengths of our proprietary SNAs is that they have the potential to enter a number of different cells and organs. We have shown in clinical and preclinical studies that SNAs may have therapeutic potential in immunoncology and dermatology.  In addition, we have shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. As a consequence, we have expanded our pipeline into neurology, and have conducted early stage research activities in ophthalmology, pulmonology, and gastroenterology.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below sets forth the current status of development of our SNA therapeutic candidates:</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><img src="xcur-20200630_g1.jpg" alt="xcur-20200630_g1.jpg" style="height:295px;width:624px;"/><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">___________</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(1)  In combination with checkpoint inhibitors.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2)  On May 8, 2020, AbbVie Inc.&#160;completed the previously announced acquisition of Allergan plc.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Immuno-oncology, Cavrotolimod (AST-008)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cavrotolimod (AST-008)&#160;is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications.&#160;TLR9 agonists bind to and activate TLR9. We believe&#160;cavrotolimod (AST-008) &#160;may be used for immuno-oncology applications in combination with checkpoint inhibitors. We have observed that, in preclinical studies in a variety of tumor models,&#160;cavrotolimod (AST-008),&#160;applied in combination with certain checkpoint inhibitors, exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. We have also demonstrated that&#160;cavrotolimod (AST-008)&#160;was active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of&#160;cavrotolimod (AST-008)&#160;also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, the administration of cavrotolimod (AST-008) in combination with certain checkpoint inhibitors conferred adaptive immunity in breast and colon cancer mouse models. In mouse tumor models, administration of cavrotolimod (AST-008) with anti-PD-1 antibodies suppresses regulatory T-cells, or Tregs, and myeloid-derived suppressor cells, or MDSCs, and increases the levels of CD8 effector T-cells. We believe these important results suggest that the combination of immuno-oncology SNAs and checkpoint inhibitors could potentially treat a larger proportion of cancer patients than checkpoint inhibitors alone.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the first half of 2019, we opened five clinical trial sites and began dosing patients for the Phase 1b/2 clinical trial. As of July 31, 2020, we had 14 clinical trial sites open for enrollment and we expect to open up to 25 sites. As of July 1, 2020, we have, completed enrollment of the Phase 1b stage of the clinical trial and have dosed all 20 enrolled patients. The Phase 1b stage was an open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod (AST-008) injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. The 20 patients from the Phase 1b stage included those with advanced or metastatic Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, melanoma and leiomyosarcoma. To date, we have not observed any treatment related serious adverse events, or SAEs, nor have we observed any dose-limiting toxicity, or DLT, among the treated subjects. The most common reported adverse event was injection site reactions. In December 2019, we reported preliminary results from the Phase 1b stage of the clinical trial showing potential signs of anti-tumor activity in patients with Merkel cell carcinoma.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, at the American Association of Cancer Research Virtual Annual Meeting, we reported additional safety and pharmacodynamic data from the 20 enrolled subjects We reported that we had observed cavrotolimod (AST-008) was well-tolerated, with a safety profile consisting primarily of injection site reactions and flu-like symptoms, which we believe reflects local and systemic immune activation. No cavrotolimod (AST-008)-related serious adverse events or dose limiting toxicity were reported or have been reported to date. In addition, gene expression analysis data from patient tumor biopsies demonstrated increases in leukocytes in injected tumors after intratumoral (IT) cavrotolimod (AST-008) alone and in combination with pembrolizumab versus baseline. Uninjected tumors also showed increased immune cell levels after subjects received cavrotolimod (AST-008) and pembrolizumab, suggesting immune cell trafficking. Dose-dependent activation of key immune cells, including cytotoxic T cells and natural killer cells, as well as increases in cytokine/chemokine levels were observed in subject blood after IT cavrotolimod (AST-008) treatment alone, and cavrotolimod (AST-008) plus pembrolizumab treatment. We believe that activation of these cell types and expression of immune system signaling proteins may help produce anti-tumor effects.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Using these data, a recommended Phase 2 dose of 32 mg cavrotolimod (AST-008) has been identified for the Phase 2 portion of the clinical trial which is currently underway, whereby cavrotolimod (AST-008) will be given in combination with pembrolizumab or cemiplimab for the treatment of locally advanced or metastatic Merkel cell carcinoma, or cutaneous squamous cell carcinoma, respectively, in subjects with progression despite approved anti-PD-(L)1 therapy. We plan to enroll two separate cohorts of patients with advanced or metastatic Merkel cell carcinoma, or cutaneous squamous cell carcinoma. Each cohort is expected to enroll up to 29 patients who have failed anti-PD-1/PD-L1, or programmed cell death protein 1/programmed death-ligand 1, therapy. On June 16, 2020, we reported that we dosed the first subject in the Merkel cell carcinoma cohort of the trial. </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The diagram below illustrates our planned design of the Phase 2 portion of the trial:</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><img src="xcur-20200630_g2.jpg" alt="xcur-20200630_g2.jpg" style="height:344px;width:624px;"/></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cavro: Cavrotolimod (AST-008); RP2D: Recommended Phase 2 dose; Pembro: Pembrolizumab</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Neurology</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are investigating the utility of our SNA technology for the treatment of neurological conditions and have ongoing research programs underway. In the fall of 2018, we completed a biodistribution study in rats comparing nusinersen to nusinersen in SNA format. Nusinersen, marketed by Biogen Inc. as Spinraza&#174;, is a linear nucleic acid therapeutic approved by the FDA in late 2016 for the treatment of spinal muscular atrophy, or SMA. We found that more nusinersen in SNA format compared to nusinersen was retained in the rats&#8217; brain and spinal cord at 24, 72 and 168 hours. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 26, 2019, we announced data from a preclinical study we conducted evaluating the biodistribution of SNAs in the non-human primate central nervous system. In this study, 7 mg of radio-labeled SNAs were injected intrathecally into cynomolgus monkeys. The biodistribution of the SNAs was followed for 14 days by PET/CT scans. SNAs were observed throughout the entire brain and were found both in the brain stem as well as inside the brain. High content of SNA was observed in all 46 regions of the brain examined. These key data indicate that the SNA platform may be well-suited for development of new therapeutics directed towards diseases of the central nervous system. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Friedreich&#8217;s ataxia </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are developing XCUR-FXN, an SNA-based therapeutic candidate for the treatment of Friedreich&#8217;s ataxia, or FA. FA is an autosomal recessive, neurodegenerative disease characterized by progressively impaired muscle coordination caused by the degeneration of neurons in the cerebellum and dorsal root ganglia in the spinal cord. FA patients may also experience impairment of visual, auditory and speech functions. FA patients also commonly suffer from life-threatening heart conditions such as hypertrophic cardiomyopathy, myocardial fibrosis and heart failure. The typical age of onset for FA is between 5 and 15 years. An estimated 5,000 patients in the United States and 15,000 patients worldwide are affected by FA. There are currently no FDA-approved treatments for FA. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have conducted extensive preclinical research evaluating the suitability of our SNA technology for genetically defined neurological diseases, including efficacy studies in animal models, and biodistribution in rodent </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and non-human primates. Based on the results, we believe we can target FA at the genetic source and meet an important unmet medical need for FA patients. FA is driven by expansion of guanine-adenine-adenine bases of the DNA sequence, or GAA, triplet repeats in the first intron of frataxin, or FXN, gene.  The expanded repeat of FXN forms an intramolecular triple-helix, which impairs transcription and reduces levels of frataxin protein. Our strategy will be to use a genetically-targeted SNA therapy to increase FXN protein. We are designing and developing our FA program, XCUR-FXN, with guidance from and in collaboration with the Friedreich&#8217;s Ataxia Research Alliance, or FARA, the non-profit, charitable organization dedicated to accelerating research leading to treatments and a cure for FA. We expect to initiate IND-enabling studies for XCUR-FXN in late 2020. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other neurological indications</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are building on our proof-of-concept work with nusinersen and our therapeutic candidate XCUR-FXN to further explore new therapeutic applications of our SNA technology in neurology. We aim to address indications with great unmet medical need and where we believe the attributes of our SNA technology would lead to therapeutic and commercial advantages. In order to select new therapeutic indications, we expect to analyze a variety of attributes including: (i) indications where there is a known genetic basis for the disorder, (ii) disorders where we can target multiple genes, (iii) the existence of a patient registry or a patient advocacy group that can work with us for easier trial enrollment, (iv) the competitive therapeutic landscape including disorders not easily addressable by small molecules or antibodies, (v) indications with no approved therapies, and (vi) indications amenable to localized therapeutic administration. Based on these and other criteria, we are currently exploring additional neurological conditions, including spinocerebellar ataxia, Batten disease, amyotrophic lateral sclerosis (ALS), and Huntington&#8217;s disease.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Ophthalmology</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the eye may be an attractive organ for locally-applied SNAs because (i) it is a small and immune-privileged organ, (ii) there are established and non-invasive clinical assessment procedures, and (iii) effective trials can be designed by dosing one eye while using the contralateral eye as a control.  We believe that the results of our preclinical studies of SNA technology in the eye may provide proof-of-concept for expansion of our research and development activities into ophthalmological genetic disorders.  Our preclinical data indicated that SNAs distributed to both posterior (retinal) and anterior (cornea) ocular structures, exhibited higher distribution and persisted longer compared to linear oligonucleotides, and did not cause inflammation in the eye. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe SNAs may possess key potential advantages over gene therapy in the eye.  These key potential advantages include: (i) delivery via intravitreal injections which are safer and easier than subretinal injections, (ii) tunable and reversible control of target expression, and (iii) the ability to treat toxic gain-of-function diseases and target large genes.  We believe, based on our internal analysis, that there are approximately 250 rare ophthalmological diseases with known genetic targets, such as CLN3 for Batten disease, BEST1 for vitelliform macular dystrophy, and USH2A for usher syndrome type 2A.  As such, we intend to continue to evaluate expansion of our preclinical research and development activities in ophthalmology. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Dermatology </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">XCUR17 </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha, or IL-17RA,&#160;a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the&#160;IL-17&#160;pathway in which&#160;IL-17RA&#160;is a key driver of psoriasis. Our strategy is to reduce the levels of&#160;IL-17RA&#160;in the skin by topically applying XCUR17. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the fourth quarter of 2018, we reported results from our Phase 1 clinical trial of XCUR17. Of the 21 treated patients, we observed that the 11 patients treated with the highest strength of XCUR17 gel had a reduction in redness and improvement in healing as determined by blinded physician assessments. We also observed no adverse safety events and no relevant changes in mean psoriatic infiltrate thickness related to treatment with XCUR17. </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2019, at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society, we disclosed biomarker results from the skin biopsies collected from the 21 patients treated in the Phase 1 clinical trial. Clinical observations in this Phase 1 trial correlated with psoriasis-related markers and histological changes from biopsies provided by the patients.  In this trial, we observed clinically that XCUR17 had: </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Resulted in a decrease in the levels of psoriasis and inflammation markers downstream of its target, IL-17RA;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Produced a statistically significant reduction in keratin 16 expression, a key marker of psoriasis (p=0.002);</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Resulted in reductions in the major inflammatory markers beta defensin 4A, interleukin 19, and interleukin 36A versus psoriatic skin at baseline; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Revealed clinical improvements that matched reductions in keratin 16 protein and epidermal thickness.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe these findings suggest that SNA-based drugs, such as XCUR17, may address clinical symptoms in patients with inflammatory diseases, such as psoriasis.  We currently are not conducting additional clinical activities for XCUR17 and we seek to out-license the XCUR17 program.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other operating, financing, and cash flow considerations</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception in 2011, we have devoted substantial resources to the research and development of SNAs and the protection and enhancement of our intellectual property. We have no products approved for sale and primarily all of our $30.9 million in revenue since inception through June 30, 2020 has been earned through our research collaboration license and option agreement with Allergan, our research collaboration, license, and option agreement with Purdue Pharma L.P., or Purdue Collaboration Agreement, as a primary contractor or as a subcontractor on government grants, or through our research collaboration license and option agreement with Dermelix.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have primarily funded our operations through sales of our securities and collaborations. Through June 30, 2020, we have raised net proceeds of $190.1 million from the sale of common stock and preferred stock. We have also received $36.0 million in upfront payments under our current collaborations, including an upfront payment of $25.0 million we received in November 2019 in connection with the Allergan Collaboration Agreement and an upfront payment of $1.0 million we received in February 2019 in connection with the Dermelix Collaboration Agreement.  As of June 30, 2020, our cash, cash equivalents, short-term investments, and restricted cash were $87.0 million.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since our inception, we have incurred significant operating losses.  As of June 30, 2020, we have generated an accumulated deficit of $103.3 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to incur significant and increasing losses in the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">continue to advance cavrotolimod (AST-008) through clinical development for immuno-oncology applications;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">continue research and development of XCUR-FXN and other neurological therapeutic candidates;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">advance our SNA platform in dermatological indications with suitable collaboration partners;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">initiate research and development, preclinical studies and clinical trials for any additional therapeutic candidates that we may pursue in the future;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">advance other therapeutic candidates through preclinical and clinical development;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increase our research and development activities to enhance our technology;</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">continue to manufacture increasing quantities of drug substance and drug product material for use in preclinical studies and clinical trials;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">seek regulatory approval for our therapeutic candidates that successfully complete clinical trials;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">maintain, expand and protect our intellectual property portfolio;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">acquire or in-license other approved drugs, drug candidates or technologies; </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">hire additional operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">incur additional costs associated with operating as a public company.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not generated any revenue from commercial drug sales nor do we expect to generate substantial revenue from product sales unless or until we successfully complete development and obtain regulatory approval of and commercialize one or more of our therapeutic candidates. We do not anticipate generating revenue from drug sales for the next several years, if ever. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Other sources of revenue could include a combination of research and development payments, license fees and other upfront payments, milestone payments, and royalties in connection with our current and any future collaborations and licenses. Until such time, if ever, that we generate revenue from whatever source, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_109"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Developments</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">COVID-19 Business Update</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> With the global spread of the COVID-19 pandemic in the first half of 2020, we continue to monitor closely the developments and continue to take active measures to protect the health of our employees and their families, our communities, as well as our clinical trial investigators, patients, and caregivers.  On March 21, 2020, Governor Pritzker of Illinois announced a &#8220;stay-at-home&#8221; order restricting all Illinois residents to their homes, with few limited exceptions, which was extended through May 2020.  However, the Governor also designated certain businesses, such as biotechnology companies, as &#8220;essential&#8221; businesses, thereby permitting us to continue our R&amp;D operations.  As of the date of this filing, Illinois is under &#8220;Phase 4&#8221; of the Restore Illinois Plan, which is intended to permit the expansion of business and community operations based on their compliance with the safety guidelines described in the regulations.</span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business and R&amp;D operations</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under social distancing guidelines for COVID-19, we were typically operating with less than 50% of our R&amp;D staff on-site at any one time through June 30, 2020. As of July 1, 2020, we took occupancy of approximately 30,000 square feet of laboratory and office space in our new headquarters in Chicago, Illinois.  Since then, we have operated under COVID-19 social distancing guidelines and have generally operated with 100% of our R&amp;D staff on-site.  Our office and general and administrative team continues to work predominantly from home. Our preclinical development program in FA is ongoing and we continue to expect that IND-enabling studies for XCUR-FXN will begin in late 2020.  We also continue to progress our collaborations with Allergan and Dermelix.  However, if the COVID-19 pandemic continues to persist for an extended period of time, we could experience significant disruptions to our preclinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our principal accounting systems are cloud-based and have been fully operational during the stay at home order. We believe that all of our fundamental internal control disciplines are being maintained despite work being conducted from our employees&#8217; homes.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Supply chain </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are working closely with our third-party manufacturers and other partners to manage our supply chain activities and mitigate potential disruptions as a result of the COVID-19 pandemic. We have observed minor delays in receipt of key chemicals, reagents and materials as certain manufacturers have had supply disruptions, related to the COVID-19 pandemic.  If the COVID-19 pandemic continues to persist for an extended period of time and impacts essential distribution systems such as FedEx and postal delivery, we could experience future disruptions to our supply chain and operations, and associated delays in the manufacturing and our clinical supply, which would adversely impact our preclinical and clinical development activities.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Clinical operations</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have one active clinical program, cavrotolimod (AST-008). We have completed enrollment for the Phase 1b stage of the clinical trial and have begun the Phase 2 dose expansion phase in patients with advanced or metastatic Merkel cell carcinoma, or cutaneous squamous cell carcinoma. At this time, and given the severity of both of these indications, we continue to believe that we will continue to enroll patients in the Phase 2 dose expansion phase of the trial as expected. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We remain committed to maintaining our development plans for cavrotolimod (AST-008) and continue to monitor and manage the rapidly evolving situation.  We have taken and continue to take measures to implement remote and virtual approaches, including remote patient monitoring where possible, to maintain patient safety and trial continuity and to preserve study integrity. Should the COVID-19 pandemic continue, our ability to maintain patient enrollment could be negatively impacted.  We could also see an impact on our ability to supply study drug, report trial results, or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority employee resources or otherwise.  In addition, we rely on contract research organizations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic.  If the COVID-19 pandemic continues to persist for an extended period of time, we could experience significant disruptions to our clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.  </span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Liquidity and capital resources</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, our cash, cash equivalents, short-term investments, and restricted cash were $87.0 million, which we believe provides operating cash to fund our current operations until early 2022. However, our operating plan may change as a result of many factors currently unknown to us including due to the effects of COVID-19, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. We have historically principally raised capital through the sale of our securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  We believe raising capital in the current market could be very difficult for early stage biotech companies like us.  If the disruption continues to persist and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our operations.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">New Corporate Headquarters</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 1, 2020, we relocated our corporate headquarters from Skokie, Illinois to our new facility in Chicago, Illinois.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Chief Medical Officer appointment</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 19, 2020, we announced the appointment of Douglas E. Feltner, M.D. as our Chief Medical Officer.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Segment Reporting</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We view our operations and manage our business as one segment, which is the discovery, research and development of treatments based on our SNA technology.</span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_112"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions, including uncertainty in the current economic environment due to the outbreak of COVID-19.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our critical accounting policies require the most significant judgments and estimates in the preparation of our consolidated financial statements. There have been no significant changes to our critical accounting policies from those which were discussed in our Annual Report.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently adopted accounting pronouncements</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent accounting pronouncements not yet adopted</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to Note 2 of the accompanying unaudited condensed consolidated financial statements for a description of recently accounting pronouncements not yet updated.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Comparison of the Three Months Ended June 30, 2020 and 2019</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the results of our operations for the three months ended June 30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.429%;"><tr><td style="width:1.0%;"></td><td style="width:41.053%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.236%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.657%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.408%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.657%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.492%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.657%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.240%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,819&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,390)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,984)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(78)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(95)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(203)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(116)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(76)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(236)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(133)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,311)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,220)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">909&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our revenue earned during the periods indicated:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.224%;"><tr><td style="width:1.0%;"></td><td style="width:44.358%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.452%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.688%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.452%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.688%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.946%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.688%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.128%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allergan Collaboration Agreement</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">n/m</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dermelix Collaboration Agreement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(420)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total collaboration revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized collaboration revenue in the amount of $4.8 million during the three months ended June 30, 2020, which is primarily related to activities performed under the Allergan Collaboration Agreement. In November 2019, we received an upfront payment of $25.0 million in connection with the Allergan Collaboration Agreement for which revenue has been deferred and will be recognized as revenue in future periods as we satisfy our obligations under the Allergan Collaboration Agreement.  At June 30, 2020, deferred revenue under the Allergan Collaboration Agreement was $10.9 million and is expected to be recognized as revenue over the next twelve months as we satisfy our obligations under the Allergan Collaboration Agreement.  Refer to Note 3 of the accompanying unaudited condensed consolidated financial statements for more information regarding revenue recognition for the Allergan Collaboration Agreement. </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the Allergan Collaboration Agreement or the Dermelix License Agreement or any future collaboration and licenses.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expense</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our research and development expenses incurred during the periods indicated:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Platform and discovery-related expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,191&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee-related expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,772&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,042&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">730&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical development programs expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,728&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">922&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">806&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, depreciation, and other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">278&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Full time employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense was $7.0 million for the three months ended June 30, 2020, reflecting an increase of $3.6 million, or 104%, from research and development expense of $3.4 million for the three months ended June 30, 2019.  Since June 30, 2019, we have increased our full-time employee staffing in research and development from 23 to 41 at June 30, 2020. The increase in research and development expense for the three months ended June 30, 2020 of $3.6 million reflects this increased staffing level and the related increase in research and development activities, in addition to the growth in clinical trial activities. More specifically, the increase in research and development expense for the three months ended June 30, 2020 of $3.6 million was primarily due to higher platform and discovery-related expense of $1.7 million, a net increase in costs related to our clinical development programs of $0.8 million, higher employee-related expenses of $0.7 million, and higher facilities, depreciation, and other expenses in the amount of $0.3 million.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in platform and discovery-related expense of $1.7 million is mostly due to higher costs for materials, reagents, lab supplies, and contract research organizations, all in connection with increased research and development activities related to the Allergan Collaboration Agreement, our FA program, XCUR-FXN, and our discovery efforts for other therapeutic candidates for neurology and ophthalmology.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net increase in clinical development programs expense for the three months ended June 30, 2020 of $0.8 million was primarily due to manufacturing costs in connection with the initiation of the Phase 2 phase of our Phase 1b/2 clinical trial for cavrotolimod (AST-008) and other higher clinical trial expenses, partially offset by lower clinical trial expenses for XCUR17.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in employee-related expense for the three months ended June 30, 2020 of $0.7 million was due to higher compensation and related costs in connection with the net increase in headcount during the period presented as well as certain salary increases in 2020 for existing employees and higher recruiting costs.  The increase in facilities, depreciation, and other expenses for the three months ended June 30, 2020 of $0.3 million was mostly due to the acceleration of amortization expense for our Skokie lease asset which we no longer use effective July 1, 2020 due to the relocation of our corporate headquarters to Chicago, as well as higher depreciation expense in connection with the acquisition of additional scientific equipment that was placed in service during the period.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our research and development expenses to increase in the second half of 2020 as we broaden our pipeline of SNA-based therapeutic candidates, continue spending on our clinical development programs, and further develop our SNA technology platform.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative expense</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">244&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Full time employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expense was $2.2 million for the three months ended June 30, 2020, representing an increase of $0.2 million, or 12%, from $2.0 million for the three months ended June 30, 2019.  The increase for the three months ended June 30, 2020 is mostly due to higher legal costs associated with operating as a public company, higher franchise tax costs, and higher D&amp;O insurance expense, partially offset by lower travel and other costs,</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest income</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in interest income of $0.3 million in the three months ended June 30, 2020 as compared to the same period in the prior year was the result of higher average balances invested in available for sale securities as compared to the prior-year period.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Comparison of the Six Months Ended June 30, 2020 and 2019</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the results of our operations for the six months ended June 30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.429%;"><tr><td style="width:1.0%;"></td><td style="width:41.053%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.236%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.657%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.408%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.657%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.492%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.657%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.240%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">610&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,886&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,021&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,865&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,856)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,562)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,706&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(63)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(144)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">627&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(128)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(386)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,506)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,345&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our revenue earned during the periods indicated:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.224%;"><tr><td style="width:1.0%;"></td><td style="width:44.358%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.452%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.688%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.452%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.688%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.946%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.688%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.128%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Allergan Collaboration Agreement</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,949&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,949&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">n/m</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dermelix Collaboration Agreement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(378)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(82)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total collaboration revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">459&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,571&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,957&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized collaboration revenue in the amount of $14.0 million during the six months ended June 30, 2020, which is primarily related to activities performed under the Allergan Collaboration Agreement. In November 2019, we received an upfront payment of $25.0 million in connection with the Allergan Collaboration Agreement for which revenue has been deferred and will be recognized as revenue in future periods as we satisfy our obligations under the Allergan Collaboration Agreement.  At June 30, 2020, deferred revenue under the Allergan Collaboration Agreement was $10.9 million and is expected to be recognized as revenue over the next twelve months as we satisfy our obligations under the Allergan Collaboration Agreement.  Refer to Note 3 of the accompanying unaudited condensed consolidated financial statements for more information regarding revenue recognition for the Allergan Collaboration Agreement. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the Allergan Collaboration Agreement or the Dermelix License Agreement or any future collaboration and licenses.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development expense</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our research and development expenses incurred during the periods indicated:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Platform and discovery-related expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,329&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee-related expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,199&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical development programs expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,265&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,409&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Facilities, depreciation, and other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,083&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,828&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Full time employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense was $13.1 million for the six months ended June 30, 2020, reflecting an increase of $6.3 million, or 92%, from research and development expense of $6.8 million for the six months ended June 30, 2019.  Since June 30, 2019, we have increased our full-time employee staffing in research and development from 23 to 41 at June 30, 2020. The increase in research and development expense for the six months ended June 30, 2020 of $6.3 million reflects this increased staffing level and the related increase in research and development activities, in addition to the growth in clinical trial activities.  More specifically, the increase in research and development expense for the six months ended June 30, 2020 of $6.3 million was primarily due to higher platform and discovery-related expense of $3.2 million, a net increase in costs related to our clinical development programs of $1.4 million, higher employee-related expenses of $1.2 million, and higher facilities, depreciation, and other expenses in the amount of $0.4 million.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in platform and discovery-related expense of $3.2 million is mostly due to higher costs for materials, reagents, lab supplies, and contract research organizations, all in connection with increased research and development activities related to the Allergan Collaboration Agreement, our FA program, XCUR-FXN, and our discovery efforts for other therapeutic candidates for neurology and ophthalmology, partially offset by lower intellectual property costs. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net increase in clinical development programs expense for the six months ended June 30, 2020 of $1.4 million was primarily due to manufacturing costs in connection with the initiation of the upcoming Phase 2 phase of our Phase 1b/2 clinical trial for cavrotolimod (AST-008) and other higher clinical trial expenses, partially offset by lower clinical trial expenses for XCUR17.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in employee-related expense for the six months ended June 30, 2020 of $1.2 million was due to higher compensation and related costs in connection with the net increase in headcount during the period presented as well as certain salary increases in 2020 for existing employees and higher recruiting costs.  The increase in facilities, depreciation, and other expenses for the six months ended June 30, 2020 of $0.4 million was mostly due to the acceleration of amortization expense for our Skokie lease asset which we no longer use effective July 1, 2020 due to our move to our Chicago headquarters, as well as higher depreciation expense in connection with the acquisition of additional scientific equipment that was placed in service during the period.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our research and development expenses to increase in 2020 as we broaden our pipeline of SNA-based therapeutic candidates, continue spending on our clinical development programs, and further develop our SNA technology platform.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative expense</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:39.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.945%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,193&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">610&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Full time employees</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expense was $4.8 million for the six months ended June 30, 2020, representing an increase of $0.6 million, or 15%, from $4.2 million for the six months ended June 30, 2019.  The increase for the six months ended June 30, 2020 is mostly due to higher legal costs associated with operating as a public company, higher franchise tax costs, and higher D&amp;O insurance expense, partially offset by lower travel costs and investor relations costs.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest income</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in interest income of $0.6 million in the six months ended June 30, 2020 as compared to the same period in the prior year was the result of higher average balances invested in available for sale securities as compared to the prior-year period.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_118"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, our cash, cash equivalents, short-term investments, and restricted cash were $87.0 million, which we believe provides operating cash to fund our current operations until early 2022. However, our operating plan may change as a result of many factors currently unknown to us including due to the effects of COVID-19, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. We have historically principally raised capital through the sale of our securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  We believe raising capital in the current market could be very difficult for early stage biotech companies like us.  If the disruption continues to persist and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our operations.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, we filed a shelf registration statement on Form S-3 with the SEC, which was declared effective by the SEC on July 24, 2019. The shelf registration statement allows us to sell from time-to-time up to $125.0 million of common stock, preferred stock, debt securities, warrants, or units comprised of any combination of these securities, for our own account in one or more offerings; the remaining amount available under this shelf registration is approximately $31.3 million. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 6, 2020, we sold 1,081,184 shares of our common stock at a price of $2.75 per share pursuant to the exercise of the underwriters&#8217; option to purchase additional shares at the public offering price in connection with the December 2019 Offering.  We received gross proceeds of $3.0 million before deducting underwriting discounts and commissions and offering expenses of $0.2 million in January 2020 in connection with the December 2019 offering.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similar to other development stage biotechnology companies, we have not generated any revenue since inception.  We have incurred losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the next several years. As of June 30, 2020, we have generated an accumulated deficit of $103.3 million. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> See &#8220;&#8212;Funding Requirements&#8221; below for additional information on our future capital needs.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows a summary of our cash flows for the six months ended June 30, 2020 and 2019:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.512%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.944%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,814)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,996)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,965)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(62)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,283)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,062)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,093)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating activities</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities was $18.8 million and $9.0 million for the six months ended June 30, 2020 and 2019, respectively. The increase in cash used in operating activities for the six months ended June 30, 2020 of $9.8 million was primarily due to higher cash used for working capital and the absence of the $1.0 million upfront payment in connection with the Dermelix Collaboration Agreement, which was received during the same period in the prior year.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing activities</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities was $9.0 million and $0.1 million for the six months ended June 30, 2020 and 2019, respectively. The increase in cash used in investing activities of $8.9 million was primarily due to the purchase, net of maturities, of available-for-sale securities of $6.0 million as well as the purchase of scientific equipment of $3.0 million.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financing activities</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in financing activities of $2.3 million&#160;for the six months ended June 30, 2020 is primarily due the repayment of the Hercules loan in the amount of $5.0 million upon the loan&#8217;s maturity, partially offset by the net proceeds from the sale of shares of our common stock in the amount of $2.8 million pursuant to the partial exercise of the option to purchase additional shares by the underwriters from our December 2019 financing. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Hercules Loan and Security Agreement</span></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital, or Hercules, and subsequent amendments thereto, or Hercules Loan Agreement, we repaid all remaining outstanding obligations under the Hercules Loan Agreement, to include the outstanding principal balance of $5.0 million and a deferred end of term fee of $0.1 million. As a result, Hercules no longer has a security interest in any of our assets.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding Requirements</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that our primary uses of capital will continue to be third-party clinical and research and development services, compensation and related expenses, laboratory and related supplies, legal and other regulatory expenses and general overhead costs. Because of the numerous risks and uncertainties associated with research, development and commercialization of therapeutic candidates, we are unable to estimate the exact amount of our working capital requirements. Our future capital requirements are difficult to forecast and will depend on many factors, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the terms and timing of any other collaboration, licensing and other arrangements that we may establish;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the initiation, progress, timing and completion of preclinical studies and clinical trials for our potential therapeutic candidates;</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effects of health epidemics, including the global COVID-19 pandemic, on our operations or the business or operations of our CROs or other third parties with whom we conduct business;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the number and characteristics of therapeutic candidates that we pursue;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the progress, costs and results of our preclinical studies and clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the outcome, timing and cost of regulatory approvals;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">delays that may be caused by changing regulatory requirements;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the cost and timing of hiring new employees to support our continued growth;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">unknown legal, administrative, regulatory, accounting, and information technology costs as well as additional costs associated with operating as a public company;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of filing and prosecuting intellectual property rights and enforcing and defending any intellectual property-related claims;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the costs and timing of procuring clinical and commercial supplies of our therapeutic candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the extent to which we acquire or in-license other therapeutic candidates and technologies; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt;">the extent to which we acquire or invest in other businesses, therapeutic candidates or technologies.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on our current operating plans, we believe that our existing working capital at June 30, 2020 is sufficient to fund our operations into early 2022.  We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. The COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our operations.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent that we raise additional capital through future equity financings, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development efforts or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_121"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Commitments</span></div><div style="text-indent:18pt;margin-top:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes to our contractual obligations from those described in our Annual Report, other than the following:</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">New Corporate Headquarters </span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, we entered into a new lease signed in February 2020 to secure approximately 30,000 square feet of office and laboratory space at 2430 N. Halsted St., Chicago, Illinois. The Chicago Lease commenced on July 1, 2020, which is when the premises leased thereunder were ready for occupancy, and expires 10 years from July 1, 2020 with an option to renew for two additional successive periods of five years each. </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_124"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-balance Sheet Arrangements</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_127"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">JOBS Act</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2012, the Jumpstart Our Business Startups Act of 2012, or JOBS Act, was enacted by the federal government. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, as an emerging growth company, we will not be required to provide an auditor&#8217;s attestation report on our internal control over financial reporting in future annual reports on Form 10-K as otherwise required by Section&#160;404(b) of the Sarbanes-Oxley Act.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we are also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended, or Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and&#160;non-voting&#160;common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and&#160;non-voting&#160;common stock held by&#160;non-affiliates&#160;is less than $700.0&#160;million measured on the last business day of our second fiscal quarter.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_130"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_133"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4. Controls and Procedures.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in&#160;Rules&#160;13a-15(e)&#160;and&#160;15d-15(e)&#160;under the&#160;Exchange Act, that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of June 30, 2020, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:16pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II &#8211; OTHER INFORMATION</span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_139"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Legal Proceedings.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A. Risk Factors. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">In addition to other information contained in this Quarterly Report on Form 10-Q, the following risks should be considered in evaluating our business and future prospects and an investment in our common stock. The risks and uncertainties described below are not the only ones we face. If any of the following risks and uncertainties develops into actual events, our business, financial condition, results of operations and cash flows could be materially adversely affected. In that case, the price of our common stock could decline and you may lose all or part of your investment. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a biotechnology company developing therapeutics for immuno-oncology, genetic disorders and other indications based on our proprietary SNA technology.  We have a limited operating history.  Since our inception in June 2011, we have devoted our resources to the development of SNA technology.  We have had significant operating losses since our inception.  As of June 30, 2020, we have generated an accumulated deficit of $103.3 million. For the six months ended June 30, 2020 and 2019, our net loss was $3.2 million and $10.5 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. Our technology and therapeutic candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, us, or any current or future collaborators, successfully developing therapeutic candidates, obtaining regulatory approvals to market and commercialize therapeutic candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or any current or future collaborators, are unable to develop and commercialize one or more of our therapeutic candidates or if sales revenue from any therapeutic candidate that receives approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We plan to develop a pipeline of therapeutic candidates based on our proprietary SNA technology. We believe that therapeutic candidates identified with our therapeutic discovery technology may offer an improved therapeutic approach compared to small molecules and antibodies, as well as several advantages over linear oligonucleotide-based therapeutics. However, the scientific research that forms the basis of our efforts to develop therapeutic candidates based on our SNA technology and the identification and optimization of SNA-based therapeutic candidates is relatively new. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on SNA technology is both preliminary and limited. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Therapeutic candidates based on SNA technology have not been extensively tested in humans, and a number of clinical trials conducted by other companies using oligonucleotide technologies have not been successful. We may discover that the SNA-based therapeutic candidates do not possess certain properties required for therapeutic treatment to be effective, such as the ability to remain stable in the human body for the period of time required for the therapeutic candidate to reach the target tissue or the ability to cross the cell membrane and enter into cells within the target tissue for effective delivery. We currently have only limited data, and no conclusive evidence, to suggest that we can introduce these necessary drug-like properties into SNA-based therapeutic candidate. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, therapeutic candidates based on SNA technology may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Even if therapeutic candidates have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable therapeutic, we may not become profitable and the value of our common stock would decline. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, the U.S. Food and Drug Administration, or FDA, and equivalent foreign regulatory authorities have limited experience with SNA-based therapeutics. No regulatory authority has granted approval to any person or entity, including us, to market and commercialize SNA-based therapeutics, which may increase the complexity, uncertainty and length of the regulatory approval process for our therapeutic candidates. We and any current or future collaborators may never receive approval to market and commercialize any therapeutic candidate. Even if we or a future collaborator obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our SNA technology proves to be ineffective, unsafe or commercially unviable, our technology and pipeline would have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have no therapeutics on the market and all of our therapeutic candidates are in early stages of development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals, including an institutional review board, or IRB, approval to conduct clinical trials at particular sites for, and successfully commercializing, our therapeutic candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we or an existing or a future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our therapeutic candidates. Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments for the relevant disease. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A therapeutic candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical studies or early clinical trials of a therapeutic candidate may not predict the results that will be obtained in later phase clinical trials of the therapeutic candidate. We, the FDA, an IRB, an independent ethics committee, or other applicable regulatory authorities may suspend clinical trials of a therapeutic candidate at any time for various reasons, including a finding that subjects participating in such trials are being exposed to unreasonable and significant risk of illness or injury. Similarly, an IRB or ethics committee may suspend a clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, therapeutic candidates, including: </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">negative or inconclusive results from our clinical trials or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">therapeutic-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our therapeutic candidates; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in submitting INDs or CTAs, or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs or ethics committees to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency, or EMA, or European Union national competent authorities, regarding the scope or design of our clinical trials; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in enrolling research subjects in clinical trials; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">high drop-out rates of research subjects; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">inadequate supply or quality of therapeutic candidate components or materials or other supplies necessary for the conduct of our clinical trials; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">greater than anticipated clinical trial costs; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">poor effectiveness of our therapeutic candidates during clinical trials; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular, especially in light of the novelty of our therapeutic candidates;  </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">varying interpretations of data by the FDA and similar foreign regulatory agencies; or</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">refusal of the FDA to accept data from clinical trials conducted outside the United States, or acceptance of these data subject to certain conditions by the FDA. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time and at any stage during the clinical trial process. The results of preclinical studies and early clinical trials of our therapeutic candidates may not be predictive of the result of any subsequent clinical trials. Therapeutic candidates that have shown promising results in early stage clinical trials may still suffer significant setbacks in subsequent clinical trials. We will have to conduct trials in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials due to&#160;lack of efficacy or adverse safety profiles despite promising results in earlier clinical trials. Moreover, clinical data is often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates. &#160;If we experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates may be harmed, and our ability to generate product revenues from any of these therapeutic candidates will be delayed.&#160; In addition, any delays in completing clinical trials will increase our costs, slow down our therapeutic candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.&#160; Any of these occurrences could materially and adversely affect our business, financial condition, results of operations or prospects.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, some of the clinical trials we conduct may be open-label in study design and may be conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Given that our planned open-label Phase 1b/2 clinical trial of cavrotolimod (AST-008) includes an open-label dosing design, the results from this clinical trial may not be predictive of future clinical trial results with this or other product candidates for which we conduct an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our existing therapeutic candidates or our future therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. We have used substantial funds to develop our therapeutic candidates and will require significant funds to conduct further research and development and preclinical studies and clinical trials of our therapeutic candidates, to seek regulatory approvals for our therapeutic candidates and to manufacture and market products, if any, that are approved for commercial sale.  As of June 30, 2020, we had $18.4 million in cash, cash equivalents, and restricted cash and $68.6 million in short-term investments. Based on our current operating plans, we believe that existing working capital at June 30, 2020 is sufficient to fund our operations into early 2022. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing development and corporate activities. Since the length of time and activities associated with successful development of our therapeutic candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. To execute our business plan, we will need, among other things: </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to obtain the human and financial resources necessary to develop, test, obtain regulatory approval for, manufacture and market our therapeutic candidates; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to build and maintain a strong intellectual property portfolio and avoid infringing the intellectual property of third parties; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to establish and maintain successful licenses, collaborations and alliances; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to satisfy the requirements of clinical trial protocols, including patient enrollment; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to establish and demonstrate the clinical efficacy and safety of our therapeutic candidates; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to obtain regulatory approvals; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to manage our spending as costs and expenses increase due to preclinical studies and clinical trials, regulatory approvals, and commercialization; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to obtain additional capital to support and expand our operations; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">to market our products to achieve acceptance and use by the medical community in general. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technology or therapeutic candidates that we would otherwise pursue on our own. We do not expect to realize revenue from product sales, milestone payments or royalties in the foreseeable future, if at all. Our revenue sources are, and will remain, extremely limited unless and until our therapeutic candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities, payments received in connection with our collaboration, option, and license agreement with Allergan plc, or Allergan, our research collaboration, license, and option agreement with Purdue Pharma L.P., or Purdue, our license and development agreement with Dermelix LLC, or Dermelix, or as a primary contractor or as a subcontractor on government grants, and proceeds from our loan agreement with Hercules Technology Growth Capital, or Hercules. We will be required to seek additional funding in the future and intend to do so through either collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms, or at all, and our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of equity securities received any distribution of corporate assets. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business could be adversely affected by the effects of health epidemics, including the global COVID&#8209;19 coronavirus pandemic, in regions where we or third parties on which we rely have business operations and at our clinical trial sites, as well as the business or operations of our CROs or other third parties with whom we conduct business. </span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes coronavirus disease 2019, or COVID-19, continues to negatively impact the global economy. Our business and operations could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic, on our business activities performed by us or by third parties with whom we conduct business, including our third party manufacturers, contract research organizations, or CROs, shippers and others. Such effects could be more pronounced in regions where we have concentrations of clinical trial sites or other business operations. Our company headquarters is located in Chicago, Illinois, our CROs are located globally, and our substance and drug product manufacturers are located in the United States and Europe.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the U.S. government imposed travel restrictions on travel between the United States, Europe and certain other countries. Further, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response. In addition, the Governor of Illinois issued a shelter-in-place order pursuant to which all individuals living in the State of Illinois were ordered to stay at home, subject to certain exceptions, until May 30, 2020. The Illinois executive order contained certain exceptions to facilitate authorized necessary activities) to mitigate the impact of the COVID-19 pandemic. The executive order exempted certain individuals needed to maintain continuity of operations of critical infrastructure sectors as determined by the federal government, and the executive order clarified that biotechnology companies like us (including operations, research and development, manufacture and supply chain) are considered essential and exempt. Although the executive order ended on May 30, 2020, there are still some restrictions on a range of businesses and activities in Illinois. As of the date of this filing, Illinois is under "Phase 4" of the Restore Illinois Plan, which is intended to permit the expansion of business and community operations based on their compliance with the safety guidelines described in the regulations. Certain jurisdictions have begun re-opening only to return to restrictions in the face of increases in new COVID-19 cases. The extent of and timing for lifting of government restrictions remains uncertain as the COVID-19 pandemic continues to evolve. There is no guarantee that prior or new restrictions will not be reinstated in response to the continued spread of COVID-19.</span></div><div style="text-indent:18pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In response to these public health directives and orders and to ensure the safety and wellbeing of our employees, we have implemented work-from-home policies to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state/provincial or municipal government and health authorities. We implemented a number of measures to ensure employee safety and business continuity.  Under social distancing guidelines for COVID-19, we were typically operating with less than 50% of our R&amp;D staff on-site at any one time through June 30, 2020. We are managing laboratory staffing and taking other appropriate managerial actions to maintain progress on our preclinical and collaboration programs. Our office and general and administrative team has been working predominantly from home. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories and facilities which have been organized to reduce risk of COVID-19 transmission.</span></div><div style="text-indent:18pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The regions in which we operate are currently being affected by COVID-19.  Further, timely enrollment in our clinical trials is dependent upon clinical trial sites which may be adversely affected by COVID-19. Quarantines, shelter-in-place, safer-at-home, social distancing requirements and similar government orders, business shutdowns and closures, phased re-openings or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could continue to occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities and CROs in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Additionally, our clinical trials may involve immunocompromised patients who are at higher risk for COVID-19 and who are therefore more likely to avoid hospitals or other high risk areas.</span></div><div style="text-indent:18pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The effects of the executive orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines (for example, our timelines for any of our product candidates), the magnitude of which will continue to depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the COVID-19 outbreak, or similar pandemics, we may experience disruptions that could severely impact our business, clinical trials and preclinical studies, including:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays or difficulties in enrolling or maintaining patients in our clinical trials, including patients who may not be able to comply with clinical trial protocols if quarantines, shelter-in-place or safer-at-home restrictions, or social distancing practices or requirements, business shutdowns and closures, among other similar requirements or government orders, continue to impede patient movement or interrupt healthcare services;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or being unable to visit clinical trial locations;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff who may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays or disruptions in non-clinical experiments and investigational new drug application-enabling good laboratory practice standard toxicology studies due to unforeseen circumstances in supply chain;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, and because, who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">interruption of our key clinical trial activities , such as clinical assessments at pre-specified time points during the trial and clinical trial site data monitoring, due to limitations on travel imposed or recommended by governmental entities, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">interruption or delays in the operations of the FDA, European Medicines Agency and comparable foreign regulatory agencies or their refusal to accept data from clinical trials in affected geographies, which may impact approval timelines;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</span></div><div style="text-indent:18pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our clinical trials that we might conduct at sites outside the United States, in addition to the risks listed above, we may also experience the following adverse impacts, particularly in countries which are experiencing heightened impact from the COVID-19 pandemic:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product and comparator drugs used in our clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in local regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the refusal of the FDA to accept data from clinical trials in these affected geographies.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The spread of COVID-19, which continues to cause broad global impact, may materially affect us economically. The trading price for our shares as well as the trading prices of other biopharmaceutical companies, as well as the broader equity and debt markets overall, have been highly volatile as a result of the COVID-19 pandemic and the resulting impact on U.S. economic activities. Although the potential economic impact brought by, and the duration or subsequent reoccurrence of, the COVID-19 pandemic may be difficult to assess or predict, a widespread pandemic could continue to result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">negatively affect our liquidity. In addition, even after the COVID-19 pandemic has subsided, a recession or market correction that has occurred or may occur in the future because of the COVID-19 could materially affect our business and the value of our common stock. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus or a similar pandemic will impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration and severity of the outbreak, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, limitations on our ability to conduct our business in the ordinary course, any reopening plans and additional closures, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions for us, our third party contractors and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. The ultimate impact of the COVID-19 pandemic or a similar health pandemic is highly uncertain and subject to change; we continue to monitor the COVID-19 situation closely. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to initiate or continue conducting clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is affected by other factors including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the size and nature of the patient population;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the severity of the disease under investigation;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the eligibility criteria for, and design of, the trial in question;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the perceived risks and benefits of the product candidate under study;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">competition in recruiting and enrolling patients in clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the patient referral practices of physicians;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability to monitor patients adequately during and after treatment;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the proximity and availability of clinical trial sites for prospective patients; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays or difficulties due to the COVID-19 pandemic.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. We may encounter difficulties and/or delays in completing our planned enrollments. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, or the inability to complete development of our product candidates, which would cause the value of our company to decline, limit our ability to obtain additional financing, and materially impair our ability to generate revenues.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">variations in the level of expense related to our therapeutic candidates or future development programs; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or a future collaborator or licensing partner; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our execution of any collaboration, licensing or similar arrangement, and the timing of payments we may make or receive under such existing or future arrangements or the termination or modification of any such existing or future arrangements; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">additions and departures of key personnel; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">whether or not any of our therapeutic candidates receives regulatory approval, market acceptance and demand for such therapeutic candidates; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory developments affecting our therapeutic candidates or those of our competitors; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and&#160;out-&#160;or&#160;in-licensing&#160;of product candidates or technologies. In particular, in addition to our current arrangements with Allergan, which began in November 2019, and Dermelix, which began in February 2019, and Purdue, with which there no active therapeutic candidates in development and which has not indicated any further interest in development, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or pharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may be unable to maintain any new or existing collaboration if, for example, development or approval of a therapeutic candidate is delayed, sales of an approved product do not meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur&#160;non-recurring&#160;or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials for our therapeutic candidates. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources away from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with applicable GLPs, and clinical trials to be conducted in accordance with applicable FDA regulations and GCPs, including requirements for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the operations of our CROs may be constrained or disrupted by the COVID-19 pandemic. Clinical site closure and other activities that require visits to clinical sites, have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on third-party partners to manufacture and supply the materials and components for our research and development, preclinical study and clinical trial supplies. We do not own manufacturing facilities or supply sources for such components and materials. Our manufacturing requirements include oligonucleotides and lipids. We procure our nonclinical toxicology and clinical development materials from a single source supplier on a purchase order basis. There can be no assurance that our supply of research and development, preclinical study and clinical trial therapeutic candidates and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our drug product manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manufacturing process for a therapeutic candidate is subject to oversight by the FDA and foreign regulatory authorities. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and process validation tests required by regulatory authorities in order to comply with regulatory requirements, such as cGMPs. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our therapeutic candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our therapeutic candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop therapeutic candidates in a timely manner or within budget. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any therapeutic candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for therapeutic candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our therapeutic candidates successfully. Our or a third-party&#8217;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including: </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">an inability to initiate or continue preclinical studies or clinical trials of our therapeutic candidates under development; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delay in submitting regulatory applications, or receiving regulatory approvals, for therapeutic candidates; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">loss of the cooperation of a future collaborator; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">subjecting manufacturing facilities of our therapeutic candidates to additional inspections by regulatory authorities; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">requirements to cease distribution or to recall batches of our therapeutic candidates; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">in the event of approval to market and commercialize a therapeutic candidate, an inability to meet commercial demands for our therapeutics. </span></div><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our relationships with our manufacturers, suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Further, if the COVID-19 pandemic continues to persist for an extended period of time and impacts essential distribution systems such as FedEx and postal delivery, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our product candidates. Switching or adding additional suppliers or vendors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business.</span></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The development and commercialization of therapeutic candidates is highly competitive. We compete with a number of multinational pharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop therapeutic candidates and processes competitive with our therapeutic candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the market. We believe that a significant number of therapeutics are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop therapeutic candidates. There is intense and rapidly evolving competition in the biotechnology, pharmaceutical and oligonucleotide therapeutics fields. While we believe that our SNA technology, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded pharmaceutical, biotechnology and oligonucleotide therapeutics companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are aware of several companies that are developing oligonucleotide delivery platforms and oligonucleotide-based therapeutics. These competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus Biopharma Corp., Wave Life Sciences Ltd., Arrowhead Pharmaceuticals, Inc., ProQR Therapeutics N.V., Stoke Therapeutics, Inc., Neubase Therapeutics, Inc., Idera Pharmaceuticals, Inc., Avidity Biosciences, and Checkmate Pharmaceuticals, Inc. These and other competitors compete with us in recruiting scientific and managerial talent, and for funding from pharmaceutical companies. </span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing therapeutics. Our commercial opportunity and success will be reduced or eliminated if competing therapeutics are safer, more effective, or less expensive than the therapeutics we develop. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our therapeutic candidates are approved for the indications we are currently pursuing, they will compete with a range of therapeutic treatments that are either in development or currently marketed. A number of therapeutics for treating psoriasis and cancers are on the market or in clinical development. For the treatment of psoriasis, marketed therapies range from small molecules like topical steroids to biologics, such as AbbVie Inc.&#8217;s adalimumab. In addition, numerous compounds are in clinical development for psoriasis treatment. With respect to immunogenic cancers such as melanoma, the most common treatments are chemotherapeutic compounds, radiation therapy and now immunotherapeutic antibodies such as ipilimumab, atezolizumab, pembrolizumab and others. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including the safety and effectiveness of our therapeutics, the ease with which our therapeutics can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these therapeutics, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing therapeutics could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any therapeutics we may develop. Competitive therapeutics may make any therapeutics we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if approval is obtained for a therapeutic candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and otherwise accepted in the market. The therapeutic candidates that we are developing are based on our SNA technology. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a treatment based on SNA technology, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for any therapeutic candidates developed by us or any current or future collaborators. Market acceptance of our therapeutic candidates will depend on, among other factors: </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of our receipt of any marketing and commercialization approvals; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the terms of any approvals and the countries in which approvals are obtained; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the safety and efficacy of our therapeutic candidates; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the prevalence and severity of any adverse side effects associated with our therapeutic candidates; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">relative convenience and ease of administration of our therapeutic candidates; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the willingness of patients to accept any new methods of administration; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of our physician education programs; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the availability of adequate government and third-party payor reimbursement; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the pricing of our products, particularly as compared to alternative treatments; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">availability of alternative effective treatments for indications our therapeutic candidates are intended to treat and the relative risks, benefits and costs of those treatments. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With our focus on SNAs, these risks may increase to the extent the space becomes more competitive or less favored in the commercial marketplace. Additional risks apply in relation to any disease indications we may pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the U.S., Europe and Japan. Because of the small patient population for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved product with orphan drug designation, such therapeutic may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, assistance in clinical trial design or a reduction in user fees or tax credits related to development expense. Market size is also a variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a therapeutic, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If a therapeutic candidate that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As in the U.S., we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made.  Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication.  During such period, marketing applications for similar medicinal products will not be accepted, unless certain exceptions apply.  In the EU, a &#8220;similar medicinal product&#8221; is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success largely depends on the continued service of key management and other specialized personnel, including David A. Giljohann, Ph.D., our Chief Executive Officer, David S. Snyder, our Chief Financial Officer, Matthias G. Schroff, our Chief Operating Officer, and Douglas E. Feltner, our Chief Medical Officer. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs or clinical trials and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and our technology and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will continue to increase the size of our organization, and we may experience difficulties in managing growth.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-top:5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, we had 47 employees. As our development and commercialization plans and strategies develop, and as we further develop as a public company, we expect to need additional managerial, operational, financial and other personnel, including personnel to support our product development and planned future commercialization efforts. Future growth will impose significant added responsibilities on members of management, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">managing our internal development efforts effectively, including the clinical, FDA and EMA review processes for our product candidates; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="text-indent:18pt;margin-top:5pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are not able to effectively expand our organization by hiring new employees, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future therapeutics. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have no sales, marketing or distribution capabilities or experience. If any of our therapeutic candidates is approved, we will need to develop internal sales, marketing and distribution capabilities to appropriately commercialize such therapeutics, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our approved therapeutics directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our approved therapeutics or decide to co-promote therapeutics with collaborators, we will need to establish and maintain compliant marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved therapeutic. If we are not successful in commercializing any therapeutic approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with U.S. or foreign regulatory requirements, regulatory authorities could withhold marketing or commercialization approvals, limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our therapeutic candidates, as well as our suppliers, contract manufacturers, distributors, and contract testing laboratories are subject to extensive regulation by governmental authorities in the European Union, the U.S., and other countries, with the regulations differing from country to country. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable requirements, these regulatory authorities could refuse to issue necessary approvals for marketing and commercialization. Even if we receive marketing and commercialization approval of a therapeutic candidate, we and our third-party service providers will be subject to continuing regulatory requirements, including a broad array of regulations related to establishment registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, pre- and post-approval clinical data, labeling, advertising and promotional activities for such therapeutic, record keeping, distribution, and import and export of therapeutics for any therapeutic for which we obtain marketing approval. We are required to submit safety and other post market information and reports and are subject to continuing regulatory review, including in relation to adverse patient experiences with the therapeutic and clinical results that are reported after a therapeutic is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval. The FDA and certain foreign regulatory authorities, such as the EMA, have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">market studies or clinical trials to evaluate safety risks related to the use of a therapeutic or to require withdrawal of the therapeutic from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategies, or REMS, plan either before or after approval, which may impose further requirements or restrictions on the distribution or use of an approved therapeutic. The EMA now routinely requires risk management plans, or RMPs, as part of the marketing authorization application process, and such plans must be continually modified and updated throughout the lifetime of the product as new information becomes available. In addition, for nationally authorized medicinal products, the relevant governmental authority of any European Union member state can request an RMP whenever there is a concern about the risk/benefit balance of the product. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manufacturer and manufacturing facilities we use to make a future therapeutic, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the therapeutic, manufacturer or facility, including withdrawal of the therapeutic from the market. If we rely on third-party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our therapeutics, we or they may be subject to, among other things, fines, warning and untitled letters, clinical holds, delay or refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension, refusal to renew or withdrawal of regulatory approval, recalls, seizures or administrative detention of products, refusal to permit the import or export of therapeutics, operating restrictions, inability to participate in government programs including Medicare and Medicaid, and total or partial suspension of production or distribution, injunction, restitution, disgorgement, debarment, civil and criminal penalties and criminal prosecution. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Price controls imposed in foreign markets may adversely affect our future profitability. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control at the national level, and in some cases also at the regional level. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing and reimbursement negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our SNA therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any therapeutic candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be adversely affected. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations or prospects. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing therapeutics, such claims could result in an investigation by certain regulatory authorities, such as the FDA or foreign regulatory authorities, of the safety and effectiveness of our therapeutics, our manufacturing processes and facilities or our marketing programs and potentially a recall of our therapeutics or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our therapeutics, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels of product liability insurance prior to marketing any of our therapeutic candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements which could have an adverse effect on our business.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include, but is not limited to, intentional failures to comply with FDA, the Centers for Medicare &amp; Medicaid Services, or CMS, the Department of Health and Human Services, or HHS, Office of Inspector General, or OIG, or other agency regulations, applicable laws, regulations, guidance or codes of conduct set by foreign governmental authorities or self-regulatory industry organizations, or provide accurate information to any governmental authorities, such as the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws, regulations, guidance and codes of conduct intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws, regulations, guidance and codes of conduct may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, including, fines, debarment, or disqualification of those employees from participation in certain government-regulated activities, and serious harm to our reputation. This could include violations of the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including exclusion from participation in the U.S. federal healthcare programs, the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Animal Welfare Act, or AWA, is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our therapeutic development programs. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical study or clinical trial data involving our therapeutic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates has not been, or will not in the future be, compromised. Although we have invested resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our CROs and other contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.  Financial penalties may also apply in some data breaches where noncompliance with the applicable law is identified.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our therapeutic candidates could be delayed. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities in Chicago, Illinois that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Chicago facilities comply with the relevant guidelines of Chicago, the state of Illinois, and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our information technology systems could face serious disruptions that could adversely affect our business. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development work. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Increasing scrutiny and changing expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Companies are facing increasing scrutiny from customers, regulators, investors, and other stakeholders related to their environmental, social and governance practices. Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, health and safety, supply chain management, diversity and human rights. Failure to adapt to or comply with regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation and the price of our ordinary shares.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of the factors mentioned above, or the perception that we or our suppliers, or contract manufacturers or collaborators have not responded appropriately to the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material adverse effect on our business, financial condition, results of operations cash flows and/or ordinary share price.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, floods, and other forms of severe hazards in the United States or in other countries in which we or our suppliers or </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">manufacturers operate or are located could adversely affect our operations and financial performance.  These types of unexpected events could result in physical damage to and complete or partial closure of one or more of the manufacturing facilities operated by our contract manufacturers, or the temporary or long-term disruption in the supply of products, and/or disruption of our ability to deliver products to customers. Further, the long-term effects of climate change on general economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses. Existing insurance arrangements may not provide protection for the costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations, our business, results of operations and stock price.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current operations are located in our facilities situated in Chicago, Illinois. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, we had $18.4 million in cash, cash equivalents, and restricted cash and $68.6 million in short-term investments.  We historically have invested excess cash in certificates of deposit or money market mutual funds that invest in securities issued or guaranteed by the U.S.&#160;government or U.S.&#160;government agencies, floating rate and variable rate demand notes of U.S.&#160;and foreign corporations, and commercial paper.  During the fourth quarter of 2019, we have made direct purchases, and expect to continue to make direct purchases of, U.S.&#160;government or U.S.&#160;government agency securities, floating rate and variable rate demand notes of U.S.&#160;and foreign corporations, and commercial paper.  These investments are subject to general credit, liquidity, market and interest rate risks, including potential future impacts similar to the impact of U.S.&#160;sub-prime mortgage defaults that have affected various sectors of the financial markets and caused credit and liquidity issues.  We may realize losses in the fair value of these investments, an inability to access cash in these investments for a potentially meaningful period, or a complete loss of these investments, which would have a negative effect on our financial statements. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, the Sarbanes-Oxley Act of 2002 and the rules&#160;and regulations of The Nasdaq Capital Market. Pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, we are now required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Further, we may in the future discover weaknesses in our system of internal financial and accounting controls and procedures that </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">could result in a material misstatement of our financial statements. Moreover, our internal controls over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Moreover, we are aware that the remote working arrangements implemented in connection with the COVID-19 pandemic potentially present new areas of risk, and we continue to monitor carefully any impact to our internal controls and procedures.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to assert that our internal control over financial reporting is effective, investors could lose confidence in the reliability of our financial statements, the market price of our stock could decline and we could be subject to sanctions or investigations by The Nasdaq Capital Market, the SEC or other regulatory authorities.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Intellectual Property </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are not able to obtain and enforce patent protection for our technology or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our therapeutic candidates, methods used to manufacture our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of June 30, 2020, our patent portfolio consists of over 100 issued patents and allowed patent applications and over 110 pending patent applications.  We may not be able to apply for patents on certain aspects of our therapeutic candidates in a timely fashion or at all. Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our therapeutic candidates or to provide meaningful protection from our competitors. Moreover, the patent position of pharmaceutical and biotechnology companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. While we will endeavor to try to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act enacted in 2011, involves significant changes in patent legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. The 2013 decision by the Supreme Court in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Association for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> precludes a claim to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and unmodified. We currently are not aware of an immediate impact of this decision on our patents or patent applications because we are developing oligonucleotide therapeutics which contain modifications that we believe are not found in nature. However, this decision has yet to be clearly interpreted by courts and by the USPTO. We cannot assure you that the interpretations of this decision or subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, there can be no assurance that: </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Others will not or may not be able to make, use or sell compounds that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or license. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We or our licensors, or any current or future collaborators, are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We or our licensors, or any current or future collaborators, are the first to file patent applications covering certain aspects of our inventions. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Others will not independently develop similar or alternative technologies or duplicate any of our technology without infringing our intellectual property rights. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A third-party will not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We will develop additional proprietary technologies that are patentable. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The patents of others will not have an adverse effect on our business. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our competitors will not conduct research and development activities in countries where we lack enforceable patent rights and then use the information learned from such activities to develop competitive therapeutics for sale in our major commercial markets. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patent term may be inadequate to protect our competitive position on our future therapeutics for an adequate amount of time. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given the amount of time required for the development, testing and regulatory review of new therapeutic candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the U.S. and, if available, in other countries where we have patents covering our product candidates. In the U.S., the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, the patent term extension or restoration cannot extend the remaining term of a patent beyond a total of 14 years from the approval date of the product candidate.&#160;Only one patent applicable to an approved product candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration dates. However, the applicable authorities, including the FDA and the USPTO in the U.S., and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We currently license patent rights from Northwestern University and may in the future license patent rights from third-party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do, and will continue to, rely on intellectual property rights licensed from third parties to protect our technology. We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. In particular, we have a license from Northwestern University, which provides us the exclusive worldwide right under certain patents and patent applications owned by Northwestern University to exploit therapeutics and processes using nanoparticles, nanotechnology, microtechnology and nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of administration. We may also license additional third-party intellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, and in particular, for those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications licensed to us. Even if patents issue or are granted, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue litigation less aggressively than we would. Further, we may not obtain exclusive rights, which would allow for third parties to develop competing therapeutics. Without protection for, or exclusive rights to, the intellectual property we license, other companies might be able to offer substantially identical therapeutics for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, the U.S. government has certain rights to the inventions covered by the patent rights licensed to us by third parties and Northwestern University, as an academic research and medical center, has reserved the right to practice the patent rights it has licensed to us (i)&#160;for research, teaching and/or other educationally related purposes (including the right to distribute materials for such purposes) and (ii)&#160;for use in the field of diagnostics (including theradiagnostics) and in any field other than the field of use licensed to us. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our therapeutic candidates. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Oligonucleotide and SNA-based therapeutics are a relatively new scientific field. We have obtained grants and issuances of SNA therapeutic patents and have licensed many of these patents from a third-party on an exclusive basis for therapeutics applications. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of SNA therapeutics. Specifically, we own and have licensed a portfolio of patents, patent applications and other intellectual property covering SNA compositions of matter as well as their methods of use. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the field of SNA therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need to apply to our SNA therapeutic candidates. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for SNA therapeutics we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market therapeutics or perform research and development or other activities covered by these patents. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to protect our intellectual property rights throughout the world. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Obtaining a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology to develop their own therapeutics and, further, may export otherwise infringing therapeutics to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor therapeutics may compete with our future therapeutics in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology and pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing therapeutics in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We generally file a provisional patent application first, also known as a priority filing, at the USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the U.S., European Union, Japan, Australia and Canada and, depending on the individual case, also in any or all of, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter alia</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, China, India, South Korea, and Mexico. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant or after grant by nonpayment of maintenance fees for the resulting patent. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We or our licensors, or any current or future strategic partners, may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our licensors, or any current or future strategic partners, may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license agreements to indemnify and hold harmless our licensors for damages arising from intellectual property infringement by us. If we or our licensors, or any current or future strategic partners, are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, or any current or future strategic partners, may choose to seek, or be required to seek, a license from a third-party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or any current or future collaborator may be unable to effectively market therapeutic candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our therapeutics or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our therapeutics or certain aspects of our technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutics or technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our SNA technology, our therapeutics or the use of our therapeutics. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our therapeutics. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our therapeutic candidates that are held to be infringing. We might, if possible, also be forced to redesign therapeutic candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our therapeutic candidates or we could lose certain rights to grant sublicenses. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell therapeutics that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights in such unlicensed intellectual property. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future therapeutics, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in therapeutics that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize therapeutics, we may be unable to achieve or maintain profitability. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Northwestern University License Agreements, Northwestern University could publish research findings relating to the patent rights licensed to us by Northwestern University, which could have a material adverse effect on our business. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also subject both in the U.S. and outside the U.S. to various regulatory schemes regarding requests for the information we provide to regulatory authorities, which may include, in whole or in part, trade secrets or confidential commercial information. While we are likely to be notified in advance of any disclosure of such information and would likely object to such disclosure, there can be no assurance that our challenge to the request would be successful. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our employees were previously employed at universities or pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third parties may independently develop similar or superior technology. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There can be no assurance that others will not independently develop, or have not already developed, similar or more advanced technologies than our technology; or that others will not design around, or have not already designed around, aspects of our technology and/or our trade secrets developed therefrom. If third parties develop technology similar or superior to our technology, or they successfully design around our current or future technology, our competitive position, business prospects, and results of operations could be materially and adversely affected. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The intellectual property which we have licensed from Northwestern University was discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have licensed certain intellectual property from Northwestern University pursuant to the Northwestern University License Agreements. The Northwestern University License Agreements indicate that the rights licensed to us by Northwestern University are subject to the obligations to and the rights of the U.S. government, including those set&#160;forth in the Bayh-Dole Act of 1980, or Bayh-Dole Act. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future therapeutics based on the licensed Northwestern University intellectual property. These U.S. government rights&#160;in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide&#160;license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third-party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as&#160;&#8220;march-in rights.&#8221; While the U.S. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">government has sparingly used, and to the Company&#8217;s knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the U.S. government requires that any therapeutics embodying any invention generated through the use of U.S. government funding be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. therapeutic manufacturers for therapeutics covered by such intellectual property. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Government Regulation </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our therapeutic candidates. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our therapeutic candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing, sampling, and distribution of therapeutics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new therapeutic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the therapeutic candidates we may develop will obtain the regulatory approvals necessary for us or any current or future collaborators to begin selling them. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA as well as foreign regulatory authorities, such as the EMA and European Union national competent authorities. The time required to obtain FDA and foreign regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the therapeutic candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in the policy of the FDA or foreign regulatory authorities during the period of therapeutic development, clinical trials and regulatory review by the FDA or foreign regulatory authorities. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign laws, regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. In addition, unfavorable changes in our industry or the global economy, including as a result of the COVID-19 pandemic, could contribute to some of the events listed above and further impact our ability to progress our clinical trials, submit for marketing approval or commercialize our product candidates, if approved, as planned.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because the therapeutics we are developing may represent a new class of therapeutic, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these therapeutics. While we believe the therapeutic candidates that we are currently developing are regulated as new drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA could decide to regulate them or other therapeutics we may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder or slow review by the FDA or foreign regulatory authorities of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our therapeutic candidates. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular therapeutic candidate for which we are seeking approval. Furthermore, any regulatory approval to market a therapeutic may be subject to limitations on the approved uses for which we may market the therapeutic or the labeling or other restrictions. Regulatory authorities also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic. In addition, the FDA has the authority to require a REMS plan as part of a NDA or a Biologics License Application, or BLA, or after </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the therapeutic and affect coverage and reimbursement by third-party payors. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Certain of our therapeutic candidates may require companion diagnostics in certain indications.  Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our therapeutic candidates.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of our therapeutic candidates may require companion diagnostics to identify appropriate patients for those therapeutic candidates in certain indications.  Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization.  We may rely on third parties for the design, development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory authorization, and the commercial supply of these companion diagnostics.  If these parties are unable to successfully develop companion diagnostics for these therapeutic candidates, or experience delays in doing so, the development of our therapeutic candidates may be adversely affected and we may not be able to obtain marketing authorization for these therapeutic candidates.  Furthermore, our ability to market and sell, as well as the commercial success, of any of our therapeutic candidates that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies.  Any failure to develop, validate, obtain and maintain marketing authorization for a companion diagnostic and supply such companion diagnostic will harm our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or current or future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics and may harm our reputation. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we do not currently have any products on the market, our current and future business operations may subject us to additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, including physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell or distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers, among others, on the other. A person or entity does not need to have actual knowledge pf the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the U.S.&#160;federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products;</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">HIPAA includes a fraud and abuse provision sometimes referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program (i.e., not just federal healthcare programs), or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">HIPAA, as amended by the HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the federal Physician Payments Sunshine Act and the implementing regulations, also referred to as &#8220;Open Payments,&#8221; issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, which require that certain manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to U.S.-licensed physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and U.S. teaching hospitals with limited exceptions. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made during the previous year to certain non-physician providers such as physician assistants and nurse practitioners; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">analogous state laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and state transparency laws that require the reporting of certain pricing information; among other state laws. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, possible exclusion from government healthcare reimbursement programs, integrity oversight and reporting obligations to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ensuring that our future business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including significant administrative, civil and/or criminal penalties, monetary damages, additional integrity reporting requirements and regulatory oversight, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">including Medicare and Medicaid, any of which could adversely affect our financial results. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics successfully and could harm our reputation and lead to reduced acceptance of our therapeutics by the market. These enforcement actions include, among others: </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">adverse regulatory inspection findings; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">warning or untitled letters; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">voluntary product recalls or public notification or medical product safety alerts to healthcare professionals; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">restrictions on, or prohibitions against, marketing our therapeutics; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">restrictions on, or prohibitions against, importation or exportation of our therapeutics; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspension of review or refusal to approve pending applications or supplements to approved applications; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">exclusion from participation in government-funded healthcare programs; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">exclusion from eligibility for the award of government contracts for our therapeutics; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">FDA debarment; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspension or withdrawal of therapeutic approvals; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">seizures or administrative detention of therapeutics; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">injunctions; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">civil and criminal penalties and fines. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Any therapeutics we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutics vary widely from country to country. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or therapeutic licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a therapeutic in a particular country, but then be subject to price regulations that delay our commercial launch of the therapeutic and negatively impact the revenues we are able to generate from the sale of the therapeutic in that country.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patients who are prescribed therapeutics for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved therapeutics. Our ability to commercialize any therapeutics successfully also will depend in part on the extent to which coverage and reimbursement for these therapeutics and related treatments will be available from government health administration authorities, private health insurers and other organizations. However, there may be significant delays in obtaining coverage for newly-approved therapeutics. Moreover, eligibility for coverage does not necessarily signify that a therapeutic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution costs. Also, interim payments for new therapeutics, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more therapeutics to the market, these therapeutics may not be considered cost-effective, and the amount reimbursed for any therapeutics may be insufficient to allow us to sell our therapeutics on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">effectiveness or the likely level or method of reimbursement. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates and other concessions to reduce the prices for therapeutics. If the price we are able to charge for any therapeutics we develop, or the reimbursement provided for such therapeutics, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently expect that some therapeutics we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutics that are not usually self-administered (including injectable therapeutics) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain pharmaceutical products that are medically necessary to treat a beneficiary&#8217;s health condition. Specifically, Medicare Part B coverage may be available for eligible beneficiaries when the following, among other requirements, have been satisfied:</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the product is typically furnished incident to a physician&#8217;s services; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the product has been approved by the FDA. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Medicaid Drug Rebate Statute, a manufacturer must participate in the Medicaid Drug Rebate Program in order to receive payment for its covered outpatient drugs under Medicare Part B (the Medicare program that generally covers physician-administered, outpatient drugs).&#160; 42 U.S.C. &#167; 1396r-8(a)(1).  In addition, manufacturers who participate in the Medicaid Drug Rebate Program are also required to (1) sign the Pharmaceutical Pricing Agreement and participate in the 340B Drug Pricing Program, and (2) sign the VA Master Agreement for inclusion of the manufacturer&#8217;s drugs on the Federal Supply Schedule, or FSS.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Id</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities eligible to participate in the program. Average prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of therapeutics from countries where they may be sold at lower prices than in the U.S. Self-administered therapeutics are typically reimbursed under Medicare Part D, and therapeutics that are administered in an inpatient hospital setting are typically reimbursed under Medicare Part A under a bundled payment. It is difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our therapeutics in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage, and adequate reimbursement from both government-funded and private payors for new therapeutics we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare, and specifically, therapeutics, and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biotechnology companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed. These developments could, directly or indirectly, affect our ability to sell our therapeutics, if approved, at a favorable price.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, in the U.S., in 2010, the U.S. Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional policy reforms.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although the future of the ACA is uncertain, provisions of the ACA addressing coverage and reimbursement of pharmaceutical products that may be of importance to our potential therapeutic candidates include the following:</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Increases to pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans.</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The expansion of the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Requirements imposed on pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221; In February 2018, Congress passed the Bipartisan Budget Act of 2018, which, effective as of 2019, increased the discount to be paid by pharmaceutical companies from 50% to 70% of a brand-name drug&#8217;s negotiated price and added biosimilars to the coverage gap discount program.</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Requirements imposed on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense. Since we currently expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare program pharmaceutical market, we do not currently expect this annual assessment to have a material impact on our financial condition. </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">For therapeutic candidates classified as biologics, marketing approval for a follow-on biologic therapeutic may not become effective until 12 years after the date on which the reference innovator biologic therapeutic was first licensed by the FDA, with a possible six-month extension for pediatric therapeutics. After this exclusivity ends, it may be possible for biosimilar manufacturers to enter the market, which is likely to reduce the pricing for such therapeutics and could affect our profitability if our therapeutics are classified as biologics. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Separately, pursuant to certain health reform legislation and related initiatives, CMS is working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Financial Alignment Initiative Demonstration, and other models. The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by such organizations.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There remain judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently undergoing legal and constitutional challenges in the Fifth Circuit Court and the United States Supreme Court; the Trump Administration has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices; and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what affect further changes to the ACA would have on our business.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs.  On March 10, 2020, the Trump Administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases.&#160; Further, the Trump Administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. On July 24, 2020, the Trump administration announced four executive orders related to prescription drug pricing that attempt to implement several of the Trump administration&#8217;s proposals, including a policy that would tie Medicare Part B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; one that directs HHS to finalize the rulemaking process on modifying the anti-kickback law safe harbors for discounts for plans, pharmacies, and pharmacy benefit managers; and one that reduces costs of insulin and epipens to patients of federally qualified health centers. While some of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, individual states have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our therapeutic candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our therapeutic candidates, restrict or regulate post-approval activities and affect our ability to commercialize our therapeutic candidates, if approved. In markets outside of the United States and European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future therapeutic candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time- consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or third-party CMOs, CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our therapeutic candidates and could harm or prevent sales of any affected therapeutics that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our therapeutics. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending. </span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. federal government agencies currently face potentially significant spending reductions. The Budget Control Act of 2011, or BCA, established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That committee did not draft a proposal by the BCA&#8217;s deadline. As a result, automatic cuts, referred to as sequestration, in various federal programs were scheduled to take place. This includes reductions to Medicare payments to providers of 2% per fiscal year, that began in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020 and is designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030. </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These reductions may also impact the ability of relevant agencies to timely review and approve therapeutic research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any therapeutics we may develop.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic candidate, our ability to market and derive revenue from the therapeutic candidates could be compromised. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event that any of our therapeutic candidates receive regulatory approval and we or others identify undesirable side effects, adverse events or other problems caused by one of our therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory authorities may withdraw their approval of the therapeutic or seize the therapeutic; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may need to recall the therapeutic or change the way the therapeutic is administered to patients; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">additional restrictions may be imposed on the marketing of the particular therapeutic or the manufacturing processes for the therapeutic or any component thereof; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may be subject to fines, restitution or disgorgement of profits or revenues, injunctions, or the imposition of civil penalties or criminal prosecution; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory authorities may require us to implement a REMS, or to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we could be sued and held liable for harm caused to patients; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the therapeutic may become less competitive; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our reputation may suffer. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">An active trading market for our common stock may not develop or be sustainable. If an active trading market does not develop, investors may not be able to resell their shares at or above the price for which they were purchased and our ability to raise capital in the future may be impaired.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our common stock began trading on the Nasdaq Capital Market on July 31, 2019. Although our common stock is listed on the Nasdaq Capital Market, an active trading market for our shares may never develop or, if developed, be maintained. If an active market for our common stock does not develop or is not maintained, it may be difficult for investors to sell shares without depressing the market price for the shares or at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The market price of our common stock has been, and is likely to continue to be, highly volatile, and you may not be able to resell your shares at or above the price you paid for them. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since July 31, 2019, our stock price has been volatile and it is likely that the trading price of our common stock will continue to be volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by a variety of factors, including the other risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of competitive therapeutics or technologies; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">results of our preclinical studies and clinical trials of our therapeutic candidates, or those of our competitors, or any current or future collaborators; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our therapeutics; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">introductions and announcements of new therapeutics by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">actions taken by regulatory agencies with respect to our therapeutics, clinical studies, manufacturing process or sales and marketing terms; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the success of our efforts to acquire or in-license additional technologies, therapeutics or therapeutic candidates; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">developments concerning any current or future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our therapeutics; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability or inability to raise additional capital and the terms on which we raise it; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the recruitment or departure of key personnel; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in the structure of healthcare payment systems; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">market conditions in the pharmaceutical and biotechnology sectors; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcement and expectation of additional financing efforts; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">speculation in the press or investment community; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">trading volume of our common stock and overall fluctuations in U.S. equity markets, including as a result of the COVID-19 pandemic; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">sales of our common stock by us or our stockholders; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the concentrated ownership of our common stock; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in accounting principles; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">terrorist acts, acts of war or periods of widespread civil unrest; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">natural disasters and other calamities; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors, such as those related to the COVID-19 pandemic, may seriously harm the market price of our common stock, regardless of our operating performance. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Raising additional funds by issuing securities may cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants and license and development agreements in connection with any collaborations. We do not have any committed external source of funds. To the extent that we raise additional capital through the issuance of shares or other securities convertible into shares, our stockholders will be diluted.  Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the prevailing market price of our common stock and impair our ability to raise capital through future offerings of equity or equity-linked securities.  For example, on December 23, 2019, we completed the sale of 10,000,000 shares of our common stock in the December 2019 Offering and on August 2, 2019 we completed the sale of 31,625,000 shares of our common stock in the August 2019 Offering.  The issuance of shares in both the December 2019 Offering and August 2019 Offering were pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on July 24, 2019. The shelf registration statement allows us to sell from time-to-time up to $125.0 million of common stock, preferred stock, debt securities, warrants, or units comprised of any combination of these securities, for our own account in one or more offerings; the remaining amount available under this shelf registration after the December 2019 Offering (inclusive of the exercise of the underwriters&#8217; option in January 2020 to purchase additional shares at the public offering price in connection with the December 2019 Offering) is approximately $31.3 million. The issuance of the shares pursuant to the December 2019 Offering and the August 2019 Offering and/or the resale of a substantial number of shares of our common stock in the public market could adversely affect the market price for our common stock and make it more difficult for you to sell shares of our common stock at times and prices that you feel are appropriate. Adverse market and price pressures that may result from the December 2019 Offering or the August 2019 Offering or an offering pursuant to the shelf registration statement may continue for an extended period of time and continued negative pressure on the market price of our common stock could have a material adverse effect on our ability to raise additional equity capital.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. Any debt financing that we enter into may involve covenants that restrict our operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are an &#8220;emerging growth company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, (2)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (3)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements and two years of selected financial data. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0&#160;million as of any June&#160;30 before that time or if we have total annual gross revenue of $1.07&#160;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&#160;31, or if we issue more than $1.0&#160;billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%;">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our stock.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business.  Our research coverage by securities and industry analysts is currently limited.  In addition, because we did not become a reporting company by conducting an underwritten initial public offering of our common stock, security analysts of brokerage firms may not provide wider coverage of our Company.  In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because they may be less familiar with our Company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development.  The failure to receive wider research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our common stock and the trading price for our stock would be negatively impacted.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the event we obtain wider securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline.  If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on the beneficial ownership of our common stock as of June 30, 2020, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, will beneficially own approximately&#160;40% of our outstanding common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions in our charter documents and under the General Corporation Law of the State of Delaware could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the Board to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, or DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined organization voting stock from merging or combining with the combined organization. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it more difficult for stockholders to replace members of the Board, which is responsible for appointing the members of management. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions in our charter documents could discourage, delay or prevent a change in control of us and may affect the trading price of our common stock. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our corporate documents and the DGCL contain provisions that may enable our Board to resist a change in control of us even if a change in control were to be considered favorable by our stockholders. These provisions: </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">stagger the terms of our Board and require 66 and 2/3% stockholder voting to remove directors, who may only be removed for cause; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">authorize our Board to issue &#8220;blank check&#8221; preferred stock and to determine the rights and preferences of those shares, which may be senior to our common stock, without prior stockholder approval; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholders&#8217; meetings; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">prohibit our stockholders from calling a special meeting and prohibit stockholders from acting by written consent; </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require 66 and 2/3% stockholder voting to effect certain amendments to our certificate of incorporation and bylaws; and </span></div><div style="text-indent:-18pt;padding-left:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These provisions could discourage, delay or prevent a transaction involving a change in control of us. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and cause us to take other corporate actions our stockholders desire. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any of the following types of actions or proceedings under Delaware statutory or common law: derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claims for which a court or forum other than the Court of Chancery has exclusive jurisdiction or for which the Court of Chancery does not have subject matter jurisdiction. Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated certificate of incorporation also provides that any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation.  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. If a court were to find this exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in any action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition&#160;or results of operations.</span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. Our net operating loss, or NOL, carryforwards generated in tax years beginning on or after to December 31, 2017, are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act, or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">87</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. </span></div><div><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_148"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Defaults Upon Senior Securities.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_151"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. Mine Safety Disclosures.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_154"></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 5. Other Information.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="margin-bottom:9pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6. Exhibits</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.024%;"><tr><td style="width:1.0%;"></td><td style="width:12.171%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.121%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.394%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.764%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.628%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporated by Reference </span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:3.75pt;margin-bottom:1.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Exhibit</span></div><div style="text-align:center;margin-top:3.75pt;margin-bottom:1.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">No.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:3.75pt;margin-bottom:1.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit Description</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filing Date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">File No.</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex32.htm">Certificate of Amendment to Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on September 26, 2017.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">10/02/17</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;000-55764</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex33.htm">Form of Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on November 15, 2017.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">10/02/17</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;000-55764</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex34.htm">Amended and Restated Bylaws, as currently in effect.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-13.5pt;padding-left:13.5pt;text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">10/02/17</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-11.25pt;text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">000-55764</span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1+*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853020000047/ex101_cicsideletter.htm">Form of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853020000047/ex101_cicsideletter.htm">Executive Employment Side Letter Agreement</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853020000047/ex101_cicsideletter.htm"> </a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">06/09/20</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-39011</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2+*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exicureexhibit102-empl.htm">Amended and Restated Employment Agreement dated as of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exicureexhibit102-empl.htm">June </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exicureexhibit102-empl.htm">30</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exicureexhibit102-empl.htm">, 2020 by and between Douglas E. Feltner, M.D. and Exicure, Inc.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exicureexhibit311-63020.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exicureexhibit312-63020.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exicureexhibit321-63020.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="margin-bottom:9pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.024%;"><tr><td style="width:1.0%;"></td><td style="width:12.171%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.121%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.394%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.764%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.942%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.596%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.628%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-13.5pt;padding-left:13.5pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*   Filed herewith.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">+ Indicates a management contract or compensatory plan. </span></div><div style="text-indent:-13.5pt;padding-left:13.5pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">**   The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exicure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></div><div style="text-indent:18pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">90</span></div></div></div><div id="i87c412b98f4a4c10b3a3081e33f1cbca_160"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%;"><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i87c412b98f4a4c10b3a3081e33f1cbca_7">Table of Contents</a></span></div><div style="text-align:center;margin-bottom:9pt;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date: August 12, 2020</span></div><div style="text-align:right;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.551%;"><tr><td style="width:1.0%;"></td><td style="width:10.589%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:85.411%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EXICURE, INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ David S. Snyder</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David S. Snyder</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">91</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>exicureexhibit102-empl.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i8bae5969b3924902b41b457da2381ac6_1"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 10.2</font></div></div><div><font><br></font></div><div style="text-align:center;margin-bottom:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amended and Restated Employment Agreement</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">This Amended and Restated Employment Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) between </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exicure, Inc.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Doug E. Feltner, MD </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Executive</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) (each of the Executive and the Company, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Party,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), is entered into as of June 30, 2020.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Whereas</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Company desires to continue to employ the Executive as its Chief Medical Officer&#59;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Whereas</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Company and the Executive previously entered into an employment agreement dated as of March 26, 2020 pursuant to which the Executive served as Chief Medical Officer of the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Prior Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Whereas</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Executive desires to continue to be employed by the Company as Chief Medical Officer and to perform his duties to the Company on the terms and conditions hereinafter set forth&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Whereas</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Parties wish to amend and restate the terms of the Prior Agreement as set forth in this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Now, Therefore</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the mutual covenants contained herein and other valid consideration, the sufficiency of which is acknowledged, the Parties hereto agree as follows&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Executive&#8217;s employment under this Agreement shall commence on June 30, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and shall continue until the termination of Executive&#8217;s employment under this Agreement. The period from the Effective Date until the termination of Executive&#8217;s employment under this Agreement is referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Employment Period.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Position and Duties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to the terms and conditions of this Agreement, Executive shall continue to serve as the Chief Medical Officer of the Company and shall have the duties, responsibilities and authority of an executive serving in such position, reporting and subject to the direction of the Chief Executive Officer of the Company or other duly authorized executive. Executive shall devote his full business time and efforts to the business and affairs of the Company and its subsidiaries. Executive shall not become a director of any for-profit entity without first receiving the approval of the Nominating and Corporate Governance Committee of the Board.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Compensation and Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. As compensation for Executive&#8217;s performance of Executive&#8217;s duties hereunder, Executive shall receive a base salary at the rate of three hundred sixty five thousand dollars ($365,000) per year (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), subject to standard payroll </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">deductions and withholdings and payable in accordance with the Company&#8217;s regular payroll schedule. Executive&#8217;s Base Salary shall be reviewed by the Board for possible adjustment annually.  The Base Salary shall be reviewed for adjustments by the Compensation Committee of the Board (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Compensation Committee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) in good faith, based upon Executive&#8217;s performance and the Company&#8217;s pay philosophy, not less often than annually, provided, that Executive&#8217;s Base Salary may be decreased as part of an across-the-board reduction in base salaries of all Company executive officers so long as the percentage reduction in Executive&#8217;s Base Salary is not greater than the percentage reduction applicable to other executive officers. The term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Base Salary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall refer to the Base Salary as may be in effect from time to time.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt;">Annual Incentive Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Executive shall be eligible to participate in the annual cash bonus program maintained for executive officers of the Company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Annual  Incentive Program</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Executive&#8217;s minimum target annual bonus shall be equal to at least 30% of Base Salary for each year during the Employment Period in which Executive participates in the Annual Incentive Program. The actual amount of the annual bonus earned by and payable to Executive in any year shall be determined upon the satisfaction of goals and objectives established by the Compensation Committee and communicated to Executive, and shall be subject to such other terms and conditions of the Annual Incentive Program as in effect from time to time. Each bonus paid under the Annual Incentive Program shall be paid to Executive no later than March 15th of the calendar year following the calendar year in which the bonus is earned.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">Other Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:96.69pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Savings and Retirement Plans. Except as otherwise limited by applicable law, Executive shall be entitled to participate in all qualified and non-qualified savings and retirement plans applicable generally to other senior executive officers of the Company, in accordance with the terms of the plans, as may be amended from time to time.</font></div><div style="text-indent:93.36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Welfare Benefit Plans. Except as otherwise limited by applicable law, Executive and&#47;or his eligible dependents shall be eligible to participate in and shall receive all benefits under the Company&#8217;s welfare benefit plans and programs applicable generally to other senior executive officers of the Company, in accordance with the terms of the plans, as may be amended from time to time.</font></div><div style="text-indent:90.03pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Perquisites. Except as otherwise limited by applicable law, Executive shall be entitled to such perquisites as may be available generally from time to time to other senior executive officers of the Company, but at levels commensurate with executive&#8217;s position as Chief Medical Officer.</font></div><div style="text-indent:90.69pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Business Expenses. Subject to Section 14, Executive shall be reimbursed for reasonable travel and other expenses incurred in the performance of Executive&#8217;s duties on behalf of the Company in a manner consistent with the Company&#8217;s policies regarding such reimbursements, as may be in effect from time to time.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Termination of Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;">Executive&#8217;s employment under this Agreement shall terminate upon the earliest to occur of&#58; (i) the expiration of the term of this Agreement pursuant to Section 1 hereof&#59; (ii) Termination due to Disability (as defined below)&#59; (iii) termination of Executive&#8217;s employment by the Company for any reason other than Termination due to Disability&#59; (iv) Executive&#8217;s death&#59; or (v) termination of Executive&#8217;s employment by Executive for any reason. Upon the termination of Executive&#8217;s employment with the Company for any reason, Executive shall be deemed to have resigned from all positions with the Company or any of its affiliates held by Executive as of the date immediately preceding his termination of employment.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt;">If Executive&#8217;s employment ends for any reason, except as otherwise contemplated in this Section 4, Executive shall cease to have any rights to salary, bonus (if any) or other benefits, other than (i) the earned but unpaid portion of Executive&#8217;s Base Salary through the date of termination or resignation, (ii) any annual, long-term, or other incentive award that relates to a completed fiscal year or performance period, as applicable, and is payable (but not yet paid) on or before the date of termination or resignation, which shall be paid in accordance with the terms of such award, (iii) a lump-sum payment in respect of accrued but unused vacation days at the Executive&#8217;s per-business-day Base Salary rate, (iv) any unpaid expense or other reimbursements due to Executive, and (v) any other amounts or benefits required to be paid or provided by law or under any plan, program, policy or practice of the Company, provided that Executive shall not be entitled to any payment or benefit under any severance plan maintained by the Company.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">Termination without Cause or for Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If Executive&#8217;s employment hereunder shall be terminated by the Company without Cause, or by Executive for Good Reason, then in addition to the payments and benefits described in Section 4(b) and subject to Executive&#8217;s execution and non-revocation of the release contemplated in Section 4(f) of this Agreement and Executive&#8217;s continuing compliance with the Non-Competition Agreement (as  defined below)&#58;</font></div><div style="text-indent:96.69pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Company shall pay Executive continuation of six (6) months of Executive&#8217;s annual Base Salary, as in effective immediately prior to Executive&#8217;s termination of employment hereunder, payable during the 6-month period following Executive&#8217;s termination of employment in the form of salary continuation in accordance with the Company&#8217;s normal payroll practices&#59;</font></div><div style="text-indent:93.36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Company shall pay Executive an annual cash bonus for the year of termination, payable at the same time as annual cash bonuses are paid to senior management, based on actual achievement of performance targets (as if Executive had remained employed through the end of the applicable performance period), subject, however, to proration based on the number of days in the applicable performance period that had elapsed prior to the date of termination&#59; and</font></div><div style="text-indent:90.03pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">if the Executive timely elects to receive continued coverage under the Company&#8217;s group health care plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Company shall pay the employer portion of applicable COBRA premium payments for the Executive&#8217;s and, as applicable, Executive&#8217;s dependents&#8217;, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">continued health coverage under such plan (as in effect or amended from time to time) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">COBRA Subsidy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) until the earlier of&#58; (1) six (6) months following the Executive&#8217;s termination of employment, or (2) the date upon which the Executive obtains or becomes eligible for other health care coverage from a new employer or otherwise (such period referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">COBRA Subsidy Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The Executive shall promptly inform the Company in writing when Executive obtains or becomes eligible for any such other health care coverage. The Executive shall be responsible for paying a share of such COBRA premiums during the COBRA Subsidy Period at active employee rates as in effect from time to time, and shall be responsible for the full unsubsidized costs of such COBRA coverage thereafter.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt;">Termination without Cause or for Good Reason in Connection with a Change in Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If Executive&#8217;s employment hereunder shall be terminated by the Company without Cause, or by Executive for Good Reason, in either case within 12 months following a Change in Control then, in addition to the payments and benefits described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and subject to Executive&#8217;s execution and non-revocation of the release contemplated in Section 4(f) of this Agreement and Executive&#8217;s continuing compliance with the Company's Confidentiality, Non-Hire, Non-Disparagement, and Work Product Agreement (as defined below)&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">The Company shall pay Executive continuation of fifteen (15) months (&#8220;Benefit Period&#8221;) of Executive&#8217;s annual Base Salary, as in effect immediately prior to Executive&#8217;s termination of employment hereunder, payable during the 6-month period following Executive&#8217;s termination of employment in the form of salary continuation in accordance with the Company&#8217;s normal payroll practices&#59;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The Company shall pay Executive an annual cash bonus equal to Executive&#8217;s annual target bonus as set forth in Section 3(b) for the year in which the termination of employment occurs, payable at the same time as annual cash bonuses are paid to senior management&#59; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">All equity awards, to the extent outstanding as of immediately prior to such termination, will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to the latter of&#58; (1) the date of termination and (2) the date of the Change in Control&#59; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">If the Executive timely elects to receive continued coverage under the Company&#8217;s group health care plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;), the Company shall pay the employer portion of applicable COBRA premium payments for the Executive&#8217;s and, as applicable, Executive&#8217;s dependents&#8217;, continued health coverage under such plan (as in effect or amended from time to time) (the &#8220;COBRA Subsidy&#8221;) until the earlier of&#58; (1) fifteen (15) months following the Executive&#8217;s termination of employment, or (2) the date upon which the Executive obtains or becomes eligible for other health care coverage from a new employer or otherwise (such period referred to as the &#8220;COBRA Subsidy Period&#8221;). The Executive shall promptly inform the Company in writing when Executive obtains or becomes eligible for any such other health care coverage. The Executive shall be responsible for paying a share of such COBRA premiums during the COBRA Subsidy </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Period at active employee rates as in effect from time to time, and shall be responsible for the full unsubsidized costs of such COBRA coverage thereafter.</font></div><div style="text-indent:65.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">i.Section 280G</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary in this Agreement, Executive expressly agrees that if the payments and benefits provided for in this Agreement or any other payments and benefits which Executive has the right to receive from the Company and its affiliates (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), would constitute a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">parachute payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; (as defined in Section 280G(b)(2) of the Code), then the Payments shall be either (a) reduced (but not below zero) so that the present value of the Payments will be one dollar ($1.00) less than three times Executive&#8217;s &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">base amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; (as defined in Section 280G(b)(3) of the Code) and so that no portion of the Payments received by Executive shall be subject to the excise tax imposed by Section 4999 of the Code or (b) paid in full, whichever produces the better net after-tax position to Executive. The reduction of Payments, if any, shall be made by reducing first any Payments that are exempt from Section 409A of the Code and then reducing any Payments subject to Section 409A of the Code in the reverse order in which such Payments would be paid or provided (beginning with such payment or benefit that would be made last in time and continuing, to the extent necessary, through to such payment or benefit that would be made first in time). The determination as to whether any such reduction in the Payments is necessary shall be made by the Compensation Committee in good faith. If a reduced Payment is made or provided and, through error or otherwise, that Payment, when aggregated with other payments and benefits from Company (or its affiliates) used in determining if a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">parachute payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; exists, exceeds one dollar ($1.00) less than three times Executive&#8217;s base amount, then Executive shall immediately repay such excess to the Company.</font></div><div style="text-indent:62.34pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ii.Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Executive&#8217;s execution of a complete and general release of any and all of Executive&#8217;s potential claims (other than for benefits and payments described in this Agreement or any other vested benefits with the Company and&#47;or its affiliates) against the Company, any of its affiliated companies, and their respective successors and any officers, employees, agents, directors, attorneys, insurers, underwriters, and assigns of the Company or its affiliates and&#47;or successors, is an express condition of Executive&#8217;s right to receive the payments and benefits set forth in Section 4(c) and 4(d). Executive shall be required to execute within 45 days after Executive&#8217;s termination of employment a general waiver and release agreement in a form reasonably satisfactory to the Company.</font></div><div style="text-indent:59.01pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">iii.Certain Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall mean the occurrence of any one of the following&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">e.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">gross negligence or willful misconduct in the performance of, or Executive&#8217;s abuse of alcohol or drugs rendering Executive unable to perform, the material duties and services required for Executive&#8217;s position with the Company&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">f.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt;">Executive&#8217;s conviction or plea of nolo contendere for any crime involving moral turpitude or a felony&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">g.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">Executive&#8217;s commission of an act of deceit or fraud intended to result in personal and unauthorized enrichment of Executive at the expense of the Company or any of its affiliates&#59; or</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">h.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.33pt;">Executive&#8217;s material violation of the written policies of the Company or any of its affiliates (including ethics and compliance policies, as in effect from time to time), Executive&#8217;s material breach of a material obligation of Executive to the Company pursuant to Executive&#8217;s duties and obligations under the Company&#8217;s Bylaws, or Executive&#8217;s material breach of a material obligation of Executive to the Company or any of its affiliates pursuant to this Agreement or any award or other agreement between Executive and the Company or any of its affiliates.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Change in Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall be deemed to have occurred upon the occurrence of any of the following events&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The acquisition, other than from the Company, by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Exchange Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more of either the then outstanding shares of the Company or the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors, but excluding, for this purpose, any such acquisition by the Company or any of its subsidiaries, or any employee benefit plan (or related trust) of the Company or its subsidiaries, or any corporation with respect to which, following such acquisition, more than 50% of, respectively, the then outstanding shares of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of all or substantially all directors is then beneficially owned, directly or indirectly, by the individuals and entities who were the beneficial owners, respectively, of shares and voting securities of the Company immediately prior to such acquisition in substantially the same proportion as their ownership, immediately prior to such acquisition, of the then outstanding shares of the Company or the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors, as the case may be&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.33pt;">The consummation of a reorganization, merger or consolidation of the Company, in each case, with respect to which all or substantially all of the individuals and entities who were the respective beneficial owners of shares and voting securities of the Company immediately prior to such reorganization, merger or consolidation do not, following such reorganization, merger or consolidation, beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such reorganization, merger or consolidation&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">During any twenty-four (24) month period, individuals who, as of the beginning of such period, constitute the Board (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Incumbent Directors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the beginning of such period whose election or nomination for election </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">was approved by a vote of at least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent Director&#59; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be deemed to be an Incumbent Director&#59; or</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.33pt;">a complete liquidation or dissolution of the Company or of the sale or other disposition of all or substantially all of the assets of the Company.</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">In no event shall a Change in Control include the initial public offering of the Company registered on Form S-1 (or any successor form under the Securities Act of 1933, as amended) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Initial Public Offering</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or any bona fide primary or secondary public offering following the occurrence of the Initial Public Offering.</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Good Reason</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall mean the existence of any of the following&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">a material diminution in Executive&#8217;s authority, duties, or responsibilities from those applicable to him as of the Effective Date&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.33pt;">a material diminution in Executive&#8217;s annual Base Salary, except to the extent contemplated by Section 3(b) of this Agreement&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">a relocation of Executive&#8217;s principal place of employment by more than 50 miles, which for purposes of this Agreement shall mean the Company requiring Executive to be permanently based in a location that is more than 50 miles outside the city limits of Skokie, Illinois&#59; or</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.33pt;">a material breach by the Company of any provision of this Agreement.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding the foregoing or any other provision in this Agreement to the contrary, any assertion by Executive of a Good Reason termination shall not be effective unless all of the following conditions are satisfied&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">the conditions described in the preceding sentence giving rise to Executive&#8217;s termination of employment must have arisen without Executive&#8217;s written consent&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.33pt;">Executive must provide written notice to the Company of such condition and Executive&#8217;s intent to terminate employment within 90 days after the initial existence of the condition&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;">the condition specified in such notice must remain uncorrected for 30 days after receipt of such notice by the Company&#59; and</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.33pt;">the date of Executive&#8217;s termination of employment must occur within 90 days after the notice provided by Executive pursuant to clause (ii).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Termination due to Disability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall mean Executive&#8217;s termination of employment as a result of Executive becoming incapacitated for a period of at least 180 days by accident, sickness or other circumstance that renders Executive mentally or physically incapable of performing the material duties as Chief Medical Officer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Non-Competition Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Executive agrees to continue to be bound by that certain </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Company's Confidentiality, Non-Hire, Non-Disparagement, and Work Product Agreement </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">by and between the Company and Executive, dated as of &#91;Insert Date&#93; (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Non-Competition Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 5, 6, 8, 9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof shall survive and continue in full force and effect in accordance with their respective terms, notwithstanding any termination of the Employment Period.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any notice provided for in this Agreement shall be in writing and shall be delivered (i) personally, (ii) by certified mail, postage prepaid, (iii) by Federal Express or other reputable courier service regularly providing evidence of delivery (with charges paid by the party sending the notice), or (iv) by facsimile or a PDF or similar attachment to an email, provided that such telecopy or email attachment shall be followed within one (1) business day by delivery of such notice pursuant to clause (i), (ii) or (iii) above. Any such notice to a party shall be addressed at the address set forth below (subject to the right of a party to designate a different address for itself by notice similarly given)&#58;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.615%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">If to the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58;</font></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exicure, Inc.</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8045 Lamon Avenue Suite 410</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Skokie, Illinois 60077</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">If to Executive&#58;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Douglas E. Feltner, M.D.</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">At the most recent address on file with the Company.</font></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement, including the Non-Competition Agreement, constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related in any manner to the subject matter hereof.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">No Conflict</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Executive represents and warrants that Executive is not bound by any employment contract, restrictive covenant, or other restriction preventing Executive from </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">carrying out Executive&#8217;s responsibilities for the Company, or which is in any way inconsistent with the terms of this Agreement. Executive further represents and warrants that Executive shall not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Successors and Assigns</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement shall inure to the benefit of and be enforceable by Executive and his heirs, executors and personal representatives, and the Company and its successors and assigns. Any successor or assignee of the Company shall assume the liabilities of the Company hereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement shall be governed by the internal laws (as opposed to the conflicts of law provisions) of the State of Illinois.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Amendment and Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. All payments and benefits under this Agreement are subject to withholding of all applicable taxes.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Code Section 409A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement is intended to comply with the requirements of Section 409A of the Code, and shall be interpreted and construed consistently with such intent. The payments to Executive pursuant to this Agreement are also intended to be exempt from Section 409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation &#167;1.409A-1(b)(9)(iii) or as short-term deferrals pursuant to Treasury regulation &#167;1.409A-1(b)(4), and for such purposes, each payment to Executive under this Agreement shall be considered a separate payment. In the event the terms of this Agreement would subject Executive to taxes or penalties under Section 409A of the Code (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">409A Penalties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Company and Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible. To the extent any amounts under this Agreement are payable by reference to Executive&#8217;s &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">termination of employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; such term and similar terms shall be deemed to refer to Executive&#8217;s &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">separation from service,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; within the meaning of Section 409A of the Code. Notwithstanding any other provision in this Agreement, to the extent any payments made or contemplated hereunder constitute nonqualified deferred compensation, within the meaning of Section 409A, then (i) each such payment which is conditioned upon Executive&#8217;s execution of a release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii) if Executive is a specified employee (within the meaning of Section 409A of the Code) as of the date of Executive&#8217;s separation from service, each such payment that is payable upon Executive&#8217;s separation from service and would have been paid prior to the six-month anniversary of Executive&#8217;s separation from service, shall be delayed until the earlier to occur of (A) the first day of the seventh month following Executive&#8217;s separation from service or (B) the date of Executive&#8217;s death. Any reimbursement payable to Executive pursuant to this Agreement shall be conditioned on the submission by Executive of all expense reports reasonably required by Company under any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">applicable expense reimbursement policy, and shall be paid to Executive within 30 days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which Executive incurred the reimbursable expense. Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year. The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Clawbacks</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The payments to Executive pursuant to this Agreement are subject to forfeiture or recovery by the Company or other action pursuant to any clawback or recoupment policy which the Company may adopt from time to time, including without limitation any such policy or provision that the Company has included in any of its existing compensation programs or plans or that it may be required to adopt under the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules and regulations thereunder, or as otherwise required by law.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Company Policies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Executive shall be subject to additional Company policies as they may exist from time-to-time, including policies with regard to stock ownership by senior executives and policies regarding trading of securities.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</font></div><div><font><br></font></div></div></div><div id="i8bae5969b3924902b41b457da2381ac6_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;margin-bottom:12pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">In Witness Whereof</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the parties hereto have executed this Agreement as of the date first written above.</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:49.839%;"><tr><td style="width:1.0%;"></td><td style="width:4.430%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.787%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.900%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:64.883%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exicure, Inc.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:0.36pt;text-align:justify;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#47;s&#47; David A. Giljohann&#160;</font></div><div style="text-indent:0.36pt;text-align:justify;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;Name&#58; David A. Giljohann, Ph.D.&#160;</font></div><div style="text-indent:0.36pt;text-align:justify;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;Title&#58;   Chief Executive Officer </font></div><div style="text-align:justify;"><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Name&#58; David A. Giljohann, Ph.D</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;Title&#58; Chief Executive Officer</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Doug E. Feltner, MD.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#47;s&#47; Doug E. Feltner, MD.&#160;</font></div><div style="text-align:justify;"><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exicureexhibit311-63020.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ifc40f1e886004a3fac2b8e6c4545e7e0_1"></div><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1 </font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, David A. Giljohann, Ph.D., certify that&#58; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; August 12, 2020 </font></div><div style="text-align:right;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:47.470%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#47;s&#47; David A. Giljohann</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-6.75pt;padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">David A. Giljohann, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-6.75pt;padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">President and Chief Executive Officer</font></div></td></tr></table></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exicureexhibit312-63020.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ibb2756cbcec445d4b45910d9c4bca4df_1"></div><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2 </font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, David S. Snyder, certify that&#58; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; August 12, 2020</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:47.470%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David S. Snyder</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David S. Snyder</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exicureexhibit321-63020.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="icd0f30600a0f4a2b8b38e19c2f914463_1"></div><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1 </font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 1350 CERTIFICATIONS* </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), David A. Giljohann, Ph. D., President and Chief Executive Officer of Exicure, Inc. (the &#8220;Company&#8221;), and David S. Snyder, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58; </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Quarterly Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#59; and </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dated&#58; August 12, 2020</font></div><div style="padding-left:2.25pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%;"><tr><td style="width:1.0%;"></td><td style="width:45.085%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.593%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.640%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.593%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:44.489%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David A. Giljohann</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David S. Snyder</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David A. Giljohann, Ph.D.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David S. Snyder</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">&#160;</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:0.1%;"></td><td style="width:2.627%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.173%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This certification accompanies the Quarterly Report on Form 10-Q, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>xcur-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:36122004-6e71-4c8e-9305-4e03dfe42d12,g:561987fc-3e06-47a9-afb8-202603d40cef-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xcur="http://www.exicuretx.com/20200630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exicuretx.com/20200630">
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exicuretx.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement">
        <link:definition>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentation" roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentationDetails" roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Description of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandLicenseAgreements" roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements">
        <link:definition>2105103 - Disclosure - Collaborative Research and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandLicenseAgreementsDetails" roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails">
        <link:definition>2406402 - Disclosure - Collaborative Research and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation">
        <link:definition>2107104 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>2308301 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails">
        <link:definition>2409403 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails">
        <link:definition>2410404 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationOthernoncurrentassetsDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails">
        <link:definition>2411405 - Disclosure - Supplemental Balance Sheet Information - Other noncurrent assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails">
        <link:definition>2412406 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails">
        <link:definition>2413407 - Disclosure - Supplemental Balance Sheet Information - Other noncurrent liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.exicuretx.com/role/Investments">
        <link:definition>2114105 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.exicuretx.com/role/InvestmentsTables">
        <link:definition>2315302 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails" roleURI="http://www.exicuretx.com/role/InvestmentsDetails">
        <link:definition>2416408 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforsaleSecuritiesDetails" roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails">
        <link:definition>2417409 - Disclosure - Investments Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.exicuretx.com/role/Debt">
        <link:definition>2118106 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails">
        <link:definition>2419410 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.exicuretx.com/role/Leases">
        <link:definition>2120107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.exicuretx.com/role/LeasesTables">
        <link:definition>2321303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails">
        <link:definition>2422411 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumRentalPaymentsDetails" roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails">
        <link:definition>2423412 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1">
        <link:definition>2423412 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exicuretx.com/role/StockholdersEquity">
        <link:definition>2124108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exicuretx.com/role/StockholdersEquityTables">
        <link:definition>2325304 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCurrentCapitalizationDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails">
        <link:definition>2426413 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity2019StockOfferingsDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails">
        <link:definition>2427414 - Disclosure - Stockholders' Equity - 2019 Stock Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockWarrantsDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails">
        <link:definition>2428415 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2429416 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation" roleURI="http://www.exicuretx.com/role/EquityBasedCompensation">
        <link:definition>2130109 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationTables" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables">
        <link:definition>2331305 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationNarrativeDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails">
        <link:definition>2432417 - Disclosure - Equity-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleofCompensationExpenseDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails">
        <link:definition>2433418 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails">
        <link:definition>2434419 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails">
        <link:definition>2435420 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails">
        <link:definition>2436421 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exicuretx.com/role/IncomeTaxes">
        <link:definition>2137110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails">
        <link:definition>2438422 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.exicuretx.com/role/LossPerCommonShare">
        <link:definition>2139111 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables">
        <link:definition>2340306 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareComputationofEarningsPerShareDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails">
        <link:definition>2441423 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2442424 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exicuretx.com/role/FairValueMeasurements">
        <link:definition>2143112 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables">
        <link:definition>2344307 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2445425 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2446426 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails">
        <link:definition>2447427 - Disclosure - Fair Value Measurements - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2448428 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exicuretx.com/role/CommitmentandContingencies">
        <link:definition>2149113 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.exicuretx.com/role/CommitmentandContingenciesDetails">
        <link:definition>2450429 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions">
        <link:definition>2151114 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2452430 - Disclosure - Related-Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exicuretx.com/role/SubsequentEvents">
        <link:definition>2153115 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="xcur_ArrangementNameAxis" abstract="true" name="ArrangementNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xcur_AllerganCollaborationMember" abstract="true" name="AllerganCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableForSaleCurrentPercent" abstract="false" name="DebtSecuritiesAvailableForSaleCurrentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CommonStockVotingRightsforEachShare" abstract="false" name="CommonStockVotingRightsforEachShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" abstract="false" name="FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType"/>
  <xs:element id="xcur_CommonStockIssuedDecember2019Member" abstract="true" name="CommonStockIssuedDecember2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" abstract="false" name="CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_ClassofWarrantorRightExpired" abstract="false" name="ClassofWarrantorRightExpired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" abstract="false" name="DebtSecuritiesAvailableForSaleNoncurrentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="xcur_DevelopmentandCommercializationLicenseMember" abstract="true" name="DevelopmentandCommercializationLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ConsultingServicesMember" abstract="true" name="ConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_PaymentsOfCommonStockFinancingCosts" abstract="false" name="PaymentsOfCommonStockFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" abstract="false" name="CollaborationAgreementTerminationPeriodUponWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_PrepaidLeaseCosts" abstract="false" name="PrepaidLeaseCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="xcur_ExicureInc.2017EquityIncentivePlanMember" abstract="true" name="ExicureInc.2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_DermelixLicenseAgreementMember" abstract="true" name="DermelixLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" abstract="false" name="ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CommonStockWarrantLiability" abstract="false" name="CommonStockWarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_NumberofCollaborationPrograms" abstract="false" name="NumberofCollaborationPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableforSalePercent" abstract="false" name="DebtSecuritiesAvailableforSalePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_CollaborationDevelopmentExpenses" abstract="false" name="CollaborationDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementOptionExerciseFee" abstract="false" name="CollaborationAgreementOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" abstract="false" name="RetainedEarningsAccumulatedDeficitInceptiontoDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" abstract="false" name="CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" abstract="false" name="FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CommonStockWarrantLiabilityFairValueDisclosure" abstract="false" name="CommonStockWarrantLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ComputersandSoftwareMember" abstract="true" name="ComputersandSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_PaymentsForDebtEndTermFees" abstract="false" name="PaymentsForDebtEndTermFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_SupplementalBalanceSheetInformationAbstract" abstract="true" name="SupplementalBalanceSheetInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xcur_OperatingLeaseAssetRemainingUsefulLife" abstract="false" name="OperatingLeaseAssetRemainingUsefulLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="xcur_PaymentsforLicenseAgreements" abstract="false" name="PaymentsforLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" abstract="false" name="CollaborationAgreementExtendedOptionAdditionalExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_HerculesTechnologyGrowthCapitalMember" abstract="true" name="HerculesTechnologyGrowthCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" abstract="false" name="AccruedClinicalContractResearchAndManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ArrangementNameDomain" abstract="true" name="ArrangementNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="xcur_CommonStockWarrantLiabilityCurrent" abstract="false" name="CommonStockWarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>xcur-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:36122004-6e71-4c8e-9305-4e03dfe42d12,g:561987fc-3e06-47a9-afb8-202603d40cef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exicuretx.com/role/CoverPage" xlink:type="simple" xlink:href="xcur-20200630.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_27e600db-d800-4417-92b4-99196d78fcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_43e3161d-453c-4fc2-b962-36ad53f11ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_27e600db-d800-4417-92b4-99196d78fcfc" xlink:to="loc_us-gaap_LongTermDebtCurrent_43e3161d-453c-4fc2-b962-36ad53f11ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_034c5828-7f58-423a-a475-ac4ef50bff76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_27e600db-d800-4417-92b4-99196d78fcfc" xlink:to="loc_us-gaap_AccountsPayableCurrent_034c5828-7f58-423a-a475-ac4ef50bff76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bea0fd36-ee1c-4081-bc59-19e31766a370" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_27e600db-d800-4417-92b4-99196d78fcfc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bea0fd36-ee1c-4081-bc59-19e31766a370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dbb17b39-9000-4b20-8694-5d8a3178d085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_27e600db-d800-4417-92b4-99196d78fcfc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dbb17b39-9000-4b20-8694-5d8a3178d085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27ab0e3a-731c-4a49-bdce-e3f1e1d6cf53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7c40e12b-10b9-4717-a228-020fdd7f899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27ab0e3a-731c-4a49-bdce-e3f1e1d6cf53" xlink:to="loc_us-gaap_CommonStockValue_7c40e12b-10b9-4717-a228-020fdd7f899f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_19077aab-43b8-4e5e-883a-62a45e25be03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27ab0e3a-731c-4a49-bdce-e3f1e1d6cf53" xlink:to="loc_us-gaap_AdditionalPaidInCapital_19077aab-43b8-4e5e-883a-62a45e25be03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7115b3be-0058-4831-94bb-99cfc8b47987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27ab0e3a-731c-4a49-bdce-e3f1e1d6cf53" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7115b3be-0058-4831-94bb-99cfc8b47987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e44ac2d-6e6c-44b8-8d1e-706c98af4cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_27ab0e3a-731c-4a49-bdce-e3f1e1d6cf53" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e44ac2d-6e6c-44b8-8d1e-706c98af4cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_98c4bb23-a332-4922-8c1a-80660dde82e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cea8936d-8e9f-468b-aa81-a99be89185f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98c4bb23-a332-4922-8c1a-80660dde82e2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cea8936d-8e9f-468b-aa81-a99be89185f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_01bb54f9-5b7b-4e49-8a66-0546dfdb263d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98c4bb23-a332-4922-8c1a-80660dde82e2" xlink:to="loc_us-gaap_ShortTermInvestments_01bb54f9-5b7b-4e49-8a66-0546dfdb263d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a0f13667-b1e9-4c59-887f-e5a064e5866e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98c4bb23-a332-4922-8c1a-80660dde82e2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a0f13667-b1e9-4c59-887f-e5a064e5866e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_2cac1148-b588-4173-88d2-77d7ceb5c2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98c4bb23-a332-4922-8c1a-80660dde82e2" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_2cac1148-b588-4173-88d2-77d7ceb5c2d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8639db48-2629-48fb-baef-3d1db3489e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98c4bb23-a332-4922-8c1a-80660dde82e2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8639db48-2629-48fb-baef-3d1db3489e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_43e001ac-e287-441f-813c-61333460af6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4e3e9876-f89f-45b1-a73d-289300586c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43e001ac-e287-441f-813c-61333460af6c" xlink:to="loc_us-gaap_AssetsCurrent_4e3e9876-f89f-45b1-a73d-289300586c05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b1db2c76-867e-463e-ba95-79f89d1d5092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43e001ac-e287-441f-813c-61333460af6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b1db2c76-867e-463e-ba95-79f89d1d5092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_02da7bdd-caca-47ae-94d7-dced58a4758d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_43e001ac-e287-441f-813c-61333460af6c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_02da7bdd-caca-47ae-94d7-dced58a4758d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_22d01ac2-bc76-41ec-92e7-b1e5874b5d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_83c5c990-6917-4f3e-b24d-8883ddf8c87d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_22d01ac2-bc76-41ec-92e7-b1e5874b5d14" xlink:to="loc_us-gaap_LiabilitiesCurrent_83c5c990-6917-4f3e-b24d-8883ddf8c87d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiability_c931e616-085c-4525-9b2b-1f45f921693d" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_22d01ac2-bc76-41ec-92e7-b1e5874b5d14" xlink:to="loc_xcur_CommonStockWarrantLiability_c931e616-085c-4525-9b2b-1f45f921693d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_35c48ecd-5a5b-4e3c-ac2c-f5633f71e500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_22d01ac2-bc76-41ec-92e7-b1e5874b5d14" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_35c48ecd-5a5b-4e3c-ac2c-f5633f71e500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_87ca08cc-d6ea-45cf-8d2f-10d6590875a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_22d01ac2-bc76-41ec-92e7-b1e5874b5d14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_87ca08cc-d6ea-45cf-8d2f-10d6590875a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f6c04d9-c999-4167-90c3-29b0a8b13b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_08133dae-2595-4ce0-adec-33268c1ea1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f6c04d9-c999-4167-90c3-29b0a8b13b04" xlink:to="loc_us-gaap_Liabilities_08133dae-2595-4ce0-adec-33268c1ea1fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4edf3379-b2dd-4ed4-89e3-0e868121cee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9f6c04d9-c999-4167-90c3-29b0a8b13b04" xlink:to="loc_us-gaap_StockholdersEquity_4edf3379-b2dd-4ed4-89e3-0e868121cee8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d78d0aa2-791b-4020-a79e-a97e766877fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5eddbda9-7b4d-4c1c-8552-5e680e139e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d78d0aa2-791b-4020-a79e-a97e766877fa" xlink:to="loc_us-gaap_Revenues_5eddbda9-7b4d-4c1c-8552-5e680e139e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f9a84e30-8653-4356-9e66-74a31d803f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d78d0aa2-791b-4020-a79e-a97e766877fa" xlink:to="loc_us-gaap_OperatingExpenses_f9a84e30-8653-4356-9e66-74a31d803f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b6e11b51-c538-4629-92b4-f42f2832a780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_14f9e8d0-4993-495c-bd11-e2eece9c876c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b6e11b51-c538-4629-92b4-f42f2832a780" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_14f9e8d0-4993-495c-bd11-e2eece9c876c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_73d9799d-674d-4184-a0a4-546cc8de448e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_b6e11b51-c538-4629-92b4-f42f2832a780" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_73d9799d-674d-4184-a0a4-546cc8de448e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_67c3efe2-658f-4064-9cee-8e0c39268e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_a0a2c5c3-b80e-4aee-a730-7211455ef1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67c3efe2-658f-4064-9cee-8e0c39268e6d" xlink:to="loc_us-gaap_InvestmentIncomeDividend_a0a2c5c3-b80e-4aee-a730-7211455ef1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_13080794-2eb4-43c5-9d49-310e11774b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67c3efe2-658f-4064-9cee-8e0c39268e6d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_13080794-2eb4-43c5-9d49-310e11774b16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_47df592e-913b-4355-938e-2e5a1380cef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67c3efe2-658f-4064-9cee-8e0c39268e6d" xlink:to="loc_us-gaap_InterestExpense_47df592e-913b-4355-938e-2e5a1380cef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6916260e-6e50-48ce-8fd4-d57653ccf3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67c3efe2-658f-4064-9cee-8e0c39268e6d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6916260e-6e50-48ce-8fd4-d57653ccf3b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b4aba8c5-e6da-4bdb-8fa6-e14c44fbd10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0e63f8b-d3e8-4d3f-9cf4-fda8cd888100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_b4aba8c5-e6da-4bdb-8fa6-e14c44fbd10b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0e63f8b-d3e8-4d3f-9cf4-fda8cd888100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5c691c7-0948-4483-a8ff-aacd364eaa33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ee953ad8-d90f-4e9b-8407-369fdb073577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5c691c7-0948-4483-a8ff-aacd364eaa33" xlink:to="loc_us-gaap_OperatingIncomeLoss_ee953ad8-d90f-4e9b-8407-369fdb073577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fd171fc4-e334-4ccc-9677-aab19c48c982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e5c691c7-0948-4483-a8ff-aacd364eaa33" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fd171fc4-e334-4ccc-9677-aab19c48c982" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ae611824-c80f-4a66-97c6-7772d7fd9998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_905808cc-f29e-4847-94bb-cb07783dd4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ae611824-c80f-4a66-97c6-7772d7fd9998" xlink:to="loc_us-gaap_NetIncomeLoss_905808cc-f29e-4847-94bb-cb07783dd4c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_894ec63b-7883-4daa-bdfe-80f7be3f0e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ae611824-c80f-4a66-97c6-7772d7fd9998" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_894ec63b-7883-4daa-bdfe-80f7be3f0e8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23169eaf-acfe-44c1-9c53-e2c1a64b0213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9336af2-62bd-4463-a3fd-ebacc631a56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23169eaf-acfe-44c1-9c53-e2c1a64b0213" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9336af2-62bd-4463-a3fd-ebacc631a56d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3707284-a53a-45fe-ac34-214e3840cfaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25c6bdf5-4184-4c47-9ca8-b42b5b7fa7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3707284-a53a-45fe-ac34-214e3840cfaa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25c6bdf5-4184-4c47-9ca8-b42b5b7fa7e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_7d5654e8-0e54-417e-a7d9-769c0b90fda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3707284-a53a-45fe-ac34-214e3840cfaa" xlink:to="loc_us-gaap_RestrictedCash_7d5654e8-0e54-417e-a7d9-769c0b90fda8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1a22f83-4e38-4993-90aa-7fa4b40f97e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_330672f1-1559-47c5-a765-8682cb5faa73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1a22f83-4e38-4993-90aa-7fa4b40f97e9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_330672f1-1559-47c5-a765-8682cb5faa73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_733eb504-f2f0-4f5d-accf-ac7e9a301046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1a22f83-4e38-4993-90aa-7fa4b40f97e9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_733eb504-f2f0-4f5d-accf-ac7e9a301046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3d544347-af74-4150-9a19-6ec95952d6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1a22f83-4e38-4993-90aa-7fa4b40f97e9" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3d544347-af74-4150-9a19-6ec95952d6b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_7c9d67bb-6bf6-4772-8092-ff18d4266a1b" xlink:href="xcur-20200630.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1a22f83-4e38-4993-90aa-7fa4b40f97e9" xlink:to="loc_xcur_PaymentsOfCommonStockFinancingCosts_7c9d67bb-6bf6-4772-8092-ff18d4266a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fe3c25ee-5170-4453-b9cd-db05cd17bdd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1a22f83-4e38-4993-90aa-7fa4b40f97e9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fe3c25ee-5170-4453-b9cd-db05cd17bdd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b684125f-bf2a-4460-a40e-59413b94e24c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_133c8701-3daa-45dd-82ae-9c37046300a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b684125f-bf2a-4460-a40e-59413b94e24c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_133c8701-3daa-45dd-82ae-9c37046300a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48cee8c9-6946-49b5-8d4c-b4f3592bfcc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b684125f-bf2a-4460-a40e-59413b94e24c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_48cee8c9-6946-49b5-8d4c-b4f3592bfcc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c119c85d-db08-4351-920e-bab5000767ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b684125f-bf2a-4460-a40e-59413b94e24c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c119c85d-db08-4351-920e-bab5000767ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ec679732-429c-48fa-bde6-955d6c4979f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_NetIncomeLoss_ec679732-429c-48fa-bde6-955d6c4979f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2687265d-824d-46c8-b42b-6921f7119835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2687265d-824d-46c8-b42b-6921f7119835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_902de7a6-92e1-46dc-8bc1-63e97838f660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_902de7a6-92e1-46dc-8bc1-63e97838f660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_28c2eaac-b063-43f8-8add-fb33bfd2d622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_ShareBasedCompensation_28c2eaac-b063-43f8-8add-fb33bfd2d622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_47abc08c-42d9-49b7-92dc-d3b3b4dfbdc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_47abc08c-42d9-49b7-92dc-d3b3b4dfbdc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_0070e38e-8917-479c-b423-371221c1e269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_0070e38e-8917-479c-b423-371221c1e269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1aa01874-8918-43e8-b38c-8a36cfd1275d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1aa01874-8918-43e8-b38c-8a36cfd1275d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_459f1e3b-0af2-4890-8852-8d3a06215f56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_459f1e3b-0af2-4890-8852-8d3a06215f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7b33eddb-a61d-4d96-bdca-36a621ff532e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7b33eddb-a61d-4d96-bdca-36a621ff532e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10cb9bd8-ffa6-4ca9-9386-021e59fee255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10cb9bd8-ffa6-4ca9-9386-021e59fee255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3c580609-a935-4d77-ab8e-ee2381b6ff68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3c580609-a935-4d77-ab8e-ee2381b6ff68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2a336539-6f5b-4847-baa1-10e41cad579d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2a336539-6f5b-4847-baa1-10e41cad579d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6ad22f5c-114b-405f-b17e-6cca76c5f298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c820069-3ffa-452c-8539-892851ff5d29" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6ad22f5c-114b-405f-b17e-6cca76c5f298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23ecf943-cbc8-4682-87c6-d809133cda75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ab6c4569-bed0-4ac2-8d79-9b107bab3739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23ecf943-cbc8-4682-87c6-d809133cda75" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ab6c4569-bed0-4ac2-8d79-9b107bab3739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_033483f3-0ebe-4858-8fc9-74b86ea2559d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23ecf943-cbc8-4682-87c6-d809133cda75" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_033483f3-0ebe-4858-8fc9-74b86ea2559d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cc165412-5938-4791-ae5d-786eb4bfbfc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_23ecf943-cbc8-4682-87c6-d809133cda75" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cc165412-5938-4791-ae5d-786eb4bfbfc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="xcur-20200630.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="xcur-20200630.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="xcur-20200630.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="simple" xlink:href="xcur-20200630.xsd#CollaborativeResearchandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#CollaborativeResearchandLicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformation"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff169937-3cef-4f36-a377-5d039b792ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_0a6c1acf-e36d-4b83-8c46-155efb65e6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff169937-3cef-4f36-a377-5d039b792ab2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_0a6c1acf-e36d-4b83-8c46-155efb65e6a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_80f52150-b85a-4ba8-9395-a7010e6d3448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff169937-3cef-4f36-a377-5d039b792ab2" xlink:to="loc_us-gaap_InterestReceivable_80f52150-b85a-4ba8-9395-a7010e6d3448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_c9af78d5-2f82-430a-bfe8-b5c5445f39e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff169937-3cef-4f36-a377-5d039b792ab2" xlink:to="loc_us-gaap_PrepaidInsurance_c9af78d5-2f82-430a-bfe8-b5c5445f39e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_a142d268-c094-48c3-be17-b7df569c8798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff169937-3cef-4f36-a377-5d039b792ab2" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_a142d268-c094-48c3-be17-b7df569c8798" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e3456818-a6e1-4ab1-bf71-34580ae1928d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0dad9bc2-b166-4637-bed8-5292a64fee3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e3456818-a6e1-4ab1-bf71-34580ae1928d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0dad9bc2-b166-4637-bed8-5292a64fee3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c7fd2b38-b4ef-4596-a6a4-0c07af842ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e3456818-a6e1-4ab1-bf71-34580ae1928d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c7fd2b38-b4ef-4596-a6a4-0c07af842ccd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationOthernoncurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e131975f-a6eb-4a21-a8eb-7ddf6c19437c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_5d09d4b9-36df-460b-84a3-30cae4ee83ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e131975f-a6eb-4a21-a8eb-7ddf6c19437c" xlink:to="loc_us-gaap_RestrictedCash_5d09d4b9-36df-460b-84a3-30cae4ee83ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_af2b4dd0-ebf4-4df6-9176-80d3a59b7d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e131975f-a6eb-4a21-a8eb-7ddf6c19437c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_af2b4dd0-ebf4-4df6-9176-80d3a59b7d85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_5cb8bd0c-491c-4f57-af1a-6b3fbd08f409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e131975f-a6eb-4a21-a8eb-7ddf6c19437c" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_5cb8bd0c-491c-4f57-af1a-6b3fbd08f409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PrepaidLeaseCosts_6217d7fa-e266-45c3-9ad3-b99ee49f07a6" xlink:href="xcur-20200630.xsd#xcur_PrepaidLeaseCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e131975f-a6eb-4a21-a8eb-7ddf6c19437c" xlink:to="loc_xcur_PrepaidLeaseCosts_6217d7fa-e266-45c3-9ad3-b99ee49f07a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_75335651-539f-4753-912e-586b1651d797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_e131975f-a6eb-4a21-a8eb-7ddf6c19437c" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_75335651-539f-4753-912e-586b1651d797" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6321f6d7-44fc-4e3d-a19e-d23ed843870f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ec4572fe-7541-456b-b115-f243da20ed09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6321f6d7-44fc-4e3d-a19e-d23ed843870f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ec4572fe-7541-456b-b115-f243da20ed09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_678e79fe-4413-4e8f-a701-743f480673ba" xlink:href="xcur-20200630.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6321f6d7-44fc-4e3d-a19e-d23ed843870f" xlink:to="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_678e79fe-4413-4e8f-a701-743f480673ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6a81559-43c1-48f0-8f1b-649fcb0266a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6321f6d7-44fc-4e3d-a19e-d23ed843870f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6a81559-43c1-48f0-8f1b-649fcb0266a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9069aa19-5ae8-40dc-aad3-56982d6a08dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6321f6d7-44fc-4e3d-a19e-d23ed843870f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9069aa19-5ae8-40dc-aad3-56982d6a08dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_54c35fe4-33f4-428a-8b79-0bcf6421ca52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6321f6d7-44fc-4e3d-a19e-d23ed843870f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_54c35fe4-33f4-428a-8b79-0bcf6421ca52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityCurrent_6ccc8dc0-b38b-4db8-8b10-5f77e837938c" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6321f6d7-44fc-4e3d-a19e-d23ed843870f" xlink:to="loc_xcur_CommonStockWarrantLiabilityCurrent_6ccc8dc0-b38b-4db8-8b10-5f77e837938c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8bb30313-3ea2-4514-9228-2890c380b6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_866456ed-e155-494b-b7b3-13632bf0b102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8bb30313-3ea2-4514-9228-2890c380b6bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_866456ed-e155-494b-b7b3-13632bf0b102" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Investments" xlink:type="simple" xlink:href="xcur-20200630.xsd#Investments"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/Investments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a00f4666-e0d3-4a84-9953-33ccb3d7ea84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9cf57f0e-c4dc-4264-a22b-4f26d95a3ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a00f4666-e0d3-4a84-9953-33ccb3d7ea84" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9cf57f0e-c4dc-4264-a22b-4f26d95a3ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_36f2647d-906b-456e-a3df-fb7858b0797f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a00f4666-e0d3-4a84-9953-33ccb3d7ea84" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_36f2647d-906b-456e-a3df-fb7858b0797f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_36df0d31-704c-4fdb-8ecb-814d5f451f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a00f4666-e0d3-4a84-9953-33ccb3d7ea84" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_36df0d31-704c-4fdb-8ecb-814d5f451f5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:type="simple" xlink:href="xcur-20200630.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Leases" xlink:type="simple" xlink:href="xcur-20200630.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47baebd8-857f-430d-aa44-6d190adf605d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6588c229-8921-494b-acbc-013db6b90f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47baebd8-857f-430d-aa44-6d190adf605d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6588c229-8921-494b-acbc-013db6b90f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6a0bcb4-38ec-470b-a80f-ce1c51d3e0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47baebd8-857f-430d-aa44-6d190adf605d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6a0bcb4-38ec-470b-a80f-ce1c51d3e0ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc404e1a-b96e-4aa1-94e3-824aeb742f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_76e583d3-1614-4b04-9ffe-71b63ffbbac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc404e1a-b96e-4aa1-94e3-824aeb742f85" xlink:to="loc_us-gaap_OperatingLeaseLiability_76e583d3-1614-4b04-9ffe-71b63ffbbac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d8b79f03-fc8e-44b7-9846-9826afac71af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc404e1a-b96e-4aa1-94e3-824aeb742f85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d8b79f03-fc8e-44b7-9846-9826afac71af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityCurrentCapitalizationDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquity2019StockOfferingsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityCommonStockWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationScheduleofCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xcur-20200630.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShare"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareTables"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareComputationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="xcur-20200630.xsd#CommitmentandContingencies"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#CommitmentandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="xcur-20200630.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="xcur-20200630.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>xcur-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:36122004-6e71-4c8e-9305-4e03dfe42d12,g:561987fc-3e06-47a9-afb8-202603d40cef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CoverPage" xlink:type="simple" xlink:href="xcur-20200630.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CoverPage" xlink:type="extended" id="i91e3654e9ee14c43b871b083c753adda_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b37400c5-59e0-4445-8d6d-a9c402f39089" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentType_b37400c5-59e0-4445-8d6d-a9c402f39089" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_63688e50-03a4-463c-b513-5c3dc826a968" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentQuarterlyReport_63688e50-03a4-463c-b513-5c3dc826a968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_153f7b06-d13c-4cfa-a54f-91fc95884e1a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentPeriodEndDate_153f7b06-d13c-4cfa-a54f-91fc95884e1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4d0aa958-6f26-4fe8-8756-d6b1d8463365" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentTransitionReport_4d0aa958-6f26-4fe8-8756-d6b1d8463365" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_aa7f99c6-9a32-4d8a-b7ad-8370c7024f04" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityFileNumber_aa7f99c6-9a32-4d8a-b7ad-8370c7024f04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cbccac6a-89d6-4ee6-98d1-d2ee936244f7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityRegistrantName_cbccac6a-89d6-4ee6-98d1-d2ee936244f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21b34f0a-227b-44c5-9751-a21cf44f9524" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21b34f0a-227b-44c5-9751-a21cf44f9524" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_40a4aee1-f02b-4f14-933c-1531793013d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityTaxIdentificationNumber_40a4aee1-f02b-4f14-933c-1531793013d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_431be4f6-d8a7-43ea-b7b1-dd29f4a676c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressAddressLine1_431be4f6-d8a7-43ea-b7b1-dd29f4a676c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d6f4b51e-c05c-4328-a8f6-aa8a62fd0437" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressAddressLine2_d6f4b51e-c05c-4328-a8f6-aa8a62fd0437" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a9bf1d0a-8f2c-4732-acbb-f15040576eb5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressCityOrTown_a9bf1d0a-8f2c-4732-acbb-f15040576eb5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ead7b568-a7cd-4b67-b05b-1812fd7087b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressStateOrProvince_ead7b568-a7cd-4b67-b05b-1812fd7087b5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9f059648-8ceb-4628-b93e-ba6ef9186547" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressPostalZipCode_9f059648-8ceb-4628-b93e-ba6ef9186547" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1aeb2ce2-86e7-4d17-983e-862554fc4621" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_CityAreaCode_1aeb2ce2-86e7-4d17-983e-862554fc4621" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f9ea793e-3c72-4fd7-b8f9-bad478d28e88" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_LocalPhoneNumber_f9ea793e-3c72-4fd7-b8f9-bad478d28e88" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c0785935-4dfe-4994-82be-37615df686ef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_Security12bTitle_c0785935-4dfe-4994-82be-37615df686ef" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_900600ce-127a-4ff9-9940-e387fe8fc953" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_TradingSymbol_900600ce-127a-4ff9-9940-e387fe8fc953" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9e49d665-cb4a-4c01-91d3-cf7ec025db1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_SecurityExchangeName_9e49d665-cb4a-4c01-91d3-cf7ec025db1f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8b94f8a3-5f48-4931-890b-6684790ff15b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityCurrentReportingStatus_8b94f8a3-5f48-4931-890b-6684790ff15b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6377c43f-f7b0-4e5f-9b87-51889790c1d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityInteractiveDataCurrent_6377c43f-f7b0-4e5f-9b87-51889790c1d1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_33cb7cda-7c04-4502-9a47-2a0c232d12a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityFilerCategory_33cb7cda-7c04-4502-9a47-2a0c232d12a5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3bf2c4cc-5178-4668-a7c0-84e60d747e7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntitySmallBusiness_3bf2c4cc-5178-4668-a7c0-84e60d747e7b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eefceeac-577e-4354-a5af-c133bab09ce0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityEmergingGrowthCompany_eefceeac-577e-4354-a5af-c133bab09ce0" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_2d363479-59bc-48c2-9ede-1121a5cfedd9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityExTransitionPeriod_2d363479-59bc-48c2-9ede-1121a5cfedd9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_356bca86-2d31-48cd-a6c2-4718d5b9d10e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityShellCompany_356bca86-2d31-48cd-a6c2-4718d5b9d10e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d7131b57-8d1d-4866-9ea6-e5562319ef51" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d7131b57-8d1d-4866-9ea6-e5562319ef51" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_278c3b36-6f27-4bef-ab2d-802475bc308e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityCentralIndexKey_278c3b36-6f27-4bef-ab2d-802475bc308e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_59f98ed9-cfef-416a-8b32-491e3c881862" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_CurrentFiscalYearEndDate_59f98ed9-cfef-416a-8b32-491e3c881862" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_370140aa-db52-45af-867c-dfb69fd3d9a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentFiscalYearFocus_370140aa-db52-45af-867c-dfb69fd3d9a7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f300c8f3-486d-4c8d-8955-1660574fd8c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f300c8f3-486d-4c8d-8955-1660574fd8c2" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_29c73837-e28b-4e96-b9df-f1a641fb6abb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_AmendmentFlag_29c73837-e28b-4e96-b9df-f1a641fb6abb" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_9fd84a27-a497-452e-9468-9d0fb9778e51" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressesTable_9fd84a27-a497-452e-9468-9d0fb9778e51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_bd933a34-728b-4896-913f-fa06146f797c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_9fd84a27-a497-452e-9468-9d0fb9778e51" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_bd933a34-728b-4896-913f-fa06146f797c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_bd933a34-728b-4896-913f-fa06146f797c_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_bd933a34-728b-4896-913f-fa06146f797c" xlink:to="loc_dei_AddressTypeDomain_bd933a34-728b-4896-913f-fa06146f797c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_ae01959f-b2e1-4630-a814-bb50d0cc2b67" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_bd933a34-728b-4896-913f-fa06146f797c" xlink:to="loc_dei_AddressTypeDomain_ae01959f-b2e1-4630-a814-bb50d0cc2b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_3c83d767-6269-4111-a3d8-48e4986fe80e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_FormerAddressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_ae01959f-b2e1-4630-a814-bb50d0cc2b67" xlink:to="loc_dei_FormerAddressMember_3c83d767-6269-4111-a3d8-48e4986fe80e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i48d5497bd1eb44f4b038a5f56f7675ae_UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ia55e917a93024b24ab82931aaed9a910_UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ieb4666f6ce0b43abab48cc540cf18706_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement" xlink:type="extended" id="if9c78fb514a24d77bb0454f8965970f2_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i11d66acd965e47078ca588e2a80c7c8e_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_18ede31e-d453-416e-902b-610b7faa8b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_18ede31e-d453-416e-902b-610b7faa8b94" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2b460e26-c170-4c59-8415-cf149eef9967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_SharesOutstanding_2b460e26-c170-4c59-8415-cf149eef9967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4275ab0e-760b-4c84-a78c-5e17cb619c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockholdersEquity_4275ab0e-760b-4c84-a78c-5e17cb619c14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ffdb9410-bbae-4215-8f02-8cd54adf9645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ffdb9410-bbae-4215-8f02-8cd54adf9645" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_de055b12-7479-4cd0-ade5-61265434d580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_de055b12-7479-4cd0-ade5-61265434d580" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8431f916-0e5b-4a9e-aa8d-b0027208dd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8431f916-0e5b-4a9e-aa8d-b0027208dd68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_91c6a931-8f18-4a4b-9dfa-3cabb986969b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_91c6a931-8f18-4a4b-9dfa-3cabb986969b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12655c74-939a-4704-9178-29b876a8dd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12655c74-939a-4704-9178-29b876a8dd0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2fcaa26a-9bc3-4f2c-9676-016ca37f0b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2fcaa26a-9bc3-4f2c-9676-016ca37f0b64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0895f078-0508-4882-9a09-0f6319b098b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_NetIncomeLoss_0895f078-0508-4882-9a09-0f6319b098b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_981ff026-3ee7-439f-99e1-61ccf49fd24c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e02911cc-c4bb-4da3-8902-405ec64e0382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2dec783-172b-44c6-a4f4-8dc20e021b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_18ede31e-d453-416e-902b-610b7faa8b94" xlink:to="loc_us-gaap_StatementTable_c2dec783-172b-44c6-a4f4-8dc20e021b88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f9a772ee-6d5c-4811-92e2-4294c6bb5232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c2dec783-172b-44c6-a4f4-8dc20e021b88" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f9a772ee-6d5c-4811-92e2-4294c6bb5232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f9a772ee-6d5c-4811-92e2-4294c6bb5232_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9a772ee-6d5c-4811-92e2-4294c6bb5232" xlink:to="loc_us-gaap_EquityComponentDomain_f9a772ee-6d5c-4811-92e2-4294c6bb5232_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9a772ee-6d5c-4811-92e2-4294c6bb5232" xlink:to="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2104e437-2f20-4344-9bed-d4cd25e2e003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:to="loc_us-gaap_CommonStockMember_2104e437-2f20-4344-9bed-d4cd25e2e003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4422da19-3853-4dcc-add0-797bb92b9616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4422da19-3853-4dcc-add0-797bb92b9616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c95ae695-0072-4f7c-9c92-5e3105ab29d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:to="loc_us-gaap_RetainedEarningsMember_c95ae695-0072-4f7c-9c92-5e3105ab29d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_999ce7e7-8bac-4d64-aaed-3db99802d72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_999ce7e7-8bac-4d64-aaed-3db99802d72b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ib616852c1411403e913865e4fa430a7a_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="xcur-20200630.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended" id="i9a09ae87cd364fc7b05bb8e544fa7166_DescriptionofBusinessandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended" id="i914507b72aa3442ba4a723e00dd02e5c_DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="xcur-20200630.xsd#SignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended" id="i8ed55c53298e487fa81d0349c79b0624_SignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="xcur-20200630.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" id="i767864fbf27b44c99adb070a542fa531_SignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="simple" xlink:href="xcur-20200630.xsd#CollaborativeResearchandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="extended" id="i685b70d907b44072abb66d494f077464_CollaborativeResearchandLicenseAgreements"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#CollaborativeResearchandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="extended" id="id1179eb1c4a94d31ab364163be698721_CollaborativeResearchandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms_3b1784ba-c5d9-4663-941f-040a23be4a80" xlink:href="xcur-20200630.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_NumberofCollaborationPrograms_3b1784ba-c5d9-4663-941f-040a23be4a80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_73c5a8c6-17e8-4c08-b0f7-65fe3b91acb9" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_73c5a8c6-17e8-4c08-b0f7-65fe3b91acb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee_c7353aa1-f601-4078-8a3d-4be2eff5f464" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementOptionExerciseFee_c7353aa1-f601-4078-8a3d-4be2eff5f464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_e135f50d-9662-4566-bf4c-8f09758bde34" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_e135f50d-9662-4566-bf4c-8f09758bde34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_314223a2-d4e5-4a29-a06f-8c68426291ea" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_314223a2-d4e5-4a29-a06f-8c68426291ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_ab8957e6-38ca-4b37-b6e9-3934f63a7d27" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_ab8957e6-38ca-4b37-b6e9-3934f63a7d27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_9c26ba8f-c40e-43cc-b3f6-20a627a23363" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_9c26ba8f-c40e-43cc-b3f6-20a627a23363" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_f6dcb184-4df1-45e0-b904-6ef8b6dd6b1c" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_f6dcb184-4df1-45e0-b904-6ef8b6dd6b1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f09a23f-a36c-4ecc-9c7c-7d4b90e2ba80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f09a23f-a36c-4ecc-9c7c-7d4b90e2ba80" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_de4406b0-5816-4c95-ae39-979e93679a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_de4406b0-5816-4c95-ae39-979e93679a2b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_21fe7bd0-e205-4401-a404-a86766c8ebc2" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_21fe7bd0-e205-4401-a404-a86766c8ebc2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerm_3b111c10-2d2d-49cb-9bc5-94a1b78d8588" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementTerm_3b111c10-2d2d-49cb-9bc5-94a1b78d8588" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses_2bebfd29-e67f-4b71-b586-d032138db5c0" xlink:href="xcur-20200630.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationDevelopmentExpenses_2bebfd29-e67f-4b71-b586-d032138db5c0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment_e89e15ec-dd2e-4082-a375-5f1ee5bc1e1d" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment_e89e15ec-dd2e-4082-a375-5f1ee5bc1e1d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_06c45e14-1d1b-4ade-b3d8-f829e79ce625" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_06c45e14-1d1b-4ade-b3d8-f829e79ce625" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_6b27e189-8069-43b1-8127-29a411df3f26" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_6b27e189-8069-43b1-8127-29a411df3f26" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_13d0e28f-2380-4206-82eb-5210bbe46520" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_srt_RangeAxis_13d0e28f-2380-4206-82eb-5210bbe46520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13d0e28f-2380-4206-82eb-5210bbe46520_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_13d0e28f-2380-4206-82eb-5210bbe46520" xlink:to="loc_srt_RangeMember_13d0e28f-2380-4206-82eb-5210bbe46520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1db1abb-94ec-4ecb-ac90-d51d30928fb4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_13d0e28f-2380-4206-82eb-5210bbe46520" xlink:to="loc_srt_RangeMember_d1db1abb-94ec-4ecb-ac90-d51d30928fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2ef530c4-263f-4da1-b086-025b46574564" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d1db1abb-94ec-4ecb-ac90-d51d30928fb4" xlink:to="loc_srt_MaximumMember_2ef530c4-263f-4da1-b086-025b46574564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6eca996b-ae7d-4e43-a32c-812fcd1cd92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6eca996b-ae7d-4e43-a32c-812fcd1cd92e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6eca996b-ae7d-4e43-a32c-812fcd1cd92e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6eca996b-ae7d-4e43-a32c-812fcd1cd92e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6eca996b-ae7d-4e43-a32c-812fcd1cd92e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_824f2191-c11a-4c35-9a4b-633ab2e18251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6eca996b-ae7d-4e43-a32c-812fcd1cd92e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_824f2191-c11a-4c35-9a4b-633ab2e18251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember_57ad6cd7-940f-4987-8010-d5e6854d2147" xlink:href="xcur-20200630.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_824f2191-c11a-4c35-9a4b-633ab2e18251" xlink:to="loc_xcur_DevelopmentandCommercializationLicenseMember_57ad6cd7-940f-4987-8010-d5e6854d2147" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_71197c88-014f-4c47-89ea-f77d77ead2a7" xlink:href="xcur-20200630.xsd#xcur_ArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_xcur_ArrangementNameAxis_71197c88-014f-4c47-89ea-f77d77ead2a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_71197c88-014f-4c47-89ea-f77d77ead2a7_default" xlink:href="xcur-20200630.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ArrangementNameAxis_71197c88-014f-4c47-89ea-f77d77ead2a7" xlink:to="loc_xcur_ArrangementNameDomain_71197c88-014f-4c47-89ea-f77d77ead2a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_3a56893c-27bf-4841-9e9a-3960c7268d5e" xlink:href="xcur-20200630.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ArrangementNameAxis_71197c88-014f-4c47-89ea-f77d77ead2a7" xlink:to="loc_xcur_ArrangementNameDomain_3a56893c-27bf-4841-9e9a-3960c7268d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AllerganCollaborationMember_00d52661-ed42-4fbc-8f35-26257d48eed1" xlink:href="xcur-20200630.xsd#xcur_AllerganCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_3a56893c-27bf-4841-9e9a-3960c7268d5e" xlink:to="loc_xcur_AllerganCollaborationMember_00d52661-ed42-4fbc-8f35-26257d48eed1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember_830b9417-dec9-4042-b3a7-3c9a18dde9b7" xlink:href="xcur-20200630.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_3a56893c-27bf-4841-9e9a-3960c7268d5e" xlink:to="loc_xcur_DermelixLicenseAgreementMember_830b9417-dec9-4042-b3a7-3c9a18dde9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b752fbd3-9534-4bc1-b3b6-985ddd214621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b752fbd3-9534-4bc1-b3b6-985ddd214621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ae303c9e-8916-42c9-b5a1-d84135840b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b752fbd3-9534-4bc1-b3b6-985ddd214621" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ae303c9e-8916-42c9-b5a1-d84135840b0f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformation"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended" id="i6b368e4f15394267ae297f639fcc7e1a_SupplementalBalanceSheetInformation"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended" id="iaad97b281e814606b0ff4813e68bde4e_SupplementalBalanceSheetInformationTables"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="extended" id="i19048e60d182495ca0e1776afdfea59f_SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended" id="i0eb84ef3ecd64a249f9e7708b04e621b_SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4b5faf5e-fe4e-4b12-b69d-4e14b37b6dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4b5faf5e-fe4e-4b12-b69d-4e14b37b6dc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99ab1ce2-5d10-41a6-aac6-61e012786782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99ab1ce2-5d10-41a6-aac6-61e012786782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a56c6ac-5834-4fd1-8f48-a781eacdc2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a56c6ac-5834-4fd1-8f48-a781eacdc2d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_0d2c47e2-0fad-4bed-bd9f-50478abd147c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_0d2c47e2-0fad-4bed-bd9f-50478abd147c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_05d53d57-d246-46a0-8501-a5aee4024724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_05d53d57-d246-46a0-8501-a5aee4024724" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ef601fe-e8d2-480c-b0e9-dd803480bc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_05d53d57-d246-46a0-8501-a5aee4024724" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ef601fe-e8d2-480c-b0e9-dd803480bc18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ef601fe-e8d2-480c-b0e9-dd803480bc18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ef601fe-e8d2-480c-b0e9-dd803480bc18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ef601fe-e8d2-480c-b0e9-dd803480bc18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ef601fe-e8d2-480c-b0e9-dd803480bc18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5d561d35-3345-4bfb-b6bc-c949a5efce7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_us-gaap_EquipmentMember_5d561d35-3345-4bfb-b6bc-c949a5efce7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_99c5b875-3689-412e-816a-ba3ced1f8cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_99c5b875-3689-412e-816a-ba3ced1f8cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember_27553b23-e769-479d-a131-dded51d6f835" xlink:href="xcur-20200630.xsd#xcur_ComputersandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_xcur_ComputersandSoftwareMember_27553b23-e769-479d-a131-dded51d6f835" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3e62fa3f-3cbe-4a26-a882-ea9ee96701a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3e62fa3f-3cbe-4a26-a882-ea9ee96701a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6015ee42-a2b3-4327-961a-79dd4576f672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_us-gaap_ConstructionInProgressMember_6015ee42-a2b3-4327-961a-79dd4576f672" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationOthernoncurrentassetsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails" xlink:type="extended" id="i5feb3af24526419ab01ed70bb9681043_SupplementalBalanceSheetInformationOthernoncurrentassetsDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="extended" id="i9b810f60bee34566838329eb7067f025_SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails" xlink:type="extended" id="idfad6cd7ff7e4356a8a4f0ed463cfdc4_SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Investments" xlink:type="simple" xlink:href="xcur-20200630.xsd#Investments"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/Investments" xlink:type="extended" id="if187d7e629954af78e93b0bdefe2762a_Investments"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="extended" id="ibe2d4c0240564c4096b452368d407993_InvestmentsTables"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="extended" id="i5c161e37e5334e4db690c61bc0a45305_InvestmentsDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended" id="ie655301eecfd456ca4af8fb44b2028a4_InvestmentsAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac9f99c2-715a-4a3f-99ca-17ad2c011a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac9f99c2-715a-4a3f-99ca-17ad2c011a18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9f449f59-fc5a-45d4-86e1-ae02f3f27ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9f449f59-fc5a-45d4-86e1-ae02f3f27ef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d24d7bd6-fb4d-4993-9c86-ae86df3dad32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d24d7bd6-fb4d-4993-9c86-ae86df3dad32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e0793c34-4f21-4a9d-bc2c-e71d9c05c315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e0793c34-4f21-4a9d-bc2c-e71d9c05c315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2117cd9d-7fe8-4661-ae2b-82801da2cf24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2117cd9d-7fe8-4661-ae2b-82801da2cf24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_97182fcf-180c-42c5-b79f-92f654d477ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2117cd9d-7fe8-4661-ae2b-82801da2cf24" xlink:to="loc_us-gaap_FinancialInstrumentAxis_97182fcf-180c-42c5-b79f-92f654d477ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97182fcf-180c-42c5-b79f-92f654d477ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97182fcf-180c-42c5-b79f-92f654d477ba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97182fcf-180c-42c5-b79f-92f654d477ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97182fcf-180c-42c5-b79f-92f654d477ba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_dd0bea72-6562-404f-966b-a2abf6cc2fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_dd0bea72-6562-404f-966b-a2abf6cc2fc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_38971203-cc19-43b8-9a89-8290fa3d3ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_38971203-cc19-43b8-9a89-8290fa3d3ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2d5ad1a9-8e88-43b4-8fcc-b3bf2a2a1069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2d5ad1a9-8e88-43b4-8fcc-b3bf2a2a1069" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ae2c66b7-9ea9-4887-80ad-db6c9f61dd35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ae2c66b7-9ea9-4887-80ad-db6c9f61dd35" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:type="simple" xlink:href="xcur-20200630.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended" id="ibbf8377f6e584ab685682ecaf82e9753_Debt"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended" id="i42710a3a935d44ac84b37acc4ac19d20_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_db000640-6dea-4779-8898-c3fb87662971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_db000640-6dea-4779-8898-c3fb87662971" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees_ce6f5a44-4207-4fea-863b-ef87de6b1680" xlink:href="xcur-20200630.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:to="loc_xcur_PaymentsForDebtEndTermFees_ce6f5a44-4207-4fea-863b-ef87de6b1680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_87c11ca6-5346-4348-aa34-e14f6ce73301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:to="loc_us-gaap_InterestPaidNet_87c11ca6-5346-4348-aa34-e14f6ce73301" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:to="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_78801cc2-ac08-4d09-b2a0-5200d9517a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_78801cc2-ac08-4d09-b2a0-5200d9517a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_78801cc2-ac08-4d09-b2a0-5200d9517a33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_78801cc2-ac08-4d09-b2a0-5200d9517a33" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_78801cc2-ac08-4d09-b2a0-5200d9517a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4d3e7c31-0bc3-445f-9692-c8fae8b027c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_78801cc2-ac08-4d09-b2a0-5200d9517a33" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4d3e7c31-0bc3-445f-9692-c8fae8b027c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_0e6a1a18-2450-45ae-a138-eaceab9c0e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4d3e7c31-0bc3-445f-9692-c8fae8b027c9" xlink:to="loc_us-gaap_LoansPayableMember_0e6a1a18-2450-45ae-a138-eaceab9c0e9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bdc2f661-8c77-49f7-81d8-409dbabe6db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:to="loc_us-gaap_CreditFacilityAxis_bdc2f661-8c77-49f7-81d8-409dbabe6db7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bdc2f661-8c77-49f7-81d8-409dbabe6db7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_bdc2f661-8c77-49f7-81d8-409dbabe6db7" xlink:to="loc_us-gaap_CreditFacilityDomain_bdc2f661-8c77-49f7-81d8-409dbabe6db7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_58967e18-51ba-473d-8b7d-1e6d77bf4641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_bdc2f661-8c77-49f7-81d8-409dbabe6db7" xlink:to="loc_us-gaap_CreditFacilityDomain_58967e18-51ba-473d-8b7d-1e6d77bf4641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b28d577d-205c-45c9-b977-b540e3a5ddd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_58967e18-51ba-473d-8b7d-1e6d77bf4641" xlink:to="loc_us-gaap_SecuredDebtMember_b28d577d-205c-45c9-b977-b540e3a5ddd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6e4f12df-2a05-4242-9e6d-28801ed9d501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_6e4f12df-2a05-4242-9e6d-28801ed9d501" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_6e4f12df-2a05-4242-9e6d-28801ed9d501_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6e4f12df-2a05-4242-9e6d-28801ed9d501" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_6e4f12df-2a05-4242-9e6d-28801ed9d501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_3c29ca3a-fc2c-45cc-a0a9-84f762ba7883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6e4f12df-2a05-4242-9e6d-28801ed9d501" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_3c29ca3a-fc2c-45cc-a0a9-84f762ba7883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_f174a7e8-cb64-4547-b192-67db32c4cc32" xlink:href="xcur-20200630.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3c29ca3a-fc2c-45cc-a0a9-84f762ba7883" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_f174a7e8-cb64-4547-b192-67db32c4cc32" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Leases" xlink:type="simple" xlink:href="xcur-20200630.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/Leases" xlink:type="extended" id="ic8b72c05466d40f5ad10188c581cae2f_Leases"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LeasesTables" xlink:type="extended" id="i880428abebf6416283fdd71d7ec4b687_LeasesTables"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="iddf16fea9c3c4258b321b63985aa7e0f_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="extended" id="i13ccccc23b894cfa8618e81f2826e0f6_LeasesScheduleofFutureMinimumRentalPaymentsDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended" id="ia06d25be132f44b8a9c39a78d04492cb_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="extended" id="id9270d1cee6d42a8a9ad620b450a323c_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityCurrentCapitalizationDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended" id="i1061855889c1420da04d9c9483930b30_StockholdersEquityCurrentCapitalizationDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquity2019StockOfferingsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails" xlink:type="extended" id="i174045c7516244d19dd3c54b241e4436_StockholdersEquity2019StockOfferingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6b9fdf67-2271-49c5-bf06-6021be525327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6b9fdf67-2271-49c5-bf06-6021be525327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c21b3d8d-0707-4e68-bfd4-d717a041cc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c21b3d8d-0707-4e68-bfd4-d717a041cc97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_10072433-439c-42e7-a5a1-96a14016fc41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_10072433-439c-42e7-a5a1-96a14016fc41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses_759e4d4a-fa58-4b1e-94b8-605884f0e6de" xlink:href="xcur-20200630.xsd#xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses_759e4d4a-fa58-4b1e-94b8-605884f0e6de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0ed74de9-ad11-4b73-a287-dfd1daeaf869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0ed74de9-ad11-4b73-a287-dfd1daeaf869" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_80e5d768-80e9-490f-8ebc-c670b2e374d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_80e5d768-80e9-490f-8ebc-c670b2e374d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_80e5d768-80e9-490f-8ebc-c670b2e374d3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cd5c5ee-2151-4f75-bdd2-f08dff808a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cd5c5ee-2151-4f75-bdd2-f08dff808a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockIssuedDecember2019Member_6167d150-02a2-4218-94e3-9c86f352a6fe" xlink:href="xcur-20200630.xsd#xcur_CommonStockIssuedDecember2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cd5c5ee-2151-4f75-bdd2-f08dff808a03" xlink:to="loc_xcur_CommonStockIssuedDecember2019Member_6167d150-02a2-4218-94e3-9c86f352a6fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_cbc7e4b2-25e1-4f93-9348-04c60f1ad918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cd5c5ee-2151-4f75-bdd2-f08dff808a03" xlink:to="loc_us-gaap_OverAllotmentOptionMember_cbc7e4b2-25e1-4f93-9348-04c60f1ad918" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityCommonStockWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended" id="i45bb81e15c5342558186f72bc63f2692_StockholdersEquityCommonStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17910401-a1b7-491d-ad30-314f4a9fdfe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17910401-a1b7-491d-ad30-314f4a9fdfe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76e31aa0-83bd-47bc-a1cc-511b877fc173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76e31aa0-83bd-47bc-a1cc-511b877fc173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired_fa184c0a-e99a-46cf-aa3e-9765df463300" xlink:href="xcur-20200630.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:to="loc_xcur_ClassofWarrantorRightExpired_fa184c0a-e99a-46cf-aa3e-9765df463300" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6f5a3810-d607-434c-8956-81a9fa7c34fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:to="loc_srt_StatementScenarioAxis_6f5a3810-d607-434c-8956-81a9fa7c34fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6f5a3810-d607-434c-8956-81a9fa7c34fa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_6f5a3810-d607-434c-8956-81a9fa7c34fa" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6f5a3810-d607-434c-8956-81a9fa7c34fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f0502e3a-edd5-4c6e-8cfb-5d7e4ec6cd24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_6f5a3810-d607-434c-8956-81a9fa7c34fa" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f0502e3a-edd5-4c6e-8cfb-5d7e4ec6cd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_82e53db0-7402-47d3-98e5-be9fbbdf4ef0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f0502e3a-edd5-4c6e-8cfb-5d7e4ec6cd24" xlink:to="loc_srt_ScenarioForecastMember_82e53db0-7402-47d3-98e5-be9fbbdf4ef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_546f65b5-5715-4a54-8cd7-dd09088f8a26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_546f65b5-5715-4a54-8cd7-dd09088f8a26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_546f65b5-5715-4a54-8cd7-dd09088f8a26_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_546f65b5-5715-4a54-8cd7-dd09088f8a26" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_546f65b5-5715-4a54-8cd7-dd09088f8a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9519bacd-8851-44f9-bfde-71aeea038735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_546f65b5-5715-4a54-8cd7-dd09088f8a26" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9519bacd-8851-44f9-bfde-71aeea038735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f18f456d-b97d-4108-8572-d483b2b4ff1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9519bacd-8851-44f9-bfde-71aeea038735" xlink:to="loc_us-gaap_PrivatePlacementMember_f18f456d-b97d-4108-8572-d483b2b4ff1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i5e82072d307c4f0fb21416fc4f0a806a_StockholdersEquityAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf6ab4c9-10c5-46a6-91b6-70b991131668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_StockholdersEquity_bf6ab4c9-10c5-46a6-91b6-70b991131668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_89da8fdc-990a-474a-ba9c-0e26426cd097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_89da8fdc-990a-474a-ba9c-0e26426cd097" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_cf36c626-173d-473e-bcb7-30960ab31dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_cf36c626-173d-473e-bcb7-30960ab31dc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1cf1d86c-9f01-4328-9cba-4d565a46856c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1cf1d86c-9f01-4328-9cba-4d565a46856c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df32eec5-83f1-4443-beaa-03e0e576e9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0737162c-2e82-4575-8aa1-72fedd974823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0737162c-2e82-4575-8aa1-72fedd974823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a20b3884-a096-4d20-8dd5-2d4007a1a651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a20b3884-a096-4d20-8dd5-2d4007a1a651" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_0df553ba-0d56-44bd-99c9-daef1bef6382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_0df553ba-0d56-44bd-99c9-daef1bef6382" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_73721d25-0738-48fe-a528-4873294f3bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_73721d25-0738-48fe-a528-4873294f3bdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_73721d25-0738-48fe-a528-4873294f3bdf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5" xlink:to="loc_us-gaap_EquityComponentDomain_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d659b8db-ceea-4fbe-84d6-23b1d178097e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5" xlink:to="loc_us-gaap_EquityComponentDomain_d659b8db-ceea-4fbe-84d6-23b1d178097e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_da4cc091-5f71-4e90-8cfb-d6c7fa7d9c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d659b8db-ceea-4fbe-84d6-23b1d178097e" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_da4cc091-5f71-4e90-8cfb-d6c7fa7d9c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7e8fb6f-4741-4657-a9db-5833ffa80565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d659b8db-ceea-4fbe-84d6-23b1d178097e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7e8fb6f-4741-4657-a9db-5833ffa80565" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended" id="i3eaa115dc70f48c683ab1626f417d539_EquityBasedCompensation"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended" id="ie51a5b5a18fb44d38d89623c15036fc4_EquityBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended" id="i47fbd3e06e8e41a2a59cc92be9725b0c_EquityBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_cce319b6-0a18-4068-9c15-b73f1e8989b6" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_cce319b6-0a18-4068-9c15-b73f1e8989b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_29cb330f-7c3b-4cd1-8740-964897d62e3e" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_29cb330f-7c3b-4cd1-8740-964897d62e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_70d9595e-e468-4278-8133-3134a51a477f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_70d9595e-e468-4278-8133-3134a51a477f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_866eaa20-6007-4ac7-a51c-7b2c6f97ae15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_866eaa20-6007-4ac7-a51c-7b2c6f97ae15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a7533eb-16d2-4e7a-8b42-50b535bd13a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a7533eb-16d2-4e7a-8b42-50b535bd13a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4fffc857-0bfe-4680-bf21-3eb8d06f9ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4fffc857-0bfe-4680-bf21-3eb8d06f9ac9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_510b6e26-6177-4e33-9e2c-bb8231e893d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_510b6e26-6177-4e33-9e2c-bb8231e893d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_70871dfd-80c4-4180-b750-7c35ba2c9368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:to="loc_us-gaap_AwardTypeAxis_70871dfd-80c4-4180-b750-7c35ba2c9368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70871dfd-80c4-4180-b750-7c35ba2c9368_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_70871dfd-80c4-4180-b750-7c35ba2c9368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70871dfd-80c4-4180-b750-7c35ba2c9368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ce176cd-d1f5-407a-845d-4984a77aa929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_70871dfd-80c4-4180-b750-7c35ba2c9368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ce176cd-d1f5-407a-845d-4984a77aa929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c6d2aad4-f2da-491e-8dcf-bff2d1a83bef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ce176cd-d1f5-407a-845d-4984a77aa929" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c6d2aad4-f2da-491e-8dcf-bff2d1a83bef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ad2baec2-d57e-446a-abc3-e69a79f07bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:to="loc_us-gaap_PlanNameAxis_ad2baec2-d57e-446a-abc3-e69a79f07bd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ad2baec2-d57e-446a-abc3-e69a79f07bd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ad2baec2-d57e-446a-abc3-e69a79f07bd7" xlink:to="loc_us-gaap_PlanNameDomain_ad2baec2-d57e-446a-abc3-e69a79f07bd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae9b7277-ce4d-4b68-9e14-dc4948122083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ad2baec2-d57e-446a-abc3-e69a79f07bd7" xlink:to="loc_us-gaap_PlanNameDomain_ae9b7277-ce4d-4b68-9e14-dc4948122083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_b4e67a98-e037-48d2-b3b5-614a2061e62d" xlink:href="xcur-20200630.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ae9b7277-ce4d-4b68-9e14-dc4948122083" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_b4e67a98-e037-48d2-b3b5-614a2061e62d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationScheduleofCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="extended" id="i863a907f67f04feabddb4d7f6b769cd4_EquityBasedCompensationScheduleofCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e8a500d-6335-4fd1-92c9-f85bfc064a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_946c9e9d-e8e7-4b27-973d-9da8c9838ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e8a500d-6335-4fd1-92c9-f85bfc064a25" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_946c9e9d-e8e7-4b27-973d-9da8c9838ec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf27bc3-ff96-47e7-b796-22fea0bd9d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e8a500d-6335-4fd1-92c9-f85bfc064a25" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf27bc3-ff96-47e7-b796-22fea0bd9d4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_99981d67-f17a-4e48-a5fe-d04f94a86ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf27bc3-ff96-47e7-b796-22fea0bd9d4b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_99981d67-f17a-4e48-a5fe-d04f94a86ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_99981d67-f17a-4e48-a5fe-d04f94a86ccf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_99981d67-f17a-4e48-a5fe-d04f94a86ccf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_99981d67-f17a-4e48-a5fe-d04f94a86ccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97ede424-9614-436d-9d6f-3d9afada5e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_99981d67-f17a-4e48-a5fe-d04f94a86ccf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97ede424-9614-436d-9d6f-3d9afada5e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_878999b1-10af-4b8c-bf00-8d73c7bed0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97ede424-9614-436d-9d6f-3d9afada5e50" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_878999b1-10af-4b8c-bf00-8d73c7bed0b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_65e97dc3-2b50-4efd-a05f-5481cf24cb43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97ede424-9614-436d-9d6f-3d9afada5e50" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_65e97dc3-2b50-4efd-a05f-5481cf24cb43" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="extended" id="i892f1cfed88f478a9eef2514aceda8f3_EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9228c5f9-2fb4-4acd-800c-49461d503ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9228c5f9-2fb4-4acd-800c-49461d503ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2dfd7623-a602-4c18-8ea8-8f0a8934c072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2dfd7623-a602-4c18-8ea8-8f0a8934c072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2c304653-a248-401c-b6c7-fd02d6427952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2c304653-a248-401c-b6c7-fd02d6427952" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d9c8f49a-ea81-4e90-a2fc-125d9272852a" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d9c8f49a-ea81-4e90-a2fc-125d9272852a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1e1341a-fa28-4c02-96ca-d27bddc8f0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1e1341a-fa28-4c02-96ca-d27bddc8f0ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98770d87-0b90-40d3-a81f-49082ce1a235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98770d87-0b90-40d3-a81f-49082ce1a235" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05dfacb2-8465-48bd-b745-cee466fc4305" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98770d87-0b90-40d3-a81f-49082ce1a235" xlink:to="loc_srt_RangeAxis_05dfacb2-8465-48bd-b745-cee466fc4305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05dfacb2-8465-48bd-b745-cee466fc4305_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_05dfacb2-8465-48bd-b745-cee466fc4305" xlink:to="loc_srt_RangeMember_05dfacb2-8465-48bd-b745-cee466fc4305_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_05dfacb2-8465-48bd-b745-cee466fc4305" xlink:to="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a0f72f7-1d7f-4a04-93d5-7cd14b03f5c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:to="loc_srt_MinimumMember_4a0f72f7-1d7f-4a04-93d5-7cd14b03f5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73fc8db5-ee4d-495a-9527-a849bef9b3e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:to="loc_srt_MaximumMember_73fc8db5-ee4d-495a-9527-a849bef9b3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_a0893698-1d96-44b5-93d3-101118c028f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:to="loc_srt_WeightedAverageMember_a0893698-1d96-44b5-93d3-101118c028f0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="extended" id="id1e79c55072648a5ae3b787e81fbdd8b_EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7eb195c-4f1c-4f73-b473-76fba5ba0648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_95e9b6b9-bac7-4bfe-bfc3-4dc35da87369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7eb195c-4f1c-4f73-b473-76fba5ba0648" xlink:to="loc_us-gaap_SharePrice_95e9b6b9-bac7-4bfe-bfc3-4dc35da87369" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_96f3798a-35ff-4443-861a-2c2eda2b8472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7eb195c-4f1c-4f73-b473-76fba5ba0648" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_96f3798a-35ff-4443-861a-2c2eda2b8472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd5e47cc-9c76-4976-b820-4564da8862e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7eb195c-4f1c-4f73-b473-76fba5ba0648" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd5e47cc-9c76-4976-b820-4564da8862e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd5e47cc-9c76-4976-b820-4564da8862e3" xlink:to="loc_srt_RangeAxis_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d" xlink:to="loc_srt_RangeMember_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d" xlink:to="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5cbc8c27-4a3d-4242-9691-2c3751f282b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:to="loc_srt_MinimumMember_5cbc8c27-4a3d-4242-9691-2c3751f282b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f26ce810-9283-441d-be6e-c2605ffb7418" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:to="loc_srt_MaximumMember_f26ce810-9283-441d-be6e-c2605ffb7418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_f00a3783-c62a-4e4e-af19-e3155333add6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:to="loc_srt_WeightedAverageMember_f00a3783-c62a-4e4e-af19-e3155333add6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="extended" id="i5a28357851a1439eb61f4b16407dd886_EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xcur-20200630.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended" id="i2895decd2460483b93acebde22cf82cd_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="extended" id="ic74d66ac528c4e0b9dbdba5e7b0e4174_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShare"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended" id="i6cf41fedcc0a47cd9b0bdb5a5567b40d_LossPerCommonShare"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareTables"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended" id="i8209fa8b6b2d47f0a6fc7a45961bec68_LossPerCommonShareTables"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="extended" id="i39a5da97a4d441e99fcd8f54c06a78f9_LossPerCommonShareComputationofEarningsPerShareDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i86a7c7460311490d89156ecccf8e3dd1_LossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8f33c1ed-d3e0-4ca4-8a29-45cf0ca0f6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_677a15ee-f2bb-4f4f-a9d7-e4d75180bbd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8f33c1ed-d3e0-4ca4-8a29-45cf0ca0f6a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_677a15ee-f2bb-4f4f-a9d7-e4d75180bbd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d8a0c0b7-a97e-40ed-a179-d506443c4749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8f33c1ed-d3e0-4ca4-8a29-45cf0ca0f6a8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d8a0c0b7-a97e-40ed-a179-d506443c4749" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d8a0c0b7-a97e-40ed-a179-d506443c4749" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c8adb6a-1218-423f-bed8-b29de600ac5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c8adb6a-1218-423f-bed8-b29de600ac5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e63e2c89-c03f-4fc4-9186-0a8aebb6bbed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c8adb6a-1218-423f-bed8-b29de600ac5c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e63e2c89-c03f-4fc4-9186-0a8aebb6bbed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1f87d1bb-71b6-4f19-9bc9-c08e7d05cb85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c8adb6a-1218-423f-bed8-b29de600ac5c" xlink:to="loc_us-gaap_WarrantMember_1f87d1bb-71b6-4f19-9bc9-c08e7d05cb85" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended" id="ifbbf797f60da4f0eb0a251ed6bdcc253_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i030d42b50f91436c999fcaf6704d0576_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="if6a5054dbe7c469582870d83fcf02644_FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a59e8773-ed71-4652-8970-b05341dcceb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a59e8773-ed71-4652-8970-b05341dcceb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc54587b-7e47-427b-b3cc-140e262cec59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc54587b-7e47-427b-b3cc-140e262cec59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_47ab5fbc-7a36-401c-9268-de43aa7d977d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_47ab5fbc-7a36-401c-9268-de43aa7d977d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_03a46860-2eb9-47fa-a133-9861f21f0398" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_03a46860-2eb9-47fa-a133-9861f21f0398" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_72063d97-ef7f-4955-abc4-264d5b0d14f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_72063d97-ef7f-4955-abc4-264d5b0d14f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_92b67352-0cae-4406-8988-4d457cb995c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FinancialInstrumentAxis_92b67352-0cae-4406-8988-4d457cb995c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92b67352-0cae-4406-8988-4d457cb995c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92b67352-0cae-4406-8988-4d457cb995c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92b67352-0cae-4406-8988-4d457cb995c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92b67352-0cae-4406-8988-4d457cb995c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f4733302-c6fa-4a93-a951-238f6980b47f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:to="loc_us-gaap_CommercialPaperMember_f4733302-c6fa-4a93-a951-238f6980b47f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23c3c8a8-893a-4983-8792-dd8e29a228b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23c3c8a8-893a-4983-8792-dd8e29a228b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7fdddde0-7c8a-4824-bb93-3b0355e300c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7fdddde0-7c8a-4824-bb93-3b0355e300c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_57ff5523-aafe-488e-aed9-d7f2368d08b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_57ff5523-aafe-488e-aed9-d7f2368d08b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_01510655-acb5-4a46-bd9a-669aaef2d0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_01510655-acb5-4a46-bd9a-669aaef2d0f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_01510655-acb5-4a46-bd9a-669aaef2d0f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_01510655-acb5-4a46-bd9a-669aaef2d0f6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_01510655-acb5-4a46-bd9a-669aaef2d0f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2a25dd7-ffae-4a2e-91e1-e4e2cccee6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_01510655-acb5-4a46-bd9a-669aaef2d0f6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2a25dd7-ffae-4a2e-91e1-e4e2cccee6ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cca65305-2615-4961-ba32-829b5bf2e9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2a25dd7-ffae-4a2e-91e1-e4e2cccee6ad" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cca65305-2615-4961-ba32-829b5bf2e9db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0659c8b2-113f-45f5-a099-cf30fe04dd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2a25dd7-ffae-4a2e-91e1-e4e2cccee6ad" xlink:to="loc_us-gaap_CommercialPaperMember_0659c8b2-113f-45f5-a099-cf30fe04dd4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feebdfe9-7162-44a2-affb-edce24497dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feebdfe9-7162-44a2-affb-edce24497dbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_feebdfe9-7162-44a2-affb-edce24497dbc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feebdfe9-7162-44a2-affb-edce24497dbc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_feebdfe9-7162-44a2-affb-edce24497dbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5eac8ca-0fc0-4fb0-9d6e-8e72dd1858f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feebdfe9-7162-44a2-affb-edce24497dbc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5eac8ca-0fc0-4fb0-9d6e-8e72dd1858f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8233cec8-6e30-4600-bc41-8b1a1810a376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5eac8ca-0fc0-4fb0-9d6e-8e72dd1858f3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8233cec8-6e30-4600-bc41-8b1a1810a376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85e99b3a-552d-4432-8fa4-7339e2570bde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85e99b3a-552d-4432-8fa4-7339e2570bde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85e99b3a-552d-4432-8fa4-7339e2570bde_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85e99b3a-552d-4432-8fa4-7339e2570bde" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85e99b3a-552d-4432-8fa4-7339e2570bde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85e99b3a-552d-4432-8fa4-7339e2570bde" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e443b905-1f93-4570-aac0-7d9138019b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e443b905-1f93-4570-aac0-7d9138019b2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7e82dafd-c1bc-4813-90b1-a71b3ea36114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7e82dafd-c1bc-4813-90b1-a71b3ea36114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_442c629d-a676-4af9-9899-cb07232671d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_442c629d-a676-4af9-9899-cb07232671d6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i2771b95109994ed2a9e0db2884463909_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2a5682da-f15b-46c5-b3ba-2da139569e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2a5682da-f15b-46c5-b3ba-2da139569e67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_5d6f48f9-8309-446c-9b9d-f1d26fb936f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_5d6f48f9-8309-446c-9b9d-f1d26fb936f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_1c46d697-1ab5-444a-ad2c-71c8ebd00383" xlink:href="xcur-20200630.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_1c46d697-1ab5-444a-ad2c-71c8ebd00383" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_7a6320c9-1c5c-4b25-bd64-341ba47c60ab" xlink:href="xcur-20200630.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_7a6320c9-1c5c-4b25-bd64-341ba47c60ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_139206df-0720-479b-9214-b43fe03a6f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_139206df-0720-479b-9214-b43fe03a6f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_139206df-0720-479b-9214-b43fe03a6f97_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_139206df-0720-479b-9214-b43fe03a6f97" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_139206df-0720-479b-9214-b43fe03a6f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06282e54-cf68-4cd6-b1ad-a35f67317541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_139206df-0720-479b-9214-b43fe03a6f97" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06282e54-cf68-4cd6-b1ad-a35f67317541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_bad1b11b-1469-46a3-b75b-06dfcbb98e73" xlink:href="xcur-20200630.xsd#xcur_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06282e54-cf68-4cd6-b1ad-a35f67317541" xlink:to="loc_xcur_WarrantLiabilityMember_bad1b11b-1469-46a3-b75b-06dfcbb98e73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_30fac164-5ff4-42b0-a05c-090518a14046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_30fac164-5ff4-42b0-a05c-090518a14046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_30fac164-5ff4-42b0-a05c-090518a14046_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30fac164-5ff4-42b0-a05c-090518a14046" xlink:to="loc_us-gaap_ClassOfStockDomain_30fac164-5ff4-42b0-a05c-090518a14046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4df440b8-0923-42d8-a5e4-c606a3a372da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30fac164-5ff4-42b0-a05c-090518a14046" xlink:to="loc_us-gaap_ClassOfStockDomain_4df440b8-0923-42d8-a5e4-c606a3a372da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_aa6602d6-cb5d-4b50-b17d-13e1ebf67aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4df440b8-0923-42d8-a5e4-c606a3a372da" xlink:to="loc_us-gaap_PreferredStockMember_aa6602d6-cb5d-4b50-b17d-13e1ebf67aef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_580e45cc-83ae-49db-a65e-2133f8bd0fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_580e45cc-83ae-49db-a65e-2133f8bd0fcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_580e45cc-83ae-49db-a65e-2133f8bd0fcc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_580e45cc-83ae-49db-a65e-2133f8bd0fcc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_580e45cc-83ae-49db-a65e-2133f8bd0fcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_580e45cc-83ae-49db-a65e-2133f8bd0fcc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_73ed96ec-3663-48be-9af6-1140a830b8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_73ed96ec-3663-48be-9af6-1140a830b8a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bd3f9108-ae3a-47cd-b709-c3322bf976f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bd3f9108-ae3a-47cd-b709-c3322bf976f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_0aede8e6-9903-4aaf-90ae-7afeaabf4527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_0aede8e6-9903-4aaf-90ae-7afeaabf4527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0f1e1bd2-365a-402b-bdae-4b8da6cd77b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0f1e1bd2-365a-402b-bdae-4b8da6cd77b7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails" xlink:type="extended" id="ia291951b6bcf4119b23dc7338e4946b8_FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_93fe9f66-2e45-4ce1-9f1e-beae9d7e24f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7ffb1241-07f8-4176-9a49-d2653015f86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_93fe9f66-2e45-4ce1-9f1e-beae9d7e24f9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7ffb1241-07f8-4176-9a49-d2653015f86d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b909db6d-00e1-43cb-8b5f-e59ce47aca8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_93fe9f66-2e45-4ce1-9f1e-beae9d7e24f9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b909db6d-00e1-43cb-8b5f-e59ce47aca8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_93fe9f66-2e45-4ce1-9f1e-beae9d7e24f9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1a5ff407-7b84-4cbc-b694-c40809c32b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1a5ff407-7b84-4cbc-b694-c40809c32b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1a5ff407-7b84-4cbc-b694-c40809c32b52_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1a5ff407-7b84-4cbc-b694-c40809c32b52" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1a5ff407-7b84-4cbc-b694-c40809c32b52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1a5ff407-7b84-4cbc-b694-c40809c32b52" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_16f495f8-a2fa-4da0-a6ca-f20a3ce89292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_16f495f8-a2fa-4da0-a6ca-f20a3ce89292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d55d1996-bc37-47b2-97a7-2bfd35a765b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d55d1996-bc37-47b2-97a7-2bfd35a765b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b8fae568-c92b-4f6d-aeda-778d9f3da155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b8fae568-c92b-4f6d-aeda-778d9f3da155" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_183f8403-f3de-41ec-99f5-b959a8a587eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_183f8403-f3de-41ec-99f5-b959a8a587eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_62d4fd21-1d4c-4b77-a494-71e2ee09cca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_62d4fd21-1d4c-4b77-a494-71e2ee09cca0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_62d4fd21-1d4c-4b77-a494-71e2ee09cca0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_62d4fd21-1d4c-4b77-a494-71e2ee09cca0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_62d4fd21-1d4c-4b77-a494-71e2ee09cca0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3ebcac36-397b-4050-95f1-08a572238127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_62d4fd21-1d4c-4b77-a494-71e2ee09cca0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3ebcac36-397b-4050-95f1-08a572238127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_3750cc54-de68-491f-aa96-d35f6b9df6f5" xlink:href="xcur-20200630.xsd#xcur_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3ebcac36-397b-4050-95f1-08a572238127" xlink:to="loc_xcur_WarrantLiabilityMember_3750cc54-de68-491f-aa96-d35f6b9df6f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a" xlink:to="loc_us-gaap_ClassOfStockDomain_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a97ec421-3c99-4b69-bad9-0d965150dfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a" xlink:to="loc_us-gaap_ClassOfStockDomain_a97ec421-3c99-4b69-bad9-0d965150dfa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3f9066a2-0c6f-4dab-b6d3-87abe82ece00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a97ec421-3c99-4b69-bad9-0d965150dfa8" xlink:to="loc_us-gaap_CommonStockMember_3f9066a2-0c6f-4dab-b6d3-87abe82ece00" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ia9aa203ec0c7441bbead0808ea1132bf_FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76b9a4b8-ecc2-4559-b966-4d9960981035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76b9a4b8-ecc2-4559-b966-4d9960981035" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ee4f3b29-21b6-4e9d-88d0-1b866bf13506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ee4f3b29-21b6-4e9d-88d0-1b866bf13506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_0add0a8d-9ffc-4b00-8beb-43de269579bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_0add0a8d-9ffc-4b00-8beb-43de269579bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3b268fed-aca2-43f9-8e0b-25df4d37f633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76b9a4b8-ecc2-4559-b966-4d9960981035" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75106b0e-c02a-49f7-abd7-41e9c8f2d998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75106b0e-c02a-49f7-abd7-41e9c8f2d998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75106b0e-c02a-49f7-abd7-41e9c8f2d998_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75106b0e-c02a-49f7-abd7-41e9c8f2d998" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75106b0e-c02a-49f7-abd7-41e9c8f2d998_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8b1e954-413c-4c46-8591-11d54a1652ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75106b0e-c02a-49f7-abd7-41e9c8f2d998" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8b1e954-413c-4c46-8591-11d54a1652ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b1022733-fe6c-4e20-bd24-173bf1e86481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8b1e954-413c-4c46-8591-11d54a1652ca" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b1022733-fe6c-4e20-bd24-173bf1e86481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f" xlink:to="loc_us-gaap_ClassOfStockDomain_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_87053994-a218-4007-82d7-95fa6b7b2022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f" xlink:to="loc_us-gaap_ClassOfStockDomain_87053994-a218-4007-82d7-95fa6b7b2022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c6f3e45a-21e3-4b30-8907-0c49e0ba0f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_87053994-a218-4007-82d7-95fa6b7b2022" xlink:to="loc_us-gaap_CommonStockMember_c6f3e45a-21e3-4b30-8907-0c49e0ba0f4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_78d3869b-389d-4d99-b6c4-f78ab8466817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_78d3869b-389d-4d99-b6c4-f78ab8466817" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_78d3869b-389d-4d99-b6c4-f78ab8466817_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_78d3869b-389d-4d99-b6c4-f78ab8466817" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_78d3869b-389d-4d99-b6c4-f78ab8466817_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1989ead2-d193-4ea3-a204-b7138d464e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_78d3869b-389d-4d99-b6c4-f78ab8466817" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1989ead2-d193-4ea3-a204-b7138d464e31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_18230613-0fbc-4f11-af59-542848563922" xlink:href="xcur-20200630.xsd#xcur_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1989ead2-d193-4ea3-a204-b7138d464e31" xlink:to="loc_xcur_WarrantLiabilityMember_18230613-0fbc-4f11-af59-542848563922" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="xcur-20200630.xsd#CommitmentandContingencies"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="extended" id="ica81e3f9a2d14f738cf316ad7ca1edb1_CommitmentandContingencies"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="extended" id="i5e467c0a68ee44e8b3c613e0d9a72ec6_CommitmentandContingenciesDetails"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="xcur-20200630.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended" id="i36d7cd95c8e6437da2d98c12e8a19683_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" id="i82dc392687cf4e61bec1917575ab8b1e_RelatedPartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_737b738c-c465-4084-bf53-513fdf2a7a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f3bc393b-75fd-4af6-be68-8ba07618b03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_737b738c-c465-4084-bf53-513fdf2a7a55" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f3bc393b-75fd-4af6-be68-8ba07618b03e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_737b738c-c465-4084-bf53-513fdf2a7a55" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19450984-26ab-48e8-bced-d2dd71b64582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19450984-26ab-48e8-bced-d2dd71b64582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_19450984-26ab-48e8-bced-d2dd71b64582_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19450984-26ab-48e8-bced-d2dd71b64582" xlink:to="loc_us-gaap_RelatedPartyDomain_19450984-26ab-48e8-bced-d2dd71b64582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5dc370c3-1017-4fcb-9317-81663427d6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19450984-26ab-48e8-bced-d2dd71b64582" xlink:to="loc_us-gaap_RelatedPartyDomain_5dc370c3-1017-4fcb-9317-81663427d6d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_8de708a3-f0b5-45de-bee1-6680e332f250" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5dc370c3-1017-4fcb-9317-81663427d6d8" xlink:to="loc_srt_DirectorMember_8de708a3-f0b5-45de-bee1-6680e332f250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b9722f91-0faf-4aa3-a34d-b59949a59dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b9722f91-0faf-4aa3-a34d-b59949a59dc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b9722f91-0faf-4aa3-a34d-b59949a59dc2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b9722f91-0faf-4aa3-a34d-b59949a59dc2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b9722f91-0faf-4aa3-a34d-b59949a59dc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e1508b58-5216-4bf8-86c1-4b8406a3b24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b9722f91-0faf-4aa3-a34d-b59949a59dc2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e1508b58-5216-4bf8-86c1-4b8406a3b24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember_ab9954a3-3536-402a-a037-48462b58244a" xlink:href="xcur-20200630.xsd#xcur_ConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e1508b58-5216-4bf8-86c1-4b8406a3b24a" xlink:to="loc_xcur_ConsultingServicesMember_ab9954a3-3536-402a-a037-48462b58244a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="xcur-20200630.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended" id="i4220c193043a4a71bf08cb523f2a9261_SubsequentEvents"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>xcur-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:36122004-6e71-4c8e-9305-4e03dfe42d12,g:561987fc-3e06-47a9-afb8-202603d40cef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_3551eb6b-07b2-4896-acd9-a6044a499e44_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e47a5e81-1849-4159-b18f-a251641bfc01_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7e34d082-e587-4a6f-912a-3b46de0dcbd7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75e248cb-b2fa-423f-8b6d-5f52100a0586_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0edd60fc-0d74-49fd-b907-d6cc3eba0d7e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_47d9bb15-4212-4640-9a07-bf3cba3db851_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions_376740a2-ab8b-4a56-b808-3f5ec8a32809_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extensions</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Number of Extensions</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Number of Extensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_7e3f948a-ce58-4400-b1e8-c21f85438943_terseLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One year or less</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Current, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Current, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:href="xcur-20200630.xsd#xcur_DebtSecuritiesAvailableForSaleCurrentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:to="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bbc97f64-4888-4b00-bfa1-f06feb23b90e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_abef3bc6-db3e-40e7-9e13-0979935c39f9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c2587905-54c2-4eba-b3f3-3e5a14a445fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_837c3799-d9cf-4163-819f-6c2ca683dcb3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2ad996a0-4ee0-4a0b-b0ab-056eb8c542fe_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2e9e2f0b-2841-4790-8240-c89192877321_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48af2a3a-05f5-41fd-8476-73f8401a085b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d3958008-f711-4df4-99c6-9860562e8970_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementTerm_c1071e96-e2d8-4a58-8a0c-ff8d8c7a3b84_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerm_label_en-US" xlink:label="lab_xcur_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerm" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementTerm" xlink:to="lab_xcur_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_4950ce59-6442-41e4-a8f7-5283f32b7673_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ad091865-b091-4aa6-b8d3-b850964971fa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_273c117d-a864-4477-9734-dacf9e63d7a2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_7d499a6a-cab2-4f4c-be0a-359a084e5216_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of long-term debt fees and issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_42d028f0-5325-4622-9f93-65f98b66a420_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4a6885c2-bb94-4741-949d-7842e6fa4c6f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4344d81c-1618-4417-9697-3557cd6c4e29_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_1298010a-daaa-45c8-85c5-692458b317ba_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal expenses</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_30195f57-c93e-4fad-9b41-d77e33f22ebb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized losses, available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_c62d0a4b-4a8f-42e6-a68b-e7afda6b980b_terseLabel_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for debt end term fees</link:label>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_label_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Debt End Term Fees</link:label>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_documentation_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Debt End Term Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees" xlink:href="xcur-20200630.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsForDebtEndTermFees" xlink:to="lab_xcur_PaymentsForDebtEndTermFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a9e0a9e9-fcc2-43db-8ee9-67ecaf4d03a4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_647395cd-89db-47b0-8124-c9f845060584_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_af5a548e-f1ec-48c8-b827-37db34fd9508_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4fccdf48-4ece-44a6-abae-8122ca03d164_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale or maturity of available for sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_9b09bb4d-f9d9-4041-a0fe-032254d5b6dd_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8e8ebb77-40e0-4f87-aebc-cd8bc868adb9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_d086b98b-2e2e-4f3a-b952-fbd629d3f9a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price of Common Stock Option (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2e052105-f851-40c9-adce-e8ef1fe6208c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fad013cf-bfc2-44c6-862a-7bb33cb62818_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d4090f61-3970-4510-a2e4-496a5899ff44_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9e9aeb6c-4081-4466-ba3b-83742cb4e3d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2cab8105-2667-42a2-870e-286145b41005_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9aa09cf8-1472-49b0-972b-327519ceaff5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_53d1375a-7bad-462f-a87a-84a9d8c40954_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_68b084b7-4d6b-4ac8-a88a-41624a301cf5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_94b40617-b4ec-45da-a24a-1539f5bef93d_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_305acdd5-4f37-4a35-b225-23d28a5c1be2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f0e39c84-5063-403e-bfb4-db9a0691beb0_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_3d2def62-a835-41bd-9f73-6341465d4746_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_938bfa89-98fd-49a6-8c1f-c5ab28a3d5e7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e220aaeb-7b45-484a-b2e2-eb49be1b38c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f6007a94-77bc-4782-bfc9-eee76beb7c92_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_be775a48-3af3-4fe8-acc6-e64912ea200d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_5da2f4be-2f98-40e4-8b4e-d8c41320fe1a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4b01faaf-0d91-4b8f-806e-c5e6842e3589_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_46a71cd8-1371-4f82-989c-40b19dac1dec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fb4474e8-c9fc-4bd0-9cbc-7be3e4d0167b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_1f4c1039-ce78-4470-b342-21dba38af0df_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled revenue receivable</link:label>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81240967-cafc-4144-9ce0-007175b6157f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_94eae3e4-aacd-41c4-bb47-d2aede3d2c32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_ca9b014f-bbb4-47b2-9458-418c43c1bf78_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Underlying Common Stock (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_3207ce3b-91bd-40c0-bcca-0714d9458a6d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_71df6c08-0575-4d4e-899c-3ad2656d8470_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c5c17d64-980d-4915-a7c8-ef94c227fa48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b4396135-0b71-47b6-b830-f6da32560011_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_eca33589-8653-4ad3-b5b6-98052668b83f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e5fa0aeb-475a-4913-8eff-a1babb80c1b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_7b01a2c5-457b-49ef-b1aa-bbbdedeb56f8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f5f3b2ca-d50e-4699-af0c-7bbcae37aedc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_dd572dda-7c18-4768-b557-06373b09e19d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d80954a5-1a1e-46fd-ad40-328676881ad7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_25fb3170-ae85-44f9-b049-5b66d7bf8910_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_485e7d60-8704-47fe-8902-54fe4c696aa0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f161a5dd-4962-4faf-9847-8c2f7fcd58ed_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_c22f94ac-734e-48f0-8334-ac99646f4932_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6be81e16-b868-48bf-aa84-b3af2bb79edc_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b49408c4-86a3-4738-88ce-830f749e0465_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6afd7212-de69-4bb0-b454-c91e57058b26_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_b60577b8-22aa-42b2-922a-eb7f6ca6def3_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6bddec95-6e01-4019-90f2-caa25a924ac9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_94c21502-52ac-48e8-b5f7-cb217486b631_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_156dd26b-9f3e-4103-b611-87f73a21d0da_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2a1ed50d-6990-472f-893e-85200643fb3a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a5a00e58-5019-4886-a124-73242b3a7a53_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares of common stock offered in common stock offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb4215f5-36b9-4a6a-a4ff-3a4a2881b89c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1e1189a0-8881-48a0-87f8-2960b34f7e54_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5c462e38-41a6-4d08-aeb6-14408e481bb1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_5d570890-3eb3-42c0-a0a0-2a56f3526fda_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical, contract research and manufacturing costs</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_87e0fcf4-35c5-40d9-abfd-b08344825de2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend" xlink:to="lab_us-gaap_InvestmentIncomeDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_bbfb9e9e-eddd-4efe-9efb-2150f4acd86c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_da6f5b71-e678-45f3-815c-5965c3060653_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6e46762a-08ec-45f3-b2c1-41a62af9bc15_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_76683c57-fc41-423d-8c93-a40aec922171_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of earnings (loss) per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c6804591-9138-4692-8105-e1abf3d09d8a_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7754a486-1321-4eb9-8cde-7d7c2a6949b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at June 30, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3caa1d1c-a6b8-4acf-84df-0716d21145f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c410cdf6-71cc-4d0d-9d1f-caa6610706e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_df8a5740-75c3-4e8b-bacc-b757fea49106_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa57ff75-d2b4-4ffe-b6c0-2bf0cbe560a7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fb2be61f-fb08-44e7-b424-0173d44778ef_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c3f60d91-f877-433e-bd1a-c8b042cf8b56_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f3bf8a1f-883c-4fa9-9772-a03d66a04b9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9ea4099d-2192-4cb2-b4ea-b8031249e023_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec8d491f-32e1-499b-8b46-32851aa48455_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_760ef73d-b08e-47f2-b430-a9492e670fa1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures (accounts payable and accrued expenses)</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_c12021d0-02ec-41dd-a2d8-03043a6329a8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockWarrantLiability_ce072330-a20b-4ba5-92c2-29d3fac87ee6_terseLabel_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiability_label_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiability_documentation_en-US" xlink:label="lab_xcur_CommonStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiability" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockWarrantLiability" xlink:to="lab_xcur_CommonStockWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_4d6ae3dd-d186-4632-8de4-51e17ba59a5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_650c7baa-345e-42e4-902c-973a40555783_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain included in other income (expense), net</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3ca7869c-e3fe-449a-9677-70f1aabe86a8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized costs</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_69288da1-a4f9-4215-bcaf-429175883e62_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_11e16ad7-7f5b-4889-b0bf-f043169a4bc2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4430c9e4-d9d1-4090-a556-d8578273f6e8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bed19d09-c0a1-4ca9-8ad5-2b2ffa4f2c51_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1a236de0-3b2c-49eb-a14f-82002d06152f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_416b690f-198c-4fed-a4ed-2d82cf07fc53_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0da05108-04b5-4a81-8ed0-8620fc69ddc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_976e26a4-fda0-4aa8-9f0a-2d5ca67962f8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_8b5d234d-7644-43cd-8e8c-35cd9bbe121c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_f3fcc6bd-90f9-43d5-b645-c54abc9b9186_terseLabel_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of 10% change in estimate of expected volatility of the fair value of the common stock</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_label_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_documentation_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:href="xcur-20200630.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:to="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_OperatingLeaseAssetRemainingUsefulLife_9580caa3-bda0-4e64-b96a-70758d6934da_terseLabel_en-US" xlink:label="lab_xcur_OperatingLeaseAssetRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease asset, remaining useful life</link:label>
    <link:label id="lab_xcur_OperatingLeaseAssetRemainingUsefulLife_label_en-US" xlink:label="lab_xcur_OperatingLeaseAssetRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Asset, Remaining Useful Life</link:label>
    <link:label id="lab_xcur_OperatingLeaseAssetRemainingUsefulLife_documentation_en-US" xlink:label="lab_xcur_OperatingLeaseAssetRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Asset, Remaining Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_OperatingLeaseAssetRemainingUsefulLife" xlink:href="xcur-20200630.xsd#xcur_OperatingLeaseAssetRemainingUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_OperatingLeaseAssetRemainingUsefulLife" xlink:to="lab_xcur_OperatingLeaseAssetRemainingUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease_61af43b9-27f7-4f4a-bbce-960877c3714a_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent annual percentage increase</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Base Rent Annual Percentage Increase</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Base Rent Annual Percentage Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4a457b38-429b-494f-892a-338b35a2a2ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f2f33077-0268-4007-bcf7-71af910d0f43_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_89d8fd45-39d4-4796-a71f-0483a5004940_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_20820d06-9423-41ef-a9bc-67b205d80da7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f54be858-cd8c-4399-a262-89715d452778_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_902d26b2-eb13-4779-b1c0-44c7baf609ac_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8b55eaaa-34c4-480d-b5a0-135275470df3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4b36df87-3be0-42a6-8aea-d509ae036c28_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_af1889d8-b87a-4fc4-a3ff-4977de2d5f40_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c5467edb-b96d-4259-977b-1330d6d5786f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a49bc801-e3cf-4af0-98a3-67e2177b1b04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement_26562a0f-ba32-4268-9e72-33149b9b42f3_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Landlord contribution towards tenant improvement</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Contribution Towards Tenant Improvement</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Contribution Towards Tenant Improvement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2ac67cc3-6474-4d05-b2a2-111473fb20f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b639d77c-8471-4ded-8e52-b6d80cfc084f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on available for sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_50b85968-efeb-4a7f-a784-d2e1dfd0f8b5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1cc73040-955e-43f2-83b2-d2283c4723a9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_32500b30-cc85-4c4e-ae51-7c3b56f69d2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_21e93bf1-46bb-40f2-95be-b6ba412e1007_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_920074bd-9c67-4c86-af1f-ebcee6c00c70_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_81bc2ce2-9539-4a49-9703-186b32f9c310_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5a700b4b-600f-4322-bcb6-e527f612fd08_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_2377ffbf-6ed9-436c-a5e4-78c65e90d0d4_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment received for research agreement</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementUpfrontPayment" xlink:to="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82281087-540a-42e3-8560-fe6a8c3776f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_5bb70f6e-b215-440e-8df8-2d8d72f1691a_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5d1cc2da-bf65-43a6-944d-397686950254_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3ef5ad24-0b1a-4ddb-a772-b626924b05cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7ca4055b-04ca-43ed-9ac2-272c8345125e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6e3161b5-981f-4fbf-bf3f-33e9226b2fa5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_06cf90ce-6680-4f17-b728-c6a177bceff6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_948da869-3818-4805-9a60-fabf8cbee650_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths_952732cf-ece1-4de2-85f2-f4720bd41840_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual base rate initial twelve months</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rate Initial Twelve Months</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rate Initial Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ca94273a-2ef3-4a5e-a50e-21d25dba8f7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_7d3d6d89-65a5-46d2-99ad-727773b48f5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized gains, available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_65ef23a2-7496-4892-a9cd-2caa5116ed22_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in- Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses_00c98bad-417d-4644-b231-4e33631c4a52_terseLabel_en-US" xlink:label="lab_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses_label_en-US" xlink:label="lab_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net of Underwriting Discounts, Commissions and Other Offering Expenses</link:label>
    <link:label id="lab_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses_documentation_en-US" xlink:label="lab_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net of Underwriting Discounts, Commissions and Other Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" xlink:href="xcur-20200630.xsd#xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" xlink:to="lab_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_aefccfee-3944-4216-9a53-0a45623b14bc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5239f2f9-0f2c-41e9-be42-47285363c453_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_1c695cd0-3225-4135-988f-99449c2a952a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d3f85bd7-b5d0-40bf-8c9d-4e0a040ce172_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_547347ee-4fb4-40c0-b845-f06a9ef15d9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_e5821056-d816-4a4c-9385-d51096e7b357_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_82d5068e-ef2d-475a-a09a-2e8e1b78c62b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_f2f1cad4-b521-48d5-94d8-2a68b7bc7169_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6bb0545e-67b9-44f4-a645-3a39ad3b33cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e5871a40-a08d-4a33-885b-3e92659272b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement_f9a38ea1-ac12-4591-b3fc-ad7e15c47ae1_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental payment adjusted for abatement</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Rental Payment Adjusted For Abatement</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Rental Payment Adjusted For Abatement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_ebbb679d-d75d-48db-9d81-39c1c3592f16_terseLabel_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_label_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_documentation_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember" xlink:href="xcur-20200630.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_HerculesTechnologyGrowthCapitalMember" xlink:to="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_95e9e1e6-b5ed-4a47-8ef4-4d38e8ed6159_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a0ee24e3-dd76-41a3-a197-81b688ea0cf8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b6ae3f94-5166-461b-a5be-e3298a91a06b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_3f2c1462-6188-47cf-ae8b-381831486a4d_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7baa37e7-5b11-4179-9a14-b1161c9473e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_761eb20a-cb5b-460b-8261-e7446529d672_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e9b0db04-89e8-4eb8-85f5-904a7816d1f7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_b23b05db-6c2d-47ec-a915-3af733cadc3b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesTable_0b8da063-5eb7-47b5-9392-6b04636717f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:label id="lab_dei_EntityAddressesTable_label_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable" xlink:to="lab_dei_EntityAddressesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_0f35d1f7-99c0-448a-9261-9d9550784b8e_terseLabel_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of 10% change in the estimate of fair value of the common stock</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_label_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</link:label>
    <link:label id="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_documentation_en-US" xlink:label="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:href="xcur-20200630.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:to="lab_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88fa382e-94ed-420c-859a-8a07305e3de4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c81b950a-4245-44d2-a97c-06f0b1ad6937_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c2fadfc5-a483-4889-a427-272eae80adbf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f6eb3de-0af0-4517-93f5-7744559787e1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityCurrent_a5c9b851-9ae5-47bb-ab25-701dbe303a37_terseLabel_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityCurrent_label_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability, Current</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityCurrent_documentation_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityCurrent" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockWarrantLiabilityCurrent" xlink:to="lab_xcur_CommonStockWarrantLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_29f580a5-9d8e-4cd6-8503-01e15621241d_terseLabel_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration development expenses</link:label>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_label_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Development Expenses</link:label>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_documentation_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses" xlink:href="xcur-20200630.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationDevelopmentExpenses" xlink:to="lab_xcur_CollaborationDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6dbde81b-c3de-419c-a882-9e009a9ad034_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_60a9f0f0-bdf1-4eaa-a471-1ddb237cef59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_4108f898-ae70-4802-961c-109323c244ed_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_39bfbcad-3e29-42fb-be38-0e60996f0726_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_75d4abf6-c64b-4d36-afb1-e8efaea14f5d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f4e93250-00cf-4b40-8c89-322f213e2ff8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_765c12ad-8125-4b8e-b442-5c4d925ebf10_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ArrangementNameAxis_b0d535a4-6efb-44ec-970c-323a4a9ea91d_terseLabel_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:label id="lab_xcur_ArrangementNameAxis_label_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:label id="lab_xcur_ArrangementNameAxis_documentation_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis" xlink:href="xcur-20200630.xsd#xcur_ArrangementNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ArrangementNameAxis" xlink:to="lab_xcur_ArrangementNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c1e53f83-edbe-4766-9597-f3f89b634d04_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b218634f-c7bc-45e5-93b7-2723efc6f654_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9e854818-a811-4618-871f-bede2177cd69_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_d4f26d92-5063-4b68-8118-d7d786a2a768_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_e2c4259e-a4ee-4cc5-bd1e-89d53e8e2471_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ba198f1b-48dc-45b0-a8ec-31fc3a2f4808_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_447be0c7-da30-46f0-b8fd-c251b1b11aab_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9953fa2d-64a2-42c7-a061-701d7d8c799f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_a5fb9e7d-7ac2-42af-8335-c92315128f9b_negatedLabel_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of common stock financing costs</link:label>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_label_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Common Stock Financing Costs</link:label>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_documentation_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Common Stock Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts" xlink:href="xcur-20200630.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsOfCommonStockFinancingCosts" xlink:to="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_5f950909-a57e-4173-8d64-4f910d5c9b48_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_a28fbc7b-110a-4d1f-b4c3-c2a5ffdcf9fe_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized, potential maximum additional shares</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths_b9b8e950-8cca-4dd3-b3b6-ac325e1c6087_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent payment initial twelve months</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Rent Payment Initial Twelve Months</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Annual Rent Payment Initial Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_bc4392d6-5379-45e3-b11c-d95b16895f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation Expense Classification in Statement of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5b7128c5-aacf-4f3c-9745-dd5a096c9941_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d2993174-7480-4f33-ae45-5d7452806354_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm_26892403-914e-41f4-a3ff-e1eca7541162_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated rental payment over original term</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Estimated Rental Payment Over Original Term</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Estimated Rental Payment Over Original Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_66741e94-7e42-4e3c-92bd-c9ec9ebe9e96_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6e20edbf-6404-44c2-8956-3e5b0f3ce2cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_54f0db83-9db3-456e-b125-e1974ec59dfa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_f74d92fa-3196-43c3-b3ce-b887a58676a7_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4e4c97b1-63ee-4136-8254-52cff0f0461c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f77215cb-62b8-4c53-8e19-698dc2b6ebd2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4d49ec71-db97-4374-b5f3-98e6fbda6396_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_AllerganCollaborationMember_6bc3b1bb-c23b-46be-9731-f5fc4a85e70a_terseLabel_en-US" xlink:label="lab_xcur_AllerganCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan Collaboration</link:label>
    <link:label id="lab_xcur_AllerganCollaborationMember_label_en-US" xlink:label="lab_xcur_AllerganCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan Collaboration [Member]</link:label>
    <link:label id="lab_xcur_AllerganCollaborationMember_documentation_en-US" xlink:label="lab_xcur_AllerganCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AllerganCollaborationMember" xlink:href="xcur-20200630.xsd#xcur_AllerganCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AllerganCollaborationMember" xlink:to="lab_xcur_AllerganCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_52741898-83cb-4503-beb2-d0e6e9996c3b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5e779219-fd5f-4daa-a7c1-5a303b2f0fc2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8e67b02e-5836-448c-b17a-c5119a4b7512_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_WarrantLiabilityMember_92147a45-2a93-4ad9-b80e-7b6c2dd0f225_terseLabel_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_label_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember" xlink:href="xcur-20200630.xsd#xcur_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_WarrantLiabilityMember" xlink:to="lab_xcur_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e685e7fc-eabe-4efe-8864-fb8ee821fee2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_16ed512c-5999-436c-8935-628c377199d8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f096f180-98f8-45ac-b379-7ad492189932_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_86d04539-a729-43fc-82f7-0996ffd96dea_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d97bedb5-98ba-4805-875b-419871276ba9_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8d3128a3-9e3d-49fa-be95-ddb68f409569_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3002b146-fe10-46e3-a7ba-67097a4458d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Determine Fair Value of Common Stock Option Grants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_44b871c9-5e62-428b-9540-225d9837a02d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8a67f0a0-f4a3-42ab-8b14-e55efd74491f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_3ebde4d7-4700-4027-830f-aea5a46848d9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_809987ad-f6db-4855-bde0-af438546dcc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c041991f-106e-45e9-acc0-4e8e8515a747_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_21369b1e-10d2-4fa2-97bb-a122f9accce1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b3070479-5b41-416d-b27e-2e33ca89ffb6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_9634b478-f2f8-4d0b-b843-1747f530afc2_terseLabel_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, voting rights for each share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_label_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights for Each Share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsforEachShare_documentation_en-US" xlink:label="lab_xcur_CommonStockVotingRightsforEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights for Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockVotingRightsforEachShare" xlink:href="xcur-20200630.xsd#xcur_CommonStockVotingRightsforEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockVotingRightsforEachShare" xlink:to="lab_xcur_CommonStockVotingRightsforEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_8df285c5-d6b8-435f-a161-c6203c836ea6_terseLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year but within two years</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Noncurrent, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Noncurrent, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:href="xcur-20200630.xsd#xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:to="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_7c80e8c7-916c-43bc-b453-42127a6ddefb_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_cab652c4-5adb-4fc0-87ca-aeabd057708e_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f4952942-50e0-4eb8-af5d-ed642faa5a57_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9505c1b3-1078-4e12-8236-36bd9a34a57a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f91dddeb-9deb-45b5-a22e-bbf64952378c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_c7433a51-f482-4a4d-8084-cf7abb9b8820_terseLabel_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaboration programs</link:label>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_label_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Collaboration Programs</link:label>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_documentation_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Collaboration Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms" xlink:href="xcur-20200630.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_NumberofCollaborationPrograms" xlink:to="lab_xcur_NumberofCollaborationPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_20bd62c5-3e36-42b8-9330-fcf0c9814388_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_d0c76574-e6ff-47ba-94f4-7503d237e7f2_terseLabel_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration paid to NU for agreement obligations</link:label>
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_label_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for License Agreements</link:label>
    <link:label id="lab_xcur_PaymentsforLicenseAgreements_documentation_en-US" xlink:label="lab_xcur_PaymentsforLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsforLicenseAgreements" xlink:href="xcur-20200630.xsd#xcur_PaymentsforLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsforLicenseAgreements" xlink:to="lab_xcur_PaymentsforLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f54fa8f3-6e9f-4fa9-895a-dcd2dee0bc13_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_f8d0c851-59e1-4559-9aed-2ca38ae842e0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_75db3595-3077-41b7-8546-3b42c389f7f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_36a6f31b-8160-47f5-bb2f-69f60caa67b0_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_PrepaidLeaseCosts_bb5fe41c-56c4-48e6-a7ef-794d3bf7763e_terseLabel_en-US" xlink:label="lab_xcur_PrepaidLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid lease costs</link:label>
    <link:label id="lab_xcur_PrepaidLeaseCosts_label_en-US" xlink:label="lab_xcur_PrepaidLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Lease Costs</link:label>
    <link:label id="lab_xcur_PrepaidLeaseCosts_documentation_en-US" xlink:label="lab_xcur_PrepaidLeaseCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PrepaidLeaseCosts" xlink:href="xcur-20200630.xsd#xcur_PrepaidLeaseCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PrepaidLeaseCosts" xlink:to="lab_xcur_PrepaidLeaseCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_b5637219-c27f-4ec4-95d6-83d287f06ff4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesLineItems_db72edc4-0181-4d40-a545-abfb21d1cc24_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:label id="lab_dei_EntityAddressesLineItems_label_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems" xlink:to="lab_dei_EntityAddressesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a06f8abb-ae0d-414c-a1f3-404b7fe711ab_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_41872a51-17cc-4c15-a43d-faa0aeec8d86_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_df638de5-0262-477a-807b-9df4fab85792_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_982c3324-016f-4b8f-8bb5-2bb66be179d1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average basic and diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_604d9cb8-0aa5-4e33-a706-9d4673ec6881_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e7aa9e5a-24e1-42bb-91ba-0438a37142fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a9e9ffb3-2d92-48ee-90fc-9a692a77bb04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d92d9f6a-e6f2-4d71-b0e4-877e93259705_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Estimate Fair Value of Warrant Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_755f1297-1a3d-4209-8c77-23366eb6a241_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5edfd3e1-d071-473e-8f46-5c08e1ccd81c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4e58d24f-2b6f-4c29-be5c-9b8e204a85e8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2b08964e-edf7-4767-8514-99ce2e104734_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_3f12617a-c2fa-4612-a883-2a513eaf56f7_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3f5fb0c3-ddde-4dc0-93ab-4c1fb4a715b3_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1e0ad86d-bc71-4997-a232-959e0b02aaf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d3dc76e6-4c19-410f-89a3-0f1f64805a06_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_cdcd5baf-e6df-4977-bbab-9fb768358c5b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4e46006a-1bcf-4eb2-bac3-d66bd423b4a3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_aa94044c-3ba8-4dc5-950c-d391ab1e907b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e5cea9de-5f01-4c9d-86de-b3213e4ca9cc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5d84b842-c6fb-4362-938a-3d7c61c9ec03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ArrangementNameDomain_851be65a-a60f-480d-9b40-1b91269a460e_terseLabel_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Domain]</link:label>
    <link:label id="lab_xcur_ArrangementNameDomain_label_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Domain]</link:label>
    <link:label id="lab_xcur_ArrangementNameDomain_documentation_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Arrangement, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain" xlink:href="xcur-20200630.xsd#xcur_ArrangementNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ArrangementNameDomain" xlink:to="lab_xcur_ArrangementNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7de721d4-e8fa-4a76-ae3f-d0b7bc4fcea2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bf68683c-02bd-4eff-b024-67e444a9383a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fed77409-d6b1-49bf-874b-f921809c767b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_050bf5a8-0183-4891-a1a3-44e0a1f76c6b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8e584420-164d-4a92-9ac0-e3a62e156bdd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_248a7ed2-25f2-4791-bc0f-29625fca192d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_50b6dfa6-2498-49b3-9d30-977ae4ef4227_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_bdf7295e-9117-49fa-88f4-eb2c24051a5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_f4e9943e-6bdc-4e18-bc8f-0e066a0eed5d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_93161ca2-d389-4cb6-a4f4-b19f774828f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_69a05e6c-b5ed-483f-8352-fe3d82d93ee2_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23f75a4d-cd38-4949-b8e8-8b11e825621b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bfad4760-0fa7-44cb-bead-851987c261f0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_98b2b6d7-7e55-4263-a573-2949b6822b38_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea_eb1b8165-0b0f-40c0-869e-1ea5946ebe79_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease area</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Lease Area</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_23d367b4-15f4-4222-a242-f508875ec462_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 87,206,346 issued and outstanding, June&#160;30, 2020; 86,069,263 issued and outstanding, December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockIssuedDecember2019Member_37cf6ac0-dd6b-4330-b457-80c5182e790e_terseLabel_en-US" xlink:label="lab_xcur_CommonStockIssuedDecember2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued December 2019</link:label>
    <link:label id="lab_xcur_CommonStockIssuedDecember2019Member_label_en-US" xlink:label="lab_xcur_CommonStockIssuedDecember2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued December 2019 [Member]</link:label>
    <link:label id="lab_xcur_CommonStockIssuedDecember2019Member_documentation_en-US" xlink:label="lab_xcur_CommonStockIssuedDecember2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued December 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockIssuedDecember2019Member" xlink:href="xcur-20200630.xsd#xcur_CommonStockIssuedDecember2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockIssuedDecember2019Member" xlink:to="lab_xcur_CommonStockIssuedDecember2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2fc0caa2-608d-4176-9a39-f23cc6e717e2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ec5e4fb8-60bd-4392-98d7-6b020c2b84dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_45db8e1d-d08f-455f-b12d-90e7fb3c2f51_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_a587b9ac-a346-4790-b341-f748ea8c910e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_45881d59-bec8-4269-b111-502b335436ee_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_0555f118-98a5-43b6-ab0a-5cedcb8e0c06_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share in sale of stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_cb1d6dad-8041-459e-8a3d-bfcda176233a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_b4fe37b3-7141-458f-8977-7d1942fb8e12_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_c3680ce5-376b-45b2-9bd2-d5c1ad0a375d_terseLabel_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_label_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_documentation_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract" xlink:href="xcur-20200630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract" xlink:to="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_131a4281-12c2-4ad9-bf0d-fa9313ce1cc3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4395cb04-47c2-4e91-9670-ab3676c51daf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5ee6c36f-587e-4d12-a897-983380c53f32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_f20c75ae-c471-4bf2-8451-adc2333171be_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_acdf2e97-986f-4759-b356-9c017ed554ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled revenue receivable and accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_FormerAddressMember_0f1f9874-6444-4986-abec-1ed88d7106d2_terseLabel_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address</link:label>
    <link:label id="lab_dei_FormerAddressMember_label_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_FormerAddressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_FormerAddressMember" xlink:to="lab_dei_FormerAddressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_ba393ffa-3ac5-4fe1-b260-d74a7a38ddd2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d80b2bb-84a6-456c-b42b-a6cdbc0a8a28_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0e27eb40-6453-433b-987b-8b2df39414a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3e4ccc9-ac4c-411d-80c2-19cc87a0dd0f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_7e1d796f-8b2f-4c6e-a8f5-8a6046ba569a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_f354624f-c75d-40da-bf76-4ce8f7173d5e_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized, percentage of common stock outstanding</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_8fc148ac-c5d4-4a68-8dca-da997384e0c3_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration option exercise fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_label_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Extended Option, Additional Exercise Fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Extended Option, Additional Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:to="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4dd56c06-cd6d-42fe-9a12-10d5ec179e5b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1351c059-d09f-4b89-b021-5924a24f5644_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_038a3f03-5961-469a-9b16-80497ece2bdb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cad6921a-7d35-4400-9349-178ab3d32c71_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b7df25d1-f577-4b33-a81f-7f3bc21b7ec6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_19fc61f7-cf6e-42ee-b521-7aa158d03470_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d0421836-a99d-49f6-81ae-e9c019f1bdab_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_be63641a-ca97-4d18-9d58-be30ce9ca7d0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_18b889a2-9dd4-42f2-abae-014fef5bed77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_800e5d6e-5f88-4e1f-acd7-3bcc2186a6d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_400e5897-579f-427e-9ca0-a6f52a164d2d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_466af6f2-69cf-48e5-9088-936fad29bcb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0bad2daa-659b-41c5-9c6d-8aef953a72fd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_039b2ce8-5a60-479e-aa49-ddac8b2ef1fb_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d7b6de0b-9f7d-4cc5-a438-cb21f3d876ab_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_01a4d15b-a878-4521-be17-f764041012bd_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_d355bc23-a072-4971-b896-a4be9bdb48bd_terseLabel_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit generated, since inception</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_label_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_documentation_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:href="xcur-20200630.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:to="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2e8e447d-6c71-4ba5-8491-995cf6a2bd12_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_a55089d2-1cb7-491f-8836-87367ce649b6_terseLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available for Sale, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available for Sale, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableforSalePercent" xlink:href="xcur-20200630.xsd#xcur_DebtSecuritiesAvailableforSalePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableforSalePercent" xlink:to="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6f63ec10-744a-492f-accd-86d5318e378f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0076a3bb-17c3-4177-a73b-77f556823811_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8a632892-c7f1-454e-86d0-f1b8167a5662_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_9adcce3a-dd33-46e9-8b02-1ac169a10e18_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_c8e57ed0-b3c4-40cb-bbef-3f0652589f7c_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product approval and launch milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_41cd5ea6-9a25-4bcd-b8d4-fc863789e46e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_fdf2cdd5-36bb-465c-808f-0df2604285ff_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_dee196b0-5a8f-47fd-8479-9cb50a3aa191_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, measurement input, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a4cf61b4-b89e-4e42-a99b-72158e1c0ac0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_31247594-a5f3-46d2-84ac-35446bb694d6_terseLabel_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expirations</link:label>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_label_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_documentation_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired" xlink:href="xcur-20200630.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ClassofWarrantorRightExpired" xlink:to="lab_xcur_ClassofWarrantorRightExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a74e36c0-44f6-42f8-938c-3efa586979a2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7d2f12d1-0b74-468b-986d-03462297f54a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2e3a2d24-64fc-4bb5-913f-200bdcb1b27c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2b764d37-9f74-4384-acae-aa8319ed6892_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_77891124-98b5-49ba-a4f2-adb5a2f75d0e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_6658ca39-a724-4852-9c42-1c212c1ef4f9_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_e2750abb-e7d6-4767-b2f7-19d0c4617292_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ac802a8f-6e03-48be-b47f-358d3097cd1b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6f09d316-4f42-4065-ba58-d0cf3973d009_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a9d1f173-5927-47ea-a92f-9452efa039ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_2cff26da-c3d9-43f7-ab71-22d47eac35ef_terseLabel_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License</link:label>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_label_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License [Member]</link:label>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_documentation_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember" xlink:href="xcur-20200630.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DevelopmentandCommercializationLicenseMember" xlink:to="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_75edb651-8d14-47b0-98ca-61218deba081_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fef2fbb7-4a83-47ce-b2a9-36db53ce56c6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_47eeb30b-20dd-4a1b-845f-59d21b9a24c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses (gains) reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7ff7509d-c26b-4851-9636-cb77499d58e7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ea91d92b-b0f9-4e11-91f6-ef24eecefb5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3af9eb03-c1ff-4845-ab4a-5a605a87f8e9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_426069f5-3c44-4e02-b97d-01dbd92ad6f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_27122791-66c0-4d97-9ef8-48069dd5cb2c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_ec60d21c-ecb6-49d4-ad20-9d1e319a066b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2ab5179e-b9eb-49b9-a733-3f826f34212c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_620b08a4-0772-49c0-a10f-58937981c695_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_deea2b84-faab-4ca7-a9de-e6243b85d236_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_524d0937-6294-4ea9-a458-2549d29c200e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d4edeca5-decb-402b-85cb-704b75d04a5c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ComputersandSoftwareMember_807bb239-05d8-40b2-bc01-56f6b7d09505_terseLabel_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_label_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_documentation_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember" xlink:href="xcur-20200630.xsd#xcur_ComputersandSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ComputersandSoftwareMember" xlink:to="lab_xcur_ComputersandSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_af2bc3d8-2ef9-4732-89ee-8487db47b171_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_0e241893-3df5-47c3-ba24-1b96ac766bd9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt fees (accrued expenses)</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_c4975237-caa9-46f7-9778-a3062c6b2657_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration option exercise fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_label_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Exercise Fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementOptionExerciseFee" xlink:to="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_f2e3ef39-8a63-45d7-aee8-432522535e68_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_c6a23207-7b84-4609-b94d-9116be7c48c7_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cef1818c-1804-4826-9d51-77dba0be6af6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e3a7422a-8958-43ac-95a5-589b8d369a0b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_db4ee10c-6ce1-40d2-85bd-ae7bf693bbc3_terseLabel_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:to="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9093c310-9283-42de-8f42-eacbfc464418_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_cfe9bf07-981d-456f-8986-b37842094a3b_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period upon written notice</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_label_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Period Upon Written Notice</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Period Upon Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:to="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09d71bfc-a2c9-4851-ac8e-59061b235857_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1aa28dcd-bf77-4eba-bb0c-8748aeebcb39_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2132d326-5b6b-4fa2-a0c5-a83a31fa5ecc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_8deb6985-0dc1-4aeb-be85-44e5de02bd65_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate regulatory milestone revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b1fbf7d1-f5fa-4e58-9294-72f424f7bcef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81e7b196-16f8-4bc0-b5e4-c2fca120984a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_7e5f3c94-092e-4fc5-82db-681e0e59694b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_98700e44-f430-4596-848d-229c0d7fb68a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_342e506e-24b7-459b-93f1-ab0e208d516e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_d1f3311d-f88d-4e06-b2a2-4e0564450b6c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bca3fc53-0186-4047-a1ec-2ee99e236003_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9be7d745-5f23-49d0-b81f-263886de482e_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9cd4d590-b491-407e-928b-1347722d427e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_66874b45-0e6e-4f97-a6a8-b8fc5fbf59b5_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1c34d90-5865-4015-8a70-af376ae6f487_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7c482dd6-3455-46e8-8570-425b0da3e087_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_db2517d0-6895-483a-ab44-ac8a320322b2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_df9b96da-e561-4725-b29d-1c0adc5c69a2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2e21a6a2-c60f-4f7d-ae7c-7781cb0f0a78_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_33371789-c23e-4c4f-bbd6-f211acee5613_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid on debt</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_e9c88e89-d538-48e6-8e6b-edd4977f006b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1c7bea05-c3d9-4b9a-954d-7ca77b1e0252_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_c74c7d27-8171-4ab0-9c9a-4474046a669e_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d6fc1417-fbbb-4640-998e-f5c488fafb27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_b9864fe6-8d79-4be1-b423-aba45b018d4b_terseLabel_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical, contract research and manufacturing costs</link:label>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_label_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical, Contract Research And Manufacturing Costs, Current</link:label>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_documentation_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical, Contract Research And Manufacturing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:href="xcur-20200630.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:to="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_75a6e8d0-aaad-47f9-8ab7-0e30f4368165_terseLabel_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement</link:label>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_label_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement [Member]</link:label>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_documentation_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember" xlink:href="xcur-20200630.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DermelixLicenseAgreementMember" xlink:to="lab_xcur_DermelixLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f9f9d9e-7fb3-4a6c-997c-a615ee859fe3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4d92888-e957-4588-8e21-9a42528a16ec_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_890d3dc9-0ef4-426e-9021-c68d6518ae55_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_92ef733a-f50a-4e11-8d82-8184596d41d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c3df43ea-3180-419b-9eb3-a571f24a4e4a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_42f2b170-afed-4d35-87d9-7001573eb40f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9e294d6f-de8c-4f08-984f-bb98bb8cde1c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3ee7e854-6fd5-4b5a-8914-e97952cd9b02_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_b273f47c-d3aa-49de-85c8-2778a6c06c1d_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6ee6c0dc-f9a2-40e5-b6e8-b2d74ef4dccb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b6b5610b-4b85-4a9f-b3d7-a25cfa7e49dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bfbf63cf-3adb-4dc7-88c4-75ab3844a340_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, stock options, exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c07d5fea-fe5a-4006-ad4d-f97484a9f867_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_67b06366-efb0-4202-b692-ee0a2e0209de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_7e026587-61ef-415a-9540-41c7f29fa6a1_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_27682ee8-7f68-467a-8546-e99e696f855a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cf58890d-6041-481d-8496-4767cf3e5e23_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_7f70d5b5-afa6-4a86-a386-60acb4e3de1f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_e03e558a-6bce-45ca-91ad-2473db2d708e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5e942b17-8319-46e7-911d-f558e982540a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ConsultingServicesMember_634cece2-f663-4dc0-9a3e-86188012fb12_terseLabel_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_label_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_documentation_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember" xlink:href="xcur-20200630.xsd#xcur_ConsultingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConsultingServicesMember" xlink:to="lab_xcur_ConsultingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_43451309-0f0d-4cad-bdd4-191a6f1a212b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3e310ea4-a997-4bf9-9e77-5a7e5db8c0cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0ddedabc-afed-425f-a7ff-ed9625427594_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_44f320fe-dce2-4d68-a9fa-b4ba140de372_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_6daa2145-01d6-41c5-9ee4-08ebad73d58e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of long-term debt issuance costs and fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a7f23781-394e-4d75-a2fb-9b6b6101651e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_9c54a984-4549-46e7-b518-e63fc66b7e28_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_1f5a606c-dce9-42f5-b546-fc102a716583_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9beb0192-1743-4902-91dc-75c195e46a08_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_81345bfe-5b80-43c9-b380-46637ac521bf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_511e8957-a74a-4829-bd51-6c9b2e60a05e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46a5143b-96b5-44f6-b63a-7c070f282117_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8bd22eb0-62cd-4c59-b087-5f51178d84fe_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3fa6584c-ce29-4bd3-bc4b-8d2450f14e59_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17bf008e-5ab3-480c-b818-8ac14feb2029_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2eb44843-f54d-41b2-acb5-4f5df0edd959_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_253fd0c1-947d-4ade-a6eb-e86c6b2a7d06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_64599131-609c-4bde-9fe4-5895cdfbfbdf_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional collaboration targets</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_label_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Number of Additional Collaboration Targets</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Number of Additional Collaboration Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:to="lab_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4bc35c1d-1e3c-4b10-8f22-29af95811cb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_fa05811e-521a-42ce-b99b-b3890055380e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes/bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_08a3f5fd-067c-48a9-afe8-b8c2aed95e22_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_c8e33ab0-fa82-4dfa-9feb-4f72d2db1668_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8328f135-0b05-4daa-9a21-4ec6b634743d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f80fac63-e652-4609-a26b-3aa81ac28ae2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_c2da690d-5e6a-4918-ae70-c2bcf5eb17a3_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_31f4bfbd-6dd3-4ec1-a1e6-7d91bcc74bde_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_a71ea94e-1b8b-4c6e-8c20-8e09300b6fb7_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0e1d24cd-d63b-4f81-93eb-886638e954e7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_c5c43ea1-c92b-46a5-9f99-943ed76de668_terseLabel_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:href="xcur-20200630.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:to="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2f77b348-7318-435b-8515-8ce3f2ded6da_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_919ffc67-e3ec-488a-90e4-1114b476c516_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0a929def-3aaf-458b-87d8-ff7a28fc05a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e4058118-94ea-461a-b0bb-5e8893acedca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment_0783d0ac-6344-4867-94b4-c67a57840678_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration option rights usage term</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment_label_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Period To Exercise Upon Commencement Of SNA Technology Development</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Period To Exercise Upon Commencement Of SNA Technology Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" xlink:to="lab_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3b8d75e7-7961-402f-90f3-f87498f36621_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_86b7b9a9-8d05-417f-88d0-2f465bb42a0a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_bf1bcd27-5ba3-4e48-bf5a-0359080ad862_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>xcur-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:36122004-6e71-4c8e-9305-4e03dfe42d12,g:561987fc-3e06-47a9-afb8-202603d40cef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exicuretx.com/role/CoverPage" xlink:type="simple" xlink:href="xcur-20200630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_34349ea2-4263-44a8-87d0-36f03f8644c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_9fd84a27-a497-452e-9468-9d0fb9778e51" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_34349ea2-4263-44a8-87d0-36f03f8644c0" xlink:to="loc_dei_EntityAddressesTable_9fd84a27-a497-452e-9468-9d0fb9778e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_bd933a34-728b-4896-913f-fa06146f797c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_9fd84a27-a497-452e-9468-9d0fb9778e51" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_bd933a34-728b-4896-913f-fa06146f797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_ae01959f-b2e1-4630-a814-bb50d0cc2b67" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_bd933a34-728b-4896-913f-fa06146f797c" xlink:to="loc_dei_AddressTypeDomain_ae01959f-b2e1-4630-a814-bb50d0cc2b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_3c83d767-6269-4111-a3d8-48e4986fe80e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_FormerAddressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_ae01959f-b2e1-4630-a814-bb50d0cc2b67" xlink:to="loc_dei_FormerAddressMember_3c83d767-6269-4111-a3d8-48e4986fe80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_9fd84a27-a497-452e-9468-9d0fb9778e51" xlink:to="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b37400c5-59e0-4445-8d6d-a9c402f39089" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentType_b37400c5-59e0-4445-8d6d-a9c402f39089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_63688e50-03a4-463c-b513-5c3dc826a968" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentQuarterlyReport_63688e50-03a4-463c-b513-5c3dc826a968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_153f7b06-d13c-4cfa-a54f-91fc95884e1a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentPeriodEndDate_153f7b06-d13c-4cfa-a54f-91fc95884e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4d0aa958-6f26-4fe8-8756-d6b1d8463365" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentTransitionReport_4d0aa958-6f26-4fe8-8756-d6b1d8463365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_aa7f99c6-9a32-4d8a-b7ad-8370c7024f04" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityFileNumber_aa7f99c6-9a32-4d8a-b7ad-8370c7024f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cbccac6a-89d6-4ee6-98d1-d2ee936244f7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityRegistrantName_cbccac6a-89d6-4ee6-98d1-d2ee936244f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21b34f0a-227b-44c5-9751-a21cf44f9524" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21b34f0a-227b-44c5-9751-a21cf44f9524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_40a4aee1-f02b-4f14-933c-1531793013d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityTaxIdentificationNumber_40a4aee1-f02b-4f14-933c-1531793013d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_431be4f6-d8a7-43ea-b7b1-dd29f4a676c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressAddressLine1_431be4f6-d8a7-43ea-b7b1-dd29f4a676c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d6f4b51e-c05c-4328-a8f6-aa8a62fd0437" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressAddressLine2_d6f4b51e-c05c-4328-a8f6-aa8a62fd0437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a9bf1d0a-8f2c-4732-acbb-f15040576eb5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressCityOrTown_a9bf1d0a-8f2c-4732-acbb-f15040576eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ead7b568-a7cd-4b67-b05b-1812fd7087b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressStateOrProvince_ead7b568-a7cd-4b67-b05b-1812fd7087b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9f059648-8ceb-4628-b93e-ba6ef9186547" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityAddressPostalZipCode_9f059648-8ceb-4628-b93e-ba6ef9186547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1aeb2ce2-86e7-4d17-983e-862554fc4621" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_CityAreaCode_1aeb2ce2-86e7-4d17-983e-862554fc4621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f9ea793e-3c72-4fd7-b8f9-bad478d28e88" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_LocalPhoneNumber_f9ea793e-3c72-4fd7-b8f9-bad478d28e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c0785935-4dfe-4994-82be-37615df686ef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_Security12bTitle_c0785935-4dfe-4994-82be-37615df686ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_900600ce-127a-4ff9-9940-e387fe8fc953" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_TradingSymbol_900600ce-127a-4ff9-9940-e387fe8fc953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9e49d665-cb4a-4c01-91d3-cf7ec025db1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_SecurityExchangeName_9e49d665-cb4a-4c01-91d3-cf7ec025db1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8b94f8a3-5f48-4931-890b-6684790ff15b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityCurrentReportingStatus_8b94f8a3-5f48-4931-890b-6684790ff15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6377c43f-f7b0-4e5f-9b87-51889790c1d1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityInteractiveDataCurrent_6377c43f-f7b0-4e5f-9b87-51889790c1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_33cb7cda-7c04-4502-9a47-2a0c232d12a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityFilerCategory_33cb7cda-7c04-4502-9a47-2a0c232d12a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3bf2c4cc-5178-4668-a7c0-84e60d747e7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntitySmallBusiness_3bf2c4cc-5178-4668-a7c0-84e60d747e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eefceeac-577e-4354-a5af-c133bab09ce0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityEmergingGrowthCompany_eefceeac-577e-4354-a5af-c133bab09ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_2d363479-59bc-48c2-9ede-1121a5cfedd9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityExTransitionPeriod_2d363479-59bc-48c2-9ede-1121a5cfedd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_356bca86-2d31-48cd-a6c2-4718d5b9d10e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityShellCompany_356bca86-2d31-48cd-a6c2-4718d5b9d10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d7131b57-8d1d-4866-9ea6-e5562319ef51" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d7131b57-8d1d-4866-9ea6-e5562319ef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_278c3b36-6f27-4bef-ab2d-802475bc308e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_EntityCentralIndexKey_278c3b36-6f27-4bef-ab2d-802475bc308e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_59f98ed9-cfef-416a-8b32-491e3c881862" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_CurrentFiscalYearEndDate_59f98ed9-cfef-416a-8b32-491e3c881862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_370140aa-db52-45af-867c-dfb69fd3d9a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentFiscalYearFocus_370140aa-db52-45af-867c-dfb69fd3d9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f300c8f3-486d-4c8d-8955-1660574fd8c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f300c8f3-486d-4c8d-8955-1660574fd8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_29c73837-e28b-4e96-b9df-f1a641fb6abb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_f920b939-bc88-4ee7-acf1-aead90707db9" xlink:to="loc_dei_AmendmentFlag_29c73837-e28b-4e96-b9df-f1a641fb6abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_79605d69-19b2-418a-a11b-0bc6735879e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e38dac3b-605a-446c-81d2-40e2b30e65cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79605d69-19b2-418a-a11b-0bc6735879e4" xlink:to="loc_us-gaap_AssetsAbstract_e38dac3b-605a-446c-81d2-40e2b30e65cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_de05b6c5-461e-4729-a818-9481573aef29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e38dac3b-605a-446c-81d2-40e2b30e65cc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_de05b6c5-461e-4729-a818-9481573aef29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4313d16f-4a5d-42d2-b360-5f524529eee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_de05b6c5-461e-4729-a818-9481573aef29" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4313d16f-4a5d-42d2-b360-5f524529eee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_895d1773-81a8-495b-8fc9-8262075da791" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_de05b6c5-461e-4729-a818-9481573aef29" xlink:to="loc_us-gaap_ShortTermInvestments_895d1773-81a8-495b-8fc9-8262075da791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ecbae988-50a2-4671-9dca-7bd3d865f00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_de05b6c5-461e-4729-a818-9481573aef29" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ecbae988-50a2-4671-9dca-7bd3d865f00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_88103801-f4bd-450b-94b5-94024e3a9901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledReceivablesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_de05b6c5-461e-4729-a818-9481573aef29" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_88103801-f4bd-450b-94b5-94024e3a9901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a859f208-78e7-4f73-a547-c9f4b79f1a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_de05b6c5-461e-4729-a818-9481573aef29" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a859f208-78e7-4f73-a547-c9f4b79f1a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_39adf663-098e-4c0e-895f-48bc62fe5728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_de05b6c5-461e-4729-a818-9481573aef29" xlink:to="loc_us-gaap_AssetsCurrent_39adf663-098e-4c0e-895f-48bc62fe5728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_86d3a000-9a40-4f01-a30b-add1e860b806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e38dac3b-605a-446c-81d2-40e2b30e65cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_86d3a000-9a40-4f01-a30b-add1e860b806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2dde081f-c289-45f0-867e-cb56ba7e36b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e38dac3b-605a-446c-81d2-40e2b30e65cc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2dde081f-c289-45f0-867e-cb56ba7e36b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b860e83e-19d2-4dd7-8fce-9effabbe5319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e38dac3b-605a-446c-81d2-40e2b30e65cc" xlink:to="loc_us-gaap_Assets_b860e83e-19d2-4dd7-8fce-9effabbe5319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_79605d69-19b2-418a-a11b-0bc6735879e4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_dde62bb2-8549-44e1-a977-4d11d44f087d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_dde62bb2-8549-44e1-a977-4d11d44f087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_af97aed7-17b3-44fe-9a6d-d791e2aaa656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dde62bb2-8549-44e1-a977-4d11d44f087d" xlink:to="loc_us-gaap_LongTermDebtCurrent_af97aed7-17b3-44fe-9a6d-d791e2aaa656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a4660935-fd8e-45bf-b71e-9cc6acefce5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dde62bb2-8549-44e1-a977-4d11d44f087d" xlink:to="loc_us-gaap_AccountsPayableCurrent_a4660935-fd8e-45bf-b71e-9cc6acefce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ed82475a-0ecc-4b36-9f76-bd35204b6c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dde62bb2-8549-44e1-a977-4d11d44f087d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ed82475a-0ecc-4b36-9f76-bd35204b6c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a6fce38-18be-4f47-a15b-cdd36d84d277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dde62bb2-8549-44e1-a977-4d11d44f087d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a6fce38-18be-4f47-a15b-cdd36d84d277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_652bbcff-52dc-4c17-bd55-19dfb0d889a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dde62bb2-8549-44e1-a977-4d11d44f087d" xlink:to="loc_us-gaap_LiabilitiesCurrent_652bbcff-52dc-4c17-bd55-19dfb0d889a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiability_7e72a495-85f9-419b-94da-7e07d71d2345" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:to="loc_xcur_CommonStockWarrantLiability_7e72a495-85f9-419b-94da-7e07d71d2345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_192ff54a-b3ff-42b5-bcfe-564b56a21c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_192ff54a-b3ff-42b5-bcfe-564b56a21c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_08e70e76-b461-4953-9d37-4bedfbfba577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_08e70e76-b461-4953-9d37-4bedfbfba577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b5ba41dc-c0de-4d2e-8def-ab3a857d188d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:to="loc_us-gaap_Liabilities_b5ba41dc-c0de-4d2e-8def-ab3a857d188d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e0dc19f7-3fe0-479f-b79d-d41db0be270a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e0dc19f7-3fe0-479f-b79d-d41db0be270a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4da06819-71fb-4da3-baa5-349b0aad02b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0dc19f7-3fe0-479f-b79d-d41db0be270a" xlink:to="loc_us-gaap_CommonStockValue_4da06819-71fb-4da3-baa5-349b0aad02b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fe052abb-eac1-40c4-9ed7-36f304b0ebdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0dc19f7-3fe0-479f-b79d-d41db0be270a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fe052abb-eac1-40c4-9ed7-36f304b0ebdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_50c99945-ee64-4b83-a91b-b36d69a8ca0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0dc19f7-3fe0-479f-b79d-d41db0be270a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_50c99945-ee64-4b83-a91b-b36d69a8ca0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c9a58cf6-11ca-466f-88a2-3809dd029502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0dc19f7-3fe0-479f-b79d-d41db0be270a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c9a58cf6-11ca-466f-88a2-3809dd029502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_193daa63-2595-438d-a8e4-f21c4a70d288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e0dc19f7-3fe0-479f-b79d-d41db0be270a" xlink:to="loc_us-gaap_StockholdersEquity_193daa63-2595-438d-a8e4-f21c4a70d288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7d3e4a2b-1ca9-4114-9576-d92cf78faf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0237230e-9924-4ae9-8898-67fe41c6c684" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7d3e4a2b-1ca9-4114-9576-d92cf78faf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcdd8b2-dddc-46fa-815b-a0c1383e7b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_058a6183-0207-440c-a68d-4233a942378c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcdd8b2-dddc-46fa-815b-a0c1383e7b8f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_058a6183-0207-440c-a68d-4233a942378c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f85cae8a-026a-42ec-88f2-08ec8dbd6a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcdd8b2-dddc-46fa-815b-a0c1383e7b8f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f85cae8a-026a-42ec-88f2-08ec8dbd6a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_706b3f8f-1000-4329-abe7-55d2e4992c49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcdd8b2-dddc-46fa-815b-a0c1383e7b8f" xlink:to="loc_us-gaap_CommonStockSharesIssued_706b3f8f-1000-4329-abe7-55d2e4992c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ed769518-2fad-42c2-a91a-1c96e569b6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cdcdd8b2-dddc-46fa-815b-a0c1383e7b8f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ed769518-2fad-42c2-a91a-1c96e569b6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8fadbc55-1981-4990-aefa-31093b0970b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e25390be-ea3b-4a06-b147-11d75cd0be13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fadbc55-1981-4990-aefa-31093b0970b3" xlink:to="loc_us-gaap_RevenuesAbstract_e25390be-ea3b-4a06-b147-11d75cd0be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_294fca2d-4a3a-44ed-a99a-0637540151c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e25390be-ea3b-4a06-b147-11d75cd0be13" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_294fca2d-4a3a-44ed-a99a-0637540151c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d97cd91a-66d6-421c-85ab-773ff1253839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e25390be-ea3b-4a06-b147-11d75cd0be13" xlink:to="loc_us-gaap_Revenues_d97cd91a-66d6-421c-85ab-773ff1253839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a0bb4df2-0af8-4545-aeba-7500df75d2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fadbc55-1981-4990-aefa-31093b0970b3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a0bb4df2-0af8-4545-aeba-7500df75d2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fb5b8d2e-a799-47c5-bc33-2884c61dd4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a0bb4df2-0af8-4545-aeba-7500df75d2ba" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fb5b8d2e-a799-47c5-bc33-2884c61dd4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0f106416-e262-4086-8152-ddc9ab3dcfca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a0bb4df2-0af8-4545-aeba-7500df75d2ba" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0f106416-e262-4086-8152-ddc9ab3dcfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_21375d3e-5359-4801-80ac-0b4e31726b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a0bb4df2-0af8-4545-aeba-7500df75d2ba" xlink:to="loc_us-gaap_OperatingExpenses_21375d3e-5359-4801-80ac-0b4e31726b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6f263892-8ed2-4cfc-b5aa-16f118d6fc09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fadbc55-1981-4990-aefa-31093b0970b3" xlink:to="loc_us-gaap_OperatingIncomeLoss_6f263892-8ed2-4cfc-b5aa-16f118d6fc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5f0981da-b3ba-4b27-810f-14ade1185b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fadbc55-1981-4990-aefa-31093b0970b3" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5f0981da-b3ba-4b27-810f-14ade1185b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_97fb1148-ea1f-4102-aee5-b860cfcacd0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5f0981da-b3ba-4b27-810f-14ade1185b3b" xlink:to="loc_us-gaap_InvestmentIncomeDividend_97fb1148-ea1f-4102-aee5-b860cfcacd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d4ad7aed-f378-4e31-ba61-c324811dac76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5f0981da-b3ba-4b27-810f-14ade1185b3b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d4ad7aed-f378-4e31-ba61-c324811dac76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_959d0b2b-4d48-4106-b996-b0fc527759c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5f0981da-b3ba-4b27-810f-14ade1185b3b" xlink:to="loc_us-gaap_InterestExpense_959d0b2b-4d48-4106-b996-b0fc527759c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_371b8d1e-1345-419d-a79e-c0bebc580558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5f0981da-b3ba-4b27-810f-14ade1185b3b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_371b8d1e-1345-419d-a79e-c0bebc580558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4ed01fb8-9da9-4cee-87b5-26808f47f067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5f0981da-b3ba-4b27-810f-14ade1185b3b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4ed01fb8-9da9-4cee-87b5-26808f47f067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_300eec90-9af1-4865-9edb-d9ad2e471b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fadbc55-1981-4990-aefa-31093b0970b3" xlink:to="loc_us-gaap_NetIncomeLoss_300eec90-9af1-4865-9edb-d9ad2e471b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_d007f4d3-bae6-4d91-b410-21bbb6f0aa3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fadbc55-1981-4990-aefa-31093b0970b3" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_d007f4d3-bae6-4d91-b410-21bbb6f0aa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_26f5d7d7-99f4-4f68-bfbd-3dc57a0154f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fadbc55-1981-4990-aefa-31093b0970b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_26f5d7d7-99f4-4f68-bfbd-3dc57a0154f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b37b279d-68ac-4c28-a889-c88250c0f070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_60072d39-23bf-4e42-9819-f98232688e36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b37b279d-68ac-4c28-a889-c88250c0f070" xlink:to="loc_us-gaap_NetIncomeLoss_60072d39-23bf-4e42-9819-f98232688e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_566c9113-c9d2-4006-86dd-27c438fbe17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b37b279d-68ac-4c28-a889-c88250c0f070" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_566c9113-c9d2-4006-86dd-27c438fbe17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_64189d89-7d41-4e13-bd44-cbe8511ac7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b37b279d-68ac-4c28-a889-c88250c0f070" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_64189d89-7d41-4e13-bd44-cbe8511ac7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_05b2d3cb-087a-40e2-b83d-7de9e5171aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b37b279d-68ac-4c28-a889-c88250c0f070" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_05b2d3cb-087a-40e2-b83d-7de9e5171aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_33d4f6e3-d6ff-4e3f-b5e1-231e6fc7dae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2dec783-172b-44c6-a4f4-8dc20e021b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_33d4f6e3-d6ff-4e3f-b5e1-231e6fc7dae0" xlink:to="loc_us-gaap_StatementTable_c2dec783-172b-44c6-a4f4-8dc20e021b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f9a772ee-6d5c-4811-92e2-4294c6bb5232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2dec783-172b-44c6-a4f4-8dc20e021b88" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f9a772ee-6d5c-4811-92e2-4294c6bb5232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9a772ee-6d5c-4811-92e2-4294c6bb5232" xlink:to="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2104e437-2f20-4344-9bed-d4cd25e2e003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:to="loc_us-gaap_CommonStockMember_2104e437-2f20-4344-9bed-d4cd25e2e003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4422da19-3853-4dcc-add0-797bb92b9616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4422da19-3853-4dcc-add0-797bb92b9616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c95ae695-0072-4f7c-9c92-5e3105ab29d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:to="loc_us-gaap_RetainedEarningsMember_c95ae695-0072-4f7c-9c92-5e3105ab29d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_999ce7e7-8bac-4d64-aaed-3db99802d72b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f158aa4f-ca98-4f7e-a6a3-b43a598963de" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_999ce7e7-8bac-4d64-aaed-3db99802d72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_18ede31e-d453-416e-902b-610b7faa8b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2dec783-172b-44c6-a4f4-8dc20e021b88" xlink:to="loc_us-gaap_StatementLineItems_18ede31e-d453-416e-902b-610b7faa8b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_18ede31e-d453-416e-902b-610b7faa8b94" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2b460e26-c170-4c59-8415-cf149eef9967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_SharesOutstanding_2b460e26-c170-4c59-8415-cf149eef9967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4275ab0e-760b-4c84-a78c-5e17cb619c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockholdersEquity_4275ab0e-760b-4c84-a78c-5e17cb619c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ffdb9410-bbae-4215-8f02-8cd54adf9645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ffdb9410-bbae-4215-8f02-8cd54adf9645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_de055b12-7479-4cd0-ade5-61265434d580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_de055b12-7479-4cd0-ade5-61265434d580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8431f916-0e5b-4a9e-aa8d-b0027208dd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8431f916-0e5b-4a9e-aa8d-b0027208dd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_91c6a931-8f18-4a4b-9dfa-3cabb986969b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_91c6a931-8f18-4a4b-9dfa-3cabb986969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12655c74-939a-4704-9178-29b876a8dd0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12655c74-939a-4704-9178-29b876a8dd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2fcaa26a-9bc3-4f2c-9676-016ca37f0b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2fcaa26a-9bc3-4f2c-9676-016ca37f0b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0895f078-0508-4882-9a09-0f6319b098b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_NetIncomeLoss_0895f078-0508-4882-9a09-0f6319b098b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_981ff026-3ee7-439f-99e1-61ccf49fd24c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_SharesOutstanding_981ff026-3ee7-439f-99e1-61ccf49fd24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e02911cc-c4bb-4da3-8902-405ec64e0382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_05ae347d-a48a-4a01-b3e6-128f3540d908" xlink:to="loc_us-gaap_StockholdersEquity_e02911cc-c4bb-4da3-8902-405ec64e0382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xcur-20200630.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a56bd978-889e-486a-a8ad-f64081e7e5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_028e4281-7dc3-4849-b2de-61c8c47ef75b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a56bd978-889e-486a-a8ad-f64081e7e5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_028e4281-7dc3-4849-b2de-61c8c47ef75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e45ede8a-b349-4282-9a95-3aa69c7dd365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_028e4281-7dc3-4849-b2de-61c8c47ef75b" xlink:to="loc_us-gaap_NetIncomeLoss_e45ede8a-b349-4282-9a95-3aa69c7dd365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8d484541-5643-451d-92d7-82d12f8191a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_028e4281-7dc3-4849-b2de-61c8c47ef75b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8d484541-5643-451d-92d7-82d12f8191a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_a08c3c73-8c3f-474d-be0d-80b60761f767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8d484541-5643-451d-92d7-82d12f8191a8" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_a08c3c73-8c3f-474d-be0d-80b60761f767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dbe692e8-d795-41e4-a09b-792cbf7d65a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8d484541-5643-451d-92d7-82d12f8191a8" xlink:to="loc_us-gaap_ShareBasedCompensation_dbe692e8-d795-41e4-a09b-792cbf7d65a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4da90e27-eddf-4ccd-8939-e6f15f721ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8d484541-5643-451d-92d7-82d12f8191a8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4da90e27-eddf-4ccd-8939-e6f15f721ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_c549d449-dd5f-4437-943e-6e84aa763c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8d484541-5643-451d-92d7-82d12f8191a8" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_c549d449-dd5f-4437-943e-6e84aa763c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_cbcb4c2d-46eb-4a75-8f1a-0c49dafe773d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8d484541-5643-451d-92d7-82d12f8191a8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_cbcb4c2d-46eb-4a75-8f1a-0c49dafe773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8d484541-5643-451d-92d7-82d12f8191a8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_78389aaa-47f0-4373-8cf3-447799216c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_78389aaa-47f0-4373-8cf3-447799216c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ad3f5fab-d1d2-4454-b5c2-828f53c6a27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ad3f5fab-d1d2-4454-b5c2-828f53c6a27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7b564b71-f57a-4775-b304-9c7e6d2d0a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7b564b71-f57a-4775-b304-9c7e6d2d0a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2e728d25-6a17-4c65-89a3-e261c6c51d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2e728d25-6a17-4c65-89a3-e261c6c51d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5121bb87-250f-4140-a7be-97825f112807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5121bb87-250f-4140-a7be-97825f112807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_67cfb4ff-6805-4078-beba-8b1ef40e5fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_67cfb4ff-6805-4078-beba-8b1ef40e5fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_07a7b68c-8e22-4747-9fab-737040d204fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42b547ef-288c-4bde-bed1-a828e6438845" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_07a7b68c-8e22-4747-9fab-737040d204fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46143bcf-ca58-45a3-bdbc-39eb14e569c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_028e4281-7dc3-4849-b2de-61c8c47ef75b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46143bcf-ca58-45a3-bdbc-39eb14e569c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c309ef22-58b0-4b2a-8ffb-68f8e0b1a6f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a56bd978-889e-486a-a8ad-f64081e7e5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c309ef22-58b0-4b2a-8ffb-68f8e0b1a6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2342d3b7-cc67-4097-bdcf-7940fb75ef9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c309ef22-58b0-4b2a-8ffb-68f8e0b1a6f9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2342d3b7-cc67-4097-bdcf-7940fb75ef9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_2c375b6f-85b2-44ab-b90e-214352993daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c309ef22-58b0-4b2a-8ffb-68f8e0b1a6f9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_2c375b6f-85b2-44ab-b90e-214352993daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d87201dc-e219-4d37-8b02-520f041163a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c309ef22-58b0-4b2a-8ffb-68f8e0b1a6f9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d87201dc-e219-4d37-8b02-520f041163a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9cb7645-2264-48c4-8fd6-9e19a60eb28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c309ef22-58b0-4b2a-8ffb-68f8e0b1a6f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9cb7645-2264-48c4-8fd6-9e19a60eb28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb78fd0a-c0a7-4efa-9c9c-d39dd529b871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a56bd978-889e-486a-a8ad-f64081e7e5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb78fd0a-c0a7-4efa-9c9c-d39dd529b871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0ac14aae-7451-4205-b0e7-e6203dfcc399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb78fd0a-c0a7-4efa-9c9c-d39dd529b871" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0ac14aae-7451-4205-b0e7-e6203dfcc399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3382424d-1fef-45e5-92fa-e162c066e7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb78fd0a-c0a7-4efa-9c9c-d39dd529b871" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3382424d-1fef-45e5-92fa-e162c066e7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_801da0b2-47b4-44f4-a44f-4cc56d2c6167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb78fd0a-c0a7-4efa-9c9c-d39dd529b871" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_801da0b2-47b4-44f4-a44f-4cc56d2c6167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_14bb8fc8-e70d-4912-a936-ddaf99c9e993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb78fd0a-c0a7-4efa-9c9c-d39dd529b871" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_14bb8fc8-e70d-4912-a936-ddaf99c9e993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_13c06591-d794-4098-bbec-b3f47193ad79" xlink:href="xcur-20200630.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb78fd0a-c0a7-4efa-9c9c-d39dd529b871" xlink:to="loc_xcur_PaymentsOfCommonStockFinancingCosts_13c06591-d794-4098-bbec-b3f47193ad79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14d8409e-b256-4b49-a1bd-4aa0f971be64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb78fd0a-c0a7-4efa-9c9c-d39dd529b871" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_14d8409e-b256-4b49-a1bd-4aa0f971be64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18366f3f-87fd-4972-9abe-d5d688fbc286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a56bd978-889e-486a-a8ad-f64081e7e5f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18366f3f-87fd-4972-9abe-d5d688fbc286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e54772d3-f0e0-4a36-9336-140e6c7fb81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a56bd978-889e-486a-a8ad-f64081e7e5f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e54772d3-f0e0-4a36-9336-140e6c7fb81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c06cf26-6458-4a51-8485-fa99a2691248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a56bd978-889e-486a-a8ad-f64081e7e5f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c06cf26-6458-4a51-8485-fa99a2691248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4a2d1597-141e-4ed3-9c7a-b1ee94d3514d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a56bd978-889e-486a-a8ad-f64081e7e5f7" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4a2d1597-141e-4ed3-9c7a-b1ee94d3514d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_945ae118-d820-4462-829e-d45740301c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4a2d1597-141e-4ed3-9c7a-b1ee94d3514d" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_945ae118-d820-4462-829e-d45740301c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9d90eb53-81a4-467e-809d-70bf47bc186f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_945ae118-d820-4462-829e-d45740301c80" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9d90eb53-81a4-467e-809d-70bf47bc186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_7232ecd0-4fde-4575-9480-989f306373cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4a2d1597-141e-4ed3-9c7a-b1ee94d3514d" xlink:to="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_7232ecd0-4fde-4575-9480-989f306373cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c22219f8-5c0e-4ad9-93b7-cd114e16bef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_7232ecd0-4fde-4575-9480-989f306373cc" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c22219f8-5c0e-4ad9-93b7-cd114e16bef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bd3d8eb-8ed6-412a-a34d-29d0d5eaf8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4a2d1597-141e-4ed3-9c7a-b1ee94d3514d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bd3d8eb-8ed6-412a-a34d-29d0d5eaf8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_029cbd1c-2098-4a65-8c6d-29ce84c83ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4a2d1597-141e-4ed3-9c7a-b1ee94d3514d" xlink:to="loc_us-gaap_RestrictedCash_029cbd1c-2098-4a65-8c6d-29ce84c83ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d5fc5bc-3f04-474c-9fd9-acca6503c94d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_4a2d1597-141e-4ed3-9c7a-b1ee94d3514d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d5fc5bc-3f04-474c-9fd9-acca6503c94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="xcur-20200630.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d8445884-6a3e-42b9-92ca-30c298dd4ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2b38b808-ba35-4239-bd0f-68f9c0cad49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8445884-6a3e-42b9-92ca-30c298dd4ce6" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2b38b808-ba35-4239-bd0f-68f9c0cad49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9a18702f-143b-433a-88e1-998bbfb8eef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea_233a84bf-f585-408c-8681-dc653a1e1cbb" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a18702f-143b-433a-88e1-998bbfb8eef4" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea_233a84bf-f585-408c-8681-dc653a1e1cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_873465bd-a3db-4eda-8254-1ccd58328148" xlink:href="xcur-20200630.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9a18702f-143b-433a-88e1-998bbfb8eef4" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_873465bd-a3db-4eda-8254-1ccd58328148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="xcur-20200630.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25bd51a4-4379-429b-b3a0-9d4c4179798c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_51803b03-f9c5-45b3-ad68-1784974327dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25bd51a4-4379-429b-b3a0-9d4c4179798c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_51803b03-f9c5-45b3-ad68-1784974327dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="xcur-20200630.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_98e41e4e-44c0-4871-b400-77de0dc94581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0fffe5b2-baa2-4b6c-a99f-aedb33169264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98e41e4e-44c0-4871-b400-77de0dc94581" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0fffe5b2-baa2-4b6c-a99f-aedb33169264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3e80bdaa-6a1f-426b-ba37-35d9f5c7a9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98e41e4e-44c0-4871-b400-77de0dc94581" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3e80bdaa-6a1f-426b-ba37-35d9f5c7a9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e548d34b-8135-4e11-a91d-06aca0b6e397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98e41e4e-44c0-4871-b400-77de0dc94581" xlink:to="loc_us-gaap_UseOfEstimates_e548d34b-8135-4e11-a91d-06aca0b6e397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e11f4337-d575-4d0a-a669-3be3cda96876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98e41e4e-44c0-4871-b400-77de0dc94581" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e11f4337-d575-4d0a-a669-3be3cda96876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_fb71fa52-4697-4a48-98af-d76f49632300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98e41e4e-44c0-4871-b400-77de0dc94581" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_fb71fa52-4697-4a48-98af-d76f49632300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="simple" xlink:href="xcur-20200630.xsd#CollaborativeResearchandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_2d73f6cf-16dd-4aca-929c-2eb4b6c810ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_49e04181-f459-47ef-b81c-3662c60ac233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_2d73f6cf-16dd-4aca-929c-2eb4b6c810ab" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_49e04181-f459-47ef-b81c-3662c60ac233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#CollaborativeResearchandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_8eb8bda4-fcb0-4396-8c48-50ebfd96cad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_8eb8bda4-fcb0-4396-8c48-50ebfd96cad2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_13d0e28f-2380-4206-82eb-5210bbe46520" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_srt_RangeAxis_13d0e28f-2380-4206-82eb-5210bbe46520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1db1abb-94ec-4ecb-ac90-d51d30928fb4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13d0e28f-2380-4206-82eb-5210bbe46520" xlink:to="loc_srt_RangeMember_d1db1abb-94ec-4ecb-ac90-d51d30928fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2ef530c4-263f-4da1-b086-025b46574564" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d1db1abb-94ec-4ecb-ac90-d51d30928fb4" xlink:to="loc_srt_MaximumMember_2ef530c4-263f-4da1-b086-025b46574564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6eca996b-ae7d-4e43-a32c-812fcd1cd92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6eca996b-ae7d-4e43-a32c-812fcd1cd92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_824f2191-c11a-4c35-9a4b-633ab2e18251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6eca996b-ae7d-4e43-a32c-812fcd1cd92e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_824f2191-c11a-4c35-9a4b-633ab2e18251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember_57ad6cd7-940f-4987-8010-d5e6854d2147" xlink:href="xcur-20200630.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_824f2191-c11a-4c35-9a4b-633ab2e18251" xlink:to="loc_xcur_DevelopmentandCommercializationLicenseMember_57ad6cd7-940f-4987-8010-d5e6854d2147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_71197c88-014f-4c47-89ea-f77d77ead2a7" xlink:href="xcur-20200630.xsd#xcur_ArrangementNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_xcur_ArrangementNameAxis_71197c88-014f-4c47-89ea-f77d77ead2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_3a56893c-27bf-4841-9e9a-3960c7268d5e" xlink:href="xcur-20200630.xsd#xcur_ArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameAxis_71197c88-014f-4c47-89ea-f77d77ead2a7" xlink:to="loc_xcur_ArrangementNameDomain_3a56893c-27bf-4841-9e9a-3960c7268d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AllerganCollaborationMember_00d52661-ed42-4fbc-8f35-26257d48eed1" xlink:href="xcur-20200630.xsd#xcur_AllerganCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_3a56893c-27bf-4841-9e9a-3960c7268d5e" xlink:to="loc_xcur_AllerganCollaborationMember_00d52661-ed42-4fbc-8f35-26257d48eed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember_830b9417-dec9-4042-b3a7-3c9a18dde9b7" xlink:href="xcur-20200630.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_3a56893c-27bf-4841-9e9a-3960c7268d5e" xlink:to="loc_xcur_DermelixLicenseAgreementMember_830b9417-dec9-4042-b3a7-3c9a18dde9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b752fbd3-9534-4bc1-b3b6-985ddd214621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1b57ea4d-7fad-4e62-87d5-15b41a93ef2a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b752fbd3-9534-4bc1-b3b6-985ddd214621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ae303c9e-8916-42c9-b5a1-d84135840b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b752fbd3-9534-4bc1-b3b6-985ddd214621" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ae303c9e-8916-42c9-b5a1-d84135840b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e442eec7-ed81-44d8-87dc-e48a673c7397" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms_3b1784ba-c5d9-4663-941f-040a23be4a80" xlink:href="xcur-20200630.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_NumberofCollaborationPrograms_3b1784ba-c5d9-4663-941f-040a23be4a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_73c5a8c6-17e8-4c08-b0f7-65fe3b91acb9" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_73c5a8c6-17e8-4c08-b0f7-65fe3b91acb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee_c7353aa1-f601-4078-8a3d-4be2eff5f464" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementOptionExerciseFee_c7353aa1-f601-4078-8a3d-4be2eff5f464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_e135f50d-9662-4566-bf4c-8f09758bde34" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_e135f50d-9662-4566-bf4c-8f09758bde34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_314223a2-d4e5-4a29-a06f-8c68426291ea" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_314223a2-d4e5-4a29-a06f-8c68426291ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_ab8957e6-38ca-4b37-b6e9-3934f63a7d27" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_ab8957e6-38ca-4b37-b6e9-3934f63a7d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_9c26ba8f-c40e-43cc-b3f6-20a627a23363" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_9c26ba8f-c40e-43cc-b3f6-20a627a23363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_f6dcb184-4df1-45e0-b904-6ef8b6dd6b1c" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_f6dcb184-4df1-45e0-b904-6ef8b6dd6b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f09a23f-a36c-4ecc-9c7c-7d4b90e2ba80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f09a23f-a36c-4ecc-9c7c-7d4b90e2ba80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_de4406b0-5816-4c95-ae39-979e93679a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_de4406b0-5816-4c95-ae39-979e93679a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_21fe7bd0-e205-4401-a404-a86766c8ebc2" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets_21fe7bd0-e205-4401-a404-a86766c8ebc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerm_3b111c10-2d2d-49cb-9bc5-94a1b78d8588" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementTerm_3b111c10-2d2d-49cb-9bc5-94a1b78d8588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses_2bebfd29-e67f-4b71-b586-d032138db5c0" xlink:href="xcur-20200630.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationDevelopmentExpenses_2bebfd29-e67f-4b71-b586-d032138db5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment_e89e15ec-dd2e-4082-a375-5f1ee5bc1e1d" xlink:href="xcur-20200630.xsd#xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment_e89e15ec-dd2e-4082-a375-5f1ee5bc1e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_06c45e14-1d1b-4ade-b3d8-f829e79ce625" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue_06c45e14-1d1b-4ade-b3d8-f829e79ce625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_6b27e189-8069-43b1-8127-29a411df3f26" xlink:href="xcur-20200630.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_432b5c96-e726-4deb-b27d-d659eab8f796" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue_6b27e189-8069-43b1-8127-29a411df3f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_127e3581-49fe-4f6b-bc22-8188efb1d05d" xlink:href="xcur-20200630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_dda36c92-d247-4e9d-846d-2b7b4311324a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_127e3581-49fe-4f6b-bc22-8188efb1d05d" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_dda36c92-d247-4e9d-846d-2b7b4311324a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_88a8d815-3e93-42b9-9b32-dbc0ae6ee9e0" xlink:href="xcur-20200630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_784242d3-aaaa-45d1-bb27-93e269c07342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88a8d815-3e93-42b9-9b32-dbc0ae6ee9e0" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_784242d3-aaaa-45d1-bb27-93e269c07342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_23d555cf-25af-4d61-90ba-acfe02baa95c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88a8d815-3e93-42b9-9b32-dbc0ae6ee9e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_23d555cf-25af-4d61-90ba-acfe02baa95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_548d0492-e55a-4c33-983d-0b4d90ca1dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88a8d815-3e93-42b9-9b32-dbc0ae6ee9e0" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_548d0492-e55a-4c33-983d-0b4d90ca1dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_33ae1507-87f1-4324-9914-94e474a64009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88a8d815-3e93-42b9-9b32-dbc0ae6ee9e0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_33ae1507-87f1-4324-9914-94e474a64009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_d081f3a1-ea02-4283-a5bb-268d4064d19a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_88a8d815-3e93-42b9-9b32-dbc0ae6ee9e0" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_d081f3a1-ea02-4283-a5bb-268d4064d19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_762d00ba-9fa9-4805-8043-43bc94d88a0b" xlink:href="xcur-20200630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_fd712ad4-f470-4551-98d1-537105d9e69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_762d00ba-9fa9-4805-8043-43bc94d88a0b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_fd712ad4-f470-4551-98d1-537105d9e69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_211ee511-a549-47fa-a569-94f9de4db8f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_762d00ba-9fa9-4805-8043-43bc94d88a0b" xlink:to="loc_us-gaap_InterestReceivable_211ee511-a549-47fa-a569-94f9de4db8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_a24a1cfe-42ba-4c70-886c-2d5a7c266272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_762d00ba-9fa9-4805-8043-43bc94d88a0b" xlink:to="loc_us-gaap_PrepaidInsurance_a24a1cfe-42ba-4c70-886c-2d5a7c266272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_1c5b9ddc-a997-44fa-83da-d2b86dd5f29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_762d00ba-9fa9-4805-8043-43bc94d88a0b" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_1c5b9ddc-a997-44fa-83da-d2b86dd5f29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b841ba19-42c2-4128-afe4-2c1ed36e5c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_762d00ba-9fa9-4805-8043-43bc94d88a0b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b841ba19-42c2-4128-afe4-2c1ed36e5c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_a4c52471-195c-4c4c-af26-975245989c6c" xlink:href="xcur-20200630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_05d53d57-d246-46a0-8501-a5aee4024724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_a4c52471-195c-4c4c-af26-975245989c6c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_05d53d57-d246-46a0-8501-a5aee4024724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ef601fe-e8d2-480c-b0e9-dd803480bc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_05d53d57-d246-46a0-8501-a5aee4024724" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ef601fe-e8d2-480c-b0e9-dd803480bc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ef601fe-e8d2-480c-b0e9-dd803480bc18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5d561d35-3345-4bfb-b6bc-c949a5efce7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_us-gaap_EquipmentMember_5d561d35-3345-4bfb-b6bc-c949a5efce7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_99c5b875-3689-412e-816a-ba3ced1f8cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_99c5b875-3689-412e-816a-ba3ced1f8cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember_27553b23-e769-479d-a131-dded51d6f835" xlink:href="xcur-20200630.xsd#xcur_ComputersandSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_xcur_ComputersandSoftwareMember_27553b23-e769-479d-a131-dded51d6f835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3e62fa3f-3cbe-4a26-a882-ea9ee96701a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3e62fa3f-3cbe-4a26-a882-ea9ee96701a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6015ee42-a2b3-4327-961a-79dd4576f672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_931501ae-df83-41f4-b430-2b6047caefec" xlink:to="loc_us-gaap_ConstructionInProgressMember_6015ee42-a2b3-4327-961a-79dd4576f672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_05d53d57-d246-46a0-8501-a5aee4024724" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4b5faf5e-fe4e-4b12-b69d-4e14b37b6dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4b5faf5e-fe4e-4b12-b69d-4e14b37b6dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99ab1ce2-5d10-41a6-aac6-61e012786782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_99ab1ce2-5d10-41a6-aac6-61e012786782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a56c6ac-5834-4fd1-8f48-a781eacdc2d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a56c6ac-5834-4fd1-8f48-a781eacdc2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_0d2c47e2-0fad-4bed-bd9f-50478abd147c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93fa05af-8fcc-4ebf-8e69-ace0f65232b0" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_0d2c47e2-0fad-4bed-bd9f-50478abd147c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationOthernoncurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_c0e12de5-254f-4707-b737-af114f0e7241" xlink:href="xcur-20200630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_1e8fb3f8-7a2a-419e-941b-da1b0a5ffbc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_c0e12de5-254f-4707-b737-af114f0e7241" xlink:to="loc_us-gaap_RestrictedCash_1e8fb3f8-7a2a-419e-941b-da1b0a5ffbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PrepaidLeaseCosts_be0b58df-459c-45bf-ac3f-f496e0d66d22" xlink:href="xcur-20200630.xsd#xcur_PrepaidLeaseCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_c0e12de5-254f-4707-b737-af114f0e7241" xlink:to="loc_xcur_PrepaidLeaseCosts_be0b58df-459c-45bf-ac3f-f496e0d66d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_9d17045d-4aa3-463f-a762-aa72f2191a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_c0e12de5-254f-4707-b737-af114f0e7241" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_9d17045d-4aa3-463f-a762-aa72f2191a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a4757a2-466f-4ca1-9491-9a626282eb97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_c0e12de5-254f-4707-b737-af114f0e7241" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a4757a2-466f-4ca1-9491-9a626282eb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_eed01323-25cc-42d3-ae53-e0916797441a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_c0e12de5-254f-4707-b737-af114f0e7241" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_eed01323-25cc-42d3-ae53-e0916797441a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_37da12b5-385d-41d9-a435-1da63651e199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_c0e12de5-254f-4707-b737-af114f0e7241" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_37da12b5-385d-41d9-a435-1da63651e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_956d74ce-be57-49bb-9dfb-44e01a5b5b00" xlink:href="xcur-20200630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d0c4807-0763-4970-886e-2ed1544fe5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_956d74ce-be57-49bb-9dfb-44e01a5b5b00" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d0c4807-0763-4970-886e-2ed1544fe5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2b7b4af9-22ca-411d-9bb9-a7875ec12c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_956d74ce-be57-49bb-9dfb-44e01a5b5b00" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2b7b4af9-22ca-411d-9bb9-a7875ec12c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_080e68eb-bfa0-462b-80ae-a0f7fdc77c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_956d74ce-be57-49bb-9dfb-44e01a5b5b00" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_080e68eb-bfa0-462b-80ae-a0f7fdc77c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityCurrent_cb611a84-40e3-4950-854e-deca24071f01" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_956d74ce-be57-49bb-9dfb-44e01a5b5b00" xlink:to="loc_xcur_CommonStockWarrantLiabilityCurrent_cb611a84-40e3-4950-854e-deca24071f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_8b9e090e-b469-459b-b302-1e189caaf89b" xlink:href="xcur-20200630.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_956d74ce-be57-49bb-9dfb-44e01a5b5b00" xlink:to="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_8b9e090e-b469-459b-b302-1e189caaf89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d947f2a7-27db-42a3-b980-2d4d6331d5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_956d74ce-be57-49bb-9dfb-44e01a5b5b00" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d947f2a7-27db-42a3-b980-2d4d6331d5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b0ab20f3-ab43-4b9f-811f-294d1866f9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_956d74ce-be57-49bb-9dfb-44e01a5b5b00" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b0ab20f3-ab43-4b9f-811f-294d1866f9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_c63527b6-961d-45a6-a6f6-28336b60b81b" xlink:href="xcur-20200630.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_701c5e1b-eb2c-4774-a278-6a86999a7230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_c63527b6-961d-45a6-a6f6-28336b60b81b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_701c5e1b-eb2c-4774-a278-6a86999a7230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_132aa371-ab0d-491a-a677-66943473a87e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_c63527b6-961d-45a6-a6f6-28336b60b81b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_132aa371-ab0d-491a-a677-66943473a87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Investments" xlink:type="simple" xlink:href="xcur-20200630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_81d93eec-4f8d-453e-9338-c55594953723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_faf9a2f3-b290-4bf5-b617-202398c45e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_81d93eec-4f8d-453e-9338-c55594953723" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_faf9a2f3-b290-4bf5-b617-202398c45e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_d17a9cd5-eef3-4e81-8771-4b879636ce41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_7ffff18d-6f5a-47b4-acc0-2fe0f723cc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_d17a9cd5-eef3-4e81-8771-4b879636ce41" xlink:to="loc_us-gaap_InvestmentTableTextBlock_7ffff18d-6f5a-47b4-acc0-2fe0f723cc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_21223906-52a7-4c8c-af9b-4b6319beede2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_d17a9cd5-eef3-4e81-8771-4b879636ce41" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_21223906-52a7-4c8c-af9b-4b6319beede2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_1f980744-b546-471f-b4b9-bb949182e4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_11c27ee0-19f2-407b-95bd-0a2e421a0599" xlink:href="xcur-20200630.xsd#xcur_DebtSecuritiesAvailableForSaleCurrentPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_1f980744-b546-471f-b4b9-bb949182e4f3" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_11c27ee0-19f2-407b-95bd-0a2e421a0599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_3d524ec0-44d4-4553-b0c4-93ef207fa574" xlink:href="xcur-20200630.xsd#xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_1f980744-b546-471f-b4b9-bb949182e4f3" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_3d524ec0-44d4-4553-b0c4-93ef207fa574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableforSalePercent_f3fbfdbe-0415-4e44-a92a-688e6e9ddbb6" xlink:href="xcur-20200630.xsd#xcur_DebtSecuritiesAvailableforSalePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_1f980744-b546-471f-b4b9-bb949182e4f3" xlink:to="loc_xcur_DebtSecuritiesAvailableforSalePercent_f3fbfdbe-0415-4e44-a92a-688e6e9ddbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_3a300caf-6187-4526-9e8e-25f32f643eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2117cd9d-7fe8-4661-ae2b-82801da2cf24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_3a300caf-6187-4526-9e8e-25f32f643eea" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2117cd9d-7fe8-4661-ae2b-82801da2cf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_97182fcf-180c-42c5-b79f-92f654d477ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2117cd9d-7fe8-4661-ae2b-82801da2cf24" xlink:to="loc_us-gaap_FinancialInstrumentAxis_97182fcf-180c-42c5-b79f-92f654d477ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97182fcf-180c-42c5-b79f-92f654d477ba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_dd0bea72-6562-404f-966b-a2abf6cc2fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_dd0bea72-6562-404f-966b-a2abf6cc2fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_38971203-cc19-43b8-9a89-8290fa3d3ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_38971203-cc19-43b8-9a89-8290fa3d3ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2d5ad1a9-8e88-43b4-8fcc-b3bf2a2a1069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2d5ad1a9-8e88-43b4-8fcc-b3bf2a2a1069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ae2c66b7-9ea9-4887-80ad-db6c9f61dd35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_215e7baa-8747-4848-ba4d-78373acce0a1" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ae2c66b7-9ea9-4887-80ad-db6c9f61dd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2117cd9d-7fe8-4661-ae2b-82801da2cf24" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac9f99c2-715a-4a3f-99ca-17ad2c011a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ac9f99c2-715a-4a3f-99ca-17ad2c011a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9f449f59-fc5a-45d4-86e1-ae02f3f27ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9f449f59-fc5a-45d4-86e1-ae02f3f27ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d24d7bd6-fb4d-4993-9c86-ae86df3dad32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d24d7bd6-fb4d-4993-9c86-ae86df3dad32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e0793c34-4f21-4a9d-bc2c-e71d9c05c315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e279803-5b34-418f-8bcd-906fee441079" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e0793c34-4f21-4a9d-bc2c-e71d9c05c315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:type="simple" xlink:href="xcur-20200630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dad9f879-f36a-47c0-a84a-ba6673cd6e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e97778ef-4845-468a-aa45-97fe82f7b2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dad9f879-f36a-47c0-a84a-ba6673cd6e28" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e97778ef-4845-468a-aa45-97fe82f7b2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7a59400d-57fb-4fe1-aa84-f9ff0a8b76db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7a59400d-57fb-4fe1-aa84-f9ff0a8b76db" xlink:to="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_78801cc2-ac08-4d09-b2a0-5200d9517a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_78801cc2-ac08-4d09-b2a0-5200d9517a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4d3e7c31-0bc3-445f-9692-c8fae8b027c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_78801cc2-ac08-4d09-b2a0-5200d9517a33" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4d3e7c31-0bc3-445f-9692-c8fae8b027c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_0e6a1a18-2450-45ae-a138-eaceab9c0e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4d3e7c31-0bc3-445f-9692-c8fae8b027c9" xlink:to="loc_us-gaap_LoansPayableMember_0e6a1a18-2450-45ae-a138-eaceab9c0e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bdc2f661-8c77-49f7-81d8-409dbabe6db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:to="loc_us-gaap_CreditFacilityAxis_bdc2f661-8c77-49f7-81d8-409dbabe6db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_58967e18-51ba-473d-8b7d-1e6d77bf4641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_bdc2f661-8c77-49f7-81d8-409dbabe6db7" xlink:to="loc_us-gaap_CreditFacilityDomain_58967e18-51ba-473d-8b7d-1e6d77bf4641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b28d577d-205c-45c9-b977-b540e3a5ddd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_58967e18-51ba-473d-8b7d-1e6d77bf4641" xlink:to="loc_us-gaap_SecuredDebtMember_b28d577d-205c-45c9-b977-b540e3a5ddd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6e4f12df-2a05-4242-9e6d-28801ed9d501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_6e4f12df-2a05-4242-9e6d-28801ed9d501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_3c29ca3a-fc2c-45cc-a0a9-84f762ba7883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6e4f12df-2a05-4242-9e6d-28801ed9d501" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_3c29ca3a-fc2c-45cc-a0a9-84f762ba7883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_f174a7e8-cb64-4547-b192-67db32c4cc32" xlink:href="xcur-20200630.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_3c29ca3a-fc2c-45cc-a0a9-84f762ba7883" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_f174a7e8-cb64-4547-b192-67db32c4cc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7f9a04eb-5da3-4dc0-a370-608627bcc0ba" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_db000640-6dea-4779-8898-c3fb87662971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_db000640-6dea-4779-8898-c3fb87662971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees_ce6f5a44-4207-4fea-863b-ef87de6b1680" xlink:href="xcur-20200630.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:to="loc_xcur_PaymentsForDebtEndTermFees_ce6f5a44-4207-4fea-863b-ef87de6b1680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_87c11ca6-5346-4348-aa34-e14f6ce73301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b2e89e30-3edf-452b-8c6d-73b7339e6064" xlink:to="loc_us-gaap_InterestPaidNet_87c11ca6-5346-4348-aa34-e14f6ce73301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Leases" xlink:type="simple" xlink:href="xcur-20200630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_11b4e422-58fc-41d0-9946-d6b4ec57f1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_98905f69-e459-480c-a090-cd7c0d96185e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_11b4e422-58fc-41d0-9946-d6b4ec57f1df" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_98905f69-e459-480c-a090-cd7c0d96185e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d3288a96-cc9f-4cc4-bcae-8de9e89b41ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f99c2356-e693-4334-94f9-5437defb1f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3288a96-cc9f-4cc4-bcae-8de9e89b41ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f99c2356-e693-4334-94f9-5437defb1f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea_755ae235-60d4-4c8b-90d3-d525b37e5139" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea_755ae235-60d4-4c8b-90d3-d525b37e5139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_d93598a0-56a5-4aa8-a628-561c16942aae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_d93598a0-56a5-4aa8-a628-561c16942aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions_bd893386-8485-4255-93e9-7d4d4b798a16" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions_bd893386-8485-4255-93e9-7d4d4b798a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_67a90960-d91a-48f6-8890-0a5de46ba949" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_67a90960-d91a-48f6-8890-0a5de46ba949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths_72692629-585e-4191-9204-1e58bb83c963" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths_72692629-585e-4191-9204-1e58bb83c963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths_05313ba0-bfc6-4d5f-9ea0-d2ebdfb9864b" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths_05313ba0-bfc6-4d5f-9ea0-d2ebdfb9864b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease_ca654fc7-8b42-43ae-96f2-7bc84229d718" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease_ca654fc7-8b42-43ae-96f2-7bc84229d718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm_4cb4f8b4-1fe4-47a3-bf1f-4ed61b825451" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm_4cb4f8b4-1fe4-47a3-bf1f-4ed61b825451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement_96d28ab2-ba29-4adc-b395-71ea9bd87971" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement_96d28ab2-ba29-4adc-b395-71ea9bd87971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_46a333e9-9e46-4dea-92f5-a1fc8bc36985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_46a333e9-9e46-4dea-92f5-a1fc8bc36985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement_c70ffd91-4c47-4dbb-bc2c-b8031c936f44" xlink:href="xcur-20200630.xsd#xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement_c70ffd91-4c47-4dbb-bc2c-b8031c936f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_OperatingLeaseAssetRemainingUsefulLife_e93941ed-9aa7-4bf9-936d-7a3e4434e31c" xlink:href="xcur-20200630.xsd#xcur_OperatingLeaseAssetRemainingUsefulLife"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_xcur_OperatingLeaseAssetRemainingUsefulLife_e93941ed-9aa7-4bf9-936d-7a3e4434e31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_56cfc788-c425-40e6-8494-5128ada7f8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c06df22a-b1e1-4b78-84c1-0e9589997428" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_56cfc788-c425-40e6-8494-5128ada7f8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c789f94d-04df-4d83-97df-ca21b1fd6843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_32993363-5e24-4aff-9e7d-827cba7ca6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c789f94d-04df-4d83-97df-ca21b1fd6843" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_32993363-5e24-4aff-9e7d-827cba7ca6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fcdf8a1b-b379-48a3-9003-0649a03227a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c789f94d-04df-4d83-97df-ca21b1fd6843" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fcdf8a1b-b379-48a3-9003-0649a03227a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce254472-7232-476b-ab02-31b20c526aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c789f94d-04df-4d83-97df-ca21b1fd6843" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce254472-7232-476b-ab02-31b20c526aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_333c2a9d-61f9-4d4f-bdfd-3c45756e85a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c789f94d-04df-4d83-97df-ca21b1fd6843" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_333c2a9d-61f9-4d4f-bdfd-3c45756e85a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a441c070-0ba6-44a0-93f2-1d67af6dac16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c789f94d-04df-4d83-97df-ca21b1fd6843" xlink:to="loc_us-gaap_OperatingLeaseLiability_a441c070-0ba6-44a0-93f2-1d67af6dac16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cd27dbc7-ca06-45cd-a684-9dcf5cd24e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c789f94d-04df-4d83-97df-ca21b1fd6843" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cd27dbc7-ca06-45cd-a684-9dcf5cd24e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="simple" xlink:href="xcur-20200630.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b3aec876-8f95-4f5b-a061-1f2cd0396184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f37f79a0-2cf0-4dc5-8461-9430378d84b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b3aec876-8f95-4f5b-a061-1f2cd0396184" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f37f79a0-2cf0-4dc5-8461-9430378d84b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ada3b06d-d84d-46f2-84c3-6a721dc7e6d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_674f81fa-cd2e-4f1c-a679-ccc29ecd4143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ada3b06d-d84d-46f2-84c3-6a721dc7e6d9" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_674f81fa-cd2e-4f1c-a679-ccc29ecd4143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityCurrentCapitalizationDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_24776839-751f-4737-ab47-47efc6a6c04a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_24776839-751f-4737-ab47-47efc6a6c04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_effd93f9-da59-44d7-ac74-ec06298c4674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_effd93f9-da59-44d7-ac74-ec06298c4674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5839b64e-4ae8-4e91-95c7-f43c238075ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5839b64e-4ae8-4e91-95c7-f43c238075ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_25a47bca-9b42-40d2-a171-415535f62bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_25a47bca-9b42-40d2-a171-415535f62bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b6d813fe-b536-4db4-9bc0-8d485c1d2105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b6d813fe-b536-4db4-9bc0-8d485c1d2105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73076ac7-f298-4ad6-91ea-037a929af9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73076ac7-f298-4ad6-91ea-037a929af9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_82874fa5-ab83-424e-a1c8-43d522707b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_us-gaap_CommonStockSharesIssued_82874fa5-ab83-424e-a1c8-43d522707b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14f94c46-4161-47dd-97e6-eacf13f1bd03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14f94c46-4161-47dd-97e6-eacf13f1bd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockVotingRightsforEachShare_7728ae06-525b-4989-97e9-5f5985158d74" xlink:href="xcur-20200630.xsd#xcur_CommonStockVotingRightsforEachShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a34bea18-0630-4f34-b395-8848243846fb" xlink:to="loc_xcur_CommonStockVotingRightsforEachShare_7728ae06-525b-4989-97e9-5f5985158d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquity2019StockOfferingsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5c71535b-d55f-4f4d-8578-1a8c99c40f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_80e5d768-80e9-490f-8ebc-c670b2e374d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5c71535b-d55f-4f4d-8578-1a8c99c40f6d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_80e5d768-80e9-490f-8ebc-c670b2e374d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_80e5d768-80e9-490f-8ebc-c670b2e374d3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cd5c5ee-2151-4f75-bdd2-f08dff808a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c83ed5c7-192a-4bdd-a470-2f1ff5e011d4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cd5c5ee-2151-4f75-bdd2-f08dff808a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockIssuedDecember2019Member_6167d150-02a2-4218-94e3-9c86f352a6fe" xlink:href="xcur-20200630.xsd#xcur_CommonStockIssuedDecember2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cd5c5ee-2151-4f75-bdd2-f08dff808a03" xlink:to="loc_xcur_CommonStockIssuedDecember2019Member_6167d150-02a2-4218-94e3-9c86f352a6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_cbc7e4b2-25e1-4f93-9348-04c60f1ad918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6cd5c5ee-2151-4f75-bdd2-f08dff808a03" xlink:to="loc_us-gaap_OverAllotmentOptionMember_cbc7e4b2-25e1-4f93-9348-04c60f1ad918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_80e5d768-80e9-490f-8ebc-c670b2e374d3" xlink:to="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6b9fdf67-2271-49c5-bf06-6021be525327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6b9fdf67-2271-49c5-bf06-6021be525327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c21b3d8d-0707-4e68-bfd4-d717a041cc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c21b3d8d-0707-4e68-bfd4-d717a041cc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_10072433-439c-42e7-a5a1-96a14016fc41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_10072433-439c-42e7-a5a1-96a14016fc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses_759e4d4a-fa58-4b1e-94b8-605884f0e6de" xlink:href="xcur-20200630.xsd#xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses_759e4d4a-fa58-4b1e-94b8-605884f0e6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0ed74de9-ad11-4b73-a287-dfd1daeaf869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_06732c53-5842-4c1a-bc68-4f5cf173438e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0ed74de9-ad11-4b73-a287-dfd1daeaf869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityCommonStockWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_196f20d3-b435-4dea-b62f-5724813206a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_196f20d3-b435-4dea-b62f-5724813206a1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_6f5a3810-d607-434c-8956-81a9fa7c34fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:to="loc_srt_StatementScenarioAxis_6f5a3810-d607-434c-8956-81a9fa7c34fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f0502e3a-edd5-4c6e-8cfb-5d7e4ec6cd24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_6f5a3810-d607-434c-8956-81a9fa7c34fa" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f0502e3a-edd5-4c6e-8cfb-5d7e4ec6cd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_82e53db0-7402-47d3-98e5-be9fbbdf4ef0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f0502e3a-edd5-4c6e-8cfb-5d7e4ec6cd24" xlink:to="loc_srt_ScenarioForecastMember_82e53db0-7402-47d3-98e5-be9fbbdf4ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_546f65b5-5715-4a54-8cd7-dd09088f8a26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_546f65b5-5715-4a54-8cd7-dd09088f8a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9519bacd-8851-44f9-bfde-71aeea038735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_546f65b5-5715-4a54-8cd7-dd09088f8a26" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9519bacd-8851-44f9-bfde-71aeea038735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_f18f456d-b97d-4108-8572-d483b2b4ff1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9519bacd-8851-44f9-bfde-71aeea038735" xlink:to="loc_us-gaap_PrivatePlacementMember_f18f456d-b97d-4108-8572-d483b2b4ff1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e12717f9-c32c-4551-add4-b9a26c8ad3e1" xlink:to="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17910401-a1b7-491d-ad30-314f4a9fdfe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17910401-a1b7-491d-ad30-314f4a9fdfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76e31aa0-83bd-47bc-a1cc-511b877fc173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76e31aa0-83bd-47bc-a1cc-511b877fc173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired_fa184c0a-e99a-46cf-aa3e-9765df463300" xlink:href="xcur-20200630.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2f03c7c-8381-465b-a38a-b5e7ad942d31" xlink:to="loc_xcur_ClassofWarrantorRightExpired_fa184c0a-e99a-46cf-aa3e-9765df463300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e62d5b48-2100-4b2d-83f2-52870a5021c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_73721d25-0738-48fe-a528-4873294f3bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e62d5b48-2100-4b2d-83f2-52870a5021c8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_73721d25-0738-48fe-a528-4873294f3bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_73721d25-0738-48fe-a528-4873294f3bdf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d659b8db-ceea-4fbe-84d6-23b1d178097e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7cbc0100-b016-425c-a8ea-ad9c3fc2c2f5" xlink:to="loc_us-gaap_EquityComponentDomain_d659b8db-ceea-4fbe-84d6-23b1d178097e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_da4cc091-5f71-4e90-8cfb-d6c7fa7d9c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d659b8db-ceea-4fbe-84d6-23b1d178097e" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_da4cc091-5f71-4e90-8cfb-d6c7fa7d9c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7e8fb6f-4741-4657-a9db-5833ffa80565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d659b8db-ceea-4fbe-84d6-23b1d178097e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7e8fb6f-4741-4657-a9db-5833ffa80565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_73721d25-0738-48fe-a528-4873294f3bdf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf6ab4c9-10c5-46a6-91b6-70b991131668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_StockholdersEquity_bf6ab4c9-10c5-46a6-91b6-70b991131668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_89da8fdc-990a-474a-ba9c-0e26426cd097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_89da8fdc-990a-474a-ba9c-0e26426cd097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_cf36c626-173d-473e-bcb7-30960ab31dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_cf36c626-173d-473e-bcb7-30960ab31dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1cf1d86c-9f01-4328-9cba-4d565a46856c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1cf1d86c-9f01-4328-9cba-4d565a46856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df32eec5-83f1-4443-beaa-03e0e576e9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_aad5746a-5e43-4587-96f5-426be7ee9b73" xlink:to="loc_us-gaap_StockholdersEquity_df32eec5-83f1-4443-beaa-03e0e576e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0737162c-2e82-4575-8aa1-72fedd974823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0737162c-2e82-4575-8aa1-72fedd974823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a20b3884-a096-4d20-8dd5-2d4007a1a651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a20b3884-a096-4d20-8dd5-2d4007a1a651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_0df553ba-0d56-44bd-99c9-daef1bef6382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1ed86b39-ac91-4b58-aaa5-1a5fcb0658ce" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_0df553ba-0d56-44bd-99c9-daef1bef6382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7a64b13-51a5-4004-8977-ea4b0ef3e7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_beb308f2-59c0-4cea-b1f6-776a8c509ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7a64b13-51a5-4004-8977-ea4b0ef3e7bf" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_beb308f2-59c0-4cea-b1f6-776a8c509ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f35f265-7a16-4daf-8445-b257709fab8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b5e03e90-cbf6-4dd8-aa2d-9255a0fb03e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f35f265-7a16-4daf-8445-b257709fab8b" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b5e03e90-cbf6-4dd8-aa2d-9255a0fb03e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_598cdcf4-651d-483b-bbcd-90c6e82aaf39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f35f265-7a16-4daf-8445-b257709fab8b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_598cdcf4-651d-483b-bbcd-90c6e82aaf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d00b65c0-eb6c-4ccd-9b5d-3ba8bbc19fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f35f265-7a16-4daf-8445-b257709fab8b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d00b65c0-eb6c-4ccd-9b5d-3ba8bbc19fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18325594-1299-4b47-8434-5a3213cbd1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18325594-1299-4b47-8434-5a3213cbd1d2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_70871dfd-80c4-4180-b750-7c35ba2c9368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:to="loc_us-gaap_AwardTypeAxis_70871dfd-80c4-4180-b750-7c35ba2c9368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ce176cd-d1f5-407a-845d-4984a77aa929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_70871dfd-80c4-4180-b750-7c35ba2c9368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ce176cd-d1f5-407a-845d-4984a77aa929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c6d2aad4-f2da-491e-8dcf-bff2d1a83bef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ce176cd-d1f5-407a-845d-4984a77aa929" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c6d2aad4-f2da-491e-8dcf-bff2d1a83bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ad2baec2-d57e-446a-abc3-e69a79f07bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:to="loc_us-gaap_PlanNameAxis_ad2baec2-d57e-446a-abc3-e69a79f07bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae9b7277-ce4d-4b68-9e14-dc4948122083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ad2baec2-d57e-446a-abc3-e69a79f07bd7" xlink:to="loc_us-gaap_PlanNameDomain_ae9b7277-ce4d-4b68-9e14-dc4948122083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_b4e67a98-e037-48d2-b3b5-614a2061e62d" xlink:href="xcur-20200630.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ae9b7277-ce4d-4b68-9e14-dc4948122083" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_b4e67a98-e037-48d2-b3b5-614a2061e62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9b80b4c-217a-4917-8416-8297885d46ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_cce319b6-0a18-4068-9c15-b73f1e8989b6" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_cce319b6-0a18-4068-9c15-b73f1e8989b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_29cb330f-7c3b-4cd1-8740-964897d62e3e" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_29cb330f-7c3b-4cd1-8740-964897d62e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_70d9595e-e468-4278-8133-3134a51a477f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_70d9595e-e468-4278-8133-3134a51a477f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_866eaa20-6007-4ac7-a51c-7b2c6f97ae15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_866eaa20-6007-4ac7-a51c-7b2c6f97ae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a7533eb-16d2-4e7a-8b42-50b535bd13a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3a7533eb-16d2-4e7a-8b42-50b535bd13a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4fffc857-0bfe-4680-bf21-3eb8d06f9ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4fffc857-0bfe-4680-bf21-3eb8d06f9ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_510b6e26-6177-4e33-9e2c-bb8231e893d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9617f36-d176-4ee3-adf6-52d6d76d7fcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_510b6e26-6177-4e33-9e2c-bb8231e893d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationScheduleofCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e56ef86b-7c7f-4b01-bfda-429054b223e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf27bc3-ff96-47e7-b796-22fea0bd9d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e56ef86b-7c7f-4b01-bfda-429054b223e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf27bc3-ff96-47e7-b796-22fea0bd9d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_99981d67-f17a-4e48-a5fe-d04f94a86ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf27bc3-ff96-47e7-b796-22fea0bd9d4b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_99981d67-f17a-4e48-a5fe-d04f94a86ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97ede424-9614-436d-9d6f-3d9afada5e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_99981d67-f17a-4e48-a5fe-d04f94a86ccf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97ede424-9614-436d-9d6f-3d9afada5e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_878999b1-10af-4b8c-bf00-8d73c7bed0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97ede424-9614-436d-9d6f-3d9afada5e50" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_878999b1-10af-4b8c-bf00-8d73c7bed0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_65e97dc3-2b50-4efd-a05f-5481cf24cb43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97ede424-9614-436d-9d6f-3d9afada5e50" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_65e97dc3-2b50-4efd-a05f-5481cf24cb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e8a500d-6335-4fd1-92c9-f85bfc064a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acf27bc3-ff96-47e7-b796-22fea0bd9d4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e8a500d-6335-4fd1-92c9-f85bfc064a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_946c9e9d-e8e7-4b27-973d-9da8c9838ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8e8a500d-6335-4fd1-92c9-f85bfc064a25" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_946c9e9d-e8e7-4b27-973d-9da8c9838ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39e8b516-fbb4-445c-a963-bc4233f5a61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98770d87-0b90-40d3-a81f-49082ce1a235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39e8b516-fbb4-445c-a963-bc4233f5a61a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98770d87-0b90-40d3-a81f-49082ce1a235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05dfacb2-8465-48bd-b745-cee466fc4305" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98770d87-0b90-40d3-a81f-49082ce1a235" xlink:to="loc_srt_RangeAxis_05dfacb2-8465-48bd-b745-cee466fc4305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_05dfacb2-8465-48bd-b745-cee466fc4305" xlink:to="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a0f72f7-1d7f-4a04-93d5-7cd14b03f5c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:to="loc_srt_MinimumMember_4a0f72f7-1d7f-4a04-93d5-7cd14b03f5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73fc8db5-ee4d-495a-9527-a849bef9b3e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:to="loc_srt_MaximumMember_73fc8db5-ee4d-495a-9527-a849bef9b3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_a0893698-1d96-44b5-93d3-101118c028f0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_789f44f2-5a76-4b60-b728-b10b9ddee182" xlink:to="loc_srt_WeightedAverageMember_a0893698-1d96-44b5-93d3-101118c028f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98770d87-0b90-40d3-a81f-49082ce1a235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9228c5f9-2fb4-4acd-800c-49461d503ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9228c5f9-2fb4-4acd-800c-49461d503ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2dfd7623-a602-4c18-8ea8-8f0a8934c072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2dfd7623-a602-4c18-8ea8-8f0a8934c072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2c304653-a248-401c-b6c7-fd02d6427952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2c304653-a248-401c-b6c7-fd02d6427952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d9c8f49a-ea81-4e90-a2fc-125d9272852a" xlink:href="xcur-20200630.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d9c8f49a-ea81-4e90-a2fc-125d9272852a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1e1341a-fa28-4c02-96ca-d27bddc8f0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2d07fdc7-b7a6-4135-b909-a58c4268da2b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c1e1341a-fa28-4c02-96ca-d27bddc8f0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74bb5b37-3006-44ce-b908-f4cb28cfb979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd5e47cc-9c76-4976-b820-4564da8862e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74bb5b37-3006-44ce-b908-f4cb28cfb979" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd5e47cc-9c76-4976-b820-4564da8862e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd5e47cc-9c76-4976-b820-4564da8862e3" xlink:to="loc_srt_RangeAxis_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4ae7948f-d2d2-4e42-8cf8-0d65908c9f9d" xlink:to="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5cbc8c27-4a3d-4242-9691-2c3751f282b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:to="loc_srt_MinimumMember_5cbc8c27-4a3d-4242-9691-2c3751f282b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f26ce810-9283-441d-be6e-c2605ffb7418" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:to="loc_srt_MaximumMember_f26ce810-9283-441d-be6e-c2605ffb7418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_f00a3783-c62a-4e4e-af19-e3155333add6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_742a6bbe-be8e-43ce-9222-da95b890bab0" xlink:to="loc_srt_WeightedAverageMember_f00a3783-c62a-4e4e-af19-e3155333add6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7eb195c-4f1c-4f73-b473-76fba5ba0648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dd5e47cc-9c76-4976-b820-4564da8862e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7eb195c-4f1c-4f73-b473-76fba5ba0648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_95e9b6b9-bac7-4bfe-bfc3-4dc35da87369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7eb195c-4f1c-4f73-b473-76fba5ba0648" xlink:to="loc_us-gaap_SharePrice_95e9b6b9-bac7-4bfe-bfc3-4dc35da87369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_96f3798a-35ff-4443-861a-2c2eda2b8472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a7eb195c-4f1c-4f73-b473-76fba5ba0648" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_96f3798a-35ff-4443-861a-2c2eda2b8472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27058fcf-ece9-4d93-930b-218dddf3e1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bca91b26-0ba8-452b-bcc9-08a8e6bf9591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27058fcf-ece9-4d93-930b-218dddf3e1f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bca91b26-0ba8-452b-bcc9-08a8e6bf9591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8cb83c88-dc97-43e3-ada0-ebb9d76d2816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bca91b26-0ba8-452b-bcc9-08a8e6bf9591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8cb83c88-dc97-43e3-ada0-ebb9d76d2816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c5704bef-8174-4c85-903c-e2d5cfdede75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bca91b26-0ba8-452b-bcc9-08a8e6bf9591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c5704bef-8174-4c85-903c-e2d5cfdede75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89904f9c-7be9-4e22-ac3f-5281acf0565e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bca91b26-0ba8-452b-bcc9-08a8e6bf9591" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_89904f9c-7be9-4e22-ac3f-5281acf0565e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_448ca529-f7f9-4d29-955d-b7736890f72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bca91b26-0ba8-452b-bcc9-08a8e6bf9591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_448ca529-f7f9-4d29-955d-b7736890f72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ff9120c-c589-41bf-9921-332162a4d699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bca91b26-0ba8-452b-bcc9-08a8e6bf9591" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ff9120c-c589-41bf-9921-332162a4d699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d24a45b-0232-41df-bd72-05b28719e31c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27058fcf-ece9-4d93-930b-218dddf3e1f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d24a45b-0232-41df-bd72-05b28719e31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a62dca93-3028-4621-bdd7-9bf10daa0783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d24a45b-0232-41df-bd72-05b28719e31c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a62dca93-3028-4621-bdd7-9bf10daa0783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8d9ccd26-08aa-4130-90b6-fb05543b556c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d24a45b-0232-41df-bd72-05b28719e31c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8d9ccd26-08aa-4130-90b6-fb05543b556c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_94f9dfc4-f455-410b-8d63-c97df3f98fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d24a45b-0232-41df-bd72-05b28719e31c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_94f9dfc4-f455-410b-8d63-c97df3f98fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b6df327f-3239-49ad-8163-3f864d6c4f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d24a45b-0232-41df-bd72-05b28719e31c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b6df327f-3239-49ad-8163-3f864d6c4f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e0afc262-fd69-430a-9027-8c034e51478d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8d24a45b-0232-41df-bd72-05b28719e31c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e0afc262-fd69-430a-9027-8c034e51478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_27058fcf-ece9-4d93-930b-218dddf3e1f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f9ee6378-c414-4265-af5e-f790173eba7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f9ee6378-c414-4265-af5e-f790173eba7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c1a21be8-83b3-4819-9e56-6cd58a961431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c1a21be8-83b3-4819-9e56-6cd58a961431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cbf9b344-aa46-47ef-9e8f-f8bbb11e79a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cbf9b344-aa46-47ef-9e8f-f8bbb11e79a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5d6bfc35-f514-4d0d-9ae5-8d3b5eb69500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5d6bfc35-f514-4d0d-9ae5-8d3b5eb69500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6339f8bb-1393-4c6f-ad4c-59cdc288caab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6339f8bb-1393-4c6f-ad4c-59cdc288caab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0ee7980e-eecb-4156-b2ca-ef2cd1743e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0ee7980e-eecb-4156-b2ca-ef2cd1743e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_70fada89-9c4c-456b-8604-1db59bcfe7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_70fada89-9c4c-456b-8604-1db59bcfe7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2c571410-7419-4472-a027-708b370a3a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2c571410-7419-4472-a027-708b370a3a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_bbfcfdda-fda4-4612-b5c4-e546d0c008b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_bbfcfdda-fda4-4612-b5c4-e546d0c008b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_ee600018-efc9-4a5b-8af2-8b15e547fa9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_937e95dd-afd9-4721-8fd7-cbf77a634a4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_ee600018-efc9-4a5b-8af2-8b15e547fa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xcur-20200630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4eb15dbd-0b5c-480a-8a52-526841c2aa3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_481880a1-21f1-4f10-b0e1-94161b46f500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4eb15dbd-0b5c-480a-8a52-526841c2aa3d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_481880a1-21f1-4f10-b0e1-94161b46f500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8d54bc86-eef1-464a-a192-9bf2acc4ecb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fd7b731e-9e12-42c8-9091-748e1a0f6dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d54bc86-eef1-464a-a192-9bf2acc4ecb7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fd7b731e-9e12-42c8-9091-748e1a0f6dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_27dfae25-03fd-4963-86a3-f3d907cfe865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7313394b-bbdb-4bed-849e-bcc999e61b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27dfae25-03fd-4963-86a3-f3d907cfe865" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7313394b-bbdb-4bed-849e-bcc999e61b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_67335a29-2948-413d-8b0f-b0c48ba5cf13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_799c9957-b863-4864-8778-7255b78123a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_67335a29-2948-413d-8b0f-b0c48ba5cf13" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_799c9957-b863-4864-8778-7255b78123a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3cf14dca-853b-41cc-a563-e004fae24ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_67335a29-2948-413d-8b0f-b0c48ba5cf13" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3cf14dca-853b-41cc-a563-e004fae24ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e762e0e2-eb8b-4b4a-8b0e-f26edcb5f436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d4c7f448-a0ae-4c8e-82b8-94ba69bf5d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e762e0e2-eb8b-4b4a-8b0e-f26edcb5f436" xlink:to="loc_us-gaap_NetIncomeLoss_d4c7f448-a0ae-4c8e-82b8-94ba69bf5d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_14c9593d-a927-46b7-8486-430d0da55a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e762e0e2-eb8b-4b4a-8b0e-f26edcb5f436" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_14c9593d-a927-46b7-8486-430d0da55a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_b13076d2-7643-4b19-bd63-47f18bc02ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e762e0e2-eb8b-4b4a-8b0e-f26edcb5f436" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_b13076d2-7643-4b19-bd63-47f18bc02ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_df0553b2-fac1-4213-afa7-4dd23e1b87c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d8a0c0b7-a97e-40ed-a179-d506443c4749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df0553b2-fac1-4213-afa7-4dd23e1b87c9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d8a0c0b7-a97e-40ed-a179-d506443c4749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d8a0c0b7-a97e-40ed-a179-d506443c4749" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c8adb6a-1218-423f-bed8-b29de600ac5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9035ad9c-4a2f-4c89-b79e-a56042dbf4d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c8adb6a-1218-423f-bed8-b29de600ac5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e63e2c89-c03f-4fc4-9186-0a8aebb6bbed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c8adb6a-1218-423f-bed8-b29de600ac5c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e63e2c89-c03f-4fc4-9186-0a8aebb6bbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1f87d1bb-71b6-4f19-9bc9-c08e7d05cb85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c8adb6a-1218-423f-bed8-b29de600ac5c" xlink:to="loc_us-gaap_WarrantMember_1f87d1bb-71b6-4f19-9bc9-c08e7d05cb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8f33c1ed-d3e0-4ca4-8a29-45cf0ca0f6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d8a0c0b7-a97e-40ed-a179-d506443c4749" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8f33c1ed-d3e0-4ca4-8a29-45cf0ca0f6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_677a15ee-f2bb-4f4f-a9d7-e4d75180bbd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8f33c1ed-d3e0-4ca4-8a29-45cf0ca0f6a8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_677a15ee-f2bb-4f4f-a9d7-e4d75180bbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bfc15f75-270d-4d34-a50d-42af01a6ccdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f5af16a3-4d97-4098-a2a1-88891faaa676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bfc15f75-270d-4d34-a50d-42af01a6ccdb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f5af16a3-4d97-4098-a2a1-88891faaa676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5e1300c4-16ae-41be-9dc8-605cb77ef747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c92e730f-8bdc-4eb5-80ec-dba126085132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e1300c4-16ae-41be-9dc8-605cb77ef747" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c92e730f-8bdc-4eb5-80ec-dba126085132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_72b7ba99-f309-4346-b164-77817626c3e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e1300c4-16ae-41be-9dc8-605cb77ef747" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_72b7ba99-f309-4346-b164-77817626c3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_bc86e050-5e92-4ee5-9d93-5654b1d2aa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e1300c4-16ae-41be-9dc8-605cb77ef747" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_bc86e050-5e92-4ee5-9d93-5654b1d2aa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_157776c3-72fa-401d-97e0-a84f9b6f098e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_157776c3-72fa-401d-97e0-a84f9b6f098e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_92b67352-0cae-4406-8988-4d457cb995c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FinancialInstrumentAxis_92b67352-0cae-4406-8988-4d457cb995c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92b67352-0cae-4406-8988-4d457cb995c8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f4733302-c6fa-4a93-a951-238f6980b47f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:to="loc_us-gaap_CommercialPaperMember_f4733302-c6fa-4a93-a951-238f6980b47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23c3c8a8-893a-4983-8792-dd8e29a228b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23c3c8a8-893a-4983-8792-dd8e29a228b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7fdddde0-7c8a-4824-bb93-3b0355e300c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7fdddde0-7c8a-4824-bb93-3b0355e300c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_57ff5523-aafe-488e-aed9-d7f2368d08b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3aad3c68-1ef2-424d-9040-22ca0188e53e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_57ff5523-aafe-488e-aed9-d7f2368d08b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_01510655-acb5-4a46-bd9a-669aaef2d0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_01510655-acb5-4a46-bd9a-669aaef2d0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2a25dd7-ffae-4a2e-91e1-e4e2cccee6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_01510655-acb5-4a46-bd9a-669aaef2d0f6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2a25dd7-ffae-4a2e-91e1-e4e2cccee6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cca65305-2615-4961-ba32-829b5bf2e9db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2a25dd7-ffae-4a2e-91e1-e4e2cccee6ad" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cca65305-2615-4961-ba32-829b5bf2e9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0659c8b2-113f-45f5-a099-cf30fe04dd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a2a25dd7-ffae-4a2e-91e1-e4e2cccee6ad" xlink:to="loc_us-gaap_CommercialPaperMember_0659c8b2-113f-45f5-a099-cf30fe04dd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feebdfe9-7162-44a2-affb-edce24497dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feebdfe9-7162-44a2-affb-edce24497dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5eac8ca-0fc0-4fb0-9d6e-8e72dd1858f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feebdfe9-7162-44a2-affb-edce24497dbc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5eac8ca-0fc0-4fb0-9d6e-8e72dd1858f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8233cec8-6e30-4600-bc41-8b1a1810a376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5eac8ca-0fc0-4fb0-9d6e-8e72dd1858f3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8233cec8-6e30-4600-bc41-8b1a1810a376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85e99b3a-552d-4432-8fa4-7339e2570bde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85e99b3a-552d-4432-8fa4-7339e2570bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_85e99b3a-552d-4432-8fa4-7339e2570bde" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e443b905-1f93-4570-aac0-7d9138019b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e443b905-1f93-4570-aac0-7d9138019b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7e82dafd-c1bc-4813-90b1-a71b3ea36114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7e82dafd-c1bc-4813-90b1-a71b3ea36114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_442c629d-a676-4af9-9899-cb07232671d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4acda377-6dd6-4adc-8a77-6bef0f4b7951" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_442c629d-a676-4af9-9899-cb07232671d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aba1b8d0-6336-409e-a7ae-cd955fe62617" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a59e8773-ed71-4652-8970-b05341dcceb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a59e8773-ed71-4652-8970-b05341dcceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc54587b-7e47-427b-b3cc-140e262cec59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc54587b-7e47-427b-b3cc-140e262cec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_47ab5fbc-7a36-401c-9268-de43aa7d977d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_47ab5fbc-7a36-401c-9268-de43aa7d977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_03a46860-2eb9-47fa-a133-9861f21f0398" xlink:href="xcur-20200630.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_03a46860-2eb9-47fa-a133-9861f21f0398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_72063d97-ef7f-4955-abc4-264d5b0d14f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f460793-d5f4-4ed6-b5a4-86b5e203683c" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_72063d97-ef7f-4955-abc4-264d5b0d14f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2bad314d-3252-44e7-92b3-8cc5aeec02f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2bad314d-3252-44e7-92b3-8cc5aeec02f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_139206df-0720-479b-9214-b43fe03a6f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_139206df-0720-479b-9214-b43fe03a6f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06282e54-cf68-4cd6-b1ad-a35f67317541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_139206df-0720-479b-9214-b43fe03a6f97" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06282e54-cf68-4cd6-b1ad-a35f67317541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_bad1b11b-1469-46a3-b75b-06dfcbb98e73" xlink:href="xcur-20200630.xsd#xcur_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_06282e54-cf68-4cd6-b1ad-a35f67317541" xlink:to="loc_xcur_WarrantLiabilityMember_bad1b11b-1469-46a3-b75b-06dfcbb98e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_30fac164-5ff4-42b0-a05c-090518a14046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_30fac164-5ff4-42b0-a05c-090518a14046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4df440b8-0923-42d8-a5e4-c606a3a372da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30fac164-5ff4-42b0-a05c-090518a14046" xlink:to="loc_us-gaap_ClassOfStockDomain_4df440b8-0923-42d8-a5e4-c606a3a372da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_aa6602d6-cb5d-4b50-b17d-13e1ebf67aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4df440b8-0923-42d8-a5e4-c606a3a372da" xlink:to="loc_us-gaap_PreferredStockMember_aa6602d6-cb5d-4b50-b17d-13e1ebf67aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_580e45cc-83ae-49db-a65e-2133f8bd0fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_580e45cc-83ae-49db-a65e-2133f8bd0fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_580e45cc-83ae-49db-a65e-2133f8bd0fcc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_73ed96ec-3663-48be-9af6-1140a830b8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_73ed96ec-3663-48be-9af6-1140a830b8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bd3f9108-ae3a-47cd-b709-c3322bf976f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bd3f9108-ae3a-47cd-b709-c3322bf976f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_0aede8e6-9903-4aaf-90ae-7afeaabf4527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_0aede8e6-9903-4aaf-90ae-7afeaabf4527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0f1e1bd2-365a-402b-bdae-4b8da6cd77b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_8b55a16d-17aa-49b9-96a0-0f83a34440a0" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0f1e1bd2-365a-402b-bdae-4b8da6cd77b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4913d099-5ef9-4f94-ac31-f833988dd1ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2a5682da-f15b-46c5-b3ba-2da139569e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2a5682da-f15b-46c5-b3ba-2da139569e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_5d6f48f9-8309-446c-9b9d-f1d26fb936f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_5d6f48f9-8309-446c-9b9d-f1d26fb936f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_1c46d697-1ab5-444a-ad2c-71c8ebd00383" xlink:href="xcur-20200630.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate_1c46d697-1ab5-444a-ad2c-71c8ebd00383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_7a6320c9-1c5c-4b25-bd64-341ba47c60ab" xlink:href="xcur-20200630.xsd#xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5219b3de-cd75-45d8-9634-c2d96527cbc9" xlink:to="loc_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock_7a6320c9-1c5c-4b25-bd64-341ba47c60ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_664883fb-53fb-4972-9756-8fef130ace22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_664883fb-53fb-4972-9756-8fef130ace22" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1a5ff407-7b84-4cbc-b694-c40809c32b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1a5ff407-7b84-4cbc-b694-c40809c32b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1a5ff407-7b84-4cbc-b694-c40809c32b52" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_16f495f8-a2fa-4da0-a6ca-f20a3ce89292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_16f495f8-a2fa-4da0-a6ca-f20a3ce89292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d55d1996-bc37-47b2-97a7-2bfd35a765b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d55d1996-bc37-47b2-97a7-2bfd35a765b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b8fae568-c92b-4f6d-aeda-778d9f3da155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b8fae568-c92b-4f6d-aeda-778d9f3da155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_183f8403-f3de-41ec-99f5-b959a8a587eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d608e965-1f42-40b5-a1ba-25b1fc30adb9" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_183f8403-f3de-41ec-99f5-b959a8a587eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_62d4fd21-1d4c-4b77-a494-71e2ee09cca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_62d4fd21-1d4c-4b77-a494-71e2ee09cca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3ebcac36-397b-4050-95f1-08a572238127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_62d4fd21-1d4c-4b77-a494-71e2ee09cca0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3ebcac36-397b-4050-95f1-08a572238127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_3750cc54-de68-491f-aa96-d35f6b9df6f5" xlink:href="xcur-20200630.xsd#xcur_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3ebcac36-397b-4050-95f1-08a572238127" xlink:to="loc_xcur_WarrantLiabilityMember_3750cc54-de68-491f-aa96-d35f6b9df6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a97ec421-3c99-4b69-bad9-0d965150dfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e9dcd64-3d0a-46bc-93eb-c4b81cf2f13a" xlink:to="loc_us-gaap_ClassOfStockDomain_a97ec421-3c99-4b69-bad9-0d965150dfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3f9066a2-0c6f-4dab-b6d3-87abe82ece00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a97ec421-3c99-4b69-bad9-0d965150dfa8" xlink:to="loc_us-gaap_CommonStockMember_3f9066a2-0c6f-4dab-b6d3-87abe82ece00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_93fe9f66-2e45-4ce1-9f1e-beae9d7e24f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0e0d9cf8-bdcd-4521-8285-03676bddbc75" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_93fe9f66-2e45-4ce1-9f1e-beae9d7e24f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7ffb1241-07f8-4176-9a49-d2653015f86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_93fe9f66-2e45-4ce1-9f1e-beae9d7e24f9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7ffb1241-07f8-4176-9a49-d2653015f86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b909db6d-00e1-43cb-8b5f-e59ce47aca8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_93fe9f66-2e45-4ce1-9f1e-beae9d7e24f9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_b909db6d-00e1-43cb-8b5f-e59ce47aca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ad21479-90bb-4dff-afb9-fb34b5ace3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ad21479-90bb-4dff-afb9-fb34b5ace3a2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75106b0e-c02a-49f7-abd7-41e9c8f2d998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75106b0e-c02a-49f7-abd7-41e9c8f2d998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8b1e954-413c-4c46-8591-11d54a1652ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75106b0e-c02a-49f7-abd7-41e9c8f2d998" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8b1e954-413c-4c46-8591-11d54a1652ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b1022733-fe6c-4e20-bd24-173bf1e86481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d8b1e954-413c-4c46-8591-11d54a1652ca" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b1022733-fe6c-4e20-bd24-173bf1e86481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_87053994-a218-4007-82d7-95fa6b7b2022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d9c3d68c-4181-4a21-8b8c-dbf32ba3212f" xlink:to="loc_us-gaap_ClassOfStockDomain_87053994-a218-4007-82d7-95fa6b7b2022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c6f3e45a-21e3-4b30-8907-0c49e0ba0f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_87053994-a218-4007-82d7-95fa6b7b2022" xlink:to="loc_us-gaap_CommonStockMember_c6f3e45a-21e3-4b30-8907-0c49e0ba0f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_78d3869b-389d-4d99-b6c4-f78ab8466817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_78d3869b-389d-4d99-b6c4-f78ab8466817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1989ead2-d193-4ea3-a204-b7138d464e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_78d3869b-389d-4d99-b6c4-f78ab8466817" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1989ead2-d193-4ea3-a204-b7138d464e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_18230613-0fbc-4f11-af59-542848563922" xlink:href="xcur-20200630.xsd#xcur_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1989ead2-d193-4ea3-a204-b7138d464e31" xlink:to="loc_xcur_WarrantLiabilityMember_18230613-0fbc-4f11-af59-542848563922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76b9a4b8-ecc2-4559-b966-4d9960981035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_de7557ed-4060-4a32-a4ca-628df5def65e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76b9a4b8-ecc2-4559-b966-4d9960981035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_76b9a4b8-ecc2-4559-b966-4d9960981035" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ee4f3b29-21b6-4e9d-88d0-1b866bf13506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ee4f3b29-21b6-4e9d-88d0-1b866bf13506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_0add0a8d-9ffc-4b00-8beb-43de269579bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_0add0a8d-9ffc-4b00-8beb-43de269579bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3b268fed-aca2-43f9-8e0b-25df4d37f633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_78591d48-1abf-4d89-b476-38b8975716d8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3b268fed-aca2-43f9-8e0b-25df4d37f633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="xcur-20200630.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31aac3c9-0d99-4def-b1ba-3a5fb26e582a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1d270f10-02b6-4a27-bdc7-13e014f4b544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31aac3c9-0d99-4def-b1ba-3a5fb26e582a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1d270f10-02b6-4a27-bdc7-13e014f4b544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_27b4155a-6382-4a6e-9419-f789bdd314f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsforLicenseAgreements_bcaa6c84-fd5b-4b6b-8d0a-2d7448c39a9a" xlink:href="xcur-20200630.xsd#xcur_PaymentsforLicenseAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_27b4155a-6382-4a6e-9419-f789bdd314f4" xlink:to="loc_xcur_PaymentsforLicenseAgreements_bcaa6c84-fd5b-4b6b-8d0a-2d7448c39a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="xcur-20200630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_786c5915-303c-4be4-9e99-1e0d0ef7fa3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_945a785a-44da-4f9b-9c48-34a75050c52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_786c5915-303c-4be4-9e99-1e0d0ef7fa3a" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_945a785a-44da-4f9b-9c48-34a75050c52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20200630.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_97aeaa43-1e96-449e-bc91-46afc75b6bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_97aeaa43-1e96-449e-bc91-46afc75b6bb5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19450984-26ab-48e8-bced-d2dd71b64582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19450984-26ab-48e8-bced-d2dd71b64582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5dc370c3-1017-4fcb-9317-81663427d6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19450984-26ab-48e8-bced-d2dd71b64582" xlink:to="loc_us-gaap_RelatedPartyDomain_5dc370c3-1017-4fcb-9317-81663427d6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_8de708a3-f0b5-45de-bee1-6680e332f250" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5dc370c3-1017-4fcb-9317-81663427d6d8" xlink:to="loc_srt_DirectorMember_8de708a3-f0b5-45de-bee1-6680e332f250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b9722f91-0faf-4aa3-a34d-b59949a59dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b9722f91-0faf-4aa3-a34d-b59949a59dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e1508b58-5216-4bf8-86c1-4b8406a3b24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b9722f91-0faf-4aa3-a34d-b59949a59dc2" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e1508b58-5216-4bf8-86c1-4b8406a3b24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember_ab9954a3-3536-402a-a037-48462b58244a" xlink:href="xcur-20200630.xsd#xcur_ConsultingServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e1508b58-5216-4bf8-86c1-4b8406a3b24a" xlink:to="loc_xcur_ConsultingServicesMember_ab9954a3-3536-402a-a037-48462b58244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_737b738c-c465-4084-bf53-513fdf2a7a55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_565cefe3-6d13-41ce-b3c2-acda97e31fa6" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_737b738c-c465-4084-bf53-513fdf2a7a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f3bc393b-75fd-4af6-be68-8ba07618b03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_737b738c-c465-4084-bf53-513fdf2a7a55" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_f3bc393b-75fd-4af6-be68-8ba07618b03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="xcur-20200630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_aebb5080-7741-459b-9e3e-7013241ecd44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ff6dd663-b95a-4ec1-984d-457b9f1f29b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_aebb5080-7741-459b-9e3e-7013241ecd44" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ff6dd663-b95a-4ec1-984d-457b9f1f29b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>xcur-20200630_g1.jpg
<TEXT>
begin 644 xcur-20200630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X@*P24-#7U!23T9)3$4  0$   *@;&-M
M<P0P  !M;G1R4D="(%A96B 'Y  (  8 $@ D !MA8W-P35-&5
M                        ]M8  0    #3+6QC;7,
M                                              UD97-C   !(
M $!C<')T   !8    #9W='!T   !F    !1C:&%D   !K    "QR6%E:   !
MV    !1B6%E:   ![    !1G6%E:   "     !1R5%)#   "%    "!G5%)#
M   "%    "!B5%)#   "%    "!C:')M   "-    "1D;6YD   "6    "1D
M;61D   "?    "1M;'5C          $    ,96Y54P   "0    < $< 20!-
M %  ( !B '4 :0!L '0 +0!I &X ( !S %( 1P!";6QU8P         !
M#&5N55,    :    ' !0 '4 8@!L &D 8P @ $0 ;P!M &$ :0!N  !865H@
M        ]M8  0    #3+7-F,S(       $,0@  !=[___,E   'DP  _9#_
M__NA___]H@   ]P  ,!N6%E:(        &^@   X]0   Y!865H@
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M"N@# 1$  A$! Q$!_\0 '  !  $% 0$               $"! 4&!P,(_\0
M&P$! 0 # 0$!              $"! 4#!@?_V@ , P$  A #$    ?JD
M
M
M
M
M
M
M
M                  TT@VLQ1A3,F<-*!M1Y&IFT&)-L+4PY>%@;*:P98M3,
M&F%P;<8@QYLYKYE"\!B37C(&S&*->/<]#:236#:0         "P-7,B;&:R;
M2:H;66YJ)NQ0:29,RQK!)NP/$U4W                 &",*9XN"U,R:N;4
M8@QYLY8FG&T'B84OC:2#30;F
M
M       ?-YT<U<R!DS0CMYQ ZN; <'.I%9RP^BC7CG!G#EQ]&'%#HI@S'EV7
MYT@XH8 ^B#D)O)M .9F-*3U+\QIN)I)NI6:B=9          -(-*+4WDY^=]
M/G@^A3GQRH[R:L8HVP\323>C<P<P- /HX                ''C(FA'2S'G
M2S@A]!'$S 'T0</-U,P:(9(VDV8L#2#FIVPV0
M
M                   'S:;X6)68H\#MA\[FXF^G/CM@/G4^BC7CG!G#%'F8
M@Z*8,T ^D"H\#AYFS;#3C>3: <S+\WH^=CH!I9OAFC13T.@&P          &
MD&AEJ=+.*FSFJGTZ<*-_-=-X.)G0S*'+C=SJ(!\['T2                #
MCQ<&G'3#EQF"T.]G#S-FV&-.:G7S2S$'03=P6I\_'?R\
M
M                          !\X':C8SD!N!R8[P<4.^&).&GT$6)PH^A#
M!'.C.&<.8GB=-,&:B=<,B:P<X+TNBZ-T-J*SF9?%\<\-G+\WT@^>2[.^
M       T@TXZB79PX[Z?/!W0X";,:X=\+L^;SL!A#J)(!\['T2
M      #CQF3>S53"'2S@AT@YN7I='62P.1F<-Y-H!Y'"SIIM9(
M
M                            /$YT9 WL  Y4=5!H1LIK!FCG1!U UHTT
MWHP1B3="U,D9(\S3#<C&F9.7%V9TW(R)R4V T\VTWXU(T(R!TLP)H)?'73G9
M[&_  U@U4WTR@      !KICC<SP.<'3CE9MAY&VG,R\-0-N-A.:$G:23EQAC
M:CH       !@C2C=3.@      &A&RF8-=,<;><R+\W R)R4R!KAT<Q9IYFSJ
M!B3E0.@FU       %L<Z,Z;B
M                                                     #P.<%\=
M                           -4-6-],N
M#7S2C=38                          6IS@S9NP
M
M           !JQD#,@                          YX=#
M              !SPZ&                          #4#-F4
M
M                     -6,64                           QQD0
M                       8XR(                          +,W@R@
M
M                            !JQKY9@
M                                                        '03*
M
M                              &K&OEF
M                                                          =!
M,H
M                                :L:^68
M                                                           !
MT$R@                                        !;'@4%1>%9;'@227
MQ4                                           :L27H
M                -2-M                          !J1MH
M                 -?-G,H#@LO<;.)RY [+9:G YET-*SFZ]VN.2.1RX0[/
M9QV7N5FLQI2[6G*67>;CJDOD;79Q698@V9.TV>@*#CDNI+DCM=QU270U[S<>
M<RY],U7%)EB3K"9VSC$RL#=$Z_9P67N-ER:K'(&5N=#3IUFHQR1EX'1$Q)NB
M79SE>TV     "DQY2>R>RT%)!!)45)4MH07!>
M                   &K&0,R                          #GAT,
M                      '/#H8                          -0,V90'
MRW,OI>X_-$RO3Z%N.CR\Q7=T]#0UZ&G2[/GF98D^D+C\^S+Z9N.EQSE=T..K
MT),R>1K!M)TZSY_F6])TBP<UETQ>]W'EDNNF:.:+UI,2;2:&9PZO9ASA4RZR
MFY6?-\R[*QX8R^E[C>'RU,OH2XY8^9)E]!,?GQE]%7'.&#,9')V603?S>K
M   ,>>9=GF>)Y'F4E)!)65GH>QZE);EZ7
M              !JQD#,@                          YX=#
M                 !SPZ&                          #4#-F4!\MS+Z
M7N/S1,NEIZFBKNR6QZ%1H2].2T.6K](7'Y]F7TS<=+CG*[H8,YXO14OCFJ]^
MN.>.42VAN:2: NP'3;-7CBS+=$]3F2[TFX''E[RQV.A\F8Y?5F6/N<0EV0Y,
MOTO<:3YCF7U7<1\\S+:$U%>W7'BTRV=.P6?.,R\CZ2N,@   'F8TO#S/ MRW
M/$J/8]2H\SR/$K/8N"X+@\"3(
M    %N>Y)JQD#,@                          YX=#
M           !SPZ&                          #4#-F4!\MS+Z7N/S1,
MOHNX_.4RSYT!,*>ADSGZX4^D+C\V3+Z6N/S3,OJ6X\]EU(VLQA<'(UZVFD+T
MU-\LX++N1028\QQVNSFDNIF:,V:P<[7N2<R7H"=(LLCYLF7?&.QU\X3+L#'A
M;+Z7N-R?*6.7U#EC=GS#,N[,>!,OIRXX&.4,OH.X\JEMCKU@   %N61>%J6I
M:E)?%P>);1Y%->D>]7))8EL7)=%R5EJF5)
M            /$MCR.:>GE99^>0   H  2" $ D @D @ D    @ D @D @ $
MD&K&U    *  (!((!(! 20 " 2H@D@$H  !  )  -5-J () ,[AZ[]Y>P
M                   U S9E ?-\R^A;C\]S+Z-N/S_,NAI48<K,D4&B+WZX
M_-LR^DKCQ>73U]#NEQP4N..DV?.4RZ<F<3B#*3.IW2SU!8'!)E:'N=VN.BRY
MDVJSYRF7;6-V<*95G34R)QU:S;D[39\YS+P-U3*G+5K.@IU>SFLO+EDWE.PV
M<VEMSJ-@   \"S+@M"S+8OSU,66P   *C(%Z8\\R\+P]RS,J
M                           "T3@&SI\,VM*FR20!0DD D ! )) )  ))
M%@%0 ) ))E $BI!,  2 22  2L@$DT!( BHBA)5$ $@ J!)( *A0$L05*))!
M( ))HHD!*?/T^O\ G=;,2@                     :@9LR@
M                         *#&%V699'D9(QY;      DR9!8EX7Q[):KD
M@                                       #B?OK?,VYSEDD@542 22
M"02@$DD@D J(*B1<!)))()*@"9F!)4*$E40222 5$D@D$A9) )J22221$DU(
M)F0DDD$DDL9)!(65J%"24 JE$D@DDDD@J)J20#P8;II]#Z.U=P
M           #4#-F4                                    !BB\+,L
M#R,A&.J@       NCW,>7Y>E1!=
M       'S)M:/%]K2DD$DD@%5 2"4 DDD$@)(*JD,2%E*@2LI4 LLI$22*$E
M4L%0) *B205 !9) )J22221$DU)(F0DDD$DDL9)!(65J%"24$K,22 222205
M$U)( N.(QS^J^7UMGF0                     U S9E
M                     "R)/(L"T,B61        ![%1:F0+Y+1<@2
M                                  #%W'X<Z/(M<L9!))(!50$@E ))
M)!(0E1%5$@$DDD@DJ ))!,2*$E3*"H1(H5$D@J@ LD@$U))))(B2:DD2R"2H
M@J!*22%DD%0H22"28DD DDDD@K%22 LR^>6&=T>A]0ZVV
M      -0,V90                                    Q1<E@8\O3S*0
M  "$\,_/7]OGZET./EM?<WWE?052@ #V+4]#(%T61?
M                      'RKN<_E>QJ2"220"J@)!* 222"0A*B*J) ))))
M!)4 22"8D4)*F4%0B10J))!5 !9) )J22221$DU)(ED$E1!4"4DD+)(*A0DD
M$DQ)(!))))!6*DD!992PP^&?TQS^GO.'H                    !J!FS*
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M6*DD E)91E+C3V_K#3WZ@                    :@9LR@
M                      ,87!8&-+P]0  #&^VM\Y?7_G'AGY@ "\\_;MOS
M7V^VZ'7  @L3U,D>Q:%T <,-Y+$Q)YFS%J61461Z&XFAG1#03KX.,&QG@4F?
M,4;.:P=#, <^-K+DYB=Z.''J=#-(-K-5+HJ*3)GB:X;,:T=7.!'T:<5-S-Z!
MH)OP          !QKWU/FO=Y\@DDD JH"02@$DD@D(2HBJB0"222025 $D@F
M)%"2IE!4(D4*B2050 620":DDDDD1)-22)9!)405 E))"R2"H4))!),22 22
M2205BI) *@39AO'U^PN=U;]0                   !J!FS*
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MAJ9T(NCFQLIAC;C72W+LSAI!LYB"X-Z..F^FO S9DS1C+EP9<U(Z:7
M      /,^,NARM>]/&0222 54!()0"2202$)4151(!)))()*@"203$BA)4R@
MJ$2*%1)(*H +)(!-22222(DFI)$L@DJ(*@2DDA9)!4*$D@DF)) ))))(*Q4D
M@$J8XCS]OKGG=/,3(                                    :,8,ZJ:
M\<5+LWLR)H9L1DC6C"'5C03LAP8[6<K.BFFF5-U.!&X&RFVG 3;#)'-3HIII
MDCH)E3BQD3J)H9FC>#'%R6!C"HS(  !JN[R_G[ZCX+PSP   &\<WM=Z^9^Z
M '@88O3)%J2                                       <J]=?YEW^9
M)())) *J D$H!))()"$J(JHD DDDD$E0!)()B10DJ905")%"HDD%4 %DD FI
M))))$234DB6025$%0)220LD@J%"2023$D@$DDDD%8J20%F+=AT#2Z7T%K[0
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MB2:DD2R"2H@J!*22%DD%0H22"28DD DDDD@K%22 3<L1X>GUYH=/*R@
M                                                    06QCS%EZ
M9L U?;YO.^KP=NT>IG=?=JE^:_K/SVWS\P  !VWY[['H',[N!V=&Q]/'>>=V
M94>9JQ>F3+HPP                                     !I^?G\P;W,
MP^?G)())))!(J02"4$@DD$A"5$542 222"2HD D F)%222R$DP)%222250 6
M20":DDDDD1)-"28E1)()))220LD@J%"2023$D@$DDDD%0JHD MUZ)H;_ '_P
MV@                                                         !
M26Z8]<67AL ,9ZZ_.^IP>C\KOY#S]\?Z>'!OH_BK_P _;1.CQK7T\@ !E?'9
MZ%R^]U?B_39'S]P /,U$OC)ER8(
M   $&%RPY#L:O)-G3\KB)!!))(H 2 "22"220 DH""10DD $D@"!)("BHAE)
M( )!(!( !( ))%2!$DU)(@"0 2"0"H D  D J(!)))) )4230$>6?V#SNME%
M                                       U@V8 $@@D$'D>P!25 %L7
M(/(D]  0"3Q/0D UDV<%@>QCS%GJ;0  8SUU]9V^=LNKT.;]3@:5O\C7MK1L
M/7P %4N2\MCO_P U]N/*X[GH]8 6QJ)DC)E)2
M             8NS#98:[Z>.%LN2_)!!(  ()   !!((!((!(         !!
M( -7-H()     ()   !!) !(       ()!!(!!(!K!LX  !L?GZ]#\_8
M                                  "S.1&5.=&^%L=//<X 9,ZF<O*C
MJ9LA;'S2=T-@.(&:,L9$T4\#I)I9XF^F+-$.K'+S<##&C'2#&'4S(F-+LQYC
M"V-S   ,9ZZW*^Q\YV;A?5\(^B^,V?4Z.G;W*L/7PUC;YV:U]SZ(^8^ZX?\
M0?'_ $!\U]O19<X^@ QIK9E#)'F91
M     +$I(7"F2,R                          #GAT,
M            '/#H8                                          !
MJ!@CIAP [^<8.H'J<+,N=#.3FU&1.DF@%@8<V8\SU+XYD=X,8<L/4LC92\-$
M.M''3K9M9P [^<Z+\W8MCS/$QABS<BX  /&X:1T.1NNAUO;'/YN^J^!^D/EO
MO<5[:W(>W\OO'/['!_HOB_IOY+]#O_/WP.SI;5I]( #7#'F5,B>1D0
M                              "DYGZ^'SOMZ&O>GD!((%"0 "2 $ D
M D$ $BP"0   3*!!4*$$P () )  !*P"22*$$@")(H"8 @J( ) )(!(% 2Q
MB9"4D  $BT02 ;+X['V!S^GZ@
M   TPQ1T@X =_.,'4#U..'J=3)- -C-X.$F1-2.MFLG1#DA!UXQ!J!:G1SA!
MU0T0[H>)P4^BC@!W\YZ7!O0,8>ACC$F8,\   #![&GRGL_,]R^>^R')^S\SU
MCC?3:;O<GCO<^5[_ /-_;Y7QV0 (-(+TR1D"U,B
M                 8^SY.W.=SGWUI))!-2"022"0$D$DD@D J(*B1<1))()
M*B0"9D!))-"2J()))!))()) )602"JA))()B2:D$RB2205 E)!)()6H4!4@%
M4HDD$DD@DFBU$@)C\<>VZ'5Z]Y>X
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M)(B2:DD3.025$%0)822"25,JA0DEB)699) ))))(*Q4D@"X67E[?7O-ZEVH
M                                     YX=#                 .>
M'0P"T*3R,<8@S1L   *4L_3ROO/V X9]#\=W#Y_["N48;WU-9V^?O_-[8%!H
MY>F2,@6ID0 <0.S&FET8 WHY>=B.8&'.FG$3HIDC13JYRL[*<:,@=4.2$FYF
MW&B&,-V.=G1CGA:G4C0"\-1.Q'!SKIS@VTUH["<B*SLAQPM3I!LIHH-L.0'2
M31SJ9RPZF7(       !HN?E\;]#E+)!))(!50$@E )))!(0DBJB0"222025
M$D@F)%"2IE!4(D4*B2050 620":DDDDD1)-22)1))()))220LD@J%"2023$D
M@$DDDD%1-22 3%GDZGSNGW/Q]P
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M222"L5)("S,IRPQ&O[?7>CT\K*
M                        +4\B"P,:6!O)[@       & -<,R9 ODL%R
M!K1J9T T8O3?33S93#&7-7,P8TS!I!FB]-5-V+DT$V@LS&'13 FHG0#43%'B
M;.8$W\P)M1II=EB;08\QQ@3?2V-)-S, 4F_GD<Z,L6I;&<-:-@-?.F'H
M    ?.VSI<+V]&0222 54!()0"2202$)4151(!)))()*@"203$BA)4R@J$2*
M%1)(*H +)(!-22222(DFI)$L@DJ(*@2DDA9)!4*$D@DF)) ))))(*Q4D@$DK
MX5O&CO\ T1K;0
M           &++LM"Q,869NI>       &MFO&:+\O2@HBX
M   ()                      !Q_8U?F7=YT@DDD JH"02@$DD@D(2HBJB
M0"222025 $D@F)%"2IE!4(D4*B2050 620":DDDDD1)-22)9!)405 E))"R2
M"H4))!),22 222205BI) )))K!^/K]B<[J9!0
M                                  !!B2]+0L3'F+-H,\2     6YJ!
M:&7+XO2HL2\               !KQL(                        . ;.G
MP?;T)!))(!50$@E )))!(0E1%5$@$DDD@DJ ))!,2*$E3*"H1(H5$D@J@ LD
M@$U))))(B2:DD2R"2H@J!*22%DD%0H22"28DD DDDD@K%22 5 BR^U=OZKTN
MA(
M!YF-+PM2S+(Q1!LIFCT   +,UPPADC(EX7968LO@  #GA9&^G.3<3!%B;2:V
M4F2,F:$=$)--*3<3FQU@U8@V0YP=D!SDZ,                        #Y
M*W>;H'OK2"220"J@)!* 222"0A*B*J) ))))!)4 22"8D4)*F4%0B10J))!5
M !9) )J22221$DU)(ED$E1!4"4DD+)(*A0DD$DQ)(!))))!6*DD DDQ$R^E>
M;U-[P]
M      /(QI?%N6I:EH8TMB[+\N"H\BT+ \S(&0+DNBZ*$QBW8   ./G8"U.>
MEL>A:FV&JG6302Z-.+PS1Y&_'+RV,H6Q[E90;R90T0VXO0
M         :OEA\=='D4V2"220"J@)!* 222"0A*B*J) ))))!)4 22"8D4)*
MF4%0B10J))!5 !9) )J22221$DU)(ED$E1!4"4DD+)(*A0DD$DQ)(!))))!6
M*DD!9BF^>1U-_P"J]3>
M                    @Q9<$EN>!;GB>)X'D05GL>Y['L7![EPF-6V+@
M Y$;,8T@P1DS;#$FLFV%D9(I-&.@&FF=+XP9CS<C!F),T5'10
M             >2?*6[SM%]]:20222 54!()0"2202$)4151(!)))()*@"20
M3$BA)4R@J$2*%1)(*H +)(!-22222(DFI)$L@DJ(*@2DDA9)!4*$D@DF)) )
M)))(*Q4D@$KB//+Z9Y_4WC',
M                         "S+8NTI7R/(\R@@@DK*ST/4]2U,6>A6
M"@QY<ET6YYEX6AZEH71400>AXEN9$M@7!;$ER6A=@
M    'DGS?MZ/+-G3DDD$DD@%5 2"4 DDD$A"5$542 2222"2H DD$Q(H25,H
M*A$BA422"J "R2 34DDDDB))J21+()*B"H$I)(6205"A)())B20"2222"L5)
M(!%RRFGM?4^IO2
M                 6!Y$EV4E) ))*CS,:68/8
M                    U//S^>MOGZ;[>$D@D$E0H"4D+(!()220"0DA)))L
M J !45 "4DDJ0LK)*B0"2H$D@J !*B0222*DD14*D$Q()) *@22"H J )!)(
M))!)))()"BHFI!B\'T]SNONN.8
M                              H+(I)+H\C#$'B4ER
M                           "#%V8;+ST+V\-$]M>NO4D$ $@(($3:2 2
M""0 !$I"D 9     B8   $6HD L"_()M (4"$D @ 5(B"0*"5 E(H  (  "@
M$**D6R0)%L@L"^ !(!M_C[_2&KNR
M
M                     #5C(&9                          !SPZ&
M                        #GAT,
M
M                           U8R!F0                          <
M\.A@                          YX=#
M
M                                -6,@9D
M    '/#H8                          .>'0P
M
M                                     #5C(&9
M         !SPZ&                          #GAT,
M
M                                           U8R!F0
M               <\.A@                          Y^=
M
M                                                -6,@9D
M                    '/#H8
M
M                                                  -6,@9D
M                      '/#H8
M
M                                                    -6,@9D
M                        '/#H8
M
M                                                      -6,@9D
M                          '/#H8
M
M                                                        -6,@
M9D                          '/#H8
M
M                                                          -6
M,@9D                          '/#H8
M
M
M-6,@9D                          '/#H8
M
M
M  -6,@9D                          '/#H8
M                                      !!(()  !!:%X""0"@\"Z *
M2W+H@D$$@
M                  &K&0,R                          #GAT,
M                                                   ^8)EM:=TL
M^8YE].7'Y*QRVNMI3T+PZC9P67I"<H96Q:G>KCX1PMEDRP/HFX\$F7:&.QUH
MLO'%OP?1%QT.7D:Y8OC.)2;ZG#67TK<0
M                                         -6,@9D
M             '/#H8
M             !\Q3*H[RQX$R^G[C\G8Y?3&6-^<KENSJ=G!)>D)R9EVACRY
M=L- 7J2;M9Q.7+FD+V=CLM?+\R^@;CGSY[F70DXJOTW<<@4%L?-,RV@Z"F]6
M
M          :L9 S(                          .>'0P
M                                          #Y@F784YTN$/IZX_)&
M.72;-\34UNSJ=G!)>D)R9E:%D?3UQ^:IEWRXY\Y/+;&J+V=CLM?)F.7U9EC[
MG#Y<H<V7Z8N/ 9E9'TQ<>/RZ.OTO<9                     ,>4E)47A4
M6QX@DNBX                                           -6,@9D
M                       %B7P
M                      !\P3+Z>N/S7,L2?5=Q^3L<OIS+'W- EU)>S7'Y
MYF7>KCQ.9=H8\99=43G9GCI%G 9EUQCREEU%-FLX%,NEIMUGSQ,N_P!Q^?YE
MU],TG#&7TW<=#ET8[K8                   !XEB070*2D@ J*BH\3R/0R
M(                                         !JQD#,@
M
M            XY+V.S5XYZO:K.&RT&P'3[.02X-=W3I5G)Y>AV86,(N\V<BE
MQB[NG2K.52Z^9HZ!9R:6T7H:;Y9A3E$M@NXIT^S6C6Y>DV
M     08LJ+D\3R/(\RDI(!6>AZ'J>Q46A<EZ
M                 :L9 S(
M
M                       !;F.+\\EMRV/ H/5/<]22@\BV!ZEPON7*4'D9
M0                                        &K&0,R
M
M                                               "S+<N2V+5;0K+
M\J+9+4\2"L]R[/<M2Q7V+M+H]BQ,N2
M         #5C(&9
M
M               +0MSV+0LSP7)%"8Q?()) !((+PR1:+;)=EX7)8F7)
M                                   -6,@9D
M
M                                        'D8XN2S+(I,@8P\@
M "^/<QQ>%\7!:&5                                       -6,@9D
M
M                                                           &
M(+TLBQ*2],>4@      'N79CB\+X]""^
M          !JQD#,@
M
M               %@5G@MB6R9 L@21"F58F6+SQ9UY9/2&2XI0!Z'J61D"^+
M4RQ(                                     !JQD#,@
M
M                                              &)+E; L"^3Q()
MR(88J7W9>+*^67AZ8;$XUB7S,@!6>!)D2[/ R(
M              +$H/*XZX7QF               "^E]5
M
M                           &//8M5QI!<I  "1,<3MZ.D;_+R?GZ<YZ7
M#VO3Z'/>AQ.CZ'8U[/PZOS?I;SQVK_PV  )+ OS(%L99
M                     !K^6/%-C4Y%M:7G8 ) !( !( !( )  !(4G==+H
M=RU]P
M                                               8LN3'F.+P]0!$
M6ZMO<7E';^<R?EGJ&[S]SY_4M_3SM,\<KXW3>ASO3#+.>&YKNUJ=DX'U6[\O
MO3E")2V)Z&1+@H+T                                      U'/S^;
M^AS<5EYR":J)B22;"U(EJ!-223$@DJJ8D%0MDE3'Q\O3Z]YW6]
M
M                                08L]3'%H9$] 3)%O,NS\QJNUS:LF
MQ:70P>UH9;7W>:=OYO/:>Y9>EQ.SS^@<KN:_[<^X]O7 /#J'.[W0>1W[_7WV
M7@N=H6IDR^+4R(                                      ->RP^7.C
MR[/+ 351,22386I$M0)J228D$E53$@J%LDJ8VAWGG=/IOE[@
M
M                            "S!;&-/,RQ42D2Z#U^%S?H?-[)K=;F76
M^3SV/2P.QH[WQ^UK^_J9_2V=2W='=]'JZ/T.+:YY[ES-[5NEH]&XWT.2\O3I
MG*^G>>#/*V,89 R)X&0                                       .8
M^WA\_;_,$U43$DDV%J1+4":DDF)!)54Q(*A;)*F,F1U_?ZIT>F
M
M                               ,:718&,*C,DTDILY5U/F]-Z?(Q^>O
MF-;8TWJ\_(ZGKL&&U?:_MJ/0Y^V<_HZ-U.'N_-[>B=;A[]QNY;96_P!;WL_7
MS[EQOK;GQ]%RMUPQ>F2/(O@
M #S/E#H\O"^GC-5$Q))-A:D2U FI))B0255,2"H6R2IC48R/J'F=;:\?0
M
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M4B6H$U)),2"2JIB05"V25,:B#;]3;^B]3?
M
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M)J228D$E53$@J%LDJ8U$F-PR^RN9V
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MJ!G];9^FM+H@
M                                       <B.J'(3K!Q\]#J1RL@Z<:
MB;Z<L.P'H<R-\(.?&X&MEB=5.+G2#8#'%P8XQI4;2(IC7MK0^<_I?C,;O<M+
MN?([.&W-:PFKONCW.==/B;]RNOS[K\/,>&QM?.[>J;W.VW5W,/[^>I]'C>OE
MG]+_ "?Z!L6ONUK:+J9DS)'F5@&NFQ&NF9,2"Q+8S!AS:3&F:,"8X]B\,\:4
M9T\3+%J98THR1L9KIL1K1GC&%N;$:V09\P1429\UPV0
M^>]W0T+8U)JHF)))L+4B6H$U)),2"2JIB05"V25,:BR/H'F]3HOG[
M
M                                  8TNBQ,86B[BE0B++#UU>:]#AZ=
MT^9E-/:YKW_F]UYG8R6CM^6UAK>WRL#M:W1>/VI\=C&;FA;9XY#S][GP]-WY
M_8Z+S^\R5R8I=?,H9(LSU
M,?9\K]+D>.6,U43$DDV%J1+4":DDF)!)54Q(*A;)*F-1X^7I]><[K5@
M
M                                   '@6Q08Y<2;<EX"$B*<,V6.I;W
M)^</J_@\EX[63U\]9V]'/:^[MO.[6C]3A8O<Y['-AL,]*ZU>K]6_)_?W6'M)
M"ZT69E3(F-*P                                      #A>WI<ZVM(
M351,22386I$M0)J228D$E53$@J%LDJ8TG2-+>[KK;@
M
M                       &+/8QRXDR9L2!$"XTXV/3#G^]QM.WN1D/+;C'
M/3-[CYKSVN>=?@L4W&,HPSV/5Z/TU\K]]ZXY4K2:27YDR_-?+H
M                            @YA[ZW&=[GR@FJB8DDFPM2):@34DDQ()
M*JF)!4+9)4QQN+ZPYG8SLR
M
M    QA<E@N-,<;NGH2! 6",2W'>NG\Y?3_%1EY;!I=+5M[FXOU\+_#TW?F=C
MKW(^FS'CN2@P2X(RYDD\S%GJ
M "V3CNUI\TW-%+)))))*2"5FR99!-2B6220354"214DJ38];8^H-+I
M
M                                    "V/ I7'F),BFS$@  AB91&&]
M]+YL^H^$G'T^I/EOO*,7I,O6>R*K)M\#2%R)DC()@0
M                  #R/,P.?GR78U+#T\O<               [CJ;W0?/V
M
M                                           Q)=EBN/,,FX&1)  (
M)8Q+1+I/0X_,^CQ._P#"^O\ 3&S?29@6%&GGDN5,@GH4ET
M                      #R+HDU8R!F0
M
M                               "W+8J+$QJXLW5+X    I!4  4&LKB
M3,)D"]+(RX                                      -6,@9D
M
M                                                     &-/8\"R
M7&F+-Q3)DD@     \S55Q9F#(I=GB7Q[
M           U8R!F0
M
M                ##%\6Y8E@8<SILIZ@D   @@L#4"HRQ>%Z05EZ
M                                :L9 S(
M
M                                     !!AR_+8M"S7&%FF>,\7A(!!
M)28DUTL%RI?I>%V4@R                                        -6
M,@9D
M
M    %)B"^/(MEMBT2P+$J+L]RH\BW+4]3)%XMR7:>YXGH7X
M                          !JQD#,@
M
M                                  QA)[G@>!XG@>1Y'F4GH>AZGJ>Q
M<'N>I8E^7(                                        -6,@9D
M
M                                                          MB
MS/8]#S/(H*"""2HK/0]3T+,J,D2
M        :L9 S(
M
M                !:EJ4%R>Q20025 M2DK,@5
M                    &K&0,R
M
M                              "W+4DNST+4\BHO"L
M                             &K&0,R
M
M
M                            :L9 S(
M
M
M                          !JQD#,@
M
M
M                         &K&0,R
M
M
M                        :L9 S(
M
M
M                      !JQD#,@
M                                                    ^<YE!6=E
M8CA#+)'3$UHU)9.T,=:7EB_0UQS)Q"7!+]&7'#GSC,NY,=072EH-G3>CD:T&
MZ)V6SYPF7T)<;LYI+S-:#I"=2LY_+RA?4W9-97K;'!K@3L-@
M                                                     U8R!F0
M
M                      ?+<R^F+CK4<69=L8\K9?0-QDX5+O)@RS/<TM=S
M3IUG YEA#ZGN/)I=:7T.]7'F4N(.Q6?*TR^EKCD3YBF7T#<?GN9?2]QI/F29
M?4-QI/EN9?2EQ^<9E],W'(%B:A+H"X0[[<<T
M                                         #5C(&9
M
M          !\MS+Z8N-P?*&.7T+<>!3+9:[7<>2RZVN-/I2X\YE]SG"])3W.
M2K]3W'YHF7T#<?FR9?4-QYU+B#JMGS',OJNXCYYF74V/#F7TO<<-'$F7TG<1
M\PS+K"<Y7MUQXA,LZG;[/FB9;(G=+
M                                   -6,@9D
M
M    'RW,OI>XZ1+S1>PL>5LOH*XCA4N\G/5WM,*9,T==6/IVX_,TR^A[C\\3
M+9# G7TM#$'8K/E3'+Z0RQOSYFF7TG<?F^9?25Q'S),OIVXVQ\W3+Z6N/S1,
MOH^XXV.5,OH.X\4EV4Z-8
M                          !JQD#,@
M                                                        X/+C
M%RZ==LMCB<RJ.DIB#;$J-"782_)-,.TV<"F6]I4= LTV-578S&G2[-(EY.HZ
M:G0K.#RXI=R3*'-5]3K3'<JTB7E*^1T).H6<NESJ;I0                H
M+$@@@O4K6V3P6H'L7@
M!JQD#,@
M
M         MRS*B[/,H*2""2HK2M82U6HR*2
M               6)96:7Z^.LY871D"  2    " "0" 2"  "2 2    %
M@$@$ D @() ! !*B"002@   $ $@      &1Q].E>/N
M                                                    !28T]#V/
M$\3R/,H*2"2LK/4]3V/4LD]UO@
M      6:<>V-;@VWH8[+  22+ *@ 2  52@"0*D$P  ) ) ) )42 230$@")
M)(H23 @D$@ J )) ))% 2A F0$@%0 ))%H$@%OC?J3F]7><?0
M                                                         "V+
M,O$\%MRV/ I+@]CV*CR/(MSR/8N"X+@);+DR0
M                 8#+#Y2WN;J?KX205@7 "H$D@J) $SJ()))%"2J()))
M))))!(!*B20"JA))()@234@3*22222"H$L9) ))922*$DH!,LDD@$DDD@%5"
M20"AA5K[?UOH]'U
M                       +,\CU+8M"U/8OR"S+6/(@K/:KPNBW+ ]"[+HN
M#'F3*@                                        8FX_'G0Y6"]/%5
M1(8 2222"HD ,ZB"8DD4)*I8))) ))))!4 %$D@%5"2221 DFI)(F4DDDDD%
M0)8R2 22RDD4))""99)) )))) *J$D@!,;E.T<SJ=E\O<
M                                                    69YE9:%D
M>1DSP,84@   %R9,MRS+PNR[,<90D
M         './3P^4NCR8LK  *@22"HD DD@J@2*D%3*"28D"I)))!5 !1)(!
M50DDDD0))J21*))))(*@2DDA1)))(H22 3$DD@$DDD@DFA)("S+&>&)U=GZZ
MT>CEU
M           'B61[%F6))?&,/,      O"Z,879>EVF.7)
M                           @^.>AR=4]M>L  J!)(*B0"22"J!(J05,H
M))B0*DDDD%4 %$D@%5"2221 DFI)$HDDDD@J!*22%$DDDBA)(!,222 2222"
M2:$D@+,R986^#;M3?^E-;;
M                            &)+PLBP!=F/( ,;[:M_Y;%<R %%QKF0
M'J7IC2\+\]2T+T  T<]B^+$@P1L)GS(',S?S6CU-B.<FUF,-W.4G5S0#9S5C
M$F[FL%J=#.=&2+HVDULW,YR>!OAK!48\WDYV7!MII1L98&.-U-;+$V UHVTP
M1Z&^          'SOM:'%]S0K  *@22"HD DD@J@2*D%3*"28D"I)))!5 !1
M)(!50DDDD0))J21*))))(*@2DDA1)))(H22 3$DD@$DDD@DFA)(!*2LVX/#+
MZ<YO4WC',                                    #E!U YN;V<M,D;
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M)) )B220"2220230DD DDFK-.D\[I=[\=D
M          #G!H9TDTDZ@9,YT;,5&K&K'9CC)ULX\?01!H99'2CEYLX.8&T&
MTG%#JII1W(X0=O.:FRFVF-.2'L=0+DY@;,;N8HY$;L6IIAV<Y"69W<YN;$;6
M"#%EP6!CR_/(@ &A]7@9C7W-DTNF .,?2?$[]R?H=IT>J  !Z'@#(%Z8LO@
M<A+DV4Y>;4;D:^9DPA9&&,L9(U\NS+$&F&Q&Q&J&).X')S>35C+%H:\0=B..
MG8P<>-]-1+,Z,<G-@-H-/,J6QX%F=$.>E)T<U0\3V-G.4G<@         #AF
MSI<'W>=6  5 DD%1(!))!5 D5(*F4$DQ(%2222"J "B20"JA)))(@234DB42
M22205 E))"B22210DD F))) ))))!)-"20"208C#T^N^;U<K*
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MQ@         'RYN\SG>SJ5@ %0))!42 22050)%2"IE!),2!4DDD@J@ HDD
MJH2222($DU)(E$DDDD%0)220HDDDD4)) )B220"2220230DD E5QL)EUKG]'
MM_CL                                     #@9U\Y(;R:(9LW<Y65G
M4SE1W(X.=+./'6C)&DG80<O-D.8'7CE9MY;ER: ?0!PD[><U-E-L,<<D/<LS
M>3FY<';3@Y]!FAGD:P0;.98YV;$;&;6#&'N6!C2^/0  QWKK<P[?S'8/G_L
M!S;L?-:WN<WMOS?VXTGI<2]\O;:=+J@ "Q*S)%R8@NP
M                     #"7#X\Z?&\LL:P "H$D@J) ))(*H$BI!4R@DF)
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M*22%$DDDBA)(!,222 2222"2:$D@$W+$^;OO/Z?4\/4
M                                                61Z):+C#S,Q$
M@&,]M;1.GP]5WN7<X>F>U=X:3TN-NW-[/,NS\ULVGT]GTNE19H?4X6]\ON09
MS7W=ZYO;2@6M8PR!D3'$                                      $'
M"]G2XUN<^4BJB0 5 DD%1(!))!,2214DDLA),"14@J!)5 !1)(!50DDDD1()
MJ03!9)) *@2DDA1)))(H22 3$DD@$DDD@DFA))(**N-3;^LM/?K
M                                                        !C2Z
M+ Q9Z&9@ <9^@^/WSF]S1NCQ<[K;NX:'7U?=YFO;6AT7D_0?/GU7P/1N3]%O
MO+[FO[6AH_2XO6.']36O,NQ\WT;D_0Y[5W@/ PE7IDRT+4
M                       &(N/!]S1YWL:4@()% 5  D%0!$ 5 !9)#*0 "
MH D D  $D@ D5)(@230D0!4 "0"20"022  "02202"220 %DD5(+3!]0\[K;
MUCZ
M         6I*8]<671F4 '#_ *+XWM_SOV7-NM\]>8>N_<SN<^Z?"5T'E]WY
MW^I^"W_F=SI/)^AUC<YW/.IP.U?/_8#0>GP[C#TW;G]@#S-<6\,F4&*
M                              !!;GJ>%QYA[Z\W&^2  2*     0
M (42  ""0     0"2*D" (H! $@        @D$$@ @D  @ $T!EO/TZ]X[$@
M
M      M3'F++TS8 ."?2?$=S^=^SQGMKVV7GLFKT-!Z7#\LL>A\OO8;WT[[S
M][O#UM\O/2>AR,WK[>"V=/7=KG[1I]+>N=V@*#52],F7QZ@
M                        U8R!F0
M
M                           "@\$QZXLO(V&@!\Y?4_!:?O<KVQRVC3Z6
M^\WM;+J]'.:^WD?+8'AEAJVWSM#Z7$T#I</%>^L!]"?,?=;YSNT!Y&H%^9,N
MBY0                                   "R/ U+T\N=^OA<%\
M         =*\-G9<?0
M                                                           #
M'%P8\QA6;2 #YR^H^"TOH<@ "ZP]+SS]H2Q]/'PSP  'T3\O]WO'/[(%J:D9
M,R909,                                     @T'T\?G_<T-=]O%$@
MDD$D@$U,"14B)) )))!*JE"DW_5V_I/3Z            \L6 Y.Y3Y9@!ECG
M>QIW.<
M                                QQ=)8+C"S-T) /G3ZCX+2>AR
M!M6ET\IY;&E[_)M<_(?17R_WF[\_L 8HUXRIDCQ,F
M                   6J?.F[H:#L:L@FJB8DDFPM2):@34DDQ()*JF)!4+9
M)4QQN-^N>9U\I,@         !!RG\T^GL.'O9?O\\ 4XW&:.QU[]7^1]J
M
M                      'B6Q08PQ1MY=@'!/I/B>R<'ZS%^VMS#K_.\\Z?
M"\\L0!GM;=[/P?K=[YW9E;//QYEUOGN4]GYKOGSGVVYZ'6 U@M#*F1/ OP
M                                    6Z?+V_S=8]O 351,22386I$M
M0)J228D$E53$@J%LDJ8^9T[1WNXZ^X          -4XF]S_\Y^DR>]X=#_1_
MFO?UPQFAL :)\-WMA^BYN]_6\@ #5<L,/<<S,MGQST//R\R\6[EQ%QRLRVG'
M/3,_/=\/3Q34,L,I,M>RP&R8YV5FUXY^)J>7GZ+G<<K.SS-AF0
M                                                           &
M+/8QQBC(FQ@'!_H_B^U<#ZZ\\_6I<1[:ND=#CX?WU?279=3H[QS^QZS( #G7
M4X.2\=C<]'K"@T<R)DC(%B9$
M   U//S^7>ERH2:J)B22;"U(EJ!-223$@DJJ8D%0MDE3&H\//T^O.;UO0
M      'C'(/R3Z_?OTKYGG/Y9]7NOZ+\W[>F./U/8#RPNL? ?0]@_8_C+[VP
M 'R%M\[W71_3R^G]3?\ DC<YW;?#:SF.?./77OL<]/\ 3Q^B-7?^/M_E?=/.
MZ^C^GE\][.EUKQV=-S\MQP]=[\O?B^QJ?8VGT<$GQUO<OOFMN\U]?#5,_/ZF
MU-_=<?0
M6A['J "T+L   %H78       !C2Y+ QIC#>#U!POZ'XWJ/(^CO?/UN</2I8*
M;   *4'+>Q\YNFAUMNTNH,"80RQDBD]CU          !!(  ()     !!(
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MD9EBW,X84Y^=K,(:.98W4YD7IT(T<M#I!QH^@SAIT8YR=#-S
M  .);6GR+;T9JHF)))L+4B6H$U)),2"2JIB05"V25,:@9'7V/JC1Z0
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MA:D2U FI))B0255,2"H6R2IC4267GG]B\WK@        :;\SU,7RMKHWW?!
MUWE[7/OSOZ.O*;Q]YP-H[6D!I7R_4QW-VNC?=<$#Y(V]#2\_+S3[ T^E\4;O
M+VG'TVC#UM[C]!:VYP#9T^E^.SP39TOMG1Z?B?&VYS>F^?OQ_P!M;+3+MNON
M?,VWSMLP]>@^.QH/MK[QY^VZ8>FE9^6[>?MVWRV
M                             .9%N;,7YKQ9'@9<RQJYF#Q/<N#$%\5'
MF88V\UP\3=BLTT@\3/E1BRW,T:X;F:Z9HP!LQGP#Q+,K+$QQB3=2_
M!!JAC3,%^7J8M;X  Y89TU4M39CHAR(Z$:R>!F30SH1IA='0#FAUTXT98R!B
MS.FJG8#0#5CLAR8ZJ<\,>; :,9DW$U4M3:#7"T.@F$.=G3RHYV=#-R
M        .*[6GR7;T9JHF)))L+4B6H$U)),2"2JIB05"V25,:BDWS3W>_P"K
MN@        8S6]>4_E/UG2OU3Y/+;'G:896^%&"T-C2OS3Z??_T+YW;_ *'G
M41R/\J^LWS]!^>V/JZ@'B>9<%1;$%14>A24E)< MRL\@>QX@K!![E)YGN
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M-!:EXLE1C4R:XU,HOD06R>@/918)?K)XIZ+;)>K4
M                                                   #$%\6I9%B
M8<RYM)[     &+-1/8RA>EZ>18ER
M        #6,_/YJZ7*)-5$Q))-A:D2U FI))B0255,2"H6R2IC47_A[_ %5H
M=,         "VQO'_P <^SS?W/!N]GS N<\?7*:G\7V]K^QXVF? _0=6_5OD
MLGL^8 YAEAG9?8M#SL]I=QF7+LO/;YEJ%G0,<N19^?8\/3DN?GN^.>,2Z-CF
M6#L\K/"7?9EJEQMC.RZCECNF.644
M                                       08@ORV+0LS&E@9PSY?$@
M'F8<UTMC+%Z7A='F8LN@
M>"?.&_S==]O 351,22386I$M0)J228D$E53$@J%LDJ8^!VGG]'K/CL@
M    #3OGNCHWP/T&[?H/SH&1W?&]V/+2?CNUKWQO:VS[CA=!^TX@ &JW',2U
MEJ27)?KBTN#5K-MF6)LOXM2Y+Y<)9Z1;V7THR:X]+*KF,59GY;I0
M
M   (,27B>:VQ;%J6)CR"[/8D\RW+<N3(EV7)=%R61CBX
M                        !;IP;=T-,V-60351,22386I$M0)J228D$E53
M$@J%LDJ8V6&7U]S.O=*          *8Y)^7?59+IZUSL>8 QO.V,9P>AU_\
M9/B[C*
M                                   8X'N>!X'@>)Y%!Y$%9Z'H>I[G
MN>Y684\D]0                                       "#2O3RXCN:&
M$]O%$@DD$@D$TB02*1)(!)(!(J25)T[3W?H?5W@          !:^>6%^?Z$X
M9 "+,IWM#(;'F
M                                          !XEB>B>Z^1Y%!00025
M%9Z'J5F.,>>X                                       !;E1A<_/0
M_7QNDOP              #H_CL9_',
M
M                "W+4@K+DI( *BE+9167Y(
M                  !JQD#,@
M
M                             \2T/$&22W/(]2[*@
M                          06)YFG^GER#8U?.XW(              !V
M/6W-Z\_8              1(AEDQBA-
M
M  8T]"]                                              !A+CP#<
MT>?;.I,2HDDD))(6JQ+)(J42R22"JD222*DE2;)K;'U%I=(
M >:XGWU49CQ]V.4V3:
M                                                ,29 K
M                                        !!PW:T^/[>C4":J)B22;
M"U(EJ!-223$@DJJ8D%0MDE3'&Q]5<SK['CF            ((1&,]O#YH^N^
M9IRQ^E_D/I\KK;3/ RJ   !!  ))
M                                                  !C2Z/0
M                                            %)\W[NAH.QJ":J)B
M22;"U(EJ!-223$@DJJ8D%0MDE3&#>M/<^@M7>           $2I/'#'C_"X=
MEACUKZ/K?._V7ST2?17ROT_!NQH^.,^C.)TKIE/F>DC!K.WYX[+SV[7V+G"X
M;TQYCN:G4-3=T+9T<MAL;[J^LI,JH)B+1.)9%JPJ8I3*6,6)DDFU9"DJ4#"F
MIG1@
M           "DQ9D
M      86X_)W3Y-%QFJB8DDFPM2):@34DDQ()*JF)!4+9)4QJ+##+Z]YG7NU
M          %)'G<1H>=OAK?/7S_S-'AK_0GU_P!9E^CL:KMZ=?EZ?)OTG)IO
MI]A_,=G9=;V4EM,L?CSZCBX/;\OK/Y?J[OH[?,>EI?,_?YGV9\QV_DWZ+E]6
MY^WW/B[\Q,*2LD8Q2Y2BX1Y9KC,L>F282L8)],6.<5,D>F$S.L P9K9T
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MR;IY,1,NPZ&SP_HZ6WX9<^V//9/+W[7RMWTE5BRP-C
M                         ,679XE@5&0->+$R)Z&<,*9 U@SA[GN6)D3$
M&>, 80W@YZ;Z8DR);%P8TR)461Y&.,T7!E      616            <>.I'
M/#(&KG83EYBSV.FF1.7G4CCAFB^-/.C&B&V&]G.BR,87AF3%&\G,3-&1-*/4
MW0UTLC=36#>3EQ6;,2;\7@               !QK9U.-;FA-5$Q))-A:D2U
MFI))B0255,2"H6R2IC425>/M];<_J         "G!3@H\6!XEN.QK<GXW)W#
MH[/0>OUHN%GEA=2VE\XRNC^\Y1T=3O'(V=F\=GS3Y(^DXW5>;N\YW]7.^?M]
M(_/]+YS^@YFH;.M]+<'J_'?U'&^J?G.IR[>\=6V=?KO/VOG?MZ7U5\YT_G'N
M\[#9X;AK>W5.=L?//=T.N\S:U;VQT?>U?J_YKK<;Z.MIN]K=8YNUQ;JZ6T^'
MO]%\'H_(7U/&VS2V+Z71M[Q^QOE.SL7AZ2LT
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M!.N&E&#+DDSQJAMII1[FZ&I%V7AKQ[FV&FFZ&MEN9TUDZ&9@
M    X=M:7+=O2FJB8DDFPM2):@34DDQ()*JF)!4+9)4QJ/,Z;H[_ '#7VP
M      !3BIQOEX3 \#._[^IS3D<G;-_;W3I]*)<9Z87OGCY^TGS]-0V];F6[
MX]JY>YF//T^6/H>1I6WX>GEZ>?KAZ6?9_P KV?DGZ3D]"T=G/ZOKP7O\SZZ^
M6['QW]3Q^EZ.SO6CM]#U-B<7QG]5Q?J?YKJ]!TMGY>^EY&)D^J.'TOG?JZ7/
MNKJ?6'S/8^0OIN+]._/=C>M3V^._I>+UOG[63\<^&=OG_:'R7;Y'U-3A/7T?
MM/Y3MW&.8JH
M         :\88W4]0        619GJ
M                   "D^8.AS,!Z^$U43$DDV%J1+4":DDF)!)54Q(*A;)*
MF-1C,;]:<SKYB9          #R\&#XV6N<;PR?2F#W.=:1TWK]'4.CK\ZZW*
MW/G=+7\[Y+VCG;?OY^NH;6O\E?1<CZNX/2VS1]]!Z&M\O?0<_P"M?F^I\K][
MF=VY.]@_3#GO3U/KKYGM_)GT7)M_3SV7P],5X9]WT-KY4^BYGV'\OV-CU??F
M'5TOF[N\V[ULKGW\\GK>_P!8?/\ 4^/?HN7.?EE?#UU#HZ?T=\_V-3]O#0M[
MQ^O_ )GL?/W8T-"W]7ZR^9['A65PM;(
M                                        :\7
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M&Y,_A?10
M                !:&&/<
M          &-N/S9T>9C<_(351,22386I$M0)J228D$E53$@J%LDJ8VD=^Y_
M3Z1Y>X           8HKRF/*>%Q[+##I_P!%T?F_ZW@L_/Z2^5^FXIT];SM[
M]QMZXF3$J"42JB%$,DC*&4R"(4Q3D\L\?F?K\[GO1U(K:-;V^F^)TL[K^PA0
MN*#))-13"LI-(F@
M                        ,>88]P
M                 8?+'@&_S,'Z>4@FJB8DDFPM2):@34DDQ()*JF)!4+9)
M4Q\?+T^O>=UO0            %*42DLO3Q^:OL/EIQ]/I+Y'Z6_\_6<;.=K
M        !1+3ECC\L?*XY3'*KS]/3*
M                                               "V,(6Y[
M                                        M$Y=[ZO(=S1MLL"B0$D
MD E0)%B60"0"02 ":[/I;_>-;<             ID8TE-MA[^,R7_G[,3)6H
M         "2"!1$57(
M                                    6IC"W+DD
M                           MCU,;EAK&6%X90               VC#U
MR$H               0I"@          @* 0H
M
M                                          :L9 S(
M
M
M                                        !JQD#,@
M
M
M                                       &K&0,R
M
M
M                                      :L9 S(
M
M
M                                    !JQD#,@
M
M
M                                   &K&0,R
M
M
M                                  8$O#)
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1_;L$\K%S%\/]%C8K'@0BO-)CRBW?.Q>'D-C^<7UY193<CMFY16AI*Z7Q9*
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MF(A]65HC-4I:9),LE<MKUD5"HR<2=2LK*BWK2,W6%PVGOU-G)Q2BJDI(TM2
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MZ/)O-/K<O^!R:@.4*%%<H*-7%'*?Z2K9-93]"2><54$\ A02@,:B2;4E:$_
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M,4&(#$!T:&!V8H59"I)5PD"SIA2=(.>)@TZ#S:M09XY7!6IC!-J4H*F"D!2
MI0NN1L6A3*G_ $(C_-<8=.*-6]LMJ.1;BM6,K>'\[VX7"C2%8<MCK2+2K\7?
MX7_Y5!ANX#F&[MMF:I;3L\M-):E#(VA6N]B4*.I2U76@>,_Y.5L[]]T+5<.K
MG8E1;QCO>L!(Q<B_69[@J']A<<PG#Q1C5.;ZS-7A+:$56:F?KNM.*E4CM0FH
M1:E2"I!5,53%4Q5'(JV(-F0;(@HT(*-RT%$Q1,43%""A!0H6>XJ1/\WZ,DBK
M#2_5C;3FI4SB';6J55O(L:P;VZ5*+&E66]B+5>:J%-6W952[&]$[F4JM&_\
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M"8'2$P.D)@=(3 Z0F!TA,#I"8'2$P.D)<=(2XZ0F!TA,#I"8'2$P.D)@=(3
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MZJ\?E+4U4R4M^/CXA63#VWUFR+5S5JYE9=Q'O&+Q-^W]6 K0)UP"5!?:$?\
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MTD@NK&'AC7*DC1W./'E$6RSH[FWUFC0,8-X^!8EA%B5F32 L5KQN1@*?L_\
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MPE;4=4>0+-1A%AY7A!PH% QKA?US47259OHY>/5]4"Q)6DI*J2:[5L9XXD9
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MR6FR)5!!-JG(0#>27Z09A_$(R#=L@5JW;0+=H^<VHT64CH)K&G^5OMY1U/\
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MB)4Y!JL8&>(%JFNFL#G*F7?-ZBE:&H<Y4R[YL$UB+4WS<$5(K2M<"DDT,?\
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M@Q@7^ZU9>T&='<W2E,>D#AY)0)_\?;JI]57T?L:(QE1>9"EN#T?H:DW?:G!
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MV-)FQI,V-)FQI,V-)FQI,V-)FPB4Y)_L.3__Q !$$0 ! P," @@#! @$! <
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M?B6X6OJ-^);A:^HWXEN%KZC?B6X6OJ-^);A:^HWXEN%KZC?B78\+)HY*5&E
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M9R28PV\*\"_\GL3+'9L8F'/@Y2IX8]5L?2I'ROD:6NIM$]T3GN+A3;E2_?\
M7LZ)K[L(RX@.-=QG>).-^2L;'F\]IH3QFBAF=)*'/;4T(]RM,,9<6W2:N5H\
M?V*U>(K1X_LV'2-W0[5O.G6JU2ONN.%,W)DT,Q,5"'-=FGM&M+M/>K'._ .
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MDVH3)XH@YCA4;<*Y?EL\C>\)P0FI=D!NO XU>I?G?@QOM5VLEID/>\ ]RO:
M.Y&O%51KG70=M"_+_A1VB+5>.A6GDN_VA6.N.TV!%#0VEXKCWHXT::2TOX2X
MX!%Y@O@> ZJ:'/=+9^&-Q]29+&;S'BH*['L]'6DC$GO$::2U/X23@%70M=R!
MX4%EETK&/==,4GL45M;EN;_8I+$\_P!<?M"EE!I(=HSG4;36XTWWGD^HZ'RI
MO.?YO'S_ $RM7_V'?W*2(8-K>C/(HY?X@VKQRI__ -C_ ';$1. #PM^V?\4(
MF&5DP&98ZJL'W_\ :K5XX]6PW[(>U0<[O6K5]W^T*Q^(H61.#W1MH\CU*:0Z
MKY,%*WO8@&!1R4[I-MW'U;$%H:*:4$.YPK5#P,<'#R_^E:ON_P!H5C\38M4A
M\,@<PP4$;11Q;>=RG8)8*-E;I/+PIQ?E YP\F:J<99W^<ID$0HUO#QGCV&DM
M!+<B>!2P2:KQ1"N$L#^E0QQ.K"Q@=Y2M*\=UGVQYN#ZCH?*F\Y_F\?/],K7_
M /8=_<M.P=U@QYV\*$;CW*?:GGX$_P#^R?[MAK!WQHM\0^=3"21LAD(U58/O
M_P"U6KQQZM@?9#VJ#G=ZU:ON_P!H0M#(G/@(KM7<',F"VEXA/"WVIK(VAL;1
M0 *V?:%6.G^F-BQMX:N/J5M=P4:/6K5]W^T*Q^)L2@YWBHR,BT;$ X1%[2OV
MC3OKX'45C<[(2M]:GC8:/?&YH/+1/D?&VZP%QVX5DH:;>FQ';F#/:/\ 85'$
M=S;MW\W\MVITAXF8K""@XW/6VE#?$"QGE69//L;JYO,L+0_RT1U9?,NZ0/;S
M;9;1X<?HQ#Y4WG/\W#FQT<.'Z96O_P"P[^[8>QN$3MO'S*-[L7.E!/3L1$X"
M^%ORS_BA78K1%([B8\%03@5$3J'R_P#I2Q3NN12TV_$5I'6J*YQWPI)F[GJM
MYE9HG8.#:D<^*M7W?[0K'XB?=%(I=NWVIK'&LD&T/-P+3TVDXSY0NP[3((KI
MVCW94XE??:H@WQPK[,(6"ZROK0+Q228WR.(<"M7W?[0K*R2U1,>&XM+D(XK5
M%(\Y-:[%3X;20Z1IYU'9[1*V*:,7=N:!PX$7R6F.G$'5)3Y[IVV#&\BA@>-O
M2K^<J2$Y U8>,<"9':I!#:!@2_)W+56D=DQ5=$X !XQP5C^T&P?M&J;[$^L?
MRJKS1=R9=;X3_<NZN,I_JR6  YOW6V8%W.2\/!D5V5NB=RY=/T6A\J;SGZJ9
MIVR0Z-\I?B37/FV RMR9AJQQ43Y)8=&UP)NDD^K8-V: MX*D^Y;K9^L[W*.T
M2R1%C0<&$URYDZ.1H>QPH0476.9I9X$F86K&.4O39K4\3R-Q#!JCW[$MIA?%
M<?3!Q-<J<2@L[R'.8VA(3!&6MFC-6EWG3WROBT3FT+6DHPSMO,/2$>QYF2LX
MGX%8MC;REZ;+:GB=XR8-7_G8DM,,L0:^F#R1P4XENMGZSO<H;1++"6,QVA-<
MN9:.88C5>,VKN,D<S>J5B(F<I>A-*[3SC(TP;L7)VXC5>,VKN$L<K?ZMJ5B(
MV\[U':)YP]S#4,8,.G8,$3FM?>!VV2DFG?&067 &'E'N_E%3@%2 ;7_4=DKS
MMO)X1_?T(!KQJL!VO@.R5W4>,VGZ*0^5-YS]>E7'F'&KT^#>"/WK#M<!59+6
M"UEK+!ZXUB.VQ&VX'(-GRX)/?]$X?*F\Y^O.FL\ZK5I)3>D/0.UR6V*PQ6U:
MLUK+6*S7&MLU<"VA\BVP[0@BH*QVT']JJ/HC#Y4WG/UY<;CJMXUI)#>E.?:8
M*KLU1@6)_=<85'*K<NTQ7' X]7Z(P^5-YS]>)<[(+32:YR;X(7LV>14&:Q_?
M4*JW-4.?::%V+#J.]GT0A\J;SGZ\:_PHSARGM,<E=;\RJ,U0[-T^0JZ_=&X'
MZ'P^5-YS]>#8V:[\.9!K<AL\BH/FE1GVC9VC5P?RA5&7T.A\J;SGZ\'SYXT;
MS=IR_O*7AT_NKVSCBC [O-7E'T+P@#AXZ[I$^/EI4+?</E>%%=M,)SR>$ ;5
M"#4YR!;[@_$"WW!^(%ON#\0+?<'X@6^X/Q M]P?B!;[@_$"WW!^(%ON#\0+?
M<'X@6^X/Q M]P?B!;[@_$"WW!^(%ON#\0+?<'X@6^X/Q M]P?B!;[@_$"WW!
M^(%ON#\0+?<'X@6^X/Q M]P?B!;[@_$"WW!^(%ON#\0+?<'X@6^X/Q M]P?B
M!;[@_$"O1O;(WC::_6?<&M(;H0:-F\>WJ30)TQ-]N6U7<H.LNRXV777KJVT_
M0%-:))"YSC1M4.Z/))XU9X&OO3ENV=Q(7WZ2,G&H4<LFJ]5BD#^VHJ;,<_%M
M7<WT-I:+,U_+D4Z7]GO,S/\ 2?K(LDC<Q[<VNP(62R62R6JM5:JU5JK56JM5
M:JU5JK56JM5:JU5JK56HM1:BU%J+46HM1:BG_9\AQ;MV#U_6>?\ IT\_:#MJ
M5TDG@A8ES(_!8K58B=N[;,JKLC"UW*I[#C>;MV*]:YV0,X1PJ.S6;<8\&\J;
M:+1W6TD5;'Q)TLF;E'$.$H1,-60"Z$'1/+2M%+M9AZ7;5V7,X"*)M<Q@?H<;
MPT<XU96HP6AM#P.X'?/[/:FY5Q":]AO-<*@_6;5&2NZ&]^XY$;/9CM^^=Q*3
M]H6PWV#)IX2J-LL0C\&B9^TS!HYCJL&2I;+.R6/C Q"=:/V>"W2/I5V859'N
M>>4J($;5NV*E?P5H.1!M*DHR2;\F&U'$$Z2^UC>%SBC*QS9HQX"9,,VFJAM+
M#>@D;DFRQFH/:'M)65P(OCZ'NBD&W[Q_@E/L\PH]GSX\:T+S62S[7R<'UFR'
MDH@T9 ?N-!$:2OSY$9YWZ"#A>[A5+*\R-B?GL6>(,N:)M%5"]GI46UNQLUG<
M2=9K *DX/EXU=B87N5^2D]M.3>!J,LSJN5.!:&O<WMH6J5K=4.3[,\ALT.2D
MK-&^,C)I_<1.\(%GT0[+B;W:$8\K?G[ XTAFVIXOK-C;X4C1V@[2\30)KFVJ
MKCFQHJC -I%%@U@3[/9@XL=F GFU6@"T4VL;>#8;"W,YGD4=BAW&'#G*JW"2
M=U+W(F0MSX3Q)UDL  <,'R\:X7D\:K:6A]KFU6>"-B7]HOVKB+L83[?;B[17
MJ!O&H;;92Z2Q28%,E@<1')22G(HY/";7MVN\%P^B#FG$$4*GL_ TU',<?GPD
M&;5#,3635?S_ %9:6.T3"*3%M'G \2%J<0VZ.Z<A&:HR>6*,NK1KB+K4^>35
M;P<:+(2\#P(S0 <JTS7R$#.X^]YE9IP]T4DA9>N&G I#+(Z0B4BKC7@"M3FF
MZX1.((YE,V6:21NCK1[J\(4+(IY(FZ.M&.IPID\=HE<US;P&G-4RS6MQD:]U
MRKM9IV8613R1-T=:,=3A3)633%CQ>'=_^5:8;7,]LK]1VDJ6X<:T=KE>65T;
MP]U:<JHQU)I=JVG!QE26J>:1[';5C7N)\JDCCM$L;&@4:QQ' GV:T/+Y&[9C
MG9D*(Q2.C)DH2PTX"H'R/+W8[9QJ<]B+D?7]PV!AH7YTXDR=N;5IIK*3/PM&
M16BL<;;+'R9H6S]HUD>_4C/"KK_V>RYQ53[98VEKI]J*]ZJJ.RT%&<*C+\ =
MJI(V1%V.MP+23$3VSO6#O4Z65U2<5IY^Y65N+G.X5<BVMGCP8U1_:(Q/8)H2
M:W3QIE1=J0QHXEV&#W6*,5V7=H1RCU]I)9HK.V2Z:#.I44;[#=8YU"ZZ[!"S
MQ0MDP&:'9-@N-/&"U=DQ:M":%3-DC8RX*BZI+-#9VR7309DE,:[]G$-)H3<<
MHFQQM??!.V5^6P49QT<$0WN<HS85$V.-K[X)VR#YK!=CXR'!:2/:D8.:>!21
M0V5LETD4 )*CCEL!CC<<77'"BCLS8V.8;M2<\4Z:4T8U'L2QWFC^DN/F4D$T
M.AF8*J2S.C8UC;U",\%+.T!SF#(ITLC6L(?=VJF;I2^SB]AP4X$;+8H=-(#0
MDXX\RCLULLFBTF3J$;+@R%AA#L.,A->TU:X5"?6PT:WA+7(Z.QMDIX()3)9H
MM#(:[52PPQ1N8PW:N44X[]M4UFA8Z!PJ#P\J-KK>CNWAR\2GFDB8R-FK=X2I
MFR1L9<%1=4LYQN# <94<,T;&-?A5O'_)891W\>/SZBEL#SM)=6O']63XN_UF
M'E4UG:ZD<M+PYEIW;I/CS-X%98N!Q+C_ )Y5I.^E<:G89]J/45+]L?4%;/L7
M^I3?9>T*'[+VE01DO=(R,-+0WAHM.&49I=*\\ QK39A^R]I5GB>]]]D8:=KR
M+2P$EE:8A,MK._VK^?@5F@>^IH(P>()D48HQ@H%]Z/V*]'@ ;\?*.+V*R31Z
MCWU'05!SN]9[8]IHV-<\W<  K^APYT0ZSR8?TE&UVIER"(7MMA4ISW:O W@
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M<A\J;SG_ +7(?*F\Y_[7(?*F\Y_[7(?*F\Y^JFUM;:YF-;*YH:UY I57J_M
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M<R,5F:;S$R1]GN0D%KS>&2LO8T>DT=Z]B!G12,M#-&]TEZE:X4"9H&WIXW5
MKF.%1SVJ'1QQ[85(-3L6=S[/1C)&N+KXRJK/%98M(P$N?B!CP>U3/M#+DLAI
M2M<-@"%MZ:-UYHX^-.=-!HX7LHXEP\BB;9F:1S7U(K3@5I=:8M'? IB#L:6-
MPBM(%*G)W.L+.YW]49JL;._GD-$)[0X2V@9 :K=BTR10:2-\A<#?;PE;U_,;
M[TZ6T1:*/1D:P->A&T69PCG.LTY.6%FDKQQFOJ6V@+?ZI7+2..EM)[_@'-L:
M5CM#:?"X'<ZP@TG]49JL;-(?'/O79-H<P4:0&-QV('V:+2AK:'$!/CM#+CW2
M%U*UPH/Y'5Q '*NYATI_I"U6,'&<5MK2[[K0%NTQ^^J5)Y]C7>/%=1;6T2CG
M-4:2MDY'-7=(3_X\50/QXCA]&(?*F\Y^O?;''@ S6U&A;QN&*JXND=QO/[NZ
MX5"[E*[Q7XA4F88SX6;5A]$MJ8J<H*J;$^<?]!S?:0KL]AM\1_KC:/\ <H[D
M-I%VN;6^]!CH;43R-;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MP
MM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+
M<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\
M2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&
M_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]
M1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM
M?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<
M+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2
MW"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_
M$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1
MOQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?
M4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+
M7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W"U]1OQ+<+7U&_$MPM?4;\2W
M"U]1OQ+<+7U&_$MPM?4;\29 UEHC<_ &1HIZ_J.))H NY#1L_P!1W#S*N;^%
MSL_W^*K ZY_0<BKCVF.3B/T3NSPLE;Q/%4Z7]G.T+_\ 2<=JC#:8C%(./^8Y
MK/8SV<UFLUFLUFLUFLUFLUFLUFLUFLUFLUFLUFLUFLUFLUFLUFLUFLUFLUFL
MUFLUFLUFLUFLUK+66LFR,.(3:GNL>U</J,XW')HS*OSX\4? .VP!*XEKK669
M6#UF"L6]';4<*JDE7Q<$G%S_ $4,5IC!\%_"U7)-O"[4E'#])J)I)[BXT>$U
M[35IQ^HH-:+TKLFJ^\WY3F[M>(+;8\ZVHJL!1:RUBLRM8K.JVS5P*K"ML*=I
M0XA5;MH.%O@JH-1]$Y+-.VK7#H3[-+P8M=X0^DUX9A=@RN[HS5YOJ) :+TCM
M5JJ[;2'6=VF"J[-4:L37]UFJ."JSH[6\W<"<1X*J/HFZ5F^(!>;RCA'TGCGB
MPNFJCM$>3A]0]YRTLFZN\W)VE3DJ-6/[ZAQ"J,U0]H(SN3CM3Q<GT3(.15I@
M;J5OM\N/TF(78,SNY/RKP'ZA])_"8:-Y3Q]I4Y*C>UO/.)R:.% TI7@[6A<*
M]ORJAV2UV2,;]T9GR\O;=A:-FCO7;W"HFQQM??%=LG$MN2LUFJ"R-C:YC[M2
M<\2HFQQM??!.V6\/0<K/,(FZ23-KN#!0S$72]M:#8EAABC<QAI5RBG'?MJHF
MQQM>7@G;*1CV".5F-!PA23/U6"JBC= P,>X-P4;V,#W.=3;(P2QB-U*M+>%%
MSC0#$E;6SLT=<*G% K00QL?=&V+N-,FI==DX#@*EC98KS&F@===BJ1V1CS_2
M"5)):8>QRT\(I@M%8+/IN4@FOD0%LL=T'D+3YUV1$;S*51T-C$M/ !*$%K@T
M#B:5XN=1M$+'PN%:G/E1M5>Y7+ZE+XF,B9PMX]B2S0V=LETT&9)0[)L)8/*W
MUH2PFHX0<PI+,Z-C6"]0C/!=C01Z:?AKP*)EKL5QDC@V\&EJ=-*:,"/8=CO-
M'])=ZEHK=!H> N&%/(G3L:'FHI5:1MAOQ^$UKJ(Q.9HI@*TK4%"SQ0M?@#BJ
MVBP76\M6HNBP<-9AS"%GBA:_ '%?)I_#<H9&Q@O><0[@6E-@[EG?NNITIU&Z
M.1N;$;+8H=-(#0DXX\RCL]LLFBTF3J$?-K-.,G,NGZ3B5F!'"FU/=H\'#Z&.
MAM$<>C:_&@-;JTUX:*[>O<B;#''&(2:G#$-1FF.' !F2J6>)C!P"EXJ."UPC
M;N#;S10A0:$,)DK6^%%:)  ]U:W<LU-:(P"]E*7LLU/I@P:.E+@3[/$R(M:!
MB\%5?9HPWE8X>U&-S-%.!6E<"KTSL3DP9E-#(XV1%U*'$[$L$<<5QE*7@:Y<
MZW.#JGWK0RLC#;I-6 [$THUZ4;SJT6IQ/@#UGV*J?HF1:.NUJ#ETJ&?*^,1R
MJ:T- <Y@P!3!:(XM$3B6 U"J,0NPW,CT5]S<!CA5.AAA8Y@ -7-)6,4 ^Z?>
MMPBZA]ZLKHF,O2YWQEDHIY  ]U:W<L]B:48EC"[%/AF;&&AE[:CF4<4+8R"R
M\;X4$S@ Z1@<:(O>X-:,22KEB:' ?Q'C/F0FENW[Q&U4&A8QU^M2\+<X.J?>
MHF&.&CG 8 ^]::)K7/+@W;9*K+/$X<88[WH-M<+6M\./@\B!&(*BT0:97GON
M)"SVAL8O#:EHX=AMI8=:DGO";(W%KA4=HV%IHY_#Q!!HR&SR*@[4N=@ G3NW
M&'5':NE?Y%V1*XTCQ_<5&?:-G;FS/E"!&1[7_P OL5EYBO\ H._L*L9&([G_
M '*S>*4QI>ZH%-568C(O]BLOB*:8]XVOE5NG=C([4/-B5+9SG&;PYBK-XI37
M912X^1W_ "HK*W6D-2.16"'P1'7GKBK/X_L7[-MC<G1L/0,?,J,.,^ YE8 =
M9[2\^57W8-:VI5OGE[YI Y"5/9'X5VP'*,T5/]G[5-=S=1J?-3;O=2O(K1>&
MJV^.2BML? W'I'_"G,[BT. I05339HW7,&EU/.GM [HW;,YTRP"I.D\W%TJ.
M'OLW<^Q_Y/8GPR"K7!30]Z65\H*E^_ZUV8&U87!S7'+F38W=QF/>NR/E5FB[
MW%Q4#&BFU!/*5!-3;WKE5"XYX#H-$(Y7.T@)-T-3K;HS'#5QY,>!0_<]:+'B
M\TX$%.@:=I>='Y$QYR:&E,C$4H+W!N('O5G\?V*.(WGRMCNW**6TO:6L+;K:
M\*=-<O N)%<G JZW:2^ [V?-H']]IP*_==])W5X5/:S40EEP#C-1[OH8VV,&
MWCP?XJ[ _JUOZ>):=X[K-CS-X%H>]A;ERG%1M#>Z.%7NXRHW2QM>YAO-/"%8
M^=WL5F^]_<5:?N_W!6S[GM4_,WU)^GD9H[N()S4);DVI=S44<T]YUP4N5P*>
MQC0Q@D;0#R;.@;KS8?=X5):W#&3:MYO\]6Q98>,EQ_SRJS\;JN/2I:';2=S'
ME5JM5-N'5;S#/U^93V4G+;M]JM7,/6%):6_PI*.YBNQWGND.7*U?^:3V[#_%
M:H_%"L?.[V*S_>_N.Q:OLG>I/^R/K"A^R]I5C^R;ZE) XEK7BE0H&P,H=)BX
MYG!#QSL2SFFU& XSP+3R;81;<GC=P)OVH]14MYP;W4YGD"K9R';4!Q;PN5F8
M_7;&T'H0@;JAPB'M]JO1"C0X2L"9(W%KA4*S2\3BW_.A0US95G:/G/?&C>;9
MIVX@:=M)GS)F&V?MCVNA:>YQ^M-J*/?MC^YO#M'0'@Q;S=K_ .7V*R^*5I&C
MNL.V'*.%6"]WCF,])6;Q2HR;,RMT*S^/[%9FNM,37!F(+PH88W!PD-ZK3P)L
M<+FLCX&[5-CFVI.T=Y59O%*AM SCP/,5#)+B(F@GR?\ *LW.SUJS^/[%9W#6
MBC:_S8JPV5^I&+OD_P#2LOBE7!K2T;Y.%--E<V.*3;\"CFM.Z$WW4X0<T2.)
M3_9^U3-:*N&VZ$^S2O$;KUYMXTJI(62-?+(+M&FM%/*X4TM2.:BM#9HQ( T9
MJY4]CN/HGW;%VZ+NE<:;)<XAK1)F>9.<V9DDE-JUAKBIK41M:7 >-2_?]:D@
M=(PN:;KF/318R,1MFL-0"K).<VBZ_G40,K6R-;=<UQHHK- [2W34EN.*CA.L
MV[7G6V8!,2:2<*?893QW0> C,*(G ;1%QM#'?TL=4E26PC:M)<><\"BKEM*U
M50^S \[59_']BC?'&!:-'>#API]ED=5S,65XD6Z2.1O"UZ8VPNJV^VE#6A^;
M66S<?=/6/I/'9H^$T44#!0-'T,<P;K-M .3A4=I+>Y/<6@IC_P"(S:O'*K17
MAH?,HI&Y.:#L6/G=[%9^2]_<5:?N_P!P5LYV^U3\S?4M.)!,P:V%*)\3(FQ3
MMUB._P"78E^T;[-FD>(+M''S*.%FJP4&Q9O$/K5D^S"BLP.$8J><J.RF"8@,
MNNP&/'PJ&0'N=ZZ:\15JYAZPK9&\58YU"/(L<F.H?ZFJH-099*'IV'^*U1^*
M%8^=WL498*O ?0<M2M[R?_URK4^V,+);C\"V[A1/^R/K"A^R]I5C^R;ZMB#[
M3V(>.=B.R-.#-L_G_P ]:94=TEV[DW[4>HJ29DP86NNW2,T&6N$$WKM7=X5-
M.>\;7RHVFT-?(:&EWC4+HHY&/94&]3$(1D[:$W?)P*/[8>HIWVI]0V0P9R&Z
M@!D-F]VX:W%H=3H5.TEEXA@HVYESZE!O$*;,D,3;S&9R=O399/X&!YNU[-O/
MTE:TK@HW2N>"SP=@3MT@(=>#*X)CI7/:6> @T9#!-9*7 --06+=)^D>Y0N+Y
M2(@ &U&P)GND8\"FT*C,KG@LPVI3X7ZCA1/T1<XOS+U':GN>'LI@#A@FLE<Y
MMTUVJ;9\XPVYCQ(RQE[G$4V_ HS*Y[;G@*/2/D;H\@TH-;@ *!,TI<TLR+$R
M($D-;=J<T]\3GN+A3;'8+Q>A<? R5YY?-R.R5S)M*8)[HG/<7^&F.D+VN;A5
MB9&"2&BE3FNS0Z325)I7#9?,]\K7.SND4]2J=))R.<@QC0UHR 3K2QSR]U<"
M<,4Z6KXWNQ-WA0DVTKQE?X$YDC0]CLP55CY(QQ9H/:#)(,G/X$89"X-..U0A
MC+BT>$NS Z1DEZ]1IPJM+(Z1KJ4VA"Q,K^1SD(XF!C!P!:61TC74IM"%ND_2
M/<HH7N>UL>5U,A96ZP4%5V5&Z0.QVM<,47-<^*O ,E?8"^3PG\'S9[6F\V)H
M;A])J<:/[0E&V=@SZ&AL>J3<9R-XT;$!1H;1G(>!:&0$->=&]O$4VT0"LS!0
MM\(+0%@<P=Y(,6J%D3='$'@NT8X.4JZS=6&\WEY$^%T6UK4QR8438&1;6M='
M'C57'[J\WG^Y3<S?4GQ/U7MNE!K^!^C?S*)K(FOOBM7)UJ+0'%P=0)T+X6L
M9>JU/NZ\FT"?:W#:Q[5O/_GKV;+-Q$M/^>10DG4JTJ](*L<\R.')Q+>D70HW
MPL#(I&Y#C3I3K7 #S@JT^/[$VTQ-K+%G3A:K/095KT'8=XK5'XH5CYW>Q6?[
MW]QV+5]D[U*3[(^L* TPT>?E*CA;%"6QM#14'WJTVU\3;\1( ;D<DR-\36!K
MKVU0@9"UXK6I4DSM5C;Q0,F(<[22<VPW[4>HJ7[4^H)EI:-K*,><*QL[]Y[I
M]U1R6B!LDDFVVPX%,V*S,9+=VI X5H3E**>4*S1<;B[_ #I4-<WU?LO)_A@
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MPL)FK=FK=FK=FK=FK&=JVUII]U5E<9W<N 0 P V"XHN/:#P8AY^UM-U[]J>
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MH5J%:A6X/6%V$<;L527]J3@<430P)EVTR&]7,(/-JD!YEOJ7H"WU+T!;ZEZ
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M=OS*9LKGMN $7$P02EPP=SCB*@@::,?4NY5&]LSR]S:WP<*J*$NOW&AM>/\
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M, H9),UO/C!8:8%/SM"!HXF@AW!&30 H/89=T W! 6''+L-I&7RAG?8,:[-
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MZ(AUA=#5IR('8#^SP@DL7H/2'ZW(( #=(F$QIX,>E. <[_ ['$!-4DYZROR
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MP;I5!?!72 1H# 1$)1R"H #6SK.X3ZO FL2#J)W67@LIYK/*[L\0[<C[0A$
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M$\_P3S_!//\ !//\$\_P3S_!//\ !//\$\_P3S_!//\ !//\$\_P3S_!//\
M!//\$\_P3S_!//\ !//\$\_P3S_!//\ !//\$\_P3S_!//\ !//\$\_P3S_!
M//\ !//\$\_P3S_!//\ !//\$\_P3S_!//\ !//\$\_P3S_!//\ !//\$\_P
M3S_!"LV.RQGG^">?X)Y_@GG^">?X)Y_@GG^">?X)Y_@GG^">?X)Y_@GG^">?
MX)Y_@GG^">?X)Y_@GG^">?X)Y_@GG^">?X)Y_@GG^">?X)Y_@GG^">?X)Y_@
MGG^">?X)Y_@GG^">?X)Y_@GG^">?X)Y_@GG^">?X)Y_@GG^">?X)Y_@GG^">
M?X)Y_@GG^">?X)Y_@GG^">?X)Y_@A(8H% /2=@?5_6W>>V=C_4UV!]7];=Y[
M9V/]378'U?UMWGMG8_U-=@?5^J#V(Z(5/2#G D=R('^"9:,O@A_J$AK246'R
MHU:8'C5]Y;E6(">A,S 4K!UM+4<!_6.\]L!:1( RQ_Z^<YSG.<YSG.<YSG.<
MYSG.<YSG.<YSG.<YSG.<YSG.<YSG+LJ K_KYSG.<YSG.<YSG.<YSG.<YSG.<
MYSG.<YSG.<YSG.<YSG.<BDTZ+_Z^<YSG.<YSG.<YSG.<YSG.<YSG.<YSG.<Y
MSG.<YSG.<YSG(?0 DEG.P/JVH$>Q0" +B8)-69$$U#=T39!RE)_8.%-:;+^4
MY AYT-#XYB"8UPT0D18*IA&?!02 L5I "VR\] #!!(]R!'(O8+_B*<R556E)
M25+\B5P!G"; %<AT$1*K.^.G(;!7#A*",!8REZP"@0<@U@IRRD$31@ B&HT<
MP PG;##3,<C2"X4.Z&., E V,6@E@A@!=P U@P+" 2]2?91 =K$?<(5:RCQ@
M0H8..(MQ!V@W@DD@!G*5\.: *@YQ4AD*NP*9E%&Y >[A7#=F!C4B@) 6*TBB
MI8ART("L Q"#6(-C HQ)6"DK@P,]C$& .DRG%%S #6 P\, 'XD^T#W0<HG40
M<RL#3I@94]2WQ\:PX8S12>IK%66Z@[B.R- 5-&6H@+#%1$"/8H! %Q,$FK,C
M8,D5@*IF8"*JYL /D]X.Z49[! EIK(?(C [!>A60DS+"4TDL,.]3W@#<.)!Z
M)5N#H[6!$/0$!!:6(J,_419U% N U]C'N%C.?'D&>4)!;$4KA3$4/RD90"Y,
MHHK/ZF,%2>.#^8V8G'&&3NG$"$%%$:PO+=G'Q-!R@_,Y#+_5CO/;/ 9_U+ZN
MX3L#ZMOAL\\IDGAL\=B0## 54X%CE$,TR PP.KE"3N6]5T,+-==Q+O'91MFO
MY<<#[B,'9>JG<HO]0U0M+EB)@@6ZE#G/,99Y7-.V[/+9=OR>^(@-R 4>H7.8
M^N[#W KR,\37LT!:#C(1,GHA##%--H*8U-:P%:F(&#'W8$L*P:5'6/T.3K+J
M-IF8RFE3J1T@U0@RCV>E#V@R$"@ " @RPJ*!J G5KK"QJO= ](MF;4=%1$=0
M>TJAWK')R/K/*9QX[.4^#>83)Z(=8PAP9@%"F;?24NG%X'E#A!  663"7-'8
M("@]2X(PD54U0&5+P<W4T!C+E@!P+#D01*L#&X6[A/#9YY3) $)* J3'O%PB
MP.D-= 4]17*#5RB&VHR,:8:&,;BZ$01]5<4CJ(A(K4QFS)]![1?P45?C@-(2
MB'N!@P<':L:\?\2\V$W/R#N!*<7#@3=U]3*R"A6)5/L.L0(K=<87OS_(=)]"
M:XY@P$JO<T$44*#3<$,'<80-PHC@UXCG!DAR7@<80U0N4/%^J=Y[9X#/^I?5
MW"=@?5M\-GGE,D\-GF;<6JO<XPZE:K]X';!@C%%=VB94<(QJ#U<[*-LV&!Q.
M%$>JCB0IG J%\+\IX:%NJZ3&2%HKW*/,99Y7-.V[/+9=OR?2*=<1#0&PL57F
M4E'<=4 ==FA"[E0!@GL[!#M!TAI$]-K0&*'")\:D!F@PAL@,]T$.XG1L '!>
MQC9R-;,G4%MPV.L?H=(QP]2!.";QCQV<(?<J 2ROFZ[27P,>L !6$=-@AW$Z
MHW'9>&SSRF2$M08=4$!7&]&T $7J=,/XT#A?[SB6#C!S-0BA0"5P<-@MB$)&
M#+D5B*N@;"8TV,,^0^T!)ET_$-GJ:<X    0&'X@!KHF'$M:N/D('!AP&]<'
MMPF3^)@-<$.=2R+FEP+E"=6XAO%VQ2?MYP>(5UT_C]03@R$(\ #,;.\]L\!G
M_4OJ[A.P/JV^&SSRF2>&SP*=W/+7N E))F5+A=BCRBGH5,Q\D>6QAV4;9N^3
MHP=W^ Q^(UBK0OS+/.) 8PF-Q=7/,98(IB34D)T<Z6KV@_ K!@B&"-"QL9/I
M%1NIU O5LG^+RC2?W'">1]=('RJ-0Q=:=-FA&A +SHCW!BC:^-+,N&'+8#08
M*T3_ ,#O'Z'-4@>I@7+7(U%J83[L*"X BN7QKZ($3+4@7'$CTV @  <$NO$@
M=X6M5[(#I%NS'-!M<,)YCTUE>1@X!74'K/'9RE0,ODCW!@((2V:F+8X,]M@E
M1@NCQP 2 ZT=A@!9QA@"[W@#$ *DG"+J0/@#9ZDRK R+L[!/#9YY3)+C2+G+
M_<.)!Q61#KC%J( @#= "(F;!BE.P"#"FH(.!_) *,,$H:?Z" 7 X7+(Y&=E!
MYK+8 8JW^0@BM5Q_B7AFP;ED(#B+#5_TW95&,=90?)$(F;K*&0PBPH7D@^I+
MHH!-(C28'<1*D0+5'ID*2+!UW$308V<8PBLC3Y1QQQQQQQQQQQQQQQQQQQQQ
MQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ[.RZ3
M@%C'TQ6CP+D,*?YB U8%-H!,22UO^N! @0($*-&O7HU:]>K5JU:M>O7JUZ]>
MK5JU:M6K5JU:M6C1HU*E2A4J5*%"A0J$*+*/$,_]?*M.G3KUZ].O7KTZ]>G7
MKUZ=>O7KUZ]>K3JU:M>O5KU:M6K5JU:M6K1HUZ]>O3IT$#U"JF_P77KU:].G
M3",2&Z"_Y_<)V!]6T."_8!,@@J!)30X%0W*?8 3((*@IFX C+=7CB(IJXP78
MJ!:8ZP]6:I!-H<1":3)FI5I\8(!G5JU+7 PA"Q"1%Q&'Q1!>*]3&H'>'7$QB
M0LKJNFQ+$&D  LM;'#2;]8IB(LNY$#D;3.R<AX90,<])Y"$DS5(!;0XB'(/5
M2D&3XP/DD=B#>7/C>. U8P@D0&F %U$)O$PIJ6AFM"V1R@84J'V*\'"19Z&!
MAS@/8JW #;0S 5<' C40T!I;QSN$RV!B_P QA9MWFK6*M"S+$)@@&=6K4M<#
M ,8YJ%4CP@J,>S8'D:QL&H:I@0(K@#4 )HQ C!%W9'0QNK+ /& 6C7%0@2?&
M!WCWV ;9B#!!YD^88B6BT/8,:A[B#!X@02L]'?M!W@  0H(=!0M!$5 @<" @
M!2A JT4&82S1L %8AK!P,;=K@.A0Q"6*&4-<H/=I$\07ML=&O4Y<P<#ZQLMX
MB 'L& IM'72*+L$#CIASV5H5"4Z-((!G5J5:?$?A,2: N64I#)#1'(:[@5"6
M@Q[T@-8G2TNB#(1.*******&*@X2B L.5]4.,<?<I!BIB#'@"C]S]1N$2>$K
MM$<:.HWX0T)!0@BHCY1\HT-#Y1HT!1IPQH-@\>/'C1HT:- 4:-'C00XXX]U?
MB'"18D2+MAL$SB9Q,XF<3.)G$SFH8F<3.+G$SVP:DU)J;(L+"G<2!(4_QDD
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MWQN!MH+PYVQ?88#+_P#,[A.P/J_2LRE[[KMYJ" U48V?P $$DT QA0"O (1
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MBX"D#2@&@%/$/>"A!L$!"*+.0^2!A/0Y]D)PY<0)BV) ]4\ ]X:#$R4Z2T3
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M*, <4446Q3VA'!MK((R-^XW!?\:H$X; [7.]#K"(]4/\=>4\)EFEH>"[QMH
MB U%X;XZ*,S!*I@<8T"F7$,!I%?[' R-@4MP!)=1%@O!,J](HT@84$*5GE:[
M"A?1Q4-:][&P;XZ ^0!A3*D)'8O$KPUPT%U$-<-L''PF^/@S)^ /%MBAS"\R
M$NBEJ2EXC4:".LQ<_P#PH%T]9A="E !50\!H6F<.D2"%LDR?@#Q;:Q^1B(UI
M+*%CS7:4[4X@,=8?PIG][&&>4\"0O0RRO >,'M A<WNZR@01RR'7T2YH'SLS
M*]I;C4'>/T480\!B^T/,/2,$Y^7785E1K*+O B@A'N/Y    #T46:D_$&P;1
M^ ;@VC<Q@WQL&X/PF#>$&^/QC<&X8-HW!^,;@WQN" (<A*Y*J=W_ # .0 @L
M! *U##U/\X[2Y 1]0$&/#,0.0 9]1TVE\3O]UWEKL 6 W[A\Y9T2Y'$17U4.
M4>T $C&VBG<##+6&["T]&SH0'X 2A'M+%P(%!DME>-ZKK%DGO A/39CL!@5S
M S[$**SQ:QWO8((1IYP0'J@SJ[<"GI" !!#!PF$ O0]-B7=;@O):JLYT+HV1
MP.(\D><$-M"!PM=C.P>"ZD?H@2UQ ?\ 2"!9(#J( Q0=T>ZG8I>$RQ/W.! G
MU'>&08T@" ?4G8$U@8'&T$ J%0]ABUBQ'X !GJA7 4_")@P2G0-X"$94C8%&
M8?6&"/?< 9$.^%+8V@D !$<E<&G.$"[Y0 4 /KSA]\"E F*K!JSC*!M38N?*
MOK)HL3N:(8@PQKJNQNO6#F3BG5: +X@#/0*\M <8D*"C$#6/HYG):0 X1,V<
MH4/,= 3I!VNY-]PJ6P0N8O47+$)E+1%+T#G!8.:@>*::P9#HLS#F&\)@GD:Q
MR$5CT4KK72TY0Y"*QZ*(K6!H2R@D3^!+1_W#$_,&#;1#ETKU-8\35?#>U>T(
MY"!.Q0Q<E4@ 4OJ^TQEFH545@]1K(E<J<^T"&B;1H&M?0Q_W#$_,&#W0M'RK
MU-9U)Q3JM!888),E=)@Y9YL#UC_APE2+L"@, 0U2M+S. U9[$KP4$1!(V 6#
M (>3$)!TII'K'" HA ([B*.DL0#@%>O*"\X1)DJ,H2&BPU0" IQ,$O0-=<4=
M$!4E,T/F4!P !$E4?R0   #\,"9 0@D%X92>C@V#:/P#<&T;F,&^-@W!^$P;
MP@WQ^,;@W#!M&X/QC<&^-S."0(, (-\ 5PQQ'K^E@(WR0C[$#N" .A>S81,B
M>J_97I&AEH#8<.4*#42$]YD\I@O7\L7UB/,4>SU/E&@K#@4)P1/.(G5QH*GN
MNFSH:W B8$&6MC"JSEM@)FBXKXH8@0] @!0(OB6IT)Z;"?*$-38D]RH3OYP"
ML[WL$"T5LXHCU0"$$&(B0]ST@XI"Q 0NI'T ;L2[K<%Y)9AEPB9'I'U4P6:W
M5&(]?RQ?39G2;%-2?"$,1"SRCT1@*A,AXX!U@M!G[DG<SL4O"98 R),:2 ^+
M,3M'H('H=AO[6OVAPJ0HF_@ *%!X.IA"F47X24X49X-\!YG*6(4*6#4ONOU
M             Q%%(7Q#SML&P;1^ ;@VC<Q@WQL&X/PF#>$&^/QC<&X8-HW!
M^,;@WQN /W5)5:LS'$^OZ8.62.Q!CS %GL?M*'1401K6L W$?@YI<C,P=PK
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M99999888888(888(888!*E67-?@PPPPP""67B1#]05T@LS0M*SYD6;?I O\
M*$5!I:"RP3B:C]AMRA=*0Z>"2-L\PA20@*",*H0V%5V('O"-\0R%R,8,-6]
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MK!'5,=-;G>=SE<X).F%0FQ!TZ$P=S G##KIQE2"F]CB8[A0_]!O@AS>![ !
M-G',$7*#L+J""XC>K=6@<L8G6/J@CZ0$TP.&2"UXT:#5 " $![4I]"'*34P<
M'#%(EO1"+%494((,'_HLC%"+0]:"-64-TM(+;HR)J,I#8!"?!@_"2 ]C^F'
M1,"(" !:]T06,!53P#O[9+:^S&YL#\050 L Q8L2)$CCCCWE%%$8C&C1HT>-
MO 0-@:<TYIS3V["+0_BI)0226_FMDG^';:;26VVVVQ^:2  ;;=L$*(G52!/
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M@HS5T5[@(&EECQ+_ %TV!U@:Z!@V6P*D:(8DX YP!E:I"U%#B$/AR((2R2Q
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M,P8:FXM$ -8$(!=3ND8R %2+'67""TR1>QSE*4"3(XCK$2();9./R(I?J79
M2AJ:PR*\NL2T CX\8*85). !UA)MHYC!<\O^*M5%%J#NB#8(-HV#\ _ ,A6,
M*LJF@^7_ %DDX6HP&W6W..&"(-"!4_0>\"\TLX  >J)$5K0% /7KN3*?@,\[
MK+L4B*QQ6 +FD&SQK>:,\-O8I"4 *#-0 ,(!49T"Q]P(@ "5P5=!VB!"38%S
MQ40LD6D\#2!/EO%^T$*8/I6VE9*!#IL ^'%%+$* PH%@8-"B-*#TC66Z51*
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MUYRZL *PA>@XQGO*'-]8XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXAO)\
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ML)@EH# :1PB;)DX/=$"MP9G@RCAM3J(I2&#CBL&@&(Y:0D8$XA$1]P D8-N
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M5##:L#C+0#D1/I\[%(BRV!:&'10$PBQ("61G%E+G'>?-&PZ?I8
M !W=H?.2A,8E:X#T$GY)FP^ $#X):/\ X"+ERY<N7+ERY<N7+ERY<N7+ERY<
MN7+ERY<N7+C[H$" 6J/[0I%C=GWEQ%1^$L#/I!ET"A$?X49J)C%SI&Q.3# P
M!&I5XC28[@Q=03F#+&)#/&4X;"\ ?J HU\D*53(#),^D3Z1/I$^D3Z1/I$^D
M3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/
MI$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D
M3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z1/I$^D3Z;.
MX!8$0 ,AL[SVSP&?]X!*EKYC PK4"G6" 5,=F @,!B0G.K\0P=MZAX2Z:]",
M(2#N,3C-/8+4H*2S7SM^G]Y[9X#/^\00.@(>!$(V *AM$8(B.,16"]<_9'X%
MNB(  ,X1CT-#!/=RN%;8)13FLAIQC!<(:_3^\]L\!G_>0$9J\T\J058J[+;H
M 1$9LA5I*XIRLC2CV O?>P4K.$(EN (-#6?2/TBIUHIFR#<H0PN/9X?J'>>V
M> S_ +R&4#((B)B$]#=ATC0*MQ\TXC40XQ5'LSD82[EDEPC)P1[6M@%@ E+)
M827+SCC'Z)XQ:MJM&#A1,5?EE!2R , R'ZCWGMG@,_[S(Q@E"#**XL_E$,,P
M+4$;?T8 W:680:XCA#J 0,#+"DC4D=AA9@4<AW(6W@8]D"49S33VXF"-RH]8
M3@)Z$(T#]2[SVSP&?]Z7A 5$ED*X61A8FN0X9QA=%LA;99",$)\$T$MPP#DV
M@'+9BPZF !)$4#TA//+*Y,8'-68/ZF=Y[9X#/^]@X,(L%".< 8! Q% #7.4
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M$U:$WKZ.T*6X!<8#$] 8E! 0VHTDN4-=T"%#6)[A=Z0 @L*;@,RY!Q813%7
M=8 %8 ;!0$F@$76=(T>6\ B@8&3:"AG4D8E''''.B?JTLG 5,0<!]1L(,%B"
MI!>37.!LP0& 8Y@P5F "-W8@ ]P=C8NI:((!=::QP!L#@#7$0$7$4'Q8@,S5
M%>6J0P"4,* 2F@H$S,80#B1)@'N(+@.MI15B[?+ IH@(6I 0& ;X@PJB (!
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M8^>LE,S&**U/^P?ZTH\J%@F (Q;<" #!0M@4Q>4D<K$>GZ<
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M8@BY;@&C-/;6E-&:,T9HS3@#A-.:<$VG-&#)FB=@&P#2FE-*:45M #; !M
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MW')H[2XGZFV JP.*I'<!=1B.9B>HX@,107&2A'VYPM =PK=?!342"4T7_1!
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M2  0YX"KS6#E*/%J8%!@#DMG/W@&]0(08XV@?L.:A@""(?31@W9<DXF".["
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MF6T@2 !-R!!B &1$1)4RVG'-F#97E7,5D&J;,M]8-9VG3@ ! (0 H 1D8 !
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M_P"!)DR9,F3)DR9,F3)DR9,F3)DR9,F3)DR9,F3)A[?D#J$X?SW''''_ %R
M8"GBB85.6*S_ )^OFUUA:3,&'@T9=P^KC'89H)H)I)IIIIHIHII9I9I9H9H9
MIYIYIYIYHYHII/R1 !F=S4U#0.RB7!]N?\\E&=(NYEY[4CT@+V#^M[4JG="
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MB4JP65Q6!%2 R)1B8J [!X02XT1B@1@8>G96S!K$0BBE#J(*D&20)Z (,D-
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M> AGX*CK%9D'H!0+3D"9JG.*)J9)R#EW@I'"P7:B%R\0!G4J 2EIL"S?\(
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M''''''''''''''  PJ-4L )1A-.'A#>$&P0;1L'X!ON8*H"()!0)C]_\E;
M2>D%<)6< RJJ)%4P6N#$.:)0&PAKA;I**@<R$'^-Z,%%2VU@(:" &X%BV$BQ
M8L2+%B/86+")SA$F* 5@@52P*R9* H #DX=AP$F8R&@;"9]K.Y10@8L6+%BN
M+2)%>,6+$@3^CA ^7NQTA&H<AU'["                )$2*[N0$:;A8/SO
MB#8(-HV#\ W[30I, 7K FPT+ ?R[Q#S09:& .XHAWJ=#F(3T9Q%H$TH%I5?E
M+Q&_BD.R2:")FM_A""Q *5&O].T,6!Q'"$R%[ OFAE".90]/UT
M     U...!F':R!X#&$M<D<!A-(30$T!- 33$T1-$33$T1-$31$TA- 30$TA
M-*-"-"-*-.-&-&-.-&-&-*-*-"-"-*-*#$+$;&K)[?SQ9Q-3,0K.O4$5):#^
MNA>B,+G""%0R7V,5W<$1N="?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)
M]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'X
MGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?
MB?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA
M^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:
M'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]
MH?B?:'XGVA^)]H?B?:'XGVA^)]H?B?:'XGVA^)]@?B$\1"2]I2#N*^O35!K0
MH"XKY0&8<J_\#4Z=.G3ITZ=.G3ITZ=.G3ITZ=.G3ITZ=.G3ITP2#20!&^I_\
M>=Y[9X#/_P N=Y[9X#/_ ,N=Y[9X#/\ \N=Y[9X#/_RYWGMG@,__ "YWGMG@
M,_\ RXN6Z96478"2F_\ ]O/_V@ , P$  @ #    $)))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))(  () ))))!))()!( (!!!))))))))))) !( ) ! )()))))))))))))
M))))) ))()) )!()))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M !(!)(! ))(!! )()()(!))))))))))( ))!( )!()))))))))))))))))((
M ))!)( ((!))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))! )(!))
M )!)!)((!)()!) ))))))))))))(()  )!))))))))))))))))))) )))()(
M!))!))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))! ))())!!))((
M ( !)!( !!))))))))))())) !! )))))))))))))))))))()()(() ()!!)
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))) ))()()!))!  ))!!)!)(!
M((()))())))))))!() (( ))(!)))))))!!)))))))()! ) ())!()))))))
M)())))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))()))))))))))))))))))))))))))
M)))))))))))))))))))))))))))(())))))))))))))))))))))))))!))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))) ))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))(!)))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))
M                                       !))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))(
M                                  ))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))
M                            !)))))))))))))))))))))))))))))))
M)))))))))))!)   )))))))))))))))))))))))))))))))))))))))))))(
M!))))))))))))))))))))))))))()))))))))))))))))))))))))))!))))
M))))))))))))))))))))))))(87 ,A9R#&_ M0*) Y*A-[!K)P9. HX$V[))
M)))) " !(*!))))))))))))))))))))))))))))))))))))))))))) )))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))*++AV- 2([K\C@%(A$74\?#%!Z)3#R06*I))))(!!
M) ) ()!)))))))))))))))))))))))))))))))))))))))))(!))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))1=A^W$B1'<2U#&VZHP_7HY')=1#(.*/)))))) ! )((  (
M  ))))))))))))))))))))))))))))))))))))))) ! ))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))**;-W@:91KFJIH<E[%7K=-(6 Z)P"S&)O))))!!)#)-I@) !):22
M2222222222222222222222222222222222222;MMML!((!);2323;2VVVW_R
M32W[::23:28 (MDM EJ2:;0()"6VEK:22:2^V[))))))))))))))))))))))
M)))( ,MDH)"(=I,Q#)()+M W)E 0!U!HH/$I))) ! ())))))!((
M                                &U3;_P!OM_\ ^V22VV6VR2VV:2VB
MRR66V2V_;_;;=[_;;?\ ^^VWVVW]^V__ /E);P2222222222222222222222
M22222222222222222222222222222222222222220"0     " " P
M                                 #6E_O\ [?[VVV6RVVR26VR6V0V2
MVVR2VS;?_P#_ ,OM]?\ [[[;>;+:V?\ _P#M_OOZ22222222222222222222
M22222222222222222222222222222222222222222 "3"2222222000"2222
M222222222222222222222222222222222222>TM]_MO][;;+?LW?=_=M$ML_
MI+;9)9)MO_\ _P"7VV__ -]]MO\ 9;_#;_\ W_VW_4I)))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))  !        !!)1
M                                     +Z2:;6W^]MME^S_ /MM_P#_
M &RW?TEM,DLDVW__ /\ +[;;_;?[;;[/_P"6W_\ _P#;[^S@DDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ DDDG-$DDDD
M $$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD%)--K;_>VVR_9_P#V
MV_\ _MEN_I+:9)9)MO\ _P#^7VVW^V_VVWV?_P MO_\ _P"WW]%+))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))(8!DDDD6J
M(DDD)!))!   ! !)))!)))!)!)! )! )(!)))))))))))))Z2:;6W^]MME^S
M_P#MM_\ _;+=_26TR2R3;?\ _P#\OMMO]M_MMOL__EM__P#_ &^_]CY)))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))(     ,
M   2  !(!)))  ( !!) )!))(! )())!( (()!)))))))))))/233:V_WMML
MOV?_ -MO_P#[9;OZ2VF262;;_P#_ /E]MM_MO]MM]G_\MO\ _P#^WW^^WI))
M))))))))))))))))))))))))))))))))))(!!!(!   !! )  (!  )) )(
M &   !H  )!( ) ()!() (! ((!!( ! ! ! (! )            J2:;6W^]
MMME^S_\ MM__ /;+=_26TR2R3;?_ /\ \OMMO]M_MMOL_P#Y;?\ _P#]OO\
M?7DDDDDDDDDDDDDDDDDDDDD@$DDDDDDDDDDDDDD$DD$  @DDD$DD@@D@@$$D
M%D@DDDG    JDD@@DDD$ @DD$ $    D@ $D@$$$  $ $DDDDDDDDDDDDE)-
M-K;_ 'MMLOV?_P!MO_\ [9;OZ2VF262;;_\ _P#E]MM_MO\ ;;?9_P#RV_\
M_P#[??\ -+))))))))))))))))))))))))))))))))))))(!(( (( )!()!)
M!(!(!()()!)))(6   !9)) )(
M    &:2:;6W^]MME^S_^VW__ -LMW]);3)+)-M__ /\ R^VV_P!M_MMOL_\
MY;?_ /\ ]OO[4R22222222222222222222222222222222222200""2   02
M0"0" 0"0" 02 2$DT&(   !*,DV20
M       ">TDTVMO][;;+]G_]MO\ _P"V6[^DMIDEDFV__P#_ )?;;?[;_;;?
M9_\ RV__ /\ [??\@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD   'O)P   E5M DD
M           D@$D@RR6SRV67[K^RZV7_ 'K_ %O*+*:0)));3;8++9K;+)))
M+()+!);;9;4O_>2222222222222222222222222222222222222222222222
M22222222222224" 98/O   $8   2
M      "&0VFDFMP3]O[)*VF79)+9;&  4PDFPDG6W+;9-W:MDDMMMVDDMNFT
MVFDV@V_Y22222222222222222222222222222222222222200 2 0"2"002"
M ""2 02"22220G]  (6N2220222222222222222222222222222222222222
M"9_]OMODTDDDFDVD2 )))))(   "DDTTVFVDDTE\DONVDDDDDDDDTFDFDDDD
MO]R22222222222222222222222222222222222222020""0"""202""   02
M22"2B221J^ZW/M"2 R"VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVTDB"22
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222"22""" 20" 0002"0222 ""2
M23JK$@KH"2020                                     "'DDGMOM]_
M_;;+);;?]MOMO99!9)++);)-_M]_^O\ _P!EEDD__EMML]FW_P#L))*R2222
M22222222222222222222222222222222220"2000 "2000"2 00"220"2222
M20&"Q\220 P                                       !TT]O_ /?_
M .MLLMEEMEEDDDMM@DMDLDLDNW_W_P!U]M__ /[??;[;_6[[;_?=R6[\DDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$D@$$$$DDDD $DDD$D@D  $DD
MD#<@LL$D@@@  D$@@D$@$D$ D$D@$D D$D @$@   @@       #EI9IM;?[V
MVV6R6WW3_P"DTDE-DEMLDLDVW_\ _P#+[;2V26[;;R&WX26VVV2RVI\DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDD@D@@ DDDG
M$DDDHDD @    $ @ @@ @@@DD$$D$D@$@D$D$$D@@        'U)--K;_>VV
MR_Y?_;;_ &^V6S^D-IDEDFV__P#_ )?;;_\ WWVVWV6_RV__ -_]M_\ UDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$%D
MDDDDADDD@,@L  D$$$@D$ D$ $$$ D  D $$@@@$D$D@        BI)IM;?[
MVVV7[/\ ^VW_ /\ ;+=_26TR2R3;?_\ _P OMMO]M_MMOL__ );?_P#_ -OO
M[CR222222222222222222222222222222222222222222222222222222222
M200 422222222060B22""2 " 0200 22  "" 200   "0 020222222223TD
MTVMO][;;+]G_ /;;_P#^V6[^DMIDEDFV_P#_ /Y?;;?[;_;;?9__ "V__P#_
M +??^4DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDD @@DDDDDDD@D$@VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVV
MVRI)IM;?[VVV7[/_ .VW_P#]LMW]);3)+)-M_P#_ /R^VV_VW^VV^S_^6W__
M /\ ;[__ $-)))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))!! 3)))))("(!!))))))))))))))))))))))))))))))))))))
M)))))!233:V_WMMLOV?_ -MO_P#[9;OZ2VF262;;_P#_ /E]MM_MO]MM]G_\
MMO\ _P#^WW^^U)))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))(( (9)))(!)0 (   ()(!) ! (!!(
M        J2:;6W^]MME^S_\ MM__ /;+=_26TR2R3;?_ /\ \OMMO]M_MMOL
M_P#Y;?\ _P#]OO\ ["DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD$$@@@D$@ D!$DDDDD @@@D$ $@@$D$DDDDDDDDDDD
MDDDDDDDDDDDDF=)--K;_ 'MMLOV?_P!MO_\ [9;OZ2VF262;;_\ _P#E]MM_
MMO\ ;;?9_P#RV_\ _P#[??TO$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDD@$$$D ($ $,$DDDDD$D@@D@ @ @@DDDDDDD
MDDDDDDDDDDDDDDDDDDE5I)IM;?[VVV7[/_[;?_\ VRW?TEM,DLDVW_\ _P#+
M[;;_ &W^VV^S_P#EM_\ _P#V^_Z%))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))) #!)!(!))!))))( ( !   )(()()))
M))))))))))))))))))))))U;233:V_WMMLOV?_VV_P#_ +9;OZ2VF262;;__
M /\ E]MM_MO]MM]G_P#+;_\ _P#M]_KR2222222222222222222222222222
M22222222222222222222222222222222220""20"200
M                         !P""0 1O);;M_K;+-]__MM-KM9__P#?[;;:
MR22V&26RR3S226VV62V226;W];PDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$@
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MDDDDDDDDDDDDDDDDAD,="!%#"+,X5B)-7D5DDDDDDDDDDDDDDDDDDDDD@@@
M$@@ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD DDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDD\[E*'FB/TH4Q],T-&E4DDDDDDDDDDDDDDDDDDD$ D$ $DD@$D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$%-)HD @II@$DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@)(!$$@AMH $DDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$DAD@D $I$@ DDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDD$$$@DDDDD@$$  DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDD@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD@$$ $DDDDDD$ D$DDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDD@L$$@DMDVULD@$D DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDD@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDD@DIDD@*A1LRPD$$ $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M C62222222222222223DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD@ELDDA*#:W,$DDD$-MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMIN;=K
M?[;_ &_^V^V_^U_)))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M),Y:!;M?%NTP!!)))))))))))))))))))))))))))))))))))))))H_Z6L8^
M_46_RWWIOA))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))() )(9O+O
MAA]+TF!!))))))))))))))))))))))))))))))))))))))))[_2UC'WZBW^6
M^]-XI)))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))!()(]U_P"PKGHU
M[R"2                                        1^EK&/OU%O\ +?>F
M]\DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DD;*R&7%@4%IU@
M                                        @]+6,??J+?Y;[TW+\DDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDD@     $@$DD$D@@@89CK5HV7[]ZD @  $$@
M@D $ @$D$ D@@$@D$                  'I:QC[]1;_+?>FY9DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDD  D@$$DD@DD$D$ G=D"#_(+,O@.D &V&@TDBD$$D
M6DFFV P4F"@"VVVVVVVVVVVVVVVVVT]+6,??J+?Y;[TW+,DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDD@$@  @@$DD@$D @D+.MI+6(?VQSDD DD@ @D@D$ @@$D$$
M@@$DD$DDDDDDDDDDDDDDDDDDOI:QC[]1;_+?>FYYDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDD DD DDD$D$@$DD$"D&HO]C[%F&YDD$D$@@D$ D@ @DD@DD D @$
MDDDDDDDDDDDDDDDDDD@]+6,??J+?Y;[TW(4DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDA!BI9F8PP750$, D
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MDDDDD  H$4+#]F!J]A'$
M$2_I:QC[]1;_ "WWIN])))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)!);))F2U(K.;Q +!))))))))))))))))))))))))))))))))))))))(G=DD
MF^JEX_LM7F[?G)))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))()"8)
M))*^!(,MQ#0(                                    !)%;;;;;;;;;
M;;;;;;;I))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))(#(3)))"-D
MK"(*)1)))))))))))))))))))))))))))))))))))))((!))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))(( 3))))())(1 !
M))))))))))))))))))))))))))))))))))))))) ))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))! +))))(!)!(8)))))))
M)))))))))))))))))))))))))))))))))(!)))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))#23!!))));38))))))))))))
M)))))))))))))))))))))))))))) )))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))(((*3! ! !33)))))))))))))))))))
M))))))))))))))))))))))(!))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))()38((((":8))))))))))))))))))))))))
M))))))))))))))))) ))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))(!)!)(())!)))))))))))))))))))))))))))))))
M)))))))))))(!)))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))((  !!((!))))))))))))))))))))))))))))))))))))
M)))))) )))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))(!( (!! ))))))))))))))))))))))))))))))))))))))))))
M(!))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))(!!  )))))))))))))))))))))))))))))))))))))))))))) ))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))(!)))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))) )))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))(!))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))) ))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))(!)))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))&X%P.K
M81#7Q*@')(@%$ Y]Y)))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))) )))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))*.' +GV'08P(N
M#8;0*);;!H#)))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))(!))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))0&W+92\=C)*%Y9 Z&)
M*A09#)))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))) ))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))+%')+AGA0;8<N'9;8+*::Q'I
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))(!)))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))1;0-O_LN)E&UHH-+/@'- IO))))))
M))))))))))( !+"( )))))))))))))))))))))))))))))))))))))))))))
M )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))!()()(00#;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;:222;;2V
MVVV_^2;2_P"VFTDVTDP "+9)2!+6DFVT" 0DMM)6TDDDDMO_ *$DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M@$@  $@@DE@                                        " VVVVR22
MVV266RVV2VVVVV?;_;;;[;[[[_\ ^W^VVVVF_P#_ /\ _P!M)+8>22222222
M222222222222222222222222222222222222222222222222222222222222
M2"4" 004  24222222222222222222222222222222222222222222A++;9;
M;;;9;)+9+9;99;;+_P#[;[[_ ._N^VVNV_TVVUMFW_VV^_\ _22222222222
M22222222222222222222222222222222222222222222222222222222222
M02$"++2""" 222222222222222222222222222222222222222220[FW_P#[
M_P#_ .F_M_I;+9)+))?_ /;?;?\ V_WVVWVW_P!M][_MO_MM]MO_ $<DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDD $D$    $@@@@                                         X;_
M /W_ /\ _P"WW_WTMELDEDDO_P#MOMO_ +;_ .VW^V_^V_\ _P#_ /\ _P#[
M;_\ ]=U)))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))()!)        ((9))))))))))))))))))))))))))))))))
M))))))))((W_ /O_ /\ _P!OO_OI;+9)+))?_P#;?;?_ &W_ -MO]M_]M_\
M_P#_ /\ _P#VW_\ [UT22222222222222222222222222222222222222222
M2222222222222222222222222" " 23:2122220 220 "02 0" " 22" "20
M" 220" 002"2222222222=O_ /?_ /\ _M]_]]+9;))9)+__ +;[;_[;_P"V
MW^V_^V__ /\ _P#_ /\ [;__ /CFI)))))))))))))))))))))))))))))))
M)))))) ( !)((()(!(!!( )! ) )! ())) !(( -  &P  (I $DD))%$H)!)
M!, AIA(HD$!$$ @%!IA$DDDDDDDDDDJW_P#O_P#_ /V^_P#OI;+9)+))?_\
M;?;?_;?_ &V_VW_VW_\ _P#_ /\ _P#;?_\ _P"D22222222222222222222
M2222222222222222202002022222"02222220 0" "20"20  22020*2220
M2   202 " "00"22" "0"""" 020 "00          )O_P#?_P#_ /M]_P#?
M2V6R2622_P#^V^V_^V_^VW^V_P#MO_\ _P#_ /\ _P"V_P#_ /?$DDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@ DD  @@ @D @@DD@D@DD@ @D $D(D
MDD@YDEMETDD@ @  @D@$$  @@ @ $ @ $ $$@$D @$D           [?_P"_
M_P#_ /;[_P"^ELMDDLDE_P#]M]M_]M_]MO\ ;?\ VW__ /\ _P#_ /\ ;?\
M_P"4Z2222222222222222222222222222222222222 200 02  "2" 2 0"2
M2 ""020" "200223R21J2.22" 0
M      #UO_\ ?_\ _P#M]_\ ?2V6R2622_\ ^V^V_P#MO_MM_MO_ +;_ /\
M_P#_ /\ _MO_ /UI<DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@@$@D
M@DD$D@DD@DD$DDDD$ DD$D@$$  $8'^ @0   @
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MDDDDDDDDDDDDDDDDDDDDDDDDD@( MMBUO%5HMM=M( @
M                  $$P0VV      0    V222P D "DFR@"4DFV2222222
M0 R&0 P  DD "DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDD  DDBXTXC4^<KDD@DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDD@HJ  D*<( Q] 0 DDEMMMMMMMMMMMMMMMMMMMMMMMMMMMM
MMMMMMMMI*K__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P DDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDD@$DF  IWX  #D@H$
M                    *G_;Z2T?=';?[= ,MDDDDDDDDDDDD>  YDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD@H%DD8    N$ $D% @
M               Z?]+6,??J+?Y;[TWIDDDDDDDDDDD@1)+%DDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDD $$DA3.  -\?XD@D@
M          __ *6L8^_46_RWWIO7)))))))))))B$]L-)))K+H, 0>MN(/LM
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))(())(%$\]I)(%(((
M      *?2UC'WZBW^6^]-R!))))))))))7R:271)(S+8&O@R!8)%>RY)))))
M))))))))))))))))))))))))))))))))))))))))))))))))())!))))))))
M)))))!!)(J6;))).I9!()           (  !      (
M +Z6L8^_46_RWWIN1I)))))))))&8#_^R))&:)*]H[T!/(J'9)))))))))))
M))))))))))))))))))))))))))))))))))))))) !(!    ()!()!))(( ))
M)!)(!;)*VV?U!  ))!!!) )) )! (( ((  (! )! ))))))))))))))(/2UC
M'WZBW^6^]-S])))))))))!_,0_649(RWOF%X@P9)%1C)))))))))))))))))
M)))))))))))))))))))))))))))))))))))!( )!!)!  ! )!)!!!)))#)))
M))))))!0),DE)!$%(HA,$%)(A-$))I($ ,$,DDDDDDDDDDDDDDKZ6L8^_46_
MRWWIN6Y))))))))(+)+7Q(Y)).?8N<>GE9ZY#U))))))))))))))))))))))
M))))))))))))))))))))))))))))!)!)(() ((!! (!) )!)() *))))))))
M(*)0    ((!(( ((    ) )( (!  !               /2UC'WZBW^6^]-R
MQ)))))))))!_E2FIF)(( (!()!)()(!)))))))))))))))))))))))))))))
M))))))))))))))))))))))( ( !!(()(!))) ()())))+(!)))))))(!))MM
MLMMLLEMDLMMEMLLLMMLEDLEMMMMMMMMMMMMMMMMCZ6L8^_46_P M]Z;GB222
M2222221>( ;0823P&^ ,> ?N#P4<22222222222222222222222222222222
M222222222222222222222222222222222222222202 F22222"&R22222222
M22222222222222222222222222222222220WTM8Q]^HM_EOO3<F222222222
M22O;.]4R2)%7#T;M9_T(9.^2222222222222222222222222222222222222
M222222222222222222222222222222222220020 220  000
M                            #_\ I:QC[]1;_+?>FX\DDDDDDDDDDF1M
ME@4DDO:3G: ;\&O\X9<DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDL @@ D @D $DDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDZ?\ 2UC'WZBW^6^]-ZY))))))))))$@  0))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))) (!((9) )!2222222222222222222222
M22222222222222222223IGVNLD.^Q^WN_P#V@J222222222221%)*J222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222 4"""22 0"22222222222222222222222222
M2222222222222 20DDDDDDDDDDDDDDDDR222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222  0""B"222222222222222222222222222222222
M2222222220"2222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222220"DFDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDVBS;;;;;;;;;;;;;;;:R22222222222222) S222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222200                                              #2
M-))?O'91[98;)$I.2222222222222222"N22222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222"2222222222222222222222222222222222222222222222207_ -+6
M,??J+?Y;[TW,DDDDDDDDDDDDDE8@@4DD$D$D@D @$@@@DDD@DDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M@                                                 @_I:QC[]1;
M_+?>FY,DDDDDDDDDDD(2%SD3()-XR*4'[]6UU$<?/!ED@$DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD6]+6,??J+?Y;[TW
M-<DDDDDDDDDD%W>;(R_'><_M*4<*%RUV$PW8-(D@DDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDD@DDDDDDDDDDDDDD$DDDDDDDDDD
MDD$$@DD$@D DD@@D$$DD  $DDDDDDDDDDDDDDDDDWI:QC[]1;_+?>FY8DDDD
MDDDDDD4PPW<%>9'1/I\@359_<]FK_'<B2 $DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDD$ D@D@DD$ $@DD$D @$DDDDDD             @D$D
M@DD @D$ D@@@D@$$                  "]+6,??J+?Y;[TW+TDDDDDDDDD
M@:4]7 ZA=I108'\QU,I )W[-2-!SDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD@D@$ D$$$D@ $@@D@$$DDDDDDD2222222222220 D0$6"B@4
MBBD@44 0$& @R2222222222222222GI:QC[]1;_+?>FY<DDDDDDDDDD?[-N9
MFKKBH^A&X?GQ:&*F@ ,Z7LLDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDD@$  $ @@$$$@@$ @ $$DDDDDD$DDDDDDDDDDDDD $$@$D@@$@$$@D
M$@$ $@ DDDDDDDDDDDDDDDDC]+6,??J+?Y;[TW+TDDDDDDDDD@U&(HWD%5$2
MWKV!/(^YY]Y#7(AQ%DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDD@
M                 $GI:QC[]1;_ "WWIN4I)))))))))(/"?67#IE#=]54A
MH(@^0DQ1RX 97)))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))()))))))))))))))))))))))))))))))))))))
M)))))))))))))*/2UC'WZBW^6^]-[)))))))))))(GI$49#M6[(D8W=*O0A3
M'U#Q33I)))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))())))))))))))))))))))))))))))))))))))))))))
M)))))))//Z6L8^_46_RWWINK))))))))))) 7W'(-0P/:)ZID1LF(PA%!+LA
MN)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)(7_ $M8Q]^HM_EOO3?222222222222201B+IP222222222 :F(222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222                                               9E[)
M=NM]3(Y+#9(+8:2222222222222?5<4V2222222222+:7"22222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222"0                                            !&VVVVVVVV
MVVVVVVVV22222222222220  ((222222222238 *22222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222222220"2222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222 2222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222220"222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222 222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222220"22222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222 22222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222"2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222223__Q  Q$0 #   #!08' 0$  P$      1$A,6$0($&AT3!1<)'A
M\4!08'& @?"QP9"@P+#_V@ ( 0,! 3\0_P#C%TEL20UMB&H)4B'AL2&EL:4V
M+,:@E2+8L1J&9"(>Z7>(B(:@E2+8E1X,S((AJ"5(B(?<V)+:E2(B&MB5(B(:
M@DF-02HTE^#BRV+(6*'L<=IQVG@AY"S'EL69D,VQ.)FVC?#8G=T;FQC)M)L9
MMAO9:+(;V)T>8LMJP&[L1,3(;NRB<&L!!O\ !Q9;%EM%@A9[1YCQ6T>0LQY;
M%F9#-L9B4>PLAY[A&1[@LQY;#P9GL9A9#SWV866Q#VK(XCR%F1#2V)T>"_!U
M9;%D(>(\C-M,PLC(8\MCW#-L-PVED//8EO@3:9AN&S,+(3:A[$H/,66YEL6!
M<:9[%F9/DIB8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8
MF)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8F)B8[$YS
M^_9IOEU--\NIIOEU--\NIIOEU--\NIIOEU--\NIIOEU--\NIIOEU--\NIIOE
MU--\NIIOEU--\NIIOEU--\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NI
MHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%
M\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOE
MU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU--\NIIOEU--\NI
MIOEU--\NIIOEU--\NIIOEU--\NIIOEU--\NIIOEU--\NIIOEU--\NIIOEU--
M\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIHOEU-%\NIIOEU--\NIIOEU--\NIIOE
MU--\NIHOEU-%\NIHOEU-%\NIHOEU-!\NIH/EU-!\NIHOEU-%\NIHOEU-%\NI
MHOEU-%\NIHOEU-%\NIHOEU-%\NIIOEU--\NIIOEU--\NIIOEU--\NHVGS,GL
M3V)X#8MHQ,;PV-[$S!E2&Z+:3V$X5,P&]U-&!4AN[#V5#S$X5,P&Z)PJ9@AO
MNV)F X)PP9@AO8F8,P&_K8:21B'_ (#33C^ ?;4I2E*4I2E^&7R2$$ML(0A"
M$(0A"$(8L(2KQG0O$&FG'V[[:E*4I2E*43^&7P,(0A"$)O(A"$(0@D0A"$(0
MA"$(0A""K%L?C1'MQ]C2E*4A"$(0A"$$BE*4I2E[9? TI2E*4NY""P*4I2[E
M*4I2E*4I2E*4IE&JD8UXSJ<P]K=L^P?R9?-\ PLQ*\!6TE6/&EN:BQK[!'=C
M]Q3Q'CP$)E3^GHKWNV?8/Y,OF[H8VAB/@'C'>!#:Y=Q9"7DWF-MY[6RZ(*J3
M7TZN%Z]L^P?R9?-\1#$-'X!3'@AB?6]]5<31EMSOIQ\*UZ]L^P?R9?.6B$;I
M(2)+P!?EQY*[%I++ _W].8W;#[!_)E\Y:I!?@%WRD\NQMQ%1D7TUD4WVS[!_
M)E\W> D8U"0I2> ,^L7R74SJV[V/"/C_ ']-X>LWV[[!_)E\XV9%5]=TI2E&
M;[ ARTB7GYE3M@QIV*AS:#F)/,5:5WY"5,J*4I?I30VKMWV#^3+YN\C ""+Z
M^7MM[J/OQYP^[,Z=;(R]!+54>PQCQ;?8X)0NB(HP=EC=Z(R=PU_F/TLFHJ!2
MEWZ4NX^P>Y2E*4I2E*4I=E+LOP5W:4NVE+N4I2E*4I2[*4I2E*4I2E*4I2E*
M4I=Y#1$5?7S%3<93D,?S$V9;'Z)$1.<EWC[X"K.(F&5A]M]HJGGY""\ER<>
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MA!D+D9_2U]X8Q#&+<?9K=FS<?%!;S8TV8#I9MC#@==P$480ID58%H+BQ&;7
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M\.L_\.L_\%V;CY_PFTU*!NBNA"+0?QLYR:U) W_49*)*XS@E^PEDE94<U/3
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MM%YS?9!)!"Q'"1>!=KD9!6>D%G0D%;"@$IRY(W%)ADNU&GHM3S AR* )&E)
M'&G3JLBM&%B6"P!@Y"JYR]XMB%$O1<FB#U<R>@7Y@K>$QK]>+5(U8M6: TL+
M("[Y+M81S<'\PJC <+QHJ4Y\)5U+>+OR1:/R8AH2EI$?D6[0P$'T>R/F/5Q2
M,N[4B_-4812JJ*O:6UZ[2BJ>5$9AUJN<GT'T<>CR_P#<7_\ _P#>RT8[P^HF
M\=S;CIQ-<#?Q#4VXZ3IP-1CE^ WP-3;AO\&\=PWP-<#? U-IIP-?!I-OB-?
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M7 KI>QD(?PT+)A7D100QD3=!' @Y35L7@;@EJ4%; (-)AE'S@JWM=2['E5W
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M\=PWP-<#? U-IIP-?!I-OB-? -0W'9P-?!I#?'2&^!J;33@:FW$U-O@-\#7
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M275;(4:$JX4YSSF6619I9:T767*(:*O2L46#-]=7!#=<+85;K1@656FA2CZ
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MX4_DN%;@<.]6?6H]> NAYDQLV1)G"-D7>P3V8?X^*^XRPBQO4)5@*F<@^'*
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M4> T8P69V9N-[!O%9#4*8*O/1B9YS2FA\TMX3@H%6<-V)WN]$5?OB# #'("
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MX=!H=+I$^2KI4&KM6MU+XE1A*'M57>7ZX9I-\0YG4X[[E^N'E,&4"WS7^R
M!A'9UG\ &;QW-N.G$UP-_$-3;CI.G U&.7X#? U-N&_P;QW#? UP-\#4VFG
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M6Z@:!KY0B\E@/3.)<TZLH8;HL$6 59[7L%\U0 5]G:!:3!&E /:BB!O<"C4
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M6TJ",F%LJZAAI8HI#)O U_G0'"4KZ)W(1I4$N\I3^W. D$R(V,VXF9Q-^(B
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M%T6?Q'W:)GVT2J &G;X6?I ;DK5J.F0_2._-!E95YON1,1(%JS?.?K_]P/\
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M6E' %EE5BGDW-Q1X =@&X@2;K<U[WBI6?S>@=HXW_$'"?2  Y8E;-.S\T;:
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M<N7+ERY<N,9[2[1'I>SF7'LXTVLJYB<#?$U-.+::<=N&D-\#4-\34TX&H;^
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M9?\ %^A-KEAU<4*5\R@)YM1=T(;1@!6'1+7JX89,HQ@5HT&%FU34 6TNL
M!J)/WHD*OS>!7#T<P=IU;P:I;K 71&G33Q8B58S =,OHS%7<'ATQ@7)*%Q5U
M<J/ Y8)90VF<BK%Z+9+D +SPAWJ4)F;$NJO!YANA@1MTBJ)>BW6>4-JQ=0J
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M,N"P<\ )1*)<-\#7$U#<TAJ!;*.&W U ME$)MP-3;@+<-<#4VX[< @IXA<J
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MAK@:FW';@:FW';@:XFH;X&N)J&^!KX$WP-<241<>0USBU!CI&1(12RCEK![
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MAVX^(!![/.4D5_(>P"OF<06A6TM#SGY1F7BTON,L:$'FGZ)+E&P'Q7W<%HN
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MV5>XN132ZDS\O^WM02%6<-ONTG(95X'(]S"7%56JP%Y1:5O.8;T=28C9(U>
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M7?MN!?D!]PP=1.K&TZ8.)Z#8C1PR+LX$V"[*0V73YF_@OYGMPKVAMHYKNW5
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MLC\J#RNL*,"5%LO4=R^>$8O/S0XY6#.GHC7H3IVCL=W*8<%?+2M5Z[(J:6;
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MP$T"D4"(G; [1"VR^N6Z(1&D>3*K#+5^ZVBC?,-)-P6B-Y@+=+KPZBM7,LA
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M]X6_??[G[U_N%']O]PL_L_N?N'^Y^,_W#_WG^X)_<_W/V3_</W']PO\ N/\
M<_:/]S]@_P!S\Q_N=:,C!$WTK_?A[:=0//76?T#,Q'Y<5F!HP;FQ_P!;M11B
MJ^:GU?4(R]#H)[3VGM/:>T]I[3VGM/:>T]I[3VGM/:>T]I[3VGM/:>T]I[3V
MGM/:>T]I[3VGM/:>T]I[3VGM/:>T]I[3VGM/:>T]I[3VGM/:>T]I[3VGM/:>
MT]I[3VGM/:>T]I[3VGM/:>T]I[3VGM/:>T]I[3VGM/:>T]I[3VGM/:>T]I[3
MVGM/:>T]H ]8.P.Q.DOWAWUDNE9>RX(@FG@;XFIIQ;33CMPTAO@:AOB:FG U
M#?P%7:)-4#?\U*M@,(   Z7_ +L=HBI6 I1KHZ^\%6A=C>JBUB*9L7TCI%4W
MR#"RND +E_\ HM%^'['C<OA<OC?"_P#2O_I%4R1GF4^3D/\ R#L& =/O_D8
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M*2DI*2DI*2DI*2DI*2DI*2DI*2DI*2DI*2DI*2DI*2DI*2DI*2DI*1,)B8P
M=F!ZLG;3;S(GS(;XFIIQ;33CMPTAO@:AOB:FG U#?PYG UDLZGBYW$GHBS_;
M,:XE1J$G732-'SF@B(VK&(&:7)T/+Q!$FT#2V1DP6#SM4^E0X9T >F8,;>[[
MSR34(<QKTA0KS*O+TF ](KT3JQ5093<%4'TD,U!BHSJ&Z;?R"#;;8V6@E, @
MJ#KR(%RR^R<IR@*D^7NM(W(TSJ"H*MP[Z,_XF5K(7>+92.]-=O\ U#"W#O,)
MM>.TKOE$;V2@6X(-#3J9S6.LZQFKC+7*Y87R8I5E]X.V("QM.1*38GF)M8"
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M?$U-.+::<=N&D-\#4-\34TX&H;^%'A:RK3-)/.RRP.G^U%D1UFB:Y$UEU.7
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MP-0WQ-33@:AOX346\$B72E_7^U="=<S Z9R(2(77?C,V9DBV>8RIK<JYZ_\
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M'VE[4;CP7[3 2JE#Y$+4_P"Q@2N4S%78*_\ 1H  -T,CS;L[/^2@
M        82"7+88WR!ZU  &B&^)J:<6TTX[<-(;X&H;XFIIP-0W\ (F@+6%"
MZI74TGDMZ_W&1$16QM86I:3[4S1B*XH!>MQ%LH%TZW$CP:NZMKZ5" 3% K]U
M*C:$LG3(N631XJIE\R]T:43(WSBT-7?)-C LV+;.4+]5P48:I"YRT]X>U+$)
M[BS)H"\$8%QKE_%-"OO,ISQ,0URS%TJUM%'G"NY557.;ZRB^EJ+:GKW@\[00
MZ=^T.5>[#[P-Q@+8O*(<^U3/>)DB>M*E/A:$:[:]ODQZ! %8'5<QXCCD"H(7
M3W@(-06BOYPW$,*W@@2,],'U@ P6[ J"^R,;Y=R/*+C;?A9#H-7N,05<F<0X
M]1-!1;#.$\6^<TJ !Q#![,-=H8/, %.EFYFB%1 1I76X_CME97?/O,"(E[<M
MS3\:F,<A[3 &H,Z=7M,P,N&W*5@.#@!OD]XDA,HJQ.O>'+$BG<U""%X%A_8A
M<JJK,:_Z-4H/1R.1'^>T+M3M8PQUE_Y*]I7M*]I7M*]I7M*]I7M*]I7M*]I7
MM*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7
MM*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7
MM*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7
MM*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M*]I7M&LM:!R:YJT1D<([8]/\ +W7@
M;XFIIQ;33CMPTAO@:AOB:FG U#?P?R +?_+ELC@7<7\@OG_N'/ EZRQZ417.
M/!%S<YC'A8)CS>F)7O51HHH?XCUXKV#JC1AE&B:V$O-G.'@NB+TS'_4:$<TP
MRTGPEZ7(J"!%8H *@,2D2@9PWN9+S*1#%+O/F9]<JF2^U14R7YBM<J;Q,EY?
M,>A6;Q,IJE@3JS!7UYS'K-5?.4F?1EHYXE670E<DY/*XL;.)0"NAJ=(B!_%.
M=,#:S>O4S[8P@'0AWJ*\R*P-2@LU%ERYQN?Q5,@Y**H8$N-RX*6G.!Z76KBV
M\S<O2J'$4BQ6?G,29@(J\=_^C@&Y8_L+I.;#:</5YGU.<IU93JRG5E.K*=64
MZLIU93JRG5E.K*=64ZLIU93JRG5E.K*=64ZLIU93JRG5E.K*=64ZLIU93JRG
M5E.K*=64ZLIU93JRG5E.K*=64ZLIU93JRG5E.K*=64ZLIU93JRG5E.K*=64Z
MLIU93JRG5E.K*=64ZLIU93JRG5E.K*=64ZLIU93JRG5E.K*=64ZLIU93JRG5
ME.K*=64ZLIU93JRG5E.K*=64ZLIU93JRG5E.K*=64ZLIU93JRG5E.K*=64ZL
MIU93JRG5E.K*=64ZL1#[)9S ,Y:+T7F& 7CV(]>IXF^)J:<6TTX[<-(;X&H;
MXFIIP-0W\#MHP""R:<L5[@JACT(H#_=X(2\Z.1 ,@ZB7.UKO-3'UBV6#BEN$
M>E5$FB6+0O-LQJK^!4SJ"QT)180;MQN5+FQ==)K_ &9%+&I0U0<P,+'P+;_*
M0S8MWSZ$/%S2BI<<&LCTAK_IQ :RQP_5;'Q!]MP:%W# .I3VC0@W@?*S*]97
MK*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97
MK*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97
MK*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97
MK*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K*]97K.@CKAXO</N2T)=
M4I7G$4C*NCL# ['P8FA_Z+(ZJKLG[&?EL _]Y^4S\9GYS/QF?E, _P#:?E,_
M.9^,S]<S]$S\IGX3/RV?A,_5LR& X$&B[B3W_O +F!B(2I8:YUMG:7+0[097
MGD+F-(M(;;/]LERJF&5*E0_Z>P;!0%>#8@Y="B;W@^<:HZPK^5,<:/.*/\7>
M/'CQX\>/'CQX\>/'CQX\>/'CQX\>/'CQX\>/'CQX\>/'CQX\>/'CQX\>/'CQ
MX\>/'CQX\>/'CQX\>/'CQX\>/'CQX\>/'CQX\>/#4U?RN2F=0&^5/Y@#@!9?
MG5^50J;JB4>Q4/1%!9X;E8;?5@<.5E@<:_X#FS9LV;-FS9LV;-FS9LV;-FS9
MLV;-FS9LV;-FI8(:U6MJN>K_ +RI1*)4HZ2CI*)1*K_<5*)1*_\ \2OE3E3E
83E3E3E0P1:JTO#?A@0D8#!;,G_[>?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>xcur-20200630_g2.jpg
<TEXT>
begin 644 xcur-20200630_g2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #__@ 30W)E871E9"!W:71H($=)35#_X@*P
M24-#7U!23T9)3$4  0$   *@;&-M<P0P  !M;G1R4D="(%A96B 'Y  ' !X
M%0 F "]A8W-P35-&5                                   ]M8  0
M  #3+6QC;7,
M              UD97-C   !(    $!C<')T   !8    #9W='!T   !F
M !1C:&%D   !K    "QR6%E:   !V    !1B6%E:   ![    !1G6%E:   "
M     !1R5%)#   "%    "!G5%)#   "%    "!B5%)#   "%    "!C:')M
M   "-    "1D;6YD   "6    "1D;61D   "?    "1M;'5C          $
M   ,96Y54P   "0    < $< 20!- %  ( !B '4 :0!L '0 +0!I &X ( !S
M %( 1P!";6QU8P         !    #&5N55,    :    ' !0 '4 8@!L &D
M8P @ $0 ;P!M &$ :0!N  !865H@        ]M8  0    #3+7-F,S(
M  $,0@  !=[___,E   'DP  _9#___NA___]H@   ]P  ,!N6%E:(
M &^@   X]0   Y!865H@        ))\   ^$  "VQ%A96B        !BEP
MMX<  !C9<&%R80       P    )F9@  \J<   U9   3T   "EMC:')M
M   #     */7  !4?   3,T  )F:   F9P  #UQM;'5C          $    ,
M96Y54P    @    < $< 20!- %!M;'5C          $    ,96Y54P    @
M   < ', 4@!' $+_VP!#  ," @," @,# P,$ P,$!0@%!00$!0H'!P8(# H,
M# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_VP!# 0,$! 4$
M!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!3_P@ 1" 1'![\# 1$  A$! Q$!_\0 '0 !  (# 0$!
M 0            8'! 4( P(!"?_$ !H! 0 # 0$!               #! 8%
M @'_V@ , P$  A #$    >J0
M
M
M
M
M
M
M
M
M                                    "NK$4>D\R2/U85>7FGHU>EN=
M:      &O]?*:N0>OS[==*;U?13MN#S^I!'ZL:O*       !K/7FJ+45U4YP
M   !4UJ'#]?))%[L&"0  #Y*&O5[[HV
M
M..^O2F\$E76HNC.=8Y8ZE7M3C7?I]D<?J,2>-1[^3F#W^$'G\2R+WL?/V#S1
M[KQZW_CT*RLQ1>7Q0EZOTISK5N5)A_/GO\[J#F6I!'ZED7O;>/NM]?,OY]\?
MJ+2^)9#[ROB%S>,KY]ET7O4>O.-Z>#Y)X_<>D\ZOUYDL?NJ;4-S4YX[)YTWO
MS.(/>'Z?!%Y?$X@D^@<#=WG]%<^S5%J&=02=&<^S%9?'B3"+WJ/7F-2^9O![
MI"[!>E*Q%9?'D;KQ]_#Q^L#U\E<7L
M                            #Y,8                     'T9( !Q
MWUZ5V4IZ3NP7/3GYCZ56TZLM7VHNW^+>YMZ-;#^_)''ZQ/K*^+!KR5[8C^RN
M;$?6_*N2"/T/-\X9[='JWEVY[!(/Y[]_G= 4+%FUI:AMPYOG[6=F+HWGV>6^
MG4L:O+H??GH"A8K"S%6MF+J+F6^7.G4G4$E968NQ^1=Y)ZM.YZ<]F5I>6.I4
MZ6YMKF/IU97%ZR_/W?\ CU6]B+[?;=J37A2G' W=Y_=W#OZKW\XR[%+ISF6J
M7NP?7Q;E2;G7HUKQHSV;6EXN[-+L#D7.=.C6^"=P25G9BEL7NN;$797'NR:/
MV /(\0                     ?9D
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M5\NWQ;V:77?)N<S=*K[?'4?,M\J]2IUKRKG-G1JWC2GL2O* -4:D
M             &J+                                   !'S+-J
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MGJT^M>5<YLZ-6\:4]B5Y0                       (434
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M[:4TLB]QN3SO(_6?\^@                       0HFH
M                    (^99M0
M     1B3Q7%F.[J4X                 BTOBB;L'J7S1L2&/T
M                !"B:@                                  CYEFU
M
M                           (434
M     $?,LVH
M                                     !"B:@  \P
M                 : RS:
M                                                 $,)F  #"
M                            !I3)-B
M
M 10E8                                  -*9)L0
M
M           "*$K                                  !B'V9
M
M                     !@F<
M
M
M
M
M         "O^?S<?SY                                D=FS);-L
M               1&G2TL,                                &1Z]6!
MT.D                                      .3,EC;;ZO7
M                      &EA@\2^.]H@                !S?F\O*[-K-
M]^P                              !4G*Y'6>MV0
M                      Y9RN0ZWU6O
M   $+IT:JYO+OCO:(                 <WYO+]#][0[J:<
M                   <D97(=3:K7@
M       #EG*Y#K?5:\                               0NG1JKF\N^.
M]H@                !S?F\OT/WM#NIIP
M    !R1E<AU-JM>                                      .6<KD.M
M]5KP                              !"Z=&JN;R[X[VB
M     '-^;R_0_>T.ZFG                               ')&5R'4VJU
MX                                      Y9RN0ZWU6O
M                    $+IT:JYO+OCO:(                 <WYO+]#][
M0[J:<                               <D97(=3:K7@
M                        #EG*Y#K?5:\
M      0NG1JKF\N^.]H@  (V;LR01TA1:X   !%R4$1)<"/'F24   YOS>7Z
M'[VAW4TX                               Y(RN0ZFU6O
M                           '+.5R'6^JUX          B52G'H*\GLVI
M/9M   "D>+PY!8L3"W<WT]C CCB]:K-[MZ)5*>MCCG]_H          "%TZ-
M5<WEWQWM$  !CE>F:3TQRLBU05,?A."-F&9A\$5+-(^;$BA-SY)6   <WYO+
M]#][0[J:<         #40PPBG1V$DD^O=    4]R>--+=W1PP63T>G\_/E?4
M.?8?0Z.C@@B56G8%_H9/KV          .2,KD.IM5KP
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MG-6<S-D='I::&&YNQV@         !R1E<AU-JM>
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M#\/@>?SY[^O5Z]OO          #DC*Y#J;5:\
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M:KSQP,[>_;[V#XCA%*C8O0Z4VNW@         !R1E<AU-JM>
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M^\#Q']ON9[]_IJ8HMM++@^/&3Z]>7SYE^_>'X\8/B/(]>O;[Z^7S.]R
M      <D97(=3:K7@                 4/?K0.>.SZLT,GCT?OS?="S0'0
MK;7QZFL/NO+$7F6!!+JO7F'S>+3JS5_8BT_OY=M&>(S>.@.?9IVY!'I//0?/
MLCDOK4]KY^RF+W!)X[GI3U!<@ZIY5P    #EG*Y#K?5:\
M                0NG1JKF\N^.]H@                !S?F\OT/WM#NII
MP                              !R1E<AU-JM>         -+!!&JU3R
M^?-S-/*+5O[^_0    !0]^MMO'JG;D&;\^R:+W9-:7FKI5;6JS9OE ;$?3W+
MMU?:BH:_6O[GV:\LQ;?QZTGOS:-6:-2^.@.?9IB[!IO?GH#GV<;[\XG[="W*
M<_J0Z;Q<]*>H+D'5/*N     <LY7(=;ZK7@
M     "%TZ-5<WEWQWM$   *]-691X&\(@6<5$99/B'GB;('N:DF!H#P)F2(
M  '-^;R_0_>T.ZFG                               ')&5R'4VJUX
M      C=:K27$X,0IT0!LI)K>[':L_J=;]    !1%^O*(O5/W(;&K2QF7Q:]
M2;G7HU9U!)-X)*;N0=/<RW5]J+#^_*GMPVA5EB4WC?1^IW!)$)O%_<^SIO?G
MDGKT[&K22V'W3MV&;0>YC#)5%N&Z*4]/7(.I^5<     Y9RN0ZWU6O
M                         $+IT:JYO+OCO:(   5Z30J(E!*2*F61\W!I
MB?$!,HM J\E1#34$L)6;@   '-^;R_0_>T.ZFG
M         ')&5R'4VJUX       $'H\_GW/9OQ^>0  +&Z/4OGO:']^_0
M   /)\U'OYN_'K]  !J/?G,\_<OY] 'B^:KW\W7CU\/FG]_-UX]?0      .
M6<KD.M]5KP               -4;4%4FP)L5R2$SR(%DD",8L$V(       !
M"Z=&JN;R[X[VB   $>-T:,CI)2+DR*C)<3TKPWA[$H(N:LS#+(^34V    .;
M\WE^A^]H=U-.               -4;4$ -86*5\?9/"NR7F$1\E)*
M  <D97(=3:K7@      #3PP<PY?)XOGP   !=/:[UK];L
M         #EG*Y#K?5:\       #Y*M) :L^C*)D0PCI,"+DC)H1HB)*RIB\
M#8E1&*3TUA%2X2,FI- 6V4X72        0NG1JKF\N^.]H@      -";X
M      '-^;R_0_>T.ZFG        @)@&\(T;LF1#C3$A(Z>Q9Q@$!-T5F6R2
M8IXFQJ#2&R)22$I0SRW2DRZ3[        .2,KD.IM5KP      !17"SU:<SE
M #*]>Y7:MPJG1 &7Z]]6:O89/OV                       !RSE<AUOJM
M>       !%S7$Y*R(J28\R5FB-&7$5 7 14B!MC5EK@YY-B6D5<38GA31;Y4
MQ<)31<H       !"Z=&JN;R[X[VB                 '-^;R_0_>T.ZFG
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M7G1R>?DZ!Y]GG+HUM=[\W[S[-;68H[)YV7G['I/-JU9?@JNU#.H)+KI6
M !RSE<AUOJM>                               (73HU5S>7?'>T0
M   '@5"?!."#EN&8       <WYO+]#][0[J:<
M        <D97(=3:K7@      :V*+E'*8X  =#=[1\\\'.  7)V>Y;G7[0
M '%7:H=C<>]G^?NG]^:CMPTM=@ZBY=OGKHUNK>3;Y-ZU/L+CWJ^L15E:BC\G
MGH;G6>6NK4O[GV(A-XGU>2L;44'GCZSY-SC_ +%+J[DW.?\ H5KWH6*ULQ5;
M:B[-XUX     <LY7(=;ZK7@                              "%TZ-5<
MWEWQWM$      !J"('V>ILR5@       YOS>7Z'[VAW4TX
M                 Y(RN0ZFU6O       _/GSDW)X["\1@"9W+MS=?M41Q.
M#':]8 =!:#2S[H=$   #EWJ5)O![EL7NO;$?M\55;BZ4YEJD;U?I_EV^..S1
MZAY=N/2>:_L1Q^3STCS;7)_6I]$<ZS5%N&:P>]5[^5K9BZ_X]WD#L4NJ>5<Y
MVZ-7P^KBIS4#?K]F<:\     .6<KD.M]5KP      !718H    !7Q8(
M  *^+! *^+! !7Q8(   !"Z=&JN;R[X[VB       %?'V2L^3:@       YO
MS>7Z'[VAW4TX      &E-82T    &@/@D0      !!29GN"OBP0 0TD9G@
M ')&5R'4VJUX       HKA9ZM.9R@!,[EW]?=;'%':]8#+]>^J]7L,KW[
M P?ORGKL'O\ /MFU9:CN0R>+U/:\D5E\SV"2N[$4-G\6E4EU_KYA^ODV@DK^
MQ'9-:6GKD&%Z^7-2G@%B.Q:TM<V8I]7DAD_C,\H'8CE</NPZ\H     Y9RN0
MZWU6O    TQ"C=D8/ LPK4B)T:"DS*+(((;DTIA&:9)KC(-^1HDQ&3Y+<,8J
M(RBPB#FZ- 2,FQ5!+2'EB%($C+*(";<TY:X   !"Z=&JN;R[X[VB
M         '-^;R_0_>T.ZFG    K,^3--4;XUIH"6$]*I,8L(@QZ&\(X8)]D
MY*]-P;0P3V-66&;HJ<QRQB!'N;(U9:161,"'FS(4;(GQ"SS-H2\V@   !R1E
M<AU-JM>       -/#!S!E\GC>?    %T=KNVQUNR
M    .6<KD.M]5KP   (R18PS[)F1D]#4EN@J@RS2&W/4PB9F 18]BURH#W)J
M:(QR8F008UAX&W/HUY;(*H-X1DEI&S9&A-B>QBEK@   $+IT:JYO+OCO:(
M       8IE       '-^;R_0_>T.ZFG   'D56:8W1;!4QXD[-,3TJ<L4JXU
MQMC;DX*V,PVIDD,,HM<I\M,KLM(J@GQ6)B&U/8M4^BLB2D5,$R"RRJC2&_-J
M34V@   !R1E<AU-JM>       !!J//Y^SV;\?GD  "Q>CU+Y[VA^OOT
M                   <LY7(=;ZK7@   1 CAG'V2<P"#&$7>#G4E98A!24&
MK).89H :PDAA$]*C/4MHP2CB2D](22@U18(*^/@U9,2MC8%CD!)0:TL$
MA=.C57-Y=\=[1   #X,(SS6&S,<\#V/0^#P,\K LXP#)*^+$,(V!]    YOS
M>7Z'[VAW4TX   \"IS]-Z6"5\81ADL)<48;0L0@)N#+)60D]S8$'-B; L$K$
MP2QC;%%&U+(*]-V?)8((*9I%S+,$\2PB"&P-J2,SP   #DC*Y#J;5:\
M   1JK4I'B<&)5*0 V,DMO=?M6AU>M^OH    %?V(O@E,7O5^_DNA]@    #
M3^_/M\^[+S] $=D\5C:BF$/O8>?L%G\3F#W,89     !RSE<AUOJM>
M  !"2;        QB-DM            !"Z=&JN;R[X[VB   %2&]->;(TYJC
M+,LQCZ-R89\&*>IN")DC,<\2U    <WYO+]#][0[J:<        0DFP
M  !"2;             ')&5R'4VJUX         TD%>-5JOCY\[F>>4VKGI]
M^@     4K=@CTGBVJDVF]_+*K2US9BTOOS+8?<SADJ2W#;=2:J[4.'Z^>'UN
MX_MF5IJ6NP8/KY.8/<5E\[GQ]L^K-XOGJ^\[=&KD?/O07/LT!T*U_P#/L@
M  #EG*Y#K?5:\                               0NG1JKF\N^.]H@
M!3Y9Y61:161DDE/4B!Y%CE>'L:<FQO2OCT-L;@D@   .;\WE^A^]H=U-.
M                            .2,KD.IM5KP                 !2MV
M"PZ\E(WH++JRV56EKFS%I??F6P^YG#)0E^M?="S1UZOC_?E\T+- ]"M?W/LU
M_8BS_/VL[45^\^S05^M?M"R*:NP3JO)^$'GCC4OCHGG6@    !RSE<AUOJM>
M                               (73HU5S>7?'>T0   TA'27$*)N:XS
MCZ-<0LVA-#6&21(FA&21$1-^2$   '-^;R_0_>T.ZFG
M              ')&5R'4VJUX                  J.W!:=6:D[L$VA]S^
MO* !55J'5^_GF^:63SO8_6S\^K7J31F7Q6%J*0Q>M9[^9_G[;%2: V(JDMPV
M)6EWWCU"IHYI#).()     !RSE<AUOJM>
M    (73HU5S>7?'>T0       &K-H        #F_-Y?H?O:'=33@
M                      #DC*Y#J;5:\                        4O=
M@NBE.            !RSE<AUOJM>            !RZ=,%9%K@%+$L/LCYZE
MJ@            A=.C57-Y=\=[1                 #F_-Y?H?O:'=33@
M          "C"=FA+6 (&0 MDKL%S             ')&5R'4VJUX
M                               Y9RN0ZWU6O             I4SST-
MZ:PF)X&E(V7"5"6\            "%TZ-5<WEWQWM$   ,<\3,, V)KS-,<^
M#., R3X/$S3Q/@R#!-B    <WYO+]#][0[J:<            5(81GDU(L;L
MF1398)7)I#H0             Y(RN0ZFU6O
M             '+.5R'6^JUX            %1&0:\E9K"8G@:4CY995Y<0
M           (73HU5S>7?'>T0   KTQS7GJ;4BY:94!L"6&H-.;8V!KS4E@$
M)/4EQ*@   <WYO+]#][0[J:<            5$3PH@O0BQNS ,\EYY%0ES
M           ')&5R'4VJUX
MY9RN0ZWU6O             CIO"-DJ *V/PL$@!.#8             A=.C5
M7-Y=\=[1   "O2:%2DV-R: Q2/&Z,8EA!S.+0*O)F5V8I.3?FS   !S?F\OT
M/WM#NIIP           !'21$0)> 0$P"8D2)H;4             Y(RN0ZFU
M6O                                      '+.5R'6^JUX
M                      A=.C57-Y=\=[1   #3&T->1(E1%2:E2$S)F0,W
MY^F^-":@V)F$5)L9@   .;\WE^A^]H=U-.
M     .2,KD.IM5KP                                     !RSE<AU
MOJM>                               (73HU5S>7?'>T0      &K-H
M        #F_-Y?H?O:'=33@                              #DC*Y#J
M;5:\                                      <LY7(=;ZK7@
M                       "%TZ-5<WEWQWM$                 .;\WE^
MA^]H=U-.                               .2,KD.IM5KP
M                           !RSE<AUOJM>
M         (73HU5S>7?'>T0                 YOS>7Z'[VAW4TX
M                         Y(RN0ZFU6O
M             '+.5R'6^JUX                               A=.C5
M7-Y=\=[1                 #F_-Y?H?O:'=33@
M          #DC*Y#J;5:\                                      <
MI9/'=%:#1@                              ",5JL1K5;X[VB
M          '-^;R]L]/J[264                               <ZY_.
M=6ZS8@                                     "C^'P,?SX
M                        FMV_8?1Z8                 JWE<B,UJ@
M                              &1Z]WAW.^
M
M
M
M
M
M
M
M
M
M
M   ,L
M
M        'L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     #Y
M
M          !@
M
M
M
M
M
M
M
M
M
M
M      K_ )_-Q_/D                               "1V;,ELVP
M            !$:=+2PP                                9'KU8'0Z
M0                                      Y,R6-MOJ]<
M                    :6&#Q+X[VB                 '-^;R\KLVLWW[
M                               %2<KD=9ZW9
M                   #EG*Y#K?5:\
M 0NG1JKF\N^.]H@                !S?F\OT/WM#NIIP
M                !R1E<AU-JM>
M     .6<KD.M]5KP                              !"Z=&JN;R[X[VB
M                 '-^;R_0_>T.ZFG
M  ')&5R'4VJUX                                      Y9RN0ZWU6
MO           \?/F(U:?V^S&Y=   %?T.=NYIXO6JV;TNH(Y7K>GW[OY[
M        $+IT:JYO+OCO:(                 <WYO+]#][0[J:<
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MV[GK]^V[UNP          .2,KD.IM5KP
M         !RSE<AUOJM>          !&Z];GS@9VVNKU]=''Z_?M>4.=/KW0
MP?$>LCBL6_TJ<Y/&FER[*[-N 4>??O=T%'<7A87CQKHXNC]#I0
M(73HU5S>7?'>T0  &F-N?0-20DLP    T)OB(DN!HSS)    <WYO+]#][0[J
M:<         "O.?S:KYG*MKJ]>"4:$SN7:NYG+WT\^^GL0VI2N#K=FEN-Q-E
M+)8M_I1JO5N/K]H<T9S,=+Z/3\Z9_-Y_N3U]?;W[??          ')&5R'4V
MJUX                  CTGGG[H5O?XZ0YMK+^?0*^L13F"3(^?0
M       .6<KD.M]5KP          (W7K4CQ>%<'6[,3JU)5:M4[R./.+MZ56
MK4"HT-_/8KOG\V6V[DKLVX!1Y]^]W05-RN1A^?$0J4^E-%I@          (7
M3HU5S>7?'>T0  &L((2 EQJRO2U@5@8Y/B)'R9AAD4+--2>Y'28'F2L   YO
MS>7Z'[VAW4TX         %><_FPBG1M#I=6L>;R[>ZW8H/A<#?3SV]UNQ2'%
MX=B=#HUQS^;D^O5BW^E&J]6X^OVM-#!SEG\WT%W=%A>(X-2HR>S:L/H=$
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MOW;RS?#Y%ZM646K6IBBV/N3%\^=Q--IH8-)#!L/<OKZ^^7GY)+-D
M  #DC*Y#J;5:\                  <5=JAV-Q[V?Y^U=:AC$OCW^?=SX]5
M-;AZ8YEJ+2^*RM1:7WYW'CU8]:6E+M>ZZ5BA.A6F4$FX\?:JMQ=F<6[QEVJ-
MP4Y]SX]0:>.S*LO._2K= \ZS9E:4     <LY7(=;ZK7@
M              "%TZ-5<WEWQWM$  !$33&\)61PKLLHWI2ILR=$%!NR>$#-
MB:XUIK"?'V2    YOS>7Z'[VAW4TX
MY(RN0ZFU6O                  '+O4J3>#W+8O>C]_(%8BQ/JRJTM46X;V
MH6.;>E5O6C8JRU#N/'JT:LM'7H+JI3T%?K7U0L[V/URQU:?47+M\T=.K;].?
M6>O-?V([ZH6/+ZYKZ57MSB7P    !RSE<AUOJM>
M          (73HU5S>7?'>T0      $-)D         #F_-Y?H?O:'=33@
M                            #DC*Y#J;5:\                  8/W
MY3UV#W^?;=IS4O=@E,7N51>]/[\Q:7QNX_6ED\R.+WD_&^\>HK+XFT$E;68H
MU+YMVG-HI/->6(K3JS;?QZIF[!+X?<MA]U-;AD\7JS:TP     Y9RN0ZWU6O
M                               $+IT:JYO+OCO:(
M  <WYO+]#][0[J:<                               <D97(=3:K7@
M                                   #EG*Y#K?5:\
M #%,H%:FV)05\2DRR(E@D),8GID        $+IT:JYO+OCO:(
M      <WYO+]#][0[J:<               8IE AAJRP2!&43$@!,# (T30V
MX        .2,KD.IM5KP        !C^?.@KUO+YYW,T^SEF
M             '+.5R'6^JUX        K8W9JS(,HE1$C1$K(B2TDQ'R($O*
M>+P-B5$8A/C5D2+8- :\T!9Y59<P       !"Z=&JN;R[X[VB   $%-*;(P"
M2D0+#*L,@L,@Q]FP,4V)K21&J, G!NP   <WYO+]#][0[J:<       "'&H-
MZ1TWQ*B*FL-F:4R2P#%*^)(5.6R28IXFYI33&42PW14!GEL%)%X'T
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MSX( :4SRUP4>:XO I(D!;1!S((L6Z5&6D90       !R1E<AU-JM>
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M(  .6<KD.M]5KP                              !"Z=&JN;R[X[VB
M     BY*          <WYO+]#][0[J:<
M   <D97(=3:K7@      "E>)P:IY7' /LYNWLGUZK^AS_E\ V,DO56JU_KZ]
M >/WX^.9.I5E,7N"SQ]%\ZSS[T*VY\>K5J34#T*U]\^Q0W0K^_S[<U*?GGHU
MNM^1<YGZ=6YZ4\)GCK"U%V9Q;W(W7I732G@T\<CC]_AO/'V@;]?K?D7-KY]<
M6]JAUOR+NV\?:&Z%>*2^)3%[FT$E56X1=U&>8PR  #EG*Y#K?5:\
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M6UJ(6G4ED<?L  <LY7(=;ZK7@    "#$Y    !CD=)4#"-&8Q,@  "$DV
M  (238 A)-@ 0DFP !"Z=&JN;R[X[VB                 '-^;R_0_>T.Z
MFG          T1^F\    !#B8@$)/0F0  !"2;        ')&5R'4VJUX
M   &OCBY/R>.  %H]+JX?GQ77/YH N?L]VV>OV0  !H9//.W1J]3\JX
M             !RSE<AUOJM> !IB%$G(T8!9Q7)!SHL^2K20&$8!,B"GX?!9
MQ'2.F,3\C!FFK-8;$SC/(R664*2XM8QBK#+)^5^2,T9M2;%4$M(J6(4:2HLH
MKLWQ'"UP "%TZ-5<WEWQWM$      !YE3'P3D@A:QF       '-^;R_0_>T.
MZFG      'B5P;(^R/DT- 14GY+BN3]-J1PL,JTRCY)Z:8Q33$]((2$_"/'L
M?1-2%DK*O-R6>9@      !R1E<AU-JM>      !JXH>4\ICP -S+/=G9[?/G
M!SWR^ "X^QW+=[':                        Y9RN0ZWU6O  TA##!/TF
MI&SZ-06^1<UQ.3GPD)(#;$-)2?9I#")8:<^S5GF2\\2*$I(63\AQFDZ/0@9K
MSQ-J8QX%N J@E!#"7$9-F:,SCX/TM<  A=.C57-Y=\=[1       :8BQZ'P;
M8E8       .;\WE^A^]H=U-.      ,<K8TALRV"IS')@?9+BGRX"C21&Z(V
M?!:16A^'P6N5*>P/DM8J8^2P"(&$?A.R/%@@      ')&5R'4VJUX      '
MQ\^<EY+&XWGP!F>Y.C-!HZ7X_%TL,&IBA %^]_1V'T>F    -?Z^?IG^?H
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MO+OCO:(                 <WYO+]#][0[J:<                5\6"
M            <D97(=3:K7@      ".UJO,N9ROG\\@   6SUNS<_:[H
MXV[-'JWDW-YX]0^:.HK<-=V8NHN7<Y-ZU*]Z%FJ[<,MA]S>"2%3QZ&3SNX_4
M$GCZMY5SESJ4]CY]6O4EIV[#*8?< L13"&3=>/LPADATT<7E\]9<FX     .
M6<KD.M]5KP                              !"Z=&JN;R[X[VB
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M,HCA895A8QO2J#;&&; CIOS<D4)R0$M<           Y(RN0ZFU6O
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MDV*Q-:2(W1&2W 509Y"2P20%=F$24]36%K@          ')&5R'4VJUX
M                                  Y9RN0ZWU6O %0DQ,DAY:AH2 &\
M-&>ADDT( 2@U19!A%5DE->685F"QRFST)P?IJ"PRHC7EDE=F,3LCA\&P)*1,
M]S--.;4Q2;$9(D?)ORS#P-85T6>0 L\ A=.C57-Y=\=[1   "*F@)<0PFQKS
M9GT:@B1EDY-4>I'29D0),1,D))@   <WYO+]#][0[J:<          5N:DSC
MU/TFY!BS 5F:0PB?D4,HVABDQ(<68           <D97(=3:K7@
M                            #EG*Y#K?5:\ 5Z6$      0TF0
M             (<2$V !"Z=&JN;R[X[VB        T)O@        <WYO+]#
M][0[J:<          0DE9E@                   Y(RN0ZFU6O
M          %2VX<+U\L.M)HY/-@5Y0    !%Y?&5\^[Z/T (Q+XK:S%E^?NU
M\_=+[^;GQ]M&K,     .6<KD.M]5KP
M!"Z=&JN;R[X[VB                 '-^;R_0_>T.ZFG
M                ')&5R'4VJUX                  I6[!K?7F=P28WU9
M5:6N;,6E]^9;#[F<,E"WZU]4+-'WJ^!Z^;CQZ\7R[:5BEKL&#Z^;KQ]Q/KP^
M_+OHV!B??E%WZ_P6Q4FIZY!T7SK0     Y9RN0ZWU6O
M              $+IT:JYO+OCO:(                 <WYO+]#][0[J:<
M                              <D97(=3:K7@                 "E
M;L%JU)>;^G5MNG/95:6N;,6E]^9;#[F<,E"7ZU]4+-%7JWA]7Y0LT#T*U_\
M/LU_8BSO/VL[45_<^S05^M?M"SYOE#WZ]UTK'I\0^;Q ;$5]T+(     Y9RN
M0ZWU6O                               $+IT:JYO+OCO:(   5Z:LRC
MP-X1 LXJ(RR?$//$V0/<U),#0'@3,D0   .;\WE^A^]H=U-.
M                   .2,KD.IM5KP                 !7UB*=P25W8CW
ML?J6Q>P (=-'!IX]WX]0N;QNO'J9P^YM!)J??FK;44T@]PR?Q+X?<X@D@T\=
M?V(Y)%ZWWCU#9O%GU9=UX]     #EG*Y#K?5:\            #ETZ8*R+7
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M@            !R1E<AU-JM>
M  .6<KD.M]5KP            *B,@UY*S6$Q/ TI'RRRKRX@
M0NG1JKF\N^.]H@      -";X         '-^;R_0_>T.ZFG            %
M1$\*(+T(L;LP#/)>>14)<P            !R1E<AU-JM>
M                       .6<KD.M]5KP            (Z;PC9*@"MC\+!
M( 3@V             (73HU5S>7?'>T0                 YOS>7Z'[VAW
M4TX            CI(B($O ("8!,2)$T-J             <D97(=3:K7@
M                                   #EG*Y#K?5:\
M                 0NG1JKF\N^.]H@                !S?F\OT/WM#NI
MIP                              !R1E<AU-JM>
M                     .6<KD.M]5KP
M  !"Z=&JN;R[X[VB                 '-^;R_0_>T.ZFG
M                  ')&5R'4VJUX
M       Y2R>.Z*T&C                               $8K58C6JWQWM
M$                 .;\WE[9Z?5VDLH
M   YUS^<ZMUFQ                                      %'\/@8_GP
M                               !-;M^P^CTP                !5O
M*Y$9K5                                ,CU[O#N=\
M
M
M
M
M
M
M
M
M
M
M           98
M
M                /8
M
M
M
M
M
M
M
M
M
M
M
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M%XO O%X%XO O%X%XO O%X%XO O%X%XO O%X%XO O%X%XO O%X%XO O%X%XO
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MN<.O"XN48!O"KN&<PZ^0TQYS,3<0J;5D%\RK]Y0U"3#(V=PR4/[X<+<!H_\
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MG"].%Z<+TX7IPO3A>G"].%Z<+TX7IPO3A>G"].%Z<+TX7IPO3A>G",PKRD;
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M1_\ Y:6\1/YX"-,*");FJ]DF(<VPLQMOEDOX@]9.]G\.?\7TFO<2D4<?-BQ
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M@D#86PN&M K-V4O+!LD81 W1L"'QBXPVQ7.(L:G-U;,6T,C_ !0Y]FR6O?\
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MQ7X,GYQJ,7$+Z4Y:?V03K/LR8+<;865D^3!$0[H16T4ZI,#3?([%1UAD9@L
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ME3LJ&.25BE ;.20?(5R9 8QRS+N1)(<8+"CAC"5:97 ,"UR,A'YR[N$)T;]
M-]9_IN(XB]H7ADS:5'%9N*&X9EDN*0GAP;:C<L_DF QGX:=N\1[:TDH$^/S#
MC=UN[C\E#M8_PU[CXI]0@7:?$7N;*RO(0*'OA[(GF<1/!CCKH<18M[KXS),D
MO$8V8?!DD4IXHX;KA?#R0,F0R;'\9XI%'-C*&7&XY(VS_'AP'?<"=9_0)EVW
M ^K^_0-FI)?B2[N$)T;] -]9_IGC+ 0;N^%K;)>PX8,\&2YIAN:N>%F"_-9
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M?V6U#C*UN&D/X$!LMH&XAVT\+.\MU15CR1XK @TG219\=N7B!]+_ /<$[(K
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M6UI)0%M;04MQW;GD@CSL.',/8<2D4T<R7# XYD",9K9=NEM3[-P]EV\3]*W
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MA$"QVVA9UCMN!OKKKX&![6X?=&1>359O9*[,.!AFZMD)B=EMD?D]M*2J??\
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MV>!_AV4"P5A>*PC*O<"=9_0)EVW ^K^Q..C-8QE+8#CMP0+O8C8R:C3.5W'
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MI46E1:5%I46E1:5%I46E1:5%I46E3_UT?__$ #T1   $ 08- P,$ P " P
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M#6@.Z SMQGI'J_P%*-0;1-G,.EFG"%T1ZI!"J1 G2VAQ1*T!HLPVAW5"53;
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MMI"'.VD(<[:0ASMI"'.VD(<[:0ASMI"'.VD(<[:0ASMI"'.VD$X.7/\ <?\
M]E_5+VDG,(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5A
MB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6
M&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU
M88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+
M5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(M6&(BU88B+5AB(
MM6&(BU88B+5AAF4H?U?A7I6VR=$Q$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#
M$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L
M,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%J
MPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6
MK#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1
M:L,1%JPQ$6K#$1:L,1%JPQ$6K#$1:L,)E[2CFX/0FFHDVB&\_00WGZ"&\_00
MWGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\
M_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ
M"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00
MWGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ"&\
M_00WGZ"&\_00WGZ"&\_00WGZ"&\_00WGZ!Z1>B@UTA@ZM.[X66UZO-@1@^FD
ME4M(AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO
M/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^
M@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$
M-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO
M/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@AO/T$-Y^@6F@HTV<'
ML5J;RX!EM0KS:,'5IW?"RVO5YL#%4FXN 7ZU5Y\'L5J;RX!EM0KS:,'5IW?"
MRVO5YL#%4FXN 7ZU5Y\'L5J;R]P9DDIS&6L;W<%+&#S4OPRN4*8FH[0ATU,^
MH)+*EOJ-*L:Y2TV<RE!M]MTYD'[B6U"O-HP=6G=\++:]7FP,52;B]LM:6RI*
M&6L;W<(E3*SHI/\ #*I4MA9)20<=-#/J$))*%/D=+&J5,H.8U8EK2V4ZC!2M
M@\U(:?;OUJKSX/8K4WE[B4U*A(FD.K,ED"D;!9Z(>?2P4Z@J6M)(C#,J;>.9
M.D//I8*=05+6DS#U$T*9Z >$&BM#4H;>U3&$OV?V&OTO]#!U8=V*6O&TW,6D
MQ)9(E:*;@;DK;:Z:?<2VH5YM&#JT[OA9;7J\V!BJ3<7MI?4B1,-ND=,@B2LH
M.DD@]*4,',H+EK2#FTAF4(?U0]*4,',H+EK2#F"W$ME248B#7\AIY#Q3H,81
MK2N#_P"E_HA@W0K%*DNKF2W_ &'VO170Q/&;\HH';,)3(VT-TD;!@]PS(T'[
M=^M5>?![%:F\O<2FI4)/ZU+_  Z0SE=,O5T?T,(ZJ1(Y.V;=-13S@R]*4S)M
M&$=5(DLD0XBFO:)<=$TM%H(,R9LFRG*<++)Y1]NP82_9_8:_2_T,'5AW8L(Z
M4AN1K>02C4&'%R=Z@9^XEM0KS:,'5IW?"RVO5YL#%4FXO;2^I$FRB8_1_P#P
M2?*:1^MH_H81UTAB2M>D1F4\XDWV2DB(81UTAB1-FV1KVB6J-;U&P%)6B31H
MAB=F4T2MF&$:TK@_^E_HA@W0K'+:\\4H;6R]ZA7AR6+=0:22,':ZO;OUJKS^
M'4JB/44>@>HHM(+/]"EDDYO@6*U-Y>XE-2H2)U#2S-9C+&-X81U4B15"?-H>
M_5?V,(ZJ1(JA/FT80;.D3@:EK9-E2T@IY6_.0PE^S^PU^E_H8.K#NQ80;,TD
MLM@DTK;0W17L#1'*)12+W$MJ%>;1@ZM.[X66UZO-@8JDW%[:7U(D3[;1'3,)
ME3*SHI,81UTABJ3<09_5?V,(ZZ0Q5)N(2U!H=IV@I>U1G/2),E3S_J?V,(UI
M7!_]+_1#!NA6)QY#.N8E2TN.FI(1*6G#HI,+E;;:Z"A*I8A:*#8D3)M(G5I/
MV[]:J\_AW#G4$)F(&4^D*.B68(52"U402C-,X4=(YPAPYY@M9D<Q"FL@A=(+
M6:= -PSU03A[<2G#_:/446D).D4X6Y-F(4UZ0AR?,86JB$*I%.%K-(2<Y3@W
M#/0$K5/,?Y6*U-Y>X,B44QC(F-WN,C8W0XTAW,L@A"6TT4Z <G:4JF99PXTA
MW,L@A"6TT4Z 9$>8QD;!_M"$);*9)!QE#VN0)"230+0&V&VCG06+2#DC!YZ(
M0A+93)+W$MJ%>;1@ZM.[X66UZO-@8JDW%[9:$N%14,B8W>X3)64'220<8;=S
MK($1)*8@4G:2JF19PXPV[G60(B24Q!2264RAD;&Z$I)!3)#DG;=.=9!2$J30
M/0&V4-:A8G&4/:Y#(F-WN$29ILZ22"Y.TX<ZB"),T@YTI]P_6JO/X=>L8+1B
M=U0SM#N@-:H=U@G0%*)(-V<II@UK!W2&R^T.:P,_L"#))SF%K)1!K:$YU8M"
M@[H#6J'=(1G0",T&$K)7Y6*U-Y< RVH5YM&#JT[OA9;7J\V!BJ3<7 +]:J\_
MAW2F.<(64TQ@W"(+SHG#2B+2'%3YB#6J'=8)44Q!6MG"E)HY@UK!W2&]4.ZP
MFG0$&1'G'V!)D99AJJ%-(+[E!W0&U$13&%JI&$9D"DA6D'IS?E8K4WEP#+:A
M7FT8.K3N^%EM>KS8&*I-Q< OUJKS^',IP;1 FBVB;8/2'IE-,$IHY@I!*"6Y
MCG"FR4":(M(2@DG.%()0(IBF"D$K.- 4V1CT?Y!%1S$%()0]'^0E))T RGS#
MT?Y'IE-,"*8IAZ02V2?RL5J;RX!EM0KS:,'5IW?"RVO5YL#%4FXN 7ZU5Y\'
ML5J;RX!EM0KS:,'5IW?"RVO5YL#%4FXN 7ZU5Y^U4HDYU&#E3)?N&6,;P2ZV
MO5/Y=BM3>7 ,MJ%>;1@ZM.[X66UZO-@8JDW%P"_6JO/V;CJ&BG68=EZU9D9@
M:C5G/Z&Y4ZUH,,2Q#N8\Q_@-9)'JI]Z;B2!.)/Z%',4X0LU&%K-)A)SE/];%
M:F\N 9;4*\VC!U:=WPLMKU>; Q5)N+@%^M5>?LI1*"83_(6XIPZ2OP226?\
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M:0ASMI"'.VD(<[:0ASMI"'.VD(<[:0ASMI"'.VD(<[:0ASMI"'.VD$X.7/\
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M% \,=>Y&U#\!1R"07J=NB_8H\,)T[8_E:$TB1MZT/ZFBGGRV7A-M1_R":;Y
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MO!<K!B'I^EM>,Y0X;>GL&;$=U^QML>C)I9_!&\QNT@J^3(*ODR"EM3YFZ)^
M#2-P3&Z#0WZ4$6GM.Y22MBV)MH:_8Y.NO-R#''<$01O\2TC>%O18X;PHGZ#K
MU-,)!</  G<B"-_@ 3N18X;QXAI.X(B[>@UQW#QT'9+=]6'$;U]@VO!<K!B'
MI^EM>,Y0X;>GL&;$=U^QGB\YFBB+C<?I6*';YA^G"+HPGG2<3X1%K77N1M0_
M 0NF8HQ_4 3@WU._"FE;(VX)C!"R\H6H7[0H[C-L5JW!6?#1E9#\C0G 2L4;
M--VBG.; U1SB0W*T1AIO"B%\0"\]C#H@)[&NVN3;0TNT0%:F[-)0R,8"2JH9
M*=H<R_ZL.(WK[!M>"Y6#$/3]+:\9RAPV]/8,V([K]E:K-I_.S?\ 1L]G,QO.
MY  "X?3A-\83Q<XCPAC\QR=Y,6PA1EKFWM3,56GT)OJ"M&&?"#$"M6X*S8:D
M]946&%9O6K5O"AQ K5Z0H<,([T_"*C]85I]"@A#_ )G(OA:;KE+AGZL.(WK[
M!M>"Y6#$/3]+:\9RAPV]/8,V([K]G/96R[1L*DB?%ZA\(!.P*&Q$[9$ &BX?
M4L\H;\KE)"V3:FV=K=KBH7M$A&:D@$AOO3-$#1:F8JM/H\&N;,Q"RB_:4RX3
M[%:MP5FPU)ZRHL,*-^@Z]/8V9JCA$>U3R:9N"APPCO3\)1^L*T^A69P+=%4S
M;[R=BD(,9(^K#B-Z^P;7@N5@Q#T_2VO&<H<-O3V#-B.Z_:;T^R1._%R/\>/P
MY:OYDVPQC?M3(VL](^N'.&XHN)W^&F[=?\-]VY%[CO/Q@D;D7..\_0+G'>?K
M0XC>OL&UX+E8,0]/TMKQG*'#;T]@S8CNOL^'$;U]@VO!<K!B'I^EM>,Y0X;>
MGL&;$=U]GPXC>OL&UX+E8,0]/TMKQG*'#;T]@S8CNOZ>S-#G&]3QB[3:HQ>\
M*< /V?5B;IO#2GMT7$?#&&D_,O-BW:*GB#1I-4,8=\SMR\V+=HJ:,,^9N[ZL
M.(WK[!M>"Y6#$/3]+:\9RAPV]/8,V([K^GLOJ*A=I7QN36Z$H!5HQ/!@B(^8
M[5HP<2D$8]!\+/Z7>$N"U0 &,WJHT=C1L4[00)&^%GD-X8I9W EJ@C!!>Y5)
M_ V*5K7,\QOB!>;@K0=%H8H/FC+5Y3]URE!$(!^K#B-Z^P;7@N5@Q#T_2VO&
M<H<-O3V#-B.Z_I[+ZBK[G7A7"31D"M&)X,$1'S':M&#B4@C'H/A9O2[PFV1-
M4.V)W@_9  ?"#$"FQ"H]L! \/39]OAO30+.-)V].<7&\H$MVA>=(=EZF^6,-
M/U8<1O7V#:\%RL&(>GZ6UXSE#AMZ>P9L1W7]/#((S>45#+Y>]2OTW7CXHI/+
M-Z\V(?,&[5)+YC0/RH#=&XKS8C\SF[5+*9#X,=H.TDZ6)VW1VJ*4QE>9#OT5
M+*9/"%[6.O*,L+C>0G/A(^4*-S&['!"6)FUK4]Y>;S]6'$;U]@VO!<K!B'I^
MEM>,Y0X;>GL&;$=U_9QRAK"T_>0XC>OL&UX+E8,0]/TMKQG*'#;T]@S8CNOL
M^'$;U]@VO!<K!B'I^EM>,Y0X;>GL&;$=U]GPXC>OL&UX+E8,0]/TMKQG*'#;
MT]@S8CNOL^'$;U]@VO!<K!B'I^EM>,Y0X;>GL&;$=U]GPXC>OL&UX+E8,0]/
MTMKQG*'#;T]@S8CNOL^,AKVDJKAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX
M>)5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B
M57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5
MP\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5</
M$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5</$K1:(GQ%K2
MK!B'I^EM>,Y1VJ%K&@E5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAX
ME5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5
M</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#
MQ*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE5P\2
MJX>)5</$JN'B57#Q*KAXE5P\2JX>)5</$JN'B57#Q*KAXE(0Y[B/9[K ^_Y2
MJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS
M"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3
M,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H)
M,PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@
MDS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"LUF,)+G']+:+(Z5^FT
MJ@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),
MPJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@D
MS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"
M3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H
M),PJ"3,*@DS"H),PJ"3,*@DS"H),PJ"3,*@DS"H),PFV!]_S'_VZO__$ %D0
M  $" P('"0P'!0@! @8" P$" P $$1(Q!1,A,Y*RT10B,C1!47.CL1 U0$)A
M<7*"D:'!XB C,%)@@:(54,+A\"1#4V)T@]+Q8W"3!G6@I+/#9-.0L,#_V@ (
M 0$ !C\"_P#H4]ROH?<= J<4D9/:8XO.:"?^4!M+Y8<-R7Q9K^=W<F&D2TMB
M6W"G*%6J \]?MU3$TZEEI/C*@B6DG)@?>6JQM@(FI5R5!\<*M@0AQM06VL52
MH<H[I 9FUT\8(30_JCB\YH)_Y0)27:F$.%)55U(I[CX$_-N E#2;1 Y89E%R
M*F,:JRE>,M9?-3[-U@M33BFU%!4A":=L<7G-!/\ R@(3,XAPW)?%GWW?8%1R
M 98"3@]88KG,;EIYJ?'_ --)GT4:HB6G'7YE#SJ2384FS>?)&YRO&MK3;;72
ME1%EY16Y+KQ5H\HY(G>G7K18FYM#2_N<)7L$$2<VAY0\6Y7L/<*)B>:0L7I!
MM$?D(LC""0?\R%)[1"7&UI<0K*%)-084XZM+;:;U+- (LG"":^1"B/;2,;*/
MH?1SH-T$DT Y8L+P@@G_ ,:5+[!']CFVWB/%&17L[LJQ*!)*7JJM*H *'+']
MHG7U/<[= F'Y)2L9BSD7SCD@I6:AI]2$^:@/Q[K39N6L)-(XQ.::?^,";EW9
MA;@24T=4*>X06WI^5:<%Z%O)!$!:%!:%90I)J#&+F)V787]UQT),;H+S88I7
M&E0LT\\+5+S3+Z4<(M.!5(Q:L((M7;Q*E#V@0'I9Y#[1\9!@K6H(2+U*-!%E
M>$&R?_&"OL$!N7GFU.*N2JJ2?;W-SJG9=+]:8HNBU7S0-V32&2;DWJ]@BQ*3
MB'7/N94GV'N4G)MME7W+U>P0$-80;M'(+8*.V'F)G,+20NIIDAIZ4P@)N80;
M2&]T(5E\P[EF;FVV5_<O5[!%E.$$ _YTJ2/>("D*"DFXCE@&9F&I<*N+JPFO
MMC=9F6MS7XZV+/MC%IP@BU_F2H#VD4@$&H-Q'=G>G7K0A0F9L+4D'A)IJP'D
MKW3*$TQE*%/GC]E3*RM)%6"KDIXO<+<S.MH<%Z!OB/R$!MB>;*S<E545]O<"
MYN9;8!NM'*?RBPG"" ?\Z5)'M(@$$+0H7C*"(%,(!2[?%MTH]E+^X6YF=;0X
M+T"JB/9%I&$I<#_RJQ>M!1+3DO,+ J4M.A1I^48EV=EVGO\ #6Z KV0%3DRA
MBMP-Y_*,5*SJ%N<B""DGV_CJJB .<QGF]*,\WI1GF]*,\WI1GF]*,\WI1GF]
M*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI1
MGF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\
MWI1GF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI1GF]*,\WI10.H)]+Z4SZ*-
M41)(?GY9IQ"3:0IT6AOCR0@RV^8918"_O'GA3JQ3=#A6D>2Z)WIUZT&<FYK<
M[KN_"7$VE*]+F@BN+FI9R\<X@.-;U;[%I.6ZHBU-.M2GDX:O=MA4XF;3,M(I
M;WE@BIISF)N0*B6L7CDCF-0/C#,C:HPAL.6>=1AF;>FWL8Z*T:I1,3:]TI?8
M=2 G)0_G P4RLI;0 IZGC$W"&IJ>F'4*>3;0AJ@H.2M82AI]511UEX9#2)2<
MN4XC?4Y[C[^ZI:R$H2*DGD$34V. M6\]$9!#+3HLO.'&K',3_*G=;<I6PH*I
M'>K_ .X^6'W-S;FQ2K-+=JONA.%&4_5N[UVG(KD/YQ-2LXO)*I+K7E3]WV]L
M;\FKZ[;BAXB?ZR1-M-IL-H#:4I'(+:87@V2*O[61;0GQJ5O\F6%S29I$PXVF
MTMI**9/(>6&&[7U$R<4M/GN/MAN7DDVG,<E2A:L[VA_E%9B?;95S-MV]D(9<
M<2\E:;2%IR1+./$J<15LJ/+2)]Q/"3,J(]L*PA.S6(4]ODEQ-I2]@A;"E6)B
M77D6GV@B/VF!]9N0O4\H36&V9J9*5/J)6Z;SRQ_89QQ+G-,4(/LB<96JTIN1
M6DJYZ(C!_IGL,%;)I,O'%M^3G,.!"Z4WSK[F6G\X7-M3*9MMO*L6+*@.?EA.
M#G%UEGZV0?%5&"O]W^"&Y-MRQ)2V4J5P4D]IAI9>$RPYD"PFS0^:)F4<5:$N
MH%%>0&N3W>_NSO3KUH9] 1/,K%0IE7MIDC!S@Y'T5\U82VPJS,S)*4J'BCE/
M]<\.S,R\MN62JSO.$M4-3,LZMV74JP<9PDF'&'U%QV5(3:-Y2;NPP53#MC'/
M6+2KFTUI[H^HG7TO<[E"GV1+23RTN.-5JI-W")AOIQK1,/LFR\:(2KFKRQ,+
MF'EMLM4M6>$HF&"RZIV7>K2WP@1 PMCFBPI"FPA-;0->7)&$/3'8(7A*=FL0
M'<J5+3:*O,.:%RSBOK&Z%*T<O,8DIIS.+1OCSD9#]'?K2FO.8SS>E&>;THSS
M>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;T
MHSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&
M>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS>E&>;THSS
M>E&>;THHEQ"CS _@=/IPES&V:\EF,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F
M,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F
M,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F,]^F
M,]^F,]^F,]^F,]^F,]^F$+QU;)KP?I3/HHU1#,XR]+):=R@+4JM_FA+F$)C=
M ']RT* ^<PE" $I2* #DB=Z=>MW,(>F.P1)33V;:DVU'0$!J34IBV=XS+#+[
M;X=>P@N:,GDMAR9M"_)O;7/2)C_2JUDPW,RI FVTV;*KEIB@+\BK[IX*O@85
M*32 B;2FT%(N6(PCTL-*8<F\24 HI. "SR>- 7,L.S"@*!3LRE1]ZHEY::R/
M"T2D&M*GNJP=(K_LPSKJ?'/-YH1A.>;HRG*RVKQC][S?080H52I8!]L<0ZYS
M;"VY)C$I6:JWQ-?;$X)WBV+-H[/+W)VG':BU7[G)3\Z^Z)_U/_R)@] KX0H+
MX%,M>:)6SPL:FGMA&+2')IZH;2JX>4PO<K\RNE^)5BTI[(:&%U.J<*=YC7L9
MD]IA/2KC"?3K[8E>B3V1,^BC5$233@M(6S94/)"G)=M4W+ U2XUPD^<0E#ZS
M.,"]M[A:43LTR:M.R;BA7T3&#_3/88P8GQ*.'\][$Z>7'?")P*X.)77V1@WI
MT]L8*_W?X(G.G_A$2_\ JDZJHPCZ"/CW9WIUZT,^@(GGE&GU12GTCD$8.; K
M]<E1'D&4]D2 Y,4>V"O!2Y@2ULCZJ9Q8M>:HC%S"9B8;K6R[-I4-:)U<ZWB<
M99"46@JM*\T/3>#V]T2[BBK%)X2/RY8Q6-6I",AEY@5I\1")MI-C+96@^*J&
M^G&M$V''4LV %A2KJB'2AH/LNTMMDTN\L,)1+TL[UIAO?'+$O*KIC1OETYS&
M$/3'8(P7_I6M40.@3\8D/7__ "*^BC?V+/DK&>_3&>_3&>_3&>_3&>_3&>_3
M&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3
M&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3
M&>_3&>_3&>_3&>_3&>_3&>_3&>_3&>_3"&[5JBTY?P.GT]L-_GV_O*9]%&J(
MP?Z)UCW9WIUZW<PAZ8[!#;;0)7N)E5!Y+)^$;HF@<4ILMV@*V;LONA>#L'A4
MSC:6W+)% #7)[(F/]*K63&X9EARQ8"L<C+?Y(F)=M6ZW7$T2C%D65<^7FA+R
M1]6RA14?.*09P)^HF0#:YE<HAJ4GF'',4+*76J$TY,A@B1DE%7WI@T]PB4F5
M@)6\RAP@<E17N2\LPHMF:M!2Q?9%,GOA#LS+;K:3EQ5NS7SY(H,$T'^H^6'V
MMR;F+20K.6J^X=UMRE;"@JD=ZO\ [CY81)&1W/;!(7C;5WY0G!3*MXWOWJ<J
MN01,NO)I-30JP3XH%WMA#Y!!;58=;YQRB)MUM5IM:6U)/.+:8;FY?AIO!N4.
M:'&926=:F74V5*72B/-SQ+FS5F7..6?-=[XD)FE6J*;)YC?_ %YH7*3BRPL+
M*PJP2%>R$O,M*3+,C%I4J\PGI5QA/IU]L2O1)[(F?11JB)>;*,9B9<KL\\5F
M%.2:^4*05#W1CY%%E%@)4NE,8>>'&G197N-Y5//:/QC!_IGL,(F&4VW)4E12
M/NF_X0[;;+TL[PDB\'G$.RD@PZWC194X[04'+2D"?6G^SRUQ/*N,%?[O\$3G
M3_PB)?\ U2=5481]!'Q[L[TZ]:$H3@P52*5+_P L(2]1+8.\8:&2OQ,*PA.H
ML3*Q9;;-Z!Y?+#$ZTFT98D+I]T\O]<\.L.M%^5<-JB3E28_L\G,.+_\ )1(^
M,.S+S:&E)>+8".:@/QBDTAR35YK8]T2VX1C%MUM/V;-1S0XZL60\[:1YJ4K#
M?3C6CZA)5BW0XX!]VA_E#TM,8,9P@VXJW]9R>XQ]5@1,J#?B"D? 1CI1=H#(
MI"A12?/&$/3'8(P7_I6M40.@3\8D/7__ "*_>0]-/P_ Z?3VPW^?;^\C,3<I
MC7CD*K:D]AA$O+H#3*!1*1R=U3ZY$%Q2K1WZJ$^:O<5,S,F''E<)5M0K[##;
M3:;#;:0E*1R"%.V7992LIQ"J _D1#@:9QBG$E"G'355#R0IZ2EL2XI-DJMJ5
MD_,P%S3)QP% ZA5%4BI<FEC[I6*=D8B492RWS#EA3,PTEYI5Z5""4F88'W6W
M,GO!@*4TY,D?XR]E("4@)2,@ [C:9YC'AO*G?$4]D<0ZYS;'$.N<VPXJ2EL2
MI8HHVU*[3W2HR J<N1U8^,<0ZYS; F)24Q3P%+5M1[3#DP[)6WG%6U'&+RGV
MPE"192D4 ')"YB8D@MY>52@M2:^PQ-R\NC%LH" E/-]8F'&7D!UI<NH*2JXW
M1;!F6T_X:7!3LK&(DV0RCEYSYS"V)EI+S*KTJBT%3*4_<#@IV0W)*DT[G0;0
M2%$&O/6!+RC6)9!K9J3VPN8>D@MY9M*5;4*GVPE"11*10"#,3<IC7CD*K:D]
MAC<:&@):S8Q?)3FBJ-T2_D;<R>\&$NI:5,.)N+ZK5/RNAQIQ-MMQ)2I)Y1"9
MF6DPV\G@JMJ-/:>X7,2J76J\L*I[KH"E;HF/\KKF3W 0EIEM+32<@2D4 AL3
MTOC\76SOB*>R%,R3(9;4;1%2<OYQB)QG'-6K5*D9?RAS<4N&<9PC:)K[>ZX^
M[(@N.&THAQ8J?R,<0ZU>V*RLFTRK[P3OO;W*'*(*PTN64;\0J@]D549E_P B
MW-@$!B5:2RT/%3"G+#LLI64XE>VL!:DNS-.1Y>3W4@)2 E(R " ^)$8P*M<-
M5*^:L2DFV2AM^TIPCQJ4R>^'U3+;$S.6Z8MX!5$^0&/J66)>>*Q92UD-.7)S
M1.$5Q.(WWGM"GQA4S,R8<>5PE6U"OL,-M-IL-MI"4I'((#TY*AUT"S:MJ3D_
M(PB6EF\4RC@I'[R'II^'X'3Z>V&_S[?PC,R3:TMK<LT4J[(H'X09N9>84G%E
M 2T2>T#]RAB8JDI-4.)O28^HG)=Q/.Y5)^,#=4ZRVC_Q J/OI&YY5.2]2U<)
M1\O[V'II^'X'3Z>V&_S[?_3 >FGX?@=/I[8;_/M_],!Z:?A].^+XOB^+XOB^
M+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^
M+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^+XOB^$^G#?Y]L7Q?%\7Q?%\7Q?%\7Q
M?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q
M?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q
M?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q
M?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q
M?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7Q?%\7P#_G3\(OB^+XOB^+_P"GTH1^?;
M_P"F ])/X'3Z4(_/M_\ 3 >DG\#A)-,M8" :T_\ 3#&FMJ__ /P=J;LO.632
MTA(IVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.BG;
M&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4
M[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.
MBG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J
M9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC
M-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=
ML9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG1
M3MC-3.BG;&:F=%.V,U,Z*=L9J9T4[86&;:5IRE*QE_<N)=QBW*5(;%T9J9T4
M[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.
MBG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J
M9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC
M-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=
ML9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG1
M3MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,
MZ*=L9J9T4[8S4SHIVQFIG13MC-3.BG;&:F=%.V,U,Z*=L9J9T4[8S4SHIVQF
MIG13MC-3.BG;&:F=%.V$MV7F[1I:6D4[?P>PQ:L8UQ*+7-4QWPZGYH[X=3\T
M=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/
MS1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'
M4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[
MX=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?F
MCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I
M^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WP
MZGYH[X=3\T=\.I^:.^'4_-#TWNS&XNF\Q5*U-.>'>@.LG]RS7JZHAA_=UC&M
MI79Q5U1YX[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^
M'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH
M[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?
MFCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.
MI^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1W
MPZGYH[X=3\T=\.I^:.^'4_-'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-
M'?#J?FCOAU/S1WPZGYH[X=3\T=\.I^:.^'4_-'?#J?FA]BU;Q3BD6N>A_!\A
MTZ-8?@&;]37$.] =9/[EFO5U1$AT"-4?@&?Z=>L?P?(=.C6'X!F_4UQ#O0'6
M3^Y9KU=41(= C5'X!G^G7K'\'R'3HUA^ 9OU-<0[T!UD_N6:]75$2'0(U1^
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M=GIQPS:LN3@IB:DWU%:F#D)AR2FIA3,NV-XV#2T8QC$P[BBFA:7"<$R[I8;
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M4[T\'EAV77P7$V85*F05/2]:I+5897.RYDY)HUQ:KSW'F&S]9D4FO+2&Y/\
M8[JW6Q92NA"8G79UI25+1E79WI-1<8DI^3;+RV#E0!7EJ(=W3(*DD) LVZU)
M[DH^EAPL@"K@3O1?RP]+KX+B2F)F3F6'&TH55"E)R'GI&%G'&7&VUJ596I-
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MAL<IY3X9/].O6/X/D.G1K#\ S?J:XAWH#K)^QQ#REI3:M;R^$(%R12,7,(M
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MW:Q0Q@__ '/X8'^F7\8F.A^([@;:-EU\V0H<@Y83-SH4YC."BM!2!,RZ5H4
M19M5'A$WZFN(=Z ZR?W+->KJB)#H$:H\&/2)B95-,XTH4 -\1V0A]F6L.HN-
MM1^,-MOH=45BHQ8&V+%I;RN4-"M(5N=1MIO0L4,-MOH=45BHQ8&V,42XZ>4M
MIR",;,N!M'EY8IBY@CGLC;!5+.6J7I.0B&>@&LJ%]"CX1/>='Q[DM+R*K#:[
M6.56E+J?&%2MO&60*J_+N&64JB ]B$_Y0#EAQ^52I#C64U56T(F)19J&Z*1Y
MC?X//].O6/X/D.G1K#PB>Z(PY^R\]8WW!N]:&MW\4RV\WS9+O+$GZ9[(1-O,
MI?<=KG!4)RT@(8R);F$V1Y.:)/TSV0)N:J[C:V4@TLY:1)X.;)Q##0R>X>X0
MR')9MYQ: I2UIJ8HP2$M.)4GS'DC!_\ N?PP/],OXQ,=#\1W)(<EE7PAIYR>
ML-E/U:*%5-D"3<<JUC,4M%=[Y_")OU-<0[T!UD_8-L/NXI2Q4%5WMBHR@]W&
M3"[/,GE5")?$):86"16MJ[[*6EW$K*Y@T39&2_N3.[J;G_NZ6>?R?'NS+S2K
M+B4U!B7>>5:<4#4T\OV$UZNJ(D.@1JCP8](F'OV5P*BWP+_6AS]J9JSO>!?Z
ML2O1_&&5.,)>6^V%J4L9<HY.:&FT'('%-^<98E>C^,-.S(4ZZ\D+J%4LUC<]
MK>-40GSF^-SF5;7DH7"-_P"V$L)5D#Q9/E%:0ST UE0OH4?")[SH^/=?\R=7
MN*GFT$MES'(<I45OH8>8;DK(*?K%@E5!\(FS_P",=O@\_P!.O6/[G,Q,'R)0
M+U&+$B@-5X+;3>,5"1A%@N)Y4O-8M7Y0S,(X#J L5YB/H;E?;?4Y0&K:13MA
MMY' <2%"O,?W!(=.C6'A$]T1AYR:<Q2%-V0;).6HYH $WE/_ (U;(D_3/9$I
MZ^N87TZ/A$GZ9[(E/7US#,XE-6RG%J(Y##29A:FWVT!)39)M>:"XA!#:E@G_
M "H$8/\ ]S^&!_IE_&)CH?B.XQ-(37$DA=.8PB7FE*0XU6F])M",>ELAO&XU
M7D37PB;]37$.] =9/V%B8:#@Y#RB"O!KVZ9>_<[D+94TIB90*J0>XTZ\T'%M
M\&U='J?P=U^60DS"2@!ID#QC3^<;K<6TIL95-) WO]>>&YA(LUR*3S&"MO%X
M.:\5+@JKLC]FX1L+6H;UQ,2JF%V I>_R U$-S2<4Q*J4/J57V?9$B'IE"W5.
M?4J">!OO-"S/33<PBF]"$TI[HPFPZY:;960@4&3?&%2\BTEEI%*S#G+YH95/
M.-S4NLTJD4^$39%Q1$IYCVG[":]75$2'0(U1X,>D3$RF:>Q16H$;TGLA#+,S
M:<7D2+"A\(E>C^,2'0(U1".G7\8E>C^,2'0(U1&Z@GZMVBDJY+0C&**P]3,V
M<M?/=&["G>)<+RU>7D$,] -94+Z%'PB>\Z/CW$;K>Q5O@[TFOLAY^77C&E!-
M%4IR1B9>8QCE*TL*':(<E)@K;6BE56:C**PN4DJN8S(IPB@I"G'4V77S6R>0
M<G@\_P!.O6/[G6S7ZN6%@#R\O]>2&%6/[0^D..*Y<O)"F)EI+S2KTJ@.RC:/
MJREM"%UH!$T9AMI"FB ,4#RQ+KEVVUJ<40<:#$WA)3+>Z&;=$(K9-!!FGTH2
MX0!1L9(D,'*98Q.1NJ4FU0#SP9"293C !5Q0M'+S" \_CFFN=R5 3V0XQ,(2
MB:;%K>7*$2[4LTRO&)*B703V&&F,$2Q4]BPIQ2&[9"J90!"481(?9M475 2I
M/LBU7>TK6#+X*2 @&R'2FTI?F$)W:DJ!\288L5]PA$TSD!R*2;TGFA4G)(2Y
M,CAK5P4>3SQNHEP2_P![<PL>VD"3G$);F3P%IN7_ #B77+MMK4XHCZT&-TOH
M0AP.%%&[HEVI9ME8<1:)=!/QAB>?"6RI)4JS<*06L%HQ:*T0$MVUJB6DL)-D
MAY01]:UBU#[60Z=&L/"%MN"TA8LJ'.(XIUB]L B4RC_R*VPE,TUC4I-1E([(
M0PPC%M(N3&ZUR]I^MJU:-\)3--8U*3492.R$,,(Q;2+DP4+2%H-Z5"H,6C)B
MOD6H?&+$NREE/^40C=;.-L<'?$4]D;E0BC%FS8\D*7*L8I2A0FT3V]P@BH-X
M,6C)IKY%* [8Q<NTEI',D>$3?J:XAWH#K)^P2E:5./+X+:!?'UROV=*'Q$\(
MQ]2GZPBA<5>>[ZG\'=7T?\,35K@XI5?9$PXO(E+JE?E9$+7(I:EI<&EIR) 3
M[K;KUG(6[J;[R1)=(>Y@;I!K#N89Z0ZQAR0P8TBTWPW%PV9^89=:Q@H&QEK0
M^2'NB$2GF/:?L)KU=41(= C5'@Q8F$8QH\D<4ZQ>V$/,RUEQ&5)MJ/QA*IIG
M&J2* VB.R$-MBRA LI',(W6B7LOUM6K1OA*IIG&J2* VB.R$-MBRA LI',(+
M;S:74'Q5"L6MQBOIJVP&V6TM('BI%(2[-,8U:19!M$9/R@RSB+3!%FQY(6)5
MK%!?"WQ/;W$;K9QMC@[XBGLCBG6+VQCI>7Q;E*5MJ/:8QDQ+)6O[V4'W0%LR
MB L7%554]OA$_P!.O6/[GPC7_&5$N4\$MII[.XKI4QA'TD?&)'I#V0KIU=@A
MSHTQ(] C5BTXV'9Y2;FTBW3RF)F5_9U \V46B]=47TI!Z%7PB2Z(]L2[J$ .
M.E16KE.^(^$/612TA)/LC')R*5)H]X ^,*FIMIQVB*-XL T//E,&7:8F$O!0
M4A3B4T'OC":3P$%"^W9$ONC?XYZVL'EY3!04@H(I9Y*189R8B;HCS!42/2'L
MA73J[!$ET1[8EV:TQC*T5\Y,*4ICZU(*%MN<HAMIQK$S0-4(= .7_*?M9#IT
M:P_ ,WZFN(=Z ZR?L&ER$FQ,&SE<<I4>\1WOEM+YX4)^5:8:LY"@\OM/<:_9
M\NV_6MO&&[FY1'[1W$UCJ4LVQ9NI]Z%G"#*&'*[T(/)[3W'&V'<2\$A2%^4)
MC<CR&FFCD4X"-]&X@:I*2%*YZWPMB699FF"JH*C_ #B5G9HAWE64D41Y(E1+
MMXRPNJLH%.Y+O2M,>R;B;X6<(-MM(IO0CG]L83?=;LMO+)0:C+OC#T[@X(?2
M]PFUF MY+8LG>RR%#VP[+MIM.EL )K$NR\FRXD&HKY?L)KU=41(= C5'X!G^
MG7K']S[M2GZF8 R\RA#4E.O)EWF182M>1*D\F6"4S")MSD;8-JOYPF:2BS:#
M3Q3?0'_N)MB:=2QC;*DK6:#)7;#,M*D.,L92Z.4^2%=.KL$*\K2:1@YE,VUC
MU-I1BK6^K3FB:,Y4M;KW_H6MD3#$L^RLO,J;;:EZ<HI^4?[*OA$ET1[8D?7U
MU0YT:8:8;RK5)-E(YR$@PH829;=EW$V;3K84$'GBVH8+(_R-H4?8(<=P=+)8
M8ME! ;"+7Y"$EQ)K*O;X<X_ZC=&[FE"E;"5;\^K?"%6<Z_CE^05J8E' -ZEV
MA_,?RA^5FIA$NM+A6,8: BG\H"F.+LBPE?WO+$M,.5L--+6JG,"8_M+LN1]V
M9WBD_P!>2%IP6XIQI+HQ*N6O_?VLATZ-8?@&;]37$.] =9/@"L(6D8DII9\:
MZG@LUZNJ(D.@1JC\ S_3KUC^YU,3#8=:5>E4$R\ZXPG[JT6]D!4U,N30'B@6
M!&YBVG$6+&+Y+/-!4Q/+9;KP%-VJ?G6#)_6;Y06IX$6R1\(W-+E:D6BJKAJ:
MPV7%J9?;R)<3S<QAF;7.J?+1J$ANS\3&/MJEIFXK2*A7G$!Z9>,Z4Y0@HLI_
M/G@S4NM]2RDIHXH$#W0TN96\A38H"TH#M$-2C%K%-UI;.6^L;J?6^AREGZM0
MIV0RPWFVD!":\PA3[2U2CJLJK JD_E'UN$5+3S(:L_$P):6!#=:[XU),8QVK
M4P!3&M_'GC+A(E/,&?YP4RR25JX3B\JE0Y+3"+;2QE$5&$%AK[I:R^VOPAF5
M&-:2T2JVA0M*)Y\D#!R;2I>P6]\<I!O@EB?6TCF6W:^(A,PM:II]/!*A0)_+
M[60Z=&L/P#-^IKB'>@.LG]RS7JZHB0Z!&J/P#/\ 3KUC^#Y#IT:P_<2VT/(6
MXCA(2JI3W2G%3)H:<$;8#25+:<5P4NBE8=?<K8;3:-(S,SHIVP0PY]8/[M8H
M8"YERQ6Y-Y,62E] ^\I IVPEQM06A0J%#EAR6<;?4M&0E"13MBB@\UY5HV&$
MNM+#C:KE)\"F_4UQ#O0'63^Y9KU=41(= C5'[A0VMY"'%\%"E4*N[B'D/+79
MM?5@;8 4'VA]Y:!3W&$N-J"T*%0H<L.L*;F%*;44$I2*5'YP&[2V%&[&BD*=
M=6&VTWJ,4 ?<'WDH%.V,;++M"XCE$-8]+BL;6F+'-_W&:F1Y2D;8M2SH<I>+
MB/ Y_IUZQ\%M.N);3SK-(RSB/5J>R.-C\TJV1]3,M.'F"LO[WD.G1K#P-3,C
M).SY3>4?]&'&2RN7F&Q4MKYH6S(R+T^49%%.01N.8EER4SR(7RPG!KC%D+&]
M>M7Y.;W0MQ>1" 5&)J<W+BDLUH+=;5!7FAK$2+C\TNM6&S6@\](3A"9295)K
MO%7UK2D%QG!+[K _O*_RA1:JAQ/";5>.XE;UI2EY$(0,I@./X'?:8_Q"?Y1N
MZ3:5-U *6TY"<M(P@^W@YQ]UPFTR#E1E\T-NNL*EG%7M*O&7N81]-/QB4<;
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MF4*>F"-\Y;(H?)"D-.&W+K"D+YQ?$R\G@N):4/S6F,(>@CXPQ_J4ZJHF^F^
MATX34L-&85CB+QE@+P<]BO\ .TO&#\ZGNSI-ZYA6M"4)%$I% .XW+-FRJ:50
MG_*+_A"IV>2705%*&PH@>?)#6Y5*2TXFVFIRI-8<F5<-<N+7GY8?_P!,K63#
M'^F3K*C!_1_3D.G1K#\ S?J:XAWH#K)\ F3CL;CE6N#2G@LUZNJ(D.@1JC\
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M[3GC!/F':?I3?J:XAWH#K)\ G F_$J[(*0=\'#419/"4L4BRJ_<Z8E/,>T^
MS7JZHB0Z!&J/MW'G#9;0+1,%6#<&6V:TMNF^"J<92Q,%O?(2:C@Q@=)%07%
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MR&A!B7D9!-9Z9X)OLY:1C?V^[NF_%6E6/;7X1,2<\/[;+7G[PN^UD.G1K#\
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MR1N&2JU@IHU=>^]_7((;EI=%AI H(+,PTEYL^*L5@NF20 ,I*W%4[8PEA!E
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M8:]-7;$C.I%<6JA[1\8$REU.)(K:)N\\3F$$YE HE7N'N\+F_4UQ#O0'63X
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M9UIFVO?_ )"!N*W1&&+F:)\G5<,0(-FDX5#:K@EW@-/!:Q\T^Y2"Z,+:=RX
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MX"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X">
MG@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X
M"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G
M@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"
M> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@
M)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X"> G@)X">
M G@)X"> G@)X"> G@)X"> G@(+LHO 3P$\!/ 3P$\!_@/T/X9XW+_P"8>2X_
MP?Z'\,\;E_\ ,/)<?X.A4F0@I@ME]_\ Y@3U$U8Q_P#P[$6[ ?:Q_@3%BQ8L
M6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%B
MQ8L6+%BQ8L:,QHQ3KA?[+2ZF"N>EVG^!,6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8
ML6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%BQ46S ?>E_A_$X
M*\ NM]?\!9F9F9F9F9F9F9F9F9F9F9F9F9F9F9F9F9F9F9F9F9F;\$23JOU_
ML[0_WGA<!J]>O^ LS,S,S,S,S,S,S,S,S,S,S,S,S,S,S,S,S,S,S,S,S-Q.
M"K(+K;3_ /#R\):'O'CPEH>\>/"6A[QX\):'O'CPEHPAB6%>C_Y--@UX]4[%
MGB0@TV;64ODKA_Q%HY=4#16=?3)&W+C1QAT];%N]0!HR_L82=9?_ )@>\>/*
MX)0ZBZS8])I_1[FZJI>K_A"5C4X89J]NL&&X&3HZ'JF/2K MMV/3?Z4]> W?
M:6\8#'1?+;IZ.B[\M,@=XF7:".X6OF#99_WR6FKS"X0!RW>/=_V]X^M#ID0_
MGKZ$D!!&W6G^BI(5JLC=C%/>%E-(TAK0M/8BE0J&BO3Z?F&9ES]'*)^67WIW
M70TYSN-692)2E96&IOL%.ETEU=;(\PM$KCE!\%\:2I2@ZG,M0>/+ *,#I 6-
MJSUG3.MFI#K^2'.M974',T#&.Y_8%Q[PTP% 4O2T])M$N@.B\T_^$*N=3H]C
MT0>8&H:2V'&\1:C+!O+0=/0\(6B@)5[86GQ47Z%PT,^"0_='_B$_4);5IP_Y
M\\>%*568CEJ$ ZFV&EU%Z7K6&GS5UBVWM%]A^8]"[8UJHV=X%BN8ZU=9KS08
M5U*QWFLD.APO5!9O ;[(AWMQN.XFSZZ)YG+Z,R,6#@,<+Z3R_5-R4\=T,'>6
MW&REN[NLRWW,<6-&F\;[,B=31])_WR6CM<Z6=7SYEP)6J@]]OR\SKII#N.K_
M %4PK46JVN(K865^Z7W:"W#_ $LK("RSKQUW8IG"3I'O/2_F>(Z'H2%H%5]=
M_91''E33][$'.E< \ATKYGG^/[ N/>>"Y@6]4I@Z632&^\]D(=VM<DKJF,\.
MI>@TW#[H%SD;P[M:Y)75*056DWOH;^IGZ(-;<0U6=2KVFH>-VKJ=3T^>=ZSX
M[IZ6!%-U\!W1/\P%J2KZ!6=9TP!V^X?FEI(.3JQ>L94TKEC_ #X>/"JFS^R=
M10E%)1HFQ>4U3)JK(& 0(1IL?$9:Q8Y2WX)JJ&,J"K!LV!.7?Y@@+N9%9GYM
M-+YTS7;VJ\2P&\4Z.1_CMZZ)YG+Z^7ZHP37/[(9N#P*SD@>'6,6[L=O^^):*
M !9I4OT2'M2AXES/M7Z#<[)LP^:<==W3H8Z<1R-O3!33T'W>JPD&+<+.:7)3
MN9BR4AUMJ?>YN:N$<U8N,>]:#HE8::;QB.]]+,:4/HM@3:I&L69-"-.QT@YT
M1B.6*!S+.9I(0^5Z[-CK52Q6 R[M5:M-H>T(5R*_U'"J$KDG%^__ 'SWG@N9
M44EFJL:<S;5'O8SCB?9PVE>KE@M\9T@L"6'L%3[.+[[Y113HKB'Y-;X%_:@"
MAVH)[NKS'5@[G5K\'T^>=ZSX[IZ_+]'I<ZU#)6]V8K-]8>Y)E7-GEP_#_A#R
MMJ7Z-+NAMUE;4OP:'93?K_2"0+-*Z5:1U0ZJM552]7KM1*0/F;9<M.RX-EG]
M&-,V<#IJ):['Y.C'6/ZYB "75G7^QO!GVB$PI12=)"'0#6-Z4O3U^'/'=/3\
MM@MU=$J6EV0,#[KLQ0IB6ZNZ!;VB:4(+"NKZ7;CV]=$\SE]'<,*-JO<=86>U
M <D;IUE8@P1-PI>L&S@)ALLLUT):0RID\%U7^Y?R-Q-VW^5?']G):>3!CE_'
M]L/>"^'^:6>\)!1O8FN7CJYIS[/U/-/L_0\K.+IHK/3 0@K-%+6M;U/:I;P,
M*A[:^3?I\\[UGQW3TEK3VC9=VG1"SV@!@#9>D<ITI\/933X?JT-2NO65TJ&;
MS72S?F(SP:3;^?[Z\+P9-P@I?=EO'VNRB/;2:*<3I9I,1?&U-X]BWQ*X@ MJ
M*O\ ,I3FLMH(^IDQW2'S!#SCZX'UU.I<>P7,!P*L)_1/)03_ $,L,IV@4^2>
M%Y]9L6!5J] Y6CYB#-X3JNVJC@$IKR/G<'V6DY'+@TQMQ<%HUKH/F9=K7U!?
MIY/IZ=-3SS_8SQQLZWP"R>&?Q-N<VPTNCEB=IPLCKA<P/%"]P,S>U C[U$[3
MA9'7"_3B+$/W.>^S[AZ9RBT2V[A<,)>E\ N#;FJ <'IK<Q7;:I/#/XB\$L4K
MUQ#0QH4O>6V4PY'L?XH2T/>:*7E3X9X9_$S[K]GA"8U2J@]K(>D:*@.A,Y1:
M);=PN8U2J@]K(>D:*@.A' "%(Z,_FM_Q#  % :$$I-*H>Z1TWEAK.E3-[4"/
MO7H82]+X!<\,_B8[]6%O<)4XK!_(QU6'%_@3^_// ])R4.H;H\.K,U=&??\
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MZZ ?F7TVWGL5_8G@,F@RL86\DY?Z;N,+V3KO>QCVBFNNEI:C_4[SZ5H\=/\
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MS&71D>7HJ7F>D^M]![4\\P-WU-PA?8LJP='5=[N.97!1C=_^\\KL^>2!P?\
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MQU)?S#T&%66XVBZ<>ZXFAV8'-1;&DTTP!^9<;/I!CJGIJ9DVK:+G#>XS1:;
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MT!BSC\.$,<@ V),D6K :8JOFGZ5%D6 .:-/<]-!J?FAO[+7WE@J3D%?X(WP
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MCY8^Y=%+^]#Y];;3V6H6#P%?/M ="0L:*,VZZP4X^V!;'OGVB7M4-Z,L9GM
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M-5UJZ]1GVOY>K@Q/:-OX]^$):(^@%9#8$R?)4UU10[!==_\ F$M ?#;LN+?
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MSG9SLYV<[.=G.SG9SLYV<[.=G.SG9SLYV<[.=G.SG9SLYV<[.=__ #H__]H
M# ,!  (  P   !"222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222226V>22222206.1VR22222221J22221E"2
M21*222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222227#YR-/X!Z2&R0VGOBIM3QP.60.0:
M3!Z71C^#=X22222222222222222222222222222222222222222222222222
M222222222202222222222222222222222"225&;VAM?^H2=2041*&+OKOK[=
M2N^23<#3JOAUKSN202222222222222222222222222222222222222222222
M222222222222220"222222222222222222222"227Y:<BS<"IP9R1U&V]R^F
M"C^_=BZ^3<D#NOB5KSV20222222222222222222222222222222222222222
M2222222222222222222"22222222222222222222222262:=_0=7WRX"05,4
M-;6&"M-^1ZZ^32"-QUB_#SV222222222222222222222222"222222222222
M22222222222222222222222"222222222222222222222222;2&6SE+Z936N
M15-O87!-K!^V=W5B2W223%6YRV:222222222222222222222222"22222222
M222222222222222222222222222"22222222222222222222222222222222
M22222221R222222222222222220Z"22222222222222222222222222"2222
M2222222222222222222222222222222"2222222222222222222222222222
M22222222222222222222222222222222222222222222222222222222222"
M22222222222222222222222222222222222"222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222"220                               "
M
M       0                                  "
M
M           0                                  "
M
M               0                                   0
M
M                   0
M
M
M
M
M                                      @                 (
M
M         6VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVT@
M"6VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVV@
M             R2222222222222222222222222222222$@
M     R2222222222222222222222222222222$
M                 R2222222222222222222222222222222$@
M         R2222222222222222222222222222222$
M                     R2222222222222222222222222222222$@
M             R2222222222222222222222222222222$
M                         R2222222222222222222222222222222$@
M                 R2222222222222222222222222222222$
M                             R222222222222222222222222222222
M2$@   0"     0       R2222222222222222222222222222222$
M                                 R2222222222<2222103*-"22222
M22222$@  "2   "2 2020    R2222222223"R2227B-3&R2222222222$
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MDDDDDDDDDDDDDDDDDDDDDDA         $))T     $,E'-9"WOM%C\,%(
M  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(     @DD   $D@    ,DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDA        %9)))S       'P   N  >C4
M      ,DDDDDDDDDDDDDDDD$@  DD@DDDDDDDDA(    D@@$@$$D$@    ,D
MDDDDDDDDDDDDDD@D@@  $$DDDDDDDDA        O))))(
M          ,DDDDDDDD @  @D@$@D$ @D@DDDDDDDDA(       @
M  ,DDDDDDDD@D $D$D$$DD $D DDDDDDDDA        ))/!)+8
M              ,DDDDDDDDD D $@DD$@@ @$@DDDDDDDDA(
M      ,DDDDDDDD$$D$D  @D$$ DD@DDDDDDDDA       #Y)*A))@    FZ
M   !8             ,DDDDDDDD@@DD$$D $@@$ $ DDDDDDDDA(
M          ,DDDDDDDD  DD @$ $D$@D$$DDDDDDDDA       ")))1))H
M  R$E+6Z'+N,RVM;      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(
M   DD@        ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA       ")))1)
M)(    <%RP?3DPJX=MM:      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(
M       @$@        ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA       #Y
M)-)))P    S,\3K)D D9;@<J      ,DDDDDDDDDDDDDDDDDDDDDD$D$D@DD
MDDA(       $$         ,DDDDDDD DDDDD@DDDDDDDDD@DD$DDDDA
M   ))-A)+X    Q"E:#'9:')&GC/      ,DDDD @$DD$D$DD@@D  @@$ @
M$ DDDDA(                  ,DDDD@ @ D$$D$ DDD@ D$@@D$$@DDDDA
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MDDDDDDDDDDDDDDDDDDDDDDA                         @
M  ,DDDDDDDDDDDDD DD$ DDDDDDDDDDDDDA(                  ,DDDDD
MDDDDDDD@@D@D@DDDDDDDDDDDDDA
M      ,DDDDDDDDDDDDDD$$ D$DDDDDDDDDDDDA(        $ @$D     ,D
MDDDDDDDDDDD@$ $@DDDDDDDDDDDDDDA
M          ,DDDDDDDDDDDDD@D$ @DDDDDDDDDDDDDA(     @$$ @ @D
M  ,DDDDDDDDDDDDDD  $$DDDDDDDDDDDDDA
M              ,DDDDDDDDDDDDDD$D@ DDDDDDDDDDDDDA(     @@$   @
M$     ,DDDDDDDDDDDDD@D@$ DDDDDDDDDDDDDA
M                  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(   $  $D
M $$$@     ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M                      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(
M   @          ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M                          ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(
M                  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M                              ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDA(                  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M                                  ,DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDA(                  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M                                      Y)))))))))))))))))))))
M)))))))))))(                  Y)))))))))))))))))))))))))))))
M))/                                       !)))))))))))))))))
M)))))))))))))))8                 "))))))))))))))))))))))))))
M))))))(
M
M
M
M
M
M
M
M
M
M
M
M                                    DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M
M
M
M
M
M
M
M
M
M
M
M
M
M   (                 "
M                                  %MMMMMMMMMMMMMMMMMMMMMMMMM
MMMMMMMM(                  EMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMH
M                                      ,DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDA(                  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDA                                       ,DDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDA(                  ,DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDA                                       ,DDDDDDDDDDDY\
MDDDA8D$DDDDDDDDDDDA(                  ,DDDDDDDDDD9\DDDC=D\(<
MDDDDDDDDDDA                                       ,DDDDDDDDD
MDDCX3%-EPE/DDDDDDDDDDDA(                  ,DDDDDDDDDD9\0E,EU
MA,24DDDDDDDDDDA                                       ,DDDDD
MDDDDDDC&XQJEPEEDDDDDDDDDDDA(   D @    $  $    ,DDDDDDDDDD9/J
MZ,5UD,+LDDDDDDDDDDA                   FZ %(               ,D
MDDDDDDDDDDC6.Q$=PCHDDDDDDDDDDDA(     $  $D$D$$    ,DDDDDDDDD
MD9?.YQMUAN>4DDDDDDDDDDA                   R$G7/I"Z/#Y?',
M  ,DDDDDDDDDDDY0  !YHGQDDDDDDDDDDDA(   @@  @ @@ $D    ,DDDDD
MDDDDD9;X?O(>A."DDDDDDDDDDDA                   <!-$GOBZ.<[HBF
M      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(   @   @ D$DDD    ,D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA                   S,*$BCED^W
M[WS&      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(       @
M  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA                   Q"TD.*
M9+XT9DB3      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(
M      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M                  ,DDDDDDDDDDDDDDDD$@$$ @$DDDDDDDDA(
M          ,DDDDDDDDDDDDDDD@DDD D@$DDDDDDDDA          ')
M                      ,DDDDDDDD   D$$DD@D$ @D@DDDDDDDDA(   $
M$D$$D D D@    ,DDDDDDDDD @D$$ $$DD@ @$DDDDDDDDA         MY))
M    1             YX Q.   ,DDDDDDDD@ @$$$D@$@@$@$DDDDDDDDDA(
M      D $@$$      ,DDDDDDDD@D$$  @@D$D$ D$DDDDDDDDA        $
M1)))X  6[^#V(,U,PVDMM QA>(!   ,DDDDDDDDD$@ @ @D$DDD@$ DDDDDD
MDDA(    @@ @D$$@D@    ,DDDDDDDD@D$DD$D $  @$D$DDDDDDDDA
M   K))))/  QIB<$\M/86GGN: K#=H!   ,DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDA(       @          ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M       9)@^)+8 /DQ8S=&$FH6WF.XZ9=0!   ,DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDA(                  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDA       $Q)E$))X =FQ>YQU-5(':=D0%5ZTG   ,DDDDD@DDDDD@D@$DD
MDDDDDDD$D$D@DDA(                  ,DDDDDDDDDD@DDDDDDD@DDDDDD
MDDDDDDA       !)))=))0    (                   ,DD   $@$ $D@
M$@@$$   $D$ $$D@DDA(       D@         ,DDDDDD@@D  DD@D@$$$@$
M @ DDDDDDDA       %))*>))0                        ,DDDD$$DD@
M D $$$D   @ D@D$D D DDA(       D @        ,DDDDDD@$  @@@D
M@ $$ DDDDDDDDDA       '1)E%))(    $    "(             ,DDD @
M$D$@D$@@@@@$$D@$ @D$$D$ DDA(       D@@        ,DDDDDDD@D$@DD
M DD @D$  @DDDDDDDDA        Q)%O)+P    !\Z C(06&8$OPS      ,D
MDDDDDDDDDDD$DDDDDD@DDDDDDDDDDDA(                  ,DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDA        8)))))     6!YC4&HV#3":<:
M  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(                  ,DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDA        $Q)));     A$:7>%D ^E;@8^
M      ,D@ @DDD$DDDDDDD DD@D @$DDDDDD DA(         $ $      ,D
MDDDDDDDDDDDDDD$@DDDDDDDDDDDDDDA         M))"X     CJ&!5'H"-Q
MMLH+      ,DDD@D$ $$D$@D$ @D$D$@D@D D D$ DA(    $  D$@$ @
M  ,DDDDDDDDDDD D$D$ D$@DDDDDDDDDDDA         "Q4(      #@( %H
M  "X  #8      ,D@@D @D$$@@$ DD@@D$$@$$D@@@@ @DA(   $@@$@@@$@
MD@    ,DDDDDDDDDD@$$DD$ $@@DDDDDDDDDDDA
M                  ,D@DD$$  D@$$@$ @DD$ @$@@  $DD$DA(   $@$@@
M DD@$     ,DDDDDDDDDD@$@$D @D$DDDDDDDDDDDDA
M                      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DA(
M    @         ,DDDDDDDDDDD$DDDDDDDDDDDDDDDDDDDA
M      09      H  %Q1      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(
M                  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M          S^$O'$$X$(H'.7      ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDA(                  ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M              W.$O#GXHK(8;FW      ,DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDA(     D$ $@@ $     ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA
M                  )6  %YT ,X "QB      ,DDDDDDDDDDDDD DD$ DDD
MDDDDDDDDDDA(     @DD   $D@    ,DDDDDDDDDDDD@@D@D@DDDDDDDDDDD
MDDA                         @             ,DDDDDDDDDDDDDD$$
MD$DDDDDDDDDDDDA(    D@@$@$$D$@    ,DDDDDDDDDDDD@$ $@DDDDDDDD
MDDDDDDA                                       ,DDDDDDDDDDDDD
M@D$ @DDDDDDDDDDDDDA(       @          ,DDDDDDDDDDDDDD  $$DDD
MDDDDDDDDDDA                                       ,DDDDDDDDD
MDDDDD$D@ DDDDDDDDDDDDDA(                  ,DDDDDDDDDDDDD@D@$
M DDDDDDDDDDDDDA                                       ,DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDA(                  ,DDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDA                                       ,D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA(                  ,DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDA
M  Y))))))))))))))))))))))))))))))))(                  Y)))))
M))))))))))))))))))))))))))/
M      !))))))))))))))))))))))))))))))))8                 "))
M))))))))))))))))))))))))))))))(
M
M
M
M
M
M
M
M
M
M
M
M
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD_\0 +Q$  @ $! 4$ P$! 0$! 0    $1T?#Q
M(3%1L1!!8&&A0%!QP2 P@9'A<+"@P/_:  @! P$!/Q#_ /"FRB.VQS"/!%E!
M?O0L0ED&G@@)IJ*X]IG;9!#T2G,*4R_6R:Q.VS (_IACEA_YIGBFS'0A^/R,
MXP]C.W#-F)O,33Q0VDHL@\Q#%N#5@V9FXH""A8LB@9OB2BX'?9! :7!M"<<4
M/"-D$(QP%D&-3A$0D4QN&8U<QA!/A"<(XF=C!VX9F%A$Q$C3R$HFB_GAF83N
M8G'(>80,#%@)SA'\,X3UFQ^/-#XQ\,'8803X9J$WF8,UGG@W@PL@%A$QJ<&S
M,0W@W_EN>*B;$:!#%&^9G"6) _H1'$7,9T#L1$=%AT'(+;,8[QP&1A$1 ;@L
M@_$W#%D?$/3XIP<2B)!MP@0'"(9R!'B<Q4G2(W>,8!JUR9!83\V/>#'(;&@S
M[F-V8R!S0H_A,+;S$PQ"P=/0RC*<S  U8'$<HN3/L,&9(9SQ0]LW+CG"R0D5
M#P5C(2S9FV\"'BG@.A/D,BOF.%@QZV%D'O:(]Q9&J&3&1TF<8U#X#(6W_EF>
M*R,6G%S(SN&<(6V@T@%HHX?)G_ [4";-#OC@$]*$8?(\8U'^C5KB[*(GX6)I
M'9W,(0QO)PPGJ9M<^ S((/#-B=Q##@/,,@SQ(JF,XK%&=XH0]-#*X&<9QYA]
MAG&7\F;BSA9(C+%B@RA%'+\CPSW(XP@WBHP@1 "R"IM$<XA8$-8SCQEP,FN?
M_EF>9/'.X9PC@+1"HHSUF?\ !&)#REB,<6@_1,7 !/(/ ;Y\&H2YC).*1*(D
M6U"'%.#B41,L$1PD<;S8V..FS0^ %0$Q(?V%<4^!C&EDN!YAD&>0#0AC/ CL
M(X#T9E#XBY$3V%P =H$?89QE_)FXLXPJ :XC-8-:)R,F\A\I#(S&= R08HWS
M%D$;P"5:<1DT HB,X\9<#)KG_P"6,XH(2"XMSBUP81:$DE!#2.1EZ'T4,2'S
M"6"#1(,;#NG'*!V=SL[F7.,7D=G<9Q0;G%H2A@-(M"F)5B*H+T'$%L$$)!F)
MS(F!@)6 ;D6C(9Q02):!L',1I-08PBEP81A 2!))!&4!;!!;!#*G%N1:.R9&
MXXID) A((-(Y#2.?#&C >DDYBIQQ9AA8D<0PBT))*"'\4$)!?^EO:A%!^RH6
M#'RF+G,00_\ @@F6%N'-)0W18%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP
M*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*98
M%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*98%,L
M"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4QTU&FN3I^RX
MC6^W_6BP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ I
ME@4RP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4
MRP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IE@4RP*
M98%,L"F6!3+ IE@4RP*98%,L"F6!3+ IB+"U'FTH;OH_'>$27^LHN*+BBXHN
M*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BB
MXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*
M+BBXHN*+BBXHN*+BBXHN,]4(80AFTM3R&Z]EV6PRGP)Y:KY*+BBXHN*+BBXH
MN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+B
MBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN*+BBXHN
M*+BBXHN*+BBXHN*+C'>,37^/H^B:KH'9;#R&Z]EV6PHFBZ!HFKZ/HFJZ!V6P
M\ANO9=EL*)HN@:)J^CZ)JN@=EL/(;KV79;"B:+H&B:OH^B:KH'9;#R&Z]EV6
MPHFBZ!HFKZ/HFJZ!V6P\ANO9=EL*)HN@:)J^CZ)JO3KBFV\<(318%,P=:P9]
M_P"O3]*SF#4(+OVB9<HQC@GE#7Y'Z1;7##^0A(<7JE##^\(\XZ%B1(;^7_&_
M3[+8>0W7LNRV%$T7IG'*[%@4Q#(WJE/],+ H1R3YO5=AS?D3_P!@8T4(<DM=
M.#:2+R'=8]R2AY:X)HP.W,9<&D_BF)KHI^GHFKZ/HFJ]/1=V,P&TN2(M#BT2
M1@4)FHQT[0Y_(G V'S]0^Q!RMAPJ4S48Z=H<_D@M#WC_ ,(<*!IR_HX\M=G'
MZ0I/BF97R^RA_#Q^':JU61O=F=NTV8B,%'Y?<3X\P<,AW,%A_G_/3;+8>0W7
MLNRV%$T7IMQ#@7 UFDQ82/5)'/64<X?3/,&@MF-W#V)'/64<X?3,&EK&'^88
MD1N>2YL:1PP_/_"(+"G)G@-V9U&1L?OAAG8H^(8<^8_9*AMPB:S#!_$X"2JG
MBP^]1S3,L&OOZ]/1-7T?1-5Z>B[LA1F6"@?1G:&<6]SE!;[LAA(L$.V*'</N
MOL5D)ONQL5TT>Q&&.";_ +%3'>6*10[L8,ROE]E#^'C\=[LQ&X>@ZA=D,H'9
MLQ,?R^O3;+8>0W7LNRV%$T7IMQ#4A%GBUL0@1K5O<\3[%&LA-]XH3E!-K<\3
M[$DMD3;??'#0:]W@H*OZR&R=@C3EJ#^1@> W9G49&Q^^.UV7!G4VFXX9I_'R
M8) Q<(8?WZ'?$6_IZ)J_<4,0AC^)<017B;AF1<(K\6D1#V1I!?LHFJ]/1=V1
MKA*&2F.45J&O_&S/^>[-INC8_9G_ #W8IS9,C:-R^5V&1S5'Z@)X@^3LC*^7
MV4/X>/P5RVUHE,7PVE'+X%FK2Q6/=?(Y?$YH>WH+_6R/>:S^7Z;9;#R&Z]EV
M6PHFB]-N(0ZW%\H30NH;U2F>)]E$T1E?+[/$^RB:(ADQ0_C1F+MK^$*&!MQU
M?8\!NS.HR-C]\,'6\67;^K47PTG#/X(=FGWA-C$L%#%=U'+#<9','_K[00_Y
MX_I>GHFK]F;!!-ND( A'VLQQS'B@W#%B;@FN+S#,HSN+PC8FGBN!]'!#F(&(
MX9D3R#(3<$UQ'M_:435>G@D.#5)EB2(]#BT20EPE[H*/^CPF*>HB:5\% 2X2
M]T%'_>"N"FN^([@$^R2X*&E:H*/^D&A0:I,0I$$N$)9O5I,L20@@A.R@(((?
MRHF3*^$EZ?9;#R&Z]EV6PHFB]-#C%:,L20L)&N:2,07\DF))(+(4-*U04?\
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M@LW,RC+(S1% 1)C/,GX,L4Q/)C7PAZ@21*(ER3@?1P6YAJ.(H9#-Y!%*_A%
M.F\G :R]OVE$U70.RV'D-U[+LMA1-%T#1-7Z+-6_CN_H>GQ;_0Y3([?^":>*
M] TGF=E^ANQ:$F1?BTGF0<8+@U',[+T%$U70.RV'D-U[+LMA1-%T#1-7Z'D
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M1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R('!ASA&.R_\
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M@:)J_9WJ2%@C"M9C8K\EPA-60'-?(2"=8D%9 0O?@IS&%K +7N8,,@KO?",
M0P17\%D> 0YPAX'"%I^THFJZ!V6P\ANO9=EL*)HN@:)J_<VJ>7K*)JN@=EL/
M(;KV79;"B:+H&B:OH^B:KH'9;#R&Z]EV6PHFBZ!HFKZ/HFJZ!V6P\ANO9=EL
M*)HN@:)J^CZ)JN@=EL/(;KV79;"B:+H&B:OH^B:KH'9;#R&Z]EV6PHFBZ!HF
MKZ/:'@D;_C*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2
MD*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2
MD*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2D*2
MD*2D*2D*2D*2D*2D*2D*2D(]]H<GJNQY#=>R[+88D9(G@^2^"DI"DI"DI"DI
M"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI
M"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI
M"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI"DI
M!H>#9K^OH^)P8<HQCLRX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1
M<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(
MN#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D
M7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y"ZS;4,/96M+'.,>6
M&C+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+
M@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%
MP<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<BX.1<'(N#D7!R+@Y%P<B
MX.1<'(N#D7!R+@Y%P<BX.1<'(N#D0.##G",=E_\ .K__Q  O$0 "  0$! 8#
M 0$! 0$      1&QT?$A,:'P05%A<1! 4&"!P2 PD>%PL*# _]H " $" 0$_
M$/\ X4XWDEU.HM:"N+45T\$UFBU^^ F+'UE:B",;0:;0>?BF*,5K0ZBUH1G*
M&^GDG+7B,<L4.GZU*)8[Y'46M!%%J*Z?H2C@/&9^W_-,KYF,JI06^8C#08F-
MD>)H$+HQC&H7@LBP:,7*--H,3-!(L3%'ZC."P,Q+%?69P:\>321>! 4I.(J*
MN*\6B-'06M2$Y0WU$46-=F--.#$,6/X(V!B,X,0DBB\@P8DVX(Q1?431P/!,
M@-#L<>!9&%X<2A3%_:0AYJ'*#3Z/PQ*,((N4::<&95;[";@N/(:E%RC4,'XZ
M!#4R@M:F*E +2@]Z^"&.$+H[/CP:P6(T(N4:;8YC^S@[>"&.$-X-YR%D7+NA
M(1#78<0B"&.%_P MROF8_&-=CF*Q$)P1H$8L20GSR:&E ?!F#+'0CM Q',9"
M3<3'%2"YBEH0:$<QP&!2PYD9IT:.FOBDVX(Z*BF-9+#Q2!HVP_T@"C&)S 60
MWC/!U, \,NXQAFXR?A8J/ GQ%.?%8C/D0$WF:5(:*$!#UDS%BA\AWC("8F3&
MBY,8:D63D17 Z"DG%)^%5#R+,16UV0FJ@V0E6*D?3]CILL1$5"#0E+Q^O'0(
MSABSF0#T8J)D1@5Q8UVN#%JR&)@)DOZ16! 6U$$S,["49! $F+&JX(-#"P8^
M%SN0W_1(7)BE.2_Y9E?,QU4XKM48D%AU&VW%F@7C69Z;<S/3U8N)7P^X&1W^
MF(BRV/@@AK8T(@R11VY"J#P[)T&C+\<A8\.A"-F/'\':9HWDJ#U-HP&7C(^&
M/LB3TF3T*,<#BN3(E')"50KYQ$[<,.B@24:-&N9E?,QVTN#%4&@^HEBD'T&9
MZ34_"JH/V^S2'"<T:-GT_9I#,[?:)WQT",X<@YD3]#7$-P1[1^AG&!/M_@G1
MHP%Q\&A?&'RAK',SL-AE$0J+@T,K;[L0]<O"ZES)[):2_P"697S,V>WCH%XU
M#F^;[.,TR_P,CO\ 3(G?@26P2ZB8K-BN>0]KL^8V,@6AX-KP82,38/F;H?Z0
MJ>*/3Q2!HVP_TC&)\?Z0ES,AZ&3-OH/?-D,89J,F-9)38I"7<W@*AQ1,QAD<
MQ9)1HT:YF5\S(_SL9<6^I&)_@E7,7UX53\B86J#@T/2[+D+A,W(^G[-(9G;[
M1.^.@0U;B]/^BEO-S%X[ 4_B&!9!H:>!O^"$Z.!FF.@K?-P%H3@C,['7)8=Q
M(99;Z''SO&I!CX74N9/9+27_ "S!"7P/#(M^*A#!\>&5-\#&;9L1<7<<*++D
M+\0O@P-\!O62W\D7,6/(D&)L8,7P3AV&XXOP>MM")O)4-Y*@K2:,/%+4)%0W
MDJ&*$O@3L NB&VW%BI@%V&D8N,F,4R#BA+4,"-&)'#!BAPP$MTQ,BQBQ6PGP
M-MN+,$)? XC>(B@X,7Q."Z#&29HR)OCP30C'N(H*"&,2+([%"(XB19'A!D+B
MC#Q2L NB-Y*A@[GXHH1CW&\H(C!BQ%",>XO@H+L-QQ9&X#X&@S0MIVN@Q8;Z
MB'J1,J;X&,VS8HP"^!X?%O\ Z6M;+(@#?SZ,0:6)O^"ZQOG;_P#!"XM$#<.2
M52R*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R
M*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9
M%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%4L
MBJ615+(JED52R*I9%4LBJ615+(JD142:X/T7$ZWTNBR*I9%4LBJ615+(JED5
M2R*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*
MI9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%
M4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%4LBJ615+(JED52R*I9%4LB
MJ615+(JB1 U'FE7V?B)"+2_ION-]QON-]QON-]QON-]QON-]QON-]QON-]QO
MN-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QO
MN-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QO
MN-]QF(A#"'6',U2:]%EI(R412>7/Y-]QON-]QON-]QON-]QON-]QON-]QON-
M]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-
M]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-]QON-
M]QON-]QON,1(P;7\]GZ=->P9::-4FO19:2-.DO8.O3?L_3IKV#+31JDUZ++2
M1ITE[!UZ;]GZ=->P9::-4FO19:2-.DO8.O3?L_3IKV#+31JDUZ++21ITE[!U
MZ;]GZ=->P9::-4FO19:2-.DO8.O3?L_3IKRZ4AMOE=%D53!AJ$,^OR^7Z4S,
M&H077I$R,1C'!<(<QMN+7A@C(74N+YPKX14Q?)$5(]W^-^7EIHU2:]%EI(TZ
M2\L_970LBJ**G%\X5_3#**$<ES?,:V9%K Q1(0X+KR\&TD600B^JRFO!3'XN
M(TX--?"J(SXI^7UZ;]GZ=->7TOVQ#!MKDB)0%'DH& @F:C'ETAQ, P._^?8M
M90X&BBQCRZ0X]Q$##UC_ (0 78J,/*7>/TA89%,RN[[-[X-)X="E6\B;DSHD
MFQQQ(8]V+H='!PR&<46'\_SRTM-&J37HLM)&G27EIZ&^EXK-)D*)/HD9Z8]8
M?3'T/Z(5&KAZ!GICUA],P&W.,/Y@1J9Y+BQI'##W_P (RL*<&:)-F9V7T2'W
MX87V*.D,./$9,M0EX1O=A@^$X":"GR#FGY9K[^O+Z]-^S].FO+Z7[9!*,L%_
M@=Y8BW,B&2WFR$EP(=,1G"ZK[$Y2;S8WJJ:,CO%!-_.V/AK'$AO1P9E=WV;W
MP:3QFY,Q=H; Z(;"VP8F+N_KRTM-&J37HLM)&G27EIZ&! +/%J0ZP"'-N9I?
ML3*R$WUBCO0U,TOV)N4R)X]1['R4$0,3H%A\.#XC T2;,SLOHD/OQDY+P8$1
M3<<,T^W<PT)BX0G]"N)T7E]>F_47053\7B/('AQY>*3;@AK46_\ '^,;R@)W
M-C CB4.G[-.FO+Z?[8UY%+I49HC4.=V3,V2TT2'V3,V(<V3(D7_5T&)C'./T
M.JH.0RN[[-[X-)X,*FVN4*BH\%'+L)E6EECU7<9^TZH:T(+^MG.%9]_+2TT:
MI->BRTD:=)>6GH3@W'E"J%I.+Z*II?LTZ2,KN^S2_9ITD0*8.'PT9L\F_@AO
MP3C'FS1)LS.R^B0^_#!AN,<NGRA4>#AGV(.VGUA4?3PABNT<O]&Q=!_U]((9
MWHZ>7UZ;]&51>PC>,-:_ @#9+%B:R<!4DH2;<$-:+;^/Q1Q8S0&D\4,6/X&S
M02!)9]OUX,7G,G)Q9C<O<6YAY_Z)-N"&M1;0[/PR.[)J9/7[-.FO+Y,ONDRS
M(B4!1Y* D0EZH*/]$,"*$,$+LH"1"7J@H_WP505-=1Y%:?1+P4 K'G!1(! <
M.:B(8$%X0XF^J19D)8(2Z*!@J'W43(Q=E#R\M-&J37HLM)&G27EH88KJ69$#
M)/LC%TONDQ))!9"@%8\X*)BZ7W28DD@LAI-09C1Q.R$DE!#>*6^J3((HKD(8
M(790\(! <.:B69#V!3Z)(R,?=1,G5V27F->F_1I448W%+0AB<9D>;C([HFSV
M./+C03G@B,$J$<Q$U7.) ^3E]C)M;Q.4M]B2C'@A#U8*9"Z*!!+CET)#/M^O
M!+=N"'P^7QXVH1=!6>") 59YF1W9-3)Z_9ITU[!EIHU2:]%EI(TZ2]@Z]-^5
MP5*>O\,FB_BL!.X?PJF"J'OA_@A(M%?ME1J%X0,&[D(^,1KC/[KZ,5]GT,DF
M:""^+B97S,Q]YFD($?-HX@IZ$\Z\CB,F+Y'36NI]OUX(7.(?I^&08SYMH3<F
MA%/%_)D=V34R>OV:=->P9::-4FO19:2-.DO8.O3?DTF.+Y<?\,%CT%7\7L7+
M?(=K&<^'^2,_URIF=D8XS1#4X#X74?$1'#CFC&Y>QQ88QT'4'R8NXQE"Z#WS
M%([GT8EJXD3T&QL#'#L-@[,;+W^O!J$X"@&:D8W+V$&86?/Y.,SBC&Y>PBS/
M$;4QECVQ'7]_LTZ:]@RTT:I->BRTD:=)>P=>F_))S-].H\/BW^AS)D9?\$XX
MKR";:*&]0;_U_H0P8OD:Q:/XIFBF-Z@W_K\$VG%$=0C_ *S/]^G37L&6FC5)
MKT66DC3I+V#KTWY%ZX675CZV+?ZH6-BLNW+XEV]3TZ:]@RTT:I->BRTD:=)>
MP=>F_(P1,IG_ )^*8J+9'HH:R_'-!1E,-1]2TZ:]@RTT:I->BRTD:=)>P=>F
M_(-PQ'M.+C^,!G4JZ:#(SC#\H*W$U]_?Z^\1-'NX";'_ !Q'.;A^A760;"I/
MIYS3IKV#+31JDUZ++21ITE[!UZ;\A"3@G+\\CM]/R_@/O]2U<3'M4<%@B,&#
M&Q#/%F1?'J[$68'H1!XLQ,<.(K(@XU%(XO ZNZ/$7%O#$5FO'F1G.(L-L7PC
M 1?#:X#&68R-B.B('Z.-2,7P(\3BR',BW6 J*80QN/=](6RR61UN"%%R1[_Z
M< G']NG37L&6FC5)KT66DC3I+V#KTWY#J(G+\\CM]/R3%[??ZM.8'CS\$%9Q
MO'[R!11@9'<:GGR(U,\V/8[!-IQ0S8?63-<9'=D5W%D<9R$17P0]0<LQZRXB
MKO/"M#/&(\KG <G]43R(Y''D)^.G_1<'I^W3IKV#+31JDUZ++21ITE[!UZ;\
M@U'!CVG!M?C'_P!*HJIC@Y<##_7=.3_'''$W]?7ZD1V:D1Y$4QS!J"ZB^(K#
M43(&^@6,XR>Y/1 .0CZXLC$B.5G*,F:XR.[-2YFC$+CQP%1<6A14P2YBL#OX
M7.-!]&I4R>B""'-C8D??@)!'3]NG37L&6FC5)KT66DC3I+V#KTWY&")E,O\
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MD:=)>684Q1O-U%V#:ZNHT3B-=7]"QE+ ZU+-U@-$XC75_0L92P(&HHQ8S.I
MU!"A&-=7],A"[!(U CW^_"#8D,L_HWFZF%6^[^V8T;_DB$G'^S\QKTWZ/IS
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M>*M'>+T8V%"BD48: YQ/7CDP(!A:>K#Q,9>J*P%:)S]4(]_0L(*JL#;B9"A
M;\C+]G"A(0>';=^_Z')%"H'D3&R\P$74^RP'I@%RU7?3^4ZY$7APKE+M.ZKH
MQ[XXCK5/M@ ],V_]*?2G#TH>HX>8HH8@!H   P05*<!A]?N:>F)+$AH#)S2#
MN93B>BMD'J).@I'-*:V1->J=!0!@=Q7K4C=^QZQ/YRCPP) %2, XW,JW@B.'
M>@ _&#L8,0J*1BN;SA3_  0.U)54*KM_R7Q?;_XRG/RIF%-*@L=*#+PY13L#
M+4  7%Z?X5.6B)010=  5S#A!.10Q8]1QXQ+&-;H[$)>^YV<INQ1#D@=-  '
M0VW_ "OQ?;_[PG/_ !?;_P"\)S_Q?;^M\BSY%GR+/D6?(L^19\BSY%GR+/D6
M?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BS
MY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?
M(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D64Q!.'.*<;D<_D6?(L^19\BSY%GR
M+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^1
M9\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+
M/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19
M\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/
MD6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\
MBSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D
M6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\B
MSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6?(L^19\BSY%GR+/D6
M!!MMGICY%GR+/D6?(L^19\B_^Y8^/A>W_P!XX^/A>W^CS9"A%H)/WS5X<46I
M_G_Y@"$C)S1-?@__  =UP(G5&-.3UF^G^A=>O7KUZ]>O7KUZ]>O7KUZ]>O7K
MUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KU1\<G39,"6'
M-*=_\*'!H*PM#5-PND[_ .A=>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>
MO7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUZ]>O7KUC@0&JL*<'K-=?]/\ Y/(>
M8TVE+.3_ $'N[N[N[N[N[N[N[N[N[N[N[N[N[N[N[N[N[N[N[N[N[OGB <)O
MP\3U_P /8^_A\AYNFEA9P?Z#W=W=W=W=W=W=W=W=W=W=W=W=W=W=W=W=W=W=
MW=W=W=W\GD/,[;2LO+_^CSNYL?;MV[FQ]NW;N;'V[=NYL?;MV[FPH?:841-\
M;Y/&LXSBI:6,X2['9U^M]RC[2"KQ1"\[T.\/U9G[H4'EM_!Q_:8R7KR-M[LI
MQ].ZQ+-@S(:2C?I];$:*1*@B/VQR@<40*%= ;[?_ ##[=NW*V/&/LZJC)>'Z
M6TQ]15?5/U+.G]E[7N<: )UC>#LMJVXG0/0PG,Y+(L .#@^GK&HC[+?H!<"D
MQ-C)HQ13]4^A<_HVGH:@]FNLF7N IWH)_P!T'K@ @B43K_[^; B7AS^L>OKG
M1J+];3<!QH#T8)ACR2R*#0T0[D^AMJ%A&P4L./Z)=5@D*AE&U.JWA+H4-MDP
M851U#SA"NJAC7;A&'33%ZZ4'=H#/ZGKTR5"W J&IV4B%W=8VGUEHM[9SIIO%
ME_\ @5%/0=0VMP2>"N!-I*"1V'& VRO@;U!TU,'6I>!AB" 0F@P-#"J!7L"+
M8$!CSDKOL<1Z/H 1$==W15I245/\!R^W4#>ZY  .[M-#]+;64""BV(..S_9O
M\<F8%5!-!.N1X'" 5!ZNDF'&I#@8:#PY/HAH18;E5T&7P&G%ZB6.X1Z+]"1,
MK0!BCT]6'KBIW"X"\R9UZLV$E.#A^R.D=B?[[NW?L.;>;;0-J-7U<;%" &S@
MEE9>[FS*WT( !K@!2GKADU DG> OIE'U!$C0G4HZY$>N4+:$N!!MP'"EU4-$
M#"P;!.QV6+N8&WG*O9H&=8ZQS-2(SKHW]<$4^H@O5@>3^$<^.[_T?>)PVN-K
M<FY=EKQ;]+HO@"2BK^2#\X#S77' GJ5!PH76L/A .S1$"@6<Z[8Y>V@HY_8O
MX_\ ?S8!-X3*S37GIHAL9)XA+T:*'U_$PBP@7O5>_D?ZIQ7$RF(O*]L?&FV1
MT3?*N@ZK,%=PW*\GY+\8%)LULBD4R"[6Z#&%C#=22ZQ7+[>_TTDF=! "BOU3
M.4T);DUB[4(:*N.I$.=X6Z"X'K_P5/+[=40QAT+(FA]L:J2M^D8":4UWQM,8
M&@:)M_;!Z@+ NJKGBP'I3>)7I#"E1"A=B#-[W&TQ@:!HFW]L$SBB[0-4XJU-
M:CBE$ A)84 *54"G5#&E/X4?L1^^<"ZPYY<99!=)2A2_T:WXBN)^4.T$$2!0
M,/)1W% D"JZ-'TJ?_I6_1*+\IY<%>M(<L-VMJ:&\M)[VBJ7WB_#W?]]W;OV'
M/F[!T#5:'89G4UY#IHQ3?)JXO2=ZVY*;+.F!;>&J@(:%(G6]XXN&] ($OR?H
M9&*Y,NTO6=<"!%08!S-G*7(7'OJ CKW74QG,026BAEJ'1OT,:D$>=/<'J'Z&
M?'=_ZOO70Y4/3L(_L.-?@6N@A_Z8@"=?J +^(_7&<(..Y/\ Z/\ [^;!A]@Z
M.D71/M^?HB2<6N("35!E>37TJD+4;^LA)?')SGP9 /Q7NR<&(I;:4;7C\_3=
MY) L!2[.*?<YPG>=!!$=RT)>.\50M[I+03=%?7%;O+UV&S6 *)84[25;4$!H
M0(V.- 0Q:@56 =2==9]"O\&+A7 *"#-ZW<,P.S<=MY9KA6[<&@5.02(,)I=W
M*NJ6J(=PT!31V/$JH$":WZA.!LVN"0!\/(4%FW3$[,H#L0'@<A_@/MU7*,=/
MI40@NW._+]WM0-!*;WGPO?D@=&$[:;I!P#-L  O6W?7OGPO?@<SV,(;DU."R
MO.$6#^@HP^]]=9I&2,I%UV=5M<]/P[D7O_V_L:WXBZ'YO7XH;3<()N/J"5,&
MRA4[=$ M^^%QLRZ$(_)^E_I&XJS+0H=0!U=1C5F2A0[@3HZ'^F$--T\ !T=J
M&L-&9)F_'1[MU]27C1#]U:,*,S%.[1> "")1.O\ 1/C<<L2O6;T.<,L4M%#?
MD(2\NWK@"\\>@+;T=SK_ (/<A$T >GP<*;6*#:D*?<,M8F8T"CZ=K.27<_HR
M2!&0D4+*-"GX<;%YH\8ECL]!(QXE'D) "HA0535)NDBCR@?NB9["MZ/CN_\
M1]YA^1RC N9HZY&4WBT^=M-@#D=<*(B)7""85R-,VQ:G$)P"L/"+LN4+8*8I
M5  :V\I>U8F\.M)Z@P>P_P /S8&]4^RU_0;.[G_&?;D4"B5#@N%<,)8@]5WT
MN%2\7%"E(+)H><^%[_IN^.[Y^%[_ *;D,0BLT^@J'A;UY7P"!<]M@M=L.KE.
M9>(@IS+'<@+4_IUOQ"\E!M.5'/R8-/G;7: Y77$.0G0:E=9Z8=ND&U9(":\K
M'C%9 ?  '(H*B4)PN%&% V E35"KZHZ?YW<S#FI9XX4T=JXG34T T!V5"N1W
MIQ!>?VYE7J-'U,2!>$+%]81>XQO'X%,==O'?>]L>>VJ0(KV 'H8-AH0/=6C\
MXL2(2WL);]1L[3+LT3MK64D+"B,D<_8OK:0J(=^&YKFC]@1$<^;[_4K,A%R>
M/5 /491@(1.U'&A=AGV,.-X$K1QT5Z_HQQ",J\C<L&CE*)67C0S]U:# 3%!!
M;)#;=?3YWO\ \+"9[B.^C<'DJEAQ])Y(*]0%P5FB\5[XL6")3YZ@][<'D\:'
M, B??$2\)Q.$$K]\6+!$I\]0>]OT&'+=J_8)A\6X.?P'Z,6=E&=!L:UN.==2
MA,K%EAQVR49&NP  'V^D=D:8P%8L "O ?2?KC%5R4$%@%],M^&(US LQ5JFD
M%;&5W_JG-C[=&^^@=I01V#])Z%MJ^DH":4UWP<.*.+R)I^, L$$,0 T $ QB
MSLHSH-C6MP<.*.+R)I^, L$$,0 T $ Q#[AZ#I$ZF+52[U/O=\ ^X> : .AF
MUQV'K!2%5AWP?JP29$R(0U.F(EX3B<()7[_1SKJ4)E8LL..WTG@P=&].2!CV
MSB7. 3F$N$WZDZ=M7^?W..I6E%PKZ"< VP2=5@/0K)G"]=C'0YA'KD;S00JR
MKUA![!A( !5>F:M67#5H'*A04T-&1C84KF91M30>NL6&\_2..THELC@,0\";
M-8.S===7%_:P2AD0$HKP!8X>8,52\CUV.!-)-#OV95Z!>F$8!W=[ET()T@K9
MO> Z4\!=BB;4.LW"Q>9L*'-08[)N;,74>ZC )S*"EG5%K"X4181^JIO;3WH?
MFOPSB;#NP7\OZ?Z?3?(]#3[@L:?L-E6NA"MN:;:5UUAFCE::C8%Q=$<!/G>_
M_P"F0F>[FQ]NW=*S*7ZO[,C#?1&"$;W,_=<;%)29]S,A3U$F[B:?[S@X2U"V
M 'U4'J&2S!S:!3]5?P]\2DYLWG_N3[/X^BSU $1'3,#@AO[SC]3N[YF!^34"
MEPB5)1'>/\1VYPX(;\#1]+Q&Q(8'HY^Y9-Q*1J2G8EO1'HP(8L')'NJNWZ =
M"*H*0[%5^ZX3(>V7ZSZ7K7E<92!C(%!&@."ZZX=PWE:B5YJ/U4?&-G0E^R@_
M#!( Z#39WT^RZXA)U8$<1.N!2/L=^IG#W2;F#Z0I U0;V*:Q HILE"ITNX:[
MY\[W_P"LPF>[FPD@S-T%[2,)1'>C%%VK<)AJH6L41B&4A'6"0_3&85B8QLKO
MOACY^(Y#HV*0]8<&1(F1P[(C>DD) XP@:OHYUR:-]N>#$F(AN&$BB,\&MW1B
MW#I%44T0R*-4V\FOO2H)#A>1[Z82$!H[#4D80 !-X6<53#:"NR/!.+(<- 'J
M4/WP&\0G5O<:'&X.E,=#\UFO<@9?1P&0>8%N(%%;8BQ#";(D=4& D>IWSW.(
M=)XZHW"!0/1!$VU-)8U P74>)NX.YUV'$'2-'14Z?Z]]NW6SW''L/1ZSU@I,
M#Z#29=/WG@9QBJUV_P!!'DL%O6O <CBR5-6W'-J>^^YP98U$HG?^V*041B85
MZ6/Z8GA4<=0.YIWA2:8N9?.5U^"IAC4>N+T^Z1AW7AM0M+Q8C/7.B(?/+2CT
M1_?$V#-?L3C:='F:1P5CT(UWZ;T_7B]^E8="V$O0IQ<9  R@C]VQ-=3#8-Z@
M#1'A,V(E U(KTN#6GF"$NXHB<(.(MKD>B%.28.5.3!3B.UI "L0%ZC0N5.DQ
M=M1@V6BRP(\ZY;LG*#04VTQ8/1L[A7L5-^N+EIRX 'A39VIW^BP:/TL .XJ=
M8G7*BLM.Z0>#<EIZ)IA)GD]]\BX3JT&UU 0FNE2:3JZ[ZI20;.0O#GJUQ/WM
MQSK-8;#^BL6%536BXAN%$$H:Z[UK F@,40S%I&G291TJ#4RO2O?_ %G=S86N
MB,\E8. ;XC;#$B*#I' @IW) &"0DF7VP6=2"("]E#I@:X4).'1I&Q>NNM</J
MQ&?=62&<S? X&9=>AZW8@/V8=+!KQ-]@OOA-@Q55?LB/[/7.IRTFL(XI1V;U
M_HTIB4ZY3. 1"/<O03*Y"@0H:JQ8TPTP$F%@TI&Y"; &(D@B,G%1^Z-(=@D!
MH_UW[=N#.FO.PWDG8VKV:I;JO]@0VE:RZ;U[_N'43TB)4#PC_P" $]3[\"$<
M[JX);;%W @* 0 X _K3"RGR\JER0<JKSC1#^G][Q[H".;-'=_6\+YP   (!T
MPEXP0_96G ADZ;??EN O8/ - !P?Y'<0AC8XIH;-;/U;*'DP=-QCJ]'F9N<^
M++ 5:]6#JF+]=TX=AE[Q^V?R9$$0UUWK"H @ 108: J@8/,9R4<'<"JZ%'=>
M@XU.!&*ZA=-Z_+..$,C*B)T1$3HCDN6F,0#X&EOZ8&)Q$D=P-X>O3.,/ 2?;
MMA>'[E$?_9S8_-EQ@]0ZKTP0($(FA4Z68S[KJ!/*NJ;CP\)6R"S;CIY&IKB9
M>S(X6ZD]#MJ]<%&ZQ#/5K/33TRW#'A5!8A8!H@!FG/C#0DZC'42:3=2_!1$=
M# .Q#\:3FV%M$3_^FS$;MOA.S&?<<29M"!/J47JJO.XIAK,7#E@?A.=_;Z%>
MK\\#'MV'&--;,*6#1KJC.[B ><=*1 I1JJUHF\.GTEC;!ZFYI'A*WC?-H/<K
M=>F-$/ 41%#NOQ.?\7]N(01L<PV-FMCZ@Y/W;R9P5_&,8"_(4 O3!\H?$>8H
M=B(B=$P5!&^1.:4U7%I&!2%@CD#8I]MB3:H5@ .5 ??%SA1QW*'K>6"1"\J"
M:2,?1H8B_<)[XI3"=,]N=,!?N9(\O@35@H2\C>*'^$W#N4HQ_P"[=KT!>F-8
M;=Q7@#H! .@']IH#6[%W.7]X- _T7<C J,$55[!FYD>O(CNJ&DF;U8&H>&)S
M0GJ-@.]DVU'0.CA+GH)WF"W$O5#$:D((V1.9%<3!OHK&@!I/RDTVA*J#U9#[
MY7WNHYI530TG#G,%H%(=,4+0-DNPJ]Z7 G>L!-5@O.A PH-V\(:IP[><*[ZN
MH-* B($*4YZ8<A.&@%4%A&@WO9+@V6%I^M(]74ZX >F.)C.H1BQ=9FC[Q3[4
MV=/8_7"?#QHA;J6=MK]3)GZ3'(-CPIZ+-Y2[K6S(ORW/D.[ &OFV;'UI!]!@
M9H "B&*&%G,,FH#B-1(]=/WSO6CER#T^G3/\&#>Z(XNE9% I/4-G6OI_@^;&
MKJ$V*#5&_-Z?XC[<N\0J*D$;<AL!%>0"CZ=0"@YCPJPK<.I4JGKS(-;W,6/*
MR7>B"&<0#.>UR4A!1\L *V*94LIMT@??><(DQ=$?93:)^SD /FFE PFA8'6Y
M-RR:3SHU*7A)LQINTE6V[LG"3_S)4N)4L* 7I:'7JF.4+63T!^4RG8&1+1!;
M9UT;JY1K:)A2#9!2L4VW6YB^4.?4NCT.V :/)(,>B#T<]>GT3;61TNAMM2U#
M5/3"(AXE0D]%?Y^FK6J\W0G5$!3T.QD%Q!HH2$4![W0><#00()J=IVR1(!Q/
M']M^?KK;/@?6U8:@AUB]7'C53>H4_9_P>ZU\2F@7?W1Z/](T&Y^9'H!U6!U<
M5N4HY 1"B[B_/]*6EU=*.UZ)1.HN4Z4WD @^I8G<?]$W,,-63^G> K:T'A"O
MX_XP&0 57IFS#94=#R!11JFX;P2C$'>J\%75/MC_ ((%AJ/V&]^-C63:A#^I
M^K< >%540U]V?G(!TC@ %[!8=*]W#55BDI9_8'/?[X$!@" ' &!^FTU2E[5/
MW?7Z/H88A@I%"H$%70<HR+%\92B1+/TO], ;MN-!N472>$ZX?KA@DM6,_+70
M[^/[8QJC*H/9VU/^<H,_=*D!X+0L T'".@8: *JO 90]M*)2/Q1.:FL ;0K@
M(?=ZKU5?JF;R>GB+&_8EQU]'_2^;'VZH>/J!L'T!78]?H]]+@?8"J@L AM3$
MPWT]_P"P:.Q<8!Y77!_BT'V7 &R V@7==L?LQ!@@>P0?RGZZPB&\W=-ZPX>,
M(ZC^G>"!Y'Y9R^H?8#()&O[/?W&*XBO,TKUMS2Z)!=0!2I ;-N;0D2(C%1MW
MJX=LP0SL$W @.^M?O_0&+E'!5V!:'(X!W(^*@F1M!"<C<A',J1T &ATP%O4V
MI1=ECP??.[ ]J%V53>U.I@#W#P#0!T,BBQOWDE..9W%9J"H4X>,$EEHOJZOU
MUZX?C8/U)D[Q[8I8U!HSK@[=O\%N,T-1T#G$A>@P1#[!#\?TOQ&6X!(*]J:6
MS,(TBRC0[5_J58[0[6GXMC^T-S.BJBAOH56@/L+T!LY*ZM[@4)Z&&Y52NBP8
MSJEOCK@L%68*D=X/["$JME)*-Q5' KKG)\^G( A1>$]+-?X[=SN@!4(1ZEIZ
MF<^Y@@;IY!:!O?;W5 1;AV8[ TUJY,!3<@!R\- 5?7!K^GK8,::;/+08"\<X
M&/\ F?AB]U2Y0";6<OW,6 >I4 #:J@!G,$:H:,!C' ZS<ACTU**R]%H4F9)4
MU4!FT7VP\'@"(!8***C*N^,&X*06/+#"(;X3JAH. (D&U4H06]%V<Z1O1HP&
M,Q?D<;014D)L$?4<3>&@H +=U*WW^G-5NMS=@04V=\ %MU(@BJ)J[L;[?GN;
M1LX$X&&$@N2D4!+]%=T3:($+&A#U'03#+A4:#9-U^Q T&)<RA/U9N"Z>&%[B
M):D%LTD_3-F,Q5O4/UV?EFQL[VA2-IX J':O^E<V/MU;%$CB[$0&D=)Q:6C-
M(#B\2Z.P3G'J$06:P=H0&-$FE"%)(!1A$$ZH-+J#_0-B;'T<,/6,T0R+<G@'
M6&""F$T!1W6KZN/W:;!@8I- ]7;+BG+DTT^JB?;"8T]M-K]':)&]\GA$ =1@
M  ) %A:($  @'3*MM)!*O2!![I=9%'UX#2FT.4-YICXJN"V0U%(GEMYP2@5(
M60=*@0WQWRBT5)7"/A!XU>7Z&TZ8H- (=G+U,%$5!+0T>JB>IFP?K'%" *#8
M:<'J,"% @#MI=?1'H%+J"!86$Y1:"8@HX(MJ"Q7:I7VR >!#&&+% X<ZKK#K
MBEUH*FN:=,O@VF#[G\;)<F+%M5*K2E:4-O\ @MSIQV]4'_/Z_@>_]1RNMEZE
M?^?[2A-E\)+W0^P8+C#!39^B@G%KK@G"Y8O0)L.@1.CB6PZ P+8_D&!2TJNS
M@;O5W]7IA3BNV&,J=2J8@F/H1YL-)S4XY.IS@^I.#F1:, 14'%16F\4G!4G"
MKIO%+8G[UHQ51H40-7#7,#+>!Y'C5X(;#K!:D"DXH&]W-JMEJV"GHT3\XV<U
M2&HB":V/?TP-JJB#RI[H4FU.!255Y(R54#HEMU%2P+P"I]@Q0G+H5TJ!90).
MJYL3^[1E]5&]\F<>4Y"LO4-]0[(@-H.#I0 @@7QUQ2O2P-HKB1B3N\XL# \!
M"?1;! "ID:C1-=+@+:NJ!T8,$I=T)= #C8<H#10Q( &%E>H$--U?A^B(U5.O
M7 QLT=:A@@A@X39_K^[FPXJHA4=#\#BBNDPH"A0E"2GTQ_>(YIH#$1+",C71
M2*$-4R?4L<:9Y\4:1$FQQ6.P*,E2M9)7VZ'^Q?;MR:8E_@_S_7\#W_J+NH7[
MA?Q_M'5;I5V;^R8-(+R0;'&N)])?/)4$B'6(!;)C[49ZC1)1.#_F0$P$E:M]
M=OY8C!0*O+AUF':P=W04ZR.EPH$,B A"[#LU@9!'>M\YJ&\[Q6<1+Q%&D>SA
MK9/#@   X#Z+?.]^/>RMBD.54YX(&@,1:Z\D'.U2^EPQPLTLH?9G*!P2!1]M
M!>R[X?JV B@O9*GV[8Q0M#2!/T_7^A(ZQ "!T/455M5MN&$:\G)$CL(S T2+
MQ$N 0)Q#%3A<Z-!_(/XST*_'5N-A4%G+#-O+%5'J#_? (A4=%-'I&?Z_NYL,
MGZ/E7_#\Y5#9.AJ/90?=8X3MW=6'L:+W&$8T+#VAZ*GX_P!DY?;MQV"H%$>1
MPK$L^Q03T2/Y_I3+ 2%_1LRW5'6JXYI'KOIAF4!()010-;26%J?TLL)5Y3/Q
M;/Y_M"*!HC6]HON^G.#D<MFSA"$"!'D!WGH\-;1]U;V%UA[ VBZX*!V%CHR
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M9(P#W>K!O"A7CI Z4C-SJU,?^(.@>1.IBW)&D.]XGI0= RPY0;Z@T[R/9,,
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M^T)=7^.11*G&Y "#4!IFI_K&[FQ427.OD.H>R)Z8-8<+MZ46_99WN;;/5("
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MV6(H_1Q@*IQ$8K1C6DO+BM!L0(3LCXX3?83 $B43 RP( @']"9-9@G)5!(H
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MW;O$+V#*4H#;&'L%6=5WP1O>"H"]^^AVOOA^_(@T .P9)C16HU#HA'=^A_\
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MM[Z_0#_ )^YS@E5WP1BKWBXVGA?)V#?5)ZYP30U$J>D(IZ#O/W[ZS%C^W?\
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M>,O8K&9Z1*?4CTP&8F:5H!4WJ$-[F.QD-(2_,/Y/7^E'=WO,']LGX_H:?O;
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M1B/1!PN9K#A,?U,,V+H5*G5@%>@'3(F-R4J>>_!^F 7S("DT"E1@."J:H=D
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MZ@3RKJFX\/"5L@LVXZ>1J:XF7LR.%NI/0[:O7!1NL0SU:STT],MPQX506(6
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0L\B>V>1/;/(GM_\ KH__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>xcur-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xcur="http://www.exicuretx.com/20200630"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xcur-20200630.xsd" xlink:type="simple"/>
    <context id="ibe98af36b5604579bf17b5244677d385_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1942a18648da4a2baa5c6f6dcbc62801_I20200810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-08-10</instant>
        </period>
    </context>
    <context id="i738818d3ada14fb59ae41e5c0547ff93_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4340bc2a3caf476e9ea1655692119072_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76587ca4c99d49da89121e59315b11c9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1e81cc37885946329de84c2812052368_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0561748f81354564b2005d72c36f00ac_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i081c44d7528546cba2417fec5251bb86_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i669ca094820a403bb6fe6191fea9d033_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69d5a6f3c0f64d0b92f3d4c01084e89b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a2b6489ddf141a7bf39c57e8c6c374d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac2f608277bb4d11b8c650acaa7156a4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia600341070154f04b665acb7c655fde4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7ae69caa952548968e3db1374a9441bf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iffcf7f98338c48b2a74d5c64bcbb09cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i99f18a5fae5146fdac7af880c302d1f0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8ebe7513efbb4572897a2eff0bbe5839_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic1abd752d57f494da5a5dcd7e17f6c8b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if4929d22fbb34f5bb8e001e11fca287f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i346241752b2b49a69f5d211b6a9d45fd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i87bf2cd1655f4fab8c904201cabea717_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id117ecfcad3043b9afe9dd6651b61ef9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i25b2e786a1684d32b3eb638cf322b195_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i629055e5f5f9450696b0cdd1b8c62aaf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i057811d1d09040a098af94d1675312a5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if3b2128138ac484d800e0f7ffac985fc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia3377b36eefd4b7dbcd8a37028612f32_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic0ac35850023477bb1b027d27cf6499d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaf91bb3242b54554bf09467575ed8032_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i251a593531414918acbfa4bea82baa82_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i42b80e31064445acb2afbf5c674a8d22_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idda7464d50394c8da8f759b3fe9c27f6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i48514485d5c5481a815ea5cb4ec4f071_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5fce0dd8830b423089b11cd5506c2b50_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id85a381bc7624171a8e7ce667919dcf2_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i16628e25dfeb457db79ff5741f4b4746_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifd3596a8daa44dafa2c2640d7eaf3704_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ibae0a4d897b84e4d9577c9afadfbfeaa_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i51b397f6da68451f925c80fb3973ef2d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2d7a7c38c82d4bb58ce35946a0c4b0db_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ibb258cc2165d4dcbaeb2ae16188d95fb_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i0b302e66ac63416b82f00e6f82fdf6d7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie9b16abc11334de6979be196b3664e81_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic80e034dbbc84fb499846b28fc08af31_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i74d996f1250448ddb4ffa272adecd35a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i235890d5628b4e7baba46b8ea6aa194f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i59a965bf3b8a48eb80d080bf600a28cd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1bb3dae634064c17b1ab1c0817e8c5ea_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia5e1c54705464203b36edb7644fc518c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if425dcd784314579ba01872343ba1d3d_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="i213132da6481483c807931ec91868df7_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xcur:DevelopmentandCommercializationLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="iec1efc8f38914d529f3fa0003f78cbce_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="ie0168a43217c4457bc65313c2af4fb05_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i56e80b2cc5be4ab4acf0eef51f34220c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AllerganCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-17</startDate>
            <endDate>2019-02-17</endDate>
        </period>
    </context>
    <context id="i3af79e6a06594c0cb23b1951b9373a0c_D20190217-20190217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-17</startDate>
            <endDate>2019-02-17</endDate>
        </period>
    </context>
    <context id="iee37ebd534aa4705869ea2175ce06b24_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4755b498baa24be79491012d4f532c62_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib68fbc221ed948318252eb995a6db2b6_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7a49e1430c4d4a889f71e3a5a377bb5a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if8a0a13c38254ea983e0bb5a38ca17de_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8bfb10b6658e4029a82a1c4c79504c5a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i352899e868b047baae4f3cc5f48173b4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7e5bb134266b43198e6a9ac71d907554_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18277ad2812a4ef9966ee81eceda653f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iad32dfdbf9ce43d4a96d7847ec6e4876_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf30ba5997b64586b6fd2b6487a3b25e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id3e2b30098dd4ce39f205fbcaecabc6e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83ab7faaf6324bbe806b1945f6ef544f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifd78f631ebaa4338ba6f8984c802d444_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i209cc24d339e4dca80c79600e75bf93a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3438766d2dcd44c49ffa9224566847b8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icbffc60721ce4820bf8a858d521a4af2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f8930d5532948af84a2e264d978cb22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf8a62227b6e4249b0ad9da0af747eac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i331baf183969422d81b4084c1e01f301_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d33f191228d4786a0f292468de4d908_D20200302-20200302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <context id="id642410749d845f68e04f5594e957ca4_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="id8e4fcd0750e4f00b604afc9f08aeaf4_D20200228-20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xcur:CommonStockIssuedDecember2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-23</startDate>
            <endDate>2019-12-23</endDate>
        </period>
    </context>
    <context id="i4be9f363b86d4627be1d61061c00986b_I20191223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xcur:CommonStockIssuedDecember2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-23</instant>
        </period>
    </context>
    <context id="ia2cea85073354474aa680437e75f26a7_D20191223-20191223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-23</startDate>
            <endDate>2019-12-23</endDate>
        </period>
    </context>
    <context id="icfa443308cf5477596e1014cee13ebba_D20200106-20200106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-06</startDate>
            <endDate>2020-01-06</endDate>
        </period>
    </context>
    <context id="ic86b7ec9cc274bf8af157b6700465ac9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i164e4b30480d4e978a2812a8cd07749a_I20210327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-27</instant>
        </period>
    </context>
    <context id="i4fde2bf7394d44a09eddfef7c0f06b5a_I20210428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="i7fb9e0113525465fa92492e072f0e43e_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i9c03ff4e8b5c4b699019abb27907654d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib61094c0deb84e1bbf2fd681155a9f0c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i63f9fe0651d84de1b85aafe4a8643eec_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic6eadd66fe2e43af9a25c3f417c84b26_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib5d6effdfbf94d41a083294b170f3969_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibebc8ba07dd245ff97b780fc24472240_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i87bbbbbd85fc49b8852959fd449af5cf_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i9527a967dad3415598f73d2c86f453fc_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i6b932d51abde4221b44077fb53a41b3b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i53eada77c822436c8d20ad774d619503_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifbfbd26204cc426c8a8cf03400f66926_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7040eb168bef4211b4772b89a21e6728_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3e1913cdd58d478da612d3f93c8f7a38_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ieb6b302afc2b47db9a9b8aa6e84aac60_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5bdba642bc224cb9b89f1de3feabde3e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4aec036201f748fd8269f237b2461bcc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie7e189a56ebb44a6ba95910fba45564d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1e9583ff1ce6495cb0331d2a1569e1b0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib66e2fa725c1452382443738ad2ef816_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6091d038421c443d91771f31d4e2744c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8ff390c5c87441f5a73f86f5f1529e92_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6b7e6c0acc9b4b93871186f77defb445_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaa95d698f7954c17a13d43f11eded42c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0b30acdba4af4f89add54dddf14c23da_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie283a4656c2e4cdaa3544e7bf804c7f9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i75055b5483aa4b45aa64e739ee644b07_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic9c0c8245bda4b29885459d2a7e6d51f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib3ade10577cb447f84773dd52aecc06c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i33522e08954144b987a6d23ea7b62c6b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3ce249e9e67f47b1986e46049614d74e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9736fd4b7b724ef987739ec27346148b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib7685322cfa540bbb195c55945e40155_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4d810f21c820439283d2493920890171_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie32d42b33c7f4559bb28b9b2c085cd77_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if786421abd8449ad82c258035991f29f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i94b2debb8cee40d0bb95dee385f1e248_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if03a9ef0110a48da8f43355f7dde35e9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i139534750c32411998ec9f0fdd20ed30_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1b43d4dad70748079a0e514fc136284e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie4b2a726e7e9422a8c57cb8fe49f6a15_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if5ffab51ce3540d2b6096242b70529a6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie2525709ae7045c3a4de1f8fb444dbbe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i42288e5a324249c8ad74cc662005b838_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if1cbfa891ae54142b5e3a160e784d461_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8b10df2779c4412ab3932dd163fe9b82_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i03266b4db72b4437b1cf9918fecc673e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2e24f66b20e44fa2a7b4a0991ca309f1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7bfcdc5fa8c740d39d1e6fc1c52b74fe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6929f02de29e445e90d7b545c93b3af6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0c0b49eff48349d3963e85732d3bb079_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibcad2a390bdd4ccab4037a9659048f33_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0091985621104c5e88db831ff8c58475_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9661f3db7077445e851858b6e5f7c6e5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i011f06514d6143e1839cabbd9accc3ca_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia02b9a6c3e74421db29f69c537e41533_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0d51345bb8494da4a30ff3ab1bc494f9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia8d4534186e24013a51b6dcd1d6b3342_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3027180e50c94a839a0b60625e670750_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i090111c614884f2a89c5715d09e61e69_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a6d01430580442ebd48b712adfce654_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if61aaf687d2943e6bc6fe6367d618ffb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic85d5d22e929404c83658bc0fc8c47ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i596ed322af7d456da621e01fa6bae736_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i62b770fba5bd404fbbf086617f231ac1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i715f59046cbd4cfbb6149afc299e8098_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b1651c5e27f48129604544f4d17c53d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81ff5dbe93184b128cf458121e2b9869_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i36aea1c3046543f0b3cc27b52ff37040_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7954e090c66944f88a4e2606c991d18b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib02e96a8734943609865d9b4c35421f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i246dadd6c8d449999b2f9717794c470c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ad9873452934a32ae8e3aeda1e17fe8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id62277363f7143ce854422660983079f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadbc031755e743459e0e460fe0824f64_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie70b0b8cf2fe4c808ff9025d45a5b3ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia533935aed984b759f799fea1a30903b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iceff6e292b6d4b45910614df9290865b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4d6b9adc9d0d410e84335056934458af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f49042851ab48aa8b238a225a70ee62_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6b2c3b884bc46fcaabeebaa66bf2635_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i649b1d02f04843e6bfb8ceea9915423c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76cfaf0a85c64451bf8e5033f3d6e411_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae71687b96be4ca7a964da2662807ebb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0591281256d2426a9cbbf549dd04a8a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1eafdf3617e8409faef961085fcec21c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7c04023fda4245f69834e13098d0ccc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic748766b36734327aef19e1e2042ee49_I20160217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-17</instant>
        </period>
    </context>
    <context id="i06fbc20f828d41caa9a80bcd7a6e2759_I20160217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-17</instant>
        </period>
    </context>
    <context id="i9977feb034be4c9caaf5b5df369b7ff1_I20160217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-17</instant>
        </period>
    </context>
    <context id="i48e54b1c09a54de19e18102cdfcb8cbd_I20160217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-17</instant>
        </period>
    </context>
    <context id="i57d24130c57c40ba8b47fd15cceac12a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic6024f8bbc354cab9a3781b1178e5869_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2082cdeebbe94488abda3ef417d3e1be_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0c9f635fc1cf441fb44103b2e37aabec_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1c5c0eb47d394449b742692f031dee63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfc5af07dc354cc8a9057ae7da0af850_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ica899e5f992445b1b2e0565819005804_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3f7894134fb44db79f503167f8288191_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="agreements">
        <measure>xcur:agreements</measure>
    </unit>
    <unit id="target">
        <measure>xcur:target</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="numberofperiods">
        <measure>xcur:numberOfPeriods</measure>
    </unit>
    <unit id="usdPerSquarefeet">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>xcur:squarefeet</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="vote_per_share">
        <measure>xcur:vote_per_share</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV8zLTEtMS0xLTA_dd91e02c-6fdb-4346-a989-006b32745baf">0001698530</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV80LTEtMS0xLTA_9af6838d-458a-4032-bfa3-f72a30c1d5a6">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV8xMy0xLTEtMS0w_327c9742-2b08-4114-8ea9-7f21855c147f">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV8xNC0xLTEtMS0w_045a763e-d33c-4c4e-a5ea-39ffc7c7fe00">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80L2ZyYWc6YmQ0MzUzNWE4NGVjNGMxM2JmYzU3NjMxN2UwNTIxN2MvdGFibGU6OWZmYjQyNmE0NzE0NDM1ZDkzYTcyMWJmMDY3NWQwOGUvdGFibGVyYW5nZTo5ZmZiNDI2YTQ3MTQ0MzVkOTNhNzIxYmYwNjc1ZDA4ZV8xNS0xLTEtMS0w_0f3e691d-c373-4569-a007-674509c645de">false</dei:AmendmentFlag>
    <xcur:CollaborationAgreementTerm
      contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTQ4ODA_7c7ddbd2-6787-47de-91af-9e663bcf7a25">P6Y</xcur:CollaborationAgreementTerm>
    <xcur:CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment
      contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTY3MzY_cca5baed-3744-4471-869d-43a351036895">P30D</xcur:CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment>
    <xcur:OperatingLeaseAssetRemainingUsefulLife
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDIzMg_bc0ddf39-3aa8-49b3-b360-0d3d3fd3ba3d">P0Y</xcur:OperatingLeaseAssetRemainingUsefulLife>
    <dei:DocumentType
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTIy_81f1c6b1-8e88-47f1-98aa-33e0fcca745f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTIz_5ba556ec-c4e8-43b1-8db5-fb53b09b9ff3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI1_44078d12-43b4-45fd-bebb-69d99edd85df">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI0_0cdf1000-4df3-42f3-b7ce-3fa347434023">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI2_20419736-d78e-40be-8f2e-8823b47a383d">001-39011</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI3_7fac0794-7d41-4e9d-8db5-c0834394dcf4">EXICURE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NGQxMDUzMDQ4NzI0NGIwMDkyODc4ZjVmNTZiYTJjMTgvdGFibGVyYW5nZTo0ZDEwNTMwNDg3MjQ0YjAwOTI4NzhmNWY1NmJhMmMxOF8wLTAtMS0xLTM0_04f80054-49a3-4817-b57d-ed3db7df20a7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NGQxMDUzMDQ4NzI0NGIwMDkyODc4ZjVmNTZiYTJjMTgvdGFibGVyYW5nZTo0ZDEwNTMwNDg3MjQ0YjAwOTI4NzhmNWY1NmJhMmMxOF8wLTItMS0xLTM2_6e9862be-3ea3-4d09-83fe-02cc07289f7a">81-5333008</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTI4_6e7b8b2f-27fb-4d42-9c36-8d4dfe75f75e">2430 N. Halsted St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTMw_3f1effd0-6a78-4a97-b15d-76222701bdc8">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTMx_2dfa486b-8427-400f-a19b-6619de457823">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTMy_ef302467-c625-4673-b911-bcce0f8ae186">60614</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressAddressLine1
      contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjQ4_0e28c671-d73f-44f5-b41b-db4cdc2f7c5f">8045 Lamon Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjQ5_1a627494-5cf2-48d2-8b84-c3bd2629dedb">Suite 410</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjUw_f078c61b-556f-4cc2-8a63-7c39a9db10d3">Skokie</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjUx_4c91a85f-18ad-4389-a3cf-47b0a3e6a30d">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iab78a5f249144c4eb8eebc6623ab1fbf_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjUz_95352bd7-2b27-4bd2-a48b-7c4d6ca0866a">60077</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM0_6047f5d1-e6f5-4b76-9ce8-21ff770a3694">(847)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM1_c788b7ee-2b92-434b-be29-1e4bd89c710f">673-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6ZTUzZTkxZGNhMDc0NDg4NWIzYjdiM2I3YjkxYTRhODAvdGFibGVyYW5nZTplNTNlOTFkY2EwNzQ0ODg1YjNiN2IzYjdiOTFhNGE4MF8xLTAtMS0xLTU1_de187fbb-74b1-4fd9-bf28-891ae8c871e6">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6ZTUzZTkxZGNhMDc0NDg4NWIzYjdiM2I3YjkxYTRhODAvdGFibGVyYW5nZTplNTNlOTFkY2EwNzQ0ODg1YjNiN2IzYjdiOTFhNGE4MF8xLTItMS0xLTU3_b5dd8cc3-36e8-48d2-a422-ac2981fd8c6b">XCUR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6ZTUzZTkxZGNhMDc0NDg4NWIzYjdiM2I3YjkxYTRhODAvdGFibGVyYW5nZTplNTNlOTFkY2EwNzQ0ODg1YjNiN2IzYjdiOTFhNGE4MF8xLTQtMS0xLTU5_f794321f-635b-4438-a35c-f61b5571a5fb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM2_75534961-52d6-462b-8f1e-c9705815c335">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM3_c12b8d29-cbda-461c-813c-05629dc6c855">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NjZiZGIyNWUwZDY1NDQ2NThkNWRhN2M4NDY0NTY0ZjAvdGFibGVyYW5nZTo2NmJkYjI1ZTBkNjU0NDY1OGQ1ZGE3Yzg0NjQ1NjRmMF8xLTAtMS0xLTY1_e9b56ad2-ef1c-43e0-8c0e-0a9ab568aa3d">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NjZiZGIyNWUwZDY1NDQ2NThkNWRhN2M4NDY0NTY0ZjAvdGFibGVyYW5nZTo2NmJkYjI1ZTBkNjU0NDY1OGQ1ZGE3Yzg0NjQ1NjRmMF8xLTQtMS0xLTcx_f5033e5f-874d-4819-8826-d13eb272c576">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGFibGU6NjZiZGIyNWUwZDY1NDQ2NThkNWRhN2M4NDY0NTY0ZjAvdGFibGVyYW5nZTo2NmJkYjI1ZTBkNjU0NDY1OGQ1ZGE3Yzg0NjQ1NjRmMF8yLTQtMS0xLTcy_3700774e-7abb-4ba4-9ec5-4b585da56fdb">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTM4_3cbfee17-1a26-43a0-85a0-ada4ecfdc2a7">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV80Mzk4MDQ2NTEzNTQy_734daa8c-8aa5-418d-910b-226042d29108">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1942a18648da4a2baa5c6f6dcbc62801_I20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xL2ZyYWc6MjAxYTJhN2RmMTExNGMwOTg2ODFkZmJjZDRmNTBkNDUvdGV4dHJlZ2lvbjoyMDFhMmE3ZGYxMTE0YzA5ODY4MWRmYmNkNGY1MGQ0NV8zODQ4MjkwNzAwNjg2_16f2cb80-6e0e-410e-a8c2-383e77b1e1bf"
      unitRef="shares">87228586</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNC0xLTEtMS0w_46e8c094-92ef-4560-bb40-a9783e2e92e8"
      unitRef="usd">17198000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNC0xLTEtMS0w_96552db5-aebc-49e7-8807-b8d68ba6c998"
      unitRef="usd">17198000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNC0zLTEtMS0w_3664ed73-41de-419b-890a-adcacccd2a50"
      unitRef="usd">48460000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNC0zLTEtMS0w_a6e352d8-8f75-437f-a252-b3480d6cb501"
      unitRef="usd">48460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ShortTermInvestments
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNS0xLTEtMS0w_2979f1c4-5deb-4218-961a-7de98eb4e739"
      unitRef="usd">68579000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNS0zLTEtMS0w_80fd6e15-fa80-4335-b62f-b516178d1f5e"
      unitRef="usd">62326000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNi0xLTEtMS0w_9cb13b90-c14c-47c7-a42d-c3eeb79eee42"
      unitRef="usd">21000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNi0zLTEtMS0w_e574a76a-0619-47b0-bcb4-4d3659d7ad98"
      unitRef="usd">16000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNy0xLTEtMS0w_9971daa5-2360-45cd-a752-1ff269fb72da"
      unitRef="usd">3000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:UnbilledReceivablesCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfNy0zLTEtMS0w_b26f6663-d63e-4dda-97f2-0c1a827efe98"
      unitRef="usd">19000</us-gaap:UnbilledReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfOC0xLTEtMS0w_49265e8a-fe6a-4584-a245-f8164e219243"
      unitRef="usd">3588000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfOC0zLTEtMS0w_be8a29dc-af5c-4285-8f25-5fea869f220b"
      unitRef="usd">1955000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfOS0xLTEtMS0w_46224a2d-a2bf-4066-941f-ca958a1dc84b"
      unitRef="usd">89389000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfOS0zLTEtMS0w_cce2bd7a-01f2-4c35-9049-935f1eefba7b"
      unitRef="usd">112776000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTAtMS0xLTEtMA_d5c478d8-7cae-4fc6-8964-cf3f8405ce32"
      unitRef="usd">4464000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTAtMy0xLTEtMA_742cebd0-bb05-47e8-b617-2b06bc9483a0"
      unitRef="usd">2099000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTEtMS0xLTEtMA_f915e929-94cd-4fdf-bcd8-d7060f01d239"
      unitRef="usd">2266000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTEtMy0xLTEtMA_0b877b09-f0b4-4e21-98b3-a2697c5cab0f"
      unitRef="usd">388000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTItMS0xLTEtMA_f43d53b2-f667-4cbe-93cf-a3d6bc171e8b"
      unitRef="usd">96119000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTItMy0xLTEtMA_1bc1572a-97bc-4136-9825-298b3e1743c2"
      unitRef="usd">115263000</us-gaap:Assets>
    <us-gaap:LongTermDebtCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTUtMS0xLTEtMA_a5d8fa25-037e-42fb-82df-b00d6dee9910"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTUtMy0xLTEtMA_19e1ce8a-fbee-4f34-bba7-53262d357d9e"
      unitRef="usd">4965000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTYtMS0xLTEtMA_0c4bdce5-3532-4449-97d0-be924ae140fa"
      unitRef="usd">1540000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTYtMy0xLTEtMA_88f8a02e-78c8-40d6-8811-ab842c85d39f"
      unitRef="usd">1814000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTctMS0xLTEtMA_fb3df85a-1724-4a1e-af3d-829f0a0a99c1"
      unitRef="usd">1947000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTctMy0xLTEtMA_8731db52-7a8e-4076-a9f7-2cddace627eb"
      unitRef="usd">2435000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i76587ca4c99d49da89121e59315b11c9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTgtMS0xLTEtMA_7d8b1f06-8781-473b-8439-1008dacd2bf1"
      unitRef="usd">10880000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTgtMy0xLTEtMA_bea8c408-cbbf-45eb-a242-13216b6eb16b"
      unitRef="usd">21873000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTktMS0xLTEtMA_1b7dc8ad-fdf6-49e8-ba39-c81fb386c6c5"
      unitRef="usd">14367000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMTktMy0xLTEtMA_d21d0947-e016-4b55-a080-7f390545e847"
      unitRef="usd">31087000</us-gaap:LiabilitiesCurrent>
    <xcur:CommonStockWarrantLiability
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjEtMS0xLTEtMA_663c0734-b9bb-437f-96d3-0764d76a3016"
      unitRef="usd">0</xcur:CommonStockWarrantLiability>
    <xcur:CommonStockWarrantLiability
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjEtMy0xLTEtMA_7db31e18-7df2-421c-ad72-95626b5cf06c"
      unitRef="usd">414000</xcur:CommonStockWarrantLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjItMS0xLTEtMA_e98462da-085e-4be8-9855-595b5698a642"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjItMy0xLTEtMA_7456f240-d13a-4377-9a7e-a638c584bea1"
      unitRef="usd">2956000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjMtMS0xLTEtMA_62c1ad92-d5d6-4399-825b-8416eeba272f"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjMtMy0xLTEtMA_e1460f36-3993-4fb8-9a3b-da90a396435c"
      unitRef="usd">59000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjQtMS0xLTEtMA_cf4f421d-ca5c-4a95-a296-3c6fb6e86b2c"
      unitRef="usd">14367000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjQtMy0xLTEtMA_665f4f50-fa6d-4873-8e5d-8a7532263de7"
      unitRef="usd">34516000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5NjY_070eac3d-b3fb-43bd-b2f4-c6848b30d09b"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5NjY_d1ed639c-dc92-4728-8c5c-d670c5abb881"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5Nzk_7414bc40-7690-4868-93af-7d179868c213"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5Nzk_f1039ac1-9936-4952-88a2-b92009d459ba"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5OTE_6bb7b3ab-f580-4594-a4a0-7a4528e2b5d6"
      unitRef="shares">87206346</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2Mjc5OTE_ec18f4f4-f23f-4907-9388-e4d9909f559f"
      unitRef="shares">87206346</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2MjgwMDM_071ffed6-c284-4844-be36-300f1563df3f"
      unitRef="shares">86069263</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjgyNzQ5MWVjODQwZTQwYzM4NGM0OWU1OTg5ODIzZWVhXzEwOTk1MTE2MjgwMDM_8eb06ff0-af88-4de4-90a5-f2058fb08e98"
      unitRef="shares">86069263</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMS0xLTEtMA_cf596ff8-d371-49b1-abe3-ce7039b04e40"
      unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjctMy0xLTEtMA_40c4007a-d2e1-43b4-aad5-2946cd6bd58d"
      unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjgtMS0xLTEtMA_eab2c4ca-8be2-462d-ab2a-41e9901d2f9a"
      unitRef="usd">165863000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjgtMy0xLTEtMA_bbcfa1ce-aba2-4be9-9e0d-b8884fcd0407"
      unitRef="usd">162062000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjktMS0xLTEtMA_237f260a-6645-404e-9252-2bbe9887589d"
      unitRef="usd">338000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMjktMy0xLTEtMA_b005d07f-7002-4ebc-aa44-cc79f7c80e95"
      unitRef="usd">-27000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzAtMS0xLTEtMA_d489427b-2022-4ff6-80a2-609e2ab770aa"
      unitRef="usd">-84458000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzAtMy0xLTEtMA_ec84e25f-7ec9-4bce-a1de-f13a71bd2bac"
      unitRef="usd">-81297000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzEtMS0xLTEtMA_6855912c-2d5b-4ef6-af47-7a1913c793fe"
      unitRef="usd">81752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzEtMy0xLTEtMA_5195bfe7-a133-4da7-8b1c-1c63c1d2b0e6"
      unitRef="usd">80747000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzItMS0xLTEtMA_0b0d5e8a-9e04-42e0-812b-db2c0c132be8"
      unitRef="usd">96119000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xOS9mcmFnOjY2ZTZlNjhjODc2ZDQwOWY5Zjg3MjA3NWU1Njk1ZWIzL3RhYmxlOjA5M2MxYTk2MmZmMTQzZmNhMDY5MmE5YzNjNmMyZWUzL3RhYmxlcmFuZ2U6MDkzYzFhOTYyZmYxNDNmY2EwNjkyYTljM2M2YzJlZTNfMzItMy0xLTEtMA_62b1c048-e16a-4d6c-8b05-45b1ae1ddcb3"
      unitRef="usd">115263000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMy0xLTEtMS0w_2af5822a-feab-41d7-9adf-9a4d3219e8ac"
      unitRef="usd">4847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMy0zLTEtMS0w_62972ec3-4ba1-4cf5-9c35-d7bfb1cecbb5"
      unitRef="usd">434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMy01LTEtMS0w_2c19b3fa-0c14-40c1-90d4-aef739c318d6"
      unitRef="usd">14030000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMy03LTEtMS0w_bd54facd-7b2b-4aeb-a5fc-b9f5e1e8e91d"
      unitRef="usd">459000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNC0xLTEtMS0w_7ca79d43-67e2-4e84-97dc-990926b879fb"
      unitRef="usd">4847000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNC0zLTEtMS0w_708a16ec-4f66-48e5-9126-2688da32c108"
      unitRef="usd">434000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNC01LTEtMS0w_895b3c3c-4203-4828-aeea-21c5b1698fec"
      unitRef="usd">14030000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNC03LTEtMS0w_789fe8ed-8683-4dcb-9f93-6deb5d1e5718"
      unitRef="usd">459000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNi0xLTEtMS0w_bc5e138e-e4f9-46f3-909e-9d078c3913a0"
      unitRef="usd">7008000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNi0zLTEtMS0w_bfb6b2b0-75ae-499f-9851-1f8515e706b1"
      unitRef="usd">3433000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNi01LTEtMS0w_d0a708c3-5934-454a-9856-7772afe47594"
      unitRef="usd">13083000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNi03LTEtMS0w_135c7669-98cd-4343-ad1c-879a1117d688"
      unitRef="usd">6828000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNy0xLTEtMS0w_1f6d9c72-5522-4911-bb07-289e5a5e1d9c"
      unitRef="usd">2229000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNy0zLTEtMS0w_5ee00b0c-421b-42ac-bc52-ffa0f8c96513"
      unitRef="usd">1985000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNy01LTEtMS0w_7a2ecf3e-a17f-4d39-803a-b8fb2d7393b5"
      unitRef="usd">4803000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfNy03LTEtMS0w_21f39e7f-33b0-408f-8162-04a73ebff26b"
      unitRef="usd">4193000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOC0xLTEtMS0w_569f6063-24c2-45a3-9cf0-8e6a9a5af9ca"
      unitRef="usd">9237000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOC0zLTEtMS0w_723c3ee4-32c2-446d-ac1c-d6850acc5ad9"
      unitRef="usd">5418000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOC01LTEtMS0w_9ef83915-2fa3-4243-aba4-8af40cbf0352"
      unitRef="usd">17886000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOC03LTEtMS0w_cd685bb9-9991-4460-b26b-a8e6e071bdb3"
      unitRef="usd">11021000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOS0xLTEtMS0w_df1d40e1-f89a-4536-9fc9-d1d6a680d616"
      unitRef="usd">-4390000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOS0zLTEtMS0w_e6da9b06-8614-49ed-8221-8d0f700c8879"
      unitRef="usd">-4984000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOS01LTEtMS0w_b760b7d0-b737-40ef-a040-669a591e2111"
      unitRef="usd">-3856000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfOS03LTEtMS0w_256f8df0-148c-4823-a600-b06247c47baa"
      unitRef="usd">-10562000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTEtMS0xLTEtMA_1d4a6f0b-3c13-42e6-87e2-6c263d575a76"
      unitRef="usd">4000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTEtMy0xLTEtMA_b6de7ae2-a2f5-4884-978d-04a636b679f9"
      unitRef="usd">82000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTEtNS0xLTEtMzYy_1f1100e2-d5e6-4378-9ec0-df37247a3ab2"
      unitRef="usd">43000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTEtNy0xLTEtMzcw_7dc7cbf0-9529-4ce9-bedc-aa2b910b8cac"
      unitRef="usd">187000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTItMS0xLTEtMA_8a5acfe0-1d32-455b-958f-df5fb348b918"
      unitRef="usd">267000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTItMy0xLTEtMA_2ce85c2e-0718-4ce5-889b-83584b930980"
      unitRef="usd">1000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTItNS0xLTEtMzYy_86094d02-0f39-439a-a5de-d4407897111a"
      unitRef="usd">627000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTItNy0xLTEtMzcw_efeab7bf-03e4-4496-b866-38843946c340"
      unitRef="usd">2000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTMtMS0xLTEtMA_839e4d37-3008-47b2-ad08-665d4265c882"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTMtMy0xLTEtMA_005c6eb9-8174-425b-ad39-d976103bf347"
      unitRef="usd">203000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTMtNS0xLTEtMA_5a2e785e-7728-4e63-abba-ab9685880b9b"
      unitRef="usd">128000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTMtNy0xLTEtMA_d9656941-27ef-486f-8413-6a8343456054"
      unitRef="usd">386000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTQtMS0xLTEtMA_6d7c1bd1-1224-4e89-8c73-62cc730f480c"
      unitRef="usd">-192000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTQtMy0xLTEtMA_accd8c35-bb62-4688-9205-033547ddf4b5"
      unitRef="usd">-116000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTQtNS0xLTEtMA_9c566e9f-ac86-46c3-80e1-efaf43b4bcaa"
      unitRef="usd">153000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTQtNy0xLTEtMA_9eaa5f55-c34f-44c7-a7d4-6ef5998294ba"
      unitRef="usd">253000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTUtMS0xLTEtMA_f9d52dec-3666-486d-b55a-1d1bd256ac1f"
      unitRef="usd">79000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTUtMy0xLTEtMA_784e4905-3a16-430e-ae09-4c48457ed45b"
      unitRef="usd">-236000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTUtNS0xLTEtMA_970b6433-ab7c-4353-a887-1c1dc408fe3c"
      unitRef="usd">695000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTUtNy0xLTEtMA_61963c8c-8986-4159-b2e5-048fed819646"
      unitRef="usd">56000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtMS0xLTEtMA_45ab79a6-d84b-4fdd-a623-72f0987e6a52"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtMS0xLTEtMA_d032db37-b24b-4e75-bb5e-e10ae0dad0c3"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtMy0xLTEtMA_be754e46-6692-49b9-a504-ee954cede3ad"
      unitRef="usd">-5220000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtNS0xLTEtMA_aa77327a-8d61-4b80-8eb1-755f7855fdd0"
      unitRef="usd">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTYtNy0xLTEtMA_a6b3785d-1d43-4588-bcbd-aeb9de41e11e"
      unitRef="usd">-10506000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTgtMS0xLTEtMA_2280e16f-c71e-4951-9be0-43252cabeee6"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTgtMy0xLTEtMA_c587e538-b4c0-430c-9b3d-e59fc5acd6e9"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTgtNS0xLTEtODY3_7c389b82-cf7f-4aa0-859f-52b7240005eb"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMTgtNy0xLTEtODY3_c8be8e55-066a-4c25-8382-450ea2623a7a"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMjEtMS0xLTEtMA_6d1b2e7e-a2c4-443e-9f1f-dc615a8f85f3"
      unitRef="shares">87174533</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMjEtMy0xLTEtMA_a3697f8a-3640-4b3c-b852-9ba91ac8fbe7"
      unitRef="shares">44368174</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMjEtNS0xLTEtODY3_6c85577f-d14b-4112-b6b9-19e0e078c006"
      unitRef="shares">87126847</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yNS9mcmFnOjAwOGI3MGU0YWQ5YzQ1ZDk5YmRkNDQyMjIyNWMyN2UzL3RhYmxlOmUxODdhOGU3NjA1ZjRjOTE4OWNiM2I0ZDA0OTNhZDgzL3RhYmxlcmFuZ2U6ZTE4N2E4ZTc2MDVmNGM5MTg5Y2IzYjRkMDQ5M2FkODNfMjEtNy0xLTEtODY3_04e67d21-fb23-4d51-bda6-44fc4a09bf5b"
      unitRef="shares">44363115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi0xLTEtMS0w_45ab79a6-d84b-4fdd-a623-72f0987e6a52"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi0xLTEtMS0w_d032db37-b24b-4e75-bb5e-e10ae0dad0c3"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi0zLTEtMS0w_73314c47-cca8-4a87-bb4f-2688a099ca0c"
      unitRef="usd">-5220000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi01LTEtMS00NDM_ec5ef035-449f-424a-8859-af879ed4ddfc"
      unitRef="usd">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfMi03LTEtMS00NDM_e1a7d887-dfab-473d-aa85-2c228c853b38"
      unitRef="usd">-10506000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNC0xLTEtMS0w_7f3cbca0-508c-4c10-a9a3-ab5645ae19f5"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNC0zLTEtMS0w_03ae76ed-08fc-4c6d-a1ab-aa6304462561"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNC01LTEtMS00NDM_8557d5e5-16dc-4037-96ab-0abdf7e8fb45"
      unitRef="usd">365000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNC03LTEtMS00NDM_669f60ee-7659-490a-a49b-74d0717aff9f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNS0xLTEtMS0w_93bf2f5b-ac2a-4ec3-9f89-e969d5297b13"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNS0zLTEtMS0w_e0a0437f-2428-423c-9fca-da4c9b694295"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNS01LTEtMS00NDM_689a63d0-17e3-4555-b409-75efc082ff6f"
      unitRef="usd">365000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNS03LTEtMS00NDM_4e7b897c-4c71-492d-8e14-844f09081fd4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNi0xLTEtMS0w_260b10f8-3e9b-41ac-9b38-ab10bf0ce083"
      unitRef="usd">-3956000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNi0zLTEtMS0w_d2d1a56a-e1d0-4063-a2c1-4890d09765f6"
      unitRef="usd">-5220000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNi01LTEtMS00NDM_5b09357d-019d-4267-ad05-96cc202b828b"
      unitRef="usd">-2796000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8yOC9mcmFnOmFiMDliZjg0N2FlYzRhOTU4NzFkNTU0ZDY5NjM3ZjFkL3RhYmxlOjZjZmNmMjE5OWQ0NjQwMDBiNzE1NmY3Y2IxODMwZGZiL3RhYmxlcmFuZ2U6NmNmY2YyMTk5ZDQ2NDAwMGI3MTU2ZjdjYjE4MzBkZmJfNi03LTEtMS00NDM_dd07070e-b394-4e65-97e2-d9caf53daa16"
      unitRef="usd">-10506000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i081c44d7528546cba2417fec5251bb86_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi0xLTEtMS0w_7ab98dd9-7800-41e7-a444-515949da45e5"
      unitRef="shares">86069263</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i081c44d7528546cba2417fec5251bb86_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi0zLTEtMS0w_bff85f59-c29e-45e1-96d3-2e071c41e6c9"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i669ca094820a403bb6fe6191fea9d033_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi01LTEtMS0w_6b2abbfd-eaa8-40b6-ada6-bfbac2b1d0d6"
      unitRef="usd">162062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i69d5a6f3c0f64d0b92f3d4c01084e89b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi03LTEtMS0w_7c6fcd16-65a4-43eb-b2d5-8f1768169b9c"
      unitRef="usd">-81297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a2b6489ddf141a7bf39c57e8c6c374d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi05LTEtMS0w_01bfc673-f7e5-4014-8ef7-7d978cf31e49"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMi0xMS0xLTEtMA_c98f29e0-1154-4731-a050-27e880df055d"
      unitRef="usd">80747000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iac2f608277bb4d11b8c650acaa7156a4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNC01LTEtMS0w_7197a969-f726-49fa-af6b-0735a34377df"
      unitRef="usd">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia600341070154f04b665acb7c655fde4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNC0xMS0xLTEtMA_c748925b-dc44-4aae-b16a-8ad4c1ab5306"
      unitRef="usd">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7ae69caa952548968e3db1374a9441bf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNS0xLTEtMS0w_b44a11d2-df0a-40a5-a568-e99941d034d5"
      unitRef="shares">1081184</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iac2f608277bb4d11b8c650acaa7156a4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNS01LTEtMS0w_d618a5b1-3a26-4f34-9a99-fd2b09eeb06b"
      unitRef="usd">2766000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia600341070154f04b665acb7c655fde4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNS0xMS0xLTEtMA_00a77981-a5f0-43a6-b931-bd1334886717"
      unitRef="usd">2766000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iffcf7f98338c48b2a74d5c64bcbb09cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNi05LTEtMS0w_3e988483-b844-41c8-8948-350379485d28"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia600341070154f04b665acb7c655fde4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNi0xMS0xLTEtMA_7e0d1749-a8c5-4604-89f4-b5a7faffb5f2"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i99f18a5fae5146fdac7af880c302d1f0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNy03LTEtMS0w_dbb5c406-9c7f-4286-a8cd-023ab51259b6"
      unitRef="usd">1150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia600341070154f04b665acb7c655fde4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfNy0xMS0xLTEtMA_b0b447da-ab57-4165-ba90-8d6219869b4e"
      unitRef="usd">1150000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i8ebe7513efbb4572897a2eff0bbe5839_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC0xLTEtMS0w_a1e59d0b-d2d9-430e-b5ae-049fb3a99400"
      unitRef="shares">87150447</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8ebe7513efbb4572897a2eff0bbe5839_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC0zLTEtMS0w_5854a279-6c4d-4ee6-8000-b6a31514c1a8"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1abd752d57f494da5a5dcd7e17f6c8b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC01LTEtMS0w_8cbe6e7f-b41b-45b4-aa90-2cdc5967daaa"
      unitRef="usd">165269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4929d22fbb34f5bb8e001e11fca287f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC03LTEtMS0w_f4104d41-7687-4c4b-ae76-d49b9977862b"
      unitRef="usd">-80147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i346241752b2b49a69f5d211b6a9d45fd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC05LTEtMS0w_87eb8775-d74a-4cb4-b95a-d1a29369f6cc"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87bf2cd1655f4fab8c904201cabea717_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOC0xMS0xLTEtMA_8ccd7e03-9539-40a4-8785-3d09fd1117c0"
      unitRef="usd">85114000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id117ecfcad3043b9afe9dd6651b61ef9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOS0xLTEtMS01MTk_fdabc364-967b-44a3-9d6e-c0fcc7ec36b5"
      unitRef="shares">55899</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i25b2e786a1684d32b3eb638cf322b195_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOS01LTEtMS01MTk_785271ac-b607-465e-8624-bd7ad5b7fa12"
      unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfOS0xMS0xLTEtNTE5_1ca19be5-9527-4b1e-b852-aad0c660ec46"
      unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i25b2e786a1684d32b3eb638cf322b195_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTAtNS0xLTEtNTE5_e24c52ea-335e-4e5a-861e-11461a0b7d6c"
      unitRef="usd">544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTAtMTEtMS0xLTUxOQ_d5420d28-8309-47a2-bbd9-d491a0740450"
      unitRef="usd">544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTEtOS0xLTEtNTE5_1c6d8ceb-dcd8-44c3-bf87-d1146722ad39"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTEtMTEtMS0xLTUxOQ_f35aa9bd-415a-4d2a-8ade-0fda0331b9e7"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i629055e5f5f9450696b0cdd1b8c62aaf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTItNy0xLTEtNTE5_450eb2f2-7e92-4b6f-9bed-cda645818bf5"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTItMTEtMS0xLTUxOQ_3a7c00d5-4b60-4b0b-b797-b98a3525f720"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i057811d1d09040a098af94d1675312a5_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtMS0xLTEtNTE5_03b33ded-39c1-4036-a394-4ead1eef59a6"
      unitRef="shares">87206346</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i057811d1d09040a098af94d1675312a5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtMy0xLTEtNTE5_181def90-9c1d-49da-9729-8075f2475cee"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3b2128138ac484d800e0f7ffac985fc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtNS0xLTEtNTE5_4be99a8a-5ffb-4732-b374-1c34f223f2dc"
      unitRef="usd">165863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia3377b36eefd4b7dbcd8a37028612f32_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtNy0xLTEtNTE5_cf526033-77e0-41ac-96e9-7794b4439c57"
      unitRef="usd">-84458000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0ac35850023477bb1b027d27cf6499d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtOS0xLTEtNTE5_59490168-09ad-4ffa-86b5-3b02d2daa6f4"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjc3NWIxNTQxMjVmODQyNTliNGI2MWQ5ZDhlZmViMGVkL3RhYmxlcmFuZ2U6Nzc1YjE1NDEyNWY4NDI1OWI0YjYxZDlkOGVmZWIwZWRfMTMtMTEtMS0xLTUxOQ_d1be7ad3-446b-423e-b411-163d7ab030f1"
      unitRef="usd">81752000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iaf91bb3242b54554bf09467575ed8032_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi0xLTEtMS0w_f9859761-f31f-4a87-9c41-67d996ab5c80"
      unitRef="shares">44358000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaf91bb3242b54554bf09467575ed8032_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi0zLTEtMS0w_4a3ce8d5-e30f-4dbf-b23c-1ad102b0aebc"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i251a593531414918acbfa4bea82baa82_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi01LTEtMS0w_e5cf7f0d-0fe5-4adf-81ac-de626b2e7d54"
      unitRef="usd">75942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i42b80e31064445acb2afbf5c674a8d22_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi03LTEtMS0w_dbfe1e72-2851-437e-bb7b-1915990932d6"
      unitRef="usd">-54994000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idda7464d50394c8da8f759b3fe9c27f6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi05LTEtMS0w_ac187b20-3304-4574-a64d-31d2ed146230"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48514485d5c5481a815ea5cb4ec4f071_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMi0xMS0xLTEtMA_13cd4755-699d-4c41-9ea5-72c34362bbad"
      unitRef="usd">20952000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5fce0dd8830b423089b11cd5506c2b50_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNC01LTEtMS0w_4188df16-8b37-44db-8320-a20c5703c1b4"
      unitRef="usd">489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id85a381bc7624171a8e7ce667919dcf2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNC0xMS0xLTEtMA_e55f8aca-e356-4ede-92c8-28d16640ec21"
      unitRef="usd">489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i16628e25dfeb457db79ff5741f4b4746_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNS03LTEtMS0w_ca4197cc-e421-4bf5-a5f9-5facb2d0b5de"
      unitRef="usd">-5286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id85a381bc7624171a8e7ce667919dcf2_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNS0xMS0xLTEtMA_8601e407-f2f6-4603-83b0-6107b477cfaa"
      unitRef="usd">-5286000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifd3596a8daa44dafa2c2640d7eaf3704_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi0xLTEtMS0w_65c5ebf3-cb95-4853-99d6-05b0c19a7b2a"
      unitRef="shares">44358000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd3596a8daa44dafa2c2640d7eaf3704_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi0zLTEtMS0w_92c1f7c7-0e87-44c9-9f64-22d141916916"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibae0a4d897b84e4d9577c9afadfbfeaa_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi01LTEtMS0w_dd54f969-31d9-46f2-bab6-f86b5300bb50"
      unitRef="usd">76431000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i51b397f6da68451f925c80fb3973ef2d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi03LTEtMS0w_9989df7e-a307-4363-8be6-4ad413e38a07"
      unitRef="usd">-60280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d7a7c38c82d4bb58ce35946a0c4b0db_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi05LTEtMS0w_d09dcc83-9977-46ff-ba8d-a5346ca67a9f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb258cc2165d4dcbaeb2ae16188d95fb_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNi0xMS0xLTEtMA_1c4f54be-e85a-4440-b42f-cc46c09656df"
      unitRef="usd">16155000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0b302e66ac63416b82f00e6f82fdf6d7_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNy0xLTEtMS0w_b4e53978-92eb-4613-afd9-1730a387918b"
      unitRef="shares">11790</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie9b16abc11334de6979be196b3664e81_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNy01LTEtMS0w_a2889ca7-d761-44fb-a3c8-25af065aee8d"
      unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfNy0xMS0xLTEtMA_b5b9788d-efc4-4c3a-9e25-edbf3ae62eee"
      unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie9b16abc11334de6979be196b3664e81_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfOC01LTEtMS0w_af33d1e2-9f9b-48e7-97ac-80ba5d910850"
      unitRef="usd">439000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfOC0xMS0xLTEtMA_02d09035-35bd-4c6e-b44a-ba9725256b9d"
      unitRef="usd">439000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ic80e034dbbc84fb499846b28fc08af31_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfOS03LTEtMS0w_a1b9b387-2020-4df6-a88e-58ad198bdca9"
      unitRef="usd">-5220000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfOS0xMS0xLTEtMA_1e9f4c59-3eea-4b61-9212-b657ffd66f6f"
      unitRef="usd">-5220000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i74d996f1250448ddb4ffa272adecd35a_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtMS0xLTEtMA_58f0af15-2b0c-4243-821c-1acc8a3bc6a5"
      unitRef="shares">44369790</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i74d996f1250448ddb4ffa272adecd35a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtMy0xLTEtMA_f7db07f1-6762-46df-ab9a-72940fb09865"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i235890d5628b4e7baba46b8ea6aa194f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtNS0xLTEtMA_5306826e-ff8a-4284-b19f-27782096ba13"
      unitRef="usd">76887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i59a965bf3b8a48eb80d080bf600a28cd_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtNy0xLTEtMA_235f6767-343e-46d9-82e5-416ddbf85d63"
      unitRef="usd">-65500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bb3dae634064c17b1ab1c0817e8c5ea_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtOS0xLTEtNTA0_55f027c5-da82-40a9-8480-822d0aa25352"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5e1c54705464203b36edb7644fc518c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zMS9mcmFnOjY5YTE4Mzc3OTExYjRiMzU4MWNlNTA2NjEyNDM4ODAwL3RhYmxlOjZjNjIxMGQxYzIwYjRjNGU4MWJhNGI4MjNmMzdiOTVjL3RhYmxlcmFuZ2U6NmM2MjEwZDFjMjBiNGM0ZTgxYmE0YjgyM2YzN2I5NWNfMTAtMTEtMS0xLTA_26bc8835-96bd-41cd-93d9-a3a7691fd335"
      unitRef="usd">11391000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMy0xLTEtMS0w_609fcf28-de4a-4349-8e57-2e8cea21b606"
      unitRef="usd">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMy0zLTEtMS0w_b63a74e5-f504-4217-839e-105094c7e069"
      unitRef="usd">-10506000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfNS0xLTEtMS0w_40ac0227-041c-4a71-9e94-7c489a096a57"
      unitRef="usd">335000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfNS0zLTEtMS0w_af7153aa-4e5f-46c4-b511-ed6901f2ebac"
      unitRef="usd">174000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:ShareBasedCompensation
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfNy0xLTEtMS0w_863ddd4b-3b3b-44b4-8ae0-42ca5a6ca8e8"
      unitRef="usd">985000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfNy0zLTEtMS0w_52f213cc-568c-4aba-8127-542191b0be36"
      unitRef="usd">928000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfOC0xLTEtMS0w_b01e0911-a74d-4431-b450-ececb8411c7e"
      unitRef="usd">35000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfOC0zLTEtMS0w_56afab92-98d5-4ea8-a5c3-352b147f9312"
      unitRef="usd">86000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfOS0xLTEtMS0w_e79bf0f1-383e-4403-8a96-3f71a55628b1"
      unitRef="usd">356000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfOS0zLTEtMS0w_5e183e08-262a-46f3-8fb4-e0c186459dba"
      unitRef="usd">36000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTAtMS0xLTEtMA_03a7f39b-1891-449c-8b78-f6b8077b0485"
      unitRef="usd">-157000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTAtMy0xLTEtMA_e0838cb3-61bc-429d-b72a-b60b68f72b50"
      unitRef="usd">-256000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTItMS0xLTEtMA_1bceb500-ff17-4e65-9a6d-f04f52a9dab5"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTItMy0xLTEtMA_3abe804b-5237-41ea-a2b4-47cca5bbea1b"
      unitRef="usd">-3000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTMtMS0xLTEtMA_23903540-dc53-4068-8578-5ba4b2596acb"
      unitRef="usd">1551000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTMtMy0xLTEtMA_f657cbd2-a468-4eec-bc78-7c1f9ae2d52d"
      unitRef="usd">257000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTQtMS0xLTEtMA_d11fd230-99b1-43e3-b8c1-a269fd13f8a9"
      unitRef="usd">1034000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTQtMy0xLTEtMA_4adfccc7-3b0d-4388-9a27-ce721c0801b9"
      unitRef="usd">-112000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTUtMS0xLTEtMA_b8ec4edb-3ad8-4fad-bc30-36aedc394e6a"
      unitRef="usd">22000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTUtMy0xLTEtMA_025f3d71-fc14-485c-807d-485dade93f1f"
      unitRef="usd">403000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTYtMS0xLTEtMA_cb755a03-2618-44a1-98df-2c9884b8649e"
      unitRef="usd">-647000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTYtMy0xLTEtMA_bf2bee19-0db3-4733-ae46-2cc44e412f2a"
      unitRef="usd">-66000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTctMS0xLTEtMA_edd9cd47-784a-4ccf-856d-d790f044fdd4"
      unitRef="usd">-13949000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTctMy0xLTEtMA_f34162a2-3ac3-4eac-bdee-ff8780e0a7f2"
      unitRef="usd">541000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTgtMS0xLTEtMA_1aa3f693-b7b1-42dc-ac65-179113a98be5"
      unitRef="usd">-59000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTgtMy0xLTEtMA_fb0e96c5-6752-4927-b2c8-9c4f20cb3702"
      unitRef="usd">-194000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTktMS0xLTEtMA_60809586-bc30-4051-a254-de84d18874f3"
      unitRef="usd">-18814000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMTktMy0xLTEtMA_6f792113-4d38-4dc7-8e88-31e57c8d2ba7"
      unitRef="usd">-8996000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjEtMS0xLTEtMA_9fcc4a74-ee9a-43ac-8e1b-3abe9d846b4f"
      unitRef="usd">38072000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjEtMy0xLTEtMA_b078ef7a-410f-4bd5-aed5-4ec30e280693"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjItMS0xLTEtMA_6573c58b-40e8-49a6-8bcd-862fce1707e0"
      unitRef="usd">32103000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjItMy0xLTEtMA_9de2251e-eb80-41df-9f76-5d91895030af"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjMtMS0xLTEtMA_4232bcf1-a869-40a3-ba25-adaecb8a21ed"
      unitRef="usd">2996000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjMtMy0xLTEtMA_2b81a5b4-09f6-4885-9415-15ec1966235e"
      unitRef="usd">62000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjQtMS0xLTEtMA_9e645ca8-018f-40a4-a676-4e08f5c406e5"
      unitRef="usd">-8965000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjQtMy0xLTEtMA_2623c23e-84a3-48a7-9378-54eb337d5818"
      unitRef="usd">-62000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjYtMS0xLTEtMA_6ad6c6fc-567f-460a-bd19-24c2ca9c5a84"
      unitRef="usd">2973000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjYtMy0xLTEtMA_0c269de5-e2ea-4241-8b0b-4433d22e47f0"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjktMS0xLTEtMA_716405d6-8c31-4132-a6e2-c06bc7ef50b3"
      unitRef="usd">50000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMjktMy0xLTEtMA_b1e76aa9-6861-476c-b791-7427d4b73204"
      unitRef="usd">17000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzAtMS0xLTEtMA_9de18113-9f3b-4a6e-a011-653fc352e690"
      unitRef="usd">4999000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzAtMy0xLTEtMA_21f96a02-a069-465b-a323-7d5db576a60d"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzEtMS0xLTEtMA_d0ea34ba-75e3-4fc2-9ed9-f6aadfec28b5"
      unitRef="usd">100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzEtMy0xLTEtMA_c4b10aed-8bb0-4358-8790-692cdd80d492"
      unitRef="usd">52000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <xcur:PaymentsOfCommonStockFinancingCosts
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzItMS0xLTEtMA_7038a3b1-b56b-4535-8d43-e596f345d0dc"
      unitRef="usd">207000</xcur:PaymentsOfCommonStockFinancingCosts>
    <xcur:PaymentsOfCommonStockFinancingCosts
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzItMy0xLTEtMA_4201ed32-3703-4aef-b189-dc94c92fbe79"
      unitRef="usd">0</xcur:PaymentsOfCommonStockFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzQtMS0xLTEtMA_1b659285-60f7-4f20-9a79-db053e77cb36"
      unitRef="usd">-2283000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzQtMy0xLTEtMA_0e36b3ee-e9f3-46cf-b011-41e12fb88e0f"
      unitRef="usd">-35000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzYtMS0xLTEtMA_f708262e-fb96-49a0-88d4-f8b5301be9b2"
      unitRef="usd">-30062000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzYtMy0xLTEtMA_b2b92055-7685-4ff2-a2be-94ccaaeb2469"
      unitRef="usd">-9093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzctMS0xLTEtMA_3664ed73-41de-419b-890a-adcacccd2a50"
      unitRef="usd">48460000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzctMS0xLTEtMA_a6e352d8-8f75-437f-a252-b3480d6cb501"
      unitRef="usd">48460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i48514485d5c5481a815ea5cb4ec4f071_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzctMy0xLTEtMA_bf036a49-f238-43fb-ac9a-49fe1519533e"
      unitRef="usd">26268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzgtMS0xLTEtMA_093afe04-fd49-4423-ba83-fb97b1f6f5c2"
      unitRef="usd">18398000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia5e1c54705464203b36edb7644fc518c_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgzM2M1ZDkzOGIwMTQ4Mzg5MWNhYTFiNTYwZGFhMTBjL3RhYmxlcmFuZ2U6ODMzYzVkOTM4YjAxNDgzODkxY2FhMWI1NjBkYWExMGNfMzgtMy0xLTEtMA_3358460d-0196-42b1-a05a-c4a909857474"
      unitRef="usd">17175000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjAzZmQwNDMxZjAxMDQ5YjFhMGJhMzdkZmQwMWQ4YmU2L3RhYmxlcmFuZ2U6MDNmZDA0MzFmMDEwNDliMWEwYmEzN2RmZDAxZDhiZTZfNS0xLTEtMS0w_04851276-d45c-4607-ab96-c0f7ffadd338"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjAzZmQwNDMxZjAxMDQ5YjFhMGJhMzdkZmQwMWQ4YmU2L3RhYmxlcmFuZ2U6MDNmZDA0MzFmMDEwNDliMWEwYmEzN2RmZDAxZDhiZTZfNS0zLTEtMS0w_b8d2b05d-8bc7-41ce-af2b-473f804b35c5"
      unitRef="usd">100000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjAzZmQwNDMxZjAxMDQ5YjFhMGJhMzdkZmQwMWQ4YmU2L3RhYmxlcmFuZ2U6MDNmZDA0MzFmMDEwNDliMWEwYmEzN2RmZDAxZDhiZTZfOS0xLTEtMS0w_616370e9-eac5-442b-8da0-7711862ae16e"
      unitRef="usd">60000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjAzZmQwNDMxZjAxMDQ5YjFhMGJhMzdkZmQwMWQ4YmU2L3RhYmxlcmFuZ2U6MDNmZDA0MzFmMDEwNDliMWEwYmEzN2RmZDAxZDhiZTZfOS0zLTEtMS0w_e2e8cfcc-efa5-465f-89f8-472e907280dc"
      unitRef="usd">14000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMS0xLTEtMS0w_46e8c094-92ef-4560-bb40-a9783e2e92e8"
      unitRef="usd">17198000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMS0xLTEtMS0w_96552db5-aebc-49e7-8807-b8d68ba6c998"
      unitRef="usd">17198000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMS0zLTEtMS0w_3664ed73-41de-419b-890a-adcacccd2a50"
      unitRef="usd">48460000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMS0zLTEtMS0w_a6e352d8-8f75-437f-a252-b3480d6cb501"
      unitRef="usd">48460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMi0xLTEtMS0w_d0f5a79e-34e2-461c-b1cc-669d3c0bec00"
      unitRef="usd">1200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMi0zLTEtMS0w_111dd177-de71-4044-ba4b-a919ef7c3d2e"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMy0xLTEtMS0w_05f7be8d-7b5e-48d6-8c98-6a027a4ed480"
      unitRef="usd">18398000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8zNC9mcmFnOjE2OWUxYWE4ZDAyYjQzY2FhZjNlYTU5NDc1NzM3Nzg3L3RhYmxlOjgxMWZhNjk2ZDRlNDRhZGVhODg3NWI3ODU5MzVlZTg4L3RhYmxlcmFuZ2U6ODExZmE2OTZkNGU0NGFkZWE4ODc1Yjc4NTkzNWVlODhfMy0zLTEtMS0w_94e75d95-8240-4d35-b093-da972413ed5a"
      unitRef="usd">48460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfOTI1MA_65581e6d-e458-46c5-af60-32b1893965e0">Description of Business and Basis of Presentation&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Exicure, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, genetic disorders and other indications based on our proprietary Spherical Nucleic Acid (&#x201c;SNA&#x201d;) technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. The Company believes that the design of its SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company is working to advance its SNA therapeutic candidates through multiple clinical trials, including the ongoing Phase 1b/2 clinical trial of cavrotolimod (AST-008) in cancer patients. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that one of the key strengths of its proprietary SNAs is that they have the potential to enter a number of different cells and organs. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immunoncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. As a consequence, the Company has expanded its pipeline into neurology, and has conducted early stage research activities in ophthalmology, pulmonology, and gastroenterology. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Throughout these unaudited condensed consolidated financial statements, the terms the &#x201c;Company&#x201d; and &#x201c;Exicure&#x201d; refer to Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed consolidated financial statements as of June 30, 2020 and December 31, 2019, and for the three and six months ended June 30, 2020 and 2019, have been presented in conformity with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Significant Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#x2019;s routine communication to address employee and business concerns and providing frequent updates to the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;).  As of July 1, 2020, the Company took occupancy of approximately 30,000 square feet of laboratory and office space in its new headquarters in Chicago, Illinois.  Since then, the Company has operated under COVID-19 social distancing guidelines and has generally operated with 100% of its R&amp;amp;D staff on-site.  The Company&#x2019;s office and general and administrative team continues to work predominantly from home. The Company&#x2019;s preclinical development program in Friedreich&#x2019;s ataxia (&#x201c;FA&#x201d;) is ongoing and it continues to expect that IND-enabling studies for the Company&#x2019;s FA therapeutic candidate, XCUR-FXN, will begin in late 2020.  The Company also continues to progress its collaborations with Allergan Pharmaceuticals International Limited (&#x201c;Allergan&#x201d;) and DERMELIX, LLC, d/b/a Dermelix Biotherapeutics (&#x201c;Dermelix&#x201d;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience significant disruptions to its preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company anticipates that the COVID-19 pandemic may have an impact on the clinical development timelines for its cavrotolimod (AST-008) clinical program. The extent to which the COVID-19 pandemic will impact the Company&#x2019;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the pandemic, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and growth prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Liquidity Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2020, the Company has generated an accumulated deficit of $103,295 since inception and expects to incur significant expenses and negative cash flows for the foreseeable future.  Based on the Company&#x2019;s current operating plans, it believes that existing working capital at June 30, 2020 is sufficient to fund the Company for at least the next 12 months. Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  The Company has historically principally raised capital through the sale of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  The Company believes raising capital in the current market could be very difficult for early stage biotech companies like Exicure.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could in the future negatively affect its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying interim condensed consolidated balance sheet as of June 30, 2020, the interim condensed consolidated statements of operations for the three and six months ended June 30, 2020 and 2019, the interim condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2020 and 2019, the interim condensed consolidated statements of changes in stockholders&#x2019; equity for the three and six months ended June 30, 2020 and 2019, and the interim condensed consolidated statements of cash flows for the six months ended June, 2020 and 2019, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#x2019;s financial position as of June 30, 2020, the results of its operations for the three and six months ended June 30, 2020 and 2019, and the results of its cash flows for the six months ended June 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2019 are unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;of results to be expected for the year ending December 31, 2020, or any other interim periods, or any future year or period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#x2019;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfOTI0NQ_35fcd2dd-1d08-4d3c-b1e5-384b650da9ba">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed consolidated financial statements as of June 30, 2020 and December 31, 2019, and for the three and six months ended June 30, 2020 and 2019, have been presented in conformity with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfOTI0OA_dc0697c9-1e96-4975-9c57-9bcb8e4a52a0">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfMjc0ODc3OTA4MDI0MQ_fc19802c-dc5a-4782-8036-f9b1eda4dfba"
      unitRef="sqft">30000</xcur:LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea>
    <xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfNTc5OA_95d336a7-81e0-4536-b8d8-80ed09802b9e"
      unitRef="usd">-103295000</xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate>
    <us-gaap:UseOfEstimates
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80MC9mcmFnOjc3NDdkYzU5NGRmYTQzNjhiOGRmNDZhODQ5OTRhMDIwL3RleHRyZWdpb246Nzc0N2RjNTk0ZGZhNDM2OGI4ZGY0NmE4NDk5NGEwMjBfOTI1Mw_c8ec7dfb-50c5-4690-a535-97338f4f4172">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#x2019;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80My9mcmFnOjkwMDNkMzdhODNjMzRlMjRiYjJkZmY2NzNiNDk3YWY0L3RleHRyZWdpb246OTAwM2QzN2E4M2MzNGUyNGJiMmRmZjY3M2I0OTdhZjRfMTk4Ng_30cc9d43-974a-48c0-b923-97edd041c8ec">Significant Accounting Policies&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 10, 2020. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2016-13)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#x2014;Effective Dates &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#x201c;smaller reporting companies&#x201d; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80My9mcmFnOjkwMDNkMzdhODNjMzRlMjRiYjJkZmY2NzNiNDk3YWY0L3RleHRyZWdpb246OTAwM2QzN2E4M2MzNGUyNGJiMmRmZjY3M2I0OTdhZjRfMjc0ODc3OTA3MTQzMQ_3e785ee6-a025-46ee-ae0c-b0ca02b33b63">&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 10, 2020. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2016-13)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#x2014;Effective Dates &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#x201c;smaller reporting companies&#x201d; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMzI5ODUzNDkwNDkxMA_b8cd01b4-294d-43cd-9475-59bee4110b3f">Collaborative Research and License Agreements&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Allergan Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Summary of Agreement&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 13, 2019 (the &#x201c;Effective Date&#x201d;), the Company entered into a Collaboration, Option and License Agreement (the &#x201c;Allergan Collaboration Agreement&#x201d;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan, was acquired by AbbVie Inc. (&#x201c;AbbVie&#x201d;). Accordingly, all references to &#x201c;Allergan&#x201d; in the defined terms including, but not limited to, &#x201c;Allergan,&#x201d; &#x201c;Allergan Collaboration Agreement,&#x201d; &#x201c;Allergan R&amp;amp;D Services&#x201d; and &#x201c;Allergan JDC Services,&#x201d; should be read and construed as references to AbbVie. Pursuant to the Allergan Collaboration Agreement, the Company granted to Allergan exclusive access and options to license SNA based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders (each, a &#x201c;Collaboration Program&#x201d;). Under each such license (obtained in connection with the exercise of an Option, as defined and discussed further below), the Company would grant to Allergan exclusive, royalty-bearing, sublicenseable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the Allergan Collaboration Agreement, the Company will use commercially reasonable efforts to conduct two Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific Collaboration Program targets (each, a &#x201c;Program Target&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of the Effective Date, the Company and Allergan have agreed upon a development plan for each Collaboration Program that describes the development activities and timelines required to advance such Collaboration Program through first IND filing (each, a &#x201c;Development Plan&#x201d;).  The activities described in the Development Plan are conducted under the supervision of the Joint Development Committee (the &#x201c;JDC&#x201d;) consisting of three members from each of the Company and Allergan. The Company is primarily responsible for performing early stage discovery and preclinical activities (the &#x201c;Initial Development Activities&#x201d;) set forth in the Development Plan for each Collaboration Program and will be solely responsible for all costs and expenses related to the Initial Development Activities. Allergan may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; testing as set forth in a Development Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following the completion of all Initial Development Activities, the Company is required to deliver to Allergan a report that describes the results of the Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Collaboration Program as determined by the JDC (the &#x201c;Initial Development Report&#x201d;).  Following the delivery of the Initial Development Report for a Collaboration Program, Allergan will have the ability for a defined period of time (the &#x201c;Initial Option Exercise Period&#x201d;) to exercise an option (each an &#x201c;Option&#x201d;) to obtain worldwide rights and license to the Company&#x2019;s SNA technology and the Company&#x2019;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each a &#x201c;Licensed Product&#x201d;) that results from such Collaboration Program during the term of the Allergan Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At Allergan&#x2019;s sole option, Allergan may extend the Initial Option Exercise Period (the &#x201c;Option Extension&#x201d;) and require the Company to perform IND-enabling activities described in the Development Plan (the &#x201c;IND-Enabling Activities&#x201d;), subject to the payment of additional consideration (&#x201c;Extension Exercise&#x201d;). If Allergan exercises the Option Extension, the Company would be responsible for conducting the IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the IND-Enabling Activities, the Company is required to deliver a report that describes the results of the IND-Enabling Activities (the &#x201c;IND-Enabling Activities Data Package&#x201d;) to Allergan. Following the delivery of IND-Enabling Activities Data Package, Allergan will have the ability for a defined period of time (the &#x201c;Extended Option Exercise Period&#x201d;) to exercise an Option with respect to such Collaboration Program. After the exercise of an Option with respect to a Collaboration Program, Allergan will be responsible for all development, manufacturing, and commercialization activities, and costs and expense associated with such activities in connection with Licensed Products arising from such Collaboration Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s obligation to conduct the activities defined in the Development Plan under the Allergan Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date Allergan exercises an Option, (ii) the date Allergan abandons a Collaboration Program and foregoes its Option to that Collaboration Program, or (iii) the fifth anniversary of the Effective Date (the &#x201c;Research Term&#x201d;). If the Initial Option Exercise Period or Extended Option Exercise Period is still in effect for a Collaboration Program or if the Company has not delivered a complete Initial Development Report or, if Allergan made an Extension Exercise for a Collaboration Program, a complete IND-Enabling Activities Data Package for such Collaboration Program, as determined by the JDC, then the Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the Effective Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Allergan Collaboration Agreement, the Company received a $25,000 upfront, non-refundable, non-creditable cash payment (the &#x201c;Allergan Upfront Payment&#x201d;) related to the Company&#x2019;s research and development costs for conducting the Development Plan for two Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such Collaboration Programs.  The option exercise fee during the Initial Option Exercise Period is $10,000 per Collaboration Program.  If Allergan elects to extend the Initial Option Exercise Period, Allergan is required to pay an additional fee of $10,000.  If Allergan elects to exercise its option during the Extended Option Exercise Period, Allergan must pay the Company the option exercise fee of $15,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following the exercise by Allergan of an Option with respect to a Collaboration Program, Allergan would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on a Licensed Product by Licensed Product basis. On a Licensed Product by Licensed Product basis, for the first Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $55,000 for development milestone payments and $132,500 for product approval and launch milestone payments. The Company is also eligible for up to $175,000 in sales milestone payments on a Collaboration Program by Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by Allergan to obtain certain third party intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, to the extent there is any Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a Licensed Product by Licensed Product and country by country basis from the date of the first commercial sale of each Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such Licensed Product in such country, (ii) the tenth anniversary of the first commercial sale of such Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such Licensed Product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Allergan may terminate the Allergan Collaboration Agreement for any reason or no reason, either in its entirety or on a Collaboration Program by Collaboration Program basis, at any time on 90 days&#x2019; prior written notice to the Company. Unless earlier terminated, the term of the Allergan Collaboration Agreement shall continue until (i) if both Option Exercise Periods expire without Allergan exercising either Option, the expiration of the later to expire Option Exercise Period, and (ii) if either or both Options are exercised on a Licensed Product-by-Licensed Product and country-by-country basis, the expiration of the royalty term for such Licensed Product in such country. Either party may terminate the Allergan Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Termination of the Allergan Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the Allergan Collaboration Agreement will not preclude &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the Allergan Collaboration Agreement. If either party terminates the Allergan Collaboration Agreement, the license and rights granted to Allergan with respect to the terminated Collaboration Program or License Product shall terminate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded that Allergan is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the Allergan Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the Research Term (the &#x201c;Allergan R&amp;amp;D Services&#x201d;), and (ii) Joint Development Committee services during the Research Term (the &#x201c;Allergan JDC Services&#x201d;). The Company has concluded that the Allergan R&amp;amp;D Services is not distinct from the Allergan JDC Services during the Research Term. The JDC provides oversight and management of the overall Allergan Collaboration Agreement, and the members of the JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The JDC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and Allergan. Further, the JDC services are critical to the ongoing evaluation of a Collaboration Program and the drafting and evaluation of the Initial Development Report and the IND-Enabling Data Package. Accordingly, the Company&#x2019;s participation on the JDC is essential to Allergan receiving value from the Allergan R&amp;amp;D Services and as such, the Allergan JDC Services along with the Allergan R&amp;amp;D Services are considered one performance obligation (the &#x201c;Collaboration Program Services&#x201d;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of the Effective Date of the Allergan Collaboration Agreement, the total transaction price was determined to be $25,000, consisting solely of the Allergan Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Effective Date of the Allergan Collaboration Agreement, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Allergan.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of June 30, 2020, the Company determined that any development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company will recognize revenue related to the Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three and six months ended June 30, 2020, the Company recognized revenue under the Allergan Collaboration Agreement of approximately $4,833 and $13,949, respectively.  As of June 30, 2020, there was $10,880 of deferred revenue related to the Allergan Collaboration Agreement, which is classified as current on the unaudited condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Dermelix Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Summary of Agreement&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 17, 2019, Exicure entered into a License and Development Agreement with Dermelix (the &#x201c;Dermelix Collaboration Agreement.&#x201d;)  Pursuant to the Dermelix Collaboration Agreement, the Company granted to Dermelix exclusive, worldwide royalty-bearing license rights to, develop, manufacture, have manufactured, use and commercialize the Company&#x2019;s SNA technology for the treatment of Netherton Syndrome (&#x201c;NS&#x201d;) and, at Dermelix&#x2019;s option, up to five additional specified orphan diseases that are within the dermatology field. Upon written notice to the Company, Dermelix may exercise its option at any time following the effective date of the Dermelix Collaboration Agreement until the date that is &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTQ4ODA_7c7ddbd2-6787-47de-91af-9e663bcf7a25"&gt;six&lt;/span&gt; (6) years from the date that the first collaboration SNA therapeutic achieves first dosing in humans in a Phase 1 clinical trial for NS.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Dermelix will initially seek to develop a targeted therapy for the treatment of NS.  Under the terms of the Dermelix Collaboration Agreement, the Company will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will assume subsequent development, commercial activities and financial responsibility for such indications.  Dermelix will pay the costs and expenses of development and commercialization of any licensed products under the Dermelix Collaboration Agreement, including the Company&#x2019;s expenses incurred in connection with development activities and in accordance with the development budget.  Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $1,000, to be applied against the initial $1,000 of the Company&#x2019;s development expenses.  If Dermelix exercises any of its option rights for additional indications, Dermelix will pay an option exercise fee equal to $1,000 for each exercised option (each, an &#x201c;Option Exercise Fee&#x201d;).  Any Option Exercise Fee will be applied against the Company&#x2019;s development expenses with respect to the particular indication for which the option was exercised.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Dermelix Collaboration Agreement, the Company shall have the right to pursue the development and commercialization of SNA technology for the treatment of orphan diseases which are neither NS nor one of the additional specified orphan diseases selected by Dermelix pursuant to its option rights.  If the Company commences development activities of SNA technology for the treatment of such an orphan disease, the Company will notify Dermelix in writing of such development and Dermelix will have &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTY3MzY_cca5baed-3744-4471-869d-43a351036895"&gt;thirty&lt;/span&gt; (30) days following receipt of such notice to use one of its remaining option rights on such orphan disease.  If Dermelix does not use one of its remaining option rights on such orphan disease, or has no option rights remaining, then the Company will have no further obligations to Dermelix with respect to the development of SNA therapeutics for such orphan disease and shall be free to continue commercialization and development activities with respect thereto.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, the Company shall be eligible to receive additional cash payments totaling up to $13,500 upon achievement of certain development and regulatory milestones and up to $152,500 upon achievement of certain sales milestones.  The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program.  The commercial sales milestones are payable upon achievement of specified aggregate annual product sales thresholds.  In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company will receive low double-digit royalties on annual net sales for such licensed products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded that Dermelix is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance.  The Company identified performance obligations under the Dermelix Collaboration Agreement for the license of intellectual property for the NS therapeutic candidate and associated research and development services for the NS therapeutic candidate.  The Company determined that the performance obligations were not separately identifiable and were not distinct or distinct within the context of the contract due to the specialized nature of the services to be provided by Exicure, specifically with respect to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Company&#x2019;s expertise related to SNA technology, and the interdependent relationship between the performance obligations.  As such, the Company concluded that there is a single identified performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential development and regulatory milestone, which is considered variable consideration, was zero, as the achievement of those milestones is uncertain and highly susceptible to factors outside of the Company&#x2019;s control.  Accordingly, all such milestones were excluded from the transaction price.  Management will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur and adjust the transaction price as necessary.  Sales-based royalties, including commercial sales milestone payments based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate.  The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue associated with the performance obligation will be recognized as services are provided using a cost-to-cost measure of progress method.  The transfer of control occurs over time and, in management&#x2019;s judgment, this input method is the best measure of progress towards satisfying the performance obligation under the Dermelix Collaboration Agreement and reflects a faithful depiction of the transfer of goods and services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company initially recorded the upfront payment of $1,000 as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to zero during 2019 by recognizing revenue as services were provided.  The Company recognized $14 and $81 of revenue under the Dermelix Collaboration Agreement during the three and six months ended June 30, 2020, respectively, which reflects reimbursement by Dermelix for additional costs incurred by Exicure for early stage development costs beyond the initial $1,000 upfront payment.  The Company expects to incur additional early stage development costs and expects to be reimbursed by Dermelix for such costs under the terms of the Dermelix Collaboration Agreement.  The Company will recognize both revenue and research and development expense for such costs on a gross basis during the period in which those costs are incurred.   The Company recognized&#160;$434&#160;and $459 of revenue under the Dermelix Collaboration Agreement during the three and six months ended June 30, 2019, respectively,&#160;which related to amortization of the above-mentioned deferred revenue related to the upfront payment for services provided during that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <xcur:NumberofCollaborationPrograms
      contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfODcz_5c16b8a5-4e86-4ebf-8260-7ca104023c15"
      unitRef="agreements">2</xcur:NumberofCollaborationPrograms>
    <xcur:NumberofCollaborationPrograms
      contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTM5NQ_76464c49-2d30-4ca7-9101-e54842a15d5b"
      unitRef="agreements">2</xcur:NumberofCollaborationPrograms>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNTgwNg_c3f39d8e-9945-442f-aa28-65607957e414"
      unitRef="usd">25000000</xcur:CollaborationAgreementUpfrontPayment>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNjM3Mg_12022e20-34d2-415a-a3d6-855abe029ecb"
      unitRef="usd">10000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee
      contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNjUxNw_5d4fccee-96ea-4da5-81ad-2231ed5bdb35"
      unitRef="usd">10000000</xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i213132da6481483c807931ec91868df7_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNjY2NQ_c4a9045c-d750-4b60-8bd5-1b8bee734d60"
      unitRef="usd">15000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment
      contextRef="iec1efc8f38914d529f3fa0003f78cbce_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE2Mw_a9053275-f56c-4a3b-8bc2-b8e16bd8e791"
      unitRef="usd">55000000</xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment
      contextRef="iec1efc8f38914d529f3fa0003f78cbce_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzIwNQ_898fac8f-b810-401e-a6f3-ba1b26ee5e73"
      unitRef="usd">132500000</xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment
      contextRef="iec1efc8f38914d529f3fa0003f78cbce_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzI5OQ_87200d14-8fbf-4a22-a8dd-f1c538cacd9b"
      unitRef="usd">175000000</xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment>
    <xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice
      contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfODcyMw_fef84101-906d-49a9-b810-8d4bc0870391">P90D</xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="if425dcd784314579ba01872343ba1d3d_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTIxNjg_68064773-bda3-4d0f-b851-4e7dbde5eb7e"
      unitRef="usd">25000000</xcur:CollaborationAgreementUpfrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0168a43217c4457bc65313c2af4fb05_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjIzOQ_2565fca0-8953-4344-b8da-96e6112db735"
      unitRef="usd">4833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56e80b2cc5be4ab4acf0eef51f34220c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjI0Mw_9055396a-6848-46b7-be62-155158682f15"
      unitRef="usd">13949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i76587ca4c99d49da89121e59315b11c9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTM5Njk_7d8b1f06-8781-473b-8439-1008dacd2bf1"
      unitRef="usd">10880000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets
      contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTQ2Mjg_a07f43c9-ac87-491e-9329-76a2aed6fcff"
      unitRef="target">5</xcur:CollaborationAgreementOptionNumberofAdditionalCollaborationTargets>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTU3OTM_df1350c6-4e06-4b11-9045-96da7f66d215"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <xcur:CollaborationDevelopmentExpenses
      contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTU4MzE_ad3c8a83-59b1-4931-bd71-a2119778d7a9"
      unitRef="usd">1000000</xcur:CollaborationDevelopmentExpenses>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTU5OTk_7fbe78d7-94e0-4e66-9a1f-711b124519b9"
      unitRef="usd">1000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue
      contextRef="i3af79e6a06594c0cb23b1951b9373a0c_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTczOTM_c6506980-17b7-4f08-b000-7f733e5175ca"
      unitRef="usd">13500000</xcur:RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue
      contextRef="i3af79e6a06594c0cb23b1951b9373a0c_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTc0NzI_634cfd1a-c28a-4d2e-a0ba-c41447307fed"
      unitRef="usd">152500000</xcur:RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMjA1MDY_0b22f599-de2c-4fdf-b341-b18fd379fb83"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee37ebd534aa4705869ea2175ce06b24_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjMyMQ_b22dcd99-da7d-4fba-b1f4-21b73531075c"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4755b498baa24be79491012d4f532c62_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjM2MA_a3f23fce-60da-45a1-85b3-b10104f8fcf4"
      unitRef="usd">81000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i65b9fc500ac842889dc919b7060bc17f_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMjA5NDM_27ce9db1-9fea-4f01-b2d2-d3915e832ed9"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib68fbc221ed948318252eb995a6db2b6_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjM5Nw_14bc6588-026c-468b-a824-cf1c6bcdcdaa"
      unitRef="usd">434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a49e1430c4d4a889f71e3a5a377bb5a_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfNzE0NjgyNTYwMjQyMw_63093a6a-a8b1-4e62-8fa6-780e39557012"
      unitRef="usd">459000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzQ3_ff2dd737-c12b-4529-a4c3-c77022f57970">Supplemental Balance Sheet Information&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depreciation and amortization expense was $187 and $87 for the three months ended June 30, 2020 and 2019, respectively, and $335 and $174 for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:9pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued legal expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzQ4_c5c5147c-2e06-4582-b9c2-7c66398588e6">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMS0xLTEtMS0w_d96e510d-182f-4552-a8b2-4885dd82e077"
      unitRef="usd">2203000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMS0zLTEtMS0w_4ab1c6bd-c393-469c-8f7a-c3d0d4f59d4e"
      unitRef="usd">481000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InterestReceivable
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMi0xLTEtMS0w_a57089cd-27f2-47d7-abdf-8d7f6c489905"
      unitRef="usd">221000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMi0zLTEtMS0w_0f076d7e-3860-45d5-a662-6f0904233a5d"
      unitRef="usd">236000</us-gaap:InterestReceivable>
    <us-gaap:PrepaidInsurance
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMy0xLTEtMS0w_1c991e57-a8b1-4a81-bd6f-f16503e0e93e"
      unitRef="usd">212000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfMy0zLTEtMS0w_1096b638-020d-478d-816f-e0af93783990"
      unitRef="usd">533000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfNC0xLTEtMS0w_315d786b-f837-4c62-9596-b00bcd4ff440"
      unitRef="usd">952000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfNC0zLTEtMS0w_605a8d3f-98ee-49b3-a71e-88f5afdf9b42"
      unitRef="usd">705000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfNS0xLTEtMS0w_0e74822f-9176-4d89-a5d6-df78d24f8066"
      unitRef="usd">3588000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmMyNGJhMGI0NjI0NDRmY2Y4YjE2MTk5ZWM2MWY5MjMwL3RhYmxlcmFuZ2U6YzI0YmEwYjQ2MjQ0NGZjZjhiMTYxOTllYzYxZjkyMzBfNS0zLTEtMS0w_f0c849d2-5625-4d96-8840-b564ffa5521b"
      unitRef="usd">1955000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzU3_b2336af2-aa5a-4508-bfd5-63cbdda2fd68">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if8a0a13c38254ea983e0bb5a38ca17de_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMS0xLTEtMS0w_fce67e07-8046-4be1-b6c9-206f8f3282a0"
      unitRef="usd">3315000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8bfb10b6658e4029a82a1c4c79504c5a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMS0zLTEtMS0w_93520e9f-fb1a-4340-ab53-344d07330de5"
      unitRef="usd">2795000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i352899e868b047baae4f3cc5f48173b4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMi0xLTEtMS0w_ea396df4-2fc2-4750-8049-7a6116d96c0c"
      unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7e5bb134266b43198e6a9ac71d907554_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMi0zLTEtMS0w_dda22972-76d4-42bf-aa26-6869b2a2f8fe"
      unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i18277ad2812a4ef9966ee81eceda653f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMy0xLTEtMS0w_d3c28815-8eb0-46f3-85f5-27924607fe26"
      unitRef="usd">48000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iad32dfdbf9ce43d4a96d7847ec6e4876_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfMy0zLTEtMS0w_f8f24d2a-bcc0-4990-bab4-f4a9b3de4d62"
      unitRef="usd">32000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaf30ba5997b64586b6fd2b6487a3b25e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNC0xLTEtMS0w_d278b349-17d6-41f3-8c51-235ddce3a4b5"
      unitRef="usd">41000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id3e2b30098dd4ce39f205fbcaecabc6e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNC0zLTEtMS0w_e06753d3-c3c5-4f0a-a60b-a5eba3c221c2"
      unitRef="usd">41000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i83ab7faaf6324bbe806b1945f6ef544f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNS0xLTEtMS0w_20ab3535-dbe8-4559-87ce-f10da52c249b"
      unitRef="usd">2512000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifd78f631ebaa4338ba6f8984c802d444_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNS0zLTEtMS0w_d9a1b90a-dced-4fed-9c7f-9fd5376af8c7"
      unitRef="usd">356000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNi0xLTEtMS0w_c569bd56-bd63-4166-bc67-ec3c3d3168e8"
      unitRef="usd">6108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNi0zLTEtMS0w_8539a432-e871-4de8-ad93-b0828798ae84"
      unitRef="usd">3416000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNy0xLTEtMS0w_a54dc94c-d356-4476-a8d5-76ae6f51642b"
      unitRef="usd">1644000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfNy0zLTEtMS0w_830b0326-25e1-43d0-9255-28b7345962d3"
      unitRef="usd">1317000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfOC0xLTEtMS0w_275519c2-acc8-4545-97e8-85408d345142"
      unitRef="usd">4464000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjM0OGM5YzdiM2JmZjQ5NDhhYmViMmQ1ZDNhMmMzYWE1L3RhYmxlcmFuZ2U6MzQ4YzljN2IzYmZmNDk0OGFiZWIyZDVkM2EyYzNhYTVfOC0zLTEtMS0w_145f5af0-ad7e-462f-ae9b-f575691bbfd5"
      unitRef="usd">2099000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMTYz_acfd90a9-a901-429c-934f-f5b67c5939e7"
      unitRef="usd">187000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMTcw_e78d4293-a380-4e16-9e1d-7f82f1e529c7"
      unitRef="usd">87000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfNzE0NjgyNTU4MTAzOQ_f3775c4f-b546-465f-98c8-f5338166e6f6"
      unitRef="usd">335000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfNzE0NjgyNTU4MTAxMw_f0823d05-33da-4c88-864c-4ffe3797d0a6"
      unitRef="usd">174000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzUx_1fcf6424-5488-44f2-83ab-7220c2d7aeda">&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:9pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:RestrictedCash
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMS0xLTEtMS0w_ee52a920-dba7-4a64-8f61-a8fb9f29f0dd"
      unitRef="usd">1200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMS0zLTEtMS0w_05cd5348-15af-4bc3-8afc-4dabb0a5eff0"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <xcur:PrepaidLeaseCosts
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMi0xLTEtMS0yODI1_ddd08885-3e2a-48ba-8d64-42148d98384b"
      unitRef="usd">823000</xcur:PrepaidLeaseCosts>
    <xcur:PrepaidLeaseCosts
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMi0zLTEtMS0yODMw_5636da3c-6789-438f-8523-7e25328a9e2a"
      unitRef="usd">0</xcur:PrepaidLeaseCosts>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMy0xLTEtMS0zNjQ4_8b015b76-9430-4cc5-8945-c6222ffb66b8"
      unitRef="usd">233000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMy0zLTEtMS0zNjUz_c082f651-4321-43f3-a435-a8a9c6fb12f6"
      unitRef="usd">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMi0xLTEtMS0w_ec3ecbcf-5261-4162-9b8c-e4d724f9b5bf"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMi0zLTEtMS0w_746d1388-b21d-4f3c-97bb-69cf0369c63b"
      unitRef="usd">356000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMy0xLTEtMS0w_25c48102-33df-4882-a6f2-ecfd4fc0d505"
      unitRef="usd">10000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfMy0zLTEtMS0w_9cc8b0c8-80ef-495b-b3cb-7d847a079e80"
      unitRef="usd">32000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfNC0xLTEtMS0w_0fbbeeca-5726-4d20-aadd-4417ff873fa5"
      unitRef="usd">2266000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjJkNWExMjIyMDk5ODRkZThhZTM3YWIyOGUxZmRjOGE0L3RhYmxlcmFuZ2U6MmQ1YTEyMjIwOTk4NGRlOGFlMzdhYjI4ZTFmZGM4YTRfNC0zLTEtMS0w_e5cfe8c4-0723-418c-ada2-19f1d4c354c2"
      unitRef="usd">388000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzUy_df733520-c163-4580-a70e-48b895c2f437">&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued legal expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMS0xLTEtMS0w_527d9da8-919d-4c77-aaa3-881343f05f20"
      unitRef="usd">706000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMS0zLTEtMS0w_20e57a44-aade-421f-843d-14bfd646529e"
      unitRef="usd">920000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMi0xLTEtMS0w_0f999d5f-d204-454d-9679-f422883ac9b0"
      unitRef="usd">362000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMi0zLTEtMS0w_319b27e3-6743-4358-8b44-4dd0789f43e8"
      unitRef="usd">254000</us-gaap:AccruedProfessionalFeesCurrent>
    <xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNC0xLTEtMS0w_bb3699e8-1fb2-4eb7-b4b3-c022011a89ac"
      unitRef="usd">303000</xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent>
    <xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNC0zLTEtMS0w_71134d21-c53e-46b9-b20c-9dde91b2b394"
      unitRef="usd">515000</xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent>
    <xcur:CommonStockWarrantLiabilityCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNC0xLTEtMS03MzU_57bcafe5-94e0-417b-8e32-8acd33b6739a"
      unitRef="usd">257000</xcur:CommonStockWarrantLiabilityCurrent>
    <xcur:CommonStockWarrantLiabilityCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNC0zLTEtMS03MzU_2e5b3b70-af1d-49db-a825-5247d55e6da9"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMy0xLTEtMS0w_0aba786e-0bed-4bc3-a735-f62696a2e869"
      unitRef="usd">196000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfMy0zLTEtMS0w_0a034201-16aa-48a2-aca9-40c8b9c3f751"
      unitRef="usd">292000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNS0xLTEtMS0w_f4148989-f5aa-4321-8a12-3cc8b9241f35"
      unitRef="usd">123000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNS0zLTEtMS0w_53087c99-f091-42bb-bf37-6f04b7718658"
      unitRef="usd">454000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNi0xLTEtMS0w_2f4de307-fac2-4060-a234-56ff966d8e05"
      unitRef="usd">1947000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOjU1ZjJjZjEyNjBkODRkMDY5ODI1Y2Y5MjFlOThjOTUwL3RhYmxlcmFuZ2U6NTVmMmNmMTI2MGQ4NGQwNjk4MjVjZjkyMWU5OGM5NTBfNi0zLTEtMS0w_5a267007-a438-48c5-a351-f1757d68599e"
      unitRef="usd">2435000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RleHRyZWdpb246Njg5MzIwZjA2OTIxNDVlNzg3MjRjYjliNmZiYjA5ZjVfMzUz_5bba01f4-f2bc-4d6c-8ece-a2cf299666ff">&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:9pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.903%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.905%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;&#160;&#160;Total other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmY4ZjgwY2EzZTcyOTRhZjZhN2QxYzkyYzgyOWUyN2JjL3RhYmxlcmFuZ2U6ZjhmODBjYTNlNzI5NGFmNmE3ZDFjOTJjODI5ZTI3YmNfMS0xLTEtMS0w_8e70f1e4-8d3c-471a-9303-097bd73ea820"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmY4ZjgwY2EzZTcyOTRhZjZhN2QxYzkyYzgyOWUyN2JjL3RhYmxlcmFuZ2U6ZjhmODBjYTNlNzI5NGFmNmE3ZDFjOTJjODI5ZTI3YmNfMS0zLTEtMS0w_75fce0b8-d9e0-4251-9bad-b175d6e7a663"
      unitRef="usd">59000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmY4ZjgwY2EzZTcyOTRhZjZhN2QxYzkyYzgyOWUyN2JjL3RhYmxlcmFuZ2U6ZjhmODBjYTNlNzI5NGFmNmE3ZDFjOTJjODI5ZTI3YmNfMy0xLTEtMS0w_c55b57fd-3f15-4d6e-94bf-04ee60bdfca5"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80OS9mcmFnOjY4OTMyMGYwNjkyMTQ1ZTc4NzI0Y2I5YjZmYmIwOWY1L3RhYmxlOmY4ZjgwY2EzZTcyOTRhZjZhN2QxYzkyYzgyOWUyN2JjL3RhYmxlcmFuZ2U6ZjhmODBjYTNlNzI5NGFmNmE3ZDFjOTJjODI5ZTI3YmNfMy0zLTEtMS0w_d628fe5a-da56-424d-be7b-08bdd5b556a7"
      unitRef="usd">59000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RleHRyZWdpb246ZTNmZTRhZjM2Nzc4NDFjYWI1Y2YzOTcwNTY3MzllOWVfMTMwMg_c35c8988-381f-4ca2-9e7a-5c0116eb8937">Investments&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2020 and December 31, 2019, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:282.75pt;"&gt;&lt;tr&gt;&lt;td style="width:1.0pt;"/&gt;&lt;td style="width:211.00pt;"/&gt;&lt;td style="width:1.0pt;"/&gt;&lt;td style="width:1.0pt;"/&gt;&lt;td style="width:67.75pt;"/&gt;&lt;td style="width:1.0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After one year but within two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All of the Company&#x2019;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June 30, 2020&#160;and December 31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.826%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.247%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.565%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.672%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.787%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.672%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.390%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.672%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.395%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.025%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.950%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.680%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.680%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.680%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.206%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:InvestmentTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RleHRyZWdpb246ZTNmZTRhZjM2Nzc4NDFjYWI1Y2YzOTcwNTY3MzllOWVfMTMwMw_dc1749dc-3a28-4832-b6a3-0693bb979666">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:282.75pt;"&gt;&lt;tr&gt;&lt;td style="width:1.0pt;"/&gt;&lt;td style="width:211.00pt;"/&gt;&lt;td style="width:1.0pt;"/&gt;&lt;td style="width:1.0pt;"/&gt;&lt;td style="width:67.75pt;"/&gt;&lt;td style="width:1.0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After one year but within two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <xcur:DebtSecuritiesAvailableForSaleCurrentPercent
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmQ2ZWEyMzhiODMwMzRhZDNhNTcxMzhlMGU5NDVkOGVkL3RhYmxlcmFuZ2U6ZDZlYTIzOGI4MzAzNGFkM2E1NzEzOGUwZTk0NWQ4ZWRfMC0xLTEtMS0w_e0a71923-c4c4-4072-a3c2-b134fa3a2091"
      unitRef="number">0.92</xcur:DebtSecuritiesAvailableForSaleCurrentPercent>
    <xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmQ2ZWEyMzhiODMwMzRhZDNhNTcxMzhlMGU5NDVkOGVkL3RhYmxlcmFuZ2U6ZDZlYTIzOGI4MzAzNGFkM2E1NzEzOGUwZTk0NWQ4ZWRfMS0xLTEtMS0w_03899ba7-d94c-47dd-b70d-15c67f1f0021"
      unitRef="number">0.08</xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent>
    <xcur:DebtSecuritiesAvailableforSalePercent
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmQ2ZWEyMzhiODMwMzRhZDNhNTcxMzhlMGU5NDVkOGVkL3RhYmxlcmFuZ2U6ZDZlYTIzOGI4MzAzNGFkM2E1NzEzOGUwZTk0NWQ4ZWRfMi0xLTEtMS0w_5ac245bb-7e30-4528-86a1-6fc77be90609"
      unitRef="number">1</xcur:DebtSecuritiesAvailableforSalePercent>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RleHRyZWdpb246ZTNmZTRhZjM2Nzc4NDFjYWI1Y2YzOTcwNTY3MzllOWVfMTMwNA_bc900cfe-af0e-49a0-9fd7-76ab8837d620">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June 30, 2020&#160;and December 31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.826%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.247%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.565%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.672%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.787%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.672%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.390%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.672%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.395%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.025%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.950%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.680%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.680%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.680%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.206%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i209cc24d339e4dca80c79600e75bf93a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMi0xLTEtMS0w_869fce11-e852-4411-8442-7021ce1267ad"
      unitRef="usd">15166000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i209cc24d339e4dca80c79600e75bf93a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMi0zLTEtMS0w_a5603ba7-513d-4aa9-afd6-d92569b67c54"
      unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i209cc24d339e4dca80c79600e75bf93a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMi01LTEtMS0w_8d7499c6-1818-4031-9530-a02d5b412204"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i209cc24d339e4dca80c79600e75bf93a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMi03LTEtMS0w_93553c03-b5e1-49e2-acf7-08621980d8ce"
      unitRef="usd">15188000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3438766d2dcd44c49ffa9224566847b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMy0xLTEtMS0w_f8e8a632-4ac9-4594-8785-2bcea13e9cdc"
      unitRef="usd">44798000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3438766d2dcd44c49ffa9224566847b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMy0zLTEtMS0w_e5b27b8b-077b-41a5-845d-4a131883497b"
      unitRef="usd">271000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3438766d2dcd44c49ffa9224566847b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMy01LTEtMS0w_ba22ad25-db90-4ae7-90ff-8aaa61193ef5"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3438766d2dcd44c49ffa9224566847b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfMy03LTEtMS0w_a7217a9b-ff64-4313-94aa-2ce356da5936"
      unitRef="usd">45065000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNC0xLTEtMS0w_57b5a00a-f8f3-47ef-b1a2-17c0ee56759b"
      unitRef="usd">2257000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNC0zLTEtMS0w_20912e34-6c84-4784-8968-f867d4e3b3c0"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNC01LTEtMS0w_5bd3f0cf-71f2-4fbd-9d3e-92d3177a0171"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0cd0d12bbd2b4499b33c4c90ea4faeda_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNC03LTEtMS0w_baf3972a-b7e3-4d6e-a1ae-21d2ec038fc6"
      unitRef="usd">2275000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNS0xLTEtMS0w_07588bdb-d057-4efc-90c6-fc78816f134f"
      unitRef="usd">6020000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNS0zLTEtMS0w_c7881b50-9ab8-4d98-9fa4-57d07804b69a"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNS01LTEtMS0w_0f1dd66f-8615-4c82-b3a4-9bccad0878bf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00f42ea0f6bc4661a1909f6b66502bb9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNS03LTEtMS0w_b4af5a4a-9d8e-4adf-a07b-3787694d4c9b"
      unitRef="usd">6051000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNi0xLTEtMS0w_299ee6f2-d65f-45a4-b1e1-d2157bce2f26"
      unitRef="usd">68241000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNi0zLTEtMS0w_a1d5b8a2-a9a7-4c7f-a17c-1303d1084a83"
      unitRef="usd">342000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNi01LTEtMS0w_dbdace94-c4e0-4dd1-b3c2-1afa346e0970"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOmNiYjhlMWQ4Zjg3YTQwODFhOTk2YWUwZTJjMjg0YzdjL3RhYmxlcmFuZ2U6Y2JiOGUxZDhmODdhNDA4MWE5OTZhZTBlMmMyODRjN2NfNi03LTEtMS0w_91b08a7e-a637-403c-b136-f8c14977f9a1"
      unitRef="usd">68579000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icbffc60721ce4820bf8a858d521a4af2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMi0xLTEtMS0w_2bc53a0f-ad3a-451d-9101-454c6c5a30bd"
      unitRef="usd">13932000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icbffc60721ce4820bf8a858d521a4af2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMi0zLTEtMS0w_7e62a7bd-abfb-4ac4-b9ee-083b2c188cd4"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icbffc60721ce4820bf8a858d521a4af2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMi01LTEtMS0w_c6633247-97d2-4992-a44a-fbff88c622ad"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbffc60721ce4820bf8a858d521a4af2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMi03LTEtMS0w_72a50f7f-63ec-4a7c-b9ba-672fdb3750ee"
      unitRef="usd">13931000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9f8930d5532948af84a2e264d978cb22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMy0xLTEtMS0w_85e848af-6e14-481c-a20d-85b06bb2ea4b"
      unitRef="usd">36620000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9f8930d5532948af84a2e264d978cb22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMy0zLTEtMS0w_4e778a1a-f916-499f-b7de-2325503125ef"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9f8930d5532948af84a2e264d978cb22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMy01LTEtMS0w_423401e8-83cd-448e-a0ca-5c51f4b617b2"
      unitRef="usd">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f8930d5532948af84a2e264d978cb22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfMy03LTEtMS0w_04f5b9b8-4c9d-47a4-8bd5-2780d4a69402"
      unitRef="usd">36597000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icf8a62227b6e4249b0ad9da0af747eac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNC0xLTEtMS0w_89cebbe7-bd22-48f6-966d-fd67dead7b89"
      unitRef="usd">4513000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icf8a62227b6e4249b0ad9da0af747eac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNC0zLTEtMS0w_93cc1a68-0e70-4039-8d8b-3f7d8ccf19b8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icf8a62227b6e4249b0ad9da0af747eac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNC01LTEtMS0w_6abc98dd-6e02-43be-82f9-49f275ff5acc"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf8a62227b6e4249b0ad9da0af747eac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNC03LTEtMS0w_4a1a8322-d295-4632-b088-87a34d7608c2"
      unitRef="usd">4512000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i331baf183969422d81b4084c1e01f301_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNS0xLTEtMS0w_0704c722-0d3e-4698-a646-854b24a69ac4"
      unitRef="usd">9786000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i331baf183969422d81b4084c1e01f301_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNS0zLTEtMS0w_7e1f1948-a9e7-47be-9ccd-e3022c34a164"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i331baf183969422d81b4084c1e01f301_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNS01LTEtMS0w_1341153a-6c1b-47d7-985b-f97ed6f2d63c"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i331baf183969422d81b4084c1e01f301_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNS03LTEtMS0w_634356f8-81ff-491b-be38-0ead4aefb743"
      unitRef="usd">9784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNi0xLTEtMS0w_81a6d54d-9f1a-401e-8c48-beb43a717479"
      unitRef="usd">64851000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNi0zLTEtMS0w_2c6b9cf0-18b3-48f0-87d3-d98c9c16e50c"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNi01LTEtMS0w_16d09b7e-6fac-4d39-aef8-bc61e37052d5"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81Mi9mcmFnOmUzZmU0YWYzNjc3ODQxY2FiNWNmMzk3MDU2NzM5ZTllL3RhYmxlOjJjZmMxMmU3MTQwNDQ0YmVhZmFjY2RlNjIxMmQ4YTA0L3RhYmxlcmFuZ2U6MmNmYzEyZTcxNDA0NDRiZWFmYWNjZGU2MjEyZDhhMDRfNi03LTEtMS0w_db35d4eb-8bed-47a9-97bf-5bdc0984db8f"
      unitRef="usd">64824000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfMjc0ODc3OTA3MDE2OA_04204069-bc3b-4f97-afd3-6a49c0fa5546">DebtOn March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#x201c;Hercules&#x201d;) and subsequent amendments thereto  (the &#x201c;Hercules Loan Agreement&#x201d;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $4,999 and the end of term fee of $100.The Company paid interest on the Hercules Loan Agreement of $0 and $152 during the three months ended June 30, 2020 and 2019, respectively, and $142 and $301 during the six months ended June 30, 2020 and 2019, respectively.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i5d33f191228d4786a0f292468de4d908_D20200302-20200302"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfMzU5_af9d3134-673b-47d0-8b01-413b8fbc8b72"
      unitRef="usd">4999000</us-gaap:RepaymentsOfLongTermDebt>
    <xcur:PaymentsForDebtEndTermFees
      contextRef="i5d33f191228d4786a0f292468de4d908_D20200302-20200302"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfMzg5_e6f3e68e-dcaa-4029-b0c6-2c490da35712"
      unitRef="usd">100000</xcur:PaymentsForDebtEndTermFees>
    <us-gaap:InterestPaidNet
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfNDUz_a731d753-7f21-4212-850e-852bd9452ea3"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfNDYw_46d822f7-38dd-4927-b807-9b654ca82507"
      unitRef="usd">152000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfNzE0NjgyNTU4MTIyNQ_7945430a-3aeb-4802-b119-670d966e2bba"
      unitRef="usd">142000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81NS9mcmFnOmEwNjkzMjU4ZmY1YzQ2MzQ4M2U4YzU0Y2NhNTQ5YjFjL3RleHRyZWdpb246YTA2OTMyNThmZjVjNDYzNDgzZThjNTRjY2E1NDliMWNfNzE0NjgyNTU4MTI1MA_0af4f955-d939-4f68-ae4f-c9695edfaa4d"
      unitRef="usd">301000</us-gaap:InterestPaidNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfNTUwNA_9dcdf5a3-20b8-439c-b96a-ccf94827f2a9">Leases&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Chicago Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has approximately thirty thousand square feet of office and laboratory space in Chicago, Illinois (the &#x201c;Chicago Lease&#x201d;). The original term (the &#x201c;Original Term&#x201d;) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the &#x201c;Commencement Date&#x201d;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;two&#160;additional successive periods of five years each (the &#x201c;Extension Periods&#x201d;) at the then prevailing effective market rental rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The initial annual base rent during the Original Term is $37.00 per square foot per year, or approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes are subject to certain abatements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Landlord will contribute a maximum of $3,159 toward tenant improvements. In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the Landlord in an initial amount of $1,200, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the Landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $87 which amount had been adjusted for the abatement as set forth in the lease agreement. Prior to the Commencement Date, the Company also paid the landlord approximately $736 toward tenant improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $1,200, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#x2019;s unaudited condensed consolidated balance sheet at June 30, 2020.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Chicago Lease has not yet commenced for accounting purposes as of&#160;June 30, 2020. As a result, the Company has not yet recognized an operating lease asset or operating lease liability on the unaudited condensed consolidated balance sheet for the Chicago Lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Skokie Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s lease agreement for office and laboratory space in Skokie, Illinois commenced in March 2012 and expires in February 2021 (the &#x201c;Skokie Lease&#x201d;). In connection with the Company&#x2019;s relocation of its headquarters from Skokie, Illinois to its new facility in Chicago, Illinois on July 1, 2020, the Company determined that the remaining useful life of the operating lease asset underlying the Skokie Lease at June 30, 2020 was &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDIzMg_bc0ddf39-3aa8-49b3-b360-0d3d3fd3ba3d"&gt;zero&lt;/span&gt; and therefore recognized remaining amortization expense related to the Skokie Lease of $211 during the three months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Maturities of the Company&#x2019;s lease liability as of June 30, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:14pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.849%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.349%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Operating Leases &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-13.5pt;padding-left:13.5pt;margin-bottom:9pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)  &#160;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Excluded from the table above are the lease payments associated with the Chicago Lease that has not commenced as of the end of the period, which is July 1, 2020 (the date the asset was made available to the Company by the lessor).&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDI4OQ_3bd5722e-0919-479a-b036-068a668c81a5"
      unitRef="sqft">30000</xcur:LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="id642410749d845f68e04f5594e957ca4_I20200228"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMTY5OQ_6f8d6910-07de-4335-9b44-fa40fa64e8a6">P10Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions
      contextRef="id8e4fcd0750e4f00b604afc9f08aeaf4_D20200228-20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMTkyMw_e8e730f8-2b0d-4560-80d3-d89349ad25f6"
      unitRef="numberofperiods">2</xcur:LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="id642410749d845f68e04f5594e957ca4_I20200228"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMTk1OQ_af624e5e-9545-4d06-aca7-549d48945aef">P5Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths
      contextRef="id642410749d845f68e04f5594e957ca4_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjEwMw_f56eba44-e613-4ecd-af0f-840ddcb8049f"
      unitRef="usdPerSquarefeet">37.00</xcur:LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths
      contextRef="id642410749d845f68e04f5594e957ca4_I20200228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjE0OQ_8220b75e-4edf-4316-83fc-846c115e0a40"
      unitRef="usd">1113000</xcur:LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease
      contextRef="id642410749d845f68e04f5594e957ca4_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjMzOQ_57ae1c02-8676-4eb3-9cfd-bb5db53c5673"
      unitRef="number">0.03</xcur:LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm
      contextRef="id642410749d845f68e04f5594e957ca4_I20200228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjM3MA_bb292d35-b429-49b5-8c9c-f20e803ed686"
      unitRef="usd">12761000</xcur:LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement
      contextRef="id8e4fcd0750e4f00b604afc9f08aeaf4_D20200228-20200228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0NQ_b8d015b8-9574-4f34-9b1f-df762259f0d1"
      unitRef="usd">3159000</xcur:LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="id642410749d845f68e04f5594e957ca4_I20200228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjkxNQ_ea4cc07e-2834-4dda-86d5-5faa08d55227"
      unitRef="usd">1200000</us-gaap:LettersOfCreditOutstandingAmount>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement
      contextRef="id8e4fcd0750e4f00b604afc9f08aeaf4_D20200228-20200228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMzIwOQ_f2d13cfe-9287-4b94-b470-7c7ba6d4680d"
      unitRef="usd">87000</xcur:LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement>
    <xcur:LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfNzE0NjgyNTU5MDk3MA_4c48e25a-88ac-44d6-93d6-5f69b74c8be0"
      unitRef="usd">736000</xcur:LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="id642410749d845f68e04f5594e957ca4_I20200228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMzQ2Ng_7504be6d-6b65-4dfe-b761-f91b2e96d617"
      unitRef="usd">1200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfNjU5NzA2OTc3NjU2MA_306cdb4d-4fb4-4799-91be-5e73f8ce4290"
      unitRef="usd">211000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDI1MQ_0524692b-c790-4dbe-8419-8034ae3111a9">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Maturities of the Company&#x2019;s lease liability as of June 30, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:14pt;margin-bottom:14pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.849%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.349%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;Operating Leases &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-13.5pt;padding-left:13.5pt;margin-bottom:9pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)  &#160;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Excluded from the table above are the lease payments associated with the Chicago Lease that has not commenced as of the end of the period, which is July 1, 2020 (the date the asset was made available to the Company by the lessor).&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfMS0yLTEtMS0xMTE1_21d82471-cadc-4f41-971f-bf9fa69a3f6b"
      unitRef="usd">147000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfMi0yLTEtMS0xMTE1_0e8e2375-42d8-4116-965c-93d0ebfea6c8"
      unitRef="usd">59000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfNC0yLTEtMS0xMTE1_2d950ead-9476-42ae-a386-524c7e048354"
      unitRef="usd">206000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfNS0yLTEtMS0xMTE1_4fd1d4d5-ee68-49c4-9488-ec0c92b80ed4"
      unitRef="usd">10000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfNi0yLTEtMS0xMTE1_cf1d14fb-e7ae-4746-8851-00f2250c8b3f"
      unitRef="usd">196000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RhYmxlOmUyZTQ1YmY4ZWI5MzQ1ZDZiOTQzNDk0MzEzZGFmN2ZlL3RhYmxlcmFuZ2U6ZTJlNDViZjhlYjkzNDVkNmI5NDM0OTQzMTNkYWY3ZmVfOC0yLTEtMS0xMTE1_0aba786e-0bed-4bc3-a735-f62696a2e869"
      unitRef="usd">196000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjc0ODc3OTA3NDIyNw_81904baf-8dfd-4e2c-ae39-5a5984ebcf4a">Stockholders&#x2019; Equity&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2020 and December 31, 2019, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2020 and December 31, 2019, the Company had authorized 200,000,000 shares of common stock, par value $0.0001.  As of June 30, 2020 and December 31, 2019, the Company had 87,206,346  shares and 86,069,263 shares issued and outstanding, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The holders of shares of the Company&#x2019;s common stock are entitled to one vote per share on all matters to be voted upon by the Company&#x2019;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#x2019;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Company&#x2019;s Board out of funds legally available for that purpose. In the event of the Company&#x2019;s liquidation, dissolution or winding up, the holders of shares of the Company&#x2019;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#x2019;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#x2019;s common stock. The outstanding shares of the Company&#x2019;s common stock are fully paid and&#160;non-assessable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;December 2019 Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 23, 2019, the Company sold 10,000,000 shares of its common stock at the public offering price of $2.75 per share in an underwritten public offering, for gross proceeds of $27,500 and estimated net proceeds of $25,344 after deducting underwriting discounts and commission and other offering expenses payable by the Company (the &#x201c;December 2019 Offering&#x201d;).  In addition, the Company granted the underwriters a 30-day option to purchase an additional 1,500,000 shares of common stock offered in the common stock offering. On January 6, 2020, the underwriters partially exercised the option to purchase an additional 1,081,184 shares of common stock at the public offering price of $2.75 per share for additional gross proceeds of $2,973 and net proceeds of $2,766 after deducting underwriting discounts and commission and other offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The shares sold in the December 2019 Offering were sold pursuant to a registration statement on Form S-3 that was declared effective by the SEC on July 24, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; As of June 30 2020, warrants to purchase 413,320 shares of common stock at a price of&#160;$3.00&#160;per share remain outstanding.  The Warrants expire as follows: 163,174 warrants expire on March 27, 2021; 132,884 expire on April 28, 2021; and 117,262 expire on May 3, 2021.  The Warrants are classified as a liability which is remeasured each period at fair value. See Note 12,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;for more information on the fair value of the common stock warrant liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.854%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.857%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The net loss reclassified from accumulated other comprehensive loss resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $23 and $6, respectively, for the three months ended June 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $9,404.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTA1_471993cc-ba0a-4797-bd45-2de7bc30d43f"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTA1_785301a1-9902-4a74-b9a6-279862db99d7"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTQ1_9c29255f-4d9e-4214-ac46-0457d32176cb"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTQ1_e077f277-8562-4119-8f48-90554dde46a3"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYz_487bfebd-0f01-41be-aac7-c36eacd28ed1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYz_558a2f9a-cf09-4664-9c30-1c8a3ed80a08"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYz_758cefc3-8f8c-464b-bc69-40a08724df8b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYz_97a640f0-05a7-4c78-8ab9-47870ae70f98"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjgx_bc1361a9-1e71-4b6f-9bb2-0fa0c3e5d806"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjgx_f63ba504-9689-4c0b-992b-1dbef6acac5d"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzE4_748b1340-adb0-47fc-949f-c4c6a39dc8c2"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzE4_81491800-a803-4227-9118-a149c69ae3eb"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfNzE0NjgyNTU4MzczOA_3276140d-d702-40ab-8d76-f43e94787a93"
      unitRef="shares">87206346</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfNzE0NjgyNTU4MzczOA_e532b872-23a1-47af-bb70-bfc64e1d1d43"
      unitRef="shares">87206346</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzk4_67f9c638-bbb6-45b1-bdbf-594d69d6ba15"
      unitRef="shares">86069263</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzk4_bf428cb2-8c21-42e0-970b-340f08c134f2"
      unitRef="shares">86069263</us-gaap:CommonStockSharesOutstanding>
    <xcur:CommonStockVotingRightsforEachShare
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzI5ODUzNDg4NjQ0OA_6277d836-1e2c-4a4c-aa30-88830f773de2"
      unitRef="vote_per_share">1</xcur:CommonStockVotingRightsforEachShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTU0Mg_f0fa44d0-8679-4b4a-9dae-fd59f7e1655a"
      unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i4be9f363b86d4627be1d61061c00986b_I20191223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTYwNA_28f9a406-913e-44bd-ad4b-492ee1db33fb"
      unitRef="usdPerShare">2.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTY3NQ_395b25d6-c0fe-473d-bfdf-2d83468f1aa1"
      unitRef="usd">27500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <xcur:ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses
      contextRef="i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTcwOA_57682cd8-70e6-4d3a-ac9a-e5ce84446718"
      unitRef="usd">25344000</xcur:ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia2cea85073354474aa680437e75f26a7_D20191223-20191223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMTk0MQ_22a86193-4a5b-446f-9be7-e78ef7596aa6"
      unitRef="shares">1500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icfa443308cf5477596e1014cee13ebba_D20200106-20200106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjA5OQ_7e2ec339-7ad5-4d53-a944-01734d36630e"
      unitRef="shares">1081184</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i4be9f363b86d4627be1d61061c00986b_I20191223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjE1Nw_28f9a406-913e-44bd-ad4b-492ee1db33fb"
      unitRef="usdPerShare">2.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icfa443308cf5477596e1014cee13ebba_D20200106-20200106"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjIwMw_9e1ef977-2016-4d48-a878-2b80afccef66"
      unitRef="usd">2973000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <xcur:ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses
      contextRef="icfa443308cf5477596e1014cee13ebba_D20200106-20200106"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjIyNg_d4979f70-faf6-410a-a55c-a4d74dc78490"
      unitRef="usd">2766000</xcur:ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ic86b7ec9cc274bf8af157b6700465ac9_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjU0MA_f7e740c8-7512-4bab-97d6-a1eb976b3ce7"
      unitRef="shares">413320</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzI5ODUzNDg4NjQ1OQ_0afa2aa4-c6a3-4127-b0ca-7f664c178d78"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xcur:ClassofWarrantorRightExpired
      contextRef="i164e4b30480d4e978a2812a8cd07749a_I20210327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjY0Ng_b1bbf427-8227-4e71-b8f8-62bfe6d4a802"
      unitRef="shares">163174</xcur:ClassofWarrantorRightExpired>
    <xcur:ClassofWarrantorRightExpired
      contextRef="i4fde2bf7394d44a09eddfef7c0f06b5a_I20210428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjY4NA_0e39e186-298e-45e4-a0ec-96f702e659bb"
      unitRef="shares">132884</xcur:ClassofWarrantorRightExpired>
    <xcur:ClassofWarrantorRightExpired
      contextRef="i7fb9e0113525465fa92492e072f0e43e_I20210503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMjcxNw_1323fcf5-5d5f-4593-a953-faa6e3c623d0"
      unitRef="shares">117262</xcur:ClassofWarrantorRightExpired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfMzExNQ_f8078312-5a3c-4c08-9be8-29fcb64efd9b">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.469%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.854%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.857%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i9c03ff4e8b5c4b699019abb27907654d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMS0yLTEtMS0w_0930064b-f431-4ea1-96fb-69d479fe3926"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a2b6489ddf141a7bf39c57e8c6c374d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMS00LTEtMS0w_9b1595e2-b836-4fce-8ad4-02d0f951bde1"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ib61094c0deb84e1bbf2fd681155a9f0c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMi0yLTEtMS0w_9fc11fc6-353d-45ab-bde6-45cbe358b272"
      unitRef="usd">10000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="iffcf7f98338c48b2a74d5c64bcbb09cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMi00LTEtMS0w_5133597d-b9f2-4bbc-9b99-201d6e5b3788"
      unitRef="usd">10000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib61094c0deb84e1bbf2fd681155a9f0c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMy0yLTEtMS0w_35c086c6-5e52-4452-8651-d528a96f7bba"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iffcf7f98338c48b2a74d5c64bcbb09cf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfMy00LTEtMS0w_86d7fb85-7df8-49b0-919e-787a533db88b"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i63f9fe0651d84de1b85aafe4a8643eec_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNC0yLTEtMS0w_d1e52c4a-24b0-41e2-a239-2344496e1a8a"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i346241752b2b49a69f5d211b6a9d45fd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNC00LTEtMS0w_68784d2e-e399-44f4-ab40-051086148716"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ic6eadd66fe2e43af9a25c3f417c84b26_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNS0yLTEtMS0xMzM1_4c622706-d500-4e54-a59e-2604860e683e"
      unitRef="usd">352000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNS00LTEtMS0xMzM1_521fd628-b712-4a5b-9995-1d81ae5eb7a4"
      unitRef="usd">352000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ic6eadd66fe2e43af9a25c3f417c84b26_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNi0yLTEtMS0yNjI5_5771663a-5ce6-4f0a-9178-2c4435ab5c50"
      unitRef="usd">-3000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNi00LTEtMS0yNjM2_7a90c008-6740-4003-b496-32b801c25ee9"
      unitRef="usd">-3000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic6eadd66fe2e43af9a25c3f417c84b26_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNi0yLTEtMS0xMzM1_8e5223e8-c261-4e83-a8b7-6e49d012274b"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0cb8a81d82ed44afba0b862817eddc29_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNi00LTEtMS0xMzM1_139033e8-f4d5-4697-b13d-a53a48b005c8"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="ib5d6effdfbf94d41a083294b170f3969_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNy0yLTEtMS0xMzM1_ea7c1e41-7582-486f-ab48-6bbb0333aa6d"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0ac35850023477bb1b027d27cf6499d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RhYmxlOjc5N2M4MWM4NzQ3MTQzNDNiM2I1YWIwYzVmNzVhNGYyL3RhYmxlcmFuZ2U6Nzk3YzgxYzg3NDcxNDM0M2IzYjVhYjBjNWY3NWE0ZjJfNy00LTEtMS0xMzM1_bc4273f8-17cd-4edd-9b9a-0596a9bad315"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfODc5NjA5MzAyNjk2Nw_90d617c2-a6e5-4d76-81d5-f79ee7e19349"
      unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfODc5NjA5MzAyNjk3NA_8f635784-5256-4d03-83ba-ffafa7281896"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV82NC9mcmFnOmUxMjk5NDYwY2U3MDQ2NGFiYTYyNmUxNGIzZGVjNGUyL3RleHRyZWdpb246ZTEyOTk0NjBjZTcwNDY0YWJhNjI2ZTE0YjNkZWM0ZTJfODc5NjA5MzAyNjk4NQ_d408a061-1737-4e14-9327-dac84ad9f795"
      unitRef="usd">9404000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjk3NA_ecd8d721-4f93-421a-b7e8-d8d74f600c83">Equity-Based Compensation&lt;div style="text-indent:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 4,600,000 shares, (ii) 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Company&#x2019;s Board. The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by 4,303,463 shares, effective January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2020, the aggregate number of common stock options available for grant under the 2017 Equity Incentive Plan was 2,283,019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:17pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unamortized equity-based compensation expense at June 30, 2020 was $4,893, which is expected to be amortized over a weighted-average period of 2.9 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.493%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.352%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.354%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.2 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.3 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.41% to 1.68%; weighted avg. 0.67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.86% to 2.56%; weighted avg. 2.34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;81.0% to 85.8%; weighted avg. 83.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;83.2% to 86.7%; weighted avg. 84.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The expected term is based upon the &#x201c;simplified method&#x201d; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#x201c;simplified method&#x201d; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2020 and 2019 are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.348%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.350%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common Stock Options Granted During Period Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value of Underlying Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise Price of Common Stock Option&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.19 to $2.80; weighted avg. $1.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.19 to $2.80; weighted avg. $1.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$2.78 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;weighted avg. $2.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$2.78 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;weighted avg. $2.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted-average grant date fair value of common stock options granted in the six months ended June 30, 2020 and 2019 was $1.29 and $1.99 per common stock option, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding - December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,697,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,075,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(55,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding - June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,698,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable - June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,372,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and Expected to Vest -&lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,442,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares
      contextRef="ibebc8ba07dd245ff97b780fc24472240_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjMy_8e881f03-4d99-4a1b-b5b5-2fda240ccfcf"
      unitRef="shares">4600000</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding
      contextRef="i87bbbbbd85fc49b8852959fd449af5cf_I20200101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjQ4_0fb505ac-4f76-42c0-b8e0-fb16ab31c3eb"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9527a967dad3415598f73d2c86f453fc_I20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfNTc5_281c2914-6bfe-4496-9451-6b8ccc840bc4"
      unitRef="shares">4303463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6b932d51abde4221b44077fb53a41b3b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfNzQ1_8c002076-b427-4621-a5e5-547efbdeeba0"
      unitRef="shares">2283019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjk3NQ_e1b82a84-a2d6-44e7-b6bb-76a57d4c7b3d">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:17pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53eada77c822436c8d20ad774d619503_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMi0xLTEtMS0w_63679f24-7681-48bd-94b9-95d823e9b223"
      unitRef="usd">203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifbfbd26204cc426c8a8cf03400f66926_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMi0zLTEtMS0w_0513d2a8-89ed-4298-8fee-a313fc9ed08d"
      unitRef="usd">103000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7040eb168bef4211b4772b89a21e6728_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMi01LTEtMS0w_8f7f29ff-41f0-40ad-b3d9-2686183ba1b1"
      unitRef="usd">360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e1913cdd58d478da612d3f93c8f7a38_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMi03LTEtMS0w_1af40ab6-a3d7-4459-b39d-aa160b78b567"
      unitRef="usd">224000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb6b302afc2b47db9a9b8aa6e84aac60_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMy0xLTEtMS0w_190b52cb-302e-4466-9351-97860691ca3d"
      unitRef="usd">341000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5bdba642bc224cb9b89f1de3feabde3e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMy0zLTEtMS0w_e821d481-7801-4ab4-86f5-9732d16bb3de"
      unitRef="usd">336000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4aec036201f748fd8269f237b2461bcc_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMy01LTEtMS0w_2f99f1e0-1ad6-48cd-8e74-498dfdf8fca4"
      unitRef="usd">625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7e189a56ebb44a6ba95910fba45564d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfMy03LTEtMS0w_c02c1745-d34e-46ea-b810-3e81e43c9468"
      unitRef="usd">704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfNC0xLTEtMS0w_d45a1c16-807d-4e77-b9a3-af8209075816"
      unitRef="usd">544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfNC0zLTEtMS0w_78f135c2-a7cf-494d-b6b8-8a2dd542baac"
      unitRef="usd">439000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfNC01LTEtMS0w_e7ac93fc-3cf0-41ff-9fe6-6ff3bf4a8da0"
      unitRef="usd">985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjZjNzRiNzZlZWQ3ZjQzOWNiZjg2ZDlkMzk1M2UyZWI0L3RhYmxlcmFuZ2U6NmM3NGI3NmVlZDdmNDM5Y2JmODZkOWQzOTUzZTJlYjRfNC03LTEtMS0w_83c604f4-f716-46b7-85ac-77fa78ceacb5"
      unitRef="usd">928000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfOTEx_32094946-e04c-49f2-8f85-0a5aa92e9990"
      unitRef="usd">4893000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjc0ODc3OTA3MjUwNQ_c3d55d3d-b86c-48ab-952e-b46490565b1b">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjk3MA_6681f1bf-6cb4-4c81-8e8d-f1e6475606aa">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.493%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.352%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.354%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.2 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;5.3 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;0.41% to 1.68%; weighted avg. 0.67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1.86% to 2.56%; weighted avg. 2.34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;81.0% to 85.8%; weighted avg. 83.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;83.2% to 86.7%; weighted avg. 84.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2020 and 2019 are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:54.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.348%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.602%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.350%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common Stock Options Granted During Period Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value of Underlying Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise Price of Common Stock Option&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.19 to $2.80; weighted avg. $1.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.19 to $2.80; weighted avg. $1.85&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$2.78 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;weighted avg. $2.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$2.78 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;weighted avg. $2.79&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1e9583ff1ce6495cb0331d2a1569e1b0_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMi0xLTEtMS0wL3RleHRyZWdpb246ZGE5ZDcxZWYwMTFlNDhhZDgwMWJkNGJiOWMyNjI3NDZfMjc0ODc3OTA2OTQ2Mw_ebaf1c08-006c-47e0-9c9d-70a1d986267f">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib66e2fa725c1452382443738ad2ef816_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMi0xLTEtMS0wL3RleHRyZWdpb246ZGE5ZDcxZWYwMTFlNDhhZDgwMWJkNGJiOWMyNjI3NDZfMjc0ODc3OTA2OTQ2OQ_853641c7-9af6-4f2b-ac09-f2ed1721f4ff">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6091d038421c443d91771f31d4e2744c_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMi0zLTEtMS0wL3RleHRyZWdpb246MWQ0MjkzZTA4MDg0NDNmZjg4MDFhYmFiMDcwNTFkOTlfMjc0ODc3OTA2OTQ2Mw_6a6cbf0c-0ddd-4d6b-9ac0-c2866f9c3bad">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8ff390c5c87441f5a73f86f5f1529e92_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMi0zLTEtMS0wL3RleHRyZWdpb246MWQ0MjkzZTA4MDg0NDNmZjg4MDFhYmFiMDcwNTFkOTlfMjc0ODc3OTA2OTQ2OA_e2d41f01-5288-45e9-90d7-e647e5e0baec">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1e9583ff1ce6495cb0331d2a1569e1b0_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0xLTEtMS0wL3RleHRyZWdpb246ZDg3MmMwMjJjMDVjNDljYzgwMWVhYTVmNGFjMzE2YTJfMjc0ODc3OTA2OTQ4NA_a000ef67-96b9-45c7-bc73-19fbf8d578b6"
      unitRef="number">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib66e2fa725c1452382443738ad2ef816_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0xLTEtMS0wL3RleHRyZWdpb246ZDg3MmMwMjJjMDVjNDljYzgwMWVhYTVmNGFjMzE2YTJfMjc0ODc3OTA2OTUwMQ_7d241415-543c-438a-9700-99d7cb80e7ac"
      unitRef="number">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6b7e6c0acc9b4b93871186f77defb445_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0xLTEtMS0wL3RleHRyZWdpb246ZDg3MmMwMjJjMDVjNDljYzgwMWVhYTVmNGFjMzE2YTJfMjc0ODc3OTA2OTUwOA_03acc9b1-181e-401f-a320-1a817238e410"
      unitRef="number">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6091d038421c443d91771f31d4e2744c_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0zLTEtMS0wL3RleHRyZWdpb246ZjgyOTI2NjdiYzk5NDY4NmFjN2NiYWMxNDQyOThlZTVfMjc0ODc3OTA2OTQ4NA_343871be-e85d-4be8-bcc8-233c9b0b236a"
      unitRef="number">0.000186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8ff390c5c87441f5a73f86f5f1529e92_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0zLTEtMS0wL3RleHRyZWdpb246ZjgyOTI2NjdiYzk5NDY4NmFjN2NiYWMxNDQyOThlZTVfMjc0ODc3OTA2OTQ5MQ_1fd717ac-8278-4be0-b381-1e55e30c77a0"
      unitRef="number">0.000256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iaa95d698f7954c17a13d43f11eded42c_D20190101-20190630"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfMy0zLTEtMS0wL3RleHRyZWdpb246ZjgyOTI2NjdiYzk5NDY4NmFjN2NiYWMxNDQyOThlZTVfMjc0ODc3OTA2OTQ5OA_04046f59-36e5-430d-ac8d-ba303595efb7"
      unitRef="number">0.000234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1e9583ff1ce6495cb0331d2a1569e1b0_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0xLTEtMS0wL3RleHRyZWdpb246OTZiZDYyMGNhY2JmNDhmMTkwMDE0MmZlOWE1YmJhNzdfMjc0ODc3OTA2OTQ4NA_095db685-a3e7-47a7-ad1d-74455008239f"
      unitRef="number">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib66e2fa725c1452382443738ad2ef816_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0xLTEtMS0wL3RleHRyZWdpb246OTZiZDYyMGNhY2JmNDhmMTkwMDE0MmZlOWE1YmJhNzdfMjc0ODc3OTA2OTQ5MQ_55fda61f-9ddc-40c6-bd6e-08d7ca681c70"
      unitRef="number">0.858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6b7e6c0acc9b4b93871186f77defb445_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0xLTEtMS0wL3RleHRyZWdpb246OTZiZDYyMGNhY2JmNDhmMTkwMDE0MmZlOWE1YmJhNzdfMjc0ODc3OTA2OTQ5OQ_a708bcef-a1f1-45a7-80e8-ba9e400e4336"
      unitRef="number">0.838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6091d038421c443d91771f31d4e2744c_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0zLTEtMS0wL3RleHRyZWdpb246ZmE4NGM1MDhlMzhmNDQyZDhlZDUzMWIyZTgwMDRiZWZfMjc0ODc3OTA2OTQ4NA_a91e34a0-0d7a-451d-9efc-2d570b7a92aa"
      unitRef="number">0.00832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8ff390c5c87441f5a73f86f5f1529e92_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0zLTEtMS0wL3RleHRyZWdpb246ZmE4NGM1MDhlMzhmNDQyZDhlZDUzMWIyZTgwMDRiZWZfMjc0ODc3OTA2OTQ5MQ_6ee7e4be-225f-417e-af61-bc1605956a62"
      unitRef="number">0.00867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iaa95d698f7954c17a13d43f11eded42c_D20190101-20190630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNC0zLTEtMS0wL3RleHRyZWdpb246ZmE4NGM1MDhlMzhmNDQyZDhlZDUzMWIyZTgwMDRiZWZfMjc0ODc3OTA2OTQ5OA_e94968ee-762d-4b74-8740-d05318707914"
      unitRef="number">0.00844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNS0xLTEtMS0w_e9d0ae0c-30e7-4ed3-8584-47366d5d2417"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNS0zLTEtMS0w_6b943bbf-eaa9-4e15-9ce9-bf52a2336865"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNi0xLTEtMS0w_1c0f1f12-438b-4b8f-9e9a-6b9e2bba312f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjRmOGY3ZGFjNWVhYzRlMjFiZDc2OThlYTBlYzZkZjU3L3RhYmxlcmFuZ2U6NGY4ZjdkYWM1ZWFjNGUyMWJkNzY5OGVhMGVjNmRmNTdfNi0zLTEtMS0w_1650fa43-abed-4617-aec9-6564ec3779e4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="i0b30acdba4af4f89add54dddf14c23da_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0xLTEtMS0wL3RleHRyZWdpb246ZjdlNzhlZDlkNjJlNDk4ZGI3MWU3MmZhOWQ2Yzk0YWJfMjc0ODc3OTA2OTQ4NA_d5d8e33b-b112-47cc-ad32-36e7b50d7466"
      unitRef="usdPerShare">1.19</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ie283a4656c2e4cdaa3544e7bf804c7f9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0xLTEtMS0wL3RleHRyZWdpb246ZjdlNzhlZDlkNjJlNDk4ZGI3MWU3MmZhOWQ2Yzk0YWJfMjc0ODc3OTA2OTQ5MA_0d0299af-0673-4752-bd27-bb689556ac5c"
      unitRef="usdPerShare">2.80</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i75055b5483aa4b45aa64e739ee644b07_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0xLTEtMS0wL3RleHRyZWdpb246ZjdlNzhlZDlkNjJlNDk4ZGI3MWU3MmZhOWQ2Yzk0YWJfMjc0ODc3OTA2OTUwMA_22476b94-37e0-48a6-a37f-8eac1870df20"
      unitRef="usdPerShare">1.85</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i0b30acdba4af4f89add54dddf14c23da_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0zLTEtMS0wL3RleHRyZWdpb246YWM5MTFkYjI3ZTg5NDNjNGJkMjM2ZjllZDIzMTFmZWRfMjc0ODc3OTA2OTQ4NA_615ededa-5dfc-4001-9cb6-185654357f78"
      unitRef="usdPerShare">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ie283a4656c2e4cdaa3544e7bf804c7f9_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0zLTEtMS0wL3RleHRyZWdpb246YWM5MTFkYjI3ZTg5NDNjNGJkMjM2ZjllZDIzMTFmZWRfMjc0ODc3OTA2OTQ4OQ_8f73c740-da95-46c3-a990-79f2285c22fd"
      unitRef="usdPerShare">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i75055b5483aa4b45aa64e739ee644b07_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMS0zLTEtMS0wL3RleHRyZWdpb246YWM5MTFkYjI3ZTg5NDNjNGJkMjM2ZjllZDIzMTFmZWRfMjc0ODc3OTA2OTQ5OQ_a56c8b80-a5ee-442e-a7d1-b83520d3bbbb"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="ic9c0c8245bda4b29885459d2a7e6d51f_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0xLTEtMS0wL3RleHRyZWdpb246YTBiYmUyYzUxNjNkNDFjZTk3ZDI1Y2M2NzNjY2QxNmJfMjc0ODc3OTA2OTQ4Mw_6307e23b-c725-41b1-8bf2-46a90b314fcb"
      unitRef="usdPerShare">2.78</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ib3ade10577cb447f84773dd52aecc06c_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0xLTEtMS0wL3RleHRyZWdpb246YTBiYmUyYzUxNjNkNDFjZTk3ZDI1Y2M2NzNjY2QxNmJfMjc0ODc3OTA2OTQ5MA_0a388ed3-641a-4363-9ff2-95b8b93c53dd"
      unitRef="usdPerShare">2.80</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i33522e08954144b987a6d23ea7b62c6b_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0xLTEtMS0wL3RleHRyZWdpb246YTBiYmUyYzUxNjNkNDFjZTk3ZDI1Y2M2NzNjY2QxNmJfMjc0ODc3OTA2OTQ5Ng_79781aa8-2fba-4964-b67c-00af05cf005f"
      unitRef="usdPerShare">2.79</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ic9c0c8245bda4b29885459d2a7e6d51f_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0zLTEtMS0wL3RleHRyZWdpb246MzlmOWZhZjhiZWQyNGU0YTkyNjU2MDU3OWQ3NGZhM2ZfMjc0ODc3OTA2OTQ4Mw_4570b37b-ce62-48a4-bfe6-1cedbf24a186"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ib3ade10577cb447f84773dd52aecc06c_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0zLTEtMS0wL3RleHRyZWdpb246MzlmOWZhZjhiZWQyNGU0YTkyNjU2MDU3OWQ3NGZhM2ZfMjc0ODc3OTA2OTQ5MA_d31ac6c5-daca-40a9-8cb1-6cbd8fd80840"
      unitRef="usdPerShare">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i33522e08954144b987a6d23ea7b62c6b_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOmQ1NmE0ZTUwYzZiZTQ4YmQ5MjU5NzJjNGM2ZjljZDRkL3RhYmxlcmFuZ2U6ZDU2YTRlNTBjNmJlNDhiZDkyNTk3MmM0YzZmOWNkNGRfMi0zLTEtMS0wL3RleHRyZWdpb246MzlmOWZhZjhiZWQyNGU0YTkyNjU2MDU3OWQ3NGZhM2ZfMjc0ODc3OTA2OTQ5Ng_3c6c3868-4859-41b1-a52a-7fa9fd82f7bf"
      unitRef="usdPerShare">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjgyOQ_2f942cc4-6e9d-4073-8973-4bced63ac3cc"
      unitRef="usdPerShare">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjgzNg_8ee5ac58-b1e0-4906-86b9-8d1500da5404"
      unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfMjk3Mw_ce363963-7455-4626-b7c8-cc1657301a27">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.826%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.942%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.945%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding - December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,697,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,075,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(55,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(18,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding - June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,698,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable - June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,372,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and Expected to Vest -&lt;br/&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,442,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMS0xLTEtMS0w_6161519a-cf09-4328-a50e-2ba25c9d1398"
      unitRef="shares">5697714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMS0zLTEtMS0w_f9d8fed9-0f24-4580-8286-6e4853821abe"
      unitRef="usdPerShare">2.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3ce249e9e67f47b1986e46049614d74e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMS01LTEtMS0w_b13ed066-b85a-469c-8d95-0aa5ddb6dfcf">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i4340bc2a3caf476e9ea1655692119072_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMS03LTEtMS0w_57a7b233-cc41-4c4b-8d7f-95ea5d7d898a"
      unitRef="usd">4625000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMi0xLTEtMS0w_c3a79cc5-6932-492a-9157-4fda1a8f6832"
      unitRef="shares">2075248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMi0zLTEtMS0w_bb426894-b8e0-41b6-873b-d7f0b6808aaa"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMy0xLTEtMS0w_e23f2160-f331-4c8c-a397-44fae53301d5"
      unitRef="shares">55899</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfMy0zLTEtMS0w_48767d30-7256-465e-ac03-4a18528ba276"
      unitRef="usdPerShare">0.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNC0xLTEtMS0w_8b929286-b7e3-4103-b17e-80fd46d55080"
      unitRef="shares">18750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNC0zLTEtMS0w_6b047a3b-1bec-4342-b930-abc2aae191f0"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNS0xLTEtMS0w_a4af8871-2621-4363-812c-bbc58362ba48"
      unitRef="shares">7698313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNS0zLTEtMS0w_70afbed9-b998-40bf-b8d2-cd8b05b1a84a"
      unitRef="usdPerShare">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNS01LTEtMS0w_32133008-f376-4599-977e-390eef548573">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNS03LTEtMS0w_1af860a7-b395-4bc5-b446-efcd9ede5147"
      unitRef="usd">4738000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNi0xLTEtMS0w_4b2a441c-7c95-4142-9df3-aeb6c92c3f2c"
      unitRef="shares">4372185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNi0zLTEtMS0w_5548f52c-b6d6-4cd6-8963-a267df771e32"
      unitRef="usdPerShare">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNi01LTEtMS0w_2643c8c5-6c0e-4e8d-981f-580bb5d12b0c">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNi03LTEtMS0w_be5caff2-79a2-465c-867b-d3286b51e0aa"
      unitRef="usd">3351000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNy0xLTEtMS0w_277bad4d-f4e5-4b3f-b469-7d318b9e0c18"
      unitRef="shares">7442992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNy0zLTEtMS0w_d2129076-113b-4643-9e0d-5f3d7cb00adf"
      unitRef="usdPerShare">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNy01LTEtMS0w_1de92007-73ea-4f80-836a-a4c6c7c04c0a">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i738818d3ada14fb59ae41e5c0547ff93_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RhYmxlOjhlYjA1NzRhZmYwMDQ4MzNiMzhiYWVhZTU0YjBmNTY0L3RhYmxlcmFuZ2U6OGViMDU3NGFmZjAwNDgzM2IzOGJhZWFlNTRiMGY1NjRfNy03LTEtMS0w_dca22c76-5812-46a7-b8ca-736feecec673"
      unitRef="usd">4613000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfNjU5NzA2OTc3MDEzNg_0cea14ae-142a-4f66-91e7-c564bfc5892f"
      unitRef="usd">89000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83MC9mcmFnOjIyYjNlZGNhOGU1MjQ2N2FhN2ZjZmY5MTJiZDhjNmY3L3RleHRyZWdpb246MjJiM2VkY2E4ZTUyNDY3YWE3ZmNmZjkxMmJkOGM2ZjdfNjU5NzA2OTc3MDE0Mg_3499e7a2-3fe6-49d7-8268-12314933c7a7"
      unitRef="usd">17000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83Ni9mcmFnOmE5NWQ2Y2U1NjQ3NzRmMDY4NGRlZDJlMWUzMzgxNzAzL3RleHRyZWdpb246YTk1ZDZjZTU2NDc3NGYwNjg0ZGVkMmUxZTMzODE3MDNfMjc0ODc3OTA3MjMwOA_996ed796-34a6-4610-b9fe-5836c082c135">Income TaxesThe Company incurred a pretax loss in each of the three and six months ended June 30, 2020 and 2019, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended.  The effective tax rate is 0% in each of the three and six months ended June 30, 2020 and 2019 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;). The CARES Act, among other things, allows for a five-year carry back of federal net operating losses generated in 2018 through 2020 and removes the 80% taxable income limitation for net operating loss deductions for tax years ending before 2021.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83Ni9mcmFnOmE5NWQ2Y2U1NjQ3NzRmMDY4NGRlZDJlMWUzMzgxNzAzL3RleHRyZWdpb246YTk1ZDZjZTU2NDc3NGYwNjg0ZGVkMmUxZTMzODE3MDNfNTIx_6306d225-3f37-4d0f-8269-de91129e0e57"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV83Ni9mcmFnOmE5NWQ2Y2U1NjQ3NzRmMDY4NGRlZDJlMWUzMzgxNzAzL3RleHRyZWdpb246YTk1ZDZjZTU2NDc3NGYwNjg0ZGVkMmUxZTMzODE3MDNfNTIx_f6f9f734-e138-4929-a25c-7358d8ca0bd5"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RleHRyZWdpb246MmUwZjRhZGUyMTUwNDE5Yzg2YWUxODQ5NzgxZTdlMTBfMzI5ODUzNDg4NDU0MA_c31b1964-6812-4d22-91a7-364f49e26e01">Loss Per Common ShareBasic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the &lt;div style="margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and six months ended June 30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is the computation of loss per common share for the three and six months ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.142%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.911%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average basic and diluted common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,174,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,368,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,126,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,363,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The outstanding securities presented below were excluded from the calculation of loss per common share for the periods presented, because such securities would have been anti-dilutive due to the Company&#x2019;s loss per share during that period:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.082%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.054%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.607%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.057%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;As of June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,698,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,078,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;413,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;413,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RleHRyZWdpb246MmUwZjRhZGUyMTUwNDE5Yzg2YWUxODQ5NzgxZTdlMTBfMTIwNQ_c48b1e7e-4346-416e-a083-0fbc628a0142">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RleHRyZWdpb246MmUwZjRhZGUyMTUwNDE5Yzg2YWUxODQ5NzgxZTdlMTBfMTIxMA_f6f68ed6-5ded-4de0-a0fa-a368511f94bc">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is the computation of loss per common share for the three and six months ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.142%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.908%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.541%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.911%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average basic and diluted common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,174,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,368,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,126,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,363,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Basic and diluted loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfMi0xLTEtMS0w_8dcc1af1-4fca-4e49-9107-c52ceea49165"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfMi0zLTEtMS0w_ec32a994-75b4-4a46-af47-b966ba32c43f"
      unitRef="usd">-5220000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfMi01LTEtMS0w_cbb955c4-d182-4a13-8a74-b0876726940e"
      unitRef="usd">-3161000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfMi03LTEtMS0w_41b0fe9b-7153-483a-a4ed-2214ba20a4e6"
      unitRef="usd">-10506000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfNC0xLTEtMS0w_6d1b2e7e-a2c4-443e-9f1f-dc615a8f85f3"
      unitRef="shares">87174533</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfNC0zLTEtMS0w_a3697f8a-3640-4b3c-b852-9ba91ac8fbe7"
      unitRef="shares">44368174</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfNC01LTEtMS04MjA_6c85577f-d14b-4112-b6b9-19e0e078c006"
      unitRef="shares">87126847</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfNC03LTEtMS04MjA_04e67d21-fb23-4d51-bda6-44fc4a09bf5b"
      unitRef="shares">44363115</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i412f9837f22b489aafc44692b0c1aada_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfOC0xLTEtMS0w_2280e16f-c71e-4951-9be0-43252cabeee6"
      unitRef="usdPerShare">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1e81cc37885946329de84c2812052368_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfOC0zLTEtMS0w_c587e538-b4c0-430c-9b3d-e59fc5acd6e9"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfOC01LTEtMS04MDg_7c389b82-cf7f-4aa0-859f-52b7240005eb"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0561748f81354564b2005d72c36f00ac_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwZWRlZWNhMjVhNTRiYjNhNDY3ZjZjMDQyNDg5MTQzL3RhYmxlcmFuZ2U6YjBlZGVlY2EyNWE1NGJiM2E0NjdmNmMwNDI0ODkxNDNfOC03LTEtMS04MDg_c8be8e55-066a-4c25-8382-450ea2623a7a"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RleHRyZWdpb246MmUwZjRhZGUyMTUwNDE5Yzg2YWUxODQ5NzgxZTdlMTBfMzI5ODUzNDg4NDU0MQ_f39aee6c-22aa-4327-9a62-b45125938507">&lt;div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The outstanding securities presented below were excluded from the calculation of loss per common share for the periods presented, because such securities would have been anti-dilutive due to the Company&#x2019;s loss per share during that period:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.082%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.054%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.607%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.057%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;"&gt;As of June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,698,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,078,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;413,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;413,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9736fd4b7b724ef987739ec27346148b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwYjU0NjE4ZjU4OTQwNWI5ZjQzZGU0ODllMTdjMmM2L3RhYmxlcmFuZ2U6YjBiNTQ2MThmNTg5NDA1YjlmNDNkZTQ4OWUxN2MyYzZfMi0xLTEtMS0w_b95bd4f3-4cea-4a2e-828c-34675734f032"
      unitRef="shares">7698313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib7685322cfa540bbb195c55945e40155_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwYjU0NjE4ZjU4OTQwNWI5ZjQzZGU0ODllMTdjMmM2L3RhYmxlcmFuZ2U6YjBiNTQ2MThmNTg5NDA1YjlmNDNkZTQ4OWUxN2MyYzZfMi0zLTEtMS0w_de9f9565-a8ba-46fe-984d-6f90f8c51792"
      unitRef="shares">5078873</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4d810f21c820439283d2493920890171_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwYjU0NjE4ZjU4OTQwNWI5ZjQzZGU0ODllMTdjMmM2L3RhYmxlcmFuZ2U6YjBiNTQ2MThmNTg5NDA1YjlmNDNkZTQ4OWUxN2MyYzZfMy0xLTEtMS0w_9bdbf203-ae9a-4bcd-a9cc-a6bd5afa9d6b"
      unitRef="shares">413320</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie32d42b33c7f4559bb28b9b2c085cd77_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84Mi9mcmFnOjJlMGY0YWRlMjE1MDQxOWM4NmFlMTg0OTc4MWU3ZTEwL3RhYmxlOmIwYjU0NjE4ZjU4OTQwNWI5ZjQzZGU0ODllMTdjMmM2L3RhYmxlcmFuZ2U6YjBiNTQ2MThmNTg5NDA1YjlmNDNkZTQ4OWUxN2MyYzZfMy0zLTEtMS0w_85cf90f7-ed4c-40bf-a638-868516909d0e"
      unitRef="shares">413320</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjUyNA_d805a2f9-c7f0-4014-86b3-29a1e3838ee3">Fair Value Measurements&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.955%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.628%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.937%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.011%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.937%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.184%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.283%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.665%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.460%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s common stock warrant liability (refer to Note 8, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, for more information) is classified within Level 3 of the fair value hierarchy.  The fair value of the common stock warrant liability was determined using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the common stock warrant liability is based significantly on the fair value of the Company&#x2019;s common stock.  At the date of issuance, the common stock warrant liability was determined using the following weighted-average assumptions: expected term of 2.0 years, risk-free interest rate of 1.53%, expected volatility of 78.97%, and no expected dividends.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following weighted-average assumptions were used to estimate the fair value of the common stock warrant liability at June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.685%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.315%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A 10% change in the estimate of expected volatility at June 30, 2020 would increase or decrease the fair value of the common stock warrant liability in the amount of $33.  A 10% change in the estimate of fair value of the common stock at June 30, 2020 would increase or decrease the fair value of the common stock warrant liability in the amount of $59.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a reconciliation of the Company&#x2019;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.237%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.259%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gain included in other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjUzMA_bfa3c533-7f70-48a3-8065-2aebf85e29e4">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.955%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.601%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.660%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;76,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.628%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.937%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.011%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.937%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.184%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.283%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.665%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.460%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;36,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if786421abd8449ad82c258035991f29f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMy0xLTEtMS0w_f6a008d1-5664-45b6-a1be-c0aef2c548dc"
      unitRef="usd">7602000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i94b2debb8cee40d0bb95dee385f1e248_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMy0zLTEtMS0w_59e3c665-3957-439a-a49d-4fea29d253f5"
      unitRef="usd">7602000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if03a9ef0110a48da8f43355f7dde35e9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMy01LTEtMS0w_9552406a-e32e-44dc-afe2-d0a873bf286b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i139534750c32411998ec9f0fdd20ed30_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMy03LTEtMS0w_5052f5f1-ebeb-439c-b026-5c0b8298b032"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b43d4dad70748079a0e514fc136284e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNi0xLTEtMS0w_b71a290f-32f0-4ebf-967e-2f575cdf65d8"
      unitRef="usd">15188000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4b2a726e7e9422a8c57cb8fe49f6a15_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNi0zLTEtMS0w_72f7be6f-106c-40f3-9d00-f361e3602849"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5ffab51ce3540d2b6096242b70529a6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNi01LTEtMS0w_11410b28-9828-4601-aa5c-9037c3c0e436"
      unitRef="usd">15188000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2525709ae7045c3a4de1f8fb444dbbe_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNi03LTEtMS0w_96aade44-271a-4bca-a858-d96a77f4c351"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i42288e5a324249c8ad74cc662005b838_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNy0xLTEtMS0w_746e2094-9e65-4f4c-8959-477590a41161"
      unitRef="usd">45065000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1cbfa891ae54142b5e3a160e784d461_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNy0zLTEtMS0w_22ba49ab-7867-41be-bab5-8a227ccc7713"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b10df2779c4412ab3932dd163fe9b82_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNy01LTEtMS0w_cae6f42c-7c7a-4e84-ab40-01ab6f48c53e"
      unitRef="usd">45065000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03266b4db72b4437b1cf9918fecc673e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfNy03LTEtMS0w_123b8aeb-64bb-4ae2-9665-ecfe19354562"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e24f66b20e44fa2a7b4a0991ca309f1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOC0xLTEtMS0w_6b0f3966-d06f-4714-aef1-229a52157bf5"
      unitRef="usd">2275000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bfcdc5fa8c740d39d1e6fc1c52b74fe_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOC0zLTEtMS0w_05f33601-e109-4185-916e-7f02eb8589e5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6929f02de29e445e90d7b545c93b3af6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOC01LTEtMS0w_28308000-8e1a-4d2c-8457-f3217a0fb5eb"
      unitRef="usd">2275000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c0b49eff48349d3963e85732d3bb079_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOC03LTEtMS0w_ff1b9069-9779-4ea6-b3fc-a81a0fbe1c41"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcad2a390bdd4ccab4037a9659048f33_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOS0xLTEtMS0w_0e9874e8-4864-472a-9f70-5bec79aa0f46"
      unitRef="usd">6051000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0091985621104c5e88db831ff8c58475_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOS0zLTEtMS0w_f55ba1b0-ab7b-407a-94c5-3f6f3230edd8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9661f3db7077445e851858b6e5f7c6e5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOS01LTEtMS0w_7251ca90-e7ba-4a03-ad23-bfbfd506776a"
      unitRef="usd">6051000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i011f06514d6143e1839cabbd9accc3ca_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfOS03LTEtMS0w_5630d29c-ba79-4ece-b27e-c457441b2fb5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia02b9a6c3e74421db29f69c537e41533_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTAtMS0xLTEtMA_c5cba3ba-65e0-4ba6-aea0-d5595cb03261"
      unitRef="usd">76181000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d51345bb8494da4a30ff3ab1bc494f9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTAtMy0xLTEtMA_4687b10d-64fa-47bd-be71-52194538c51d"
      unitRef="usd">7602000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8d4534186e24013a51b6dcd1d6b3342_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTAtNS0xLTEtMA_7008064d-3f69-49bb-83bb-8f4a12d9d282"
      unitRef="usd">68579000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3027180e50c94a839a0b60625e670750_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTAtNy0xLTEtMA_60c7e5b2-dae4-457c-8ac2-6c05cdaa7d08"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="ia02b9a6c3e74421db29f69c537e41533_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTMtMS0xLTEtMA_8ed7427b-9ffc-4146-b4e1-9a786439ca8a"
      unitRef="usd">257000</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i0d51345bb8494da4a30ff3ab1bc494f9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTMtMy0xLTEtMA_4e5d4cfa-2db1-4d7d-8dd5-d5371d094817"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="ia8d4534186e24013a51b6dcd1d6b3342_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTMtNS0xLTEtMA_c978af8a-a2ea-4114-b73a-f860a7dae8ba"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i3027180e50c94a839a0b60625e670750_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTMtNy0xLTEtMA_04cbeaf0-fca7-4dd5-9145-3a0352c8f408"
      unitRef="usd">257000</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ia02b9a6c3e74421db29f69c537e41533_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTQtMS0xLTEtMA_8c4afb5b-2858-414e-8c76-9497b6b5cd46"
      unitRef="usd">257000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i0d51345bb8494da4a30ff3ab1bc494f9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTQtMy0xLTEtMA_1149dbcd-920f-41d6-a4ac-edff43f44787"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ia8d4534186e24013a51b6dcd1d6b3342_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTQtNS0xLTEtMA_4d87dbbe-1164-474c-b293-f0c26e7ce013"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i3027180e50c94a839a0b60625e670750_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjkyMTgxOGFiOTk0NTRkZDU4ZGVlZjViOTc4M2U5MDQyL3RhYmxlcmFuZ2U6OTIxODE4YWI5OTQ1NGRkNThkZWVmNWI5NzgzZTkwNDJfMTQtNy0xLTEtMA_8f36495b-6706-4e13-a950-907078a6194a"
      unitRef="usd">257000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i090111c614884f2a89c5715d09e61e69_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMy0xLTEtMS0w_acc1edbf-5d6e-44d1-85c3-5eff63c949b0"
      unitRef="usd">31078000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0a6d01430580442ebd48b712adfce654_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMy0zLTEtMS0w_b79e25be-93b6-422b-91b2-6c966c00f5c4"
      unitRef="usd">31078000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if61aaf687d2943e6bc6fe6367d618ffb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMy01LTEtMS0w_b3482d0a-683f-4ede-b224-b305af0472f0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic85d5d22e929404c83658bc0fc8c47ed_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMy03LTEtMS0w_83f4d23d-8c2f-48a8-8f76-ff10521fda8e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i596ed322af7d456da621e01fa6bae736_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNC0xLTEtMS0w_0f55eb67-8ecf-4654-b648-efd532739fe5"
      unitRef="usd">2498000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i62b770fba5bd404fbbf086617f231ac1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNC0zLTEtMS0w_c89886f6-a387-4b65-ba74-50b6a6666679"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i715f59046cbd4cfbb6149afc299e8098_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNC01LTEtMS0w_b68d009a-ad3a-42ba-9c3d-b738df388295"
      unitRef="usd">2498000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6b1651c5e27f48129604544f4d17c53d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNC03LTEtMS0w_37973ae5-0d8f-44d1-bd96-8f11b271b01b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81ff5dbe93184b128cf458121e2b9869_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNi0xLTEtMS0w_51730853-2ed1-4feb-876d-1ea824e501ec"
      unitRef="usd">11433000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i36aea1c3046543f0b3cc27b52ff37040_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNi0zLTEtMS0w_b4d7a6ea-09ef-47d4-bb86-2c6e22445721"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7954e090c66944f88a4e2606c991d18b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNi01LTEtMS0w_eddf49b1-3f5b-4208-8171-642bbd92a6d7"
      unitRef="usd">11433000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib02e96a8734943609865d9b4c35421f7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNi03LTEtMS0w_4da3446a-0757-451e-b824-83329c82c180"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i246dadd6c8d449999b2f9717794c470c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNy0xLTEtMS0w_886d141c-bf42-4bb7-9902-861311c4a3f8"
      unitRef="usd">36597000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ad9873452934a32ae8e3aeda1e17fe8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNy0zLTEtMS0w_0af71f8b-4c5d-4678-92e3-79ec592a80f6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id62277363f7143ce854422660983079f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNy01LTEtMS0w_c2f37950-54db-469c-ab68-6efca72e5bc5"
      unitRef="usd">36597000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadbc031755e743459e0e460fe0824f64_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfNy03LTEtMS0w_d781c801-7632-4d92-a44b-3329ba2403f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie70b0b8cf2fe4c808ff9025d45a5b3ff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOC0xLTEtMS0w_0735d388-f916-4e91-afc5-5515b26e948b"
      unitRef="usd">4512000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia533935aed984b759f799fea1a30903b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOC0zLTEtMS0w_a897662d-af6b-4ac6-80ba-6b63af889c7e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iceff6e292b6d4b45910614df9290865b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOC01LTEtMS0w_5b31e5d3-ed41-4a19-9a62-968c4d06bc6b"
      unitRef="usd">4512000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d6b9adc9d0d410e84335056934458af_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOC03LTEtMS0w_dddb019e-6c6a-4392-a9c0-37d7695924ed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f49042851ab48aa8b238a225a70ee62_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOS0xLTEtMS0w_8c0666b8-68de-4ab8-a47b-e4db257f88f7"
      unitRef="usd">9784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic6b2c3b884bc46fcaabeebaa66bf2635_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOS0zLTEtMS0w_912e1157-ff69-4be5-9322-e83148b2c864"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i649b1d02f04843e6bfb8ceea9915423c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOS01LTEtMS0w_dbdd36fa-099a-41da-b4ff-bd721dfa6e03"
      unitRef="usd">9784000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76cfaf0a85c64451bf8e5033f3d6e411_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfOS03LTEtMS0w_bc1e4581-db46-43cf-9bc5-1ab90073f315"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iae71687b96be4ca7a964da2662807ebb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTAtMS0xLTEtMA_fd77f9d3-b86d-4be5-bbfb-12fd4644ac26"
      unitRef="usd">95902000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0591281256d2426a9cbbf549dd04a8a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTAtMy0xLTEtMA_828fb80d-853c-45cb-ad25-bc1b3063b4fa"
      unitRef="usd">31078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1eafdf3617e8409faef961085fcec21c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTAtNS0xLTEtMA_16beeb32-0617-4fc9-877b-e09745ec1364"
      unitRef="usd">64824000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c04023fda4245f69834e13098d0ccc6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTAtNy0xLTEtMA_07b7b836-74cc-4af1-89d2-d7ae0b2d1976"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="iae71687b96be4ca7a964da2662807ebb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTMtMS0xLTEtMA_ed8f1cf1-d4a3-48a6-b7d4-f64f93bde73e"
      unitRef="usd">414000</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i0591281256d2426a9cbbf549dd04a8a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTMtMy0xLTEtMA_ae550ee3-1aed-4c81-a585-a770b3af7e1b"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i1eafdf3617e8409faef961085fcec21c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTMtNS0xLTEtMA_ef455c49-a19d-4121-a339-bae439f46e47"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i7c04023fda4245f69834e13098d0ccc6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTMtNy0xLTEtMA_43f742aa-c774-4143-8fad-41b9f3e9f711"
      unitRef="usd">414000</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="iae71687b96be4ca7a964da2662807ebb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTQtMS0xLTEtMA_1fc7bed2-1f86-4dd4-8661-d1b49cd16322"
      unitRef="usd">414000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i0591281256d2426a9cbbf549dd04a8a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTQtMy0xLTEtMA_00183fc3-2741-448e-83e0-1fa753d42bfc"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i1eafdf3617e8409faef961085fcec21c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTQtNS0xLTEtMA_0d60dd45-bee3-4e45-a0c8-423d3597a6de"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i7c04023fda4245f69834e13098d0ccc6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFhYzJmNjllMjdmYjQxYzJiNjM3ZDI4NmVhYWFlNzI2L3RhYmxlcmFuZ2U6MWFjMmY2OWUyN2ZiNDFjMmI2MzdkMjg2ZWFhYWU3MjZfMTQtNy0xLTEtMA_b42bb224-649e-4bbf-8f1b-90b16e9a8bff"
      unitRef="usd">414000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic748766b36734327aef19e1e2042ee49_I20160217"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMTc1Mg_215bc4a3-1fee-407a-bd42-ae6f1dcc5dd4">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i06fbc20f828d41caa9a80bcd7a6e2759_I20160217"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMTc4Mw_c9c9358c-49c1-4691-af44-8105d8318e0d"
      unitRef="number">0.0153</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i9977feb034be4c9caaf5b5df369b7ff1_I20160217"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMTgxMA_14a1e0aa-c626-411c-a536-8e30a4867801"
      unitRef="number">0.7897</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i48e54b1c09a54de19e18102cdfcb8cbd_I20160217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMTgxOA_89d2dc40-3b84-48ad-82cb-c174a06ae7a7"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjUyMQ_0375c84f-41d1-48cd-88d9-2301bc4a34d3">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following weighted-average assumptions were used to estimate the fair value of the common stock warrant liability at June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.685%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:19.315%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i57d24130c57c40ba8b47fd15cceac12a_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjAxYjhiOGM4NGZmNTQ2NTFhODc1YWJjZGYyMWMyNjg0L3RhYmxlcmFuZ2U6MDFiOGI4Yzg0ZmY1NDY1MWE4NzVhYmNkZjIxYzI2ODRfMS0xLTEtMS0w_f155f63a-67ce-4040-be70-a1317617e92f">P0Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ic6024f8bbc354cab9a3781b1178e5869_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjAxYjhiOGM4NGZmNTQ2NTFhODc1YWJjZGYyMWMyNjg0L3RhYmxlcmFuZ2U6MDFiOGI4Yzg0ZmY1NDY1MWE4NzVhYmNkZjIxYzI2ODRfMi0xLTEtMS0w_f310bf2b-7049-4e5c-8013-875c5604e3d1"
      unitRef="number">0.002</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i2082cdeebbe94488abda3ef417d3e1be_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjAxYjhiOGM4NGZmNTQ2NTFhODc1YWJjZGYyMWMyNjg0L3RhYmxlcmFuZ2U6MDFiOGI4Yzg0ZmY1NDY1MWE4NzVhYmNkZjIxYzI2ODRfMy0xLTEtMS0w_2d05b15a-71dd-4638-91ae-4dfaa37a63a0"
      unitRef="number">0.9309</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i0c9f635fc1cf441fb44103b2e37aabec_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjAxYjhiOGM4NGZmNTQ2NTFhODc1YWJjZGYyMWMyNjg0L3RhYmxlcmFuZ2U6MDFiOGI4Yzg0ZmY1NDY1MWE4NzVhYmNkZjIxYzI2ODRfNC0xLTEtMS0w_6715a11c-8f9a-46f5-9592-2e7fbf95efc8"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjE0OA_674b2e63-c9f7-40a5-bca4-752e9d7a4154"
      unitRef="usd">33000</xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate>
    <xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjMzMA_fbcfb370-abc8-4efd-afab-d16001a4b5ca"
      unitRef="usd">59000</xcur:FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RleHRyZWdpb246ZjEwMjFjNmU4YTBjNGU1MTkzOWI3YjEzNGYzYmIwOGJfMjUyNw_08de2858-864b-4da6-8335-b6d88ea1b0f4">&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a reconciliation of the Company&#x2019;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.237%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.259%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gain included in other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1c5c0eb47d394449b742692f031dee63_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFkYmZhNjcwMDdlZDRlYTE4ZTg3YzAxYWU2MWUzM2VmL3RhYmxlcmFuZ2U6MWRiZmE2NzAwN2VkNGVhMThlODdjMDFhZTYxZTMzZWZfMi0xLTEtMS0w_93684e95-baf0-48ac-aea0-7a95a1c757ba"
      unitRef="usd">414000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFkYmZhNjcwMDdlZDRlYTE4ZTg3YzAxYWU2MWUzM2VmL3RhYmxlcmFuZ2U6MWRiZmE2NzAwN2VkNGVhMThlODdjMDFhZTYxZTMzZWZfNC0xLTEtMS0w_03a7f39b-1891-449c-8b78-f6b8077b0485"
      unitRef="usd">-157000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icfc5af07dc354cc8a9057ae7da0af850_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV84NS9mcmFnOmYxMDIxYzZlOGEwYzRlNTE5MzliN2IxMzRmM2JiMDhiL3RhYmxlOjFkYmZhNjcwMDdlZDRlYTE4ZTg3YzAxYWU2MWUzM2VmL3RhYmxlcmFuZ2U6MWRiZmE2NzAwN2VkNGVhMThlODdjMDFhZTYxZTMzZWZfNS0xLTEtMS0w_0ca82810-5ac0-417c-83e0-1855d801f0ef"
      unitRef="usd">257000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85MS9mcmFnOmIxNGI2Yzc3YmM4NjQ3ZWJiMmY2NDFkMTlmODVlYWRhL3RleHRyZWdpb246YjE0YjZjNzdiYzg2NDdlYmIyZjY0MWQxOWY4NWVhZGFfMjgxNA_e99b23a1-85ea-4c4a-8a7e-b0c2205ee6b2">Commitments and Contingencies&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Refer to Note 7,&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, for a discussion of the commitments associated with the Company&#x2019;s lease agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Northwestern University License Agreements&lt;/span&gt;&lt;/div&gt;On December 12, 2011, (1) AuraSense, LLC, the Company&#x2019;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#x2019;s 2009 license agreement with Northwestern University (&#x201c;NU&#x201d;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#x201c;Assigned Field&#x201d;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#x2019;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#x2019;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#x201c;Restated License Agreement&#x201d;). In February 2016, the Company obtained exclusive license as to NU&#x2019;s rights in certain SNA technology it jointly owns with NU (the &#x201c;Co-owned Technology License&#x201d;). The Company&#x2019;s license to NU&#x2019;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#x201c;Wound Healing License&#x201d;). The Company&#x2019;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#x201c;the Northwestern University License Agreements&#x201d;).  As of December 31, 2019, all pending patent applications under the Wound Healing License have been abandoned.  As of June 30, 2020, the Company has paid to NU an aggregate of $8,229 in consideration of each of the obligations described above.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <xcur:PaymentsforLicenseAgreements
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85MS9mcmFnOmIxNGI2Yzc3YmM4NjQ3ZWJiMmY2NDFkMTlmODVlYWRhL3RleHRyZWdpb246YjE0YjZjNzdiYzg2NDdlYmIyZjY0MWQxOWY4NWVhZGFfMjc1MA_9e66a424-1b9d-40ba-bc0e-16e4658002dd"
      unitRef="usd">8229000</xcur:PaymentsforLicenseAgreements>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85NC9mcmFnOjIwMzU5MDM0ZWViOTQ4NGZhOWY5MzhhMDY5NWI4NjdjL3RleHRyZWdpb246MjAzNTkwMzRlZWI5NDg0ZmE5ZjkzOGEwNjk1Yjg2N2NfNDMy_25147056-76d9-4689-a328-ee1f689602b4">Related-Party TransactionsThe Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board. The Company paid $50 in each of the six months ended June 30, 2020 and 2019 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited condensed consolidated statement of operations.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ica899e5f992445b1b2e0565819005804_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85NC9mcmFnOjIwMzU5MDM0ZWViOTQ4NGZhOWY5MzhhMDY5NWI4NjdjL3RleHRyZWdpb246MjAzNTkwMzRlZWI5NDg0ZmE5ZjkzOGEwNjk1Yjg2N2NfMjAx_a9994309-37b5-4298-b5cb-e7b3fbd4de34"
      unitRef="usd">50000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i3f7894134fb44db79f503167f8288191_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV85NC9mcmFnOjIwMzU5MDM0ZWViOTQ4NGZhOWY5MzhhMDY5NWI4NjdjL3RleHRyZWdpb246MjAzNTkwMzRlZWI5NDg0ZmE5ZjkzOGEwNjk1Yjg2N2NfMjAx_c768b270-d39a-431a-a2a3-76e6a1e6dd5f"
      unitRef="usd">50000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ibe98af36b5604579bf17b5244677d385_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV8xMDAvZnJhZzo0YmViNTAwNTM1Yzk0ZDgzODA4MmMyZjYzOTJmMzE0OS90ZXh0cmVnaW9uOjRiZWI1MDA1MzVjOTRkODM4MDgyYzJmNjM5MmYzMTQ5XzQzMQ_5f457193-3802-417d-9b18-187f1a9f7576">Subsequent EventsThe Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246667974392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXICURE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5333008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2430 N. Halsted St.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">673-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XCUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,228,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001698530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8045 Lamon Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Skokie<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246668102408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,198<span></span>
</td>
<td class="nump">$ 48,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">68,579<span></span>
</td>
<td class="nump">62,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Unbilled revenue receivable</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">89,389<span></span>
</td>
<td class="nump">112,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,464<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">96,119<span></span>
</td>
<td class="nump">115,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,947<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,873<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,367<span></span>
</td>
<td class="nump">31,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiability', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,367<span></span>
</td>
<td class="nump">34,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 87,206,346 issued and outstanding, June&#160;30, 2020; 86,069,263 issued and outstanding, December&#160;31, 2019</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">165,863<span></span>
</td>
<td class="nump">162,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">338<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(84,458)<span></span>
</td>
<td class="num">(81,297)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">81,752<span></span>
</td>
<td class="nump">80,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 96,119<span></span>
</td>
<td class="nump">$ 115,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246594210632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">87,206,346<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">87,206,346<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246667978024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 4,847<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 14,030<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">4,847<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">14,030<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">7,008<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
<td class="nump">13,083<span></span>
</td>
<td class="nump">6,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
<td class="nump">4,803<span></span>
</td>
<td class="nump">4,193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,237<span></span>
</td>
<td class="nump">5,418<span></span>
</td>
<td class="nump">17,886<span></span>
</td>
<td class="nump">11,021<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(4,390)<span></span>
</td>
<td class="num">(4,984)<span></span>
</td>
<td class="num">(3,856)<span></span>
</td>
<td class="num">(10,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">627<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">79<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="nump">695<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,311)<span></span>
</td>
<td class="num">$ (5,220)<span></span>
</td>
<td class="num">$ (3,161)<span></span>
</td>
<td class="num">$ (10,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share (in usd per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average basic and diluted common shares outstanding (in shares)</a></td>
<td class="nump">87,174,533<span></span>
</td>
<td class="nump">44,368,174<span></span>
</td>
<td class="nump">87,126,847<span></span>
</td>
<td class="nump">44,363,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246595423608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,311)<span></span>
</td>
<td class="num">$ (5,220)<span></span>
</td>
<td class="num">$ (3,161)<span></span>
</td>
<td class="num">$ (10,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on available for sale securities, net of tax</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (3,956)<span></span>
</td>
<td class="num">$ (5,220)<span></span>
</td>
<td class="num">$ (2,796)<span></span>
</td>
<td class="num">$ (10,506)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246593857560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in- Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 20,952<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 75,942<span></span>
</td>
<td class="num">$ (54,994)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="num">(5,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">16,155<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">76,431<span></span>
</td>
<td class="num">(60,280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">20,952<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">75,942<span></span>
</td>
<td class="num">(54,994)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="num">(10,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,369,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">11,391<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">76,887<span></span>
</td>
<td class="num">(65,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">16,155<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">76,431<span></span>
</td>
<td class="num">(60,280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="num">(5,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,369,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">11,391<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">76,887<span></span>
</td>
<td class="num">(65,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">80,747<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">162,062<span></span>
</td>
<td class="num">(81,297)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,081,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,150,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">85,114<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,269<span></span>
</td>
<td class="num">(80,147)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 80,747<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">162,062<span></span>
</td>
<td class="num">(81,297)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="nump">55,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net</a></td>
<td class="nump">$ 365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="num">(3,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,206,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">81,752<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,863<span></span>
</td>
<td class="num">(84,458)<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,150,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">85,114<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,269<span></span>
</td>
<td class="num">(80,147)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (loss)</a></td>
<td class="num">(4,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,206,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 81,752<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 165,863<span></span>
</td>
<td class="num">$ (84,458)<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246667597128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,161,000)<span></span>
</td>
<td class="num">$ (10,506,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">335,000<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">985,000<span></span>
</td>
<td class="nump">928,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">356,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(157,000)<span></span>
</td>
<td class="num">(256,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Unbilled revenue receivable and accounts receivable</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,551,000)<span></span>
</td>
<td class="num">(257,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="num">(1,034,000)<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(647,000)<span></span>
</td>
<td class="num">(66,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(13,949,000)<span></span>
</td>
<td class="nump">541,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="num">(59,000)<span></span>
</td>
<td class="num">(194,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,814,000)<span></span>
</td>
<td class="num">(8,996,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale securities</a></td>
<td class="num">(38,072,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sale or maturity of available for sale securities</a></td>
<td class="nump">32,103,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(2,996,000)<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(8,965,000)<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="nump">2,973,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">4,999,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of long-term debt fees and issuance costs</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsOfCommonStockFinancingCosts', window );">Payment of common stock financing costs</a></td>
<td class="num">(207,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(2,283,000)<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(30,062,000)<span></span>
</td>
<td class="num">(9,093,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash - beginning of period</a></td>
<td class="nump">48,460,000<span></span>
</td>
<td class="nump">26,268,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash - end of period</a></td>
<td class="nump">18,398,000<span></span>
</td>
<td class="nump">17,175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Debt fees (accrued expenses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures (accounts payable and accrued expenses)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 18,398,000<span></span>
</td>
<td class="nump">$ 17,175,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsOfCommonStockFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Common Stock Financing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsOfCommonStockFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246593382136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">Description of Business and Basis of Presentation<div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Description of Business</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Exicure, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, genetic disorders and other indications based on our proprietary Spherical Nucleic Acid (&#8220;SNA&#8221;) technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. The Company believes that the design of its SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company is working to advance its SNA therapeutic candidates through multiple clinical trials, including the ongoing Phase 1b/2 clinical trial of cavrotolimod (AST-008) in cancer patients. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that one of the key strengths of its proprietary SNAs is that they have the potential to enter a number of different cells and organs. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immunoncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. As a consequence, the Company has expanded its pipeline into neurology, and has conducted early stage research activities in ophthalmology, pulmonology, and gastroenterology. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Throughout these unaudited condensed consolidated financial statements, the terms the &#8220;Company&#8221; and &#8220;Exicure&#8221; refer to Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements as of June 30, 2020 and December 31, 2019, and for the three and six months ended June 30, 2020 and 2019, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Risks and Uncertainties</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#8217;s routine communication to address employee and business concerns and providing frequent updates to the Company&#8217;s board of directors (the &#8220;Board&#8221;).  As of July 1, 2020, the Company took occupancy of approximately 30,000 square feet of laboratory and office space in its new headquarters in Chicago, Illinois.  Since then, the Company has operated under COVID-19 social distancing guidelines and has generally operated with 100% of its R&amp;D staff on-site.  The Company&#8217;s office and general and administrative team continues to work predominantly from home. The Company&#8217;s preclinical development program in Friedreich&#8217;s ataxia (&#8220;FA&#8221;) is ongoing and it continues to expect that IND-enabling studies for the Company&#8217;s FA therapeutic candidate, XCUR-FXN, will begin in late 2020.  The Company also continues to progress its collaborations with Allergan Pharmaceuticals International Limited (&#8220;Allergan&#8221;) and DERMELIX, LLC, d/b/a Dermelix Biotherapeutics (&#8220;Dermelix&#8221;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience significant disruptions to its preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company anticipates that the COVID-19 pandemic may have an impact on the clinical development timelines for its cavrotolimod (AST-008) clinical program. The extent to which the COVID-19 pandemic will impact the Company&#8217;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the pandemic, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity Risk</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, the Company has generated an accumulated deficit of $103,295 since inception and expects to incur significant expenses and negative cash flows for the foreseeable future.  Based on the Company&#8217;s current operating plans, it believes that existing working capital at June 30, 2020 is sufficient to fund the Company for at least the next 12 months. Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  The Company has historically principally raised capital through the sale of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  The Company believes raising capital in the current market could be very difficult for early stage biotech companies like Exicure.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could in the future negatively affect its operations.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unaudited Interim Financial Information</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim condensed consolidated balance sheet as of June 30, 2020, the interim condensed consolidated statements of operations for the three and six months ended June 30, 2020 and 2019, the interim condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2020 and 2019, the interim condensed consolidated statements of changes in stockholders&#8217; equity for the three and six months ended June 30, 2020 and 2019, and the interim condensed consolidated statements of cash flows for the six months ended June, 2020 and 2019, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of June 30, 2020, the results of its operations for the three and six months ended June 30, 2020 and 2019, and the results of its cash flows for the six months ended June 30, 2020 and 2019. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2020 and 2019 are unaudited. The results for the three and six months ended June 30, 2020 are not necessarily indicative </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of results to be expected for the year ending December 31, 2020, or any other interim periods, or any future year or period.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588497192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 10, 2020. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588623624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Research and License Agreements</a></td>
<td class="text">Collaborative Research and License Agreements<div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Allergan Collaboration Agreement</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Agreement&#160;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 13, 2019 (the &#8220;Effective Date&#8221;), the Company entered into a Collaboration, Option and License Agreement (the &#8220;Allergan Collaboration Agreement&#8221;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan, was acquired by AbbVie Inc. (&#8220;AbbVie&#8221;). Accordingly, all references to &#8220;Allergan&#8221; in the defined terms including, but not limited to, &#8220;Allergan,&#8221; &#8220;Allergan Collaboration Agreement,&#8221; &#8220;Allergan R&amp;D Services&#8221; and &#8220;Allergan JDC Services,&#8221; should be read and construed as references to AbbVie. Pursuant to the Allergan Collaboration Agreement, the Company granted to Allergan exclusive access and options to license SNA based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders (each, a &#8220;Collaboration Program&#8221;). Under each such license (obtained in connection with the exercise of an Option, as defined and discussed further below), the Company would grant to Allergan exclusive, royalty-bearing, sublicenseable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the Allergan Collaboration Agreement, the Company will use commercially reasonable efforts to conduct two Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific Collaboration Program targets (each, a &#8220;Program Target&#8221;).</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of the Effective Date, the Company and Allergan have agreed upon a development plan for each Collaboration Program that describes the development activities and timelines required to advance such Collaboration Program through first IND filing (each, a &#8220;Development Plan&#8221;).  The activities described in the Development Plan are conducted under the supervision of the Joint Development Committee (the &#8220;JDC&#8221;) consisting of three members from each of the Company and Allergan. The Company is primarily responsible for performing early stage discovery and preclinical activities (the &#8220;Initial Development Activities&#8221;) set forth in the Development Plan for each Collaboration Program and will be solely responsible for all costs and expenses related to the Initial Development Activities. Allergan may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> testing as set forth in a Development Plan.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the completion of all Initial Development Activities, the Company is required to deliver to Allergan a report that describes the results of the Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Collaboration Program as determined by the JDC (the &#8220;Initial Development Report&#8221;).  Following the delivery of the Initial Development Report for a Collaboration Program, Allergan will have the ability for a defined period of time (the &#8220;Initial Option Exercise Period&#8221;) to exercise an option (each an &#8220;Option&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each a &#8220;Licensed Product&#8221;) that results from such Collaboration Program during the term of the Allergan Collaboration Agreement.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At Allergan&#8217;s sole option, Allergan may extend the Initial Option Exercise Period (the &#8220;Option Extension&#8221;) and require the Company to perform IND-enabling activities described in the Development Plan (the &#8220;IND-Enabling Activities&#8221;), subject to the payment of additional consideration (&#8220;Extension Exercise&#8221;). If Allergan exercises the Option Extension, the Company would be responsible for conducting the IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the IND-Enabling Activities, the Company is required to deliver a report that describes the results of the IND-Enabling Activities (the &#8220;IND-Enabling Activities Data Package&#8221;) to Allergan. Following the delivery of IND-Enabling Activities Data Package, Allergan will have the ability for a defined period of time (the &#8220;Extended Option Exercise Period&#8221;) to exercise an Option with respect to such Collaboration Program. After the exercise of an Option with respect to a Collaboration Program, Allergan will be responsible for all development, manufacturing, and commercialization activities, and costs and expense associated with such activities in connection with Licensed Products arising from such Collaboration Program.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s obligation to conduct the activities defined in the Development Plan under the Allergan Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date Allergan exercises an Option, (ii) the date Allergan abandons a Collaboration Program and foregoes its Option to that Collaboration Program, or (iii) the fifth anniversary of the Effective Date (the &#8220;Research Term&#8221;). If the Initial Option Exercise Period or Extended Option Exercise Period is still in effect for a Collaboration Program or if the Company has not delivered a complete Initial Development Report or, if Allergan made an Extension Exercise for a Collaboration Program, a complete IND-Enabling Activities Data Package for such Collaboration Program, as determined by the JDC, then the Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the Effective Date.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Allergan Collaboration Agreement, the Company received a $25,000 upfront, non-refundable, non-creditable cash payment (the &#8220;Allergan Upfront Payment&#8221;) related to the Company&#8217;s research and development costs for conducting the Development Plan for two Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such Collaboration Programs.  The option exercise fee during the Initial Option Exercise Period is $10,000 per Collaboration Program.  If Allergan elects to extend the Initial Option Exercise Period, Allergan is required to pay an additional fee of $10,000.  If Allergan elects to exercise its option during the Extended Option Exercise Period, Allergan must pay the Company the option exercise fee of $15,000.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the exercise by Allergan of an Option with respect to a Collaboration Program, Allergan would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on a Licensed Product by Licensed Product basis. On a Licensed Product by Licensed Product basis, for the first Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $55,000 for development milestone payments and $132,500 for product approval and launch milestone payments. The Company is also eligible for up to $175,000 in sales milestone payments on a Collaboration Program by Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by Allergan to obtain certain third party intellectual property rights.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, to the extent there is any Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a Licensed Product by Licensed Product and country by country basis from the date of the first commercial sale of each Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such Licensed Product in such country, (ii) the tenth anniversary of the first commercial sale of such Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such Licensed Product in such country.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allergan may terminate the Allergan Collaboration Agreement for any reason or no reason, either in its entirety or on a Collaboration Program by Collaboration Program basis, at any time on 90 days&#8217; prior written notice to the Company. Unless earlier terminated, the term of the Allergan Collaboration Agreement shall continue until (i) if both Option Exercise Periods expire without Allergan exercising either Option, the expiration of the later to expire Option Exercise Period, and (ii) if either or both Options are exercised on a Licensed Product-by-Licensed Product and country-by-country basis, the expiration of the royalty term for such Licensed Product in such country. Either party may terminate the Allergan Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Termination of the Allergan Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the Allergan Collaboration Agreement will not preclude </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the Allergan Collaboration Agreement. If either party terminates the Allergan Collaboration Agreement, the license and rights granted to Allergan with respect to the terminated Collaboration Program or License Product shall terminate. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting Analysis</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that Allergan is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the Allergan Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the Research Term (the &#8220;Allergan R&amp;D Services&#8221;), and (ii) Joint Development Committee services during the Research Term (the &#8220;Allergan JDC Services&#8221;). The Company has concluded that the Allergan R&amp;D Services is not distinct from the Allergan JDC Services during the Research Term. The JDC provides oversight and management of the overall Allergan Collaboration Agreement, and the members of the JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The JDC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and Allergan. Further, the JDC services are critical to the ongoing evaluation of a Collaboration Program and the drafting and evaluation of the Initial Development Report and the IND-Enabling Data Package. Accordingly, the Company&#8217;s participation on the JDC is essential to Allergan receiving value from the Allergan R&amp;D Services and as such, the Allergan JDC Services along with the Allergan R&amp;D Services are considered one performance obligation (the &#8220;Collaboration Program Services&#8221;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of the Effective Date of the Allergan Collaboration Agreement, the total transaction price was determined to be $25,000, consisting solely of the Allergan Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Effective Date of the Allergan Collaboration Agreement, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Allergan.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of June 30, 2020, the Company determined that any development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at June 30, 2020.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will recognize revenue related to the Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and six months ended June 30, 2020, the Company recognized revenue under the Allergan Collaboration Agreement of approximately $4,833 and $13,949, respectively.  As of June 30, 2020, there was $10,880 of deferred revenue related to the Allergan Collaboration Agreement, which is classified as current on the unaudited condensed consolidated balance sheet.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Dermelix Collaboration Agreement</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Summary of Agreement&#160;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 17, 2019, Exicure entered into a License and Development Agreement with Dermelix (the &#8220;Dermelix Collaboration Agreement.&#8221;)  Pursuant to the Dermelix Collaboration Agreement, the Company granted to Dermelix exclusive, worldwide royalty-bearing license rights to, develop, manufacture, have manufactured, use and commercialize the Company&#8217;s SNA technology for the treatment of Netherton Syndrome (&#8220;NS&#8221;) and, at Dermelix&#8217;s option, up to five additional specified orphan diseases that are within the dermatology field. Upon written notice to the Company, Dermelix may exercise its option at any time following the effective date of the Dermelix Collaboration Agreement until the date that is <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTQ4ODA_7c7ddbd2-6787-47de-91af-9e663bcf7a25">six</span> (6) years from the date that the first collaboration SNA therapeutic achieves first dosing in humans in a Phase 1 clinical trial for NS.  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dermelix will initially seek to develop a targeted therapy for the treatment of NS.  Under the terms of the Dermelix Collaboration Agreement, the Company will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will assume subsequent development, commercial activities and financial responsibility for such indications.  Dermelix will pay the costs and expenses of development and commercialization of any licensed products under the Dermelix Collaboration Agreement, including the Company&#8217;s expenses incurred in connection with development activities and in accordance with the development budget.  Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $1,000, to be applied against the initial $1,000 of the Company&#8217;s development expenses.  If Dermelix exercises any of its option rights for additional indications, Dermelix will pay an option exercise fee equal to $1,000 for each exercised option (each, an &#8220;Option Exercise Fee&#8221;).  Any Option Exercise Fee will be applied against the Company&#8217;s development expenses with respect to the particular indication for which the option was exercised.  </span></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Dermelix Collaboration Agreement, the Company shall have the right to pursue the development and commercialization of SNA technology for the treatment of orphan diseases which are neither NS nor one of the additional specified orphan diseases selected by Dermelix pursuant to its option rights.  If the Company commences development activities of SNA technology for the treatment of such an orphan disease, the Company will notify Dermelix in writing of such development and Dermelix will have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV80Ni9mcmFnOmRlODc4ZWUyNTg3MTRlNDFhMTI1OGZjNTg4ODgwOTUxL3RleHRyZWdpb246ZGU4NzhlZTI1ODcxNGU0MWExMjU4ZmM1ODg4ODA5NTFfMTY3MzY_cca5baed-3744-4471-869d-43a351036895">thirty</span> (30) days following receipt of such notice to use one of its remaining option rights on such orphan disease.  If Dermelix does not use one of its remaining option rights on such orphan disease, or has no option rights remaining, then the Company will have no further obligations to Dermelix with respect to the development of SNA therapeutics for such orphan disease and shall be free to continue commercialization and development activities with respect thereto.  </span></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, the Company shall be eligible to receive additional cash payments totaling up to $13,500 upon achievement of certain development and regulatory milestones and up to $152,500 upon achievement of certain sales milestones.  The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program.  The commercial sales milestones are payable upon achievement of specified aggregate annual product sales thresholds.  In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company will receive low double-digit royalties on annual net sales for such licensed products.  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Accounting Analysis</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded that Dermelix is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance.  The Company identified performance obligations under the Dermelix Collaboration Agreement for the license of intellectual property for the NS therapeutic candidate and associated research and development services for the NS therapeutic candidate.  The Company determined that the performance obligations were not separately identifiable and were not distinct or distinct within the context of the contract due to the specialized nature of the services to be provided by Exicure, specifically with respect to the </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company&#8217;s expertise related to SNA technology, and the interdependent relationship between the performance obligations.  As such, the Company concluded that there is a single identified performance obligation.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company used the most likely amount method to estimate variable consideration and estimated that the most likely amount for each potential development and regulatory milestone, which is considered variable consideration, was zero, as the achievement of those milestones is uncertain and highly susceptible to factors outside of the Company&#8217;s control.  Accordingly, all such milestones were excluded from the transaction price.  Management will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur and adjust the transaction price as necessary.  Sales-based royalties, including commercial sales milestone payments based on the level of sales, were also excluded from the transaction price, as the license is deemed to be the predominant item to which the royalties relate.  The Company will recognize such revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue associated with the performance obligation will be recognized as services are provided using a cost-to-cost measure of progress method.  The transfer of control occurs over time and, in management&#8217;s judgment, this input method is the best measure of progress towards satisfying the performance obligation under the Dermelix Collaboration Agreement and reflects a faithful depiction of the transfer of goods and services.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company initially recorded the upfront payment of $1,000 as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to zero during 2019 by recognizing revenue as services were provided.  The Company recognized $14 and $81 of revenue under the Dermelix Collaboration Agreement during the three and six months ended June 30, 2020, respectively, which reflects reimbursement by Dermelix for additional costs incurred by Exicure for early stage development costs beyond the initial $1,000 upfront payment.  The Company expects to incur additional early stage development costs and expects to be reimbursed by Dermelix for such costs under the terms of the Dermelix Collaboration Agreement.  The Company will recognize both revenue and research and development expense for such costs on a gross basis during the period in which those costs are incurred.   The Company recognized&#160;$434&#160;and $459 of revenue under the Dermelix Collaboration Agreement during the three and six months ended June 30, 2019, respectively,&#160;which related to amortization of the above-mentioned deferred revenue related to the upfront payment for services provided during that period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588540648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">Supplemental Balance Sheet Information<div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid expenses and other current assets</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical, contract research and manufacturing costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">705&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and equipment, net</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scientific equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers and software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, gross</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,644)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,317)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expense was $187 and $87 for the three months ended June 30, 2020 and 2019, respectively, and $335 and $174 for the six months ended June 30, 2020 and 2019, respectively.</span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other noncurrent assets</span></div><div style="margin-top:5pt;margin-bottom:9pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid lease costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total other noncurrent assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued expenses and other current liabilities</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll-related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">706&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical, contract research and manufacturing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">292&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other noncurrent liabilities</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total other noncurrent liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588623624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and December 31, 2019, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:282.75pt;"><tr><td style="width:1.0pt;"/><td style="width:211.00pt;"/><td style="width:1.0pt;"/><td style="width:1.0pt;"/><td style="width:67.75pt;"/><td style="width:1.0pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">One year or less</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After one year but within two years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All of the Company&#8217;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June 30, 2020&#160;and December 31, 2019 were as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.826%;"><tr><td style="width:1.0%;"/><td style="width:44.247%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.565%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.672%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.787%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.672%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.390%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.672%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.395%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,166&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,241&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.025%;"><tr><td style="width:1.0%;"/><td style="width:43.950%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.852%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.680%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.852%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.680%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.680%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.206%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,932&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590116520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">DebtOn March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#8220;Hercules&#8221;) and subsequent amendments thereto  (the &#8220;Hercules Loan Agreement&#8221;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $4,999 and the end of term fee of $100.The Company paid interest on the Hercules Loan Agreement of $0 and $152 during the three months ended June 30, 2020 and 2019, respectively, and $142 and $301 during the six months ended June 30, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246593425240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Chicago Lease</span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has approximately thirty thousand square feet of office and laboratory space in Chicago, Illinois (the &#8220;Chicago Lease&#8221;). The original term (the &#8220;Original Term&#8221;) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the &#8220;Commencement Date&#8221;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;two&#160;additional successive periods of five years each (the &#8220;Extension Periods&#8221;) at the then prevailing effective market rental rate.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial annual base rent during the Original Term is $37.00 per square foot per year, or approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes are subject to certain abatements. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Landlord will contribute a maximum of $3,159 toward tenant improvements. In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the Landlord in an initial amount of $1,200, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the Landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $87 which amount had been adjusted for the abatement as set forth in the lease agreement. Prior to the Commencement Date, the Company also paid the landlord approximately $736 toward tenant improvements.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $1,200, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#8217;s unaudited condensed consolidated balance sheet at June 30, 2020.&#160;</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Chicago Lease has not yet commenced for accounting purposes as of&#160;June 30, 2020. As a result, the Company has not yet recognized an operating lease asset or operating lease liability on the unaudited condensed consolidated balance sheet for the Chicago Lease. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Skokie Lease</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s lease agreement for office and laboratory space in Skokie, Illinois commenced in March 2012 and expires in February 2021 (the &#8220;Skokie Lease&#8221;). In connection with the Company&#8217;s relocation of its headquarters from Skokie, Illinois to its new facility in Chicago, Illinois on July 1, 2020, the Company determined that the remaining useful life of the operating lease asset underlying the Skokie Lease at June 30, 2020 was <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg3YzQxMmI5OGY0YTRjMTBiM2EzMDgxZTMzZjFjYmNhL3NlYzo4N2M0MTJiOThmNGE0YzEwYjNhMzA4MWUzM2YxY2JjYV81OC9mcmFnOjc5NmNjZDZkNjlkZjQyZWFiMzY3ZDE4NWYzYmZlYWQ1L3RleHRyZWdpb246Nzk2Y2NkNmQ2OWRmNDJlYWIzNjdkMTg1ZjNiZmVhZDVfMjc0ODc3OTA4MDIzMg_bc0ddf39-3aa8-49b3-b360-0d3d3fd3ba3d">zero</span> and therefore recognized remaining amortization expense related to the Skokie Lease of $211 during the three months ended June 30, 2020.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of the Company&#8217;s lease liability as of June 30, 2020 were as follows:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:75.849%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.349%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Operating Leases </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:-13.5pt;padding-left:13.5pt;margin-bottom:9pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)  &#160;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Excluded from the table above are the lease payments associated with the Chicago Lease that has not commenced as of the end of the period, which is July 1, 2020 (the date the asset was made available to the Company by the lessor).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590080296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preferred Stock</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and December 31, 2019, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and December 31, 2019, the Company had authorized 200,000,000 shares of common stock, par value $0.0001.  As of June 30, 2020 and December 31, 2019, the Company had 87,206,346  shares and 86,069,263 shares issued and outstanding, respectively.  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The holders of shares of the Company&#8217;s common stock are entitled to one vote per share on all matters to be voted upon by the Company&#8217;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Company&#8217;s Board out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of the Company&#8217;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#8217;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#8217;s common stock. The outstanding shares of the Company&#8217;s common stock are fully paid and&#160;non-assessable.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">December 2019 Offering</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 23, 2019, the Company sold 10,000,000 shares of its common stock at the public offering price of $2.75 per share in an underwritten public offering, for gross proceeds of $27,500 and estimated net proceeds of $25,344 after deducting underwriting discounts and commission and other offering expenses payable by the Company (the &#8220;December 2019 Offering&#8221;).  In addition, the Company granted the underwriters a 30-day option to purchase an additional 1,500,000 shares of common stock offered in the common stock offering. On January 6, 2020, the underwriters partially exercised the option to purchase an additional 1,081,184 shares of common stock at the public offering price of $2.75 per share for additional gross proceeds of $2,973 and net proceeds of $2,766 after deducting underwriting discounts and commission and other offering expenses.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The shares sold in the December 2019 Offering were sold pursuant to a registration statement on Form S-3 that was declared effective by the SEC on July 24, 2019.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock Warrants</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As of June 30 2020, warrants to purchase 413,320 shares of common stock at a price of&#160;$3.00&#160;per share remain outstanding.  The Warrants expire as follows: 163,174 warrants expire on March 27, 2021; 132,884 expire on April 28, 2021; and 117,262 expire on May 3, 2021.  The Warrants are classified as a liability which is remeasured each period at fair value. See Note 12,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;for more information on the fair value of the common stock warrant liability.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%;"><tr><td style="width:1.0%;"/><td style="width:56.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.710%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.854%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.710%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.857%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net loss reclassified from accumulated other comprehensive loss resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $23 and $6, respectively, for the three months ended June 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $9,404.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246667957720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text">Equity-Based Compensation<div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 4,600,000 shares, (ii) 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Company&#8217;s Board. The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by 4,303,463 shares, effective January 1, 2020.</span></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, the aggregate number of common stock options available for grant under the 2017 Equity Incentive Plan was 2,283,019.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="text-align:center;margin-top:17pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">704&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unamortized equity-based compensation expense at June 30, 2020 was $4,893, which is expected to be amortized over a weighted-average period of 2.9 years. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.493%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.352%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.354%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.2 to 6.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.3 to 6.1 years</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.41% to 1.68%; weighted avg. 0.67%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.86% to 2.56%; weighted avg. 2.34%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">81.0% to 85.8%; weighted avg. 83.8%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">83.2% to 86.7%; weighted avg. 84.4%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeiture rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2020 and 2019 are summarized in the table below:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:54.500%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.348%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.350%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$1.19 to $2.80; weighted avg. $1.85</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$1.19 to $2.80; weighted avg. $1.85</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$2.78 to $2.80:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">weighted avg. $2.79</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$2.78 to $2.80:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">weighted avg. $2.79</span></div></td></tr></table></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted-average grant date fair value of common stock options granted in the six months ended June 30, 2020 and 2019 was $1.29 and $1.99 per common stock option, respectively.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding - December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,697,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,075,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55,899)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,750)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding - June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,698,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable - June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,372,185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and Expected to Vest -<br/>June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,442,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588497192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company incurred a pretax loss in each of the three and six months ended June 30, 2020 and 2019, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended.  The effective tax rate is 0% in each of the three and six months ended June 30, 2020 and 2019 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). The CARES Act, among other things, allows for a five-year carry back of federal net operating losses generated in 2018 through 2020 and removes the 80% taxable income limitation for net operating loss deductions for tax years ending before 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246589956120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common ShareBasic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the <div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and six months ended June 30, 2020 and 2019.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is the computation of loss per common share for the three and six months ended June 30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.142%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.911%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,311)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,220)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,506)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,174,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,368,174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,126,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,363,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted loss per common share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.05)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.04)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outstanding securities presented below were excluded from the calculation of loss per common share for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%;"><tr><td style="width:1.0%;"/><td style="width:69.082%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.054%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.607%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.057%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">As of June 30,</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,698,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,078,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">413,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">413,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590138408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASC Topic 820, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.955%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.982%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 are as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.628%;"><tr><td style="width:1.0%;"/><td style="width:45.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.937%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.011%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.937%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.184%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.283%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.665%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.460%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,498&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,498&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,902&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s common stock warrant liability (refer to Note 8, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stockholders&#8217; Equity</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for more information) is classified within Level 3 of the fair value hierarchy.  The fair value of the common stock warrant liability was determined using the Black-Scholes option-pricing model.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the common stock warrant liability is based significantly on the fair value of the Company&#8217;s common stock.  At the date of issuance, the common stock warrant liability was determined using the following weighted-average assumptions: expected term of 2.0 years, risk-free interest rate of 1.53%, expected volatility of 78.97%, and no expected dividends.  </span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following weighted-average assumptions were used to estimate the fair value of the common stock warrant liability at June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:76.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.315%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A 10% change in the estimate of expected volatility at June 30, 2020 would increase or decrease the fair value of the common stock warrant liability in the amount of $33.  A 10% change in the estimate of fair value of the common stock at June 30, 2020 would increase or decrease the fair value of the common stock warrant liability in the amount of $59.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.237%;"><tr><td style="width:1.0%;"/><td style="width:71.741%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:24.259%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain included in other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(157)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590008120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Refer to Note 7,&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Leases</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for a discussion of the commitments associated with the Company&#8217;s lease agreements.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Northwestern University License Agreements</span></div>On December 12, 2011, (1) AuraSense, LLC, the Company&#8217;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;Assigned Field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#8220;Restated License Agreement&#8221;). In February 2016, the Company obtained exclusive license as to NU&#8217;s rights in certain SNA technology it jointly owns with NU (the &#8220;Co-owned Technology License&#8221;). The Company&#8217;s license to NU&#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;Wound Healing License&#8221;). The Company&#8217;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  As of December 31, 2019, all pending patent applications under the Wound Healing License have been abandoned.  As of June 30, 2020, the Company has paid to NU an aggregate of $8,229 in consideration of each of the obligations described above.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588243896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party TransactionsThe Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board. The Company paid $50 in each of the six months ended June 30, 2020 and 2019 in connection with these consulting services and these amounts are recognized as an expense in the accompanying unaudited condensed consolidated statement of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588603560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying unaudited condensed consolidated financial statements and has concluded that there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying unaudited condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590068568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements as of June 30, 2020 and December 31, 2019, and for the three and six months ended June 30, 2020 and 2019, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 10, 2020. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per common share</a></td>
<td class="text">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246677366008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expense and Other Current Assets</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prepaid expenses and other current assets</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical, contract research and manufacturing costs</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">481&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">221&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">705&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,588&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,955&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and equipment, net</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Scientific equipment</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computers and software</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, gross</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,108&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,416&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,644)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,317)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,099&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Other Noncurrent Assets</a></td>
<td class="text"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other noncurrent assets</span></div><div style="margin-top:5pt;margin-bottom:9pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid lease costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total other noncurrent assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,266&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued expenses and other current liabilities</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued payroll-related expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">706&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued legal expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">362&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued clinical, contract research and manufacturing costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">292&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,947&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,435&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Other Noncurrent Liabilities</a></td>
<td class="text"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other noncurrent liabilities</span></div><div style="text-align:center;margin-top:9pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:67.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.903%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.905%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;Total other noncurrent liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588459416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Investments</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:282.75pt;"><tr><td style="width:1.0pt;"/><td style="width:211.00pt;"/><td style="width:1.0pt;"/><td style="width:1.0pt;"/><td style="width:67.75pt;"/><td style="width:1.0pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">One year or less</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After one year but within two years</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;June 30, 2020&#160;and December 31, 2019 were as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.826%;"><tr><td style="width:1.0%;"/><td style="width:44.247%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.565%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.672%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.787%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.672%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.390%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.672%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.395%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,166&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,798&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,241&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">342&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.025%;"><tr><td style="width:1.0%;"/><td style="width:43.950%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.852%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.680%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.852%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.680%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.680%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.206%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Holding Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,932&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,513&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,786&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588603560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of the Company&#8217;s lease liability as of June 30, 2020 were as follows:</span></div><div style="text-align:center;margin-top:14pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:75.849%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.349%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Years Ending December 31,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Operating Leases </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (remaining six months)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">147&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:-13.5pt;padding-left:13.5pt;margin-bottom:9pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)  &#160;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Excluded from the table above are the lease payments associated with the Chicago Lease that has not commenced as of the end of the period, which is July 1, 2020 (the date the asset was made available to the Company by the lessor).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588574728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.980%;"><tr><td style="width:1.0%;"/><td style="width:56.469%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.710%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.854%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.710%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.857%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590022424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Equity-Based Compensation Expense Classification in Statement of Operations</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="text-align:center;margin-top:17pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">224&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">341&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">704&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">439&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Fair Value of Common Stock Option Grants</a></td>
<td class="text">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:56.493%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.352%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.354%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.2 to 6.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.3 to 6.1 years</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.41% to 1.68%; weighted avg. 0.67%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.86% to 2.56%; weighted avg. 2.34%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">81.0% to 85.8%; weighted avg. 83.8%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">83.2% to 86.7%; weighted avg. 84.4%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeiture rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the six months ended June 30, 2020 and 2019 are summarized in the table below:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:54.500%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.348%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:19.350%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$1.19 to $2.80; weighted avg. $1.85</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$1.19 to $2.80; weighted avg. $1.85</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$2.78 to $2.80:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">weighted avg. $2.79</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$2.78 to $2.80:</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">weighted avg. $2.79</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Common Stock Option Activity</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:39.826%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.942%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.945%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding - December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,697,714&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,625&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,075,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(55,899)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,750)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding - June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,698,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.2</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable - June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,372,185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.12&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and Expected to Vest -<br/>June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,442,992&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.22&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.1</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588597576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of earnings (loss) per common share</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is the computation of loss per common share for the three and six months ended June 30, 2020 and 2019:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.142%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.908%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.541%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.911%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,311)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,220)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,506)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,174,533&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,368,174&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,126,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,363,115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted loss per common share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.05)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.12)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.04)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="text-indent:18pt;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outstanding securities presented below were excluded from the calculation of loss per common share for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%;"><tr><td style="width:1.0%;"/><td style="width:69.082%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.054%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.607%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.057%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">As of June 30,</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,698,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,078,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">413,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">413,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588588744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.955%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.660%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.982%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,188&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,275&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,051&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 are as follows:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.628%;"><tr><td style="width:1.0%;"/><td style="width:45.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.937%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.011%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.937%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.184%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.283%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.665%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.460%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,498&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,498&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes/bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasuries</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,784&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,902&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,078&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total financial liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value of Warrant Liability</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following weighted-average assumptions were used to estimate the fair value of the common stock warrant liability at June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:76.685%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.315%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.09&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended June 30, 2020:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:73.237%;"><tr><td style="width:1.0%;"/><td style="width:71.741%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:24.259%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">414&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain included in other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(157)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588561352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate', window );">Accumulated deficit generated, since inception | $</a></td>
<td class="num">$ (103,295)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Lease Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retained Earnings (Accumulated Deficit), Inception to Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246586010440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 13, 2019 </div>
<div>USD ($) </div>
<div>agreements</div>
</th>
<th class="th">
<div>Feb. 17, 2019 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,847<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 14,030<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_AllerganCollaborationMember', window );">Allergan Collaboration | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_NumberofCollaborationPrograms', window );">Number of collaboration programs | agreements</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice', window );">Termination period upon written notice</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember', window );">Dermelix License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue', window );">Aggregate regulatory milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue', window );">Potential milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember', window );">Dermelix License Agreement | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets', window );">Number of additional collaboration targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationDevelopmentExpenses', window );">Collaboration development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment', window );">Collaboration option rights usage term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember', window );">Development and Commercialization License | Allergan Collaboration | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Allergan Collaboration | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment', window );">Development milestone payment</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment', window );">Product approval and launch milestone payment</a></td>
<td class="nump">132,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment', window );">Sales milestone payment</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Extended Option, Additional Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Number of Additional Collaboration Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Period To Exercise Upon Commencement Of SNA Technology Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Termination Period Upon Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Development Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_NumberofCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Collaboration Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_NumberofCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_AllerganCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_AllerganCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246595294152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid clinical, contract research and manufacturing costs</a></td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,588<span></span>
</td>
<td class="nump">$ 1,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246667604728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,317)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246685318616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Other noncurrent assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PrepaidLeaseCosts', window );">Prepaid lease costs</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid services</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="nump">$ 2,266<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PrepaidLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Lease Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PrepaidLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246593988856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll-related expenses</a></td>
<td class="nump">$ 706<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityCurrent', window );">Common stock warrant liability</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent', window );">Accrued clinical, contract research and manufacturing costs</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,947<span></span>
</td>
<td class="nump">$ 2,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical, Contract Research And Manufacturing Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockWarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockWarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590076472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Other noncurrent liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246593164104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableForSaleCurrentPercent', window );">One year or less</a></td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent', window );">After one year but within two years</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableforSalePercent', window );">Total</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableForSaleCurrentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Current, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableForSaleCurrentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Noncurrent, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableforSalePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available for Sale, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableforSalePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246668261080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments Available-for-sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">$ 68,241<span></span>
</td>
<td class="nump">$ 64,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">68,579<span></span>
</td>
<td class="nump">64,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">15,166<span></span>
</td>
<td class="nump">13,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">15,188<span></span>
</td>
<td class="nump">13,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">44,798<span></span>
</td>
<td class="nump">36,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">45,065<span></span>
</td>
<td class="nump">36,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">2,257<span></span>
</td>
<td class="nump">4,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized costs</a></td>
<td class="nump">6,020<span></span>
</td>
<td class="nump">9,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 6,051<span></span>
</td>
<td class="nump">$ 9,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246595640296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 02, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,999<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Secured Debt | Hercules Technology Growth Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">$ 4,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsForDebtEndTermFees', window );">Payments for debt end term fees</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsForDebtEndTermFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Debt End Term Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsForDebtEndTermFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246667649944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2020 </div>
<div>USD ($) </div>
<div>numberOfPeriods </div>
<div>$ / squarefeet</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Contract term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions', window );">Number of extensions | numberOfPeriods</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths', window );">Annual base rate initial twelve months | $ / squarefeet</a></td>
<td class="nump">37.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths', window );">Annual rent payment initial twelve months</a></td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease', window );">Base rent annual percentage increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm', window );">Estimated rental payment over original term</a></td>
<td class="nump">$ 12,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement', window );">Landlord contribution towards tenant improvement</a></td>
<td class="nump">3,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement', window );">Rental payment adjusted for abatement</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_OperatingLeaseAssetRemainingUsefulLife', window );">Operating lease asset, remaining useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rate Initial Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Annual Rent Payment Initial Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Base Rent Annual Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Contribution Towards Tenant Improvement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Estimated Rental Payment Over Original Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Lease Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Number of Extensions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Rental Payment Adjusted For Abatement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_OperatingLeaseAssetRemainingUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Asset, Remaining Useful Life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_OperatingLeaseAssetRemainingUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246589996136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Rental Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (remaining six months)</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246595640696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Current Capitalization (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>vote_per_share </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">87,206,346<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">87,206,346<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockVotingRightsforEachShare', window );">Common stock, voting rights for each share | vote_per_share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockVotingRightsforEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights for Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockVotingRightsforEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246668222536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - 2019 Stock Offerings (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 06, 2020</div></th>
<th class="th"><div>Dec. 23, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,973<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xcur_CommonStockIssuedDecember2019Member', window );">Common Stock Issued December 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share in sale of stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="nump">1,081,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="nump">$ 2,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">$ 2,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Additional shares of common stock offered in common stock offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock, Net of Underwriting Discounts, Commissions and Other Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xcur_CommonStockIssuedDecember2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xcur_CommonStockIssuedDecember2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246673580200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>May 03, 2021</div></th>
<th class="th"><div>Apr. 28, 2021</div></th>
<th class="th"><div>Mar. 27, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ClassofWarrantorRightExpired', window );">Warrant expirations</a></td>
<td class="nump">117,262<span></span>
</td>
<td class="nump">132,884<span></span>
</td>
<td class="nump">163,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ClassofWarrantorRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ClassofWarrantorRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246595715672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 85,114<span></span>
</td>
<td class="nump">$ 80,747<span></span>
</td>
<td class="nump">$ 16,155<span></span>
</td>
<td class="nump">$ 80,747<span></span>
</td>
<td class="nump">$ 20,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">81,752<span></span>
</td>
<td class="nump">85,114<span></span>
</td>
<td class="nump">11,391<span></span>
</td>
<td class="nump">81,752<span></span>
</td>
<td class="nump">11,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains, available for sale securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized losses, available for sale securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of debt securities, available-for-sale</a></td>
<td class="nump">9,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">338<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 338<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246667394664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="nump">$ 4,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition period</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, stock options, exercised</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares', window );">Number of additional shares authorized, potential maximum additional shares</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding', window );">Number of additional shares authorized, percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">2,283,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock | Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,303,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246595709320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 439<span></span>
</td>
<td class="nump">$ 985<span></span>
</td>
<td class="nump">$ 928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246668153816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.0186%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">0.832%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">0.0256%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.80%<span></span>
</td>
<td class="nump">0.867%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.67%<span></span>
</td>
<td class="nump">0.0234%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.80%<span></span>
</td>
<td class="nump">0.844%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246668093304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price of Common Stock Option (dollars per share)</a></td>
<td class="nump">1.19<span></span>
</td>
<td class="nump">2.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="nump">2.80<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price of Common Stock Option (dollars per share)</a></td>
<td class="nump">2.80<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair Value of Underlying Common Stock (dollars per share)</a></td>
<td class="nump">1.85<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price of Common Stock Option (dollars per share)</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246595718760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares) | shares</a></td>
<td class="nump">5,697,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,075,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares) | shares</a></td>
<td class="num">(55,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(18,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares) | shares</a></td>
<td class="nump">7,698,313<span></span>
</td>
<td class="nump">5,697,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands) | $</a></td>
<td class="nump">$ 4,738<span></span>
</td>
<td class="nump">$ 4,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">4,372,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 3,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares) | shares</a></td>
<td class="nump">7,442,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands) | $</a></td>
<td class="nump">$ 4,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588250904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246675952456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Computation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,311)<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="num">$ (5,220)<span></span>
</td>
<td class="num">$ (5,286)<span></span>
</td>
<td class="num">$ (3,161)<span></span>
</td>
<td class="num">$ (10,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average basic and diluted common shares outstanding (in shares)</a></td>
<td class="nump">87,174,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,368,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,126,847<span></span>
</td>
<td class="nump">44,363,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share (in usd per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588345672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">7,698,313<span></span>
</td>
<td class="nump">5,078,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">413,320<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590621400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 68,579<span></span>
</td>
<td class="nump">$ 64,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">76,181<span></span>
</td>
<td class="nump">95,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">7,602<span></span>
</td>
<td class="nump">31,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">68,579<span></span>
</td>
<td class="nump">64,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7,602<span></span>
</td>
<td class="nump">31,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7,602<span></span>
</td>
<td class="nump">31,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">15,188<span></span>
</td>
<td class="nump">11,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">15,188<span></span>
</td>
<td class="nump">11,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">45,065<span></span>
</td>
<td class="nump">36,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">45,065<span></span>
</td>
<td class="nump">36,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">45,065<span></span>
</td>
<td class="nump">36,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">6,051<span></span>
</td>
<td class="nump">9,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">6,051<span></span>
</td>
<td class="nump">9,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">6,051<span></span>
</td>
<td class="nump">9,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockWarrantLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246667421064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 17, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate', window );">Impact of 10% change in estimate of expected volatility of the fair value of the common stock</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock', window );">Impact of 10% change in the estimate of fair value of the common stock</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability | Preferred Stock | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant liability, measurement input, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability | Preferred Stock | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Common stock warrant liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability | Preferred Stock | Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Common stock warrant liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember', window );">Warrant Liability | Preferred Stock | Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Common stock warrant liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246594829640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details) - Warrant Liability - Common Stock<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant liability, measurement input, term</a></td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Common stock warrant liability, measurement input</a></td>
<td class="nump">0.002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Common stock warrant liability, measurement input</a></td>
<td class="nump">0.9309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Common stock warrant liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246594682984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain included in other income (expense), net</a></td>
<td class="num">$ (157)<span></span>
</td>
<td class="num">$ (256)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value Measurements Using Significant Unobservable Inputs (Level 3) | Common Stock | Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2019</a></td>
<td class="nump">414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at June 30, 2020</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246588571576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsforLicenseAgreements', window );">Aggregate consideration paid to NU for agreement obligations</a></td>
<td class="nump">$ 8,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsforLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsforLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246590092184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Board of Directors | Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MAF_=9S('32)0DPA4Q;,'XBU+QD@A .:<"/YY)*+=1+2KB,Y01,P3(',#(O5
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M-*\>$X(ENS*0OS]2*EY?U#58<^VY^ ]02P,$%     @ E$4,48G@4G.= @
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MIPA7!K"_9DP^3Y2#YH$V^@-02P,$%     @ E$4,48AM*VLO!P  #"H  !@
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MUZ[C=DTS/HDN=L!;/09 BZD[)!VBYJ-[R35^<*YQ_2Z/JCOEYQVB9K02?OP
M\., _!C%Z@Y\IZP9HV0D?U%&\GT9R24C^<$9R77X08P$9-I+';H$9"2@ QD)
MZ'1&#K;>BRO?DQ1 $9C)41S>"ROKC2/2G*U?/5Q_*=)E]:K<Q[0HTD5U. ]]
MT5=+@?C_?9H6SU_*M^\V+X">_@]02P,$%     @ E$4,4=!U2Q;,!@  .!T
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M;"]W;W)K<VAE971S+W-H965T."YX;6R]6FUOW#82_BN$[ZYH@;5W[21MVKP
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M<K0 [U<6V2[]H /Z#V&?_Q=02P,$%     @ E$4,48,/OR$^!0  :@P  !@
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MYZ,R(J:_1O4/3K?AZK+0#B]"85OCS1.,%\#SE=9N]^ -#'?9^6=02P,$%
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M 23T,ES9HY)#3MC'EFM:.LYT(-FC7/L8I\J69XQ:.Y5QNTXJD'6D%@ E108
MIX%=L5\&X[D:].;STP:(?&Y=^-SE-NG-$R1QI%"N((</:F$T6B:C=:4SEN/Q
M&#!&R8"@8"G#M_-ZI9>J&1W8! .@<CI(7B$'/QEX 7_DU8I#'7V,_@A '>K[
MNV[8:9L!S.!H'&]ELC28L*X:1)3!,1N00)/K0O\#0H[+S,O1U9I-UH1B<T;M
M1$5;J3%R<9#%QME">]'@868K:S"-Q4>TX'8D8[-(!2AE[)1]TK7(*0MJJ[21
MB%/\')QZ):&\O-/E2&DP)?5E'9_3'WBK63DY82.%.4OI)YJOD _9_=H"N4A.
M2#KL;+1YFL+OK0THPJ3?EQAC]L3:;7_^89HFDZ?^&T25.TI%M#YFC@"J<!K8
M6KH'04[J$S^#;8.<27\J'*3'Y+_?@:@77MM&2'5@Y^]O?H>IO&=IT"TC39S?
M.H]H*%#IW6/QO2V$$0I39Q4$.,(K5$T+OI,.] N+!!=<6YR\ "Z40?<"./[,
M9T!ORD#!,8!LAA/W2&7M+,ZC*M'V)IIS:S*IDC4*W3^R;F#GIC!72CO:*E-Q
M'"PR=!BU!TL<-K%?'SV<14VAWL3HUEK+//B.:4@[EH/U;7G[\\^"YH=T;Y"N
MI^<QG7=WZ;QHTWDNZ3Z\_'N3[3/)]'W,%.=?L(OS<:-0*/0C):-N,A[C(4WQ
M$0LS?=K:IU-$-!.7J;1HX-["2H\/A]W);$KI)*$GPQ,:CKK]\>C>+!:%TFXZ
MFE R/:#",&G=GG\VA^MC:<==D6&0' )A&"4@-9YVTZ$\#(;"5O:.QM%D]A69
M_U\=!]W90$@)O2?IR=Z4/"#A8-P=(TD(F"(+O(UFDR\4''9'R>"@PI/D)%K2
M[Y!PUIU,QW>1X".6H<@U[$ZCF%'!=';2VM(A?>W"T3NZLR'G=;R98C38J@S-
M]>U@/5Q^Y\V=[\Z]N3F_4FXM0AM>(;1_-AEUR#6WT>8EV$V\ 2YLP'TR/N:X
MP+,3!ZRO+ 1L7V2#P[\$5_\"4$L#!!0    ( )1%#%'DZ@N'] (  )\&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;)55;6_3,!#^*Z<PH2%539IV
M+]W:2GL!!F)BV@9\0'QPDVMBS;$S^T+7?\_9:4-!K&A?$I]]SW//.7>7R=+8
M!U<B$CQ52KMI5!+5)W'LLA(KX?JF1LTG"V,K06S:(G:U19$'4*7B-$D.XTI(
M'<TF8>_&SB:F(24UWEAP354)NSI'99;3:!!M-FYE49+?B&>36A1XA_2EOK%L
MQ1U++BO43AH-%A?3Z&QP<C[R_L'AJ\2EVUJ#SV1NS(,W/N33*/&"4&%&GD'P
MZR=>H%*>B&4\KCFC+J0';J\W[.]"[IS+7#B\,.J;S*F<1L<1Y+@0C:);L[S"
M=3X'GB\SRH4G+%O?]"B"K'%DJC68%512MV_QM+Z'+<!Q\@P@70/2H+L-%%1>
M"A*SB35+L-Z;V?PBI!K0+$YJ_U'NR/*I9!S-+G%.DYB8R=MQMD:=MZCT&=0A
M7!M-I8.W.L?\3WS,"CH9Z4;&>;J3\&.C^S!,>I F:;*#;]BE-0Q\PQUIP:5T
MF3*NL0C?S^:.+)? CQWDHXY\%,A'+[RS_Z,^:[@6-BLA;3/M0=U8UPA-0 :H
M1""TE0.S"(8R@NNVL(C<!L25025<H<T:A0[N,2NU4:98P7M.@(\N1"U)*-A_
M_>HX39/3C6LP!Z=O0.B<NV_N\+'Q?()9<\_L?#2++ 'V?=R_\/#)ZSC;Z-C0
M]8+&"U/50J^X06LA<Q!*\=)/ ZD+X"G@B*.&]5S)0OA6=-!PV=@ ?R8&B.X2
MN/,:*VD%N2#L@=29:@*A/]P.4%L^DS5?P%PHH3/T#'NCWG@\#IE[?TXX\/(M
MPP);CT&2].^W,@EY2,T^Z AX<NS2Z0F20+\W.$@A9ZEK:52R#U1MGZ#O$^ J
MQZ[* RA-!N,>7YBK,8PGM>JMR49INQ@F@VU6)Y]>SMG_5]''6T.C0EN$T>@@
M,XVF=GYTN]WT/6N'SF_W=G1S31>2/ZO"!4.3_M%!!+8=AZU!I@XC:&Z(!UI8
MEOP'0>L=^'QA#&T,'Z#[)\U^ 5!+ P04    " "410Q1M_3J]B4'  !)$@
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MO7&FBW([7S[4N'<\,#@H@HNQ,5+W66*XHVD$_,<.:72Y#QG%1"L53H%SGH7
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MBUAJ1#,Y;:4I6_+\53..UN]MX5J$C^J$89D21Q1[6ES0USTZ_P+Z)7QPEIH
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ML0>JO<BT+T;6[O*PD8:N(DXLZ.Z'RBK0_E;25.U>K(/^-KG\%U!+ P04
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MU@?P?6&X:X/A$XR/Y/(G4$L#!!0    ( )1%#%%14.*AK (  /T%   9
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MOET4QP63L.%!^RL</L+6SV'D$ZA=>K,AQ];O"B:"\]AMP:2@4R9_^?WV'/8
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M5\/OXUGL^6^5!2QDF36QQP%HKA[Q,@4X-,4.;5'>A"]&E!]B1%HLF$(WH4:
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M70>J?X?[CI&M>_O6TM!+ZIHE?;J@L@DTOI%DX-"Q$XP?0\M_ %!+ P04
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M9OOG'Q?Y]/R-!Q4R B5%(96D+8B(Y+KA6#?HD#7QQMHJ?G?^$GZ@</&2I-G
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MGX5API(@9JD7H6(<T1B%$QPG64QCD+$]R8Z'9,=[DSW5V-W:[EB^T_$:R3Z
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MEAK+?->S>EGLOK:=A;A(8]#))&[Z6B9RT39>1',09JF@PQRS _LW^"S$2A2
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MG,KQ=(77R )>TN#5_@W04[=C3V,?"4OL='?4>PYM@SEBT\5"P8+J\PM*"'S
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M$L#]N92F_R 'PP^K\_\ 4$L#!!0    ( )1%#%&'G5@&@@,  "L(   9
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M&AHN3BQIFJ.R"G2^D]*<%M9!__]@^1]02P,$%     @ E$4,41O'Q[?W!
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M.0JUF0:#8.>XXV5%SA&F2<-*7"'=-TMMK;!'R7F-TG E06,Q#6:#Z_G8Q?N
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MEVSM6*]#%EFJ96R#D4$<)KM/\6 WHA+ :4L LP%L+X -6@*X#>#[ 6TS]&Q
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MN!E@TJJZS*N.D86[#Y?2X.WJFAF^?Z"L <ZOI32'CKUBFQ=U\A=02P,$%
M  @ E$4,45+BJV4<!   K1$  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&ULO5A;CYLX%/XK5M2'5IH.V%QR41*I20;MK-I5U&QW'U;[X $GL0HVM<UD
MNK]^C2&0$,*@=CHO"9?O.^=\YQR.,=,#%U_EGA %GI*8R=E@KU0ZL2P9[DF"
MY2U/"=-WMEPD6.E3L;-D*@B.#"F)+63;OI5@R@;SJ;FV%O,ISU1,&5D+(+,D
MP>+[@L3\,!O P?'"9[K;J_R"-9^F>$<V1'U)UT*?6965B":$2<H9$&0[&WR
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MPSW!$1$Y0-_?<JZ.)[F#Z@O-_']02P,$%     @ E$4,42I_M*FJ @  IP<
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MU66*YEIH)HI7]F1=<Z7/:3LL]$T*P@CT^PWGZG5B#NON;D[_ E!+ P04
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M&N#\4DJS[=B'K?Z.F?P!4$L#!!0    ( )1%#%'<@;E+,P(  $X%   9
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;*5476^;,!3]*Q;J0RMM@0#IUHH@
M-8FF==+4J%FWAVD/#MP$J\9FM@GMO]^U(8@J'YNT%_QUS[GG'JZ=-%(]ZP+
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M L&X %HOM,;#P&TP/*KI"U!+ P04    " "410Q1(41H$D\$  #T$P  &0
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M&$X%R#Q-B=A<(>7KOM-T7@_NDE6LS($[Z&5DA3-4#]E4Z)U;L41)BDPFG('
M9=_YV+P<=XV]-?B6X%INK<%$,N?\T6PF4=_QC""DN%"&@>C;$PZ14D.D9?PJ
M.9W*I0%NKU_9QS9V'<N<2!QR^CV)5-QWN@Y$N"0Y57=\?8-E/&W#M^!4VBNL
M"]LP=&"12\73$JP5I DK[N2YS,,6H!D< /@EP#\6T"H!K6,!00D(C@6T2T#[
M6$!8 D*;^R)9-M,CHLB@)_@:A+'6;&9ARV71.L$),XTU4T(_331.#48X5W .
M7XD0Q-083D>H2$+EF3Y]F(W@].0,3B!A<!_S7!(6R9ZKM&,#=Q>EDZO"B7_
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M/CUY^)XSO;NY0]-%<"\RC"=%K$=NX N1DABWP,<9U82EZ@JIST\S^/CA"CZ
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M/QY4F@MXOA18+LJ->:#Z*S/Y'U!+ P04    " "410Q1]0"OT!H#  ##"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6S-5EMOVC 8_2M6U(=66ILK
M 2I XK:MTRJALFX/TQX,^2!1$YO:#BG_?K83TA!2A+8^] 5LYYSS7>-\O8RR
M)QX""/22Q(3WC5"(S:UI\F4(">8W= -$/EE1EF AMVQM\@T#'&A2$IN.9?EF
M@B-B#'KZ;,8&/9J*."(P8XBG28+9;@0QS?J&;>P/'J)U*-2!.>AM\!KF(!XW
M,R9W9JD21 D0'E&"&*SZQM"^G=J6(FC$SP@R7EDC%<J"TB>UN0OZAJ4\@AB6
M0DE@^;>%,<2Q4I)^/!>B1FE3$:OKO?IG';P,9H$YC&G\*PI$V#<Z!@I@A=-8
M/-#L*Q0!M93>DL9<_Z*LP%H&6J9<T*0@2P^2B.3_^*5(1(4@=9H)3D%PZ@3O
M#8);$-QS+7@%P3O70JL@Z-#-/':=N D6>-!C-$-,H:6:6NCL:[;,5T14H\P%
MDT\CR1.#Z7,:B=WU2.8Z0&.:R ;D6)?P&LUE5P9I#(BN#A]-7]0:T.4$!(YB
M?B7!C_,)NKRX0A<H(NA'2%..2<![II!.*E/FLG!HE#ODO.&0B^XI$2%'4Q)
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M41.:'@)>Y?/Q[AZS=40XBF$E35DW;=F8+)^8\HV@&ST2+*B0 X9>AG+*!*8
M\OF*4K'?* /EW#KX"U!+ P04    " "410Q1\I'QBYX#  !J#P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T.2YX;6S-5UUOHS@4_2L6TDJ[TA9L2"@=)9&2
M3$<[HZU4M9J9A]4^..$FL0HX8YNF^?=K&PK)#IA4NP]]2;#Q.=QS/[C<R8&+
M)[D#4.@ESPHY]79*[3\$@5SO(*?2YWLH])T-%SE5>BFV@=P+H*D%Y5D08AP'
M.66%-YO8O7LQF_!29:R >X%DF>=4'!>0\</4(][KQ@/;[I39"&:3/=W"(ZBO
M^WNA5T'#DK(<"LEX@01LIMZ<?%B2&P.P)[XQ.,B3:V2DK#A_,HO/Z=3#QB+(
M8*T,!=5_S["$+#-,VHX?-:G7/-, 3Z]?V3]9\5K,BDI8\NP[2]5NZB4>2F%#
MRTP]\,,?4 L:&[XUSZ3]18?Z+/;0NI2*YS586Y"SHOJG+[4C3@#AN <0UH#P
M4D!4 R(KM++,ROI(%9U-!#\@84YK-G-A?6/16@TK3!@?E=!WF<:IV>V/DJGC
MU4)[(D5+GNOTD-0Z^ K-I0[NWBPD^FKNZZQ!GR@3Z!O-2D!W0&4I0 =5H5\_
M@J(LD[]- J7-,N3!NC9A49D0]I@0HSM>J)U$MT4*Z3D^T'(:3>&KID7H)/Q2
M%CZ*\.\HQ"'NL&=Y,9S<.,R)&A='EB_JX7O<40%7JY\]/!>"%MO*?ZLC.CUW
M3X]V>WZ@(D5__:DIT6<%N?S;8="H,6AD#1KU&*3S?P-,Z= A015T1<Q-,/8Q
M_J7+L6^&G=D_;NP?.WEN7_;Z):"]E+)GED*1HB.#+.W2X2;"?3K>##O3$3<Z
M8B?/'2M87N8.INN&Z?I]I%C2&)1<%B(%(N\*C!L^1D>@0J(0Y=6K@80HI4?9
M%:O+F**&*>E@.M-XTVB\<5(_,/ETM1$ B!5:)DC56TYN(NR/2&<:#L$P26)7
M(A+<=@%\6;R>>:8S)],]H?-%[F9)2%]!#0"QGT2A4\E)/R/NHJ(O T5%PI8K
M?!]E1=I>0J+_5E@#^+BN!U+5 XI[Z^I_(#K7V+8GXNX3;RBL 2;BQTEW/KIQ
MNK3"L;NTVF9%+NQ6 Z7E9DG&?M)36D/-*HFOG4K:=D7<_>J[_2;62N;/(/0W
MOHNT[5SDG;0NTO8NXNX9;\D_-Q/V?_)]';0A' ZCD3-J;9<B[C9Q:?ZY69*H
M-_^&NE0RZE82G$PM.8BM'>8D6O.R4-7'?K/;#(QS.R;]:W]A!DD[#;4TU11Z
M1\66Z>DE@XVFQ/ZUKA51#7;50O&]G8U67.E)RU[N]# ,PAS0]S><J]>%>4 S
M7L_^ 5!+ P04    " "410Q1.$![B^X"  #P"@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6S-5MMNXC 0_14KVH=6VI(+4$(%D2AMM5UMM:BH[<-J
M'TPR@%4[3FV'R]^O[:0I%$AY6%5](;[,.9XS,]C36W+Q+.< "JT8367?F2N5
M7;BNC.? L&SP#%*],^6"8:6G8N;*3 !.+(A1-_"\<Y=ADCI1SZZ-1-3CN:(D
MA9% ,F<,B_4E4+[L.[[SNG!/9G-E%MRHE^$9C$$]9".A9V[%DA &J20\10*F
M?6?@7PS]I@%8BT<"2[DQ1D;*A/-G,[E-^HYG/ (*L3(46'\6, 1*#9/VXZ4D
M=:HS#7!S_,I^8\5K,1,L8<CI$TG4O.^$#DI@BG.J[OGR!Y2"VH8OYE3:7[0L
M;3T'Q;E4G)5@[0$C:?'%JS(0&P"_=0 0E(#@6$"S!-C(N85G5M855CCJ";Y$
MPEAK-C.PL;%HK8:D)HUC)?0NT3@57;_D1*W/+G4D$C3D3)>'Q#; 9^@&$X$>
M,<T!\2EZ2!,0=$W2F;%CVF*L>/R,<)J@ZQ6(F$A (T%B:UWL_<X,E40G5Z P
MH?)4LWY#+I)S+$#V7*45&#_<N/3VLO V..#MSSQMH*;W'05>X.V!#X^&^]UM
MN*OC5@4OJ((76+[6 ;X[DA*6LQJF9L74M$S- TQC$Y"SR6X6!D+@= ;ZCZ/0
M9(TV[49X;9<'2RP2].>7ID2W"IC\6^-0JW*H52OMN-R?))Q2+"3*0!1)/=V7
MU.*HT!YE[I5%Y#=, A:;J=LU"AJ=L#+:4M&N5+1K5>S6Y9;[17D>JZ(XJENO
M8M?HL(KS2L5Y?9GAU0=EUJF8.E^CS,+*H?#SRBS<$_OP77[J;;8T="L-W<\K
MLNX1&NIMMC3XWML[X-6J>+(/GL[W8 %"/^ UR?4W'A?_:]2;_W9E^_5W]G^M
MN/*L[3LA;+_+UQXK?2ET#V3L[<GPFY]7=^59X0=*=JWV*'$WVA'3"]YA,2.Z
M"Z PU3"OT=&7I"C:JV*B>&8[E E7NM^QP[EN24$8 [T_Y5R]3DS34S6YT3]0
M2P,$%     @ E$4,43AR:9SO!   6Q,  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3$N>&ULM5A=;^(X%/TK%IJ'5FI)[)"O$46B='9W1AIM5::=A]4^F,1
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M9I(>'.L 7X.YY$Q<I 30)9@+&CV#/S?J%0</-%44VF$6@XL[(G"2\DOP 5B
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M"JY@8XAMI63FYQ*$[N;1-#H8[OFN1F^@>=:P'3P ?FHVQFET9"FY!&6Y5L1
M-8\6T^O5S/L'A\\<.GLD$U_)5NM'K]R6\RCV"8&  CT#<[\?L (A/)%+X_O
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MO9PK.5-9&:!_?Y.FQ=.;\ASW]N#^Y?]02P,$%     @ E$4,45>(>$R! P
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M;[6 6\[F9%N.9N>< +.PQ^$*XY"YUEPN8<@,-W V1LNX,!5BG4W'</:A A^
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MRM*D\,N49CEJYT#O%TK9G>$^4/X[&/P&4$L#!!0    ( )1%#%&YHAHT,@(
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M;W)K<VAE971S+W-H965T-C N>&ULC53?3]LP$/Y73A$/( T2TA8VU$:B+=-
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MB'96;W\SR_-7MF#_WR'^ U!+ P04    " "410Q1EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( )1%#%'8-:)9T@0
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M'O-9_TO-[ U02P$"% ,4    " "410Q1!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )1%#%'3[(4.
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( )1%#%&97)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ E$4,4?X:G!'2!0  VQD
M !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( )1%#%'<FB[\>P4   (5   8              " @18.  !X
M;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "410Q1B>!2<YT"
M  #D!@  &               @(''$P  >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&UL4$L! A0#%     @ E$4,42T%FR;V!   V1,  !@              ("!
MFA8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( )1%#%&Z
M;RT8,@,  *P)   8              " @<8;  !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6Q02P$"% ,4    " "410Q1B&TK:R\'   ,*@  &
M    @($N'P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
ME$4,4=!U2Q;,!@  .!T  !@              ("!DR8  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )1%#%'6IOI?& \  !0K   8
M          " @94M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " "410Q1@P^_(3X%  !J#   &               @('C/   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ E$4,40] A!&&&   E%@
M !D              ("!5T(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " "410Q18G(?UDX$  #7"@  &0              @($46P
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( )1%#%%K72>7
M* 4  !X,   9              " @9E?  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ E$4,4>3J"X?T @  GP8  !D
M ("!^&0  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "4
M10Q1M_3J]B4'  !)$@  &0              @($C:   >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )1%#%'0S(L!@P<  *$4   9
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M970Q.2YX;6Q02P$"% ,4    " "410Q1P#+#_$L"   P!0  &0
M    @($9CP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M )1%#%%14.*AK (  /T%   9              " @9N1  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ E$4,42>*L11Y @  Y 4  !D
M             ("!?I0  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " "410Q1WJL/%DP(  !)%@  &0              @($NEP  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( )1%#%&KWT[L<P0
M )8,   9              " @;&?  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ E$4,44MZPXK, P  & D  !D              ("!
M6Z0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "410Q1
MQ:DU8@$#  !1!@  &0              @(%>J   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( )1%#%% E>!L!@,  / &   9
M      " @9:K  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ E$4,4875EM*,!0  9 T  !D              ("!TZX  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "410Q1AYU8!H(#   K"
M&0              @(&6M   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( )1%#%$;Q\>W]P0   8.   9              " @4^X  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ E$4,4?*L#Z1A
M @  '@4  !D              ("!?;T  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " "410Q1D9#$R58%  !L&0  &0
M@($5P   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( )1%
M#%$A-+P"L0(  %T'   9              " @:+%  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ E$4,45+BJV4<!   K1$  !D
M         ("!BL@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " "410Q1*G^TJ:H"  "G!P  &0              @('=S   >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( )1%#%'V"HWX"@,  -,(
M   9              " @;[/  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ E$4,4=R!N4LS @  3@4  !D              ("!_](
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "410Q14K9;
M 1\"  !@!0  &0              @(%IU0  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( )1%#%$A1&@23P0  /03   9
M  " @;_7  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
ME$4,4;N,LY#( @  A@@  !D              ("!1=P  'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " "410Q1PX#L[L4#  #4"P  &0
M            @(%$WP  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( )1%#%&^9Z>\E0(  -0&   9              " @4#C  !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ E$4,47I'DBH' P
MD@H  !D              ("!#.8  'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " "410Q1:;GYV&,#  "U"P  &0              @(%*
MZ0  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( )1%#%'I
M=@]GQ0(   H(   9              " @>3L  !X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ E$4,48^92A_3!   "A4  !D
M     ("!X.\  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )1%#%$X<FF<[P0  %L3   9              "
M@7,# 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ E$4,
M4?EG+5(3 @  #04  !D              ("!F0@! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " "410Q18/Q\ SL#   M"@  &0
M        @('C"@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( )1%#%$)BA&(S0(  !H(   9              " @54. 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ E$4,4>!RDT.:!P  Q#\
M !D              ("!61$! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " "410Q15XAX3($#    #0  &0              @($J&0$
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( )1%#%$$T8>3
MU@(  %$)   9              " @>(< 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ E$4,4;"4S[ * P  *0@  !D
M ("![Q\! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "4
M10Q1N:(:-#("  "?!   &0              @($P(P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( )1%#%$#4M /:0(  *0%   9
M          " @9DE 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#
M%     @ E$4,4=H&WL)3 @  2 P   T              ( !.2@! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "410Q1EXJ[',     3 @  "P
M    @ &W*@$ 7W)E;',O+G)E;'-02P$"% ,4    " "410Q1V#6B6=($  #'
M)P  #P              @ &@*P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ E$4,49@;6I[[ 0  RR,  !H              ( !GS ! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ E$4,4732QF+> 0  6B,
M !,              ( !TC(! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ $0 1 "3$@  X30!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>190</ContextCount>
  <ElementCount>331</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Collaborative Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements</Role>
      <ShortName>Collaborative Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2151114 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2153115 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Investments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2321303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/EquityBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2340306 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/LossPerCommonShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Collaborative Research and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails</Role>
      <ShortName>Collaborative Research and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Supplemental Balance Sheet Information - Other noncurrent assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Other noncurrent assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Supplemental Balance Sheet Information - Other noncurrent liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Other noncurrent liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/InvestmentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Investments Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Investments Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails</Role>
      <ShortName>Stockholders' Equity - Current Capitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Stockholders' Equity - 2019 Stock Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails</Role>
      <ShortName>Stockholders' Equity - 2019 Stock Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Equity-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails</Role>
      <ShortName>Equity-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails</Role>
      <ShortName>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/IncomeTaxes</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails</Role>
      <ShortName>Loss Per Common Share - Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Fair Value Measurements - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CommitmentandContingencies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="xcur-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Related-Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related-Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="xcur-20200630.htm">xcur-20200630.htm</File>
    <File>exicureexhibit102-empl.htm</File>
    <File>exicureexhibit311-63020.htm</File>
    <File>exicureexhibit312-63020.htm</File>
    <File>exicureexhibit321-63020.htm</File>
    <File>xcur-20200630.xsd</File>
    <File>xcur-20200630_cal.xml</File>
    <File>xcur-20200630_def.xml</File>
    <File>xcur-20200630_lab.xml</File>
    <File>xcur-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>xcur-20200630_g1.jpg</File>
    <File>xcur-20200630_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xcur-20200630.htm": {
   "axisCustom": 1,
   "axisStandard": 24,
   "contextCount": 190,
   "dts": {
    "calculationLink": {
     "local": [
      "xcur-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xcur-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "xcur-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xcur-20200630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xcur-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "xcur-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 435,
   "entityCount": 1,
   "hidden": {
    "http://www.exicuretx.com/20200630": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 8
   },
   "keyCustom": 43,
   "keyStandard": 288,
   "memberCustom": 9,
   "memberStandard": 39,
   "nsprefix": "xcur",
   "nsuri": "http://www.exicuretx.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exicuretx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Collaborative Research and License Agreements",
     "role": "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements",
     "shortName": "Collaborative Research and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Supplemental Balance Sheet Information",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Investments",
     "role": "http://www.exicuretx.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Debt",
     "role": "http://www.exicuretx.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - Leases",
     "role": "http://www.exicuretx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Stockholders' Equity",
     "role": "http://www.exicuretx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Equity-Based Compensation",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensation",
     "shortName": "Equity-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Income Taxes",
     "role": "http://www.exicuretx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Loss Per Common Share",
     "role": "http://www.exicuretx.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - Fair Value Measurements",
     "role": "http://www.exicuretx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsAtCarryingValue",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - Commitment and Contingencies",
     "role": "http://www.exicuretx.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151114 - Disclosure - Related-Party Transactions",
     "role": "http://www.exicuretx.com/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153115 - Disclosure - Subsequent Events",
     "role": "http://www.exicuretx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Investments (Tables)",
     "role": "http://www.exicuretx.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321303 - Disclosure - Leases (Tables)",
     "role": "http://www.exicuretx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Equity-Based Compensation (Tables)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationTables",
     "shortName": "Equity-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340306 - Disclosure - Loss Per Common Share (Tables)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareTables",
     "shortName": "Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "xcur:LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea",
      "reportCount": 1,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business and Basis of Presentation (Details)",
     "role": "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
     "shortName": "Description of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Collaborative Research and License Agreements (Details)",
     "role": "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
     "shortName": "Collaborative Research and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "if425dcd784314579ba01872343ba1d3d_D20191113-20191113",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xcur:NumberofCollaborationPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreements",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails",
     "shortName": "Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
     "shortName": "Supplemental Balance Sheet Information - Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i4340bc2a3caf476e9ea1655692119072_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Supplemental Balance Sheet Information - Other noncurrent assets (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails",
     "shortName": "Supplemental Balance Sheet Information - Other noncurrent assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "xcur:PrepaidLeaseCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails",
     "shortName": "Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Supplemental Balance Sheet Information - Other noncurrent liabilities (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails",
     "shortName": "Supplemental Balance Sheet Information - Other noncurrent liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xcur:DebtSecuritiesAvailableForSaleCurrentPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Investments (Details)",
     "role": "http://www.exicuretx.com/role/InvestmentsDetails",
     "shortName": "Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xcur:DebtSecuritiesAvailableForSaleCurrentPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Investments Available-for-sale Securities (Details)",
     "role": "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails",
     "shortName": "Investments Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "xcur:LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea",
      "reportCount": 1,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "id642410749d845f68e04f5594e957ca4_I20200228",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)",
     "role": "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails",
     "shortName": "Leases - Schedule of Future Minimum Rental Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stockholders' Equity - Current Capitalization (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
     "shortName": "Stockholders' Equity - Current Capitalization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Stockholders' Equity - 2019 Stock Offerings (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails",
     "shortName": "Stockholders' Equity - 2019 Stock Offerings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i76dc8df5d0f54a069fda9b63bd6295a9_D20191223-20191223",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails",
     "shortName": "Stockholders' Equity - Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i87bf2cd1655f4fab8c904201cabea717_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Equity-Based Compensation - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
     "shortName": "Equity-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails",
     "shortName": "Equity-Based Compensation - Schedule of Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
     "shortName": "Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statement",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i0b30acdba4af4f89add54dddf14c23da_I20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
     "shortName": "Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i0b30acdba4af4f89add54dddf14c23da_I20200630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i4340bc2a3caf476e9ea1655692119072_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails",
     "shortName": "Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Income Taxes (Details)",
     "role": "http://www.exicuretx.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i412f9837f22b489aafc44692b0c1aada_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
     "shortName": "Loss Per Common Share - Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i9736fd4b7b724ef987739ec27346148b_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i9736fd4b7b724ef987739ec27346148b_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i738818d3ada14fb59ae41e5c0547ff93_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ia02b9a6c3e74421db29f69c537e41533_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i57d24130c57c40ba8b47fd15cceac12a_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Fair Value Measurements - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails",
     "shortName": "Fair Value Measurements - Schedule of Assumptions used to Estimate Fair Value of Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i57d24130c57c40ba8b47fd15cceac12a_I20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i1c5c0eb47d394449b742692f031dee63_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:PaymentsforLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Commitment and Contingencies (Details)",
     "role": "http://www.exicuretx.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:PaymentsforLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "iaf91bb3242b54554bf09467575ed8032_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "id85a381bc7624171a8e7ce667919dcf2_D20190101-20190331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i3f7894134fb44db79f503167f8288191_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Related-Party Transactions - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related-Party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "i3f7894134fb44db79f503167f8288191_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Basis of Presentation",
     "role": "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation",
     "shortName": "Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.exicuretx.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20200630.htm",
      "contextRef": "ibe98af36b5604579bf17b5244677d385_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]",
        "terseLabel": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]",
        "terseLabel": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]",
        "terseLabel": "Former Address"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r223",
      "r225",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r361",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r223",
      "r225",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r361",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r213",
      "r223",
      "r225",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r361",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r213",
      "r223",
      "r225",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r361",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r190",
      "r224",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r337",
      "r339",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r152",
      "r153"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r35"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued legal expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r184"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r50",
      "r51"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on short-term investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r48",
      "r49",
      "r50",
      "r392",
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r98",
      "r99",
      "r100",
      "r288",
      "r400",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Additional Cash Flow Elements, Investing Activities [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r258"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in- Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r226",
      "r228",
      "r261",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r228",
      "r251",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r64",
      "r83",
      "r313"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of long-term debt issuance costs and fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r137",
      "r140",
      "r146",
      "r166",
      "r284",
      "r289",
      "r301",
      "r377",
      "r390"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r42",
      "r94",
      "r166",
      "r284",
      "r289",
      "r301"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r157",
      "r175"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized costs"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r155",
      "r158",
      "r175",
      "r381"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value",
        "verboseLabel": "Debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r229",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r97",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures (accounts payable and accrued expenses)"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r85"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r79",
      "r85",
      "r90"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r302"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r92",
      "r94",
      "r110",
      "r111",
      "r112",
      "r114",
      "r116",
      "r122",
      "r123",
      "r124",
      "r166",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r278",
      "r279",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Research and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 87,206,346 issued and outstanding, June\u00a030, 2020; 86,069,263 issued and outstanding, December\u00a031, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r62",
      "r383",
      "r397"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r208",
      "r209",
      "r212"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r208",
      "r209",
      "r212"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r214",
      "r222",
      "r406"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes/bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r37",
      "r96",
      "r200",
      "r203",
      "r204",
      "r205",
      "r311",
      "r312",
      "r314",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Debt fees (accrued expenses)"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Gross realized gains, available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Gross realized losses, available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expense and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r117",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Scientific equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r121",
      "r169",
      "r199",
      "r206",
      "r255",
      "r256",
      "r257",
      "r271",
      "r272",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r83",
      "r195"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liabilities",
        "verboseLabel": "Gain included in other income (expense), net"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Estimate Fair Value of Warrant Liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r291",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r292",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r295",
      "r296",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r214",
      "r215",
      "r220",
      "r222",
      "r292",
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r214",
      "r215",
      "r220",
      "r222",
      "r292",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r292",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value Measurements Using Significant Unobservable Inputs (Level 3)",
        "verboseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at June 30, 2020",
        "periodStartLabel": "Balance at December 31, 2019"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r298",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedTerseLabel": "Unbilled revenue receivable and accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r136",
      "r310",
      "r313",
      "r384"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r78",
      "r80",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid on debt"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeDividend": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of dividend income on nonoperating securities.",
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeDividend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r67",
      "r135"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments [Abstract]",
        "terseLabel": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r164",
      "r375",
      "r387",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020 (remaining six months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r94",
      "r141",
      "r166",
      "r285",
      "r289",
      "r290",
      "r301"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r94",
      "r166",
      "r301",
      "r378",
      "r394"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r94",
      "r166",
      "r285",
      "r289",
      "r290",
      "r301"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r32",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r52",
      "r55",
      "r61",
      "r84",
      "r94",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r113",
      "r137",
      "r139",
      "r142",
      "r145",
      "r147",
      "r166",
      "r301",
      "r382",
      "r396"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r50",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r137",
      "r139",
      "r142",
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails",
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r35"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets",
        "totalLabel": "Total other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r53",
      "r56",
      "r282",
      "r283",
      "r287"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income",
        "verboseLabel": "Other comprehensive income, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r44",
      "r48"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gains on available for sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities",
        "totalLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentliabilitiesDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r182"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of long-term debt fees and issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r70",
      "r73",
      "r156"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchase of available for sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r229",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid clinical, contract research and manufacturing costs"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Prepaid services"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r7",
      "r180",
      "r182"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from common stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sale or maturity of available for sale securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r70",
      "r71",
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale of debt securities, available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r254"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r183"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r185",
      "r395"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedTerseLabel": "Net losses (gains) reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r221",
      "r322",
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r221",
      "r322",
      "r323",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r221",
      "r322",
      "r325",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r320",
      "r321",
      "r323",
      "r326",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r264",
      "r412"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r90",
      "r376",
      "r391"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash included in other noncurrent assets",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r206",
      "r258",
      "r393",
      "r403",
      "r405"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r169",
      "r255",
      "r256",
      "r257",
      "r271",
      "r272",
      "r400",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r133",
      "r134",
      "r138",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150",
      "r210",
      "r211",
      "r362"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r60",
      "r94",
      "r133",
      "r134",
      "r138",
      "r143",
      "r144",
      "r148",
      "r149",
      "r150",
      "r166",
      "r301",
      "r385"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Additional shares of common stock offered in common stock offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Price per share in sale of stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r50",
      "r308",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Equity-Based Compensation Expense Classification in Statement of Operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of earnings (loss) per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of noncurrent assets.",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r95",
      "r324",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r229",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r231",
      "r238",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Common Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Determine Fair Value of Common Stock Option Grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r39",
      "r92",
      "r122",
      "r123",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise Price of Common Stock Option (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, stock options, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r233",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding ending balance (in shares)",
        "periodStartLabel": "Outstanding beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value (thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value (thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r227",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair Value of Underlying Common Stock (dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r245",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r379",
      "r380",
      "r389"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r92",
      "r94",
      "r110",
      "r111",
      "r112",
      "r114",
      "r116",
      "r122",
      "r123",
      "r124",
      "r166",
      "r199",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r40",
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r121",
      "r169",
      "r199",
      "r206",
      "r255",
      "r256",
      "r257",
      "r271",
      "r272",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r121",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r199",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock, net (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r199",
      "r206",
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercise of options (in shares)",
        "terseLabel": "Exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r199",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r199",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r94",
      "r154",
      "r166",
      "r301"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r206",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r328",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r214",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r214",
      "r222",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.",
        "label": "Unbilled Receivables, Current",
        "terseLabel": "Unbilled revenue receivable"
       }
      }
     },
     "localname": "UnbilledReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Common stock warrant liability, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant liability, measurement input, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average basic and diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical, Contract Research And Manufacturing Costs, Current",
        "label": "Accrued Clinical, Contract Research And Manufacturing Costs, Current",
        "terseLabel": "Accrued clinical, contract research and manufacturing costs"
       }
      }
     },
     "localname": "AccruedClinicalContractResearchAndManufacturingCostsCurrent",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_AllerganCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allergan Collaboration [Member]",
        "label": "Allergan Collaboration [Member]",
        "terseLabel": "Allergan Collaboration"
       }
      }
     },
     "localname": "AllerganCollaborationMember",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ArrangementNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement, Name [Axis]",
        "label": "Arrangement, Name [Axis]",
        "terseLabel": "Arrangement, Name [Axis]"
       }
      }
     },
     "localname": "ArrangementNameAxis",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xcur_ArrangementNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Arrangement, Name [Axis]",
        "label": "Arrangement, Name [Domain]",
        "terseLabel": "Arrangement, Name [Domain]"
       }
      }
     },
     "localname": "ArrangementNameDomain",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ClassofWarrantorRightExpired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Expired",
        "label": "Class of Warrant or Right, Expired",
        "terseLabel": "Warrant expirations"
       }
      }
     },
     "localname": "ClassofWarrantorRightExpired",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Extended Option, Additional Exercise Fee",
        "label": "Collaboration Agreement, Extended Option, Additional Exercise Fee",
        "terseLabel": "Collaboration option exercise fee"
       }
      }
     },
     "localname": "CollaborationAgreementExtendedOptionAdditionalExerciseFee",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Option, Exercise Fee",
        "label": "Collaboration Agreement, Option, Exercise Fee",
        "terseLabel": "Collaboration option exercise fee"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFee",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementOptionNumberofAdditionalCollaborationTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Option, Number of Additional Collaboration Targets",
        "label": "Collaboration Agreement, Option, Number of Additional Collaboration Targets",
        "terseLabel": "Number of additional collaboration targets"
       }
      }
     },
     "localname": "CollaborationAgreementOptionNumberofAdditionalCollaborationTargets",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Option, Period To Exercise Upon Commencement Of SNA Technology Development",
        "label": "Collaboration Agreement, Option, Period To Exercise Upon Commencement Of SNA Technology Development",
        "terseLabel": "Collaboration option rights usage term"
       }
      }
     },
     "localname": "CollaborationAgreementOptionPeriodToExerciseUponCommencementOfSNATechnologyDevelopment",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Term",
        "label": "Collaboration Agreement, Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Termination Period Upon Written Notice",
        "label": "Collaboration Agreement, Termination Period Upon Written Notice",
        "terseLabel": "Termination period upon written notice"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationPeriodUponWrittenNotice",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Non-refundable upfront payment received for research agreement"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Development Expenses",
        "label": "Collaboration Development Expenses",
        "terseLabel": "Collaboration development expenses"
       }
      }
     },
     "localname": "CollaborationDevelopmentExpenses",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CommonStockIssuedDecember2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Issued December 2019 [Member]",
        "label": "Common Stock Issued December 2019 [Member]",
        "terseLabel": "Common Stock Issued December 2019"
       }
      }
     },
     "localname": "CommonStockIssuedDecember2019Member",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_CommonStockVotingRightsforEachShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Voting Rights for Each Share",
        "label": "Common Stock, Voting Rights for Each Share",
        "terseLabel": "Common stock, voting rights for each share"
       }
      }
     },
     "localname": "CommonStockVotingRightsforEachShare",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "xcur_CommonStockWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Warrant Liability",
        "label": "Common Stock Warrant Liability",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "CommonStockWarrantLiability",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CommonStockWarrantLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Warrant Liability, Current",
        "label": "Common Stock Warrant Liability, Current",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "CommonStockWarrantLiabilityCurrent",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CommonStockWarrantLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Warrant Liability, Fair Value Disclosure",
        "label": "Common Stock Warrant Liability, Fair Value Disclosure",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "CommonStockWarrantLiabilityFairValueDisclosure",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ComputersandSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computers and Software [Member]",
        "label": "Computers and Software [Member]",
        "terseLabel": "Computers and software"
       }
      }
     },
     "localname": "ComputersandSoftwareMember",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consulting Services [Member]",
        "label": "Consulting Services [Member]",
        "terseLabel": "Consulting services"
       }
      }
     },
     "localname": "ConsultingServicesMember",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_DebtSecuritiesAvailableForSaleCurrentPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Current, Percent",
        "label": "Debt Securities, Available For Sale, Current, Percent",
        "terseLabel": "One year or less"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleCurrentPercent",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Noncurrent, Percent",
        "label": "Debt Securities, Available For Sale, Noncurrent, Percent",
        "terseLabel": "After one year but within two years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNoncurrentPercent",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtSecuritiesAvailableforSalePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available for Sale, Percent",
        "label": "Debt Securities, Available for Sale, Percent",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSalePercent",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DermelixLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dermelix License Agreement [Member]",
        "label": "Dermelix License Agreement [Member]",
        "terseLabel": "Dermelix License Agreement"
       }
      }
     },
     "localname": "DermelixLicenseAgreementMember",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_DevelopmentandCommercializationLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development and Commercialization License [Member]",
        "label": "Development and Commercialization License [Member]",
        "terseLabel": "Development and Commercialization License"
       }
      }
     },
     "localname": "DevelopmentandCommercializationLicenseMember",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExicureInc.2017EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exicure, Inc. 2017 Equity Incentive Plan [Member]",
        "label": "Exicure, Inc. 2017 Equity Incentive Plan [Member]",
        "terseLabel": "Exicure, Inc. 2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "ExicureInc.2017EquityIncentivePlanMember",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate",
        "label": "Fair Value Assumptions, Impact Of 10 Percent Change In Expected Volatility Rate",
        "terseLabel": "Impact of 10% change in estimate of expected volatility of the fair value of the common stock"
       }
      }
     },
     "localname": "FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock",
        "label": "Fair Value Assumptions, Impact Of 10 Percent Change In Fair Value Of Common Stock",
        "terseLabel": "Impact of 10% change in the estimate of fair value of the common stock"
       }
      }
     },
     "localname": "FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_HerculesTechnologyGrowthCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hercules Technology Growth Capital [Member]",
        "label": "Hercules Technology Growth Capital [Member]",
        "terseLabel": "Hercules Technology Growth Capital"
       }
      }
     },
     "localname": "HerculesTechnologyGrowthCapitalMember",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rate Initial Twelve Months",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Base Rate Initial Twelve Months",
        "terseLabel": "Annual base rate initial twelve months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Rent Payment Initial Twelve Months",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Annual Rent Payment Initial Twelve Months",
        "terseLabel": "Annual rent payment initial twelve months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Base Rent Annual Percentage Increase",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Base Rent Annual Percentage Increase",
        "terseLabel": "Base rent annual percentage increase"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Contribution Towards Tenant Improvement",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Contribution Towards Tenant Improvement",
        "terseLabel": "Landlord contribution towards tenant improvement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Estimated Rental Payment Over Original Term",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Estimated Rental Payment Over Original Term",
        "terseLabel": "Estimated rental payment over original term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Lease Area",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Lease Area",
        "terseLabel": "Lease area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Number of Extensions",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Number of Extensions",
        "terseLabel": "Number of extensions"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Rental Payment Adjusted For Abatement",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Rental Payment Adjusted For Abatement",
        "terseLabel": "Rental payment adjusted for abatement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_NumberofCollaborationPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Collaboration Programs",
        "label": "Number of Collaboration Programs",
        "terseLabel": "Number of collaboration programs"
       }
      }
     },
     "localname": "NumberofCollaborationPrograms",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_OperatingLeaseAssetRemainingUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Asset, Remaining Useful Life",
        "label": "Operating Lease Asset, Remaining Useful Life",
        "terseLabel": "Operating lease asset, remaining useful life"
       }
      }
     },
     "localname": "OperatingLeaseAssetRemainingUsefulLife",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_PaymentsForDebtEndTermFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Debt End Term Fees",
        "label": "Payments For Debt End Term Fees",
        "terseLabel": "Payments for debt end term fees"
       }
      }
     },
     "localname": "PaymentsForDebtEndTermFees",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_PaymentsOfCommonStockFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments Of Common Stock Financing Costs",
        "label": "Payments Of Common Stock Financing Costs",
        "negatedLabel": "Payment of common stock financing costs"
       }
      }
     },
     "localname": "PaymentsOfCommonStockFinancingCosts",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_PaymentsforLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for License Agreements",
        "label": "Payments for License Agreements",
        "terseLabel": "Aggregate consideration paid to NU for agreement obligations"
       }
      }
     },
     "localname": "PaymentsforLicenseAgreements",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_PrepaidLeaseCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Lease Costs",
        "label": "Prepaid Lease Costs",
        "terseLabel": "Prepaid lease costs"
       }
      }
     },
     "localname": "PrepaidLeaseCosts",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationOthernoncurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from Issuance of Common Stock, Net of Underwriting Discounts, Commissions and Other Offering Expenses",
        "label": "Proceeds from Issuance of Common Stock, Net of Underwriting Discounts, Commissions and Other Offering Expenses",
        "terseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsfromIssuanceofCommonStockNetofUnderwritingDiscountsCommissionsandOtherOfferingExpenses",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity2019StockOfferingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Retained Earnings (Accumulated Deficit), Inception to Date",
        "label": "Retained Earnings (Accumulated Deficit), Inception to Date",
        "terseLabel": "Accumulated deficit generated, since inception"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficitInceptiontoDate",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Aggregate Regulatory Milestone Revenue",
        "terseLabel": "Aggregate regulatory milestone revenue"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsAggregateRegulatoryMilestoneRevenue",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment",
        "terseLabel": "Development milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Potential Milestone Revenue",
        "terseLabel": "Potential milestone revenue"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsPotentialMilestoneRevenue",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment",
        "terseLabel": "Product approval and launch milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment",
        "terseLabel": "Sales milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "terseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding",
        "terseLabel": "Number of additional shares authorized, percentage of common stock outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares",
        "terseLabel": "Number of additional shares authorized, potential maximum additional shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_SupplementalBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information [Abstract]",
        "label": "Supplemental Balance Sheet Information [Abstract]",
        "terseLabel": "Supplemental Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "nsuri": "http://www.exicuretx.com/20200630",
     "xbrltype": "stringItemType"
    },
    "xcur_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrant Liability [Member]",
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://www.exicuretx.com/20200630",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsScheduleofAssumptionsusedtoEstimateFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r414": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r415": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r416": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r417": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308"
  },
  "r418": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r419": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r421": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001698530-20-000059-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001698530-20-000059-xbrl.zip
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MYZVNKM869CZ6YA+#M1NOZYQ@VRTD%I$%"ZDGF9X'Z"*+2U15\%-_!+"_\9_
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M'J"BZXK+8CDP92[X;TM['H 01\P.Q(#!O=&4L26&%%8(_B5U-D"$<>(<Q#:
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M*$SIDK=&9PM-#K$BW0+S;,(J*\*[BDU AKJN8!*/A28USWSGDIS]IHF4<<"
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M!_HZ5D -JMU#AB!\W0VH]D=),3UV.Z.AG'@@_2VE+J#11&J!2G0B6+QX5:)
M$'X@)H")(P=B#P:!$'*R0]Z"ZM^08)4RCJ4W]1(>TP1>8F$0/ K&$??$I.I3
M-W^&V<I;9D1Q'&6,@@A]/ G<#[:H/OR9_:ED&+Q-8-,R]6CSKWMMFC>S@9M9
M-,9Y@PZMW)GI/C7>H[/WYG"W:(U-8#M6#<'NS<@<KL'+N4W:A MHP.!Q"A,Z
M)[3-7?*@3C%^[C?=\6O-^>XSX)77W[I,"5[#\WQ4)I@KLV>H=:XQ5S)^4FR_
M_RP[*[:&>NQ!-J I".8LDARJQR .VC-3195UFE"J'M8"8P[GRXG- A^O&D-M
M#F*]YAAY>ZQZ3(\UWXKMT)F;R(4[56 T*MJL_G#9@!; H[W1$-6#,?.SC;-\
M*C/YK]?'/M2&[WVLV>:U&_ HR:S'ZG+M\&RTC[F7B; 1G1$-<G=X$&E1IC4'
MQE A/JV1"6'"+ I'BF: NOIR?S?VISA[D\@N>QEGW[_+WF.K F^@[7_R8*V#
M@@7;18.YYRYUIZ8Y^\6'44(]+ ^4&G0+*^P/FGNOHPI^.]*X)-7C!COUH#^V
M3_VQ?2_-@^##ZDD8%7&[I#251F(A*/7"B$9A,\_\O)S1E;D\F$H31=3',0QR
M%?V9HJGH(NJ1TE$Y1P,WDNP)8BP8#YLQP)EQ9C&8N;,U#&)R=7$FZ _'_ _&
MB+%&\@9*3!Z\GBDY"7X#,P4>QZ ?0M/M[>7<0M_GN\77.W0*9@,4&WX2D&S!
M.ISS;>S4<NX'F72M!3+73,AX2<<X7]8@X1)$!GCNNRYOU&5Y=[;+_0;-7/MP
MX..U 8AD2($&%F=%#6$0VV0[8&$__G ]>O$V1:^<">-=G[[8@T247M]=UTWJ
MD0F*BYX*B@^E7JJEZ 6LP[ 'S*Q+-_0\@$E=A,%5&%SO_HI,4_3=G^B=6S\Z
MV_T%P$YC)RVN9@1K)*>[6>MR(&TW"K0D(O[*=M)N;4%=QYQ&0R8/T2QO]G]J
MVCB4)5/9.=QR[+$Q]<N>,O7?R>W2BQJQ8? 2B*_I)VIO#^8*#[S&D[5>=K%,
M$,,;$534P"'989DL.I;06$ [@7W9<Z&2$!%."VQAM\#.!"JF'_(O?Y$QP8*_
M,?#GS@*'7Y8%F=%15FIL+FK@5#&_NDR$3DP$GC',<$$F)F*FMV8LD2":88/O
MG+NC&%<X*/7%&H."+GS-6S/@/J-J27.;B"A7F/'!P)OO;GZA!%_\2&A$AQ<&
MIP\;@*:!-&NM%="9!LT)\,L%>0KH5_[#;ELY.&V:@:B4X(JQD>JXS!5Y)V*L
M[5U7ZVNX^5L=?0-S*+0L_(L89]@AYZ5%"ZF"6<)NBROFB6,\$QE;[$'S@8<L
MSPVF#AI=@!BDGD+V/"06U4A$R1?4=RQ6F-M,CATSXH3A0V0RP16:.9F=AH.>
MPH+3P=VQ^3K?NV"VQQ1D+R6UT<$+F8A%+I_;O[S ^HE$K)^KE*X./?1BB30<
MB<2PUR);&(?\U=GP8G1./OE"P_]C.[[QUP_97W]4Q)M?7E\-CX_O^+[V\!$-
MSZ^ N8(IFO[]V>FS*J; + EF]OQD<>M8E-D!_*@C&_*D"/*WMJ77^!]:X/8#
MS6QF(QK4(IF^NQAZ<*W"I!'D[0.K;[DE7:C)#G(.;_DZ9,-TV)%R>DKP/B'<
M<U2=C[Q.*1U7A$D+*BK1<?4VK6+B3]OZI=MZ=7QV'OQ#S-%#!$((3(,/I0(I
M=C8Z?MKDK[7)S:S9X.+X^/+R(?O[Q+Z^(0E<6A+8%*#?D"A8^GIA0E^N/9'$
M_G.%FZR<)B(/W@S!3$R*%"$#?AO>/ FWK[;#+]FNFV>481;Y%AFBLJ#IV^Q)
MTK+[1V0P/1IWU55/W55OTD)IV:\X%S:#]9U385#AUB-1;@WB^2!5#(\F>?D5
MM#IW7L"D#NN@]2.CZ+@@>+P&. BA+QAWQUQ02V+C328?68GN,!D;6+@%OFM!
MC?DL!E[MC=1WT,PGYTI+TYK;P-DS;DC+O,(*F07AVH3MFTP <)2D;N%:T6$-
M;X>S2*6^<P6/S>]\W=.+_'M&>0N@@_7D#E=Y)HZ^^7ZLA-;"-=BN?H8(15C-
M8Y-/*F#BN:TBU2(J"*6QT(JC+E$&]IG J^\YD<W7P!H6FK ^ZJ6 5,C\E C=
M.1'ZJI>)T+UA5%MV/8)KLJ;2NM9JH\WR_*S6 H4N!$L'E5MY +N.LA2?RPM;
M>,)0I1B];*EI]*]-J6V0ILMUKNKS8I5'29:WM4Y1V+E/UCZ%'V$4@R'$JT0M
MTW@=Y*DL$&A%I=3DSP(H5=6;V"EM2JI"9B2P7*JLS"W(>=6CO6.WE/V1?:/C
MW@F_D<FDJ?5S?LG-EW=J+1UU6=NX/2VUK. S&73?J)-8SII2"@+%L6IY_?@]
MCH?)!]1D'K^PV^+:B_D*Y=)KDEW+_&/@_GJ?;-Y7%R@TD%4$B(??R(T.9 9#
M*\_+.=_B1 G'D1J_17V3%.%'=^U&/;UVOX)RI0G7]1]BM5-+>-AM@QLUI:7(
MN&J3 /("[PKV!PL.,.MU@2@3L5>@3LHVD3'\J"IJSZN^,X6I[;$N[$='V2<]
MI>R7B*WG' *?J#W]3JWD#@*7'BFV8*(P&+SK=X1:("X/<0F3=:7PL6.B4;.^
M :Y:SQ#'?Z89Y>9P,TK;>1EQ#85*4*8AF"483H1"RV+,NFWNG+41))QNA[]>
MPMV(*3M_K-A18W+Q,)W&BD<JA7HP$L?^7</3GE[#3T"-LRR)>X(%"8H1$.E"
MK.?.^C&Z6]6#LD;5A#)2I4FMJN5:R%8?24W<=FW@N$>D>]93TGV=Q=(AF9T=
M7[_<J65TU8]47FM53/#$GI P/>R-IWI26V\E*V(C&KP<4E"NP 2A>B).L,X+
M74K^&[L>[&LH'Y'A,8QPL]?+CP/?U4T5+YE(\JRV$C2B;M$-S]Z^;1.WVMY<
MW*IY.;>(=: )Y@KN9&BNM==(+I=8',;.19!R_!+ZES?#C]B'H=1KD[9*W__X
MP^CB\L5HB%,X'!V,!P?7 \[.9,#Q?);IXA#],"! )U)K[,[Q\$'/!GP8$P*#
M1OQW Y\6<CLAL[WUW6UE7NXXZ=!BROT5=OWNG(;!6P,?2J#*=_B2@E56)K'C
MA_6.NLC[R,4C02DGZY'GM/7@#GI=AT;+>6?7NAMKZ%9\%FY7$ W%1%FVD$0B
M,>AG4[[KZ(Q#C;1)(+(.#2:6F8J9;NM;%#8P)>T-!9Y1^YPF-8=MNTLD ^E:
MUXJ6E)0<;0&&ZC61;2VMWXWE= 0/X%QZX(HD8DP>/E-02[<$.L\]/$M/[' C
M+ZZ+"'=C-=V.\NX&OTT./PR:B(.=  :;C()" %:EF(M8FCYG%2*M\TOZ/9/2
M+/VKA,.A>A:6QZ2^S$% Y:9OVOWK";G;"U;,D/!E@6PDL O..#@HVS5[DW;9
MT>OU%$RH[1/%7^PP!N$4*UXR756DQ*8M6%6,$5N0#(K84/,FBA!A[0D(8F*-
M:XG5+M0R,.;PD0&YK_TBK*[@QGO-SN >5PWQ5EGM>;:AJ%9%3>JA8.%A8[GV
MM/?TB&Z2T,"#I=X.P[/M:K4<F86'M0)DRVEM&9&/BY0@2M888WH'[9OKE$@:
MIKH]Y'YM(DW1,94+KOMYP-3]LBVQIJ;)A4KX7@B=*.:1C# $(Q^\'#!4IM)Y
M025'MN4(:74STS^N0M+LOF:L07HUN.<(8BF*&8<=M%3S,?J7:,/M1G>U!7R=
MU=TITVP)%,^YRO-6E-$$(?;P:E.V BCBN6FE!F^W>,+L/+::#W,,_-M3)D'G
M3(+KITR"[R!_/1]31>2U6X8-K-8-(YX84^W>&>9KX0<K;M"$(&Q<)>YCKKS6
M.RP47.^K1-2Y3B02B>U46 K56ZC4OW.MSCS9D5*/E=@X,'B=_N*9S["10'HQ
M?PQ"%LX9;0JRG6L[%'*NPN&?JG+Y>;W-G(BM3Z[*@/#\VE_^7B/G-][NM*/:
M+-BIPL69)B.B?OAM*[N/P1K49<^UV>AG)6\C[JID&U/RS,P+'IV3LW]05\;)
MF8@5SK(7'HHO<!]ZA P$.Y%@ W H"SA;1F77331X734$;#K_*'/);)P=HUQX
MC-:P+'\\#-J).+/NRD+-V2T&?_K9SQ9\FEH/"(,W;&JZS=B9;QV1OEK+P1"Y
M[6[FDH2!%6$ @R"&&26],G)PK*D6<_;-)2+-N?<AJL$NU.C4(UP\+:+J;W:3
MQ?'A+UJD?P:?D'-\*&#?B^"]I#YH*'!>4\=T^/D[G15&D<=6:)2C@MWRYB:!
M4Y>)R;"N'*"4Y6W,M] X4NE@5BJ7-;T-#N31L9W^ 2?9V I3ZSMJK-D/_^AP
MPP]:%Y"X3*18D;C+N##+,[W<F0O0-:RXP&&1'3:Y@'O.E"E,L7,H=F@M,N0X
MJQ1,QIE:(-7G,E4DCLW43**8'8"?)=5*"QN6K+K3?ZL+TZ)Y/YE-=]"65W7\
M(+L)5ZKBOS]35V,ASZ\OKL>GUR=GU\<GX[/1^.S\,A8GIU<C$5W\[]FS;V5K
MM6PU*:,/(X]'PK'?IL$G51#NRR<NS^D#ZPMKM5,X;VP*AQXNYCMDB]5UKKI;
MCMU.-A>)P6JZ---I(Z1OB %S=CV\.KW^/ R8L^'9:5<(F =]>3J\O+K\%@./
MKH;7G5%K'O3EQ=GPZNKT2_!P1B=[4.M[^9!;^=7Q0=HKI^V%2#-"]ON6/VT]
MV(L].-=_1PWWJ_4F,L)G'M-.;_D6B7\\[";SCX<[)?4?#JV)^3W'+]K^>W;Y
M(J?_!C=BJ>+@Y3#X527_S&8B3?DWG93W1[R3OXLYXXNT[& 8O)L-;X9/&]EE
M(S^J(C$[&9C6!I4M;)H;;(^2;<>,:[,#OJZ0^5X(,?O(JG=(.F[CFO??^,\5
MJ/< TNP6G>W";)Y(^<M(V>.Y6SCN5R7EBYT"V/IB@V1W%[$+,WLRN;\4P*R.
M7G;S9'GO#T-^K);WCJ$Z?UN+NN4*=S$%OY,5LPLRXTDD__M%\EY00&\7<3<*
MYE,0>Q,%Y?."V$?C+%[#'[-BGOS\_P%02P,$%     @ E$4,488GBA3$!P
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M7-L[UA^GR)X64<"/0%G^\^F[G4T6?$M.KL*C2B-/CP5\2<]N6&W\5P7A]'\
MPC_(\?\XWUXNE$S8VTWQ?1^Z^VT?]SSE?L$[]AWOYQNK"AU^TC )#R&7LOF:
MO_GVO[5[&8\0U*63TPK)_G,_$_A66P*VZZ<+U6?X&87_0<?Y7U!+ P04
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MULX8W'8S9_%9WA(R]Y4._@-02P,$%     @ E44,42K;;NBT] ( 7>H@ !$
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M)$^QQ-3/YC4V/=_[(F%+")/IU*L:^T_ 45,-FH[8\0+_$U<,([O^V&;M.\+
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M1;([*K2L7$OWC<4SZF$M1FO!ZEY5E:,?SU*I*KA4@XVS<&>-C5LJQE3&1Q7
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M.,(HM07K(_>YLG)IRUJ,Y&(D%V'P:<Q<A,%%P."%Q>L3V""I)<%7#;Q5\M6
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M;@IX,E8E8@POIEO2U8@+#^7&::NLI=[Y9IOQJT.!$-@0V'YR8%M \!&![5'
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MA#YD=U1Q5/&%L_L<@L_([DME]^EHLM64)4D-R3QK(C45Q I/B6;4%./,A R
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M$$!<XHJDZ+. I'E*"6, JUK4\'0=8G!4YLIA/DY56<&ZUAH)IE9K6:QIB$"
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M_*UOOOU)]LQ)_L WTV?LMB<UO?7I6YZ\>\GBGF^^PXNXIRK/,\5XQ?1UC^J
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M3I37"UT<FC]AG8]@F3O6F56U^_7V%')*:9\C[UYB:$H8^+%$>+Y/HI :2<-
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MZF7+S-'T0\*^ -&Q$PQ/ @K519KP>C:RRGX,IGMZ7X [UG?]=$ $+,EXR_>
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M(3%A) D3- 4])P.2<NU'*029<>*_>A,NB2510ML1W(*-B;MG,Z2HW'?;I8Z
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M?I_!\TXW:-,Z#$02>$2E(B9,1(QP$_E$<),F)DB,IQ3"R&"YUJYX>=,./-8
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MG3;W/=M8!4V??F@UOS</&Z<'K+'ZE39/&Z"YM]L70Z.W-YN'VZ6%T(!SP+(
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M.+*>2Y2UP\! FY#>7>]SNF(4?P'%ZU&\ZRA&K%2B2B$M),V;) P"NT<C@X4
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M7Q4D[P_&Q<FGT.G8]F'4<\E-@,Q0?LV/S5&!,': _F?Q@4O%/[VNCS%D<*J
M$D#MN4&I*L4.]_HY>-<9'H;N8'3\HOB.&Y_#'+/ ;J2+(CP1[BSJM1!70LR;
MGW8"Q]IB24#)8PJ4/,*1852A8+WF-AA +U#RS"+'_)(@7RAUGP]G&6AUAJ54
MG5,ZCKK]5O[Q72E@(/FC(M($ X6/Z%S12M>8=9EUH*4-!_&/D5J"IZ^?487<
M3E=6?7$:#147NG;J;W[34FJU\C#+G-&)6^X)=LPRK$ED+!'OO-U1>&%\T5YO
MHG[O1N1 !SE -D'GO+/M8WO27_C]7!\"9(R;9')_7=G9C]"U*3U(UZI975O*
M!L!(MU>*Z#N ,# &\FFYW?;E-;H T@"\_9];2 ,HRF45>&"*]QFJR_K+=OF\
MI+W0>32SWQ:6U_YO_?W7SVN+Q7KS_=(=7G3.7ZNYL;GVI=C<*+XV5[ZNKF^N
MK1;O-YJK:\TOU:<O&W^OKZ[DGS^L-U>:[]=7_BZ^;,(/C;7FYI?7/.#_;G5
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M:)$\-TYK08TP*7!N;!(^C5:E0+RFI8H^F>#$7IZA8,QU,\G!+"^7OS:&@_X
M%!V8=V>B@^B;DYU/? >G#/C6 Z$I"83F,7(Z8I0<D=8QXEET"\N7PVK_-?:D
M#;H#VYZ)JMUAKP!>:^7C%;1V)]V>X6XU^EA>QLCX;D<]^*T\G@>E$VQOA).
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MT"M37UVUZ./K"KL/B_?12<<PM<E3L!>",]8X;:V,FEOK):Z7+^8 [T^FEB^
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M:_J>M48$:7121G /;2 L<)8(B2$&3F_"5UG+[)N4V:SO<<P!W@QB,@JP47!
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M"ZW9&=9A:LO_ALO.1-[M-^O8M5YLP:_?X]NC9ACL0_\ 2L9!B(J.)#'K-NM
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M&& !0H$%&#/(V<B925Q&K@H+%!8H+%!8X(&=1PK>/QG>3[1^SI+BU%KDE>*
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M!,"C14(*J/$Y,OCH&G,!T[+ =*HJVQL>2E/"!;A),V+/F%F([T7NSW.J/2S
M]EZH&N!X@=@G4V>&P<0Y[HJD,[#:82U-+LT)6\DDQ=]_I=Q/;_1C;^D.'%C@
M7V=I >K'+ V=9Y=7GTZZW0NJP@AP3%@] HN%-O:*C*YC.KH5F:'3(]&[]EDL
M8-0@1"88 9:45SM:2(51KCTL"\[&I!* %$T27&G89;(W@#MPYS@Z/"3943P%
M(H[EF<XFOB1\>@SHE3<);8?:.O*'9T+_G1>PY8J<:3!(TVH,FI"JL6#",#$8
MR5[HB<!40,.0' !3EWV)W05:V?)0OO7MB2@SR=C2^13NC&?RSWD)OZIZ'AS6
MQ(>U3VGIY-B0-Q$3DCRE&A]H3CYIEK1#T5S@1G..M?%&=HU=$T_#1'],=?=1
M(V9F#6J9(.U1GF*<&ZJWNX[SB \+&D&,+@YG)KU!M2^7>A\53$J5"_7.4A9+
MD:C3J0@;V=P=..AWKEPT Y4W"SA;6,<:_COQ.K_/)]\Y?ERL^TJ^1DZV-SR=
M?Y%.HK/> 'Y'?U*3]\4Y9*'M*C#R%6/\;_7?VGUNS('8<DY8CHD<$S2[$5C/
ME<$/.DCP>8[U(4:%QGK.T+IY]V#>']#:7C@7RM2^'(W^&2%*>=#A"@W4=V-!
MAB(5Q8EK-#Y1\4N2%*U,,+J#/\HHCU32^64<"Y2"SCP.UJ^6=;_OY'[O[:6O
MEW6D-WG0+7*DMT$KVA4+X>VR%?]RI:W5#'B,73WASC&;@ZLW2I:S4V(NZJ]U
M3PA<'I_$T6<*>(LYB'IG2/Z53[]\Q J_29I$B*' +@STM-]V]-2*_J3\Q-NK
MNT'!X&)$]%6CA8)!=[S$=)5(P;O:LN<OI2>US+<8" <SMM)MM-G*.'HR[\!=
M9S0BU &YHP5Z2V -RQF,!<8KXMS=- OY)8U2A*L'*&MC5PX44\SH=]0^P"X]
MX3>#\3=/N: _P82'[!H6.'8RZ7[!U 9,H%#EZ_!)(EW?H9B1BTPYXE>^%8R/
M-!'5(OEQGM;OQ'=LFC=_AP$2VGSAW$RQYC,$D1SE7%.<EZ.@+/Q$D):%2X_/
MQNF1NPWW&C^Y%HF^P(&3.275#&UT&0G!FME1'.53>.8LQ7IA<W>X-$:]6!<,
MWCUVFC/7V&-5>PKDH/+=;T0<4][[* _2.7DZ],YHGQJ,ED<CW5-J. IJ'"?)
M1:ZW!K?)U[43]>#)EW7!?NC/:2/H ,D!H@:5%Q*K [:\&BL.7(WX;;)B7=WM
MATWCI"7Z]=6)1[^-4CI6>3DG/!+TBXI)">IQFBV<3R?D96*>!)_G[+F8+< V
MCT+0(3*JN%(WPU75]>]>7;V4UZMFSCG[--&T)R/_Y:L+1XS' B,UZEW+_MM<
M&$$G&0"#%TXF0&S:?U;;#*SG6F)-[)[&M5VS-Q@TT_XFK C'XPJ,)@8Q)-AW
M!T/0BUOS<O*9WG1ZCUCLO2HSY3L>1QELR=2/Q[A(,CHKL(J$(12NE[W/#IA5
MDF^.!!IO89K+:G9>6!4!7NN-[NAZ==@SC@FC04G>O=#Q!JM?B"-B+)8D PFL
MX61NR!\(U$AI=GA1.<=?>Z=\8^UM]9=="]>IK%;CN=(CK&8@/88*)ZP^.NUF
MA'60 #R]KGP8@Z)(K_JGVT^\X>(?'/5)[,/Y<=GG?\*JMGR#5B30MRQS$"7Z
MP1CDJ8L:B<@D0JWKS*=^-O,#C EC@":O/@D7"9"3C&? V<? ;H*>;3C.,*.
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M)W UYNBAJ7\UCY+,_^K_W_]XYX,7+FKAOH-KZJ\O?J@L#%F"]>;5)7ETT'Y
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MOA]T+AP838Q7&:B"!>%>S5+"O1*(>^4HS"L'865<YV8:!5,GRIUY%B%28;R
MM\0(0.@4J>,'170=%1',;RZR<9K-X'-8*I'1X^\JV>TX;Q/G?7HM9B.X V%+
MX(4T/Q%=PY/@SG(^SF!XSMQ?X!TTF=YIIZMG W,-TB01 3WZ)BJF6[W:@<'*
MR:E5F_JY,Q("%DB,19;1^T-X8AS#Q^:BPW7&2H_+HLPJ@$;X$J:0P^OR\8)
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M$=D1JY5VERR4"!ML@_6>H//-29.[C5N6?.,R*YCQTQ4LA-Y?.H4(I@F; <H
M:[>V12_>H5'T7ZG[.3MD_!"8'R@@&4F<.UM%VR;']2];VG[7#MDV.;;-]VR3
MXX-141-&T^@NB+93L.T4?$@F9CL%6X)8(@C;*?@(E17;*;B9258[V.BV^-,6
M?^X[H=V]Z!X\Z]<6?^Z[^UWSEJU18U&;9_FNY;N/Q7>]H>6[C>&[+2_%.*K&
MJ&=>UQZ,%AR,UJ-1'-6I\2R$2Z,A-._E+6NE@^/QBLWO7--C*E]\>(3^!UF^
MIE+A_:7@ ?S:]AALCP9MCX$]!O88//-NA<H/O73V".RWQOV11G._BG?2^GO-
MS*+]UIQ9+ET?[%@KSI7KLGIH5>UZMW-6JUWW3E7M.KRKMWM=>JUZ:,MJH'4%
MI[&8P))P#96?YRE6U\#-5$:#59(^SPB^=.;E*,;<[G0&F[S0U<;CS$^":01#
M*?PO_*1:7?&K__-G\Q<?8,1YB9?JU=Y470<;@_7F<EP)UN-<B[Q(,R[[PM)6
M64SUI-*^WV+: JP#;G\Z6Y_CW8:Y[U9@&-5GOGRN5$'Z':< "_J0?+.JECGW
M9[H"4#YD#G]DSD+X&3$$!CS(RY@*W255 WEF_D0X(S]&FLXE@7+EF'_M1S&E
MT./IS'W,I1=!F7$Q]8I!T!M/Z(UWE9C=VMH[<$>B\,_?W5UKXWD7WZVO%6@@
MV:RL._KN+[]$?Y11&!5<'O[2G^/9<CZ*/"VSP'!/'-^!N21TAR6Q1&4V?CYU
MZ2>5.UX#-1*60#Y-L^($3M5,TNZ,/^?:6A"-44#EM7@CL&3A?']QWNE6@DQ7
M?HY$'(EK).+T.@H194++#;H9:'Q<RJI_. 09EOG(2Y"-ER T8P=('\0 C+K7
M<7X&$0#'BX=?/6P.)\V9^0LGH(0G%DK5P80E7& A+0B)7+T''EDFGY/TAM!&
M2D(VB4LJ0C)J8+E8E=;OY8=_OGUU@C@ON PP.7Q?(OBDYD)\-@M)<5:YDZ=I
M0I@%/J%!)(D($9L$2&,R53(3N  <\6L0K;0'0)XI%C6-"F<<)< _8$ YWA1E
MX0D*Q04]&SYU80#99R'5"D*8@(T9E5P%G66X$&K?JG)9+A@.3' &W'#4=L0$
MA@,B-V*NA<^$ 8(XIC?4'@A#Q"4%7C6"01HE^5C\.X?=]H,I8K/\)A%Q0 >
MM6=T%IPN3&M.OV=^E!,E\6E4:\/<-]:E_!6+!!U'TP!>I78%% 8XHC-20KBH
MC$K6,GAP".\1UVD,XR#= XDC!ND1+B2)2,X,$F*2$(8,UH!'>5;.U<PF<3K"
M7>4=@=]XZ7$TOU54CI-ATN;92)FA")OO@?&5<0CW.(1P$49C>"/2*56+$ZGG
M!8F/*,5:-JE4H72(H\\"*!5>^I;Q#XQ!UF8-YR*'%9?%? )5*D(GXE>CCI5%
M M4M4D?]$1:8+_!&+/G.<Y.0Y5S4F>8GR(F-RZ+,L)!^0JHRC-RGXV(>3B"O
M=NMA=VE=SCNJF]0(4.,H1I@ X*$B'@.!3:0ID>(<X)!1*2/\\0:18:Y.^E59
M^M7KEYIU(L:!"&)2!*J">="!Y87X!"J?[PV4[H]JT<:7PH%+;W)D=<2P@!^0
MH8%>>C#=&**JG..7WWN]TXJ?XP$ (IS1P]+@LXMP"&.1900"11\0OZH.*4R#
M^(5D%642%:S89'3:L>9^'?<P'Z*P!9!' V42-@.07HKEI8@2D"%_@($@BWPA
M=;&9#\8;\BN&'ZK4+:HS9@RK%:L$GQ+?^A(AN ZLZ_=]K\)Y.FH<F ] 27Y2
M(H3%F5(.@([S% ZZYX(JZ'H7 U@SH,5<\6.3'!":S$>F'K#JW>N<GR('XEM
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MJ)Y@6*%7D#2%J9^!,0$O !LGR->;15K#)&^1L)O>S*&NW_1*G:PZ$K%/2K.
M+=5)N_?-'.KZO4_+ CL.+5D2.?DO#"<-(<M?VQUN[%!7[W ()ME",FBT_T?H
M9Z+XW$@VFL$]-_;9]#[9K6[F4-<?9CJX=;\1*&OX6P)OUFVLJ7E&.9^G62$C
ME.PKIKX!-\73<0X=Q<:K%E#D8G>7>C^ZQN%V50>2"#LO<=O!"OR]UG: ^R7J
M7 \CN'R/7HJ6G)HYU,U\A'K^8<<IF<L1*^T % &,1W+3,K^@. J&>0)I-%)W
M"22L0-V!X5 90.7K@]B/9D]'OAR-$X+I J3*&G+ \'0<BZ H@5/ %\ 5"M I
M\-&;Z0*C&RMO/E&AQ"=&,D?&2NHZ"69.<?9M+11=16)UX%B9G[O&)"PU-),:
M8%L$9Q/I_II^0!8'^A=A-SB:*;2K<:6_B:A)J2M )2_P$TL+C1SJ_6GA6N8Y
M,2DHE[*@3J(KR0)]V095M#L=:K,N\9-/30B355UG92]9SE91?3UUTI#X$G$R
M^:UZC.)VMFU>8NI))+=)M[DU(@0@M--:=UO==&Q$0Z1FA3I)AC+(\W(VYYNU
M6P)]2RI3Z29+E7EBM/N<^F4NC56=)R.['M=:U-ZH-*F69[)NWOY_4%/AO(13
M@RTO72<:.]Q/EHPV/!2Z5QIE5Q8^Q_9AH2E (WO&N=5ZT093&K"HFL10ZR_=
MT=9?;G>IFOVJ!I;N[::_P=U=>GFO=2-@M]X%& [UZ@Z^JOS'"$9Q(<7!V^G:
MSK8-.2:?5+M.%C0R2D7]FE>LHJ9SN7*2NNLMK 5V<H4-G$;S*AE7=7C&#/]I
M&H>8:4^Y>2.D LQM"5U=[V:F4->:Q1(G5)G',75Z]]418!G(/6L%M;:FV?@A
M'/K<V%LJB&!S2PY*\WNS#$$.LH.DNFI%N/6WV<DZRC$/G!.>;W7*O343)D2D
M>I]*]H#9^%4J&GVI #V6R7&[(6W!5JB_[@,P%5?ESI%40P8"(C6!W0'^>.W'
M)65KR#7'QIYE70MQ%3GI-IT%,)I9[E:9MQ1^\V<Y]U%G!EU7:R;8B%@.&3])
M)!5I 8I=08'8QOXUK(E,32WU8M935N]8VK4=W"LZK*_85"0D*)#(Y5*-A HD
M4&=YBD+@A&%JI-S!"LY0C@@96^0YFYFY8CQ.LX+>J?)C;^7IRFO<:H6J;9#/
M,D3+JJ75?4N))&ER-[@X?-#6/ >&#$?N>J6"&85__N[N)!^OYWVWOH=: _GK
MNL9Z< FF"*##YH-19(&+]1+;!A?WR\JG"IIV2ARL69'ZK\!SD6(QF<#8.(?;
MA&82@;%X9H6*K"9+<^S/G ? LV35-MQSF21X^4>!H1M7&\F^E/BJ_=_ZC&^;
MJ[E3KN:YS=6TN9KMR-5L*K_<M:P+G_PRS>8IV:X_@TWV1PF*&*K4]Y(CC5B$
MNS 7G#=BE)58RZ7[G1-]$.='RX_B]S'! Z!)RA*A=A/%]%$#%YRK\X4\+F 9
M('I8M^ODN(P"BQ#97D''#EN_1NT6K!)^6#B]0;_KO.\X/_MQCL;P5=%QG9=@
M9/J3U'7>@HZ=I)&RM_ECYQ<:'JEIU%4>-+2_E3  3W=Q)R,UDBHC)YZ!?8X:
M+4TMY))/+M&\$:0SHTE.)0I!4,(6!@M7=:^/L,;9ZW+?>)::YNM8D_<3HU8:
M+"?!_<^+F[16,%V290WB4** R!@7_,U/%WXPW<6A=$^\GSMNVU:Y'!R%<OEA
M/#Y15;974R3;2\/L.&*OQ6_H- C)I"-%T@"J4=0Y1]LQT6X%8!=A2C=(5W#,
MUJHK:X2KA<QI(4W[C5R&H0 S3VC7449%R)P%2LDC*AD<O[QZ_7('G]$#D?3Y
M49#TWS[\=.5<!KM#"C1PBNMEV>4\BV+$E>BQP^QOY6R>%R##J=KU)U5I<(4?
ME?,<%P1IBV\ YJQ6R250&Y'XA/HJT2S&(J3ZX D6""=(P1W$;"@TE(C7/5>4
MJAY$X84HU$ZSQ '2SRCSD?/=5*(2^<T+_S-Z1Z[]I #%7CV+?(B(2 (V6\+&
MD$*,0H%"M7<+"JN@V$$YDV*1\W6$8JU*NW((2L#/0I*=)?F^-XZ&7"<,&1*F
MVODL*YU7/M@I*3C %F3UZ;*+ U-VR*L,NW6-JA:_E;SH*H03 3.Y3@/0<1>.
MP,P,P6P)-1*$#:I<(;Q,&.I9OTXP$I?3PQ3> 7I>T$U*4]MFT1R)U@+6J[@F
MGSQ[R!*I6YAK1-&1ZLXHKUQ2X\JC:B:J'7G,$(ZFTGEX']927K4STJ]H.O/D
M8<+;J7EEFFG<'+\HL,"8=B 3G%[*C@MRE7/Z8%)D*=?W&\$3OII3B)3#SV=G
M!W]%F_PFS6:@\IW\/QQ^1<IZ=, C:KQ@T!T\&_V@!9>?C7Q@/2<?OL1B@8SA
MR>RV] &#,H^V1#[SXY@P&-2B*XYS6Q6XJISZK[^P!TLQ;&_8'S AS>C($_,V
M+R)&@N[@)2R*32- )[E#;A0UZ H+93W!ZC?=9MZ*54HBR ,_1O"_* _B-"_1
MAM (:&1"K1F9JG=181UU_4IID:]\#W*=G">#J_8L^H&.QG5:R'PX)MHD34[X
M,_Z[!A\U%3&1.5[DCS$+CQA@A!94GK,K\/O>:== I)F!:55F;(\1:@^B1^AZ
MO]#7(#)@/:8PPW&$8W>DU8U[^BR20]4GDB,9];=Z7?.MAM(ZPZ1TA%TDO516
MJ0O](K2P&+K@GHM175FM"']6'^ Y#I"_>)BU>70UN-\]"C7X;2%FO _]CO-W
MA)>*"G)&$QG !['Z^Y5Y3$=I62 ^%<9@/D;YY_7+O^3^:>X"K<T4WM0VX?9/
M I%:RU-K%A[PCH]@W3E :"<]Q11KG)WK AS<))"US\8_//-(A'[4IJ!S=?+_
MM$PAO9"4M&6.9XPD70H.D9\'H6PDAR]6:AB,>E%5*. U(M?& )QN'.1#"/%O
M/9?](SN7@PXYM$%1X_WZ%:$.0SR&[5:9MG=&<Y;E:PKP*XNBXD;K5J?5BW.G
M5PJQ]4B7HN33[@OCJ ?F>LSU>KATI?>BKE@RC2$;DG+:Z_LGWNDS\0/_J:6_
M=QJ:GVOL/O[3Y%JN-.TS"IJRAQP3$Q,:'7VWS$D4MZ$<'9I(%6=EBQ6S23 M
M7:97*D-$)0V KB$J#.JKUR\-<,$:1R73,T!,_-#EQ<ES_#4O9XAE^E6$TM>&
MSY<555+]QNP^[?5#Q.!H'!G*^>N7VO:J?'8XS5SE&\%0R1 V9P_C >.ZG)5<
M6:%2[TO,Q"]X47 1@&;\B<1$K  F)/"<A$$47ZCTXUK(@$(F"4!]7UEX\GLV
M&#!  1?!VPANT<>X-<T5<5UADCE)BDQ,P'3G E6Y7Q7)=4 54..CY9TDL)+:
MQ;-82Y(R)H^Z[13>2B5NFF9(#Z5D)-P@=, H890F,28'^GG*B328QYJIC"@_
MF$;B6BJ\4;8^4F#C[SO%WR]L_-W&WYL;?V_=@4I'OS/H?"X3VC0'301*)4;6
M]F7M503"[O<RG*C6"T)J0]*NQ\JNDY%(0*X7C/B)7!L38['$*\WS"/=F#1MN
MMQZY>94OR1U>*Z9P;TE4K3A0FBE*2Z5F?K.$E?O$\70)' 4/8'PGF9M. L\0
M=\:[[U;K&+=TUESY6]&Y>W!"I[7ZAOWD4 P\G1+#0UE7HX'K166B5.F"_BB5
M-3^D;ZVFQKOWF9,P- %A8@A'7U;L0HR)LNT^U;M:AR]E0B=Z2U1\XZ49WWBC
M]_*C<H6T>H&VR7TEDH$C'E2+LV, *.0V(FSFK&KW8Y"\&?IAOQ:;DN$/1,K2
M@ Q_6.GIXIJX@.R[6C^@)1?XJE84="^=3)7?JXLP9"3$SXR3LG#BZ+/@@.NM
M&]S=5FB?#J_&/L@:3CL93L/UAM,N?LVS[ZRY9<VM9II;WEF#SN$:C_JOEQ\_
M.6_?DL/4\UXX'S[]_/JC\_;]FP\?WUU^>OOA_?U##L,C"SEX'><7ZA'Q*[=5
MPHJSW0.L!Y_GNE9@5-2#SES,&:"2[:I4+B_)7,&ON$W&W%@"S&Q00;(JN]-W
MN)4'NFI!U;C!*V23 .-F[:I6* "4O<"9H;!X$1A6)3>WRG1CJLD$W:[HF/6K
MTB599RI- 974HP+EKJ&E8)@\4C66)H;H?0J.K6KP\)1XVGT0U6#0>PC58-#K
MG)]:[:"Y@VZM=M"DD[A!]CG>98>269PWW+>GY; E:UTH=V<IDBRCI%PS5BDQ
M!%3,,\HQ/PBM<I!:'W6*J4H,_;M;+X25[:'R*24_C\C1E4>A+*PR_7RF/.,H
M*B>A(KK=G(#WJ;.;ZL:J/(7+_1VY(FI=4ZK*00<".;W1<IU@)="_F2;D=,,F
M3H**]V6/MU636O5XJE67H#RRM!AS]:A&_BZ![:X6UQP>1C"8,;Q>03N,ZGZ/
M)1@*$<+@$]8^ NH]*ULJL[?V5E-,?F9("..<!+9(2]*.,"I/G?T0&@%+".#V
M!7M+U#9L.#$-/"";6<)'VMF/$O(0-M&LF-ARFEZO"?/<M>Q3:KF^1@2$)V!"
M[2A*:\"TG"7,M7T.L ,J6P2B $+)9>E"A6=DYAU'28!YG :>#]^B6S=C.EHN
M!,DPG8$>,KH&8BO)((-@7!&9"0/L80R39(R>.@P/GR:&$5*D+95L"22!W&?E
M@6BY$+@SD8AW>O762B8F7;$*YHVW*<(DE?0D30*ZQR6,*P2!"Z,<TVNRW.B!
MA@:.@J0=F7!IG'LB"JR<O7I_:0 ?&^AEOH,0)7@**U0U26YPU56D8++P%RXY
MB1)V$?>ZGD?6'1?OB>N4GE)F!F*9[*9J IX &:P=S-0/:Y1;#4G2<'Y[/'#[
MRCBD&IB"!R.A9J8#89Y6$'%O8J_;KUHU=U#,;M.FN>IRCB/"5LDX3.ZBWN_T
MZEW4O6[G5'VRW!;]JD(N0]F"8H /BYPV340#=E$)L&XF2><]6QU$D)NQA+Y#
M4A^?H7I0DL2OH6FO0[]>@C#Z8&( +73&ZRHDRXR8 @/H$<?+&6%)$X:N\,1+
M#4]!H?4,+%7VH[BD1V$,AE63%02V9A#Z="0I7%['4#QR3D04A"J8/@Z\WK*<
MMA(EZGM7^5A,&+T-,D1OW[92Z=;9WB"?0GZ(1OZGEAVKV[FZJSJXN,OM6RJ4
MLA6M/U3JHAK1"E)B];=J@"K'*6<2Y97"RH>D!F['TG5)HFI@PWJO4Q=?@FJ[
MZDA%\&PE8T%1]H'"Q#3PHV*-=("(85SS/R[C>)W0J75^34>%;"V]JBL*Q_5(
MJB_WE!5K'PD47&*[5@X\4OT5/4^$BL"HZJUZ6#T#@B# W*JE)SV$>M"K[!X)
M?@:+,/$3W=T6Z*W$%8[K78']F.*/G!TTELNX/"!.5/4C DXST$$EA%@%(5G9
M4LC-(T9G)#2R[;>H#EMF(G'5UQ>L)E+*TDQK4^L18H&@>(GTV466C^-9>0\;
M,5B]Q%E3ZBQ$*&&J!:A73*ZA95,[E$K&MWA8-QELVFS=VCIJI]E 3 3WQ$<H
MU%3A;B+BH&Q%O20"HP2$',MR<[\1DX_!RNJZHB'%B7O1:4@JPX J5Y2>SP>.
MZ%6=WV.7GP@T7#N<SCR:"[)UMM W[M+&?UO"+U[S/"-C1*MCYJ4501C;.?,E
M<"TY=6:2S9FW:;HBTT16"U"5%;":6 0ZX1XUU%'* M5HFI*CX.*CS=6A.:=T
MX.KXH##&T21-RB 6:0$S.!EI!!QE\W2<G],;EGY<NAKQ/(-*RM.R4,(_70+/
MB"KD3PFA:&S/-AM2WP2M$*A%#JHV\%AK/S.:IL.=MV=1VZC<43&:&*WJ&S I
MR@POOC5#@4E_*$B,5D6,_P!3E%I#I2@O"^Y5QWEI7C 6.&FH_DLP2LDOI-EW
MU ?WTQUDL+146DDF2$-">,AY"PLNQP/>-RUG!#E.YT%UD<3RZZ5VT[)#*&=L
MJ7[FJL"Z)+5BZ6#4[)&EL51*G*X 5X==<XR[R5(J^W/24G-=,2Y;D$1B"3EB
M):')2B*=*^ERV8W/Y]+0<S.!SB,G9SDA[31:/:!'"7950?T0%\6P\?((UFDK
M^ *2A7@)T"4HI 5B]PK5Z=482I"E.8\O0)8U$[-1YDL'+$5DV)&,7^:UHJ3:
M<W% 58IH"*<)62WM1QV-B%W<RJT"P_697))49K<2 )<Z^"Z?_,D$ 995'#L@
M!WQ!PE7(2GN5T M;GY63D__/WKLNN9$<6<*O MN=;TPRRRJQ6ST]TO2O$OLB
MSHHBMTE-_\X" H44$YGHO%01_?1?^''W"(_(3%2QAYJM*L%L;4?- A*1<?'P
MR_%S"&=GEPZO<,\6")NG1WAA"=/9L26X,I'6DYEI)R,POY9F#+$]^7QL6GC,
M+1+CD9CA/H.<G41L<.<C'^8[]IM]N^6 ?[TCIG-)6AQV9;<OD23#OR7301I,
ME1,V9BSHD4Z _X,E@N, \7+U';D[U>)5CG6-IS!XI)3U;*J]#37Q0^HTV9>
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M0QH8D-<E:O'E'\\(PK5?!0MFV2[H9]S'\N:&SW7.SR'<!V4?6]7(ISG]NZQ
MYA=(",58_#2LB[:MG1S_5 VMU.VDJWU=E;UN*-XZ88S>0/ =Q]G7_K@_^(,.
MGPN^3*#X]#<)F:'(G5V)@)K6A>*XL3_HKJ.Q8Z#A/:+O$4;@K1MW,FZG75>A
M'PM^B?"$<%<^[2ZT%09_JPNM@/9%:'KP)F ^O$;:C\CH^+W(82$? 4UD$7A[
M9\><W$LG%G1F(<+!3D[E=#F&'01;0*3(,ZC5%!W387?L(S-;[/^=-VUQ;_D/
M,'-'F&]A_\>J;PP38T(*1VZ>',8H*J0-:2CY^BO.6_T#TT=KQ>BXNJ%*X0J*
M0V1\:K>Y<9>K'^1?2[[ B/ZV88T(G4SQ$Z]_]^6,H[,N;ZDSU!_)=K/ZS=6[
M]Q<O7OSAMY$WIDP.FC_X-&MLN(LD9I#V73^X[$=^7<P>* L,\&%BK3C<X$4P
M5TYYPCBP1>#-O^'*AZ@;UT34U-Q67=M@T43118PN)XU$<0&?7[[IS_BZ3\77
M_?Z,KSOCZQXUONXY)'4U3]005ZBEE#4EO2"; (YP)I3-&>M/!<>B+>+_"1HF
M8PG:.F%+O[.)JHE6@Y ,1 YBN2!.*RU05#JAB5O*&3SCX$PXS4+TL) @D'[B
MD_,D+=$2),LN\*]ZLWMHHMZ(3SQDKWF75M,AB4!,3 YE9#1%E!(1JB1D!];E
M@5,(0C2@@ <AX8<3895'\./DK$JAB)@"[",X=7495*_&WLUQ,9L->HJ_BDX&
M38D2J=@49GB0^C":0UU2SQ$VMX>53>Y+:/D(S[D/\S(RI^D:-3,<5T<UZI"_
M4]&)2'D7V U#=+M-:/6PDB>5PDBAZP^77P7-+LIAE?VN8$G(R-#9AVH3B V=
M:$;2O_W+UW^X_-H^H-^UW7!!J4$CXT@<65:&()B9H(=$SC;O]404(IS!N[;[
M@,1:>2 K34%TJDOFO=LT+4K[(!/O8FH"CM[\E[YDEC-UGN7)"?Y'*SE"V)[X
MR"+ZE)B*A"U!<_S9(,B+IVRUW;7$:D)>_YW8=GXVCP]B;+7PET,["ND"?D:4
M]_+&#R>_N6DYL$@WN/<:#BWG!(QH#VO=T1L:UM%0>PH?G(BB&5;P!]]HRJ)B
M2V"%BI]%*2"*0/=*/"80*S[3:@CUU(,--,^-6EVC2&Z9WW:B<V%FXCW93K<>
M!Y?*Q=+&3&WPG#S5F1GBD0YUH=L^T*,.0:"!ML@<[4EL#8B74X%D8'&"OY89
M3Q9L^;G1_OGLH^NQJC>RN$*42^%CUTHMLJ:\X5@&C8/CBNZ$;>OO2S98MVU%
MV9,M.6,QSSWW162V#/'D>;,\TJ$N;I8@YY=N&'.;^O@3$J=%SJ DS*X5Q1#G
ME7^L0UU<^=XO8Q^P(19AGLLH!7[!.;9'0[!XW@./=*@///TYQV[8!7,(D7LP
MV>>=\"B'>I_S.9<E."_F(QWJXF+Z!X.#E+2>-40O>U43#[!>(/,$ "3UZ0>G
M .=IU&>#VO/^>:1#O<\8F&RNIJ(2G.C&YG9C.ND;_.F\YH]RJ"=L1D@$!#5P
MJ[(0>RIH=0GS*?T2@3K8G_NQ(82?WSJ"2W_N19E)JE!.#F4'P8QIFB]%++?#
M/_)L&EEUP>XJRAL03K*RT'TTR%:VZHN% Z':[!<K"%.NSIB^!W1KQ0[@#3'J
MXZ#3FLHW4=V]:7E8H;V4!D3)\&W;\5A59U73N\C2CT%XWJ0X20ZJ[EO!<&8J
M0RA;2.U$*E1EUU';(\<I2/NN$\TH_7$#/=/4[-@S,MF_O/\'[_%VM):<%1>P
M8]:GN$RH&NJ=&'9LQSV,':1/>4[:N\;"NR4YSY*I*&\FDO )%+:@^H6?-<(L
M'LICZ/SMVF,9M 50167^82:?0]6 EQ/=O9RLUU_1["%K+<1ZU1Y);W\:*?XS
MBJEC4RN2=VR&JKY/OD6W5=#I+9;*0"'9G<N@L TB->3WW)L@52&T'U7^KQ55
M)9 1=9-*BNX1<."5C":@M?<&J7?K4<GRPG0&*!=W@372D!\DO9-L1P'U:098
M;S0ELBIO.N<BGNBJKAT5(%>'>@TXNOY#D1[:[,GR-$&-'WAJTB>_'3MRT-ZB
M>V+UE\NWEW@^_S,_/8PI+R6F3_K6VQ%_!CZN_O*7EWB&_@-WSO6@ZZ6IMMWJ
MX4_]>&W_U=MY B4RI H:=N(# @;N-H;/N&[+R5O]V6\'J)J_CX?NAZZ]\W]Z
MR?X&!J4?B[TP<X8B*ST+ [I!&C#(EX0E8& !?-4](P#=-,'E]\KH@^,U0\"K
M6_1*\(9J1=="*$FO!\W3^W\J5FM"P@&Q@+?>EFM3MH: R;5A"Q45'^ ! \!=
M7T$.[43\J"O)WDS*[=+R <9UZL[0XH$_WW[=VCW)S =R_Z!\L9?F ZXC,E'\
ML16_3@%QJZO\QPSV+Z([B%2^G[_B NO ;'_$Y(W4Y11X:$3T5_M#J1(>AY;0
M0H#^^5=QX("]J=MK2EKH&YL63QR.JN_&0T (T#_=M@3EJ\5W0>J#ES"MP+!Y
M"K8W:3QEB]IV]>:.\ 8,=$R43[0,^O+-?[WZ]N*+/Z[(=28%8DC6W;FE-27"
MY+X?P=P_-6>(\4BX=]?6&[KX[DR_V::JQV!I 4&EE="6N+!E,<5SJF9Z1\K=
M:'\G@_?".D19DX"\P(4_ PHA\4HYEUR35\5'/R-^L(7M&Q!QS$)'XP,0Q_H^
MK0" R=)KO3L=Y+?)V>2[4?=J(;!=-+Y&C43_O\_@S\\&_OSJ#/X\@S^?$/CS
M"9RIM?>Y&K#LPU5'G$F@(5+OO0ZWF&#-< 6QH0T DAB!P<X6>J&Q6 DIOC0]
MV4304L.["9=+C-,.947_"S*#^N<YCSOZV6A-S/0%#0:H[]T_A7)I6(80].97
M;V085ZD%/U,['S1ZQ]@=*C@-$QX?\7K@75 VZL4?O_$^AI]??_'>5MW8!W^C
M$-(@>$#<1\-2CDDIGWRX "Q#"Q-W ^GH,^U9Z5"9H2_K"]8W]FZ)D*#'9R0!
MG'@9+W]\8]I"TC$A;+C;$2PM=H3HXWY%LFEH#__Q]23W]/5CV%JG;<![YG+
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M#C&6@TJC/C<^SJ@X9/%MJL@SEQ?E1$U0*"=X&/'6D4/.<KK^7V+LK3_D8PE
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M'<O2UE*'K^CPL&;R0X22"4.IV(P;1^74PTXQ.^D&#N3 H9AZWIB/<Z@G8TQ
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M$'@_HR_;1EQV?INM-VQBGM@EF%0[[[D%K"3)M9.628R!+%X?8L.Z/(IL2.H
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MY@"'2#M4R4B*RK L]Q!=3+RYYPP0>K6UD.Z9@-)8(<F1P.2'[5LL;%T+)YD
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MO!S GB^,:=@/427N@U,^L)AW"UWLQ%W7-HT/$D3L8W\HJRZ'M_M_K47V[A,
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M3&X#$&L#8!R4NO!A$J<A-N71+^+%AIY)HZDTM@VJV=XHM?2H1$8E/AAI*-9
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MUU?%1$"!MZQZR\J5EM>UPA]HGF7E(Q6;-O %HF*(;?-FR)?=?!^_? 9H?3:
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M[>4NK\GCD[@Q(7NCTU2$JB:2'XC0)1YP3<'_H]UKV#YX'Y0.";>C3'PHZ]O
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M-.I62R=40*)-_E#.]&[E48Q8II4J)1*B3NP'TN'WO26TGP*TG[H/M2&[Z(B
MX%@B8&'J-QP4,C4[$"0Z$1I8 79>N"QDOD+U&#L$"VL(\)<Q;$W(DVT/6,S-
M8-T>-Q2F,.NVIL(_ #<[JVDXRK'( $[:J)(O7U?B30'B2V_(4VNSIK[UNKW;
M;J?$*0:<";./V5#QU?R#R8_;ZOM>'\$2O]!Y@-M/ZABU8V![@$&17U,T$A/8
MH&P7^V-(1<?)(%']H$H6%2KW^#4&DM<^8CZ)KC0GQ&YZ 9G"AH>GEL0"2+HZ
M@@C7"<SLZR4L%3JTW4G["&&1%&@+ZE>6*)N#)1*V5W/PHGYUJ$O2TI0XE&,=
MD7GA\A2N@.Q>D_NG2[(0;$RUU6[<D4X_#&XM5X+97?-';!K1J7@#$4Z\>V6+
M(@Q!#[.#?P:W\A#\PV-M"C-@K=9R*>ICCTQ?V+,HDD<2(10I8<1>2&**>F$[
M%)ZYJ+2[>(+04/ L]Y1:^RC8.!=DJ_;Y;*TD=+C)D[E]Y%\KXKTG/0?W6U\D
MXLZ!A#TA".;8RZBED5\;XV2O1> /---:I@S"2VI-4'6BQ&%I0J1> SHI.^HY
M9FEFUQ"K1.^WK.C2Q1MJC:Y^T-%BX,VP-@59AKH]9A\)9@*B>#"]=LL4Z#23
MUR^ECCTF'OQX93!=R'Z\YH!S1P)S]>#EFB)8-ZLAC(Q1-Y"0HQ(!)ET: 2Q?
M#, R'0$L(X!E!+!\40"+/PS)1"W;!H-FBQ)*EC%ZC=>L.W(9N^)N#U*Z[!S0
M0CC7O^!Z6L2_#2N#4>-(6856?'"?W#A-2 A=,71$-"&=F+4+P%%Y3H89"WLP
MN^C7C7'$8-Q3DHN".#TT8YTF5.CT]'E^K-Z K^EO:#%.P(4![PW,Q>[(=09N
MX,J.7:TYR1PEH+R;U UZVS&7-%2K9(-&0-RYOE2>#_^?0O /&S@[E!YTPN\*
MN4Z[PNKJ2?NK5D+Y8X^5>=>+^NT'L$(NU%'![I!.SA:!GY$:2)M)Q15CD!JR
M P8$"W"N?)S$T3YV0ZI?0,G@@1KA/BL=EHH(+AL,18ID$$_ 8JLR*;T@&5&!
M!.6B@9HUH=UU IZ0$@PX^-E:DD '0V7F9R_BZ,R^/[EHO*IWM2"8'TBF(^LL
MOH3BC:>OV451LTPN-<6R<]::7- +V@5@S?+,:=836EL6]_ZZ5I/7YL:5 VW:
M6<[I28C#?LQ@(]G%.'W>!RH1 U[=,!X)#T9AF&$($X#^P%6 .CLT>8EZL/-#
M?'FJ720O(6>6/H[8<<K:M8KLFE3#!%,P7 \9UC!TSANU[=2Q,3.FD,G=>I9O
MVI;0#,#'[*=+^_0+EZV%9,6^0F(:$O\ /\1S0%JI(+FL%W2W$TXISR "A!BD
M-:!'B(0 (AZ%K!WQ_ZXYSHT%5\I;'!R E:%:BOYYC&#-6PALB(P!@N6& RFX
M'1.)A<RJ7N9*7$9VC-M:"RHOVP2!('XCXS8(HC.JEK V39,;=Q1BTI\#2B(V
MV'NRA#232L<@AYJ5X"6'X@HF\]4Q6RJUO''U2#J^;/W7A+0ZD5>;@R22U@KU
M._'2M]OCQ"6Z@A0@$ZG-C 0D!=* YQ-H'Z+DMT:28F0'=[D"R/9F6$5W&:B'
MP\:EL,C^JG6E:6_ZI':0%_"C %6NUFRN,F)9 Q+AQ-H5#>$N5MDL<R_0I6;0
M&C[#,6!'IX-^,2EX^RN22)E@56(P7NX%!B/.=$;>#C]=R#L>5)=N$5K3+2_M
M,O*)*MPXMQ,\R2U\H4D-2#;;AT ED@2!/CYFO=W6+>0E?#3'//6$+S* L64,
MD5.5O"ZVZ/<4MABPE,IR3LUU2;SG=X02'T-N/\QQ8*AWZTNJ.(6(9S@E$2D<
MSGD/G]L(8JT^N;CK?%";1U5;HY5]2P&C*#RZO %F)$/.$X7"VK.9X*8V^LE]
MJB("KM1P61'RYZAMRK>>+]I#G0#_51M/S!PR66(A,[KJ,&\E3DV>?>!M++\5
M+&3 V=&#*4!Y(EH0P&R7 \=U :K!Y3;!(&5J[:0E*0F["<$OVZN49&-CY1"Y
MF**J]Z3G>B='+VX M+L[ >)5\U44L+&H+\=,3[@'/->AA,+[!6Y<0IS^-W&]
M%(J[[);]@6A%S@A[/)?+EW*))FHK&_7E3LK4UUT EQ;>9]X*X,GIDZF@3&M8
M$"J[L,/=Y=\ZR+G2PRFBC'ICOJ;3;C%T>8.T[4 SD^@G:^26R#7>)[%CNAE$
MQI7Y/I))H.LBO\(4W4E"9#^61= XZ;G1!BJ:1$"XN4RJE" 2"T?48FWSV-TU
M'>*[P%3CFAPF]I+W<:F[#E2T+?:S%':3K AF]G$93V7KN?R:4)X"EA)MM6!?
MN!MS8(':/0-$<_C^ [6WA @H.%5#CW()1P6BI4B7[XHJY1WLD2*'9,1TI_!J
M)]^>YS[KK.4;$QK!3MFJ Z<R\DZ!YZ5LF;NUTAFFFX&2?LG/XW9G:L8@5W]G
ML^0@+IY/LTI"-T4"392;]FZ_H@-M*D@!V;._,D(K', Z!]&B;GT#Y.G(*83?
MA#Z-X".'R5%W!21WP AOF$@%W+@,:\/"V?!XJ2!H0Q%KZH$]6R"\<+(J;Q3P
MG*\%7:_203+H^40OR*T5W06!#-SZ[%CX7F-4? ;SAESYIL3D*-"068O1LXV%
MBU%AZRC%*2CG%>/ _'6'A[N+J,0L9D6@.^M(YN76&.0SJL"I;'J"PA(64_1T
MG6]<OG^+#1!H7%_N%?T=Y4W05$_2ZXS0VX5G=@Q0[K_Q%"N+K_?R> !?"[>2
MR[XG-1SY#&P/QR=X61E1Z1:G\1G*" MA'?#5#CV?GL5WLJ(:95C72U-O,FJ+
MJ)P XQ%''?(]3\+%YB#>8K[K5*F*"\'TBFI5IEHO_($S2N.,0[(<P9N)@):@
M]CW/)W4,)N856KC$<Z+0#\+8G>424)<>ISVD*=(#Z<Y!X-*5G,08:RF0;; ?
ML(F=D2H)JWYF*3!0L*0'A6?[P5@Y=H8KB-'#$))HMJK:0OZAKPD]SI0A*H8O
M"I<NPC#CC6;$IW$:U&@FLU>;LRI?Q+PNFD76 ;;7%/TABF^<IA&4\,5 "6<C
M*&$$)8R@A"^YI[H :H_!XH"A(V%J[W[.^GL(;KI['+$[B[[^2&;\KXY[@=(R
M[,#OTISXD4'X%RHNN^N[%*SA_)Q'Q@)>&T&=74K>V_C:;]'A^!2:S:.>6M%:
M 3-;HDZV]ZN>F=3+B-LAET"KDLRK@3\3P=00KB*T.N)X?+V_WM(WQFF\8YJH
M)[VGRD9)WPBKC&,JTR\I(>F\IW#[4XC.>U]*;U=UP7H9$KT*H\E8#@(^#N=_
M002/7$$BEG8^F92JZO<BICXJD< &2Q?0DZP?_SQFU!)7K!20>N< LX<4>Y N
M;P,>5'\*^4C0<4=J?ML=(W6Q-49O>Q^/5H)S\:@XJBJ+)=G>+?LG_I(0^'-G
M02W"=H5!/VQ>_@J+P;AO5P(!R%#]T!1<%5*[I+>K Q=F8<*7D8>[4!2"8=#/
M+JAR7UA_71;D(^KX/G)?@",)Q=;$2[DO#4:)Y1J0U/N6U\,_#7]2MH1?/FA'
M@$<%AYT=<_X$***L4<A7#%?.ARQ<6 H7,'4YHH>NGZ[1:TCVV_AC2SZ81!<Y
M(&.6*S@G>N@.RI&XV#L#9/;F%1QN$FX_O5\$UP4"W9#_IB:#E$)_V_3.WWY-
MDCXD71ZCNU4FUH3P13]<FJ<KMV1K\*LW:A]U@18=3@Q)IW30%G:GP%>ZF\6-
MW2=OE@N'GOR 4G5LW[AO^%/AIJP^>#UBME/LU%?](J @0Z#*LZ5TKH/TZ,&1
MPCBJ,HRPK@.NJYX0CR^RY(O2GT+A* _-2:P1-K=QLM$)!8$IDIU)YC))'FAQ
M_" )Y\T I(B3LKB[BF1M/*FK1.L\S0K _NS8%SNB?+,VRU-L1+@)I?2(BOI(
M:8,)"D'YN4]8\<=40WP;3DA9!?,AE[?2.' UU[$2'. 3T]A] 7<TUKC:_8A_
MXTQI'VB%#@F>I/AL)X;7F5J-C ZXB  ZL'LI^3)AC]>JFW+C(H;P>_QJ[)'S
MR%$!!GUO)5D?S-]=4B>.)E)K6UTSI<Z.Q38,&+0?).0?]I\65"GO?,E=!/$2
M3M UI5]DO1_#*?1+3QYD,&H2U9GM3U*1R"L )/]0M&%[73>!,S.\?'#\\ 9W
MQ.Q)7IDD52&I6(\OUG.P)ZKP*BQ]V*W5_XZ,BX&.!.41NSH 7P$CE[^TLT[$
M*<SU G ^KH8^+M@FHD"O5I9CDO<M#BZILE>32[;3M@N#Z)9^]$D2NE#MH0A?
M/"!"&.]A:W+%J(K8"K.#?[QS8Z<&92!9&JH#[PH0WB2UT^'"A822$IJA#&!\
M!E&8RRI9"X"MK0><GH5)L6Z9 TTX;Y(#![_][!3.H/G*GDKXS^EWCD3!H34-
MZK!P8,N7/.-4@R6.>F-SO$TI4&9W/3"[;DE>(,_P?/"5&;HOZ&JXPO^^JJB\
M"B&3,45J?1@.0GGP<9??;%^?=_(,8/X>6P(, KY)D,T_ZH/]M^X:E>D?7MA[
M5S#2C"A@R=W#Y@15N_OWD1=X[LJ:%+_-G0/E[-LI$JD BTIL>:ENFI,!'3%6
M'=X@_L3:-$X6U,>7OT^VJY.7$,B]F",<;_KB^2F>[,$GUI'62,F!!WJ8:A]7
M/3QI9CTKT\S3H0Q<$QJY-].4T&X\=PWC#M@D1?RZ7:>>TN@H.G0%)?$W*</B
MU<]/P@-08N0@FA[2&<$_[;8N:GM$)5BID=DWOB[G: X[81GJAR)/)!RCZ\N"
MN8=\#^ 520/VCBJ] 9(X++<@#+SJ-9H)>)NJ/Q)MA#\@-55F *P)X3@A-4BV
M0$Y\<;PH&/:M%]1U4!@[NYO:FTB(YFU IJX7CN$$!S_S.R6&JYDVYU(-'02U
MD& #,V'S:&62'*!*H*V\, V1 M9HT-DFLV^B.S:GSWOBF:;V84II)0U<B5S!
M$Y8#TEMT+DDINI'+DE(I;M9'H,D7 YJ<CT"3$6@R DV^Y)[JW$FVJQ!OXWP@
M0PS) +K$I,W654LX!*T]<:$"./ _S4>X#; )M.\[9R4!/^5+8CUUOB05+MV[
M4]("')S?[[;&JD[1&O1R)P]ZK[$4LI&?RUYZOP/2[WK'NW&8K;(74<:$V/9>
M5K1, /($:S75(HX[WA9,H :*0W,"\%3&E9LP'&#&X$SB@1-U3C0L^LA6MCCM
M2TNA+E@K0Y:A,!@.65M1U]JJ0_"$JBG?Y7;-.VZ@?Y_0%"+_+DB0*/*Z(_:^
M;K4A>9RD-*S8AJ8Z6O9;J7'V\' _KQ)&4#7YW6=P=2!%=)S?&TQ''LHS_K+2
M7R72&!<.4$M  H8W289LC+35B#R=SX,=:MXP95"LP')0?@.UD(E6*3EA$O04
M",A6UJ>6AZ(J#K81M@L2"2Y^SU]S]<P2XO(H&5V]-SPR!5:@7S52!(LM>34?
MRHW [R!RD99KX/R9!^UF5$3G#6V0];$OGR'0&V6NAN(N0;2B$UJY/=:ATZ5A
M2SW=>U66R$"@0=_O(<%R]D?XWF?UASIZ#[8[N0=_]=OFO?,CCCO*.22,RQ<-
MKI^R<A4%&M8&]0_75 K4J?[TS80>Y>[<_5'? 6]W5])W0E0HLH)1@" BH>.J
M"D4:0^DGY%2EX*A88G4M 3/L=0/G#Y'?J^KQX%B/V2F/X9C-YLG<_I=,;(SI
MR2K]8,P&O^J, "#"G!E2$:OM8DB6&-R8?TB65-*".!NB.&=C;%W2%;BILCD5
MJ@N_"'0!C BIA4&D1#;3O):*>N1]MBPK &JB2DM6(#2)7Y1J8-P?(7'!^G>%
M&MFA)8S<JS5-AT:=S3IUJ<3GVX0J:%RX1=HEPZ4W3/:46"/[IKL4Z%:&P8!T
MRI6=W'K!<1 7^O%E9:KW04 $]1&'I0_:PI4CD@DFJ\UN4WO#S;,-GGU$_2*J
M32$U5L'LLD1?,KB2G0879< P/\>'"*$\>Z->=Z@HVOIN5. US<P2 #>&BY=6
M9GW41X@$\>V^VCHQ&L7A0^5\@+>2?8 ((RF2[VZ*(+K&LS0T0SKT[38+NSBO
M7U[ J7\#' =)/7A#:."SY*;@IZ]^NL ^ANJ!7@6-L0P0$/1-D%&*BUMO4>X]
M]J9(]UU4=:^T#HW-9KN!H0$;,/F Z "[ K?V"*T5=R153MN[K)@[)97.H&IM
MPW8C]?7;C8F%!ER*+)D]>.^&HK<%6S)-JM2#&]V+9HT?<Z95AE!PC3[ #:"F
MY-: _BB8%<;1B&,,?3\9#29RS #!R/E>.)WFUA]%QK("_I;DVSK#S6Z7'GP3
M7L+V-Z&\D3Z4@\-8"W+7@8,)L'8--4?\C&V'&,Q@L>V'TBM&\EBL8@\C'%@&
M#G/$];BB$=86L)_F_B@D//X<?!/(FB&>+VW1K(%C//#A5, Y(/C$41'B%U#0
M$S59>]"EJ!2%DGI8V4P7))QY"'S$<7<UGIO2&G-NR< BV&&5^1$2ND_\.0 /
MTLYUVF&5&;@X@]OF.K-OK3;_K1V0NP3);/@V*67%P1K%&\T-R[5Q+RWT;:9(
M" :(W(#T_<ZC0=\@#F=@V=HMA 4.56<Y^9;I2=(R[RUA^>0J".Z-9^,@*[F3
M&&H+%!_ \T1-&JK><[I<*/.6>3FS VRMJJ)<;X/#U9O/,L>7;__^YN7)](4U
MK$!C)IL+IQ=Z>6 @$04=RQ/ 3X@BS.Z"&FN29R67'"_:"H=.WB_T&C'\(WHU
MO4/-[E784XM2:R:[NP#K!;HFOD/^*F@N#"'^R)"SL,F!Q2>='/&=_;U7<0B=
M;$8%*NHM"IAMP'1'N3<X7^9YX@ARY+?QW:X E][;FL9##@W14*5F@<H#UWRH
MX%FZ06SRG"7S[/X!ZYX6,CD<!%MF!&9@D;N:(_ (S'7O?7LL?/SZFEG'<Y!5
MSE2$[M8X$FG5+FL59WG->;[796D7TTO[*7D.EV6]-O#$BWF#&_OUR\L+/V1R
M4\S#$BUF1G 0_^Y4::O6=FB6(4QMKCOTCC*1/U"F\\I4UW8H*=?_"XIEDFK
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MBP'/GH[ LQ%X=M# LP>WI_P1[VH>X,#U ;# :N>*S$[Q-UV.KHZ+JV\GD:M
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MQT=*H_J!]I5_&5YW]D?VI%K=UMFA1AUE%C3*>K+URN0H)IN)W%_D",3AC>W
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MC8'("I7*J+7!+\8]@XL)R>AR]-J71KQ[E:!GY*TPB]'5!FQ0/(G])0U;I-W
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M+;1CSZ'_]?*OES_*)2+#5G<NCQNL[ :9BX\BXCE]\F=Y3,?4F2$0N*R622'
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M"OV3UY^']YHL3$E.*6*V,>/4%+^V( F'OZB1+BH:2%$B2?I+\R/!!U:!(/;
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M/2C]*E=XWE3N5<IOMPIU&$/(/3 1?Y4F?L57]&X$72C<KMA]+4;77BJ!HNS
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M'7#KJ(K\,56ENFRJ:<W99!3_=3X:('>[DW]/$0X2Z@,%-&1&%.WUTI&0(A#
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M@O\6!K[.O-N?^?.6GO^G-E<,M!(1=2'OP8-C6F&=>2(-35F&HL$ZF]JQO@+
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M;15D.@3-O(R$S5EA<K&DN]* T^7WWG-.]S+C"D[W"I*]GT)-VGKW]21.1H/
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M#H3(UD+*Q#MJQYU/8+Q'"9XGE_QMT_*&"'9SG4]G[ / I\$W)7T/#@F/&95
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M*QV2"Y%;J0<;@V]IY6[6/IS5-[*^L\[3(!6+=%'K% +DR!T'HV4!H\3-UF_
MPM/)B'S,Q46>G^GO9D@^QT?J6"^'B5P8?/)ABHOPRDY,;/[P%FSLV)0E1FB"
MCZ[N!%9"R,&'&*W-.NC"G=-6#W9J5"]6]I@YMG['03G:9-;(0KB 420-06<E
M(-*$+ZR*M#KS3HK-J;IXV[[!N4NO>S*=ULLD%H]_,LZO)K046/WK1<';6I%^
M,KY4%D@K&4T*EJ&K-Z!GC"Q*EUFV)B!$7USHLIQOV8A=E[I5K(.S>Y FY1*@
MR?C-=/)A"B>UZK=P7D=@R>10JWXK%K0HC&L.DA2@83FC^GH/N/TUAU^@'DU#
M%^O:QK9O&!-=(+N"Z%L'_N,367(\?P-?ZW<#IY(!GRP3#GV]O,6SR(MCUA14
M,0A(R^DP:\2QR=L>JT::,]$P5'H#P+,4_XL,_^>(@^2440""%4O#H:Y9/1Y4
MO0$3)99BBEY.S]M*+==>^$,P[?AH&%^] >.S<[_C#.OWS8'+J%$H4PS/+%A;
M*Z%:RV+1J1Y,"L[XF%'MHZ(-(/S054_.&IXC6Z!^BY]Q?(J7CE[\?CJ:#\EQ
MSS@B>TUKGLMEF_Y&?S":?*I?_SX<X6P^&>/%,*N$EE*!9%FC81ID8,!M833R
M>BVM# )A(_&U1/58]7@T9AL>0-NM(>0AYM,T?_+ITW3R&49UI06GX_3Q6JO(
M?,$XM$SY!#2P*\>BQ<!44+I8!2Y+UT>OFT+\(=YC<M[P3-ENK7H'A/Y:$T*2
M-H(O+&E>;QU*B455+.D2K'2T]E%6]9'M2CP_-'HP-AN>3;O!9WF/TY/A^&RQ
MO3@']<>GR?B?T^&<7)E7D_DPX:#8G*+PNEXA3,ZQ0<YBX)I9+#[:G&T4:0\W
M\W8$CU5T!V&LP^&U\\[RG,SZ=%)O9$GS?P[G'Y^>4E\XP>FS+VET6L]M/*E5
M:6>8W\.7@2+_E_1?&"B;F,94,UQ<8BYK@HXR7@NNM4HEVAKK(Y3CH9CM<&IM
M%<Z70XC#T?<;>0<9M>8V<F:\()ND8!B@"BRX@$%91PWHDK:T";A'++?FW#4\
M%W=K?.DBH/T]#G#ET^]A^@'GLX$4!5W,G*'DM-K2)!+0-%:#M\[:Y#$N7QRS
M0RAP,RR/4&G'8'%%T+G'!D7U$^J^B1!)<":SS$R'%.OA8<."!A&=S]XL'_?;
MVG?[H9J]K+Y"#0WW("[%>9Y]J259D+0:,98L T/K"JV*G6#1>,LR5U(HG\D<
MF^UCWO:F'\IHP, *??38;S@;[<X6%.\G%Q'KNK2H!U1PG,X^5=Z]>O(>T\?Q
M9#3Y\/52VP;H PJ#B>4L:6G+O22'SQEFBD T,0D4>>]Y;'=\/[1X-+97*/C
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MJ"W"O)OQOP[-82.ZC9B:]#+SP310N.$2%<UB.1NFDT7F4ZF'61UJ3#;EC>Z
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M[M"7:$O=X5@<V'$, AG)>*5* <^-[>*H;(SP@<FG(1T'*AUP9HY?@3SKBIM
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M[UG&8[CJL[7.%&\$IUNJ> ]S+>>*!P#)%2:>G-8B1H3,/?<(0B@9R]H[_EH
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M4'OTR6]LUZ-&(00P-)>H$3 -%!R&0D2?XD=!+*_?;7B9ULOY,95X.?TO-?Y
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MY97LC((5. 4QWZA$XC-"2@ M\S":KT$AZG364O_C#ZMW9'3N)Z("+/!$$Z'
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MS2@ HX_:<Q$3J%'\Z;9[X,E#*"#CTMGW%PRFEOS_"SIHQ5J6!:\=ZEL1;A'
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MH_-^'7<M EX)!Q@$ERXP/5-TF[=$-OG..)O<?,>8I:BT='52.Y[^-GW(Z70
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MHF+D:N=3 N.Q.!I[4 52QOONEJDZYU$V+Y1>'Z\B8'%5"_W[;@.HA($3QI?
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MS$?W7+B@N=!$F3-SF?LN2(XWBLQCD81>/JII30^!,!Q<7>8'TPCGK?J7/M)
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MO/>8LS49G?V*6?^ *,\ '[X# S3/#UC(8DZ<X#75U.B5CNKM.E9_ "- .Z5
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M4"^<48LWP^>N<6YS$P7GU^*_YA^V /% A#2^\@ ZO<N&PU$M33V?S;0DZ=5
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MJZ]D-D:C)0VA*#;-0,-0#0=P2+ZYZ['W>3EVC7,;=BX>@R[SFUJA\KF%@#6
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M6 (5QB3V>MZC$?@5TU0:8[5D9@A^.+J <ITPG48M^S/I(LAO(.HG9,7 ZY)
M<_@$2Y!-_#R,=TCJ4(,,_!9$_9NZ<G*IVXBN)E)WW@Y8 7BGI#&V$EJ8U^9_
M+#76CB ,.?]&1 -CMV'1)=9((RC$ .SG64OJJG=1--$;PA#]_4!DG (W&ZDT
MGQ!K:#0Z=FWEJE,VT"0C,KX'E0DDSF)V"+:DTN:],Z4(+IAC0>"\Q/X]Y,D[
MMW(ILWR9J\#XD,I5/B8;C21V"?5NYAZQW DS_:_ >]MM(\H3/6A6$>TFXYPU
M2W_,E$YF*(:&2[1I83U(VAR?'_3RP%003[V_9,E&4.J+SP<%#[T^H[=>*".Q
M&;!72>IUPD>X=F!ME0&B!)O/NVRR [(*-MB;ZG7)EM+@*6;-)(NJCP0TR3IF
M"U#4PR5(%TQWO*760!.<$0R.A.C(69'SH5>AY8&?-<O"-5Y%02T/%XB+\H8N
M7I[-P8WL,=1-'A?'YS.HEM,C7F84:N46;4GRGQE,5&)$^6/_W*"0UQ73!%)3
M32?Y9RLB?+C)NK_WG/'($6>RTUO]_-7' I!2SW/U.=F8I%=SLL$F!8OIGEHJ
MD>>\&KH$Q^JQ(.DF7:%L$OY;K)TV!S+=NE*4G  FJ<;LJ**0/J<&A3T<;AAX
ML4V%U:6N3(9$"T O6@Z/16 N$B2*V)\P PW<NS4M;)J@C8W?QPOY<.D#3C(=
MFMR=^8$5@U)%K[ V/=+U%Z&'>G4B1:JD"KU"B@N<U01%\G4QSAG$[[I1J"!U
M&,R(J7X5K;=$_67,^O>T3!HAA>/*G PUO\OU\FG*A?P227TAR&I2!#R^HZO>
M<$@Z^UA$<;L?PIMP]H:D+NK*]FU*OE5\).<D,V::@ENG9#2+G79\+-U;NM4A
MBE0"JU<HP@A_HC&PYV$0\OJ82CK>&WK"+*AI 5XL;9'9FSV@&&^"U539&'L=
M++]_W.TYQMN,5@OY<GV9!L,X'>@)??%3<QHX'6W!\(=JKH%^IDXQI@V#]RJK
M75HR5M9,21NVE!19+FJO@8<>Y8D687.DDS0P'BY- HVTGWGC-I8KY.(1'E,_
MPBFGUT_2L+;!]"@I&XH,ZG KF8"HR[T.'\O_*7+[!/U%:SX?C?O:M>*;IW5
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M'';Y>^Q7SEE1M79WZ=WBG36!$]^B)U985\#I-52G*X0CMM:(I@;I,IUUJ#Q
MJI3XC$E8L0(,I:%OM ^V1,LM>"-<A8/6S2>P6;C).EPX(0F1&WGMAJ\:0S#N
M,JTB-TLS?VH8,S&4J[#_K:]636<JWRNX7.Q]BKF%3NV9YSA+M=6@J IK <%7
M0F%];)H;('Q4-VZ(DJ]%KK!M>XBN!=]]>13O'NL!:3K\"^)CB]N/2I$#N7E
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M7X4J3<EE<6R_BE,+<V;MSXV%+%.<KHFOB !DOF=BMT)%]V#/*R6\MMT-ML'
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M8#<VN2'7&OMB"B5XM6 /*+0MN,:+\VG2;(B2#[N9SR1/CEW+9>.0CN9_.SF
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MRU/+ YU0WZ3E=^&?IZ*FXQR6.J80\U.59<-#Y(%U ":,MX1BF&"JBZ?W')J
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M\I4]P2B-TX6SDPY;:7WWEG(H?DW<+/K'+._D$JR[$0-K@/YV)A%0T=#T-%@
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M)._U.).UHVJ1I=2Y>?94K6R-E8IFK\Q8TDP>:<%GN/>>'.&%9PR$A;&$![[
M@?_XQ?<,Q_G[&IG]5ZZ;HBI0T91Z,?"/2^<OH!C-I-/40E^9:;$FK4!@XREW
MKCI^Y]UM-?'5^@SD/\UCZDKNDJK"9)[.072LO9%$@OU77?>#&.\,]2;/7=FV
MZI;?AQN1EWX*HF-\@1$YK]V?X0";2[*^J&[F:7T9MGD0L(NY&%S]9!^%KL&@
MC2N*-!%L]?TM5KRD)J[+DBZ?NY0IH7%0\RYGZ&N%4V3[^SEU GXI&O6]9,O
M=TH];O7]C.Q%;K(<F34O_]@L1'0C9H=3@%E%K=(C?$JGD+)'63G3,YSU8U^R
M&C[AN?@2=W%E]QP",:)B!8(.6OJ^5D]$IXZ91\,[=&X/?\P>$@%PDMX)X19_
MIO&144) (@T#N>57&JT4!;RZ\-!#F!R+,U[]B@0^NAB2'M]Z:'41%31>F]7!
M52!0 $54[\MB*RB:9T#?2?[$%6-"_<3/0HEH'QVX=D=LXF>TM3K2FN]W?5@F
M\72%5B# \"[ZR:CAW0#*NN7T(LFE!I30V"TN;X ^W'ZC21C]95;PN<S.@#3C
M(0:+ ZGW96.[RV2[<;>^IU"^O]0^0[[)]0=+ P8Z2:OD;#^VR5^T:";UH]1P
MXDF99M!FSO%\,W-E"%8Y-ON*EN,E%K;/3)-/BF9!Z($=XOX#YT;IA^IMV#?H
M63_1/;1^(3Y"!G'*99"VC16#3E,=N*\R9+*:V;@QJVLYS2Y!SA@&-Y!W*V/L
M Z<59>R&LVU>]03=V;37O!:XFJ&8<UX;,X4F)6^K3".Q6>L6\*&(4UI%1HN(
M4J6MJ05\-E@,@&G>0"U=G5[-Z TA^*#T5XK;.,+2[2,&M);ZJO@>"#-H6VH/
M\*DI.0A<)TBLJ/Q.TU(6 *B[<PUD3NO !ZE Y<#@-@Z7,W[P6!)PSK[6A7M"
MHY-7*)=BA)NYKL3"CS-,\.EM#7/>E\6??1PV W%LF8J8[Q(D-<,!J3L$CVQZ
M,F<:4XN.F6]QKFJ*U?/E3K\GOCG-%\EBYDGPES7+36K/]($BE>.DH:05219Y
M9%0_PKZ]K=*D?].@;=BD-:/^ CZ;#6RNPI93MTW)R=XXM,1/]4"J1\Y?!YGS
MQY>AU%BKQ:-L" -R=&22)[#7['?[WS5+&'1GYD+JPOA(IH!RR?KB&#S%%E;,
MI\O/<'Y]ZZ_8%U[C)*.>A778$0$7Z2/,76!W>0,H99_RYT0I$LRKR]Y'*P?I
M2Q?DYH@S$+*R*\D]@I#S/NLR?S"P!GX@"*!&4%N:O@$"<?QFPXQ4H]3AHQW
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M@GB*9'+&B6$'D6H"I$8D+V?W#R%#K>.<SRA-@/[Q:7HC3RA8J]B$+#S/W5R
M.HAW1>UMOK/EE?;+3V-GF\)1IE9%C(B<F(;/&N6-@BN9Z2*W(5T.*QZ$"1+G
M5669H]$"S\UCH\W"29G&%E02H:.Q'$6?\SX\XN7R$+<;-[#U(]D &0)*HRS*
M92A'<ZH7LO3./U5<)WY59LUO4C36Z)^2VZ_+?+U (#ZAT'[>UU5C/O&-J]'<
M4 [79'BG_F"B&_71SSM^_#J>5&\O?8'1&W?@NIKV@O+>%=WE17UH&+:=_([>
MYFA5[&B5&3#4C P!X[>G?K7H.>/Y 8<T,3]9XF<&SMV VWGKY?L+NB];O3/
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MAT'P0<ZAZX)V5NUT*:2<$.)7M[(N.WJNV_'QU)LH_ ^DI7JQTI[YDEPA] '
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M,H1]Z>_6"+K$V,!LT?\58 ZA]3FK%:UC*H"U%)2S-R).BI1=3SCH=!E1*NI
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M$&A#O!A?UO%*CHZ:TS,Y>HN8_(553"5%<6O_;5&[:_X$L6NQK]0*QU1<U6W
MYI[O1ES.L',..LEYZ%7OL<W8)ZT'0,V6J#5R7CQ <!R&W#I'.YL(1E=\KA!L
M^Z:!?/_(\FE%DW8C58E!SG[B[X/,"1E\(4HC8B'+>23K:%[&'E9+^AB*H_,
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MV;,[1C)]5-9$];C1/-[2%H+C.I8BL7>+T.'<^7Q<,?F&(QPG4HV];70DB&\
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M1)R83_57+9,&-\G[#R'*J:V)LD:,FC+??[H(KE^]GY[/)[(HS*'2;A%_E75
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M1*]5O?<L#&>.B$R.;,5L,JDK'-)2J.@J9R<L"%O!AZ1M#CLGW/!2LTRD@T1
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MK)H(G>Q4<C;B:JHRX+(TN 9 R;46&0H0XY>D]IJ2N)4@LOS[14&6P4+%BN@
MHAJCI8<XN4FB[/P;ENN#<3N<K-4I!IV$L^H@W04[X3V?=7ZRPA ]3;!8!5K
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M&SQ:@#MNY9EA;L00*(*Z6XCH4PJ*$9+)Q=DC;@ 9U?'<0I4Q?_ !D4>G])J
M-5C$_H).2-E)F$)G2A:/_E 07):#3]EO%OW U(O.5V\<5G.8UCZR%99528D;
M*HJI1;OJ\''=V=#1^-E'=0XA:U%YKGTAF4QE>KH^?P+=0>H/P&PR- %&WU_/
M,C@7FM)$S'EPF OXG8 8>:8+/.ZIL%W"[HS1*TZU/*J>6PC@I3YLH:5'IW'[
M9\FZO"!8N+W9:Q+?P <#DAFU=$\0F(52=E-3(#27"", T6F(%/^RU"-F)%\D
M2#ZFN*01L$%S-$HZ0<&CG5#(7M1G @+EZE)^(0L88$'0<-]4^6# # !KF3SE
M^F-BUZ(\*&5BPLWT_"2R"-=K F\OIBS\:RDR_)4N4R_9V1^H6A/U^N.!_>7O
MW Q'10"0[P'F,!_6-Z68Q,_*M_KA&Q@YNF8[*HZ']<MW4PLS,4O>NR1DJI&7
MV0IEI(N?!RYBSJE#%>^DNPK""8GQ5!,< 3X%E1^[//<]O#G02IEMHE43UF@>
MUX[Z./HP<A2&&OJ:NW(J_P7QYTA)*:Y+ :HWN:#FGF.$,$US'.<\(!)ASZ&R
M]B4B3KD?+%+R&'"__U4M/H0[RZF71Z/DL0G>N=W$7O&IT#V][!E/8Z-'[#!5
MH<_)JF@!*O9M3$#XE,M'K;6)@1O$F8#A-$9-\G@Q>8V"L/U IA]6/PM[2_A>
M7 'X#(+ELI2SU:ZT]*E=(AX198]:1)%82-[H^HD"_$LBH%!C?Z0RL?K/)]_;
M 5JFU3>9[]0?1&1J'BLEBQ+F#YWP^9LH,2XTD/4_@;OYWA0-(L&15E^KI ^]
M91 +N0N"T])_ !,+#V2QTR<^!-KE;?"/&.?T]+\-:JG0N"6VS4>C++HIU(OA
M&[C[N C;5-BPJNV;O5$Z3ORFIEYKJH&\BH;(5LG9FJ78I/!AMN$0E3J)NGQ\
M)E@9AT^Q"G^"1A,)$ YQTG,7%)* :?/MBL8.@"P8AE'71T7$6\?:O3)Z]&N@
M(4O++3D-M8E4[&B'0'&D!.:T ,!8E<M=G;:7G:P[FXZD?D !M=*V;W(O*O*(
M><U-2V OF;9%90.*7"9#NJRA2)DU)R !D4CQ$C+3'M53U!VP!6"YM]QN23B2
MD6Q*&Q&V^:Q[0U.O@>80*\UID.4-1C\E)PB'@>9H#[.X' G(3*!K9!MOF>[>
MI',YV/A7I;-82GIS-GY4PC#]4[4_T(1 &9%9@'"'F%_'7D(KY-S4ADI0,9WK
M3>+G3RC&< 5+Y_O<'=UH!HH(,\I3#9OL:WY'^A6>L "@ :25<N.VX V2 6KC
MTEX'R#BE6O(![E_K4 Z6[L_S1?34D RBE!H\V1+ND^-N0]>8DF1@/B<^0RV>
MH7W>3XA8CY;@T]=BC<>AZM-BZKU&V@\FJ8Y^=%"D[W._4"DMFWEFW !U8*0<
M,51$6Y%6+K%)ATDJ()?G$Q2\LW-V-64J'M)+GY/O?-&^G8L31]B1F3"W8Z#?
M=0;)7MP ?K_W&_#__OQ256KR7W+W16S=P=*[BF+4?J#]$G,)R<@;H1(2/OK"
M'6MGS8_#.@C\#_F*KC=P4<M,^5(V%.*QZ;I%O;N47)H$Q,2DZ2#V/TF:4ND*
M]PRE&G&&X\(\T]AHH3UAB\O10J8M<4X?@:W,\Q5_ PR@>J 9[NJ^2*68G%X>
M>TNE(7=G[J_,"-!.7R0-'8%\E!W%R,>'UJS3,%9[A#S;BS;*-BL0,+R_EU%*
MH&I9F1CL06G/8^\!C68(KPH>K0[8;%F)D&/!1%!RB@;%%)/3GC:N'T=@,/@3
MAD_$\1^P!#,D,=9@C9IA4A%IU0E)C#B:"]GWHH;Y7N%+6>]2ZCN&0B+S%!B*
MKA$:3:6$%(NHSW=N=Y__F/R_*^OU&%HPS$01'#$4H*AFZ*A$B$45MSR]#<8+
MV?],EG58>O9H9G:LIE,Z@U.ZI5.F)CL6RHYE<,JT_)OH[;#T=N%_#E&^6F&_
M ?7/Z)&1FDBLI1HM@],S2R=:!L?P?Y6U=/HCBX7^34 !T^>25Z)],%$H]_-8
MQ$\E6V2SA+#@+4?+]@/0;P"?FE)I01->)B=YR6N43ENE/%QS5:&7.@53D" 0
M*45C&\-ZFG@&BQH>A$D^0!$UX#['4/*?<<H$[=:*$%"E1J5F&<8X3"4^']=@
M9T'$;N9H%.;DBV0>%_YH8$W)(*BPEGP1&]X0P;=X[S,S?6O@M%""&))4VCRY
M?\*UN&Z3[R6GEERO* FJXD@I@<:"Z9&ZW/U@1:\9RE/^J+GA)%LCM[%;:,O'
MP+CL%C517A;5.FL3\8H-J.@MCFMVT7VQB,/;W>&%Y5"KUT4L3R+],?V@I+I/
MSFKGMFA<"?0 3ZC^+0S4-PDUV%%0.D4"$%!44S?,1JX0&!YN%^\\ZB"4$ X0
MHXS)NL+2ZL4)VT^J%J5"E2PX[)QSE>Q)[\O3/\M H>+H\\*>EHH"QMSRE:9^
M]+(0DC[*#)/0UMQ5@#Q=6B_&\A]LGQ#$^Z<V;C1Y'AN=A?!F3)+UMR0^LSB-
MH>;'#0$]LO0QVH2=Q/X(_[&-LPKL7H!_DN@(7G^ MDINJ%OL(,F#]FOTQ[G/
M^"_81L 9@/C"D)2&J@#QT8X2Q8X8CO0<3D&84*6A-M._IQ$5D<$P!@2-<X A
M'\"U@4JCIMXS<6_D]_<U%/-BL]9Y>WX9$\1R=@8O$/[[NBQCQ'WP+I\,9-E7
MF:R/U+>_,&U$2X<= U!2/F,4OA$-7>&D,>NU\P6^@[P6WPN22\"S!%A-X>#I
M@GD $DS4RO^%?51/EYE93#/SB[*0*8-!.(SMNU""0;S*0KBD$]G,#.G]A-B*
M414TXB6$O%>3W.&['4X5%P,%6%VJTHK2&./D?SBVO1Z[[TG>3X,B!0S$_\&?
M[23%76I#^@37Z6*-Q&XP65BYQ(?<V=6&>)6K2F[P,^MOM<^>1GN5S5A[M:VR
MY6@"F+Q6P7RQ\YI4.*CX3X6"QHGJ=?!VQ/POJ6"A%_+4W7>U=OUPE@4P^ [Y
MAYVEMT+?!Y>$$]J/GOB92*;YF&,JOC]C,O+P!&L9 J>("I<$]!2LV7P[5;GQ
M%6&N:EK4K#(N5(8 B]I0NM%[8R>@F*]0I>#BL;JYLX?*:R;ZP!YY_):N7'6%
M: -DJ1(2>:K/:BXHKLD[%9 7IVU"PP,MC)R#9\E^8_Y;Y]3H2"FC\+)(.2+H
M/#XJ_*5>;W1LY)=43;MW!*MV<!.U'-(8Y#%?QVQ'Q35O0!Q#UI(IC\N1:R62
M1:FA&R! T(7 MKKN,5\SM0L'1=HW9$/T9'3DV3/$DD"WI\7^TZ$8?.]GJ-6<
MAP#FQ*0MP@=U6V!)6OUHI> 7:-U0C>X#$W4H9/$J]RG&B\EL?]5=>]WI,/.G
M0GC"_/3=#:2;4S+E;X"M%)$%XSZ]E#6HQ!7+M0'WAIA5DAJJQ*AL#H=3C@BA
M1B7"HA*(KOK5';EC@8FH7JZ"TGY;53*6L7I6,\PZ"0[<VS*]C#N""7%L&]P,
M)5WP1/39XS[8B0!&Q-U)#K3\/U1T0UL41/I?4=\(!'.S"ETK\>1_8DMD7X(S
M[__(&6_1;U2F@? :4P?@@9TR!+GL6V^5"N+=10"\'!"&0WA+ ?UI3)SVTHKV
MY]\ @@AAF+#OP+)) Z!>WKCAZV(DZ-3JF#[B,(Y<!<85]2W9MD,]&?HU,4F&
M.F 3A!!"7(XHX1Q7@A'%D2,T1R^T>[<A&*)N0DP@-880909':3%R2-9=21,)
MKW2>#7K=,HS&$\3.R>8&D=# .UJGE&?OILWN4K83SFO7W+*[J<=)4H$$Q=[(
MLD16*#/S3K]FGY[BV126Q')L %43-$6FG7OIV,\[G&24P<2C;%DILE(FC+B$
M5$<QUMF#]PC7@@>FLJI3]_\\5^W;C.(F<:*JXD:B:D&_ 3%[30YU>(=?/&MA
M4CF[3$S=/BH,81$M0;+R;!B5!F::NMIF2[NI1,B@.YP5FSI.CG#*\D>BH@:W
MX.I4NX$G&04$], X.$*7RE;Z3$#3,BPI]9LC"YFDFU-_NARE(9 +-D>/1*(3
M'+J-$,#(>DVR#?+N-L>?Y]"P"%IZOWY0Y=N*R#/+*L\VD@YQ3SAS02PEC2ND
MC.]KO'<ZO0J:$S:,@NH"JO2I15$#Q 2J/4^']Z*I662TO70J=4^C%2@JTA%6
M0"[9OYH2/D5\.QP2-?$<X2G+K/X?!%K_$1M<C5OJ5:AI'@! ^5+K#RYT3X;)
MJH3N7"MG?+N!C+7K>"BI/BS +:V_L>&SDD5\]Z?ZU1^WG3%1G$XX",8-E9L^
M 5)Y,P5SA:8'23BO6WMO(MDS2>$4:++75T$E>A&+ ?U<#.22<(]N+P93QF E
MI(I>73ZG8JI[OMTFIFZ4GP#V(9P%ZT@_]TUN*"OU\W4#'MV@SX;F'8"^BFXA
MHN'!TYU/V@T$M@96CA*R60]?)2(A9[QU>9'N)4W%W*P1Q[ @%MZDB>"Q\N>C
M]U*4^HF=/HAZDO$EP\AKJ!&;M!8@]F^YQ$IEI.7,G;CQ* #]'*,[&IGM79DV
M<$Y?H:5FJHRLGP(,A_<,:2WWX?;RKFV9'@7;^H=!2@YO'LHI-XULT*MD1TQ]
M\\6,U_C2*E*C%XX7DC6 +O0IU4(9*-W9Y_W$GW2%^_A-"P_)T%\578+:OCMU
M0AI0QNG46@:0S9C? "EQE, PP]>H[T[A!7S Z5Z!$@"-DM^>@$2I)'UYR0#+
M</YMV:VFO[-?B*<FYA#F/@06!(J1^0]"NG_'Q]G"\AC&90/8NLV+&D6TU-<\
M$K758N04R =M.(8WKSS4Z%2S.U=EMDINOCKUI1AB]MZTX('9XL;E71DZY ?/
MP81BSH>CDA"R#LYFPWTTH;(PRA-)26E QR,MS@IA'R6HMCLF;7*RD-ES<8*\
M$)]E)=["<(*A'UA7;U'!E;!EK!R5=07,1V/(\344Q%D2,&$LKC'CTG#$3_;
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M-<$IID]T3N;<YT%S^ T.2&AK#K$.!DL>G.QJ>2*.S;/^@K=G,AE0%* &AS<
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M8:&!4Z:*:&=[F"#!H!^_W)I0E.MWS%Z8GT&_IRT:Q0A@\>?/& NO"BQ08P2
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M1"03#O2C][@/> FTUT7U+T/\X1P084:FX5NWI"K%=YGV/5#QR7+,8ORFXM)
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M.*3[;UGQ$.20EPEQG!,8AHG-%9[I/%4V_@(7U H>NXSWZIR7S:C(LQ,(U=A
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M-=''*PY"' 4#!#!1Z,C>E/ +ZG^;>!PR57%@\HJ7VYC!B*!(^Q8\(OJ82BU
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M0_*)%I/()XC"<5@+5M*PN?_7?X>S!%,OLW-9J^_ -*=C2/G\@3P@+I/[&E
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MTLEHK3:FAW0/,FO;@R![0 _(UJWP11\WFV?"^% FL>VJ67#"')D-7 )@F)K
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M5+"1!!*]UJ+YN>%)E#T/'XF0;!@B0V[Y[RM? H.$4DE2+U;:M4/N_LNZ/"X
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MTYH=-[3FG/M/]JXU/EE^+(R%O1I@!T4^8##A9M'-'/,!7H-DPP*XPBU+V*4
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M9 IN/F))-[QZKB!2<F3+R_V=_$RY>]A5HBNH#'7*D>A.HD D\Y8MXKHWK9J
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M<:$SY/9*ICS .R*4*$[1Q6XG%O1P\*;)0'_7+#8;6S?U%U[YX'M#4_['&4&
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MD5E$A;%*:]KW"S6C8-+[9WG+U$R! R@"FDR D1BS1P %P5B-38&@29P I B
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M_K\_.C^Y$NXT>_^C9%ZF4.K)W7[NET<.W(<=20_8>\DA["RSE7YODJVAO9=
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M=@@(F\^*"E;E_LLVJ7U3*(UVI,B(H2"4*UV5!AUROKGK)"J<D-;0 N  G1B
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M0GJ0>'#D8!=VHIGT'0,V<B4Y<BM"SAV^+N/._BGI*\"C]Z#YFH;K6>:;#&<
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M%Q\T(ZK6HT09HG?4H8-=9'.&RF&MJ #C@Q.=JH%A29I<!+$)=T2$R*E$6:1
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MN1'>;&057C,<^DC& %PDA8+OXUSFWV\/_K\!YO)/T"RAWP;@*0)V2GYO@Z&
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MK:0I$'N&]R.F4S73#M%/,'8,CO)"_/']0=C**"(6+/!Z@K+9ODBYXQ$YU5<
M=;["Z0BT<QYVLSG*N7-@W%&?55U2694B;A&B-0RG#,3!*+&(KH=C!QQN9,,H
M"Q/D<"GBI77L7)UBSZ'D8[#NXZVH,QO!];>\@0>'O'OAD3L13"X]HD2;<%J0
MHRX.3#Y4>^N5O72)8>X:L1@.>7<#UZ;^47I-MD)#SH_+H15,M]!;2KN<+?#1
M>T&X."W R-UY >_$KYP=[>AX*W R8.R*LWZEAY;==,I>[N:ML>D%-Y0S I:K
M6%JC;MJ;=J H(CG;&#9E-QNAZFLLS8+_U#D=MB8^!KAJ!1X4*\1*C 6FB^JO
MGC**RF#43YRW]@:</2WMKI@TH".-L++5_WP7/X'K"PN6CP#YY*B!-?5]RW0O
M)YD"N7>WR@79S/CC["5!]Q)Q,HY^Q'/99Z/.7!/B>I)%/XN0:4=PQ7W&E=VF
ML4\Q<]M@Z$>&YP?$H17WHUO\L1&)%P18+\REEI2?@E)%=85ECNX4K=8I9H5\
M\9X\9<0,L7-Z]9Y%G2)=2B@M"C_U+(^0[=<_EAK9Q-F-U8&55,Q,Y-?:1%2/
M=T!=>2*T2(K3V,SV8&=^' 1^HUY$3GEK92.1);795T.MTCPFXNCCC&Q]N@B(
MAAC8A7P-@AI/B:)N:(4;MM$K/Q;X!!",[$V0($DU$FJ(6 $S=P"V5YHD/.<D
M41IUFNUSET9\6BU?TG%O@FRFF!%ZT<)E\70N&F.P!/U*>#MX8^V=KCI=IZ,S
M-TZE)!F'Q#XN>-VF(3_+OK2>1:#6T<258:JU;\F4K<)DZY7!N<5@V AUAA',
M1QR1@@DE.S ?X@7!;X>7_OIE+\A7/2J<960B]6[09710QA6"'Q']88K](:K"
M"*P1H7,8;^Y$#990=9-=X+^>X]I$A:DL%?@PLPN&8(XHEQ/3*LAVVR"3YW17
MY13+SNJ[I\V6WBF,?TV6)/A1?YW\QAD>?9R$3QIDGT0C606.56B]-(_7LV/L
M+L&V:,6]PMR2GN"9"97W@U?1!LG-=H,Y:Z7<#QQ)=P.ZV8UV^U--B!$3JM:#
M0]>5/KBZUJ"%'XF)/3 '&#Q72*<=)-IH1QGVH"UC/#[+%8467QA!^7Y%53TP
MG3QBAR9P%DE"*L2JS&N_8S9>OJ6(\KOERTRQ&[H"+::#%FYA4YA%C?".3N#F
MP3V:_N%H#2;AYW/G[UMSV8HDOW:(/+&"D:3(:8R648#P(?N\IY^BCHLX3&N#
ML\IK#S+R P'P+AM.#202*P6*MR#D!"_NUE%E&3JFH-0^NFC]6AD6N>=>I9/P
M$L 2/-H-(S+U..-^48H5-\8&ZUYDB8F'VD\PU@0&:7/D:_SH?'@^RB]>.FV?
M-T/U#L/:T0#-*IOV8U6]]_3CY(5(JA8$!0[O C?M-(ZTO/4_!=39K7MV5VX'
MYL/64<1%\$JFN.S(!#%0A 4FS5:705F2N'&TLD&?RAB$N9NTY#=C;N\VK<25
ME\.DU5Q[ADKKM_HN$%]=28&KMS^-/H-"(\&I)H&.Q:+>,,$?//A\G,CT=H!8
M3U]C,KY0A>3J[ZHD%4OIL">7[;,R$%>J>(-F9#B0M4B=,%M.\X!\82O5*15$
M7VB%>(#Y>&!@13,HF/L3U%O+CU) ;:6T'?DTP)9>:1==8ZLDT-15&5P.YVA/
M:8\<#D"?YP\ICAXD"M:BNSCN72J%(*F3R@![^#*0D$-MJ6VXOOW>L\[[^J8]
MY@K9T=UO8MOU&;2"EM6*3G\, 6&EL:-!%$M P""#RD6C[D<&/R: O]ZP,$\S
M@-)=+?/%="YZ-MET$LH1FY(3ZN,%[&@256K0JOP&Y(A( V&,\)@#4R##4;KA
MSO8=&@#C\\FQX/# +20_N#D_.(AKJ\IBNMPHD$'_T&&PQG7( ,[FH#X5@&EV
M,QF:"4U7(@>OA$-X12%;K^-]&='65/8+,9_/]6V9)56*#W4+#<(]EJH!G_#A
MU/S6]VRKC^R&CEQ*VGA@XD[T#HH%-95;J>H5P  [B[7&J%["N5:T"R2LFB6[
M '\)-+SR?P7LVRY"Z-F2?DXV_(I#4%G%3;\(,>M(._'%L&_?FE1M#9SKNRG.
M]WGWLQ//-!66\A+ J;[1]D]/.C_Q^X#]E[97 /-3G_I+^_AG<+M](>H7P](L
MZW\I->N,6%^FO@*8%A0Y_J6DVT07]Z&S<ONIZU^LH*@F4!7!/_L*N/R2G,3F
M(J4D,UY."2S4N86JUCS:\7W@,/V Z5E,J8DLW)5L?B0<=2\3U0SE7]QPG'T_
M7? 3S@=Y8I>>IK#@./A.E.&E^!40<S,YXY6MO$%]COX3[E?(\Z#_KK!37OO_
M? &R1+[&DL#S_X4K(_&K,;E=?/H_=\&_%^3)D,)=OL.A3H2DJT6HHN^IPU#5
M$VC"T8MAG*1/>YA*=5<] W$4NN(/L^I7=DR02WM*>_ ^4%J2K>Z;S_"M@T,.
MML39*2/%A@$Z^+5I4DS49PJ?&DBC"!AG6Q]F!9T(Z'G;I<K!\;IZDR&13K&B
MX1(_JK4ID3!0"X11VJKX%LS3&G[$]6(4BX!M[L(5RT0&HE++(Y&FR*1E,6 K
MQ.UZ7?NXTGR4TEI,6KOM&3 <P4]H>4\#M&-76SRNI)]'.6P9?0C[D2MDDY?4
M#,^,73&T,O]$XIMOL54>S"?^:PG<#>S\A'T5::2!*.**-]V*;+$3$.N1>/T=
M*46[H#QJ;IH-^"NNVK60?,-+(L4.!=ATFMAKQCH>^!X#S&6=(.*+%]IZ.@HN
MTU@X$C_>4",%9U1S1*PX4U$K7Q14(+, R!H.T')\8[PVR] E6AC=)'\I.(0F
MCZQ >AW39C$X[J&'SEOZ('92> ]C.JMKJV4O2E2' 9.:E8?A$<U=,ZNLP/(I
M,C66[QEX= 8N"H\Z* K211&KW)EH[%J[DL0LFAR\.UX]&%&P62R2XY2_DS:5
M#(TM3/HHP391+PV1]EEFOD6*R876(%EW\4BS)V9XJ$<S-X2!8-KY>DX&]>:Y
M>SW-4-\"I_(0V=PF"JBIPF_@3H8](,]E95*2,;Q#'K:((35-.'=-L*LE@NP$
MJ4++[=NW!"BPRB<3TPX[:SIB%4CV]%F</)!>GH*J<S AV'&/]_U0EHQTO!EX
M$VM6 QJ77FRQWEL?%&VS<U-[!1!+$):UY+N76;J^Q.TKEP<@/_4MOYF[5T#Z
MB:\W\6Q R4]C\6L*U?XE12.0H*(3#V]WT?YXK 5K=K&'H?3!X\R7(1IQ\3JB
M =0L4M;/*/Q@WJH+^5W%Y$KG<6< JQ6]?,%VT"KQJ)L_=I5?2F&P$5SXV'M(
M0GK9X 'Q.M9OQXK8>#S4,_P:=W&\G6 32!F&J9KVD;[%$(7\0<4L"R)(NJ03
M(R"V_D8WU1ME7[TN,(ON7[YC<;1XW,T$_9'3DT"JAH%^#K!"W!KKDD)>E-[W
M>N0D(^L8?;1$OY3K@CP*KXFG@3<9?'3577FV>TH&:/[DA5P$)#M2[B5KM:74
MR .628.!1+KX_0URSIWT"#V0-) ]\DSR"ABH)1[6"1H_Z@K=0.6D5/N/8;B:
MW5!J<9#"SD%'WO:M%I]#;F$GIN5M-!_$3Z,? 1ER'(3F(;=;VPK?Q:?O8K^=
M3$1##S@1PJ\U("?UUY8.);U+_T;G%&CAJLJ8Z\4!"G=_^GJ=9UIBWN\;-ZX0
MB^Q]F)W/XFFO<#X'.(K;$:K3O[7J7^9@^^IB@FB&(X!%L&.''>E"K%1R3=+N
M5Q(8?71)K;'7$:Q\_V7O^A6@"E]29"ET/#NE49-L3/)T3I(A"<A/O<D=W\A=
MW8QWXR_8YK]^<=ER[6$ZI%/;UU/*'V=3Z""X* AU<=VBAT[PZ$12?L:=R%-Y
M(7X(J'D%3+ZYJL7[:^'\-Y\SAC/-)1@H,&(>5<8WOD)^P,6U=$AW:LY/T2*5
MS"0X_B$O^U38&$A;H]!U!W7"4.GDX>]MI!XK=W0SDL=\J& /)N41;H$LH#7V
MPE]TV:-_GB>>/7MVE$TD(QD)EIH -JO7R4G7C+%>W6/*GW*SHU4+WALL/4LZ
M"\_H+O;L"-+4($;(&^!H:SLX_9G*%(&:@!9+GHSZ51&-!3C; F]NF._M\ ++
M&GK4A?G68O"H=]A?D)?+A.VU%;;E\XSAM33PD4O3%]5SFG*RRNFZ4QX'?+1<
MI;Q<*^[C(NTB,&_QA((@542UU?Q+OF5-NE:>(YB(\*FU0VK:>)F_Z#;W,//Z
M;QC/#DO2+E8BF(GXO/^:J,_H\PJ0E&]F7@E^$"G  ][R/C^FACFUF<-*)8V=
M.-)($&DAR393Y&N.T_9<HDFU)YTS998?#?FO(^-\:#CS%B<!@HD$%-N@S=WR
M?V)HJ2_XF<WG@ ^;?T2IG2%Y8#?%GM-0T(=NJE0)VQ!Q0H&V^- ?ZH- ?CSP
M,Y2[N^X^E>+7IXO/3UA-,+@ARR;0Q F^B$A3:*%/@VX_+6?N?0*K1/DIK/VU
M 3S'$GZO@&F7LD7A\!?CTX W]9B\$Q*(/Q(VC$(2 ?=)@)4W2,>^5FJ<M!(2
MZW>L>8Y#%.9>]N\+RB;2R!_>(+*[EW$B0<M$3GX*H6(@BKY#_+!K[X2#+T7,
MQ1G1B;7#=Y8&\ V1:4 WD]AQVF!2+PF>7 6E5.7;^?8J$UNXAH@0=.6-&_&9
MT[O^*E8?>'X"VC6S!N:-7L=^Z]E(06_X<<Y#!IQ?H!'HYS\1$\!GEWQ"1P%J
ML):*-@Z8C>2R%H*OBX6.;(7%DCS%)9U<+V'-T*#/9#E)Y$*581<4\X:P3]FS
MRM^EU]Z<WJ,[I>SFP.4-*+M^9K2(ZC1.57ZQ_,I'+JB2A@_AYU\?XT)' 5-A
M(B[M"=YG&EAN&M2DSWO.\0MD7_N ]KD;09=V#(I?,,-?4BG0WDB"W:>;$OE]
MU50YTO2XC,K#PD7T([A?Y@_85P +>&O]\LQ4V Y8"S(8R]/M*)H/N;UN_K:Z
MS/ 7\6HA/#?,R8;;_'$LB19J>:%W6%KVGC!C!\* GB5%<=H$!Z'P"7Y@"FW6
M,_)M)E_M4!J2TPF+,TS/71^MP7IF%[N_92YI\"'RV3$0<V?F M:'U$FY$Z.I
MX*MHZWH+]<W8Q_YH)Y7>K[6@#8*73ZT MXTR090*^_=XN+DK=#/BY(O>@OL8
MO''Z=2UENM)/'']_Z(+!HM:\\D5F/U2-]!CB7)5\2>ME*#X3=C@."?XY+M[J
MRWOJ9-_13_N3Z4SJWPBHI#.5XQ0&B*"(;X.A$7!85 K$(8U_!(F%(>"0B 2!
M0\*B_#Y)1!E#RB22I8^B4<@D-DIJ#L1BG(P:48C$7X8C83%(WD.$1N-[#0,Q
M7@ -9L/"(":= ND8WP?L'2 *C\H]!#00XSX,B-<WA_ ',TB@@1@D[*-C1";;
MX4S2O(HA7S53UY.03@.(&6>ND!D%@E3%V,WM%1#_%BWOC/&C^>V@1"2V7$A
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M01QI!,^$[[!U4<I['<2:5J![ =]72_ P$H;W-$"J@>Y,] !F=A-#_9NH8)5
M5%M&@,^.@RBI!!1G"'H)RMQQL9\<HD7\"2IT[H5M+"^7EC7TN#6X]W=ITN*P
M<URP>FV5!-'QGV%5,CIUS"06OO@R9Q@UY*F0F+Y30Z9@R0; XP^XL &(\%28
M>Y*0K(G<H@2PO(KZV$'ME!6B^H!@V3#5&U#-=W>FT53#?A;8!MN*<8Z<Y*#*
M_)8T)"\^F.NVCD:[S#(JM4/#TV?D0]3 'OOU;9B99ZP^0P,=RV,:9./P=1&;
M^Y12BSO69!EE.TR(&\$9N%T!\AFU&,D,E9I.<S)<-&\ S@<.(1L^J_,]4=5W
M6.RA[0D^2Z@%12:9(Y9[WPO'92*^883BUY1:;SB.M&KJ2"&<>6^YB\L>*!&/
MN95:I_KTJEN5%4U6XC?6##TD5-93JPZ$-60$&L=X)QM&+[#.*P^J[@.[QM5"
M%((S](BE%R_SDEO#)/JG*^D$1=:H-%EH7=:_L%][)&T(9PI36PN0HG$08FD^
M29&1?DOH?3[<N(QF$8L-!=#K#9Y9\)*J.V!!XR&=K4YQYP!ZUI\GAG1$]MFH
ME=0^ B'(F#(:>@_8 M]_ET.LN,:-B/#:8^[S_BE ^9T_6:6&A=CYV3&[$YNL
MA@]^$>^[0MDM.Z=V@!H@[=T-L$+W)O\Q'X+D5R?8XS#:.0C6=E_VG+S$E7'S
MP8A(K9BEC.5IR+&=)+#Q.KZ2&()&Z-LHHSU":F[2-S7S) IP+H0[93BG0621
M :23')O=S:P6YTX3M5^_Q4P=<OD1?=!+^9^![DM]'Z4/_B<<MZ*H;5;A 676
M-3L9G+3UV)7LQ0MK#L,LG=:*X" LJ=V[L[R+;!18SO<4X.HW5*C[34.QL)]A
MA!S[\0]$-U0\Z7*/8J4P7-L?$3\6:;*$<6C?"%2WX:8.8.CFJQAV*:W\N&0W
MV_)E>T=O(XR$3$.6#=73#-62:>60U(2[9Q+5.7\=Y5EY;]0- 5^4:J$\@1V8
M<"C2QY\7?I(7=(QN:LN5B8*F[=N:>HM<<XI03RL9"2/U[KCYIYF_>MG T<5U
M+M4T"^K]O6]^4>]6K.[6'@_KW%CD><4A2+_6ZGNA4$1P5SX;/[.1,A@B'$MC
M0D!&BXE1X=TULX%O 61@ KLR,Q_>]2EZ N51W]2O76\\:57E2JG>B!X;\_=C
M3AV5E!HN:4>3;A:=;)NX#C%M4OI%.*!&0Q,_Y%L/FI_G5/J=QA/Z18QS?Z-Y
M_C"$+=51J*\V%B5R](CQ0=GZ.YL??0K8:&;-.;BN@'T(5@WW1HQLE?,[%^L(
M4T([251%4"HV#1!H%]9HZWJ=UXW5S&,  D_Y:O*VTH,>)3,NA2LHGQ[7JJ#A
MSAIP;=O,<>IV=':?2U54J,ZW+=P;2MU99A^PSD)<$:>MPK!2%2]N&M2F^EC*
M'M$" 2]-KK\OL^@I'Z:J46]9>MA< E:S*YI3$31RG/5<FWQJ(_HTI H*<@OG
M_*PF,PR1K1-Z=>ZMD1WG_+D!#E73%#A<GTX.?I.L4.7'72X3506KQ1@BAANZ
MGS9L?6"&S(?(L.8U(9BFWX_EQ^L2%'UM4(]ZY89BN_,-)_4]C>(8MAR$HGAG
MGEUTYG@I?I5P7']4 ^;/J#X7V-('#8*<^8FCZ!'X+:9]TTW2PL$8^QUXH9P.
MD>$')G(6QI"TNVJ>$>H+KBT>EPTRX(UU@;C1CGR:K</ .=@=(X>3K<:"2)LS
M+"?>NIL![)HAKD<H^D$$D'&PC-U/MW<, GSUI$[;IB'?:X\! Q$=(T'%)2X!
M9L-+%6P+#JKP&-"?:YUO]:7#X L=H%A0S@=%VF==2Q]9'\0^M2ROE4;1_,C1
MKN)"_N['QX6UWV,G6-;\S\$.6/I O:<(_F"+2OF/);G+CH33[<>?OD $H"RN
MQR670:C&&0>^N48'_"?\4:=M"(/?/C/+B?/2FNL^UA="9</C-XQX-?_G:L+&
M_M/B^LZ?\];WK9; ;BV?,ZG\N&0OZ8J3HX.QE,DS"["]SSWOLGDW'+ZTKIH(
M+E>VGS_EM/#6"P&VFL%)R69\F_%^EU>%23U>F05^B8^.#"WE!URJ/.E)LQ?C
M5:8\)*X6,@;&KBBE2Z@1,AE+I13N5FX*CT(XK5N29DW*GBG^JD)UN DA9TG,
M3JT(9G*MK/O=G;'&A>UZX,)@L0AFIS&9'UPU]2+[Y;/ZI2"YO&@6.FG6^#E"
MP9SX&O\S6XA>8QLDO:NE N;Y?TQ):HCG4XZ._;+0#,OP]JZ3R*,,R$:D"LLT
M8B(XASRP<:<\&@PN],19WWAPT<?F*BRA[Q!3I@0YT:;7QLK$-([)XLV0MUQ5
M^0+CMGLAI>%3C+L\)EWU?*EA5!:*-U.>/]\6/'/_,"LUAOH+F?/EO4[W;;U>
M 1*76H8SUP@L!15_SM??I%/V2X3<:M99!30RHR5Y74_B__7SUK_R%0U;:I=@
MUN[__8/I9,FLFE\47%5^[N@"VB!B>04@+/4445)82+X_/I\MTW04<V6X1LXB
MK$@K"]"@P GTG&DMS! !"BYE6.E(HNFC>HA<X_E)]!/IR(MP?O?Y?(-VBYPT
MW'K)0Z!*^]YZ*O]VN"J#7]2#M#K)AH:+U54PN\:)+F%B> A6L3KL.FC%^RO4
M=8WR\%DV1CL68O"J(0G8>)/B=YW\$T^IT!_].115[N6E_<,+#NW4+<#,4OAT
M&<$A49'Q]\2JZ+,NYYKC!,\$;),QP/2Y^(0R;Z-&\99\*B(L%-^ENBV%I?G:
MHP%U\E%&" T9ST-ORN Z+F SC5Y=.U54/Y5S\4S.R+V4)HEDL\L-Y/>(?'Q6
MH[5@B@S#?$;RD 7"(]'E,<C&K+G/ZNO&F$X/T8X=4> CFB*-WCJ'Q$QR@W2G
M&1E*EA+H9G2UTSK8&QIZER5'DKU[>L?I !PDL37^.EYY3,SEU 'H.@5T)RA*
M"!HP%47"P=@BL\\G7RK:/S"=H(H0!/)PVG/O9 UQ2WLH+2M_VX6$U^,?6LA"
M;;LD6:5 -+R-WVM<](Z; 0,JW\JK:/K4IBG(YO>$^^*'$K&(.D0[L5/F1EX"
M'=T"^ 0ERPN7+CA+?\G]6P])(UQ+*Z3TMD3GGI6"@B 7B+#_@7";+!->ASX*
M^F2C-^8Q4D'%I=';_A7 A8U/5:V;SKGXI;O.V^B&.L/DQP_"_;RK/-^?_(HX
MA\09XUI^Q =XF(14M)_K(8#$?%3@^I[0/<:/8%;XYG12-J#!SBFQK *5#+,8
M)LD3^>78:.[I(@3YC3=FEX+CGLU;O"1&MGRLR2?_72#S[P?)(_!T:,.[Y8WT
MVM,5=P0UO ^Q+*9PVQE3)DPC.U2\\.\UAB!UT]\$DQEGC.Z288/(-AX,OL^6
M&8S1SIN^&J(%O,219K$-Y 2<AOYXGV +>@&+,FBW?8?U:9P)B6I?#H2"34N'
M$YSI1&B6#E'=3NE 7MWAM,@RF=J_T:BK_F865&QTEPT(%#+5<BUY@!M-U1W%
M/Y3?N4,))!K22_9 U-*^.#A!-O+[^%&-5R$:=-7FX7[C7@(SF("<ZBA(/:<B
M.I[ ]:GC_89D64[O@V37GVBMK1> B>:ZQ6'E*/X5R0.DI2"D>97@65;TH "8
M79I#IQA9DGFH>??G AO'W@2C+QO)/$F/5K7V7CA3]M]UR)"5PW#I)(V4\^D,
MXT0ZGU&G;O1-='^LG.3GG2T1 &[L*I$P;S-(=D[>13,OZU>WZ>1:Q+GV(+#U
MG](N>RO3V@[Y@R%.7GX0B^EPV9^Q,OUT#2(9,3(BE$#MS*T03T%*RJ7DDW,#
MN:2RTT/IQOV*V^(X:VI\!11%.TA$F74P;7G65]H]824Z@I>%@L]\H_Y&TCX.
M^>T5T)?RC3G86HPF?E LPCM/ N85@'Z)4O0HZJIT[<E6Z[WU^6<0S6'NIW-*
MN\#H M<CRT5TRDZZ9>WF5T $#],M0T/).F>H(%FEZ%'3#Q6/,-\)A&A)T'WI
M\Q%)0U-%/UQ);>#Y=(A3\K0PC+\9Q/77?+I943I;;:XK)[LF ^@J*]L;<W7#
MB#SJ0'@5_H'&J421*M&6,$"6U+@TC9'%4SL%_HEC]'N;9C(OF6Q9(<NS_$KP
M6YS:D#0-$VL=&%N>+KPKF(M%+'9T%E;'>N2B*S+HP8S.I:@K+C(@OPC,*:ZO
MSKE[%]O.7=SAQOX)FG$]_" :5<[!(*'$T.FN-;8<>;T<*"G_)[1,&C2Z5#/!
M0J:GO#\V79IVN4RX6I&HNPKKS.Y>*,U)5FE$O3Y)3TYW>M*UD?RX-S/EWO\4
MJ ;D#$_"-^:M._Q!&9L4*A0Q^6/D%? CY$,5X?>PM)[<KP8KF6&=,P-"E\S]
MCS/]0C>7RMU/P1?"-+]F!H5NKI&[U:^$FJX=NY_0+X2I?DT(XY\*8_R:&>^]
M>2LKNNIMNKKH?LK^C?I;V6\ZR%_]?1"GPH!?;VQ_\X._%&JZ1/Y/=/\\\YL,
MXN)WU=]-^<^9?ZQC"NM!17SBK_@S#^2W0QQTEY?@=[A'['W_<\M?].??,@_<
M6ZKWV[J_RP1_YB6]E6W_+OM=*=GO:U[LW=OI\-NVM^=7/\N_H>!^\_L+W?\^
M\V>=G3SO!Y@_+I[T1^;^+0/V,\H?9ODW0>!_E+&M#[6V2?Z6#\FOF;$_1 SQ
M)I^;-RFL7Z 00D["EKB6/8F(,H:S43=)MZ]W\-+!>[<*+'4F3\N,M$U07[>N
MPK_KG)'!]^#&J8YS7B;W+H)A[H_8JW(9)X_0* @Q?VZ>35ET_65!Z7P<@L0%
MM+-.R23$R%<9,'6?<B^/QK1 6]ST^*Y27TDWS8EWU)\)D^ZE'\>I@993@TQO
M!!L*V-2))5RK<\EW.<>0GEF(6U*K_(+?^W#7/JUM_S&X,]]3)I.K4W![SN(&
M#R'$J91M\Z4=?A/=L''UNTK)>>$O^X*45*)W8E?)\X)\Z8QZ1*OJ#;IA7Q(=
M6@R#JS#VEM(F8TA3!L8'.:-AL%7/PAM G+7E0A+B=GOY;H1V<742<D"=YK,L
MBDJ,]/(#*<0MF_ K+.<^ID+M++4+M=E%12YP%ESL'''"58'10W=9=WU2J9"J
M4-X9WC1=+&N+&FQ=EPBKJOD&R6#N+]J0W :,H?HU.%B:U@5R0H%W_=$<JD<
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MJ:)A?/@M%V%2:<'V+.$Z>F35,TGMV8[#42W@ N4B4AFCOVPVG *OF!\X6X'
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MEBH\/]BP0\$'_"3"-0[IVQ."15T:H2K0\W4*@99)[A"JN/Z9028"W1:LBMN
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M&A:<18*)[=X_8/?BTCYI4L#O]AECCVE==6.QU0HU^!(R*CHCR#6VA/&E98N
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MD66CUH@4'@B&P'GJT)-RV2'[1'WCK&+G&BOW08PYO92$"I!ED\T8H*8M@I8
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M9T<:;UZ55G[G@\J_;T+C?P:53>P7?)O_S-C8T_*\#G\$H/A;UE;ORYZ+W#E
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MVW# Y8107HS3%(2C"CP)83>]?T<>.$V!3E$.S5XO<$)1FJ&%L:IF"HO[X$?
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M(_A*VJ>/"B(^V$%QG'K*#PB4(AQMV7Y-ICTNPYVU^(9U239\I*Y/-)TGRH_
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M. ,=B9Y@(YA3)8D-QO^)KNJ1BJBV-+&5 2-E"!.R"UY!345ATHWQ]NE3FT@
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M3X)Z1G(*31WN"K6I#;?:8$-",D_><=HB[E^?%CBX%9J7[[E.%).DJ\+ODG3
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M7Z@INY:"9D%(?\TSUZXF+<CH9_+*+5XJ+<'Q5LB4.ZSN7,<IOF"-YE.Q#\\
M6JOC0'Y=_W))&.#,Z^NZCMEBD=<[Z;T]+K*>64#NG,SUM_(0#6+]KAUV%!/4
M8#;^ NNG4C6W/5F5=L\ATC+]@"[UMYUILPJ"BT;F1[L#=#">YU<;]"K?Q3BK
MFFB_<KO8'/2UT<24\-S<;2F 5?0I7%]5Z. GS('O[V1P]<LHYL(7&_)R+])
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MGR%8W]]]V9?4I5J][#-%*L+.4XM39T ??P90+KJPLIZ1C3W,WAS\7\30^N>
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ME+F6Q<Y026-08I8.'U*RZV?-;M.''G_ZKPR&]!?H8UT>R'SYG6-JW4S'95:
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M!@>X/4ZOB*Z+NCP./ /:GP%NW^-O14U^6^[)SSV*J&$5K^MNM\[*5(1NE@+
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M=Q5G2$ E(\GIN4U[%T:/C*$8">CM759\.)32#+OF$[_EE9,0#.O@BW8VV'W
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MVW#9 &# 0PO#U4)!8 "0&!!0&!"73<!-,.N04%>[[@][AH4#LP@%"8$ [B8
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M8"PFK41OB-QUTAL00"9_>_-EB%3N53)(RM+^DYB=M7F]SIZC&Q^O_ #7 8E
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M\TFL:(3OO-0,:5"1\>K+AT<H8VY71.#I?@''3EV7)]I43Z]M+",T4("X-Y%
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MBOFOU0WV"NMM<FG1QQD1PMWU:31-T!T,D+E4CU@',!OD3(%K8Q,8/,EN!".
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MC BA9^/M4%K=?LG=PS]J,2'3,SGK9KE]6L27;S7H)L1V)N-6?]$4]EC$CH%
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MTPH1JMO.C\DGW?))Z$7X>$6&+QXK61)&SU2HAVQF.YC,H3UR%DWQ_L@9UR6
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M:ET,O>^;BRR*<2GB _D%-M[:.JKFBN]>1="8M78&#X6, 5X':H]67E$3HEO
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MR5/0-:WU.6!J4)AY1ENCPN[[J.4!-:R98AQ<!MBXD^IO[AD<PTX;4(H=/\>
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MBT;^PN2CUTJ3!>,:YL34HGOKH,O]1.%1_0WJ2<> \HX32MGS7U4S,^>IM%L
MVJ5=G*6G8LXG:Y/&*-,,OAW[J0)A,BOT]HP3PX-ZVG+/12P<_Q8DU9OYJ/'
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M\3C?1.UT.43$F^-@*32"D@.E3R2)6WTH26(!>^:,XUP_>C>)>C 2K3B__/$
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M?5R=9US)(,@;R:&9";'LASTW5>MC;UP:6J<P)V'S/;.)9S,#)?O1-1=I2M<
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M<>)$A_Y7;8$]\R8BZ^E]-0;?K_#^%M!?CIF9$[W1B#TNGL\WF7@A]]+IM@O
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M]LYF!\73X/F25F;.-R7?A[ZX7(H:=$5K=HK;:YC'<GN>= PAV55!,XL:NH4
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M H;Q>4ZIVZK/3,@8S%^[Z#7L5A*+SH;5HC#JO^$?9 Z@HEU9M\>F(E<F36
MD:,8]\)F];8)5KQ31'J:'O@)D$2)M7D?J)^9KEEP/Z*@/$31I.L0L8BPSB&A
M0A6P+AXD0KE O%09"/)[ZW](1X.*[-9WD9A++*^=_/JAA#%<:R+2!/0$J$=5
M1H[#X(Y*[??TIL!*U5)W*O/!+3[<J$>%E[/5"H^R;7\)>GF*J'Q]U\,_665*
MF[9&28US][+8G*Q,7EG*8FL8W>^[2;*T D&!/_2*^N'527CA"(/ )F8B\>#F
M!VU5O#6@S2C!^TE#*(5\,1LO\]F-J1(G,KIFX12S]BC.9A1EHT<-"O+$( '=
MI/;Q%0U;8FEO$I,/HLA94*F!E _*'P3:,<Y0X1$AKG#<+0,H9/@S&2Z;9;8Z
M-SQC8NEL_6[CG66D6&G(BLP+$ H9M/#/^,IB:.^E-(B<TM L](ZT@1LX3,P=
M;ZV/9U/KPAI(<5JP#2*:TCOKQJ[:='KGJ9+PN*Z/VY55+'9TU;7UN%GW\6R2
M&1? PM"M/D; GF09?AV6^S%R$/Q64PA]G3'@[)L#L:*B7F=T8U>&9H7\$+S@
M,;^4-.%9EMW^FJ<=>6.>HNYK'7!H?*B>-^5KU:'TGB-I$UIYUV2:<('IEZTU
M[VE_+*N_[]O$E.."3<:F8Y0W)WRK#WU\%QNBCZ<OFON*;S<GU$%W*+F::B"K
M'?[O@&)4E.;:BP_ECTI7CECQ^XS6CG[DFZ%!*QB@--LD'2VUE#$TA>LA,^^=
MS?" '13E%HQ6T@QG/H[6V0&1+#,D7-HB)$:5V".WGC6E2]&KL.0Z7JWPLQF:
MS,=C ;'MDE/,H:0N>K@[BL'0:&+18=D^V57(.MJ0J_:E]"M.M)!L>N[QC(^E
M46@[1,O/YS B.0*P,FY,L.N>  N$XL&-*[@A9%:ZXI.QSIY4*%$D=[9\T>_R
M5Z'Z9P02S8;N+C0BR_F[N0-4EP;1!AG>7A7"]!]FD:?M,[7YHK#W*JZ]XQ5?
M5@ CRM":KH#8J^H/_!<Q'[1>^ZRL1[1_HD)HI#4LUHR,R5*S7:G4%9$E7YD8
M$A8AJ^/$1AQ(1)TR[8F U5QMG/3H%9=^9=R<K0&=83%*Y&3[!%N*BKM-M4]K
MD,BHD)^Q:0COU#-A2>9E\B%B>AI737-'F/"/3N.!7<D:L"ZO^$;;X8V7X310
MOU*P; :N,,^VB.5Z>B=TZQ.:DV,18QY8&CTC+5$=O &/%:>/7,TL]*8B4TY1
MGA(<JL;*H(D*RFUOJ^5*#"C"2P20M)!3;"=/G 3-Z^2%#!/2ZKY5UM-B5UYU
M?^=CW@< S6.8"%+UO5LM.+RBWMG\_LF@9?31-7BX-B"%"4S-TN\)3?O+Z:%>
MD/&>J4D.A2Q3LT/M%%9J[OUN@:PMK:HSBT.5C7G'# 6<QG2M:XFHW*I+354L
MCKAAU,;A  O%\4;U]NIT8HG1LJ(%K0O3D,<-I[I*_@TF7$<E\O0;BI><3X#N
M20K*L_;R&!$$TOX!/BK3Q#Z/E35L]>C5G>W8RH N)72Q8=G>H=6DH=+-QB.Z
MQMB-:E9"[B.D,T]!E+_BEKMDF^GI5Q3C5!H>6,?)&#8NW$=HM4<AB^\1"7$T
M]!T/[;^]"K:P&%E L2JDO2M#YUY!<](SL-#1*9]-B95,)Y$3[S8M4\U[Q=U3
M@,ZH9Q6H43C?WE8SB;3:&)O:Q<J0@C640<ZKWB;X6L?MG0\^MB4NHSFN$*M>
M88..A7/=MK)<@8%>M5!_JNV#I10M%!*R^00P:VW2QP.V8J9FN;D6T2A(:\ZO
M)*@YAC/<< \/&V^)XFZ5AKHK!A3&QC(O5LD=R@LGDS!_8%Q5/C<:QE"H?@X
M4TMEBU!B>5P-!KD!SST"W7Y"Q\:9(EV]!-&J*SK'WD%(B>6;%Y20TPD2AU6Y
MLK2DE=. T.-NVY://Y+%JUTU<Q_8 Y-[OB00U.5+@*J7(W@^Y,BWS%IGQ6;2
M!(<U9L-2)61\W?EC0@*D:W/*"Q\5YTAUA$YDJ;#+'=S1U!M5).,!3D^?X;&L
MB98(1#AV(V)K>!#%U*(0.E$M7T TR=WMI@]NW3P5<])L"'D"/ HVY,V9L*R1
MDUI#=&LM0.%I$$#=I(4Q<91B2NI[%_.7<PC90*?N?65!4EL.+?@/]-9\T.,6
MP==86O/Y*UH&T"YLMELM'1XSB]+ FW&9 [<%9:[&)--I5SG8#6PT1<@0.P@%
M/E<&%#W4S<Q2$YMO@%#R YT.IJ;MV_)A486UL!%Y2%%-N$)5JVVH[3P#6],[
M50DKO,2" 2K<0.)>RLTCEBK5K#D,&;;>B+L@Q$4\/)[/W#[JJ D]M2WZ>L B
M>F*-+9[NSZLSR3T)_BL(57=*7:^5<? 2@Q;$%W&8!,=I,\02$_\'>^\9#H>Z
MM@V+B-YB$"WZ,#.,7A-$+Z,/HPN#$5VTB"!1!E&CC"Z"Z"W*(&JB!H,HT44O
M*8CH-;XDZUEK[;V?Y_O>Y]^W]W&\?_QQ'S.7ZRY7.\^3_OQ(1OYIEU*%%A"<
MX0PU\(R0$1IH!IL/A;@*+#&<RH2[US6JO'!EU] %2HU3E?E(\ZW><?[GXO08
M_Z/Q-1*(T.:'L:]N)I!^<V5)2:!0G:A3?_QKO]4="P>0DIMV&U8SQQ1%O!6>
MCC6.5M<N\#PF^)?,EV#4;T;O*%#L%'HNA_G2V$_D/HUDNL2+*4X%+Z:,Z=[S
M>,>[Z6:WQM&NOQDM,DKF<94=6Q5;M;EXSVL%W%)W5_W)!>].I^L SZR#AN=[
M68X3="Z'MIB#8^^U$1#K0K1*YUTSTL-V6!!<1Y%<AP.+YN"HHDF0E_P<.?_T
M0>=S)AMYL:!HEURG(C!G?M=6L'SJEIZ"NMB[6RGO6\XY'S@$66@S:ZQO'"OW
M8S(J,J1"!U-XS2J_:U^[OD9TTG6)5WB;0*C3M0!*^+9:*T&0'SMC-S %ELFK
M1C.#Z0$"-43BU]3L^/H[FI7%SI?A#=T>\MQT/RQ&E*U'\R_QTK\$<,H'VU=^
M/*SYYQ%7D':N.-8, 5X/PU)-<-AAWCJ\*/>P"2%S6@(&FV#V6,<6_UNY2"NI
M-,"V/6&P_[#(Y'E5NI%Y_<7UUN+5&.^!-FC3=$6.O]Q34T9+4^/.I4/S.O!I
M>I#('D@);O"*QW)=!5WA1Y._BPHQ$(ILD&:VGGFUP<!IS9U;]*.JL($FXUD,
M?\L>O\XU9M28RO4^];3TU!*'87P_!S#5)5[^#X9+/)05L<]+KTCP8:> 7&(6
MK/\FZPK#BEQ_F!1(W+B&AR<#R^S-H3A^+M;U3?DV<BA6./3)F&0I%[%WX4T0
M'7_Q;5U>01<MS4$I)M<OM!7&^!Q]TJ9H+9F#*]W,"IQGRVX^BD^Y:)\)@H^5
M?SM;]!-QRB6>\;D^^LV8=*GM17( QX/7'-BIO2<?D04U9^I7J@_4AP#KD71>
MK59UOT<"A*;P2IM^C',K4<.6D UPKBHU1;$[WCGY=L U$:GWFP5TU7:!\T]R
M)>PM>DPL :U7:S\MGAC-U73FF&LGI(+/P']M2NH:CT7B_04;@JZYCHVL&^9-
MK*D-M@Q@I^1\<:@[HVU/ =_?V_*6)]MAVH,8R,/\"/G@(X1S''SH)2A21LDA
M3IC ?]9?_Z6]I$ ZX$H#RJ*[O E@=C4Q(IM9OR6?]8N=QXMI&)]-[UG+)9[:
M3?X6\Y2W%5<B?>F=ZNJ3 2>!F#]V&Y2A/B\#"N38?[A@]#RAYQ3K$J,UT"/<
M-%,0?ULNU$6RTZR8HUZ_75%1;1H<&=Y9 =DO)4E][H&^&,^;[R7-2/=TH*(E
MPY<$# :JX*GK:(HU)5C-D'4'SAE9N3ZF[E>5SC(I&B]V;RG,H^-N6C:<%SC'
MAHIT+'AT9-XQRTV:NIUV!DM)7S.3<9=Z5ME!YB'3Z_:^Z]UFK:-(O:)OD8"2
MB8\GSL_IOEZJ(95U[(?3!25,[8$3[6:XB;O$*#[@+I)2NZDQJ(&B ,A'[\\9
M 0I9+>M/>A5I/VK-F#[)IOM1D=^XGAH'HL &*^=[*B6Y52(%I),U%,-NLW-;
MB"C>2UQM]Q"PQ8>%99QQ?/;EB_:Y1EHD'"HJT#"QEGG')%>G5^=614L<6?&;
MP2M>HM%I+D\>8$Q>;9AHG:FL0B'US 0FK-]^'PRYWDHCBX%6/7R"&[Y:38C'
M[-PNQQVX$I+ ERC#UYVCY;'#F>P2@R\8@D_>9@7V6-C=SU1G7I#3C1&7D(PT
M<V7:]>I\>0VCJ2GA&'/_R9PH']KL2A=-?E-FRNWF#$N.Z=)QW7(\# \3@U:>
MO>G[FU=KV<,&!0,2VJ_VR,3S9/I%JDXF4V#F9</9$K+EW7RRG3'L(@N38N:]
M;V\4GRWJM-1KWA4%J\^?7.)M$VUB>1#YL6=#%]L.7H1(=K(5B-$U+H+7GF@H
M;#Q4; AB>J,@BDSYL0V+4A]Q^KTP'2M^6<C[2>Y\PO0:*65BCX?ZAZG0Z+K6
MPOTSF9V-S9Q(/SLF6POJT?L5D9$^EW@/IX)RG"CUD&M%G(DA:C4T7:6*+QBG
M4_'PO)2TD#81:0\V:&1W&L.B#7LQ%ROXCE35D&24)E FNY.J;TB".<OFU/.I
M8;.514@0]6!"A]QQ);5/057^?0-8_MGMIY\N\<*9[A'A;%D\ZWPL:!4R/1TC
MPT<ZY=7[MJF[AND]0K9M<0#X:^F<HCG+O.5M^?"XZP9><)P8-DB"V' YMO!M
MJ>.*E^H7U#KWC)$A>^'W3:%#R@YBXBQWJ%HL ^_ ;=UI[=.,Y9N?*&N>>/Y5
MH-?P.=\(-?L.7RQMYCJT!U35%;O?U()!PZ9([U[B/:)09BP),'QIG)M\Q5%I
MC_J+E;I6)T]4$3\OH757J.@*_Z[2IQ?=@[BF:*F><UUO\<]E#8W"$'0Z&H.'
M8W^X_N*%C-L["Y0K>:DCF/!]\PIQ!O/[%KG/$:IDT/[^>L>X^T95 Y7T55]U
M[90^T:);?U[?M+<9PRSIMMX:RVLFWQ7?8C?J);D\VP> 3H.E=E>S.B$=9&[V
MEIW+5VIX>OM).2(#F#":V"$5N6_@5]R\1$B]9/#0U2!_@4B5JK6@@F]'.1^4
M#!R@PJ"ZJT\1A[+Q0F[D\A;O8VKOQX[NE0^*997"Y']Z-C*E.V,5[O?,TTT_
MWRTK4I-_=$WO9G73O$>J&0O/:$+KWBI:AV)9O;1L>:^SB! #@[$/2RV6&(H#
MP\JE4FLX]NTB4;C&:(AG5"^%,H]KC&%+7G(KRKM$M_;U>QUQ!,,$HR@EF@=G
MFR+<7&@9^I@GU$[N0[^BO8D80MJ6:5;ER ,)DE\#BH5*-3!"BP(*X5=J[KSB
MY[0F@RR6R/3<M"58GD:6AR-MZL+UPVCGNFH+TU9)X53J:4F?]*</_ZA+&@5:
MDA?+TCJF?20L%'+94,T?F==()62R+O'^:'#4O#/M@:KV ]:"/CTP0T#ZJ7//
M8Y!\I@A7\:..TSN+D?,Q'26/.;[X(PA35Q!6WAJG]YK%1P,X2G>J.[([&01.
MW?DVJBF6-U#X_-'2TF*VA^BOFU(NP\LGG@89P%MWE@QU]NV!LH&VY(_8?M0R
M,.?+EFPCG5DH+N:S!%_^('Y>^QC4X1A89P0P_Y[WOHV[XGXUZ%4-SR/Q!XI-
MME.<!M_,91-"VRM. O:#[1_IO <2X4@[ ,^$:O)'3"JMO"6M=B[Q(IKBGATC
M(Z550\?<+9V6 &3I:2E=)A*S5Z&R">"O7]->?"8@78C5EOT>>F>F,CC<PZ F
MN R_MP@HRZ!*_3PP@IB Q7(#*/V2X"3"\>_P%%*2?RM,*IL&O^89WE\C YL&
MN@00?0STH2QY/XY[FLQ3Z'X'9?W>A"=]9>%9WT8D9?R1T/ -(LKJ&+!SA,KT
MJWQ.WY="DX65\\N__-ALP0(OVXSAU?Q1GX'/QR$J,$8_=-">TM;KH*W=7RSA
M!-;7'2/Y'(&,=(N530@/^#(1_LBCM-@K1[>#^_R=20]);59Q\^CO[ZAK63-^
M!: _9J@SG@;0+=K6^!-YNK_\0=NUU48)#$Q @ZV^R6*HD[A^?47<@2TT,+X]
M,R/9Q!%![W='"[;_@AB/]$K?W+TBIE+T %AB$%, WA!*'6YT-)J  B$L/S?5
M1$8QFW0!,Z?]TD1-[9SZHI(2BOA95G,VE&;["WUN'Z/9;(A9("(T&_;C@&H-
MPJ DB-R^<R$, )[,;L1]2OO@S\!J,E&<CB5_L<XR7#BG\;/6SK\(L;<WL#=$
MX1U?XO6#1*CF/7^E:M.$LWJ:Q8C\B15\$RQ.3N SA&[K6'DG79?"IK^4HFRW
MHZCZR;0+_&/ND5^>8TI8$7T(#4>D*<;4A)14Q?E1S.TS<>@ CG_'Z$E:L,AI
MZ!C*D#P_",,KN+O=+!EJH2,,J2HT]NP2:^&SN6OY9GL8Z8F;#QR5,< W)1>5
M&A4!H@*R1R@%B</-G(8.ZD^6[SZ4O$@&Y5KF'NER:XL,8Y>'%94UJTY=;F4B
MM)U7&)Q^_AK#"]FB:E(9"1T=?5P",1+V81YV:4]V$3LE5!XP-"NJI[= -*9Z
MEL?I<D/\;URD=$-GV'PS:,.BU?5RJ3<VYRP^- VZ\'>Z(6W"4;/B73D+M(P$
M6OM.FZ&W0XV2QQ_<$&A.IM!:<J80&Q_(WPS3+)Z6X2Y+>YM*LSG$P4A3TZ;K
M$'$#K:3=H/W5=:_CWD_/*(+=AL]:/GYX;W.)5X/^PTWFQ.H@MW 5_K+3W8YI
MOWJ[V1HG#!]?1,9Q*G)_RD>B-&.R1VCU0R.%EGDA$$8 %9K<$HITM-^=4OAA
M3P>J^ )NY>I>CQV8)1^JR<:/JF0=(;M+K<E?;<OENM=#E>':K"5VK<Z,4>1%
MS5_@FDCX4Y@:.!JJA5UNC*_R3_$UIV^L#GUMVO.2161YR[TU(5H+!_':OA;U
M5O!6>/":60G]K)F%[KQ&,1I;I)=*UZY@9$#/DHXB.RLU(6H,DWF'5> >IC2@
M9\Y .9^5W ?0?_2 <GWC'U;>R<IRX.!C*$.!^U)G^ZXXZ)E1]&L4"R.]M'*?
M^.C@V;P$W;']L_\DU]V3W&X&TQ*X:YIB/P4IAB?[MBCG[T]KSI6!.9_N*N>D
MN#,B?8R.27V%RKY)(HM28!0YSFU"6;PAO>^.>Z7Y2+4.!4SSH\+-9,0]/3L8
MTU2APWF.9D<W72,\J BN<3S62V".71494^/\2.#>NA.I\$9;LNMX;N?;YL\P
M7";>+>46[E&NV5]%#QW^D(#KMQ;GGQ<>L$9 B.[(B(39P?6N'*K2I/LT\[=H
MAYDQ>G:ZPAIB[M^B@P7_S%YO0- S3V@!]BU5L7W(Q6H$[K7JP=TI!DU2S,KU
MMR[_8/@=1^NZ D%6P+T42=&M6E#_:R<-QL!UYA1WD/:7#9F+/BQ.]FF:(AS+
MAT,) =F4^$4>ZG#''K5=YY;<0D\C IQ^ELE$-NMK]$[,]T?C)V33_4SO5UQ0
M:+".D7,B6FP2FY[OL&3?_?K+-!-O2/)5()4,B74996&8>%,> ,2 Y.#L38,P
M$C4L ?K3%Z[-;3U\;&+8J48=%*1W\(K!?\6C:1;D:DJ[PQ4@^X;8S91GA-&P
MTHNR-<1%5F!MD_\C,>'=N_IT_:63R[8 _AC;E/8"^<@'$R"L!";AK]S\B0G_
M+0$?R7:I%B^K9<G43].I*)T7P.&;SSG6=B6DN-QG:C:;72O<I.]]Y=/,_=""
MKI,86>"0O/X>8* =5("=UB-M8LX,!"E%<5-_G+PHJWUV#5SX62]Z-R, F5X8
M$NH6+0^YQ,LK*8(71$W##/IMO26#X>G.1Y_U$3\M-B-[&)FR6T)7S)6E:+38
MT](RJY0BJ;MIWR"[CW/+=D8<*::@E[-5U9AX_LB!9:ZO+Q@X\5GF1LOA?[4Y
MX"[BIV>%TS:CS'$M G_/S]J[42(5*#V6QCNY5[UF4WPDI9(!-*^AR2;OUDQW
MC1)L^K<N\:+=!7HSVMTJ9\Q+E&\+1'@H.-!_D-LB8(S4RY<:A[@:?>#Q)Y$J
M26Z2+*G3Y.2Y_XC6L)TN=\]0E4J3K+LI%\6W7A(28E3T_JC;HLTA/<E[DMJW
M39<;J2N\13U/Z;&I_-+/0J+$(CE"4G10[!1@&'_@%%B%&>*]B332UMZ/X4Z=
MI@06! 4;)$%R2QQU2WN8\<.7KE#)X"H3VKQNXK8B!UA8WPD]WW-Z=? /D]:W
MX^@*R:>@6OOFKR6+NDN<A=_Y5.(SOE5>75I*^I6'A"3NUSKI?R]1VHI)6[^@
MVXI9;=\K=HF*M%[:N#\3A.$&<L53U?^:B'-7=9+<3M\1+F'Y(73^+7+2'%$X
M*6"8**W"\4P[L/4=D,T)I<.9#%(OU+_[<$#GE^[$3HKKJDV)A9/\FP'_M)^7
M?=-<\+JKA$+E66,XT.K!+#E4 3N-/W2:P!U4VTCV8,Z%&V&JQ5@O3 /-*DYA
M-^/:8^;X[(@EW#!I2X=2KHZ5I#M8YV#,;#)W7:EX9:5M5%R0)';J=AP%O('V
M;<]ZF)5<5S98%R6_QSS^E.J>ZA6?<1B _$QR& K8\K*H?+S8P\%7XTJFB)7Y
M;A"O2I-A!S<Q+Q#H+P\]78^AM0<!>P3#?,F/A&*:38N@JS<\V7X?G#MX@_^5
M>3_N[I9QD=CI??G :H/AW;RFP]X"@]S#$!-VPV<<4[9L<:H\9SY]@+$^(@#F
MZO0TV:^2@.>\$ZO\(I?J$=M;+L*6IBD56L>-V/$X5<[D!I,7F04T=7H/>FCW
M6$?89L<NTA=%DA1\;BN;S<W.?HTQFJKEH6'D:1XWPS&8%C#S\550Q9=60TY]
MMW+MF/R>?*'9$SD<?G4>-4LJ4E$@>$7I#83=_W'/GWW4QU?^ !KU>R]<94X8
M2)FE1QPA>FW)%TU;O^YN";R5F<MCV)^<G?/4/RPT7 ;#T5$HNHV8KE^Z'E0D
M]O.JD.2>?++S=XW! 9\GMY]\)U)_<XG'$4-(,9%YB;?KRUL=</,B<(%U]:BD
M,JW]@D4=.(_O8OIJW=\_UN:5S"UO_]MOJG:,)P::6WT<OZN!9DF0MS<H3][)
M?4?GGN9VW;^ILGP5UCFF:G[.'7(GBM< :@#E3^8&94PFN<_T>G^:8 NRO]#V
MH-PG,KUC Q"*PLSEKW+BQXE_VWU=GOVIJVW*[#9G_4+11ZR$/ I-.,L20DF-
M;?&@=[3<&EYM#E,@:RD\=K.L@5&#H%:D'1*I<7H%?*U-"2&)N8X\0:&?5=Y4
MJ)\%FW) 18)F'5\3/_8@-?79IN;EMEF_[D#V#!2SV:[[L1X\38Q,4!WQ0>J6
M,<R,=W1G+L),L&^U,R$X$R!?8$Z H>")XO<K1JE^^J_^'I>^%?UUE;;]#'%"
MJQVAXQSYR9Y*\JL<G-?1=DSF<2";>27%_)/'U)WNV$(+[,N?"<8E7@%4G!NJ
MK<E*!:8&FK[]DIPF32>RI:B&,3[I 0! WE$&K-AX%O$6AG87;(MY'! ,^_&9
MKXV\[#6CER@7>[H\D!<7K]Q#W<'RP#:QCOVN\UPFQET*^\UYB.+Q=<%0NF!+
M1)CI.T@NA_B>P0+-L1)1A@YNURBE486+]M4/-A\#MF5]H]MR0H?T'6BWR4JU
MC]L&A#4KSZ3*2 TT('!ED.0E7F>M0%L;<[_BE\!AG."B9,&,:=YS.$+Y+#=9
MO9=DG5BJ_WYP2%<VX0,56*_E@T:9<7S:9)"TR&?LEW?W_F4GY0@^=%;,^%7B
MEWH^9/GGINB/O;>OZ@2^QN1JSW@0<_,^P2TE_DH\PV^C,[C#7]2\@3I3M(V4
M.=.CD2^D)TX!@N#;X0HYVJ$=GDS[R;/$FHP\;!)PO\851G&IPTUI6' QT0I
MBL?U8;>X.:F<+ME_1Q>QWN#'!8ATPV7J# E>.PL-'?BLK0L'WU(HEPO!C?6[
M:0+#S8\F&#,3TCW;$1E\+U;8L/R7>)XL)+N9+WV7P*F(&)X.&K=PH,>7!ZJV
M[&2KJSM]OP"9.P&_L!A+:6ZF<S/]JE@M:[^L: 7@F[BI3CFO"DH(S">\H,94
ML4<_:23N1-/A/%Z5VH_JC3-G)B-X\_KMD3]FORD?'#*5S%^7>A9=XDTN>?V%
M'\#N/7641#CE!*7R,+FJ+A8$FW!G7.FWZ?32JGCB(X#OGW(S'547.,Y_]8H&
MAX9,'GV^S$QBW'521DZ<*,6M2CM^UK740B:'/:BU2N%$*F HR41'_(.DP[ Y
M@H_>,LVQP MJ+0\6)\*H%%DH:6R8E;#!]]Q.2<OI0.A\S[2J.9R X';!6]WI
MOT#M9.W9(?X(XDSU_*SWY)0Z@=5!O>+7NM8.T.)G$LA&3SYW!L$CAF^8^F=]
M!$LD]58V[Z]=A7JK>9H3]'_#)"/NQ;.M4:K7_:!6Y%MMKB&(HT[QJZLSY^;A
MIH\T9G2%2-!_*FAYV<G[-^T@'.FN?:>;?,G1):Y&I<D_!LG[-N>^6='&_\ZI
MZD/YQO2EK"/?@T52#2(YZR.;WP/2%*0QI,"[2]L[C7_6E%-%!3?#:?:_&XQ1
M!N656;!Q2X9F^5\'S1M3E!H#D8,#>]IRZ'%N6;,7+C*+$H5FL&$J,+M="(_#
MZI)^L5GO'8P-8YU-W0)#INL[3+KJ'+9P;(7![8'J&$0QB'/\B93RBM]-/_#5
M7BU.&V_P43;];G&4$;":S&CU"8?&45=R-KW0*.47^$+Z7<1MAX75R,]TB4J0
MOM55H2]"><5O:5U (W*Z,20E>@:&HY$(.%*$ZL[3Q'N0HP\E^5(EQAF.AV..
M0$&CMF/'=Q1%@!;]C3/&/U'M2P\%AW5J<GMD'M-0B;R\JMEJX5*[U-(R\?^Y
M4\HDC(+EV;X\1UT_[ALM]6@W=EIUD&(4X0EP76[;J\70BS-33D2]7(V1<4#!
M+JO!#BOC/Z#219!:)=TW!A$N)X<=LQX2\;F*5/RW5DCO)T>Y#RXH: IJC:NV
M<&\&E7L/*=VE>:"8[G>E9_R1EM'88N"LS?-XQE07B:G5?]D5X*G8H=KA_B6>
M_4/R_&%+G1'Z!HG#TQ6Z>LH-D)M9?53%!W^D^S?4N*;)*LN++"E6?1-7(_C+
M:4#YK1:SYY9PA"\_B;-\RW+X$88X145RP 0>(:&[06YB@D435,CD)7" !<KM
M^;]ALG4>_P5NZHC_8NZGWJ?GVQ?,Q;_[/-6*A.!C(GWZ3QON^4,TN,GR)M9I
M-WKX7 A@>(P5OJ7_$ 3(; *=O%AZ\^1O+WP5]!"]Q#.)" GYE-3*'4C$P^*Q
M7]$)I\G5Z7VO]9G7CI%VUIP Q'P/3'A<T1@DMY5;(^PY&/X.O";W#P[]A^SC
M'?5N"F:FKJ6-.MA3A>N&4+2\A9_R/7O2QUO5.KUS'$1>HYCR>SS\%[\<F6*B
M$C[6QZ !(*Y@H=5KL;HR3+\;-C5FID!@R-P>DAM[[[S82#> 15%R_: ,'![:
M;^9A/USEGR1*48+R(ARM8$F=H#\Q&(3:%]$70U#<KSW-34N"(M%F!?TWGO9O
MMK-YEQO44'<JXAR:-^U;+?5I;N*+JRTR_OT,_@U)6Z1D?/#]82<"Q=/V%Q[E
M#MX_L%7>BO[YS/VFJ/WCI.=8[A?,^/SJ?P<O_.\_07^2(F5XE_;E:KE'6X4_
M5^R!\S2+>]G=WI5 LT,UYB^3-5(+1JT)/:=UFW&2XZ_L_N\B.RVAKNX&A'UD
M5>X*%???D1,FMCJ>2MU/DQN-V-_[_]_*_XQ%RK,5F=H5:R6\?5;M7[I:^IR:
M9^U"IQFG78$N,9OUB?6J#\PUS+EN0_,K$IZGC!KU#N$<^>SNH;#)-:(U,[#_
MN_!_L3""U:\+[*0==-WGCF>IO>5$=Q44V'_R\M_6WO_ A?%97@/A96U5&K(O
M+O%Z)O\-U!#^\WY<XEUPE;KAADS%L.A_>^[]?]9")#+3T<P34XZZP$7Z,C2
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M.9B+B CJ8NST=128XVQ,/0UDGEKQ\Q*^[HZO;GTT?B+=.MQP(X'XFBI/D:0
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MQ".&.R/:J+VHGEBRQ":!4Z @)#"<NY]"%2R;$,JH:NP\HR(GS#7*^CM)COV
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MR]?HVG':6#[L,4Z&;,2^%Q>/>I!<BU2K4K2$!;LJ#ALGDEXM2^<ZI_W@KT4
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M;^WA&C^5 O6450\&RL!Y]:L@2Q_#F--36:!**=DKYD#/[\Q@4M'CXU+I0^>
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MQ!AO([?XP5A1?P&8$X[JUB!?4YDVB>Y >??/_!\63G6]P"8@@"LH[A7(0+\
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MA*[T<N//H4,/S(-. \F@.D6"9AMLL&&CYT) S(342R:I!,*F89;GC%%GP[X
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MVH*SSQH> 68P42.#V(KY,DMXI'?\1T6-@YJBKJGU?$R:%8ID,W;&G!=HCV:
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M%!#F!U,<_*U^J 5ELPD2G?R S333/->TPI4+!<3Q=>Y*"J\-P01\)!AQXS0
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M!*2R\7I\+3!T)HQG,:[-:DZM;5V[>9R(!4=A5-1/.:%>:R761YB&TV;V"D1
M:^DK^US U_0%9<2GJK=ZO>9,.M^S_M0[\))*B/(#AN DN=T]M^=FJ!E3]] '
M[.0)$XM5IL\C_("A)N;"103$,(VY7C_:#"P_FW*!.G8B5EY5?]>VE8G\0?Q.
MY5B^J,(O]9&>;Q&X@H(E\<S-VEU4]AE1&7KO:VE]8C,A+I*;,_V"CUEJ&"'K
M)/-P*/"B9,\_JEOJX.VLDCGN9.*X$5< &_$E;K^P<QYJG#FJ$K]9>7T]M381
MONTAV</G;5IB1;246'N\%O?0C-H<S72Y&L4G9UW>IO-9P\0$UX7C.ZMUO4'3
MC^GC>)H]WKG*C%%RGTMW;]OM[LUCYUD=&X3WSH($:O0"L'-PHP5UGYV4/ZED
M[5(?E;E%56_;2FO%%=AQ*QS? D;VS*RYX=-<\7"#SYX66Z9^%EJN\:QR.AKH
MAIJ#*ZSZ!%AOP135LLJU?G%H$3Z^:7O6?V(&6XV/+61E-(FCW3>&ZCPZ< >N
MA%XGNX3NF=_;:U'?H[ON*/A;=NUO)S[X;;S@6,4XB#/)0>6Q'CU61ZZ;O.YC
ME/] D\,5/>,JN#I=.(A\6,VE-Q2T*E<]H(3\WH54FB9:-%PE4FLN K$>GG"2
MN:^HV[90LLS,**D@^5&A3;/<]B<A#$9=WY3):^H>\:P=D:3WU@([?20/LS\1
MQ*FI[J1%JH9(:]B6UEH3SN0&'Y$XM.?/$X/OG!!8NBR>Z@R-[KVS5%V8HU[J
MUC4B'#<_B^68,A8<N,G+P2$Z(7U9%%9#2/:@?:+2?&<VW<%DXFY9U? )?"A>
MOLLMH)KSH' G,1:V..[T\()"V/IY\=2%^BQ+SPWD\8Z?.JAR%-'Z>F2])#4O
M82$5WHH-=DV':P";J:[W'=95UDH6*HU4"Y+;0+O\FZ1LTE DJ]18LMP '8=#
MJ04!6#8+/#D\KF&SP@I&F5WX*!2BG(=5["5BJC.)C.8AN02G+^@8C+>Y7"[(
MX]COWVVG8_M,!"YT5YU"Y^K)'K,WAUXG87NO [6#X+>N;S&I3R29:TL>5Y+
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M%/N?@PU9-M%\]-XWK-MS8#O*' D%,"HJ/;R+Z*Y'<7P/=\/]9G>-()UV?.0
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MTC_+AO@;V69_%P[S&[U#6OK/91/^&_X?A8.@(1F@_A-P>\@6!YMNY!LXE0\
MQ$!180G_*]M+9,C6->*!U5^#0Y.&3]0X)KS[5G+(^:__;>\;>/2KQK9VYV2)
MH[\&AUK<+^-R()S_!@Z&".\'F9&_A;^\!=;'G:.Z5WZ;3@3 ^K@#S&W?TBVN
MFBJ/'7Q@?]ZBX%\(\=)Z:!77V8?F_??A3/Q#OO>@Q\6;S6CTOX4K2XC*T6'B
MA_^^ND2G?+3^DN0S^N3[<+RP>.7.@R"Q-H.?P_]KN@AC]T-"-D#(>_>QISCT
MW!_#H44 +(0?ANP_@F/$.'U-Q*B))T4_74I$=L*"_Q".")E]03%_#(>%5-/
MC[)#2BT [ER_OE^0#T 5@_@O> P"R$>$"NL7V:2I_""B_@S."MGY1]O_NC(A
MLRDX!@H<)0S^%OXK;0%'03J5""A&&!2%^"T<D6I/AMGGM^!4T,(@/QF0'P#&
M^AG\%]E 6")4  (5AO _;_!'^#E5@0S-UXLT0 8,_5^6 D/(6! ^%(#Q>W
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M]- / ?#[8>""##60^#.O(F34^NK'_+-#KI\,1+VI?"!8!"K(J(B%\+5/8/T
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MH%(;<J1R@8:1<U# I],=B%V_[XHH**:&H2N6L6,@G=@H)8-C$PRL+4NP!9K
MA'6AF#9F5OGJ=-_,,7*/;IOD)X;3Z8J?ORS_KGE@A;6+>S3G9VMX$;97>[IC
M,"TEIF:7^KA0$ZX2(2]:_B\*N*(4211U!RDK5^%3[N#9X&A;&L+XV5ML@5T8
M2G,-2';8T[D&%$,]0,@(NAC21P,O9'O)W<0.#\\^&BA2X^+OPU<;H*%=]T8_
MG:!$R,?0G1-&"T'$&EV?4-Z#05=RI0[I,$$H/?PFR1T\E;9KCQ;(F1"4=;K5
M*IUB ]> W$"$^047>4H$UYU%WK3%S"P7P2 -QM=XV"+)I,.DS-;RP*]HA7!A
M!&I) LHA\+4$BJ!18DUD5?Y$S#Q*ZAV6) ^J"U%C)8(68;NE)W>#V$EV;O%G
M$H&8]]!+H,.AB 7LU\G4W&]WW3:EUGR_HX3=)I$SNB+%P M2=?E;?6E7A28U
M\,"#,>$-28\D<0-MQ</LMI9M-D*J;=],B.N0%=#QT<[C=(7D/24YE+(%*#*]
M(7JH<X7 L.(:<(L2-ERMQ2IU+@TS6!\=/8ER(X_Q5SE?ODGT!9C:/'5CN9+I
MQ1P4[X39JSHE,F *V2';O2%1)O "0BGB:*B+81PS<*+C/5# J):P$!0W%8^=
M/!+!)BC0-4@,UK^L_ZW;U'W'0S#48=JXQ.+NU+*<8 4F.[01KKL,5]KJ1;$@
M%R.JE[ZLX8>Q=1GIM>L_4SZW_ZV.[&!,!3R1C80J8=< UCM08(+<(:KFL3Z$
M.6I3VN=GZ+>0 QV/G!BP':GC-^(FYE8&YA"7A!/FB HF1M[;AG.S[#?PM_FM
M5L8.?@M>=>PW\?!/N_D_._&!___]X79(,&.O =3J:OKZY"GA;) _2(/A7#'Y
ML^=?%$RHUD^&_&6.]7MC^J=&J"*RSGQJ;$]<X#NXU]:$+CHTT>4Y'[$RLJ])
M@@J'&;7R!Q&%?W$JL]Q^^\0JVVJ0B/KWQ_.O1$PNEI] <8/7@(U F_ F-W5%
M]]^;)OYK4:^62N;*QCD?R^.=:X#Q[XWF7XM@/+RJ61JT'^-[O972S@;^W23S
M4 &L0%W?\!^O<6E[CG%5TK^3:=]\+-,ODYDO_W?8JF(G*I6-C0G)SO%U\&#Q
MS+LNGM/+.)'7"OO<@C,LKS#,X]3/0I[QV#Z]NFUS8?+O*5/.+"9"0YZ8[>,G
M\V(+FJ?BO8_F[27O@#EFP82?-8"#K2\^\HG_W/KJ$BIHVI/@+8%7A!C\*X^+
MQTHD92T<=C,F)(69SG6O--+S15J^FXFA#/QFII;IH$B5-.?>0E47C8BAXL]6
MLU\7U&%8YF1=Z#X:BUBVW^<,))KZJCSO$@.V")2(GA[K]V2R*=V/+/M'[A-/
M0^3F8 MI;Y@?,GSLM(%72$OKV<*LM]0LW1W^[EM")O.<><=@?_@XC0GDBGS(
M$'+U5S**>G7" 6[K\YIB9B&W)&I26073)[FX@1_@S*>OU78'NAT<_'D/,BM$
MV@K=HZN]RIVQNK!,E<BQHEP&V0U2AK^!L)) HYM.\FK#Z'"7V_7-J!*]WST1
MG9FR(A[HKXH<7,^_$#.WH?) [I[+%E")$%+RZ0(%$D--ZN/_<04LU3YS?LJ1
M7KM[,D,6?5G.+=_S&6H=;L@IE-0^QR5,\U$'9EMSX@YC0. /*Z9/SDF#_[F"
MY8:O+KYFH.!?<2[6E$\JS/A)\EVE_,]\V:N^CB9:>:*)A=F3F8?IDB$01_CL
M;R:]>8(218B=,T>U7<R(5=.'ORQ++1[XQ,P_@X1T &&+* 2UW9Z:VF/L:T#7
MF\N_*O]^]MB)Q\IC=T9KF+P**'K[#8G>/Y0#%!C(C5>^]3V.<JY+7/)/T0*]
M_'4NK5,;50 YZ\"Y? !*7_M*TMJ:.&:1;:ZV2ULG&1,;OX#[D/PY\D-$(?EB
MHQMUX^[5:-]1YDX$MW21@)6J6"H&(K_F3QX4,!)FS^5;@X<6'_DF'K*9R6#9
M300'J[DPE7F7UKSTB=,'"Q(TN=2CF#LL<',L@PM14:LD!J-]P0-JH=4S6&RK
M5S,W:Y;FXT+IN^%IW^D?,BL@/3T#4F%*K192B1-,*IC+*J"C0BCA):+,%]E]
M4%:%FOQ47D=Y6S7%ZGG @N>Q'XTZMG!T_]L,;.L/*G_+.<PR=J":1:N4*.,?
MJQ)Z1%X.MCS<>!9QIV7=GS!> J<\W\$Z\E)Q0SDK5UF])!)LL*958AT(%R:8
MWDDPW7E*'F!V 3$<':1\QR41P[XP>&[-.CO%"P>K7GZ3^1,/#4[LZA.,_8&M
MT[Y U]<K%)S"Q6+2'4JH=X0*(;P'VL7#E^Y[#HEH%N+\)A@6%!,A%FKXIU7^
M<PSX>O4?-. :L *N[YA_3O0#@S..W=DEF1UE0RTR$K1[1Q'?A?8!'>Z8"[EK
M,Y$&E.(:X.H"1290!"?18%B33"OE7[;<,NYH@I41E&>,*2+XC;<,."SHDQMI
MB15\I1=DGR!G1<FK)@Q79U9SH A*3C?&9MY'L04I=,D#OP5+@JK8!:*[;X-Z
M2[AJT\A!XSNA/@MD/B*37>SK)+T&?/QY"Q>2%A,+Q+EC%O@=)HF8_7FB0*Y<
MV/VHO=M/I8UDZT F=$B33$O9]]UBM%3>*F.8.NZ3 AJU8+&U6P;BS%CZRKTB
M\8[_0)"KC61CY/(BHR%?0)& $/=A*+K5.J05/!)"RFF'3::E]".4F-I%5['K
M"6$?<!?*!&$.XS'T7Y;!-:R3)(!U3-<$0XL$EWIQ((1\?'H6$0E#_E@9V787
MU('8CVZ;F"YG="M[D_'U&']-X$@WJ7"O-]PR)A(',LHHQ"EP8REI3 1?QW O
M E*0R#1W)_V<</1"AR@^5-%RG:6,):B9A#(0VS+MEQTQR7<:UP#QW!4-L(LC
MC@P^N:9.3>ZNS06U^6WLR"@IE7\M[28[II @/O'N3@AAQ!&.R))?.[$+>AU-
MK<.(K*^Q4J]0Y=H'B?AM2V,4DVECZR5).J&ULL/=:('S*GK)^T>V%RY"\7E=
MO?>A!1T=C*%2]'(QBUT/";5/PER4@"^99C1XUJA'"S"]__72*<56=TXLI6$Z
M%[8\R((,$#1.)P><G0"^J.HA]ZDS?R';(1EB^%0J<>\7%:YR?]"H,S=*A+E.
M89%0&]CE'1?B!9A:)3;&8XD 4?(DTN8=YX.#'/8Q/V.J@GO2NQ.>MB*#<5MG
M$=(@YGMAA ]A=AB+ZH)>:(1BD.%D:'->]NCS^Q>W^)W\3-?1Q?2Q(4?:-0!+
MJ5HMT.<*6K_C$].F$[[#=HLF*?'<G-K8<K</%'ZX<;7LBL[PRW8+!,:W/;^%
MW6*HTUAEVV:9KRUFD#%SRWX_WH[TI+66&[^P^CET82G[99_0".=,-]'6_;:*
M13[2Q]EH9'>X^*DAW2!&!H8Z9R_N9>,)SYHTYG/]R$V8&Z'<D$D4K=JJ]#*I
MM=]#^=CB]%<A5C.A7V9#-8?4$W>?9$1SGK1V!F5ZYS=CGQPI//E^&]53*-VW
M_:C"*E\UV4=,P-]X]@V"9L)$M^2511-LE%\P;"\VP,*+2=H6JH]<8M%M'?I!
MVMT9P@G=9V@JD("M"&GW<4ZG,T+IS%B6!HMJ09W0UR:YM]%\2HF[@^;G31/:
M) <V>VZ^1PH=J+0M-8%=1D(C6SLR,)ERQ@(=X3JUM)!#QJOVO32T5AM;=\UK
M0*BX$0O_REXN6B7N+]D2U=M&9CR;[;\8"L2E/PULBQ'H/@+SL)7*_@BY&7_;
ML[K3!RPIYY,]NHVI8IN?NW<"<JE65%H5:F( IL/7!Q6F@=/QHGP0:YN+'"JT
M-^K1 $/$^*WPF4GQR&'@5]5[:<&MAQ?Q,Z1N;\ZL^"Y$TY/PS3^L 6L)(H0M
M3^IS"#6Z^8=+K'D*+F;B8#ULYV7_XU\DCCR9.0F=UN(FZH44 QMVY*.=NW?I
M5+KIEE5S9.A6+7K%3_:I;@.:R^F.V<@>\0A+P*5R[8GY6*: XEYWIJ<5OGB'
M5A_JW5Q'&"S6MA87MD<SWUV?"*N!/E/!5,C\)7M+U>E<1@\++:JVMHDK--Q+
M2N,J9BR$3HB.@4<1&?_N DKTY^I$D'-$/!]1)U6[/ $@+%1)VH+[7MIML%YM
MJAFRX'^Q@K6Q=9 ]E',SAS"]@LD;H1$LA&3W4%83F*T2"N+_]&,!*&(^VC5B
M0"-VB0SNH,R]K0 Z7.[C._!?3H#_Q[_^S##@T5X))B44%7%QX6LH_$$:=X\B
M.<JW_Y*'@1.3.$)7/O[NF/ZI@1T9:MM65;CD8CD C1OZO7GXOQ815,SJ=GXU
M'N\5[TVE$?S]\?PKD1RJ,YN%_F9ODFS[VW$53&R,OYY6 :"!:L;V(-#\77D]
M2U>@G*Y%,)))X.^.JZ#_Y;C*HK98DJEVP9>0I@:*":1()F_ "5XTHY$QG(56
MOF34YZ2$L]M!L:PAGWJ =F,ENV$).D@N&=# F2JUXD%9#U(NJ\S-YT1)VP8L
M[&M69<24IU">PCOEHV(3E^R!+="8IU0A?=7VW0/",X2:HVHU4-5-H9#VH7L4
MAQG(*@8M5C-,+"YQ!**IBA(^-FH\&?:=Z!"D'.MII24.)32\PIT&QZ"Z6!'\
M3,@H452,GK_26/NN9M#HMBO*"&Q&IT'>?5D$6<T?()*)[R2-88I.>5**;?/P
M'*^)3SJBF(IS4B! $E-$,.1+";<N@0:)[PDD#M@B)2--@X0),W^G<8JS.A>7
M\KX1?B-:@UB;O,^' *<LNYAQK<*O ;P#I^D75J9QL!I@-BA/A4<=;[\_OQAM
MUY:P9C1N%$K7HZ#5U4O!U(PP!MJK0MLM]#LSJ$M5XC)/BF9#)+FY8JVK]]1H
M1#LOF?"A44-8"=^$D)/MTH(_H!'/! ,HN:7Q]LC7NF%"*W):JT_T:3CE%+]H
M=B,8(=\$T6'6/=')X*?*R8D4[>M<'.2YX0;2T5"*AJ]XY:'6;(:O&76F-VJ[
ME R81E-: UK=<3^!ZS( ![ ":Q4L5RO32D+C6G Z7M)5HB&0<E)>2*@ZQ1J(
MF5Y3C@I5),"6H9)*6#A0,TDOEN _M7TTU/M O/(S.,'0@]:I.Q-KV2@GRTUH
MXG-TE#E)$S7]53J\=OJ$*>*=,#-AHNHSA3)I*0[Y0OY>B%5G/N[7>$;DC&WL
M2ME=K4*TM)CX")F^Y''K \Y>#,1*7\ISA0?XIUW:<P+K>>HJL32K-GY#GN.H
M;EU[F0+#(D;YC T16?QRDMGM<3H.8?NO!Y>9BD*-,QQ^-XNA"\T@.Q#I$L-\
MH;IN!R;;N<(;*T1SW;4W!_OE5[@)54_;@/"C0Q7O.+\''@YV;)KT;Z<F70-2
M;R;XNK.<9W9#9[.VEX4'+PCCK@&:40O!;-7WRM(KIBM]2!SJ5D4%L?)1,[N6
M+&06IUGY5PFOE^)UR(,+'67'H5%[5PEI0I!UZ^&/H0NBBF#;0G:1I/NPA#0W
M;_Q(<LT>:KKN)+U"E>8,<R&6BVV;[H]%L,"0!T/F9A0Z?>G&>:C1@_=\"HM"
MSV5RZ]1L/<^5?L8%$SV.GKA"/!X>,I-"TUD"4\KGEP:WH<+64;;IZW?\YK#R
MQ5F$:J;8(ETAJ8_77?=;G\K'AT\V)W_E9;L&\"#Q_$@(HP.X@<B]Q9=B[3U.
M62!7+SK.VA7^+OY0##_LPZ2%?BJH55\"S-&B>U>;/F(Y>M=W5H']EX%84MY;
M]AAI_4G6FV8^@O2$K)J@X,:^B'2LZ2?@IOZ8^TQ+80V$N&-1= *P2$+,1DW-
M:'#-8[Q=T=EH 05S#/@W9DYQJ)\V05Z/>J8@^\FN%FYO$P(?UXJ4)ZX;-XY9
M.7$16V'I9H*;86\F"&T^*0BSFG/F9!: =>G&O(A&Y;TGZJ540<E@APKSECKD
M=4><P7T3!4M.P,-UL!CT$P9&RFO AL-C'CA&H$R,?'%4&ZJEYW3V&H DB%8B
MZDQZP(,H3C2HY4Y5UN\K-Z*XQ_S:^H\B*E)6RD1=4I&]/6CY@R"Z152@1*2:
M^> H@%F!EW_CX[)_SWGL,>T/L3GGI@77?ULW':Z(ZQ$I9)!Y8/2$A0VD_GUD
MY=\X^S]TN]20#1=' :]$MJF?%/X%D';2$?$'L>U+28=IP0F5UR+KM>,JK]BV
MZ7V=OYZY3U7;E,3J.XS9%,5*WIN6/%BH.]BHLAC4HBF:*AA4IW%/J_;8:+/;
MF#!#IF:*J%<IIR8);_!;;$T$C$R4M+;HTSJ_'+-^(&!9IBC3QI^VH3E$$T9E
MEB@(!?=B==#US$:;@5D@'GS\V7<6*:!^B10L\U=BW[__;<)!61OW&QLBLLW%
M'QUT<N;3I8D-.=@J5Q#J08@)JOBQQY43%/C+!QR0F@%\+-I$(KOE+#)<I_Y_
M09XV?EE#2.N0Q*Q+[L,)QF5_"OT^3J>)@=%V>L1K0XR-X+$:+!(_!F&0&%X#
MP@"FB!CIXF^R:H;6]P7??QS^&:J^.%K\N"\K69(UB\X5$N_)%ZF*0QCAJARY
M?_%K_&]Z^EZ:_S$-,<RN$"431;T1;^@//9 MH*!I\L7VM?K"J-GN]$G@RD*E
MQ(>/YPF=P/$U '>@(YNZ0"OC5=H8Y'@Q_(AS@U!\CUIPDFV1=CZ") S%'I++
MM)J;ZO!S:_ _M/@Q;2=!0Q 9&/S-,-J-F9IWM4_=!3(!RN9[LZVM[RPJ5EX2
M$[<G+[;_3H:FEY1V#)EANF![C"S:RTJ&>D:TKT=TS&*S\]T,=^]O1DO-B<!$
M'Z$LDFR'##=GFM<(UI+YP^(.1(3N';%_%^2(U]OV2P%AD.49^HG+L& H90E)
M\1<H_NS1OH<,!FGU$D[LS'4JP!;Q+O&7W,W,S;(.J>0-+LQ8^ACH?+QO-GR:
MR<?7 ,9EV@%T+U$!EBC%TNT_K2)W)]:'O,7 %CXI,9\L9%T_!CG2'(:[6?<E
M!GX>A5G1+1](EA,KWGF__>U$.(>0VZE2MZQL5V^P.N-AJN&A:4_ 1#G-:,C5
M.[=PNX5_7$H8:LY'H<Q8F[_@=?&Y\ ;+S1#CEYGNB>CIXG["MB/L5[C.2/'>
M+&'U.J':,U:9"P'+IEZ^7$X#;W&[Z=!WN88&_M(0Q Y=VUB-.^/A00CUM[B<
MFS4=V.B]P/TF\*4-'?"5QS"SO]T@*2S+1=&8MRV^F\YP&*UH3Y%2-KA.GDG=
M;O80U;TF^-S55HS?]9GEVM5-<A;10#FZ?2$H5?O4^O &4Q5_,G^+9ATS&YIJ
M4E BGF]>X26P'0%$$M3^1V_W 9:6!X/RDX-[2+D[#"YZ3$ ZB3*XA;RW8M3'
MUY36;"&DZWD69?Z3FC&F*=*M]6/E6KX\]8FEZC[VEHA-HT0,UG,6JGL_DDG5
ML1+R*.+%.=-;S-W_>M9'V%4*PIH"_,;E7*X9PEFI (9XZNX&R;FL%A@E'&')
M1+&P,'J0<3RR3DN?*KFD,="+[>;%A;EF,#P3E"IP/!+_M2PO@8(CN4%#2I_=
MHC!6OA\).CF3I31.)\5X0T@>XEOS(3!)E],4%&46JC ;G^'ZR9@SB.93R1NA
MHM >^F30?Q41]+TQQV\"R4ND?DY;)WOT207F#\:.UR%E+Q:O<-7J'^V\I E?
MQ,#^H2 #I5F6;3F#FMN-]K/;,WWD8W\T-.2_^@07M&^_A.]+]JDUCH6=/W'"
M>-._S0S79(FQ=#'!2L8I7XP]['[WQ;^>.%D]CC^-<1=I-?K@PJQ[T"_2@7HD
M\I1%=HK;UE-%?!@XB9*ATML#T8FOQCPSZZ4$]\I/,K+S+5,KK-_=)X];&XMZ
MNJ1T0$N+02=%%%I'RQ]8A9TOCH^6F1@[."V?;K1_*CZT=//%#IX14 ,T]6X-
M?6!@G7;F$>'?C/8"QRSKE_K0@G9AY]+"NAN[BOFNMG@54Y9]_@?YML.K, '8
M*4UWX4F)?8E8F=A5&^:,JY('[C6@8N3XECBKO!6>]E#F'>]5F>%TQ?OG)VG.
M]R=*/H3R"C]--HOF97TR;H:<*KF( 0EF7 -R$;""KPP(FL&]82QJ31%&_5N>
M#'7I>J'-)QN#[<&]D=?W2> B[VW7U,+"UD^0\(LFO)IK )VJ1%- N$>"([=.
M:?8M X2QHK+;I.,6= 9/2-HF&URA.WI("S@RE!8X0FEMSE#9912\KL3 T]5+
MS%S+M*RGMK0K^;ZPR^1Q)\BHBL':3CR:J,:/!8VJTR&HQR@F%KX.9RR,5>O>
M9>E:ZG-CGK?@Y@J#-AW[0QQKC>B?X>H]5VT[<\'K/;I%,XIE48/[?3L'%\E4
MC0N;$^D,TA? AZZM ;^PR"VLO6AR_."3(Z)WXY"BV;K#D5\TIZCIOU+,&='9
M04#FF'?E!Z%;?,R5^QWU0CTL VMH_9=ZTO 5UQ6.Y=)+*IS2G=LTIX>,?X)L
M..F]!F@4E%N%IF&0',Y+R/;2N?[I[%$B?68B@])].F097\$)HE-/$/L,*V:9
MH_DND%A!IJD6RBQA-"!HV]3W8_A>1B&P::_=P,28W #)!ZN6.C%9EC]X:M"_
M'H+K9@5370A*4-69+=5Z@6UL_YG] Z6QVD31A] JK5,PLXW@-4 6'+BH^TTC
M0G:K5M\\PI[PH:$&8[FX1?<7SQ!<A<FH(4V^@&7;75<F;-<H0@UZ:: KI/AH
M>E7W)9OA<XB1G%N6*,MK2]0[ M AKG&,9C1LDQPX9V)$11JAF))1 $[!\5/?
MA:CIG%D8TUS-_S9CZ/O@9PI>2A<YRZG>\WDT>4NNP-H:Z[$AO^CB<""N$78-
M0"5I$-SV&'MD9%;\&4Q@DW?QI!9A%1YSZG)#8:K-:W;2695*QBR?>=>,W#DJ
M6H7&?S)/LFYDX(_=O#L1<Q]2'&)41TLC>6\[(H=KY1KP[+>)SG=7]\:J0VKR
M1\/W2<5O3!4A6?@S_@1BD6#^7HU%@N=CI/"PD-0R\BZ"Q"^NX$N(^[S5(%)C
MZ36JML;G&H"C:%3--&>[UADX!FRC"M-T/-D=;!O-S'ITO![CU,0TNBLV17-)
MH!/MS=YWP1A?/89';M=C1K>M>YO#7#*J"5*E9R?-"'V4)IO..^[;Y+7GT/HB
MW2HFY?W$(*K9&Q8[T>&K.9EN_GDQZMU(MXJ&T3/%@EJ46)QJNZN%X?X,V#-P
MYI9AZ1-V.Z.BX*&=82KOQLR36Y-I#;O[093OGP.CR N9I7";"5(?(QV?*XYS
M6+X8(98F(('_1)D.>*O&8S;'[RFE$7)+%<PLABN]578!R[GSUNQ]P;,Y=_^M
MA>Y[X(E1^PS__YXU_F8]N;]U]7/9WT;4_W)2>VK#GE/RRUTL.;_U%='*NC.'
MHH\D;?_H-^V(/YXPS(.W,W2UY2]Z W?KW^,8K/E# ?S?"%/O.VUMGX3A>L12
MN[OSQ86/C;9(4JDJK*^;TA,4YO]!1%3(=_F1!?5L<:Y7'G\(0+>*PM Q)56B
MKP'C5V,8+BLO_T@$^Y]$(#WV)EGEKBU_ON@_"*+?BLH2,?167_KGPA.B[YW]
M6PL!?]>U909VT%L._26J]2OI^[B=_INK$O_9A9(*. 7>_6^$V54&>LS8E75!
M=;OUC3,7=?%>F83-YD2D%?8U(*1% U]<I:H''7K5UZ/U,S?][P(\3\<TBX\D
M/I3WP/WR3I^6")W5\.&Z<"&8XS(H?(Q3D;>-;OC*)"V"5,T)*W]4B_51VE^"
MOT\L&16FOJE/I2+K%[/* GW:>-[\/*=WA5BY_2 G&4T-1=?O]:R.)@8635Y=
M096AG,N33S"S3MX(>/8F#WT[X?@XS#^S"S>49J13GC-<@>L\.>X<^D<J/*<F
MX[R!$.#U\"!-F/,Q<8MJ'(U71J#V_]R#N_I7JEP )Q=)%@WB<H3^DT62?L!<
MIKJX!JC5ZX6Q+8*_@4Y@HLPD;Z!OJ6$?_3[^9>L9LL^(^VZ5:L[1[WKBWBND
MV[4>9K3;@WZ"KJ@[M*K*!T2YV'*KW>-]5^/8V403:=>Y_E>XCGSQZR%1BEBO
MPM,LP2*=;7^O1=Z[]*">&W+=^08U?IDH;!OU[NS7BNH0D>;X97I_O4X*LU4E
M/I[?JC*6O_<U0$6=D6IW\/(_45NOM-+IA<%RB@0,8?O539<R%S=0-^B7V..]
MT$1EE^%K8B0=0BG8T"9?[!LS"VOZ ;4\5IOQ*@D4\\NL#[Z^^GKPE/JNJ-R#
M,*8N\EUEPCI2,+)MZ?%5U@+F\=?B<S,\Q3<K)NX,!60\+%1C/E%_VXQ_38QF
M!5/U7T(\>3_&1:1M3Q3%5/ZLNW?T9%R)TU#N2G=2Y0Q2K]H0XAJH-L8^]&EP
M/>%\-]1"E><J@HQ\D86F\>ME?E2LR 2QE0R/FY4":F7Q^^%&FZIQ4_I1&:I:
MR0(9'73:'3?V3;IWY?0Y""<TN,,EOI'N.)C1D)IS(?# @! 9-^S]G,60<S$&
MMXV :1G-I?V23E5P,00J<;XLA, -T$ECYJP.NIA?[(N'@? 8TR&]U,]=+UO<
MI]*]#>Z+994E+35(PLF5I"X)UD-4C5.?50,YX5YG5&.880+,$5-4KR=#DY1H
M2:GM#N14U.3L@YS?G.\^$<$6CI[<M&1M[?H[OFY+WDT[/&D:ZO"F;$P\UB-0
MH4>_?4M_^ N&TI+(YTL"ZGOHV 4QAD.;<I/ ?/#4HX,^A6U2$?2[5Q=,TPF#
MLH4^+>D//O[<21]K6X&K]Y[+0JNTSF2RV_?6%MF22])3K;UL7R>@NXQ*A2SP
M'^0X1$9X<ZIYCM]5:IJ; 5$06_MP^HW"/V?%CUYB@9YTZ9!%^=/ C"J9_6+]
M@0AO?&/QRMS QM^^\0?NJK9%JHGDO0)/"<K*[^XKN%NAL70Z!_,X:=ID@KP1
MIWT.^%$;WN+=R6.5;$4Q<=L:/0-<Z1G8S81Y#5!/KF-X-$Z05K=_H)+$<UWR
MQ%%]$Q=J#"&Z0M'1ZJV3+FL:^4[&6\C,F;0+,KIB!Q,87O8R&IX4ICKGF-C9
M*1T +KG[!M,7(: ,1(>\DM,8K_")EX@)MT'[Y/B5"*3H[=^VV'4:!#.!YT>T
M[?J0AEWHYEO%-W6&=\4TK[+6!:AQY[7=0@EN2Q,'RA%)F[:O)?#:%D?;DZ[\
MS6_A\*[\>'4AL8'#2]+15%.[[4M\.A0?.\-G)(X"\WD()>$%>3U"CA<S6DT0
M/Q,JUP#<RMR0G#TJL_T(EJUO+NWZWQAS?@MEI= KVKJQW<?:?-W]_GO94O-^
M)T%';[4M<J_1V,[T%JY(4;8A4T) 6OO;^AB<,/E"(-NNJ#9/MVN8%&(I[YR:
MFI#:^WWB:QBG:[NW)C4&%.8[[(SJFD+#<W4,1^(FY%.*!V/S(Q:'S.D8G<E=
M51.VD$O"$2)E8S1DO7Q+AB!3(O7$A8V,5U>)KR]NR=A9TFBH]Q<VK>]OFZ\M
M';#;M^=R]N:0*.*%+:/IW><)VU;:Y2@T<3P2E*KEZ+OJ:39-41YFA8RCY^&*
MH^M=$0Q"5_A)*&M/A=Z"[F7"&UQ;55B\F5DT^_H[!*TW,F9W:.19Q?.#\@D8
M3KQ+[5,B9ET#\!SFK(%N3:/A5=C67F>V=H%%3P/OWD8Z)0BH%B+.KKBJY:=<
MF;JDZ/5IG'!.7(S)*TI/H'F),*>".FAP)"FVE*:;O8L]S"'S!B:KJ L8'FVU
M,@M\F6WQM(.:>@&[F<4@YM/ZP*G,0B&QR<>(3!<K9O&8S(;A_N@XH91P(J:/
M(N0VZX6E_!V2&Y#M '2MO%1VRJK2Z>V?:Q>BO1<T$49U+&T30E*7+/=/;Z$V
MJE4ZN^UJR-(+.JO08C5$S'-Q)1'SF+LR-L?')[RE:"OP:P"G^&,_2#!\3WT/
MG@B? 5N]OHOW=&#(4INV#Z&,U?X#"M]:P^"6[EQ>BOS<C6M]BOL$62"^=*44
MB8*Q6C(6AA 31F$Q7 ,4_*PC>;V)*3?I<M#UOD&=ZO45=!?C=UTG%HG=;"_
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MQYBNG&C*ATWI-6MO_6!:'MH)H)-T952/W$">2%$45,1>S_G LKP))X"G%)9
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M&58KE8[HOI@] #^??W.$%]G=)'&!L][]*L5.ON;M,XDI_;"![E0ZSWX5E?<
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M ]6J=B_L$GA@]87)@NS2/1 &B2KY1;>9F.BT$B%7==T&O# Q5K(-"/$%S4H
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M&#"SLZ1/ JTEQX4Y>6!SLOJ2?*I" +0((<I+\3*J)\FXF]*-,I76Z3JGNN7
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MJF*CMYXO;:[\.X\,Z&K4>J\0M2CJEZ9L8$[LN_ %$=AP,+FVO&BHN;"+E >
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M:(*V,LK;C,".#Y^-D<CB^(FP%I.&H;ZI1%SCY@JNE4"3F<B]TJ^1N95V\R@
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M*7TO$)0%-6QF-4KO_4W'.(@"!182;7V?F^3%F6KX"-(T57;S;=O$<ORMSR2
M 75_W0GH;=J6XIC.:C"R^'G^P:?R.56WI,7[U<C"-"$06#-'JD.N/F:0"Y^.
MKI;_&T^63HKF]\V#_^V5X$=TYWQ2V$176>19RE/DA&)M2.&2*=9 4QF=>Z!@
M[?]((YO;N[F%R>*V';3LO[K+]_10#F!W[%&N/R0:A7I.@ :,D8F)60/DI$]M
MR]L$I_KK?X)Q<39,QW)_64$O%:Z=S(TDA(X*VZ(E*I\;DEE2Y:L6Z8$<N?W$
M,CNJ'SM/OI3^O-3_^ICD"JDH]_IU.V5AO*5!U?#8K-=C)L$@D(S5;X;-ZI$L
M\LB+XSNAVDXF<,6,95&>"HW5;8R4 /O!.O%E\-I2EL5VB 6V2<:U_["&1-,P
M-FW5DK?7H7%DY9=%P]7]\(1[(-/H[W%F#69B(*;L0XJ'Y-]@FBD?^;CR@>6:
MS\34.@RJEC+<__H@0S!V)^O6?H,A$4*:>-9%Q6Z0I1*&7SXI=N0&BNLCCRW+
M:MU74HZZ'YD=5)2 BB/G$0-4081M/[][-"@=><Q$G%M34$8KH/>I>DJ+-:-4
M"BVD,SBT(*352H\]T00O MUP?9';*[LEO^>T#1 PQBO&-D\2^1G:C9G@35UO
M7TGWY4$X"OP(>2[#0+LB>[0Q>(Q/D#W@&1YN[F).#_YCTRK*PFQ?U][O_E%X
M1%<]V\._T,H\&OVYDGA2CL:%]X7$B,)C.XP57TS=/%9-#&."TP]X$%8JE2J<
MDA$]Y=D;V$>1+,MDMD!R-?*91<L>K@#ODH(1!6_E!UW-N;=GJDI@N)R3146Z
MW4R&D#-J45+.[XDC-?VC:4$!67WD 8DFAW4R!O,C64&4!S*)\>O26?P<[4<L
MK.U2N"_-Q LIL)JD\(0:A!Z0/ 3_2(^C(INQ?+\;)*-S-5 [4:-$G*HKC]MP
M?7?FKO?U;2^,@NKVSZ_3D0+V@9/8Q@,2*8F.K\A;)M>KAIIX=M'#;LUD^> ?
M77E_Q0\'8KZ.E'HIY$#T*"_G@GS@$/B\8Z#GCS.6#N9*-CQ<ZC^ 256U\V0.
MB?5I<ZG'>Y06LSLG#1T[0CV/21Z$%(=')CC1T5Y,,?N3F3\#.(3CLB$6H:@#
M2^#P5')@:HB^'S"QQ)HC6:2]+'TQZBI$QF;'<&Y*]$V\;LIMQ6 55"/P([=)
M/\\.A_3-9AQ%<2$MEI7]X?RVA %H=GA+Z2%*(O74_>]77A8_*SQ "O!?[>[^
M$L#"$NX YL2/$I]8.F,SH[NE]C5/ 0AG]<&*M$/43.TO0#8IST>9F%B>>HP=
MYD?"S&]#%HF8V.^!OWK_)J#KN ?<%?D6ZU>6@DTU'"T?I+6<47,F:+!"06B#
M(#O38;Y(E.;MW,%3@S^.)Q0XU^\6G;?97-E:5KE-(;Q)>#/(0 W&&AQ< ?)B
M"?B^O")$NZ>)W*_K6/QNF41JHG??9I_3]K+>/?C?=]E(6D'?VK8;=C,)['52
MU_E1RJBI_!(JU'^3R^(022X:!])\% 4;>BR"]P-3<KGHPDY'E'-3B6LB#'+7
M?KRG/M2\0GYC\UDMNGCGR"!4TB!Y(LG"-^MFYK:QO+^RZ(!9VH8A_H[U>8E7
M4&K:!*;@"W:@S,BM_ 2G>N_?Y\ESMYS>#P">'F&B(%WVJGEZ9*!8Z[A02*$A
MKCH);"(0O*RJ1)TLH]\CH!_A9L]K"L%A2 P;FK^AA^6)UD4'!\WH6,@IC'QS
M_A(3!!KZ7.X)7[# YRFRK_I4UE;X (2MWAB5W6_U\K H,CT]PPVG-)]P]KNN
M5*2 1NR2=Y$=I"SHX$6_EG+,(R'( <ON<_-)4P-H:;)<+V\3O0>."$,MX<^V
M)]!NY)9+L,X#5C3%)-?6Y)>@X6;\0K&*NWJ**'!,-0=^-QO&":#$6%[Z*AFP
M*9Y_&#;(8_<E^>#M;<O43,2:V4BAOY8?_[=A1C2<4E!C'WKBHX(V(\5"%<**
M[H&FJ6@<??2[PB=$08ZL;T9;K7"9:I#:TC!.3R&N U-(#-THCG#SAP70JF?J
M(HU[L66EI+J@TE.SAZ+O=$2-@EFFZB^V)W$V:PD]?UYYJV!,GD#+N3SJ7-IE
M-Q4A"[O,.'E\YL]Z8T8,I\_ZMW.CW:P,YXJKONUM[3M G3ZJ%WY4]3UO'5*V
M:)DI_]T_/=,O+K26F]Q[)C+\!IN9OEC0TOK4O?Y#DSU\'2!MRW3!?U98%S*F
M$T"IM6<Z%^2I8*[D=K?_D%4STH"(T'TLS+$R*[.$^Z#@1G9-&@J%?,/I!,Q:
MU2@/=9VPX]+%89Z"[M81A.0 Y<KGCRJRDA(>D&#AJ8**U#RF)#G3(/X@"SGE
MJ=,5IJ+#Y:-Q@TQ"0H868Y5%ZMBY/^/B"*_*S!=WDE3XST9AR*!G+P)6W7-%
MBU#VW<N^O_U<L1H]3!ES*\I' 7\LJ36,XP#3]S74!.D F7W-\- %A6_Z8B.Q
M)(EF>$DT57Y>2&RKE_=HU_837'^IK98G[MEKF-N/F'D'Y<0@Y]_X+Q*^];,K
MN7J35$^=GWQ*T%$D]61-3B8TIN]MDPL\;,@*D[P)<QRR([$,Z4: WU 3P![B
MI84.GBD?*\[X25L%4;G8]=6*456+'RMH/Y?Z%>IG>_!L;O)CD_GM*/EP>H$[
MN,'XE>T)=THN;E/E1N&U R_^H\O0+:<) V?]H)A[X%B+D4'#V 6K)EY#W/%
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M" B@CP;69>L((;435C6Z>R?.:V)ZN*S4 )!1W];;)R_7SWGV/,PD<("Z9D-
M/)]J8NGA F>]MPZ1<M4A7D7AN5S(]2?SN_5[H'PMR #6<:-_)_0\HQ_:6B'O
M+Q8QC&L(L*&X#6!5R#,[FQ*%!=P,JI0H!KH?$E]JZ/%'#NV(&I8+$BR^^<VC
M,=W362[TVQ$=//GMA,[RBX*^K-6CF*R_[^*U%$\7DZT\[612'R&1%AHW7W$/
MGX.8AL3?('] ]P7E52RHV+R_1&BG3#:3BQL017C^6JJ:AD%"^F5PYUZ0J4ZW
MR]IO)_EB:%;>(<)1X&'$>QEA*+YY7^!L+W.5 J=*8A!9#TBIGBP$951T94+'
M6$<8_7)#*G"X+:+Q/8BCH\,8'M9;4S@GN&;?T,.!<:ZEI0;\E>X!6W'&\%CO
M,I6Y\N</GJJ7]HB]I?3ATD61(,*?^&&$ LLJ"'J-ZGI[?,[5\_!UF,C>E21E
M#9T1"/A1!0=<#HSC7" 7T0 DJ,=[$KQ8WN>3M,_RT*"J.$A<'%[$]S=:9J&C
MS ^*O9@RDO=5N-Y19#T^KONQR5NEYFQ1T,P@OWQUO]3;^I8#46ANF#*UCL"9
MWG,6YD#Y+65.I00E>54#MAY% -IEM<8_ 5'!-@.WJ!_Y?- W#HF9+@GVZ>\E
M-SPRI93!2I+[%=QAAC?J(A1%XO?F)\[X1WTB.%,G:'D'?$8D>B5%I1 FI5I(
M5ORL'=]ZH3MO0(ML>>R$S;K":(:XV>?-GYW)P)_L?T8I1;(=/_2&$#Q#XV.$
MU9<:%0NK=(NRV:<GXCA5R"=-I40=?/J9[-;UR)1[EO2/4-.<N>4X7;S*]>NU
M[16+]I3;@2[[H9X/V@$V9T)J(1D23/^7-)Q/KF+6 7ZR<9II.TP1,?2,)S2_
M!_X<3G$?#H3^W<J#GP9FSA: <"A)#E:/2TRW]#2P#U4M:@#F,#KEN.I<$L_@
M[6YQC? 7X>]59)?=BVE#-$ZCFV>WN-J,L;W!H1&>#<3V,(BU.N/K;72)PC7P
MI7[#]E0.95R";#!1"(I;M3U\8U_OJ;',SQ!C9T/V@G&-5OF2):_B@#?BW=S3
M=(EW5I6HATU+:@ZL+0)05"5S )^4BA2-D2G?0^;40J>PV$OGIGL@[WQ0=F[&
M."C'8=RH$*8MU;4U@&PQ=>7P$ZA:%&83J,:[!1T(T]FZ%.&MXR%4I+[%2 ?<
M-0*1W,;+7RVO"W.5!<"Y6!8>J@--UF!K!W*&UO!75F';Y"NBKSJZG-(JRY[@
M*LS@9](,E1CA+>YY'XY*Z'H PG_E3-U#'<8'A+"YF<!AV.2T6],2Q :%A4EA
ML2UOC[O'IK^!CK#EJ%\1"V!C7>#.,$U5X5G[/5O6[7AH2[&52L$$2*Y61@H;
MLZ8JDK;>\ @GBRI3MM?F\5TW.=X$7D]UY8!9#:0@]\#\<9+<BNQZQU'DL_"6
ML\T#)J"F4&IK?1M>< ^@J)L,-%MJ>6^(@F#2N>4T<8B8(SET_8.:V<-;>(CW
MCTAZ^H)4N4(2[R4G*+*:[J5VRI/FNQBT!()_/RN 2MD57^*CA#3C!=:?9XE<
M4%/@IIA#\O&B5N]!].;!%'XVZ# MC!0!*DED&^I./HJGF=?-FBQSD43(B]0.
M5[3R:-$1'<-1XO+P6/MU^/J'I3=R:"A50=[I=9B^,_:CRG,_#N:FWEAEC)J4
M^0V?WCK%<52=] NNOZPQAOZ:87W1ET)VM8FW@LBKJ:>PD)%4\+5D5"6)O/E9
M/-\K#6,H!*[UV_N;5B^N4KLHHUYQ-=94 0K-.<O)H7]B5ZH*(V$L&704XJ+R
M1>+6) R2#QYQ3U'?V#OIS1KWA*XQJJZ.G32N/4KCA34LQ#.N]EU#_L65UD#&
M6&Z8\8 @7H6_H-]WB?C+;P]I,K5H7GQ<JG4.4JZ83];&<7!.+Z1X6*GT*NO$
M232B3^A.S_90+?#5)\95SIUKVI!?_0\@$'P<8I@A? %4>5[%O$M/+MQ2$04K
M2_CPT=NL6?PD\W7F8S ]32G)KO??6F0"G0NO.@]!Y:&$XJG?SH.@S7+55J-9
M[\6EK]J?X \_03]TC*8.F[PFDH[#/!-'T"H&8<LHD?6)6Q:'3Y>^;5Q;4JT+
M:^1XDS1/R@GHQ7>SJA]Z@U*M8\.;:,6[/T%8L\#0@Q4OTO+Y;23W=91RL^4>
M! M6%4LM_]SR4]#GUU*E2LJCS$R*V&$<VTDV+["%_6+HE< !NM$X5-4$1:P^
MJ(&XG^\6X9C^0N/O,HYL0NKZVDE@P8=2S/(G-9;#/7.R OH\4FT01R,"H0%^
M%Z_C7-T;0S,5?_FJ%9/1?KWEC&13NE>WB%GU0&,E.Q-0W"&" ?[>1Z%I9M*B
M%BEL=H:&O+G5EIR64GH%1KXX(VRE935*R3#5X"UY07/P7:&84=,_J[,2>5P)
MJ6QY\\D]BTMKT(ZOI5Q<FX3]T/N-UA<\67HJ4]HGV5\V[P&.;5]Q>6+5P(\A
MFZN7N0$$?]!RDBO5IM\\9YXJ_0XII7]NJ( WZ<G!]N/47)7EO#>PU%&9H.H]
M<X/1#8A]_($T[/WY[> J-]?=>)4,(K38RHH?LI#G5^!UJ%%Y=,.E&LW;<,TH
M+KLV&#GCMRN0B1]E]YI*5=/%MV_U9%3"V, 5J3=T"TE7M>!6B41[[G**'T)1
M1644^16_H.K82$?1@&C<W_SCA(^N:W[?M6MQ(#Z=J5CW:(N%2;6R71,$E5Q;
MUXC[U8:._3)1I)4'8&80ON*2)S89H4EK-*FR=T;>/8Z_?,R'3'NS.75NA0MF
MC/*8N"P"E \-O^-[J Z==4KZ(=7A;)W0:.PVL;@B_1G\WL'*ZR2>6?["0NN8
M735<&JQN9\(R&]T#3!!U C2!Q.05CJ=3T _6SJ+2=SWFM-%1G**<E4NP7SK+
M[P[-Q4L&TX'C9]62AU3K,W261D]R<L\<GFF3IZE]L'U_O14>WLX?A-\:*59U
M2*[V\%G=89 WWML>,$N\2+F:JY%&J]^AM@>1&97!8GT/H? [@93&9'G^9Y40
M&SA61RU3L_8ANIX@6#\X[^3@EHFO^L&$)I] >" SXH'R.=C6^.Q0A)U<:0P/
M1_/7B!&N#=PH,6>=FMDXDDU!X8E^0AWOG%M:0!B/;H",0EF0PP:-3B<3U9/(
MA0T1D#!381Y9Q)E$4AJ4D,O74A,QI]C&%0$A0A/T*W1M@Q54R.H9=5(-^R>J
M[53UAS(UJZ:8ZS"39D:C85U^!T$8UJ2OI@-5AO]0$&2'7X1Z=)VWA$:05<6&
M04XU6#Z.)W<MDU:O991TDWM]SMPG B#KH'):2 DIZ-RCRH6JE%(9U+E5^TO<
MI)&BYCE,!=?&E>0>S=OJJYVF)+8X1R!X1Z3F%[;KF8@,*%2 S M4_MLAT%HI
M[,@.T;\[[\KIX*)0YLRO;\KT1)I$LX&%_\M=R.LE[EP08<T%S/"]!,<[RW9K
M,%;N<NA%CML<N(C65;3%)-=W@&LZ6GS"S2Y!Q56!B:MI1W97.6DUY&S#)K0_
MN#V9K;9*J08F8G]G5 C:QY M[,/H!MT [")BKD1Z=/ZWOVG+)V[4V$ZNM)/<
MD&+I'I7WZ<<HBGD2\C._CFK\@*X)%75U7!E'HTB>')6Y=+6W?M="]48\N)6F
M_4BI2<-%KC0>&7M=1P[U$T_O _ ')(6:T^BQ821WJS]]T\NL8D=#FK"#,#EW
M(@R.=9%;?&%86:(J^ 4$;U"1X$_4#[CSPV)1/N'U??[<"K8M\CB&H6AS\N4O
MN366KPF==;2,S<&(0]/=5Z]Q!6?!',-CA+5V0+6OLBJY#GVPK"*7_&@%-.J+
MP/=PS)YKF)K0Q3,\)Z;)'R1H2ZPN 3P6JL?%%DJOQXQS,AC43>M,EHCW::(9
M]KZ.TKE3)3[D#AENR=#1S;FVR^RKW/*,BU!%Z&9U/9>Q.(*25 H4\D8F8D=D
MRN>7JWXM@:O#X <D9.WW '+]9GPI]M: LNMI5<&)O_W;+^HL[^OXMXZ0Y$G[
MW!ENF6Y=#9BN]@^=4?? V)_$.2[29^2>8= >T'[$*E#2P9R;4^H^^O8'4)B'
M:S%Z5"P9/^CG"R 9"@LJ'>2/2.10-#Z=DNIA/['LC\[SX_Q]'S\7V)^)HFT.
MU;V@>%]X$1G*^!U3IR$V2R=5D4]C(P9.2!?G'K.*>A5J):ZR.*?EW))HH! D
M<%QW[5!J#\[E.WS<O>"#*(ZK,FHAOQ%@>=.\>7 MF?V6N51L-GN1(>U(O#7
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M_D"\"I7Y?:U#6+FKE0GCEB#\MWKS' !UEBO8F[$?^PH@T3V.1Z>@R ,Z"S5
MZ@?_Q1F;SZ-J/ZP$YNCS^0R/F<D0$ YX"U4-J;7?<"NG2"_FLB5</P>.(Q[$
MW2_:F*IGU)^W;FW?:]Y/6C771>(LS %..YA7?Q7GZR"D<D04"4WVK4,212YW
M%D]7*M='(TR.,/.+-O+,24\Y] J7T_WOXD-$E;OSBH/H#FFQ*Z<\S<03.) M
M4"Q^\;L=C*J/&B>V$%0N !XNZH06LFW_&RB(\O<G'6KZT,$YF\YD5!&*#6(.
M)-R(7AR4^!AY=L=-E-\3J3WQ/?#>+>.$-H2>>'%HUJ5D NSE?._:ZJM27QHG
M^T!^XX#&PBJSY>I^R1]964!*:1A_ 75,A5X.=ZS@^UE_ F,29A,"@ST:'F^V
M6J"SD-O=_E\T$<=2UR@$K=B-BJ$]13RY;:545O5NM+L-R,I>[DGK>SC KO^M
M/ZQ5[;E@D6\NZ7)^M1/,19][Q<\H@C<]>ADYL?>T_%_' 728+VZ!XX:;.&@3
ME5#*/C%AEH$#+$]\F7SUP=3[0HC)I6ZC%H@IG/=#LK#P*.XB($< ?<S9>40+
M\T"Q]/DX70Y/%:[(Y_5^3_]H);%U*;,]_)>F:Z[FA2+S2]N[_]M3$_$P<6YA
MS!2>%D<$/,IP NM1EM_]Y%Y+,!1[$3-$'\N<B#0$PH<G9\MBLY>&>!D;EJM[
MPJ($2\U)!IG*PH)/L1!F;HZ>L<\&Y:>\M<$C86,JS8\:TL#!)UI'1TY35/ R
ME[$0/>5"W@;XP\<3B]&]/]I:.<I)DY/54O'NID3D_^&'AI/,;JTR59=A3U64
MT%S>Q36#Y;_'XK=B=B\ ES07QE=.#H:CZ/'%/6%"=0>(.5'%9=*HF84_1VE#
M^71(ZBL>[5J<L)-.+G;H<,H+!QB+]9\#VAY^%KH$;B3LP_PKSCJSP[R^-U5M
MJ@_T'B,1MRXL!ZK[ACY['E@_]M7QG1T355P4=9Z'SV\'E==OI+IK8#>(0I[$
M$0:(^)C_E[1OV8?6/*J55A94DB%K1P+-YEV#,GDIL/IY,./R7,B'D]3/"DBX
M5P"<?^L4J?:4<9Y.<]T@^5AZ1A\8]0C,/P<,OH6(\K*MEAPX5=,+MXR5]#TO
M&X+>-@.JWN0/6"M<OL#]6, [5L-/>(*S IE^237*P9D.<II"$^_#4TYQ+,U?
MGE_\[J22C@O'%(3!F2++VD&QKHP<,3TK$YX*V\NFL@BUB$@27K/3W2G\YO2?
M"&V/Y'8X^(X,^Y[/<O\-(2S'B]S(T@&RVR :Q;(PT?NZ&[VK>!;1MJ'#73>Z
MNW%QIGA:=[/_9WZ*/<[>@GLCA6O.;RGXRLRC26BM0BP976UTRP#\[:X/B@?%
ME=1V"J8QQ?+71[MYY+F^?F\[@C^6_XKC80/7S6>W'X_F7GTFHLQDR+2__G<9
MCL&? (+VE,NJX[+.VANQ=9*A%M=SH68. >W<00$Z YM:ICRAS4.; 3_\FJ3$
M8E3TZOV8VDO4UH3]UGI%/>2$I6* 3;N5Q,^-F=?>"J27IOO!S@&63A/W>^5+
MA*6(B(C%EH1_?B\!F=WC[#KL.?5G(V_2.QC?:%9FCA A1<<1XU_I;N^X.O7%
MVK<7RE&6Y=W+.Y^O%)6+D+60.JL1[5:6';3(WS>[/[\#=LO2+=+KCZDE6<,A
MM.W[N"*\P).HV)V78?%':344FF=E5"%'U4+A^/''!K,*98/36:I(KY>-'W2D
M""CK==/LDP#WYLU.06&S(1T]ME:*3LV+9;K T12E3"H90UV!8]^M/N52,17\
MC;VG1T\T]_8?A.PES=R/]8N)OY(5[?E +W34I*S,H]R5?;4:*+@F_,)WHT3R
MA(%K%1]C*ZXXOD&\IEGA_N;!9:]LZ9Q=]_;L1EO"Y7$JF.)38QDK<1]"NF4&
MD/<4C<3;T<NWG%ER9]E>KHJR-08F[&_-7!'K0('X;3<?>"=MTO3%Q#SJ<1=Q
M+"N._A;I_<,1X <Q!$$'*&(/E:^O=CY3ZQ;_&S-/IG[*V2^\D88BGP-W^L0W
M"HB[?0[IUI=J7PVQ4O_Q? V<:&OQ #O#]_4*<2PU%)B3E6NT:,S,%V;.J6QW
MPF5W!B[CG&V5<AZL/#_RQ2TA'<X*9ZE2DQ7,X;8$X8@T_2M2:RM"I[+_X< .
M@4L5DJ"MPD)J?A0^74@GL_=MX&<*0>EP_!G$17O\3*O\^-)W@:X#^W/ (84T
M?D&2Q,A 2\\P<W]TVHLA84Q=*;,IJ$'$LR/B5P>'R%>!M GV*O6E3L8?-]?,
MBPZ^8]WLU=859?E'Z#?^<-P&?)0;NLD84^AG*IGHC).(6Y5E^[0)NL) R</&
M(B@55N0-9]LGXI^=&F;.1VC&F,&?A_$)#&XDRO<V)3M[M$WWL5;M\ O?Z%+(
M-9>!VD3_+>7%FA(HTY>7IRC<4[GZWW)4BD<7.:5.[[+!X7!60S&V;4\,T4H\
M#W1[-^(>O)B6Y4:CVL>.Q=>Q:DW4"Z#=@L<Q&BUM*LJ]=_O<C>!>&8'<?:T,
MT5->WB<T80,G <[5MT<HC*]U%$R<OY@X?A_PR>-B1 :YV4N\W^/D0>43^$/6
MFAQ9ZRJ=:JU.'TGW2LI+;Q1WGP-<7=L7?CRH),[UG]+>_Q7_JVJ R:24(MON
MGK5$U4D1?3[,>2S40RNV%K=&_2?^7B6FSF='0D0"U/55(PUO&UQA/V0#?Y+T
MHY0M-%5-K#> OQ:M3&SYD ?RV^DKXJ!31#3V;%QP+#RL7@*X/"3+7KWE:F<L
M#TG?R0ZL45+HN_P15@<M@PF-N<M-%.H0'BL?$3A6,FV:R)K@SHX4*GKC+]/4
MQ@BJ[O'"P!7.V(TAMRJ13C-P:5//(K[# !L)6Q?,[P47SLQL]DFHFAR019NU
M.;[2#V]DE:.2801<VWMLL45\OO45&KAWG"EES?"4-G(.[<D5\R8!IY9N\!;Z
M_2U<T20-EN\6R%8[P[S.]7A7&+0PW!IW7US[&$^1(_C/.3M4,+YQD\Y1H$1>
M(6JDZUB;_GG)W588OC7PW2?NMQ0S^H/LU/'G5_YE^\VJ#=+&/4X_/@Z]C4RU
ML*R5\M2E70WRC_XU/^-00L1I?(^C<FI98FU#;1V)L[9"K]S@F9#.Z#(9G,A-
MN/*B*75A4JG-2))V0M*ZZGW]]#,.QM!<=$CP-A]6A_A0;8?!BLF886;NEJT7
M:Q"&JSSYHJ$Z/=HUE>,%>87T2\EBGSJ7T[%Z!EL1;';!6EFM1U+:ZBD"IG@X
M=!J@."26_T@I!X3&;L8J'D#W7\>N>B?5F+;NHT@-G;-AS^1R?YM\+1Q)^:>D
M)WK$&Z)3VCTL[BG.#BZUND7P<(_'9/> \(3TSQB<:SKFNL[ _!9AK=DV6PLN
MV.6$QEO9[X(\G5R(/+48E\. 7-7FRJ Q_PR!X>)U1M9EO.6&AD;(X=1&H[3V
M\4S]C*"UVB54GA0#6OA]L5:?'-]+)1-Y\?+Z_5)>_J8NS0\E72/E\=5-COSO
MFM&A!#6BWB4V>\2N\#<9.R],[JU>;CX7F]G2! Q&CB!.SE >)27R"-C3E,*D
MHB=:T@I$'T;*UCT,3-.ZTH2@E\1=,E]$P[H6RTZC0O(;1&_EP_/6XAV6.#5,
MER#NH 2.YS,UGL_F!7>6D#MV'-%QS'0X4.$,TXR=5JS0F&58]D=PX$)X1-^;
MJ-V')2N)I@PT#Z+0\Y7QA5%%L\'M:^XNQD4F-(&\ZC.,QLP\WY0&JAE?H' ?
MVI7YIV9-'%U'M0]%"'V[ZI ZK\@J=N^TY+Z[C/QZ_!<9YG.^LHZ^;&^,RDG%
M3LFE"8_A;9N^[-F._A25T!51:HED&5'R\#'!U%X*D9BME5O07H2GZ$A"]L#Q
M.RG#>/G4G(]/PL3KU_>C2B4NRW_*$#6^W[!1XO]0R$9@'66J-+'8VGL.4#U4
M1@:7'>?;TGL;SKUD8FPL-CBC_O*.*^C42)?8)*&'0.=H(4[IN!5I(YG\ </F
MT.F,)=+Z#(TW()7V.G6QD@'COJMZYT@>-59QE88 #E^ZR+9M^MJT#G&M]_[^
M%1@MV=S_TZYXY2317#$P/71ISV">P9TW$!E95W H4*#;O28]<T?BTF+2K3LI
M B,0YLE$V\8>\"1'+3?<W0+P+Y;\*FI!A?0FUABQVVG=-0V82#<3N'VF%+Q1
MEE&UGU;<RF])O5_SUYGRX&U!02@'UVX#NVY-WH&1[## _M&DGG(TN.:+YO."
MZ3#JXO-F3)G,@Q[8[T54/R'\B:)2R;=FR8IAI$1T*"W1YK^I2WJU?8_B[Z#-
MU=KV_,E5C7CJ-VSGP"?2JRL4I^3?IZJ4\5UY#)A$1=Z*Y6E=?9V%::H!JBJ$
M+^QNQHX7-8"+5V0U0_XM"7'N%HS_&39"['MD1%=&W:72.C[[.T+071<37" A
M,,S:MG;_ZF'649[VK\M 9?E0:>YDNPT--QTH>*V<:Y[!; 0Q@F %UN3J]W>!
M[S]8YFCZ#&YVL8)/Z#@.]I)^LQAQ6 &*K'W1T0O?TOM+%'$L=4$[.X6[QO((
MV0F^1=)OZ#F R6R?CQWDMG@]".N-7*BQ*@3#.\X4AO1&#Y$C2!RC'B:O>@E:
MH!@>R6/5,.GTXI$'[?&B:V0<5A@T>'?D$-%$/CD-^ U]5_^N9ZOT9Z%#:=]9
MLAV_O\P[Q[TX8W&JIX+E,')T'),^$:\'4?:*0C^@D]U+.P=TAPAKW)5=;2HC
M][!/AX/=)\/ZZUZ63,,[O^%>DM R#D[]O/L5%F)36SPCLZ]1;81V_K!6Y3U4
M?L8R:ELB;^\JX6_$^,\N?']/5<'1+W2MG,ZH:6@9Z.?D37J/*(?!=SVT("'Z
M(>\O3_E*&Z&G3#^N_C@'RJ=^LE0.WE(LBS<L(N0@(%P'N45]K9I)7=(#0[*D
M4PLQC9QH[(.$]TSZ2=",P73:8><6@]E7!+4,I&/\B?SA[W(CH4 *_R,'\[+$
M9!7<Q"5X-Y]CQR_9#N/$/(B4FGK=F>\=(U-($?3XSS?@DZCPO(#,@SQ55AXN
M_YN,49LZTV4]D37K#!D["*O[S\GL5^E@#(5\GDXI@GY5),LE ;F2WI-W3_>'
MAN6B%M1JK>JZ0@*7/<34H\/X%?WN[BY0J;>M1X&R10110Z1'2-9CZKCWS3\6
MWG<XVMT9H?5M=T3W!S9M\(.L&9NB<PR410D@[D*_'D.)E18JL1NOCVO'=%Q;
MN:GUDINJZMVS8XM;-D$$\I.FA$J=0=QM@G,&FHB=+=+)OE;HLE$?M<RL*_K8
M>QM:,QQ+I?_>HT'R%;/>?/!\V 7.OS<[.>$0Z""5"S@J:Q;8[FDKWFJ.2E56
MY.1-5B7.)I=<R8VO2]R]YYV'UY5E:P!C['PCLGB7(ENRJ&E4#&CB%+_L4VBG
MN*+AD"(&CX]T#;/C97/W8WJW*.H*+>'):9YW5P>7$(S<)C(78/3:XC$0@*%)
M8D0A';BLY<)NM^=:FQWL\2TIK.+SH!C<$4T^4<[54>3 H5R(EW6K(R*_<HBW
MMSDQ-Z@LB).S0XT,6)AYY0,L>>NJ:4;P$<ZZ%HVKMK@UE+L(G&P=N\ML&V.J
MJX,2/GV&-LD?WVK^<GCIU<?R%.Z-OHU6%=C[^:E3.-;;RA;P6O&YNP<DCU(C
M&.1CY-Q>/E* &92&J&]>ZHT59D>*CH3Z1;T\8$S3TPQD"I&E@O3H*RJ"%JD7
M/5P('B^U'?S:+#'6?!8(J,\5<8B3J""OG=$NU8=H>ZA \YVU"T,F&3"33V36
M\;)[@>:T7/7-9?&17G'9L+2SN%"$@>=J'HO;:DPT)P^[WPQPK/!YEMJ98:_V
MU]E/9<4X1G7W)JI:/.<'4J(Z >M^5<B)2%_T;O)II7XF$L8=?-4UG"T\9D+T
M4'YPYU][L;P[K]6%Y0[@EE??AF^?34V0/V\S?5R0ZW ->.6_(;9N%N%HI=XU
M(F)06VGH-3<GM@D(4/+&#COP1K=ZI4:PB@ M<P_%?&[?=YOGISWBF<7"-4%!
MMG:D*RGP4$EI=(BKKBSAZL([@[?4]IL&;:RV>E_"EVAZ4ZXZKT#?[!$YOB(-
M]ZI#<5UV !G<S6GQ.&+H^JJR*N5N:E^"EV<&_YK%XE/#["*^*SNVA&>FIARQ
M[?90DN!V]:K4]YZ\(R(U4(K#;J[8]ENE*008-M6!;YV<-K!NYK R>"TG?LX&
M:UOB@ !\$2J-N"D>14-MHXI!@O0Y0;>3$0IE,EN.H(NB!M1,CQ>4C(MSPOPJ
M\ZU?S'(Y(=("L=PGIG3('<<G+^[-@UK,K>K<E:+O)0]E@XUC%;^=+?<$[LII
M!]$SU!-MM#Z(RHMD*$8J03BZM4;CJK%1N3?TLD=Z[O=/9WQV-'=\_O?ODOZ6
M@DM.TQ^)7P,=MI_XF:6A>HT?;O"MR-,;JPN=,!.^8%89)GIRY7K=))Y\;B<F
MMM>LN50]IR8S)Y*&BWSD0$'.C0.K%U?QU,/<$@8MPW_J-VC9F(,<!X[QY5I8
M[1AL#<0>-O!)&G9#MYOR>704-\DO"6+WK8R.5_J0P3-2'FD3)',5M7/-"F.O
M0GE*CUF/)(/6VL^!DS>DI3_!WTBM5=LA.+KYZ[^>-5&W:PJC:\!_'09,;ZP2
MU_6OI@A@%RD*O H[(EA%T/7J9_GMN(2)0PJ077)YB8DDLJYJIO,D1K#[S2_Z
M-M(Q%MD(RG$\UN'\8FA'Y\MCF;MF*>MM<XDYX.9>Y0+@0?BX+ ]YPPR0!OG
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M 4TC"6IZ:4DE6J3^U9Z4R+59V;;[)@^+_:AB0<^KS )OE-K@RJ+6]E EH5*
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MF-VNOXO5A^5B^2!6RE=:?+M1CNF]>/OC02Q*,1/*"TP%BD"$( 8P2C&@$9*
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MB>VS5A]4V#Y_AWUJYUOE>*V?KCE7#RMU;4]QNU(D]5@H(V9(($%IGNM^""&
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M\%Z04E2S^">AMYO41VKM)3?S]X44,YRBD!&2 %IM!8D, HHS O(P3Q'/L%H
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M;8=0&1A<O^@0>BB!Y70H)UL"Z[(A]5,!RQAY)Q6PSDN;7@4L8X0&5< R?_J
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M$2 B#P%$H?+/LHB!*,1)G+ 80F%5V.6DI,DY9TI1L-6TR;RS=,Q.HFKHD+G
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MFGVB@CF RGJ-<BZ!H,K\CRNJJ%=+MTL#3<U$Z\B95((V#A&/XNA7L77;+\9
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MN\/U81;7\;'>_L#O\/AO5N889H020 JS?X-E6@"N> YDJI"BE")#K3[6E^O
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M2>_H2:T?LAE1)8'0P)XA* %D- >4B12H@J%<927B4GH;NX.(.C7^V1LL1KH
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M&D!.*.!IGH&2YI#E4)<(PO ,Z]TX4Z."H]S@Y \K:5*)>E-.]1Y8-T:( -?
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MKC]N5VKN>CQPS-*[_GH>5> ->$!@?X3COEVM58-+)3DJ,T!D!HVER%- B6
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M/-M17H6DOQGEY=M';$5Y58?#1I37+X]MJ^U[H.N<B\+P9*YLBA$N<D"H4H!
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MJ-%U%P<;-[[NFLXG$797;PC,E5NOA%)R\]:(6"?F'2\%^T7"+ADSJG(*)=)
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M8K;0C&K "XD!RTNA&5;&!/=R&O:,-36FZ?8<JI/B^'-2I\D%G3/WP>Q&))'
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M?3A!>L!HA].Q HN!VR )&SY853Q)I522<=%4I,Y+#1C6&BA)45["')<4>A4
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M *8E%E)SS:53D'4@/%/S 2UJJQQLO]8CNL"3=8O<*R'LU=W6K^8WZ(S(&GX
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MJ0(]UD85A,NM?JD-#G<,..'TYMO<_&=7%G[*4EA8 5H_F]^L[_MJ9QS5=ED
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M)^R,O-1\OJ7'"\ ]UYX;[]U.^=7\]/,/V[^8?^R^RL\__ -02P,$%     @
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M)[@Y7-8# ,PE_:-(4,9ZEYO[RGW.MH:0"!Y+"3&BEKQA+G$(?G&'R<.=I#F
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MX-OR8K$<GU-HL;J$X+)4$1ROR3?DG-8#S\!,2(%%@](WN61_EXR>#]#;H.8
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MG(R_W3].6;/B)(M><0L9DP?%B)\H@P69ZE69G-'';7V6I][33_C8 A<=RG,
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MJ>$_!%W=::77+>S.E83+JO!?QXN$$Y(<SBYN=6 8(6;&I9 DK1JRK!K/H):
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M$0>=<VYRT^0!)4/"RC[*O5]^<)"D!P"5FI1^6S:L(8.J<)$+D">G00DEP)-
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M2P$"% ,4    " "410Q1,CF%V98J   *7@$ &@              @ $
M97AI8W5R965X:&EB:70Q,#(M96UP;"YH=&U02P$"% ,4    " "410Q1AB>*
M%,0'  !B(@  &P              @ '.*@  97AI8W5R965X:&EB:70S,3$M
M-C,P,C N:'1M4$L! A0#%     @ E$4,4>'!L8JJ!P  *R(  !L
M     ( !RS(  &5X:6-U<F5E>&AI8FET,S$R+38S,#(P+FAT;5!+ 0(4 Q0
M   ( )1%#%'"/17%- 8   HE   ;              "  :XZ  !E>&EC=7)E
M97AH:6)I=#,R,2TV,S R,"YH=&U02P$"% ,4    " "510Q1*MMNZ+3T @!=
MZB  $0              @ $;00  >&-U<BTR,#(P,#8S,"YH=&U02P$"% ,4
M    " "510Q1''TU;7<1  "ELP  $0              @ '^-0, >&-U<BTR
M,#(P,#8S,"YX<V102P$"% ,4    " "510Q1 $M^T7L=  !9*P$ %0
M        @ &D1P, >&-U<BTR,#(P,#8S,%]C86PN>&UL4$L! A0#%     @
ME44,43"@^QFJ3   :SL# !4              ( !4F4# 'AC=7(M,C R,# V
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( )5%#%%HN_-_>>(" +;6 P 4
M      "  2^R P!X8W5R+3(P,C P-C,P7V<Q+FIP9U!+ 0(4 Q0    ( )5%
M#%']CFL=VR\" $$7 P 4              "  =J4!@!X8W5R+3(P,C P-C,P
M7V<R+FIP9U!+ 0(4 Q0    ( )5%#%&+<C]_O,D  #B:"  5
M  "  >?$" !X8W5R+3(P,C P-C,P7VQA8BYX;6Q02P$"% ,4    " "510Q1
M4*)P@O-X  "7CP4 %0              @ '6C@D >&-U<BTR,#(P,#8S,%]P
<<F4N>&UL4$L%!@     ,  P ,0,  /P'"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
